{"config":{"lang":["en"],"separator":"[\\s\\u200b\\-_,:!=\\[\\]()\"`/]+|\\.(?!\\d)|&[lg]t;|(?!\\b)(?=[A-Z][a-z])","pipeline":["stopWordFilter"]},"docs":[{"location":"about/","title":"About","text":""},{"location":"about/#education","title":"Education","text":"<ul> <li>Cardiology Fellowship<ul> <li>Charleston Area Medical Center (CAMC) | Charleston, WV</li> <li>July 2024 \u2013 July 2027</li> </ul> </li> <li>Chief Resident<ul> <li>3<sup>rd</sup> Year Chief Resident</li> <li>Charleston Area Medical Center (CAMC) | Charleston, WV</li> <li>July 2023 \u2013 July 2024</li> </ul> </li> <li>Internal Medicine Residency<ul> <li>Charleston Area Medical Center (CAMC) | Charleston, WV</li> <li>July 2021 - July 2024</li> </ul> </li> <li>Doctor of Osteopathic Medicine (DO)<ul> <li>LMU-DCOM | Harrogate, Tennessee</li> <li>July 2017 \u2013 May 2021</li> </ul> </li> <li>Undergraduate Coursework<ul> <li>University of Tennessee \u2013 Knoxville | Knoxville, TN</li> <li>August 2012 \u2013 May 2016</li> <li>1<sup>st</sup> year Course work in Engineering</li> <li>Completed 127 credit hours towards a Bachelor\u2019s degree in Mathematics</li> </ul> </li> </ul>"},{"location":"about/#leadership-experiences","title":"Leadership Experiences","text":"<ul> <li>Chief Resident<ul> <li>Charleston Area Medical Center (CAMC) | Charleston, WV</li> <li>July 2023 \u2013 July 2024</li> </ul> </li> <li>Cerner Training/Onboarding<ul> <li>Charleston Area Medical Center (CAMC) | Charleston, WV</li> <li>June 29, 2022; June 30, 2023</li> </ul> </li> <li>APDIM Chief Residents Meeting - Academic Internal Medicine Week<ul> <li>Austin Convention Center | Austin, TX</li> <li>April 2-5, 2023</li> </ul> </li> </ul>"},{"location":"about/#academic-endeavors","title":"Academic Endeavors","text":"<ul> <li>2023 Internal Medicine Guide<ul> <li>Charleston Area Medical Center (CAMC) | Charleston, WV</li> <li>August 2022 - Present</li> </ul> </li> <li>Presentations<ul> <li>Journal Club<ul> <li>Statins in ESRD - 10/18/2022</li> </ul> </li> <li>Morning Report<ul> <li>CIEDs - 09/29/2022</li> <li>ALF/DILI - 10/04/2022</li> </ul> </li> <li>Quality Improvement<ul> <li>Project: AMD \u2013 03/23/2022</li> </ul> </li> </ul> </li> <li>PGY-2 Development Curriculum/Bootcamp<ul> <li>Residents as Teachers &amp; Feedback in the Hospital \u2013 06/22/2023</li> <li>How to Navigate Night Float as a PGY-2 \u2013 06/21/2023</li> <li>Upper Leveling 101 \u2013 06/19/2023</li> </ul> </li> <li>Orientation to Presenting on Rounds<ul> <li>WVSOM | Charleston, WV</li> <li>Taught upcoming 3<sup>rd</sup> year medical students the components of an oral presentation on hospital rounds</li> <li>Evaluated and gave feedback regarding presentation skills</li> <li>June 2022</li> </ul> </li> </ul>"},{"location":"about/#research-experience","title":"Research Experience","text":"<ul> <li>CHEST Poster Presentation - Case Report<ul> <li>CHEST 2024 | Boston, MA</li> <li>1<sup>st</sup> Author/Presenter</li> <li>Case: A Massive Disturbance: Pituitary Apoplexy Causing Bradycardia</li> <li>CAMC Department of Cardiology</li> <li>PI: Dr. Vikhyath Terla, MD, Assistant Professor, Department of Pulmonology/Critical Care,</li> <li>October 09, 2024</li> </ul> </li> <li>CAMC Research Day Oral Presentation \u2013 Clinical Research/QI Abstract<ul> <li>2024 CAMC Research Day | Roanoke, WV</li> <li>1<sup>st</sup> Author/Presenter</li> <li>Case: Evaluating Resident and Patient Satisfaction by Creating a Polypharmacy Clinic in an Internal Medicine Residency Program</li> <li>CAMC Department of Internal Medicine</li> <li>PI: Amna Anees, MD, Program Director, Department of Internal Medicine</li> <li>April 2024</li> </ul> </li> <li>WV ACP Poster \u2013 Clinical Research/QI Abstract<ul> <li>2023 ACP WV Chapter Annual Scientific Meeting | Roanoke, WV</li> <li>Co-Investigator/Presenter</li> <li>Case: Evaluating Resident and Patient Satisfaction by Creating a Polypharmacy Clinic in an Internal Medicine Residency Program</li> <li>CAMC Department of Internal Medicine</li> <li>PI: Amna Anees, MD, Program Director, Department of Internal Medicine</li> <li>November 11, 2023</li> </ul> </li> <li>WV ACP Poster \u2013 Case Report<ul> <li>2023 ACP WV Chapter Annual Scientific Meeting | Roanoke, WV</li> <li>Co-Investigator</li> <li>Case: Name that Rash: Delayed Dermatomyositis Identification and its Sequela</li> <li>CAMC Department of Internal Medicine</li> <li>PI: Dr. Ahsan Iqbal, MD, Rheumatology, Department of Rheumatology</li> <li>November 11, 2023</li> </ul> </li> <li>WV ACP Oral Presentation - Thieves Market<ul> <li>2023 ACP WV Chapter Annual Scientific Meeting | Roanoke, WV</li> <li>1<sup>st</sup> Author/Presenter</li> <li>Case: Drug-Induced ANCA-Associated Vasculitis</li> <li>CAMC Department of Internal Medicine</li> <li>November 10, 2023</li> </ul> </li> <li>WV ACP Oral Presentation - Case Report<ul> <li>2023 ACP WV Chapter Annual Scientific Meeting | Roanoke, WV</li> <li>1<sup>st</sup> Author/Presenter</li> <li>Case: \u201cMy Neck, My Back, Antibodies on the Attack\u201d: A case of Statin-Associated Immune-Mediated Necrotizing Myopathy</li> <li>CAMC Department of Internal Medicine</li> <li>PI: James R. Campbell II, MD, Interim Associate Vice President for Health Sciences, Charleston Campus and Interim Dean, WVU School of Medicine, Charleston Campus; Associate Professor &amp; Department Chair, Department of Internal Medicine * Charleston Campus</li> <li>November 10, 2023</li> </ul> </li> <li>WV ACC Poster \u2013 Case Report<ul> <li>WV ACC Annual Meeting \u2013 Waterfront Place | Morgantown, WV</li> <li>1<sup>st</sup> Author/Presenter</li> <li>Case: Pericarditis associated with a Pericardial Cyst</li> <li>CAMC Department of Internal Medicine</li> <li>PI: Dr. David D. Francke, MD, Cardiology, Department of Cardiology</li> <li>August 26, 2023</li> </ul> </li> <li>WV ACC Poster \u2013 Case Report<ul> <li>WV ACC Annual Meeting \u2013 Waterfront Place | Morgantown, WV</li> <li>1<sup>st</sup> Author/Presenter</li> <li>Case: Oh My! Mycoplasma Pneumoniae Myocarditis</li> <li>CAMC Department of Internal Medicine</li> <li>PI: Dr. Sarah J. Rinehart, MD, Program Director, Department of Cardiology</li> <li>August 26, 2023</li> </ul> </li> <li>Prospective Observational Study \u2013 IRB Approved - Ongoing<ul> <li>Charleston Area Medical Center | Charleston, WV</li> <li>Co-Investigator</li> <li>Project: Acetazolamide use in Outpatient HF Management</li> <li>CAMC Department of Internal Medicine/Cardiology</li> <li>PI: Dr. Marciano Lee, MD, Cardiology, Heart Failure</li> <li>01/2023 \u2013 Present</li> </ul> </li> <li>WV ACP Oral Presentation - Cross-Sectional Observational Study<ul> <li>WV ACP Annual Meeting \u2013 Stonewall Resort | Roanoke, WV</li> <li>Co-Investigator</li> <li>Project: Words Matter: The Impact of Language on Healthcare Provider Clinical Judgment</li> <li>Department of Internal Medicine/Psychiatry</li> <li>PI: Dr. Adina Bowe, MD, Psychiatry, Director of Comprehensive Opioid Addiction Treatment Clinic and Assistant Professor</li> </ul> </li> <li>Prospective Study \u2013 IRB Approved - Ongoing<ul> <li>Charleston Area Medical Center | Charleston, WV</li> <li>Co-Investigator</li> <li>Project: Impact of Communication Modality on Heart Failure Clinic Follow Up</li> <li>CAMC Department of Internal Medicine/Cardiology</li> <li>PI: Dr. Marciano Lee, MD, Cardiology, Heart Failure</li> <li>02/2022 \u2013 Present</li> </ul> </li> <li>Quality Improvement<ul> <li>Charleston Area Medical Center | Charleston, WV</li> <li>Project: Improving AMD documentation in IM Clinic Patients \u226560 y/o</li> <li>CAMC Department of Internal Medicine</li> <li>PI: Dr. J Anwar, MD, Internal Medicine</li> <li>11/2021 \u2013 Present</li> </ul> </li> <li>Research Day Poster \u2013 Case Report<ul> <li>Charleston Area Medical Center | Charleston, WV</li> <li>Co-Investigator/Presenter</li> <li>The Confused Crab: Hyperammonemic Encephalopathy as an initial presentation of Multiple Myeloma</li> <li>CAMC Department of Internal Medicine</li> <li>PI: Dr. R. Scott Morehead, MD, Pulmonology and Critical Care</li> <li>April 19, 2022</li> </ul> </li> </ul>"},{"location":"about/#work-experience","title":"Work Experience","text":"<ul> <li>Internal Moonlighting<ul> <li>Worked with GME and hospital administration to allow internal moonlighting and create a pathway within CAMC to allow this for other residents</li> <li>Included Neurology and MRI Observation</li> </ul> </li> <li>Ophthalmic Assistant<ul> <li>Regional Eye Center | Kingsport, TN</li> <li>Worked independently to prepare patients for their visit by performing preliminary eye exams</li> <li>Conducted diagnostic testing via fundus photography, topography, and visual field assessment</li> <li>Assisted physicians as a scribe by properly documenting exam findings</li> <li>P5/2015 \u2013 08/2015, 12/2015 \u2013 01/2016, 07/2016 \u2013 07/2017</li> </ul> </li> <li>Teaching Assistant/Peer Mentor, First Year Studies 101<ul> <li>University of Tennessee | Knoxville, TN</li> <li>Semester-long course for incoming freshmen created to provide guidance and the means to thrive while at UT</li> <li>Graded assignments, assisted class activities, and served as an in-class liaison</li> <li>Fall 2013, 2014, and 2015</li> </ul> </li> </ul>"},{"location":"about/#volunteer-experience-and-community-activities","title":"Volunteer Experience and Community Activities","text":"<ul> <li>Project CHASM (Charleston Homeless and Street Medicine)<ul> <li>WVU | Charleston, WV</li> <li>Check blood pressures, provide basic toiletries, and other necessities twice monthly</li> <li>Provide compassionate care at the men\u2019s group home and women\u2019s shelter in downtown Charleston</li> <li>April 2022 - Ongoing</li> </ul> </li> <li>Hospital Flu Shot and COVID-19 Contact Tracing Volunteer<ul> <li>Tennova Turkey Creek Medical Center | Knoxville, TN</li> <li>Assist pharmacy staff by administering flu shots to hospital staff on a weekly basis</li> <li>Assist the human resources department by contact tracing COVID-19 positive patients</li> <li>October 2020</li> </ul> </li> <li>Clinical Rotations Student Assessment Team Volunteer<ul> <li>LMU-DCOM | Knoxville, TN</li> <li>Met with rotation staff from multiple rotation sites to assess the current third year curriculum</li> <li>Received feedback from peers to adjust current curriculum</li> <li>Created and submitted recommended changes to the assessment staff</li> <li>February 2020</li> </ul> </li> <li>Clean-up Crew Volunteer<ul> <li>Girls Inc. | Kingsport, TN</li> <li>General facility maintenance in preparation for after school activities</li> <li>Repainted and resurfaced the schoolyard, cleared brush and improved the facility\u2019s exterior</li> <li>Fall 2014, Fall 2019</li> <li>February 2020</li> </ul> </li> <li>Student Peer Mentor<ul> <li>LMU-DCOM | Harrogate, TN</li> <li>Provided guidance and served as a source of answers to an incoming medical student</li> <li>Attended regular meetings and mentoring events</li> <li>Recommended resources tailored to each course</li> <li>2018, 2019</li> </ul> </li> <li>6<sup>th</sup> Grade Assistant Football Coach<ul> <li>Boys and Girls Club of Greater Kingsport | Kingsport, TN</li> <li>Assisted in practices and games on a bi-weekly basis</li> <li>Independently coached defensive backs and wide receivers</li> <li>Implemented known techniques to improve skill, Led individual drills</li> <li>Fall 2016</li> </ul> </li> </ul>"},{"location":"about/#hobbies","title":"Hobbies","text":"<ul> <li>Intramural Sports/College Olympics<ul> <li>LMU-DCOM | Harrogate, TN<ul> <li>Football, Soccer, and Dodgeball</li> <li>Dodgeball Champion</li> </ul> </li> <li>University of Tennessee | Knoxville, TN<ul> <li>Football, Racquetball, Floor hockey, and Basketball</li> </ul> </li> </ul> </li> <li>Microsoft Word/Excel/PowerPoint \u2013 Expert</li> <li>Snowboarding \u2013 Advanced</li> <li>Cerner - Advanced</li> <li>Python, HTML, CSS- Intermediate</li> <li>Javascript - Working</li> </ul>"},{"location":"about/#honors-and-awards","title":"Honors and Awards","text":"<ul> <li>Outpatient Resident of the Year<ul> <li>Charleston Area Medical Center | Charleston, WV</li> <li>06/15/2024</li> </ul> </li> <li>1<sup>st</sup> Place Clinical Research/QI Resident Abstract Poster Competition<ul> <li>2023 ACP WV Chapter Annual Scientific Meeting | Roanoke, WV</li> <li>11/11/2023</li> </ul> </li> <li>Outstanding Contribution to Quality Improvement Projects - 2022-2023<ul> <li>Charleston Area Medical Center | Charleston, WV</li> <li>For contributions to QIPs</li> <li>2022-2023</li> </ul> </li> <li>Outstanding Contribution to Quality Improvement Project - Quarter 1<ul> <li>Charleston Area Medical Center | Charleston, WV</li> <li>For contributions to AMD QIPs</li> <li>Fall 2021</li> </ul> </li> <li>Dean\u2019s List<ul> <li>University of Tennessee | Knoxville, TN</li> <li>Fall 2012, 2013, and 2014, Spring 2015 and 2016</li> </ul> </li> <li>Dobyns-Bennett Quarterback Club Scholarship<ul> <li>Dobyns-Bennett Highschool | Kingsport, TN</li> <li>Single year college scholarship for my position as a team captain and my academic record.</li> <li>Fall 2012 \u2013 Spring 2013</li> </ul> </li> </ul>"},{"location":"about/contact/","title":"Contact","text":"Loading\u2026"},{"location":"about/disclaimer/","title":"Disclaimer","text":""},{"location":"about/disclaimer/#terms-of-use-agreement-and-disclaimer","title":"Terms of Use Agreement and Disclaimer","text":""},{"location":"about/disclaimer/#terms-of-use-agreement","title":"Terms of Use Agreement","text":"<ul> <li>This Terms of Use Agreement (this \u2018Agreement') is entered into by and between the author and \u2018you', the user of this website, also known as \u2018IMTechEd' (the Site). Access to, use of and/or browsing of the Site is provided subject to the terms and conditions set forth herein. By accessing, using and/or browsing the Site, you hereby agree to these terms and conditions.</li> <li>THIS AGREEMENT CONTAINS WARRANTY DISCLAIMERS AND OTHER PROVISIONS THAT LIMIT THE AUTHOR'S LIABILITY TO YOU. PLEASE READ THESE TERMS AND CONDITIONS CAREFULLY AND IN THEIR ENTIRETY, AS USING, ACCESSING AND/OR BROWSING THE SITE CONSTITUTES ACCEPTANCE OF THESE TERMS AND CONDITIONS. IF YOU DO NOT AGREE TO BE BOUND TO EACH AND EVERY TERM AND CONDITION SET FORTH HEREIN, PLEASE EXIT THE SITE IMMEDIATELY AND DO NOT USE, ACCESS AND/OR BROWSE THE SITE.</li> <li>BY ENTERING THE SITE, YOU ACKNOWLEDGE AND AGREE THAT YOU HAVE READ AND UNDERSTAND THESE TERMS AND CONDITIONS, THAT THE PROVISIONS, DISCLOSURES AND DISCLAIMERS SET FORTH HEREIN ARE FAIR AND REASONABLE, AND THAT YOUR AGREEMENT TO FOLLOW AND BE BOUND BY THESE TERMS AND CONDITIONS IS VOLUNTARY AND IS NOT THE RESULT OF FRAUD, DURESS OR UNDUE INFLUENCE EXERCISED UPON YOU BY ANY PERSON OR ENTITY.</li> </ul>"},{"location":"about/disclaimer/#medical-advice-disclaimer","title":"MEDICAL ADVICE DISCLAIMER","text":"<ul> <li>The Author provides the Site and the services, information, content and/or data (collectively, \u2018Information') contained therein for informational purposes only. The Author does not provide any medical advice on the Site, and the Information should not be so construed or used. Using, accessing and/or browsing the Site and/or providing personal or medical information to the Author does not create a physician-patient relationship between you and the Author. Nothing contained in the Site is intended to create a physician-patient relationship, to replace the services of a licensed, trained physician or health professional or to be a substitute for medical advice of a physician or trained health professional licensed in your state. You should not rely on anything contained in the Site, and you should consult a physician licensed in your state in all matters relating to your health. You hereby agree that you shall not make any health or medical related decision based in whole or in part on anything contained in the Site.</li> </ul>"},{"location":"about/disclaimer/#financial-legal-and-other-advice-disclaimer","title":"FINANCIAL, LEGAL AND OTHER ADVICE DISCLAIMER","text":"<ul> <li>You hereby acknowledge that nothing contained in the Site shall constitute financial, investment, legal and/or other professional advice and that no professional relationship of any kind is created between you and the Author. You hereby agree that you shall not make any financial, investment, legal and/or other decision based in whole or in part on anything contained in the Site.</li> </ul>"},{"location":"about/disclaimer/#information-disclaimer","title":"INFORMATION DISCLAIMER","text":"<ul> <li>The opinions expressed in the Site are not necessarily the opinions of the Author and do not reflect the opinion of his employer(s). The Site is created by the Author in the Author's individual capacity, is the Author's personal web site, is not edited by the Author's employer(s) and, as a result, may not be attributed to the Author's employer.</li> <li>Any opinions of the Author on the Site are or have been rendered based on specific facts, under certain conditions, and subject to certain assumptions, and may not and should not be used or relied upon for any other purpose, including, but not limited to, for use in or in connection with any legal proceeding.</li> <li>The Information may be changed without notice and is not guaranteed to be complete, correct, timely, current or up-to-date. Similar to any printed materials, the Information may become out-of-date. The Author undertakes no obligation to update any Information on the Site; provided, however, that the Author may update the Information at any time without notice in the Author's sole and absolute discretion. The Author reserves the right to make alterations or deletions to the Information at any time without notice.</li> </ul>"},{"location":"about/disclaimer/#posting-disclaimer","title":"POSTING DISCLAIMER","text":"<ul> <li>The Site is open to the public. Therefore, consider your comments carefully and do not include anything in a comment that you would like to keep private. By uploading or otherwise making available any information to the Author in the form of user generated comments or otherwise, you grant the Author the unlimited, perpetual right to distribute, display, publish, reproduce, reuse and copy the information contained therein.</li> <li>By submitting or posting content on the Site, you grant the Author and any company substantially under the control of the Author, the right to remove any content or comment that, in Author's sole judgment, does not comply with the terms and conditions of this Agreement or is otherwise objectionable. You also grant the Author and any company substantially under the control of Author the right to modify, adapt, and edit any content.</li> </ul>"},{"location":"about/disclaimer/#third-party-links-and-advertisements-disclaimer","title":"THIRD PARTY LINKS AND ADVERTISEMENTS DISCLAIMER","text":"<ul> <li>The Site may in the future, from time to time, contain links to third party web sites. These links are provided solely as a convenience to you and not as a guarantee, warranty, or recommendation by the Author of the services, information, content and/or data on such third party web sites or as an indication of any affiliation, sponsorship or endorsement of such third party web sites. The Author is not responsible for the content of linked third party web sites and does not make any representations or warranties regarding the privacy practices of, or the content or accuracy of materials on, such third party websites. If you decide to access linked third-party web sites, you do so at your own risk. Your use of third-party websites is subject to the terms of use for such sites.</li> <li>THE INCLUSION OF THIRD PARTY ADVERTISEMENTS DOES NOT CONSTITUTE AN ENDORSEMENT, GUARANTEE, WARRANTY, OR RECOMMENDATION OF, AND THE AUTHOR MAKES NO REPRESENTATIONS AND/OR WARRANTIES ABOUT, ANY PRODUCT OR SERVICE CONTAINED THEREIN.</li> </ul>"},{"location":"about/disclaimer/#disclaimer-of-all-warranties","title":"DISCLAIMER OF ALL WARRANTIES","text":"<ul> <li>The Information made available at the Site is provided on an 'AS IS' and 'AS AVAILABLE' basis without warranties of any kind, either express or implied, including, without limitation, warranties of title, noninfringement, and implied warranties of merchantability or fitness for a particular purpose. Without limiting the generality of the foregoing, the Author makes no warranty, representation or guaranty as to the content, sequence, accuracy, timeliness or completeness of the Information, that the Information may be relied upon for any reason or that the Information will be uninterrupted or error free or that any defects can or will be corrected.</li> <li>Without limiting the generality of the foregoing, the Author makes no representations or warranties with respect to any Information offered or provided within or through the Site regarding treatment of medical conditions, action, or application of medication.</li> <li>Under no circumstances, as a result of your use of the Site, will the Author be liable to you or to any other person for any direct, indirect, special, incidental, exemplary, consequential or other damages under any legal theory, including, without limitation, tort, contract, strict liability or otherwise, even if advised of the possibility of such damages. Without limiting the generality of the foregoing, the Author shall have absolutely no liability in connection with the Site for:<ol> <li>damages as a result of lost profits, loss of good will, work stoppage, failure of performance, delays in operation or transmission, non-delivery of information, deletions of files, mistakes, defects, errors, interruptions or computer failure or malfunction;</li> <li>any loss or injury caused, in whole or in part, by the Author's actions, omissions, or negligence, or for contingencies beyond the Author's control, in procuring, compiling, or delivering the Information;</li> <li>any errors, omissions, or inaccuracies in the Information regardless of how caused, or delays or interruptions in delivery of the Information; or</li> <li>any decision made or action taken or not taken in reliance upon the Information.</li> </ol> </li> </ul>"},{"location":"about/disclaimer/#reservation-of-intellectual-property-rights","title":"RESERVATION OF INTELLECTUAL PROPERTY RIGHTS","text":"<ul> <li>The Site is protected by United States copyright laws. The Author hereby reserves any and all intellectual property rights in the Site.</li> </ul>"},{"location":"about/disclaimer/#indemnification","title":"INDEMNIFICATION","text":"<ul> <li>You agree to indemnify and hold the Author harmless from any claim or demand, including attorneys' fees, made by any third party as a result of:<ol> <li>any content posted or made available by you on this Site;</li> <li>any violation of law that occurs by you through the Site; and/or</li> <li>anything you do using the Site and/or the Information contained therein.</li> </ol> </li> </ul>"},{"location":"about/disclaimer/#invalidity","title":"INVALIDITY","text":"<ul> <li>If any provision of this Agreement is held to be invalid or unenforceable in whole or in part in any jurisdiction, then that provision shall be deemed ineffective in such jurisdiction but shall have no effect on the enforceability of the remaining provisions.</li> </ul>"},{"location":"about/disclaimer/#governing-law-consent-to-jurisdiction-and-limitation-on-claims","title":"GOVERNING LAW, CONSENT TO JURISDICTION AND LIMITATION ON CLAIMS","text":"<ul> <li>This Agreement and your use of the Site, along with the Information contained therein, shall be governed by and construed in accordance with the laws of the State of West Virginia without regard to conflict of laws principles, and you agree to submit to the jurisdiction of courts in the State of West Virginia. You further agree that any claims or causes of action arising out of or related to this Agreement and the Site, along with the Information contained therein, shall be filed within one (1) year after such claim or cause of action arose, or such claim or cause of action shall be forever barred.</li> </ul>"},{"location":"about/disclaimer/#entire-agreement","title":"ENTIRE AGREEMENT","text":"<ul> <li>You hereby acknowledge that this Agreement represents the entire understanding between you and the Author concerning your use of the Site and the Information contained therein.</li> </ul>"},{"location":"about/disclaimer/#modification","title":"MODIFICATION","text":"<ul> <li>The Author may, in the Author's sole and absolute discretion, modify the terms and conditions of this Agreement in whole or in party at any time for any reason without any notice to you, whether prior or otherwise.</li> <li>Such modified terms and conditions shall supersede these terms and conditions and shall become binding when published online on the Site.</li> </ul>"},{"location":"about/disclaimer/#waiver","title":"WAIVER","text":"<ul> <li>The Author's failure to exercise or enforce any right or provision of this Agreement shall not be deemed to be a waiver of such right or provision.</li> </ul> <p>THE SITE AND THE INFORMATION CONTAINED THEREIN IS MADE AVAILABLE BY THE AUTHOR FOR EDUCATIONAL PURPOSES ONLY AND IS NOT INTENDED TO PROVIDE MEDICAL ADVICE. BY ACCESSING THE SITE, YOU UNDERSTAND AND ACKNOWLEDGE THAT THERE IS NO PHYSICIAN-PATIENT RELATIONSHIP BETWEEN YOU AND THE AUTHOR. YOU FURTHER ACKNOWLEDGE YOUR UNDERSTANDING THAT THE SITE SHOULD NOT BE USED AS A SUBSTITUTE FOR COMPETENT MEDICAL ADVICE FROM A LICENSED PHYSICIAN IN YOUR STATE.</p>"},{"location":"about/license/","title":"License","text":"<p>MIT License</p> <p>Copyright \u00a9 2022-2024 Austin imteched@gmail.com</p> <p>Permission is hereby granted, free of charge, to any person obtaining a copy of this software and associated documentation files (the \"Software\"), to deal in the Software without restriction, including without limitation the rights to use, copy, modify, merge, publish, distribute, sublicense, and/or sell copies of the Software, and to permit persons to whom the Software is furnished to do so, subject to the following conditions:</p> <p>The above copyright notice and this permission notice shall be included in all copies or substantial portions of the Software.</p> <p>THE SOFTWARE IS PROVIDED \"AS IS\", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NON-INFRINGEMENT. IN NO EVENT SHALL THE AUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER LIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM, OUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE SOFTWARE.</p>"},{"location":"about/website/changelog/","title":"Changelog","text":""},{"location":"about/website/changelog/#9.5.20","title":"9.5.20 April 29, 2024","text":"<ul> <li>Fixed deprecation warning in privacy plugin (9.5.19 regression)</li> <li>Fixed #7119: Tags plugin emits deprecation warning (9.5.19 regression)</li> <li>Fixed #7118: Social plugin crashes if fonts are disabled (9.5.19 regression)</li> <li>Fixed #7085: Social plugin crashes on Windows when downloading fonts</li> </ul>"},{"location":"about/website/changelog/#9.5.19","title":"9.5.19 April 25, 2024","text":"<ul> <li>Updated MkDocs to 1.6 and limited version to &lt; 2</li> <li>Updated Docker image to latest Alpine Linux</li> <li>Removed <code>setup.py</code>, now that GitHub fully understands <code>pyproject.toml</code></li> <li>Improved interop of social plugin with third-party MkDocs themes</li> <li>Fixed #7099: Blog reading time not rendered correctly for Japanese</li> <li>Fixed #7097: Improved resilience of tags plugin when no tags are given</li> <li>Fixed #7090: Active tab indicator in nested content tabs rendering bug</li> </ul>"},{"location":"about/website/changelog/#9.5.18","title":"9.5.18 April 16, 2024","text":"<ul> <li>Refactored tooltips implementation to fix positioning issues</li> <li>Fixed #7044: Rendering glitch when hovering contributor avatar in Chrome</li> <li>Fixed #7043: Highlighted lines in code blocks cutoff on mobile</li> <li>Fixed #6910: Incorrect position of tooltip for page status in sidebar</li> <li>Fixed #6760: Incorrect position and overly long tooltip in tables</li> <li>Fixed #6488: Incorrect position and cutoff tooltip in content tabs</li> </ul>"},{"location":"about/website/changelog/#9.5.17","title":"9.5.17 April 2, 2024","text":"<ul> <li>Updated Serbian translations</li> <li>Fixed #7003: Confusing keyboard interaction for palette toggle</li> <li>Fixed #7001: Blog posts now show time by default (9.5.16 regression)</li> <li>Fixed edge case in backport of social plugin font loading logic</li> </ul>"},{"location":"about/website/changelog/#9.5.16","title":"9.5.16 March 31, 2024","text":"<ul> <li>Updated Russian translations</li> <li>Improved error handling and reporting in social plugin</li> <li>Improved error handling and reporting in privacy plugin</li> <li>Fixed blog plugin not allowing to use time in format strings</li> <li>Fixed #6983: Social plugin crashes because of Google Fonts API change</li> </ul>"},{"location":"about/website/changelog/#9.5.15","title":"9.5.15 March 23, 2024","text":"<ul> <li>Reverted fix for transparent iframes (9.5.14)</li> <li>Fixed #6929: Interference of social plugin and auto dark mode</li> <li>Fixed #6938: Giscus shows dark background in light mode (9.5.14 regression)</li> </ul>"},{"location":"about/website/changelog/#9.5.14","title":"9.5.14 March 18, 2024","text":"<ul> <li>Added support for hiding versions from selector when using mike</li> <li>Added init system to improve signal handling in Docker image</li> <li>Fixed edge cases in exclusion logic of info plugin</li> <li>Fixed inability to reset pipeline in search plugin</li> <li>Fixed syntax error in Finnish translations</li> <li>Fixed #6917: UTF-8 encoding problems in blog plugin on Windows</li> <li>Fixed #6889: Transparent iframes get background color</li> </ul>"},{"location":"about/website/changelog/#9.5.13","title":"9.5.13 March 6, 2024","text":"<ul> <li>Updated Slovak translations</li> <li>Improved info plugin interop with projects plugin</li> <li>Improved info plugin inclusion/exclusion logic</li> <li>Fixed info plugin not gathering files recursively</li> <li>Fixed #6750: Ensure info plugin packs up all necessary files</li> </ul>"},{"location":"about/website/changelog/#9.5.12","title":"9.5.12 February 29, 2024","text":"<ul> <li>Fixed #6846: Some meta tags removed on instant navigation (9.4.2 regression)</li> <li>Fixed #6823: KaTex not rendering on instant navigation (9.5.5 regression)</li> <li>Fixed #6821: Privacy plugin doesn't handle URLs with encoded characters</li> </ul>"},{"location":"about/website/changelog/#9.5.11","title":"9.5.11 February 24, 2024","text":"<ul> <li>Updated Finnish translation</li> </ul>"},{"location":"about/website/changelog/#9.5.10","title":"9.5.10 February 19, 2024","text":"<ul> <li>Updated Bahasa Malaysia translations</li> <li>Fixed #6783: Hide continue reading link for blog posts without separators</li> <li>Fixed #6779: Incorrect positioning of integrated table of contents</li> </ul>"},{"location":"about/website/changelog/#9.5.9","title":"9.5.9 February 10, 2024","text":"<ul> <li>Fixed navigation pruning with tabs and sections enabled</li> </ul>"},{"location":"about/website/changelog/#9.5.8","title":"9.5.8 February 7, 2024","text":"<ul> <li>Added Tamil translations</li> <li>Updated Esperanto translations</li> <li>Fixed relative images not being resolved for instant navigation</li> </ul>"},{"location":"about/website/changelog/#9.5.7","title":"9.5.7 February 3, 2024","text":"<ul> <li>Fixed #6731: Small images in figures are not centered</li> <li>Fixed #6719: Instant navigation breaks table of contents (9.5.5 regression)</li> </ul>"},{"location":"about/website/changelog/#9.5.6","title":"9.5.6 January 28, 2024","text":"<ul> <li>Fixed #6700: Missing styles for Mermaid.js labels with Markdown</li> </ul>"},{"location":"about/website/changelog/#9.5.5","title":"9.5.5 January 24, 2024","text":"<ul> <li>Updated Tagalog translations</li> <li>Updated Pillow to 10.2 to mitigate security vulnerabilities</li> <li>Improved resilience of instant navigation</li> <li>Fixed #6687: Updated Mermaid.js to version 10.7.0 (latest)</li> <li>Fixed #6652: Keyboard events in custom elements captured</li> <li>Fixed #6582: Instant navigation doesn't correctly handle alternate URLs</li> <li>Fixed #6565: Instant navigation doesn't allow for <code>onclick</code> handlers</li> <li>Fixed #6345: Instant navigation sometimes breaks browser back button</li> <li>Fixed #6334: Instant navigation doesn't correctly position anchors (Safari)</li> <li>Fixed #6275: Instant navigation doesn't correctly resolve after 404</li> <li>Fixed #6102: Instant navigation reloads page on same link navigation</li> </ul>"},{"location":"about/website/changelog/#9.5.4","title":"9.5.4 January 15, 2024","text":"<ul> <li>Fixed #6645: Local storage with invalid value can break site</li> <li>Fixed #6635: Tags icons before default ignored if default is set</li> </ul>"},{"location":"about/website/changelog/#9.5.3","title":"9.5.3 December 23, 2023","text":"<ul> <li>Limited version range of MkDocs to &lt; 1.6</li> <li>Updated Macedonian translations</li> <li>Fixed #6520: Group plugin crashes when using mike</li> <li>Fixed #6494: Hide author's email address if disabled in git-authors plugin</li> </ul>"},{"location":"about/website/changelog/#9.5.2","title":"9.5.2 December 11, 2023","text":"<ul> <li>Fixed types for <code>slugify</code> settings in blog plugin config</li> <li>Fixed #6469: Horizontal scrollbars on MathJax containers</li> </ul>"},{"location":"about/website/changelog/#9.5.1","title":"9.5.1 December 8, 2023","text":"<ul> <li>Updated Greek translations</li> <li>Fixed #6464: Privacy plugin cannot be enabled</li> <li>Fixed #6461: Sorting blog posts ignores time component in date</li> </ul>"},{"location":"about/website/changelog/#9.5.0","title":"9.5.0 December 7, 2023","text":"<p>Merged Insiders features of 'Goat's Horn' funding goal</p> <ul> <li>Added privacy plugin: automatic downloading of external assets</li> <li>Added support for card grids and grid layouts</li> <li>Added support for improved tooltips</li> <li>Added support for content tabs anchor links (deep linking)</li> <li>Added support for automatic dark/light mode</li> <li>Added support for document contributors</li> </ul>"},{"location":"about/website/changelog/#9.4.14","title":"9.4.14 November 26, 2023","text":"<ul> <li>Added support for linking authors in blog posts</li> </ul>"},{"location":"about/website/changelog/#9.4.13","title":"9.4.13 November 26, 2023","text":"<ul> <li>Fixed #6365: Blog plugin pagination links to previous pages broken</li> <li>Fixed #5758: Updated Mermaid.js to version 10.6.1 (latest)</li> </ul>"},{"location":"about/website/changelog/#9.4.12","title":"9.4.12 November 24, 2023","text":"<ul> <li>Improved blog plugin to generate Unicode-aware slugs by default</li> <li>Fixed non-deterministic order of categories in blog plugin</li> </ul>"},{"location":"about/website/changelog/#9.4.11","title":"9.4.11 November 23, 2023","text":"<ul> <li>Fixed #6364: Search plugin crashing when enabling theme while serving</li> <li>Fixed blog plugin crashing when disabling pagination</li> </ul>"},{"location":"about/website/changelog/#9.4.10","title":"9.4.10 November 19, 2023","text":"<ul> <li>Fixed #6356: Version selector can't be disabled via mike's configuration</li> <li>Fixed #6281: Navigation not rendering due to Safari bug (9.4.2 regression)</li> <li>Fixed #6261: Navigation expansion animates on first load (9.4.2 regression)</li> </ul>"},{"location":"about/website/changelog/#9.4.9","title":"9.4.9 November 17, 2023","text":"<ul> <li>Fixed #6344: Long entries cutoff in table of contents</li> <li>Fixed #6336: Custom template for glob archive not working with pagination</li> <li>Fixed #6328: Blog plugin crashes for locales with dashes, e.g. <code>pt-BR</code></li> <li>Fixed #6327: Copy-to-clipboard button doesn't trim trailing line feed</li> <li>Fixed #6302: Version strings not matched when using mike, only aliases</li> <li>Fixed instant navigation progress indicator for gzipped content in Chrome</li> <li>Fixed rendering bug on details marker rotation in Firefox</li> </ul>"},{"location":"about/website/changelog/#9.4.8","title":"9.4.8 November 5, 2023","text":"<ul> <li>Fixed invalid local address replacement when using instant loading</li> <li>Fixed #6275: Crash after navigation caused 404 when using instant loading</li> </ul>"},{"location":"about/website/changelog/#9.4.7","title":"9.4.7 October 27, 2023","text":"<ul> <li>Added Azerbaijani translations</li> </ul>"},{"location":"about/website/changelog/#9.4.6","title":"9.4.6 October 14, 2023","text":"<ul> <li>Updated Danish and Norwegian (Nynorsk) translations</li> <li>Fixed #6169: Blog post metadata layout overflows on small screens</li> </ul>"},{"location":"about/website/changelog/#9.4.5","title":"9.4.5 October 10, 2023","text":"<ul> <li>Fixed sidebar auto-positioning (9.4.2 regression)</li> <li>Fixed #6166: Improve group plugin compatibility with Python &lt; 3.10</li> <li>Fixed #6157: Hiding tags does not work (9.4.3 regression)</li> </ul>"},{"location":"about/website/changelog/#9.4.4","title":"9.4.4 October 5, 2023","text":"<ul> <li>Added support for overriding text to be copied for code blocks</li> <li>Fixed broken layout in some browsers at breakpoints when using zoom</li> <li>Fixed #6132: Incomplete search highlighting for code blocks in titles</li> </ul>"},{"location":"about/website/changelog/#9.4.3","title":"9.4.3 October 2, 2023","text":"<ul> <li>Added support for instant navigation progress indicator</li> <li>Improved spacing and alignment of tags</li> <li>Moved back-to-top button into separate partial</li> <li>Fixed #6104: Indentation for some code blocks lost in search</li> <li>Fixed #6094: Blog post metadata overlaps with footer on small screens</li> <li>Fixed #6069: Blog plugin crashes for categories with non-ASCII names</li> </ul> <p>Updated templates (diff)</p> <ul> <li><code>base.html</code></li> </ul>"},{"location":"about/website/changelog/#9.4.2","title":"9.4.2 September 25, 2023","text":"<ul> <li>Updated Slovenian translations</li> <li>Added animation to sidebar navigation expansion and collapse</li> <li>Added support for auto-replacement of document head for instant navigation</li> <li>Improved compatibility of new emoji extension with Python &lt; 3.10</li> <li>Switched regex dependency to use minimal version</li> <li>Refactored alignment and spacing of sidebar navigation</li> <li>Fixed expansion button not focusable via keyboard in sidebar navigation</li> <li>Fixed viewport offset restoration on first load when using instant navigation</li> <li>Fixed accidental highlight of non-clickable elements in blog plugin sidebar</li> <li>Fixed #6041: Blog plugin crashes when <code>nav</code> is defined and blog not included</li> <li>Fixed #5972: Blog plugin ignores section index pages in paginated views</li> <li>Fixed #5954: Repeated click on anchor ignored when using instant navigation</li> <li>Fixed #5742: Keyboard navigation broken when using instant navigation</li> </ul> <p>Updated templates (diff)</p> <ul> <li><code>partials/nav-item.html</code></li> <li><code>blog-post.html</code></li> </ul>"},{"location":"about/website/changelog/#9.4.1","title":"9.4.1 September 22, 2023","text":"<ul> <li>Improved colors and contrast in dark mode</li> <li>Improved admonition borders to match font weight</li> <li>Switched content tabs to neutral color</li> </ul>"},{"location":"about/website/changelog/#9.4.0","title":"9.4.0 September 21, 2023","text":"<ul> <li>Added Belarusian translations</li> <li>Added version info to entrypoint of package</li> <li>Added emoji extension as a replacement for <code>materialx</code></li> <li>Improved slate color scheme (dark mode) - now even darker</li> <li>Restructured project to improve development experience</li> <li>Updated MkDocs to 1.5.3</li> <li>Fixed #3890: Development mode crash on Linux</li> </ul>"},{"location":"about/website/changelog/#9.3.2","title":"9.3.2 September 19, 2023","text":"<ul> <li>Updated Slovenian translations</li> <li>Updated Python dependencies in requirements to use minimum versions</li> <li>Fixed #6017: Code highlighting inconsistent in Community and Insiders edition</li> <li>Fixed #6001: Contributor avatars display incorrectly in Firefox</li> <li>Fixed #6000: Blog post drafts are included in navigation</li> </ul>"},{"location":"about/website/changelog/#9.3.1","title":"9.3.1 September 11, 2023","text":"<ul> <li>Fixed crash of group plugin when used together with hooks</li> </ul>"},{"location":"about/website/changelog/#9.3.0","title":"9.3.0 September 11, 2023","text":"<ul> <li>Improved configuration sharing between Community and Insiders edition</li> <li>Added experimental built-in group plugin for enabling plugins conditionally</li> <li>Added new settings in tags plugin for enabling/disabling</li> <li>Dropped support for Python 3.7 (EOL)</li> </ul>"},{"location":"about/website/changelog/#9.2.8","title":"9.2.8 September 4, 2023","text":"<ul> <li>Updated Italian and Russian translations</li> <li>Fixed #5952: Combining blog and tags plugin leads to wrong links</li> <li>Fixed #5951: Blog plugin ignores post title in metadata</li> <li>Fixed #5949: Blog plugin ignores post linked in nav</li> </ul>"},{"location":"about/website/changelog/#9.2.7","title":"9.2.7 September 2, 2023","text":"<ul> <li>Switched dependencies to compatible release clauses</li> <li>Removed <code>readtime</code> and <code>lxml</code> dependencies for blog plugin</li> <li>Reduced size of Docker image to improve CI build performance</li> <li>Fixed #5945: Incorrect footer navigation for sibling pages of blog</li> <li>Fixed #5939: Page jumps when changing color palette (Firefox 117)</li> <li>Fixed #5901: Announcement bar reappears when using instant loading</li> <li>Fixed #5824: Allow to customize styles of sequence diagrams</li> </ul>"},{"location":"about/website/changelog/#9.2.6","title":"9.2.6 August 31, 2023","text":"<ul> <li>Added Basque translations</li> <li>Added template for simple redirects</li> <li>Improved blog plugin interop by moving view generation to <code>on_files</code></li> <li>Fixed #5924: Social plugin still checks dependencies when disabled</li> <li>Fixed #5916: Blog plugin crashes on Python 3.8 (9.2.0 regression)</li> </ul>"},{"location":"about/website/changelog/#9.2.5","title":"9.2.5 August 27, 2023","text":"<ul> <li>Fixed error in dirty serve mode when using blog plugin</li> <li>Fixed page title not being consistent in blog plugin pagination</li> <li>Fixed #5899: Blog plugin pagination breaks when disabling directory URLs</li> </ul>"},{"location":"about/website/changelog/#9.2.4","title":"9.2.4 August 26, 2023","text":"<ul> <li>Added version to bug report name in info plugin</li> <li>Updated Afrikaans translations</li> </ul>"},{"location":"about/website/changelog/#9.2.3","title":"9.2.3 August 22, 2023","text":"<ul> <li>Fixed blog plugin rendering wrongly with <code>markdown.extensions.toc</code></li> <li>Fixed blog plugin entrypoint generation</li> </ul>"},{"location":"about/website/changelog/#9.2.2","title":"9.2.2 August 22, 2023","text":"<ul> <li>Fixed #5880: Blog plugin failing when building a standalone blog</li> <li>Fixed #5881: Blog plugin not compatible with Python &lt; 3.10</li> </ul>"},{"location":"about/website/changelog/#9.2.1","title":"9.2.1 August 21, 2023","text":"<ul> <li>Fixed #5879: Blog plugin failing when building a standalone blog</li> <li>Fixed error in blog plugin when using draft tagging on future date</li> <li>Fixed error in blog plugin when toc extension is not enabled</li> </ul>"},{"location":"about/website/changelog/#9.2.0","title":"9.2.0 August 21, 2023","text":"<p>Additions and improvements</p> <ul> <li>Added blogging support via built-in blog plugin</li> <li>Added support for Chinese language segmentaiton in search plugin</li> <li>Added support for adding custom dates to blog posts</li> <li>Added support for paginating archive and category pages</li> <li>Added support for annotations (outside of code blocks)</li> <li>Added support for navigation icons</li> <li>Added support for navigation pruning</li> <li>Added support for navigation status</li> <li>Added support for customizing site icons</li> <li>Added support for customizing (code) annotation icons</li> <li>Added focus outline to admonitions and details</li> <li>Added prompt for bug report name to info plugin</li> <li>Added Luxembourgish translations</li> <li>Improved rendering of (code) annotation markers</li> <li>Improved print styles for (code) annotations</li> <li>Improved customizability of navigation tabs</li> <li>Improved interop of plugins with external tools like mike</li> <li>Improved interop of blog plugin with awesome pages plugin</li> <li>Improved header partial by moving buttons into separate partials</li> <li>Improved clarity of <code>site_url</code> warning in social plugin</li> <li>Improved blog plugin to automatically setup directory structure</li> <li>Switched info plugin to <code>importlib</code> to mitigate deprecations</li> <li>Automatically download ResizeObserver polyfill when necessary</li> <li>Automatically add iframe-worker polyfill when necessary in offline plugin</li> <li>Automatically focus and bring up keyboard on touch devices</li> <li>Updated Serbo-Croatian translations</li> <li>Updated MkDocs to 1.5.2</li> </ul> <p>Removals</p> <ul> <li>Removed Universal Analytics integration</li> <li>Removed ancient polyfills to reduce size of bundled JavaScript by 20%</li> <li>Removed necessity for <code>Array.flat</code> and <code>Array.flatMap</code> polyfill</li> <li>Removed announcement bar button when JavaScript is not available</li> </ul> <p>Fixes</p> <ul> <li>Fixed rendering of tags when announcement bar is present</li> <li>Fixed tags plugin rendering pages excluded by other plugins</li> <li>Fixed #5132: Blog plugin requires <code>nav</code> entry in <code>mkdocs.yml</code></li> <li>Fixed #5599: Insufficient contrast for default link color</li> <li>Fixed #5715: Blog plugin missing integrated table of contents in pagination</li> <li>Fixed #5806: Version selector not hoverable on some Android devices</li> <li>Fixed #5826: Blog post drafts with tags show up in tags index</li> </ul>"},{"location":"about/website/changelog/#9.1.21","title":"9.1.21 July 27, 2023","text":"<ul> <li>Fixed MkDocs 1.4 compat issue in social plugin (9.1.20 regression)</li> </ul>"},{"location":"about/website/changelog/#9.1.20","title":"9.1.20 July 27, 2023","text":"<ul> <li>Updated Sanskrit translations</li> <li>Fixed deprecation warnings for social plugin</li> </ul>"},{"location":"about/website/changelog/#9.1.19","title":"9.1.19 July 18, 2023","text":"<ul> <li>Added support for MkDocs 1.5+</li> <li>Fixed #5699: Improve error reporting in social plugin</li> </ul>"},{"location":"about/website/changelog/#9.1.18","title":"9.1.18 July 3, 2023","text":"<ul> <li>Updated Danish translations</li> <li>Added support for installing user requirements in Docker image</li> <li>Fixed #5655: Search separator with lookbehind breaks highlighting</li> </ul>"},{"location":"about/website/changelog/#9.1.17","title":"9.1.17 June 23, 2023","text":"<ul> <li>Fixed #5633: Code annotations with nested lists incorrectly mounted</li> <li>Fixed #5628: Regression in new social plugin configuration scheme</li> </ul>"},{"location":"about/website/changelog/#9.1.16","title":"9.1.16 June 15, 2023","text":"<ul> <li>Updated Indonesian translations</li> <li>Ensure scroll bar follows color scheme of operating system</li> </ul>"},{"location":"about/website/changelog/#9.1.15","title":"9.1.15 May 29, 2023","text":"<ul> <li>Fixed #5566: Indicate color scheme to operating system</li> <li>Fixed #5565: Update <code>Dockerfile</code> to latest version of base image</li> <li>Fixed #5554: Add additional version tags (<code>9</code>, <code>9.1</code>) to Docker image</li> <li>Fixed #5536: Strip tags of ARIA labels in table of contents</li> </ul>"},{"location":"about/website/changelog/#9.1.14","title":"9.1.14 May 20, 2023","text":"<ul> <li>Updated Armenian and Greek translations</li> </ul>"},{"location":"about/website/changelog/#9.1.13","title":"9.1.13 May 16, 2023","text":"<ul> <li>Fixed #5517: Social plugin crashes for some fonts (e.g. Open Sans)</li> </ul>"},{"location":"about/website/changelog/#9.1.12","title":"9.1.12 May 12, 2023","text":"<ul> <li>Updated Bengali (Bangla) translations</li> <li>Fixed #5503: Docker image publish errors on uppercase characters</li> <li>Fixed #5407: Auto-pause media when in hidden content tabs</li> </ul>"},{"location":"about/website/changelog/#9.1.11","title":"9.1.11 May 8, 2023","text":"<ul> <li>Fixed #5487: Social plugin crashes without options (9.1.10 regression)</li> </ul>"},{"location":"about/website/changelog/#9.1.10","title":"9.1.10 May 8, 2023","text":"<ul> <li>Added <code>cards_layout_options</code> setting for social cards</li> <li>Deprecated <code>cards_color</code> and <code>cards_font</code> setting for social cards</li> </ul>"},{"location":"about/website/changelog/#9.1.9","title":"9.1.9 May 2, 2023","text":"<ul> <li>Added Telugu, Kannada and Sanskrit translations</li> <li>Fixed #5428: Fixed margins for light/dark mode images in figures</li> <li>Fixed #5420: Social plugin crashing for some specific Google Fonts</li> <li>Fixed #5160: Instant loading makes code annotations jump (9.1.1 regression)</li> <li>Fixed #4920: Social plugin not loading logo from custom icon set</li> <li>Fixed social plugin crashing when only code font is specified</li> </ul>"},{"location":"about/website/changelog/#9.1.8","title":"9.1.8 April 24, 2023","text":"<ul> <li>Fixed #5417: Theme breaks when <code>palette</code> is not defined (9.1.7 regression)</li> </ul>"},{"location":"about/website/changelog/#9.1.7","title":"9.1.7 April 22, 2023","text":"<ul> <li>Updated Persian (Farsi) and Turkish translations</li> <li>Fixed #5401: Added missing flag to disable built-in tags plugin</li> <li>Fixed #5206: Ensure defaults are set for primary and accent colors</li> <li>Fixed unnecessary inclusion of palette CSS when unused</li> </ul>"},{"location":"about/website/changelog/#9.1.6","title":"9.1.6 April 7, 2023","text":"<ul> <li>Updated Persian (Farsi) translations</li> <li>Fixed #5300: Boxes in Mermaid sequence diagrams not color-abiding</li> </ul>"},{"location":"about/website/changelog/#9.1.5","title":"9.1.5 March 31, 2023","text":"<ul> <li>Updated Lithuanian and Japanese translations</li> <li>Updated Mermaid.js to version 9.4.3</li> <li>Fixed #5290: Footer previous/next labels cut-off for short page titles</li> </ul>"},{"location":"about/website/changelog/#9.1.4","title":"9.1.4 March 24, 2023","text":"<ul> <li>Fixed #5239: Instant loading breaks anchors in details (9.1.1 regression)</li> <li>Fixed #5211: Anchor following not working for Chinese (9.1.2 regression)</li> </ul>"},{"location":"about/website/changelog/#9.1.3","title":"9.1.3 March 14, 2023","text":"<ul> <li>Added Kurdish (Soran\u00ee) translations</li> <li>Updated Norwegian (Bokm\u00e5l), Portuguese and Romanian translations</li> <li>Improved compatibility with <code>mkdocs-jupyter</code> plugin</li> <li>Fixed #5198: Built-in search plugin not filtering <code>script</code> and <code>style</code> tags</li> <li>Fixed #5176: Back-to-top + instant loading not working (9.1.1 regression)</li> </ul>"},{"location":"about/website/changelog/#9.1.2","title":"9.1.2 March 9, 2023","text":"<ul> <li>Updated Icelandic, Korean and Swedish translations</li> <li>Fixed #5168: Mermaid text boxes overflow (9.0.13 regression)</li> <li>Fixed #5155: Table of contents not highlighting percent-encoded URLs</li> </ul>"},{"location":"about/website/changelog/#9.1.1","title":"9.1.1 March 5, 2023","text":"<ul> <li>Updated Czech and Thai translations</li> <li>Improved instant loading (scroll restoration, slow connections)</li> <li>Fixed #5023: Instant loading not allowing to go back to initial page</li> <li>Fixed #3797: Instant loading does not work with section anchors in Safari</li> </ul>"},{"location":"about/website/changelog/#9.1.0","title":"9.1.0 March 2, 2023","text":"<ul> <li>Docker image now available for <code>amd64</code>, <code>arm64</code> and <code>arm/v7</code></li> <li>Updated Chinese (Taiwanese) translations</li> <li>Generalized tag identifier implementation</li> <li>Fixed flickering of header shadow on load</li> <li>Fixed occasional flickering of announcement bar</li> </ul>"},{"location":"about/website/changelog/#9.0.15","title":"9.0.15 February 26, 2023","text":"<ul> <li>Updated Chinese (Traditional) translations</li> <li>Updated Hebrew translations</li> </ul>"},{"location":"about/website/changelog/#9.0.14","title":"9.0.14 February 23, 2023","text":"<ul> <li>Fixed #5072: Rendering bug on navigation expand button in Firefox</li> </ul>"},{"location":"about/website/changelog/#9.0.13","title":"9.0.13 February 18, 2023","text":"<ul> <li>Updated Uzbek translations</li> <li>Switched back to pre-9.0.0 headline detection in <code>content</code> partial</li> <li>Fixed #5062: Version warning not readable when using slate scheme</li> <li>Fixed #5061: Improved discernibility of table row hover color</li> <li>Fixed #5034: Sequence actors in Mermaid diagrams not color-abiding</li> <li>Fixed #4919: Allow to hide version warning in multiple versions</li> </ul>"},{"location":"about/website/changelog/#9.0.12","title":"9.0.12 February 9, 2023","text":"<ul> <li>Updated Catalan translations</li> <li>Fixed #4975: Mermaid entity relationship rendering diagrams bug</li> <li>Fixed #4924: Header title not reset when using instant loading</li> </ul>"},{"location":"about/website/changelog/#9.0.11","title":"9.0.11 February 3, 2023","text":"<ul> <li>Added Mastodon verification for social links (<code>rel=me</code>)</li> <li>Updated Italian translations</li> </ul>"},{"location":"about/website/changelog/#9.0.10","title":"9.0.10 February 2, 2023","text":"<ul> <li>Updated Arabic translations</li> <li>Updated Korean translations</li> <li>Updated Hungarian translations</li> <li>Updated Russian translations</li> <li>Fixed #4977: Improved accessibility for content tabs</li> <li>Fixed #4960: Sometimes anchor following doesn't bring last item into view</li> </ul>"},{"location":"about/website/changelog/#9.0.9","title":"9.0.9 January 30, 2023","text":"<ul> <li>Updated Bulgarian translations</li> <li>Updated Chinese (Simplified) translations</li> <li>Updated Dutch translations</li> <li>Updated Hindi translations</li> <li>Updated Japanese translations</li> <li>Updated Polish translations</li> </ul>"},{"location":"about/website/changelog/#9.0.8","title":"9.0.8 January 29, 2023","text":"<ul> <li>Updated Croatian translations</li> <li>Updated French translations</li> <li>Updated Hungarian translations</li> <li>Updated Portuguese (Brasilian) translations</li> <li>Updated Spanish translations</li> <li>Updated Ukrainian translations</li> <li>Updated Urdu translations</li> <li>Updated Vietnamese translations</li> </ul>"},{"location":"about/website/changelog/#9.0.7","title":"9.0.7 January 28, 2023","text":"<ul> <li>Improved accessibility of sidebar navigation</li> <li>Moved all translations into Community edition</li> <li>Updated Polish and Portuguese (Brasilian) translations</li> <li>Fixed info plugin terminating on subsequent reload when serving</li> <li>Fixed #4910: Sidebar navigation labels have invalid ARIA roles</li> <li>Fixed #4884: Search query terms can't be separated by colons</li> </ul>"},{"location":"about/website/changelog/#9.0.6","title":"9.0.6 January 19, 2023","text":"<ul> <li>Fixed #4883: Automatically disable info plugin when serving</li> <li>Fixed #4885: Search plugin crashes in some exotic cases (9.0.3 regression)</li> </ul>"},{"location":"about/website/changelog/#9.0.5","title":"9.0.5 January 14, 2023","text":"<ul> <li>Fixed #4842: Improved accessibility of search result list</li> </ul>"},{"location":"about/website/changelog/#9.0.4","title":"9.0.4 January 12, 2023","text":"<ul> <li>Fixed #4823: Improved contrast ratio in footer (9.0.2 regression)</li> <li>Fixed #4832: Set navigation items back to black (9.0.3 regression)</li> <li>Fixed #4843: Emojis broken due to maxcdn.com shutting down</li> <li>Upgraded Python Markdown Extensions to 9.9.1</li> </ul>"},{"location":"about/website/changelog/#9.0.3","title":"9.0.3 January 8, 2023","text":"<ul> <li>Improved discernibility of section index pages in navigation</li> <li>Improved collapsing of adjacent whitespace in search plugin</li> <li>Updated Indonesian translations</li> <li>Fixed view source of this page button when edit URL points to blob</li> <li>Fixed #4829: Search overlay does not close for active anchor result</li> <li>Fixed #4824: Search plugin crashes for <code>h[1-6]</code> contained in other elements</li> <li>Fixed #4804: Nested navigation items not expandable with keyboard</li> <li>Fixed #4689: anchor tracking not working for anchors in tables</li> <li>Upgraded to Mermaid 9.3.0</li> </ul>"},{"location":"about/website/changelog/#9.0.2","title":"9.0.2 January 4, 2023","text":"<ul> <li>Fixed #4823: Improved contrast ratio in footer to meet WCAG guidelines</li> <li>Fixed #4819: Social plugin crashes when card generation is disabled</li> <li>Fixed #4817: Search plugin crashes on numeric page titles in <code>nav</code></li> </ul>"},{"location":"about/website/changelog/#9.0.1","title":"9.0.1 January 3, 2023","text":"<ul> <li>Removed <code>pipdeptree</code> dependency for built-in info plugin</li> <li>Fixed appearance of linked tags when hovered (9.0.0 regression)</li> <li>Fixed #4810: Abbreviations run out of screen on touch devices</li> <li>Fixed #4813: View source and edit button links are the same</li> </ul>"},{"location":"about/website/changelog/#9.0.0","title":"9.0.0 January 2, 2023","text":"<p>Additions and improvements</p> <ul> <li>Added support for rich search previews</li> <li>Added support for tokenizer lookahead</li> <li>Added support for better search highlighting</li> <li>Added support for excluding content from search</li> <li>Added support for configurable search pipeline</li> <li>Added support for offline search via offline plugin</li> <li>Added support for multiple instances of built-in tags plugin</li> <li>Added support for removing copy-to-clipboard button</li> <li>Added support for removing footer navigation</li> <li>Added support for button to view the source of a page</li> <li>Improved readability of query string for search sharing</li> <li>Improved stability of search plugin when using <code>--dirtyreload</code></li> <li>Improved search result group button, now sticky and stable</li> <li>Updated Norwegian translations</li> <li>Updated MkDocs to 1.4.2</li> </ul> <p>Removals</p> <ul> <li>Removed deprecated alternative admonition qualifiers</li> <li>Removed <code>:is()</code> selectors (in output) for easier overriding</li> <li>Removed <code>.title</code> suffix on translations</li> <li>Removed legacy method for providing page title in feedback URL</li> <li>Removed support for indexing only titles in search</li> <li>Removed support for custom search transforms</li> <li>Removed support for custom search workers</li> <li>Removed temporary snow feature (easter egg)</li> </ul> <p>Fixes</p> <ul> <li>Fixed Norwegian and Korean language code</li> <li>Fixed detection of composition events in search interface</li> <li>Fixed search plugin not using title set via front matter</li> <li>Fixed search highlighting of tags</li> <li>Fixed search sharing URL using post transformed string</li> <li>Fixed theme-color meta tag getting out-of-sync with palette toggle</li> <li>Fixed prev/next page keyboard navigation when footer is not present</li> <li>Fixed overflowing navigation tabs not being scrollable</li> <li>Fixed inclusion of code block line numbers from search</li> </ul>"},{"location":"about/website/changelog/#8.5.11","title":"8.5.11 November 30, 2022","text":"<ul> <li>Let it snow, see https://twitter.com/squidfunk/status/1597939243090788352</li> </ul>"},{"location":"about/website/changelog/#8.5.10","title":"8.5.10 November 11, 2022","text":"<ul> <li>Adjusted CSS to better allow for custom primary and accent colors</li> <li>Fixed #4620: Primary color is not applied (8.5.9 regression)</li> </ul>"},{"location":"about/website/changelog/#8.5.9","title":"8.5.9 November 8, 2022","text":"<ul> <li>Fixed #4600: Illegible link colors for black and white primary colors</li> <li>Fixed #4594: Need to set schema to change link color</li> </ul>"},{"location":"about/website/changelog/#8.5.8","title":"8.5.8 November 3, 2022","text":"<ul> <li>Added support for always showing settings in cookie consent</li> <li>Fixed #4571: Buttons invisible if primary color is <code>white</code> or <code>black</code></li> <li>Fixed #4517: Illegible note in sequence diagram when using <code>slate</code> scheme</li> </ul>"},{"location":"about/website/changelog/#8.5.7","title":"8.5.7 October 22, 2022","text":"<ul> <li>Deprecated additional admonition qualifiers to reduce size of CSS</li> <li>Fixed #4511: Search boost does not apply to sections</li> </ul>"},{"location":"about/website/changelog/#8.5.6","title":"8.5.6 October 2, 2022","text":"<ul> <li>Modernized appearance of admonitions (with fallback, see docs)</li> <li>Improved appearance of inline code blocks in admonition titles</li> </ul>"},{"location":"about/website/changelog/#8.5.5","title":"8.5.5 October 1, 2022","text":"<ul> <li>Updated MkDocs to 1.4</li> <li>Fixed compatibility issues with MkDocs 1.4</li> <li>Fixed #4430: build error when enabling consent without repository URL</li> </ul>"},{"location":"about/website/changelog/#8.5.4","title":"8.5.4 September 30, 2022","text":"<ul> <li>Fixed expand icons shift on sidebar overflow (using <code>scrollbar-gutter</code>)</li> <li>Fixed #4429: Text in sequence diagrams overflows in Firefox</li> </ul>"},{"location":"about/website/changelog/#8.5.3","title":"8.5.3 September 20, 2022","text":"<ul> <li>Fixed build error when enabling cookie consent without analytics</li> <li>Fixed #4381: Code blocks render ligatures for some fonts</li> </ul>"},{"location":"about/website/changelog/#8.5.2","title":"8.5.2 September 18, 2022","text":"<ul> <li>Updated Mermaid.js to version 9.1.7</li> <li>Fixed overly large headlines in search results (8.5.0 regression)</li> <li>Fixed #4358: Navigation sections appear as clickable (8.5.0 regression)</li> <li>Fixed #4356: GitHub repository statistics fetched before cookie consent</li> </ul>"},{"location":"about/website/changelog/#8.5.1","title":"8.5.1 September 15, 2022","text":"<ul> <li>Fixed #4366: Removed dependencies with native extensions</li> </ul>"},{"location":"about/website/changelog/#8.5.0","title":"8.5.0 September 13, 2022","text":"<ul> <li>Added support for social cards</li> <li>Added support for code annotation anchor links (deep linking)</li> <li>Added support for code annotation comment stripping (syntax modifier)</li> <li>Added support for sidebars scrolling automatically to active item</li> <li>Added support for anchor following table of contents (= auto scroll)</li> <li>Added support for tag icons</li> </ul>"},{"location":"about/website/changelog/#8.4.4","title":"8.4.4 September 12, 2022","text":"<ul> <li>Moved comments integration to separate partial (<code>comments.html</code>)</li> </ul>"},{"location":"about/website/changelog/#8.4.3","title":"8.4.3 September 7, 2022","text":"<ul> <li>Added Simple Icons to bundled icons (+2,300 icons)</li> <li>Added support for changing edit icon</li> <li>Moved page actions to separate partial (<code>actions.html</code>)</li> <li>Fixed #4291: Version switching doesn't stay on page when anchors are used</li> <li>Fixed #4327: Links in data tables do not receive link styling</li> </ul>"},{"location":"about/website/changelog/#8.4.2","title":"8.4.2 August 27, 2022","text":"<ul> <li>Updated Slovenian translations</li> <li>Fixed #4277: Feedback widget hidden after navigation with instant loading</li> <li>Fixed numeric tags in front matter breaking search functionality</li> </ul>"},{"location":"about/website/changelog/#8.4.1","title":"8.4.1 August 21, 2022","text":"<ul> <li>Updated Croatian and Hebrew translations</li> </ul>"},{"location":"about/website/changelog/#8.4.0","title":"8.4.0 August 13, 2022","text":"<ul> <li>Added support for cookie consent</li> <li>Added support for feedback widget (Was this page helpful?)</li> <li>Added support for dismissible announcement bar</li> <li>Added Armenian, Lithuanian, Tagalog, and Urdu translations</li> </ul>"},{"location":"about/website/changelog/#8.3.9","title":"8.3.9 July 4, 2022","text":"<ul> <li>Updated Taiwanese translations for search</li> <li>Allow ids for content tabs with special characters (for mkdocstrings)</li> <li>Fixed #4083: home not clickable when using versioning (8.3.5 regression)</li> </ul>"},{"location":"about/website/changelog/#8.3.8","title":"8.3.8 June 24, 2022","text":"<ul> <li>Fixed #4053: Limit width of videos to content area</li> <li>Fixed empty tags in front matter breaking search</li> </ul>"},{"location":"about/website/changelog/#8.3.7","title":"8.3.7 June 22, 2022","text":"<ul> <li>Fixed search being stuck initializing when using tags (8.3.4 regression)</li> </ul>"},{"location":"about/website/changelog/#8.3.6","title":"8.3.6 June 16, 2022","text":"<ul> <li>Fixed #4028: Links not clickable when using versioning (8.3.5 regression)</li> </ul>"},{"location":"about/website/changelog/#8.3.5","title":"8.3.5 June 14, 2022","text":"<ul> <li>Fixed #4012: Stay on page not working for alias of active version</li> </ul>"},{"location":"about/website/changelog/#8.3.4","title":"8.3.4 June 11, 2022","text":"<ul> <li>Fixed #4004: Tags with multiple words not searchable</li> </ul>"},{"location":"about/website/changelog/#8.3.3","title":"8.3.3 June 7, 2022","text":"<ul> <li>Fixed #4000: Mermaid diagrams too dark in dark mode (8.3.0 regression)</li> </ul>"},{"location":"about/website/changelog/#8.3.2","title":"8.3.2 June 5, 2022","text":"<ul> <li>Fixed #3987: Custom admonition icons don't work when defining color palette</li> </ul>"},{"location":"about/website/changelog/#8.3.1","title":"8.3.1 June 4, 2022","text":"<ul> <li>Bump required Jinja version to 3.0.2</li> <li>Removed unnecessary conditions in templates</li> <li>Fixed scroll offset when content tabs are brought into view</li> <li>Fixed #3977: Content tabs snapping oddly in Firefox</li> <li>Fixed #3983: Missing condition in footer partial (8.3.0 regression)</li> </ul>"},{"location":"about/website/changelog/#8.3.0","title":"8.3.0 June 2, 2022","text":"<ul> <li>Added support for custom admonition icons</li> <li>Added support for linking of content tabs</li> <li>Added support for boosting pages in search</li> <li>Added support for hiding footer navigation</li> <li>Added previous/next indicators to content tabs</li> <li>Improved typeset link colors in light and dark modes</li> </ul>"},{"location":"about/website/changelog/#8.2.16","title":"8.2.16 May 28, 2022","text":"<ul> <li>Fixed #3957: Only animate code annotations when visible (save CPU cycles)</li> </ul>"},{"location":"about/website/changelog/#8.2.15","title":"8.2.15 May 14, 2022","text":"<ul> <li>Added Uzbek translations</li> <li>Fixed spacing for code block results in content tabs</li> </ul>"},{"location":"about/website/changelog/#8.2.14","title":"8.2.14 May 8, 2022","text":"<ul> <li>Fixed missing top right rounded border on admonition</li> <li>Fixed #3886: <code>4xx</code> status codes not handled when using instant loading</li> </ul>"},{"location":"about/website/changelog/#8.2.13","title":"8.2.13 May 2, 2022","text":"<ul> <li>Fixed #3865: Tags index links to tagged pages 404 on Windows</li> <li>Fixed #3866: Bump required Python version from 3.6+ to 3.7+</li> </ul>"},{"location":"about/website/changelog/#8.2.12","title":"8.2.12 April 30, 2022","text":"<ul> <li>Added support for GitHub-style hash fragments for dark/light images</li> <li>Improved rendering of nested code blocks in content tabs and annotations</li> <li>Fixed #3862: Upgraded to latest Pygments and Python Markdown Extensions</li> </ul>"},{"location":"about/website/changelog/#8.2.11","title":"8.2.11 April 25, 2022","text":"<ul> <li>Temporarily pinned Pygments to <code>&lt;2.12</code></li> <li>Temporarily pinned Python Markdown Extensions to <code>&lt;9.4</code></li> <li>Improved rendering of code annotation markers</li> </ul>"},{"location":"about/website/changelog/#8.2.10","title":"8.2.10 April 24, 2022","text":"<ul> <li>Added Macedonian translations</li> <li>Updated Mermaid.js to version 9.0.1</li> <li>Switched sidebar title in mobile navigation to bold font</li> <li>Fixed color of arrows in class and state diagrams for dark mode</li> <li>Fixed #3836: Inline admonitions overlayed by code block titles</li> </ul>"},{"location":"about/website/changelog/#8.2.9","title":"8.2.9 April 8, 2022","text":"<ul> <li>Mitigate flicker on color palette switch by disabling all transitions</li> <li>Fixed search suggestions not triggered when following deep link</li> <li>Fixed incorrectly computed header height when using instant loading</li> <li>Fixed #3782: Admonition titles have extra pixels on wide screens in Firefox</li> <li>Fixed #3802: Always render table of contents container (except when hidden)</li> </ul>"},{"location":"about/website/changelog/#8.2.8","title":"8.2.8 March 27, 2022","text":"<ul> <li>Bumped MkDocs version to 1.3.0 to mitigate breaking changes in Jinja</li> <li>Reverted Jinja version range limitation (added in 8.2.7)</li> <li>Improved styling of annotations and fixed borders of code blocks in tabs</li> <li>Added background color to code blocks in focused/hovered links</li> <li>Added check in tags plugin whether tags overview page exists</li> <li>Fixed #3744: Content tab indicator on wrong position when using back button</li> </ul>"},{"location":"about/website/changelog/#8.2.7","title":"8.2.7 March 24, 2022","text":"<ul> <li>Temporarily limit Jinja version range to &lt; 3.1 due to breaking changes</li> </ul>"},{"location":"about/website/changelog/#8.2.6","title":"8.2.6 March 23, 2022","text":"<ul> <li>Fixed #3695: Deprecation warning for unescaped backslashes in templates</li> <li>Fixed #3696: Annotations not mounted in some Terraform code blocks</li> <li>Fixed #3698: Annotations not mounted in long code blocks (8.2.5 regression)</li> </ul>"},{"location":"about/website/changelog/#8.2.5","title":"8.2.5 March 6, 2022","text":"<ul> <li>Fixed #3596: Mermaid not working when headline with name 'Mermaid' present</li> <li>Fixed #3643: Reduce time to render pages with thousands of code blocks</li> <li>Fixed #3665: Missing styles for Mermaid.js flowcharts cluster labels</li> </ul>"},{"location":"about/website/changelog/#8.2.4","title":"8.2.4 March 2, 2022","text":"<ul> <li>Fixed malformed Google Fonts URL when a font setting was omitted</li> <li>Fixed #3648: Fixed specificity issue with admonitions in lists</li> <li>Fixed #3653: Invalid outdated version banner URL when using instant loading</li> </ul>"},{"location":"about/website/changelog/#8.2.3","title":"8.2.3 February 27, 2022","text":"<ul> <li>Fixed #3578: Active element in table of contents off-by-one on large screens</li> </ul>"},{"location":"about/website/changelog/#8.2.2","title":"8.2.2 February 26, 2022","text":"<ul> <li>Added automatic removal of query parameter when search is closed</li> <li>Fixed #3599: Anchors always overridden when using navigation tracking</li> </ul>"},{"location":"about/website/changelog/#8.2.1","title":"8.2.1 February 17, 2022","text":"<ul> <li>Fixed module <code>material.plugins</code> not being found (8.2.0 regression)</li> </ul>"},{"location":"about/website/changelog/#8.2.0","title":"8.2.0 February 17, 2022","text":"<ul> <li>Added native support for Mermaid.js diagrams</li> <li>Added native support for tags (with search integration)</li> <li>Added support for staying on page when switching versions</li> </ul>"},{"location":"about/website/changelog/#8.1.11","title":"8.1.11 February 10, 2022","text":"<ul> <li>Added Portuguese (Brasilian) translations</li> <li>Updated FontAwesome to v6 \u2013 check which icons were renamed here</li> <li>Fixed #3545: Color palette toggle and search overlaying version selector</li> </ul>"},{"location":"about/website/changelog/#8.1.10","title":"8.1.10 February 6, 2022","text":"<ul> <li>Fixed cutoff of very wide logos in the sidebar on mobile</li> </ul>"},{"location":"about/website/changelog/#8.1.9","title":"8.1.9 January 30, 2022","text":"<ul> <li>[Added support for <code>mkdocs.yml</code> validation and auto-complete][validation]</li> <li>Fixed errors in Latvian translations</li> </ul>"},{"location":"about/website/changelog/#8.1.8","title":"8.1.8 January 23, 2022","text":"<ul> <li>Added Latvian translations</li> <li>Updated Giscus example integration with dynamic theme change support</li> <li>Fixed #3479: Back-to-top button not hidden when using sticky navigation tabs</li> <li>Fixed #3491: Logo in header and drawer doesn't honor aspect ratio</li> </ul>"},{"location":"about/website/changelog/#8.1.7","title":"8.1.7 January 16, 2022","text":"<ul> <li>Improved back-to-top button behavior - now not shown on anchor jump</li> </ul>"},{"location":"about/website/changelog/#8.1.6","title":"8.1.6 January 11, 2022","text":"<ul> <li>Fixed spacing of blockquotes (8.1.5 regression)</li> <li>Fixed edge cases for rounded corners on code blocks (8.1.5 regression)</li> <li>Fixed issues with code annotation line heights</li> </ul>"},{"location":"about/website/changelog/#8.1.5","title":"8.1.5 January 9, 2022","text":"<ul> <li>Improved browser support: Chrome 49+, Safari 10+, Firefox 53+, Edge 79+</li> <li>Improved rendering of inline code blocks in headlines</li> <li>Added Bahasa Malaysian translations</li> <li>Fixed #3354: MathJax formulas show vertical scrollbar</li> </ul>"},{"location":"about/website/changelog/#8.1.4","title":"8.1.4 January 2, 2022","text":"<ul> <li>Added indicator to navigation expander icon</li> <li>Improved support for reduced motion preference</li> <li>Fixed jitter of active content tab indicator</li> </ul>"},{"location":"about/website/changelog/#8.1.3","title":"8.1.3 December 19, 2021","text":"<ul> <li>Added animation to active content tab indicator</li> <li>Fixed #3360: Highlighted lines add blank lines in copied text</li> <li>Fixed usage of subsequent index files when using section index pages</li> </ul>"},{"location":"about/website/changelog/#8.1.2","title":"8.1.2 December 15, 2021","text":"<ul> <li>Switched CSS sources to logical properties</li> <li>Added transformation of logical properties to <code>ltr</code>/<code>rtl</code> equivalents</li> <li>Fixed spacing for admonitions inside lists (8.1.1 regression)</li> </ul>"},{"location":"about/website/changelog/#8.1.1","title":"8.1.1 December 13, 2021","text":"<ul> <li>Added support for <code>#only-light</code> and <code>#only-dark</code> image hash fragments</li> <li>Fixed copy-to-clipboard adding blank lines when using line anchors</li> <li>Fixed code annotation directionality for right-to-left languages</li> <li>Fixed header title positioning for right-to-left languages</li> <li>Fixed admonition borders for right-to-left languages (8.0.0 regression)</li> <li>Fixed footer navigation link positioning (8.0.0 regression)</li> <li>Fixed footer navigation title breaking out of container when too long</li> <li>Fixed shrinking arrow in navigation title when too long</li> <li>Fixed #3343: Filtered stopwords appear as missing search terms</li> <li>Fixed #3346: Site unusable due to usage of <code>:not()</code> (Firefox 78 ESR)</li> </ul>"},{"location":"about/website/changelog/#8.1.0","title":"8.1.0 December 10, 2021","text":"<ul> <li>Added basic support for code block line anchors</li> <li>Switched code annotation markers to <code>+</code> signs to improve usability</li> <li>Switched main site title to bold font</li> <li>Improved admonition icon positioning to align when <code>font-size</code> is increased</li> <li>Improved and simplified footnotes CSS</li> <li>Improved and simplified code annotation positioning</li> <li>Fixed syntax error in Russian translations</li> </ul>"},{"location":"about/website/changelog/#8.0.5","title":"8.0.5 December 6, 2021","text":"<ul> <li>Fixed #3302: Footer refactoring induced ellipsis in some browsers</li> <li>Fixed #3313: Details always rendered closed on load (8.0.4 regression)</li> </ul>"},{"location":"about/website/changelog/#8.0.4","title":"8.0.4 December 4, 2021","text":"<ul> <li>Improved support for deeply nested code annotations</li> <li>Improved code annotation and copy-to-clipboard interop</li> <li>Improved styling for code annotations inside admonitions</li> <li>Fixed #3274: Invalid anchor positioning when using instant loading</li> <li>Fixed #3294: Lists after code blocks without code annotations disappearing</li> <li>Fixed several positioning issues for code annotations</li> <li>Fixed JavaScript source map roots</li> </ul>"},{"location":"about/website/changelog/#8.0.3","title":"8.0.3 December 2, 2021","text":"<ul> <li>Removed deprecated <code>google_analytics</code> setting (was forgotten in 8.0.0)</li> <li>Fixed syntax error in Swedish and Polish translations</li> <li>Fixed #3283: Invalid back-to-top button position with sticky navigation tabs</li> <li>Fixed #3285: Default details marker showing due to Safari bug</li> </ul>"},{"location":"about/website/changelog/#8.0.2","title":"8.0.2 November 30, 2021","text":"<ul> <li>Fixed #3275: Code annotations always disappear on click</li> </ul>"},{"location":"about/website/changelog/#8.0.1","title":"8.0.1 November 28, 2021","text":"<ul> <li>Improved rendering of code annotation markers</li> <li>Fixed #3265: Wrong margin on nested admonitions</li> <li>Fixed wrong <code>box-sizing</code> for code annotations in details</li> </ul>"},{"location":"about/website/changelog/#8.0.0","title":"8.0.0 November 28, 2021","text":"<ul> <li>Added support for code annotations</li> <li>Added support for anchor tracking</li> <li>Added support for version warning</li> <li>Added <code>copyright</code> partial for easier override</li> <li>Removed deprecated content tabs legacy implementation</li> <li>Removed deprecated <code>seealso</code> admonition type</li> <li>Removed deprecated <code>site_keywords</code> setting (unsupported by MkDocs)</li> <li>Removed deprecated prebuilt search index support</li> <li>Removed deprecated web app manifest \u2013 use customization</li> <li>Removed <code>extracopyright</code> variable \u2013 use new <code>copyright</code> partial</li> <li>Removed Disqus integration \u2013 use customization</li> <li>Switched to <code>:is()</code> selectors for simple selector lists</li> <li>Switched autoprefixer from <code>last 4 years</code> to <code>last 2 years</code></li> <li>Improved CSS overall to match modern standards</li> <li>Improved CSS variable semantics for fonts</li> <li>Improved extensibility by restructuring partials</li> <li>Improved handling of <code>details</code> when printing</li> <li>Improved keyboard navigation for footnotes</li> <li>Fixed #3214: Search highlighting breaks site when empty</li> </ul>"},{"location":"about/website/changelog/#7.3.6","title":"7.3.6 October 30, 2021","text":"<ul> <li>Added support for adding titles to code blocks</li> </ul>"},{"location":"about/website/changelog/#7.3.5","title":"7.3.5 October 27, 2021","text":"<ul> <li>Added support for setting table of contents title via <code>mkdocs.yml</code></li> <li>Fixed back-to-top button position for right-to-left languages</li> </ul>"},{"location":"about/website/changelog/#7.3.4","title":"7.3.4 October 17, 2021","text":"<ul> <li>Bumped MkDocs version to 1.2.3 to mitigate CVE-2021-40978</li> <li>Fixed spacing issues when using integrate table of contents with tabs</li> <li>Fixed some spacings issues for right-to-left languages</li> <li>Fixed race condition in search initialization</li> </ul>"},{"location":"about/website/changelog/#7.3.3","title":"7.3.3 October 11, 2021","text":"<ul> <li>Rewrite of entire documentation</li> <li>Adjusted height of new content tabs to match single line code blocks</li> <li>Fixed new content tabs missing right padding in some browsers on overflow</li> <li>Fixed new content tabs bleeding out of flex container on overflow</li> <li>Fixed new content tabs overflow scrolling bugs on some browsers</li> <li>Fixed new content tabs stealing keyboard access when active</li> <li>Fixed some spacings issues for right-to-left languages</li> </ul>"},{"location":"about/website/changelog/#7.3.2","title":"7.3.2 October 6, 2021","text":"<ul> <li>Deprecated prebuilding of search index</li> <li>Improved graceful handling of broken search for <code>file://</code></li> <li>Added minimum Jinja version to list of requirements</li> <li>Fixed #3071: Section index pages render empty directories</li> <li>Fixed margin issues when using navigation tabs (7.3.1 regression)</li> <li>Fixed search placeholder sometimes being shown too early</li> </ul>"},{"location":"about/website/changelog/#7.3.1","title":"7.3.1 October 2, 2021","text":"<ul> <li>Added new experimental content tabs implementation</li> <li>Fixed #3069: GitHub stats broken for users/orgs (7.1.0 regression)</li> <li>Fixed #3070: Sections not linking to index page</li> <li>Fixed title not linking to index page when using tabs</li> <li>Fixed Disqus integration when using instant loading</li> <li>Fixed some spacing issues for right-to-left languages</li> <li>Fixed syntax error in Serbian translations</li> </ul>"},{"location":"about/website/changelog/#7.3.0","title":"7.3.0 September 23, 2021","text":"<ul> <li>Added support for sticky navigation tabs</li> <li>Added support for section index pages</li> <li>Added support for removing generator notice</li> </ul>"},{"location":"about/website/changelog/#7.2.8","title":"7.2.8 September 20, 2021","text":"<ul> <li>Fixed #3039: Search modal overlays menu on mobile (7.2.7 regression)</li> </ul>"},{"location":"about/website/changelog/#7.2.7","title":"7.2.7 September 19, 2021","text":"<ul> <li>Updated Serbian and Serbo-Croatian translations</li> <li>Improved appearance of outline on details</li> <li>Fixed #2934: Scrollbar when header is hidden on some mobile browsers</li> <li>Fixed #3032: Anchor in details doesn't open on load (7.0.0 regression)</li> <li>Fixed back-to-top button being focusable when invisible</li> <li>Fixed broken admonition icons (removed in upstream)</li> </ul>"},{"location":"about/website/changelog/#7.2.6","title":"7.2.6 September 1, 2021","text":"<ul> <li>Fixed rendering of <code>blockquote</code> elements (7.0.0 regression)</li> <li>Fixed #2973: Custom search worker setting ignored</li> </ul>"},{"location":"about/website/changelog/#7.2.5","title":"7.2.5 August 25, 2021","text":"<ul> <li>Updated Portuguese translations</li> <li>Fixed execution of RxJS teardown logic (7.2.3 regression)</li> <li>Fixed #2970: Search results show escaped characters (7.2.2 regression)</li> </ul>"},{"location":"about/website/changelog/#7.2.4","title":"7.2.4 August 11, 2021","text":"<ul> <li>Fixed #2926: Version selector not working (7.2.3 regression)</li> <li>Fixed #2929: Missing CSS class for banner (consistency with Insiders)</li> </ul>"},{"location":"about/website/changelog/#7.2.3","title":"7.2.3 August 9, 2021","text":"<ul> <li>Slight facelift of data tables, now closer to Material Design</li> <li>Fixed instant loading not respecting clicks on search results</li> <li>Fixed #2881: Invalid anchor offsets when using instant loading</li> </ul>"},{"location":"about/website/changelog/#7.2.2","title":"7.2.2 July 31, 2021","text":"<ul> <li>Updated Korean translations</li> <li>Fixed #2879: Search highlighting does not properly escape HTML</li> </ul>"},{"location":"about/website/changelog/#7.2.1","title":"7.2.1 July 25, 2021","text":"<ul> <li>Fixed #2862: Back-to-top button overlays active search bar</li> </ul>"},{"location":"about/website/changelog/#7.2.0","title":"7.2.0 July 21, 2021","text":"<ul> <li>Added support for search suggestions to save keystrokes</li> <li>Added support for search highlighting</li> <li>Added support for search sharing (i.e. deep linking)</li> </ul>"},{"location":"about/website/changelog/#7.1.11","title":"7.1.11 July 18, 2021","text":"<ul> <li>Updated Spanish and Galician translations</li> </ul>"},{"location":"about/website/changelog/#7.1.10","title":"7.1.10 July 10, 2021","text":"<ul> <li>Refactored appearance of back-to-top button</li> <li>Fixed graceful handling of search when browsing locally</li> </ul>"},{"location":"about/website/changelog/#7.1.9","title":"7.1.9 June 25, 2021","text":"<ul> <li>Improved search language support for Thai and Hindi</li> <li>Fixed #2761: License comments lined up at end of file</li> </ul>"},{"location":"about/website/changelog/#7.1.8","title":"7.1.8 June 12, 2021","text":"<ul> <li>Refactored analytics integration (because of MkDocs 1.2)</li> <li>Added support for Google Analytics 4 (<code>gtag.js</code>)</li> <li>Fixed missing escape for <code>aria-label</code> in footer links</li> </ul>"},{"location":"about/website/changelog/#7.1.7","title":"7.1.7 June 6, 2021","text":"<ul> <li>Improved screen reader support</li> </ul>"},{"location":"about/website/changelog/#7.1.6","title":"7.1.6 May 30, 2021","text":"<ul> <li>Deprecated <code>seealso</code> admonition qualifier</li> <li>Added Mongolian and updated Chinese translations</li> <li>Fixed #2429: Version selector not touch-friendly on Android devices</li> <li>Fixed #2703: Printed 'Initializing search' albeit ready on mobile</li> </ul>"},{"location":"about/website/changelog/#7.1.5","title":"7.1.5 May 19, 2021","text":"<ul> <li>Fixed #2655: Details breaking page margins on print</li> </ul>"},{"location":"about/website/changelog/#7.1.4","title":"7.1.4 May 6, 2021","text":"<ul> <li>Added support for git-revision-date-localized plugin creation date</li> <li>Improved footnote styles on <code>:target</code> and <code>:focus</code></li> </ul>"},{"location":"about/website/changelog/#7.1.3","title":"7.1.3 April 24, 2021","text":"<ul> <li>Fixed #2586: Empty table of contents shown (7.1.2 regression)</li> </ul>"},{"location":"about/website/changelog/#7.1.2","title":"7.1.2 April 18, 2021","text":"<ul> <li>Fixed #2554: List markers sometimes overlap floated elements</li> <li>Fixed #2563: Adding a class to a <code>h1</code> breaks the table of contents</li> <li>Fixed #2566: Back-to-top button clickable when invisible</li> </ul>"},{"location":"about/website/changelog/#7.1.1","title":"7.1.1 April 10, 2021","text":"<ul> <li>Fixed #2501: Nested definition lists compound bottom margin</li> <li>Fixed #2508: Switch <code>extracopyright</code> block to template variable</li> <li>Fixed #2533: Search (and other parts) not working in Safari &lt;14</li> <li>Fixed #2538: Visual quirk when opening language selector</li> </ul>"},{"location":"about/website/changelog/#7.1.0","title":"7.1.0 March 29, 2021","text":"<ul> <li>Added support for back-to-top button</li> <li>Added support for color palette toggle</li> <li>Added latest release to repository info (GitHub)</li> <li>Slight facelift of repository info (lighter fonts, spacing and icons)</li> </ul>"},{"location":"about/website/changelog/#7.0.7","title":"7.0.7 March 28, 2021","text":"<ul> <li>Updated Hungarian translations</li> <li>Fixed #2466: Docker image not based on latest Python and Alpine</li> <li>Fixed #2488: Inconsistent header shadow behavior</li> <li>Fixed #2492: Inline code blocks in admonition titles missing background</li> </ul>"},{"location":"about/website/changelog/#7.0.6","title":"7.0.6 March 14, 2021","text":"<ul> <li>Added trailing slash to version selector URL</li> <li>Added support for out-of-order anchors in table of contents</li> <li>Added <code>extra.homepage</code> option to link logo to arbitrary URL</li> <li>Improved security of Docker image (always update apk)</li> <li>Fixed horizontal spacing for nested inline admonitions</li> <li>Fixed text color of nested code blocks inside links</li> <li>Fixed version selector to always use version title</li> <li>Fixed logo link when using versioning with instant loading</li> </ul>"},{"location":"about/website/changelog/#7.0.5","title":"7.0.5 March 7, 2021","text":"<ul> <li>Added <code>extracopyright</code> block to allow for custom copyright info</li> <li>Fixed evaluation of third-party scripts when using instant loading</li> <li>Fixed edge cases when using instant loading without directory URLs</li> <li>Fixed handling of version selector when using instant loading</li> <li>Fixed regression with header title not being updated correctly</li> <li>Fixed expanded sections not opening on first click (7.0.4 regression)</li> </ul>"},{"location":"about/website/changelog/#7.0.4","title":"7.0.4 March 4, 2021","text":"<ul> <li>Added Icelandic translations</li> <li>Fixed #2386: Section close requires two clicks (navigation expansion)</li> <li>Fixed console error when search is disabled (7.0.0 regression)</li> <li>Fixed localsearch integration (7.0.0 regression)</li> </ul>"},{"location":"about/website/changelog/#7.0.3","title":"7.0.3 February 26, 2021","text":"<ul> <li>Fixed JavaScript errors in older browsers (target ES2020 -&gt; ES2015)</li> </ul>"},{"location":"about/website/changelog/#7.0.2","title":"7.0.2 February 25, 2021","text":"<ul> <li>Fixed #2343: Invalid source map URLs for JS and CSS files</li> <li>Fixed #2347: Version selector missing when using versioning</li> </ul>"},{"location":"about/website/changelog/#7.0.1","title":"7.0.1 February 24, 2021","text":"<ul> <li>Fixed #2334: Google Analytics triggers page view twice (7.0.0 regression)</li> <li>Fixed #2336: Details bleed into inline admonitions</li> <li>Fixed #2337: Images don't align correctly (7.0.0 regression)</li> </ul>"},{"location":"about/website/changelog/#7.0.0","title":"7.0.0 February 22, 2021","text":"<ul> <li>Added support for deploying multiple versions</li> <li>Added support for integrating a language selector</li> <li>Added support for rendering admonitions as inline blocks</li> <li>Rewrite of the underlying reactive architecture</li> <li>Removed Webpack in favor of reactive build strategy (-480 dependencies)</li> <li>Fixed keyboard navigation for code blocks after content tabs switch</li> </ul>"},{"location":"about/website/changelog/#6.2.8","title":"6.2.8 February 4, 2021","text":"<ul> <li>Updated Japanese and Polish translations</li> <li>Fixed #2261: Print dialog auto-closing when using instant loading</li> </ul>"},{"location":"about/website/changelog/#6.2.7","title":"6.2.7 January 31, 2021","text":"<ul> <li>Fixed #2251: Updated Docker image to latest Alpine Linux</li> </ul>"},{"location":"about/website/changelog/#6.2.6","title":"6.2.6 January 26, 2021","text":"<ul> <li>Added Bulgarian translations</li> <li>Fixed #2233: Search not shown when using header autohiding</li> </ul>"},{"location":"about/website/changelog/#6.2.5","title":"6.2.5 January 17, 2021","text":"<ul> <li>Fixed syntax error in Swedish translations</li> <li>Optimized navigation partials to improve build speed for huge docs</li> </ul>"},{"location":"about/website/changelog/#6.2.4","title":"6.2.4 January 9, 2021","text":"<ul> <li>Fixed #2156: Missing syntax highlighting for binary numbers</li> <li>Fixed #2186: Disqus showing on 404 page</li> </ul>"},{"location":"about/website/changelog/#6.2.3","title":"6.2.3 December 27, 2020","text":"<ul> <li>Added back hidden overflow on root container</li> <li>Fixed #2142: MathJax formulas sometimes have vertical scrollbars</li> </ul>"},{"location":"about/website/changelog/#6.2.2","title":"6.2.2 December 22, 2020","text":"<ul> <li>Removed Markdown version range limit (6.2.0 regression)</li> </ul>"},{"location":"about/website/changelog/#6.2.1","title":"6.2.1 December 22, 2020","text":"<ul> <li>Fixed all import and asset paths in templates (6.2.0 regression)</li> <li>Downgraded webpack-asset-manifest-plugin - broke all asset paths</li> </ul>"},{"location":"about/website/changelog/#6.2.0","title":"6.2.0 December 22, 2020","text":"<ul> <li>Added support for navigation sections</li> <li>Added support for navigation expansion</li> <li>Added support for integrating table of contents into navigation</li> <li>Added support for autohiding header on scroll</li> <li>Added support for hiding navigation and table of contents per page</li> <li>Added support for arbitrary items in navigation tabs</li> <li>Refactored navigation tabs to simplify grouping behavior</li> <li>Fixed anchor offset for permalinks in Safari (partial revert)</li> <li>Fixed #2098: Active tab sometimes not highlighted correctly</li> <li>Improved appearance for horizontal rulers</li> <li>Improved Spanish and Swedish translations</li> </ul>"},{"location":"about/website/changelog/#6.1.7","title":"6.1.7 December 6, 2020","text":"<ul> <li>Fixed #2081: Fixed stats for private GitHub repositories</li> <li>Fixed alignment for admonition icon alignment for right-to-left languages</li> </ul>"},{"location":"about/website/changelog/#6.1.6","title":"6.1.6 November 22, 2020","text":"<ul> <li>Fixed #2048: Math formulas show scrollbars (Windows)</li> </ul>"},{"location":"about/website/changelog/#6.1.5","title":"6.1.5 November 15, 2020","text":"<ul> <li>Fixed search reset button not showing/hiding correctly</li> </ul>"},{"location":"about/website/changelog/#6.1.4","title":"6.1.4 November 7, 2020","text":"<ul> <li>Fixed sidebar jitter when scrolling footer into view</li> </ul>"},{"location":"about/website/changelog/#6.1.3","title":"6.1.3 November 5, 2020","text":"<ul> <li>Added support for keywords <code>meta</code> tag</li> <li>Fixed #2027: Line numbers don't scale with smaller font size</li> <li>Fixed link colors for black and white on <code>slate</code> color scheme</li> <li>Removed focus outline on scrolling code blocks for pointer devices</li> </ul>"},{"location":"about/website/changelog/#6.1.2","title":"6.1.2 October 31, 2020","text":"<ul> <li>Fixed sizing of icons in admonitions, task lists, etc. (6.1.1 regression)</li> </ul>"},{"location":"about/website/changelog/#6.1.1","title":"6.1.1 October 31, 2020","text":"<ul> <li>Fixed #2019: Page title not correctly updated when using instant loading</li> </ul>"},{"location":"about/website/changelog/#6.1.0","title":"6.1.0 October 17, 2020","text":"<ul> <li>Fixed #1973: Added support for printing in dark mode</li> <li>Fixed #1974: Added support for printing content tabs</li> <li>Fixed #1995: Improved customizability of details extension</li> </ul>"},{"location":"about/website/changelog/#6.0.2","title":"6.0.2 October 4, 2020","text":"<ul> <li>Added Georgian translations</li> <li>Added escaping for link <code>title</code> attributes where necessary</li> <li>Fixed #1956: Pages with whitespace in names have invalid links in search</li> <li>Removed unnecessary (duplicated) link <code>title</code> attributes</li> </ul>"},{"location":"about/website/changelog/#6.0.1","title":"6.0.1 September 26, 2020","text":"<ul> <li>Fixed stemmer support for <code>file://</code> protocol through <code>iframe-worker</code></li> <li>Fixed details marker showing for search result in Firefox</li> <li>Fixed tabbing behavior when search query is not empty</li> <li>Switched TypeScript compilation target to ES2015</li> <li>Reduced size of JavaScript by 30% (<code>176kb</code> \u2192 <code>124kb</code>)</li> <li>Removed <code>mkdocs</code> and <code>readthedocs</code> themes from Docker image</li> </ul>"},{"location":"about/website/changelog/#6.0.0","title":"6.0.0 September 25, 2020","text":"<ul> <li>Improved search result look and feel</li> <li>Improved search result stability while typing</li> <li>Improved search result grouping (pages + headings)</li> <li>Improved search result relevance and scoring</li> <li>Added display of missing query terms to search results</li> <li>Reduced size of vendor bundle by 25% (<code>84kb</code> \u2192 <code>67kb</code>)</li> <li>Reduced size of the Docker image to improve CI build performance</li> <li>Removed hero partial in favor of custom implementation</li> <li>Removed deprecated front matter features</li> </ul>"},{"location":"about/website/changelog/#5.5.14","title":"5.5.14 September 23, 2020","text":"<ul> <li>Improved spacing around image captions</li> <li>Fixed #1939: Long tables cause header overlap in print view</li> </ul>"},{"location":"about/website/changelog/#5.5.13","title":"5.5.13 September 19, 2020","text":"<ul> <li>Improved abbreviations on touch devices</li> </ul>"},{"location":"about/website/changelog/#5.5.12","title":"5.5.12 August 31, 2020","text":"<ul> <li>Fixed #1638: occasional <code>404</code> for images when using instant loading</li> </ul>"},{"location":"about/website/changelog/#5.5.11","title":"5.5.11 August 28, 2020","text":"<ul> <li>Fixed Disqus integration, as the minifier killed the config</li> </ul>"},{"location":"about/website/changelog/#5.5.10","title":"5.5.10 August 28, 2020","text":"<ul> <li>Improved rendering by moving Disqus integration after page load</li> <li>Fixed #1887: Moved navigation icons to CSS to reduce size of HTML</li> </ul>"},{"location":"about/website/changelog/#5.5.9","title":"5.5.9 August 26, 2020","text":"<ul> <li>Added Esperanto translations</li> <li>Fixed #1884: External links not included in navigation tabs</li> </ul>"},{"location":"about/website/changelog/#5.5.8","title":"5.5.8 August 23, 2020","text":"<ul> <li>Removed focus outline on <code>details</code> and content tabs for pointer devices</li> <li>Improved accessibility of content tabs (now navigable via arrow keys)</li> <li>Fixed #1877: <code>404</code> on search index when search is disabled</li> <li>Fixed some memleaks in observable subscriptions</li> <li>Fixed color definitions for <code>theme-color</code> meta tag</li> </ul>"},{"location":"about/website/changelog/#5.5.7","title":"5.5.7 August 16, 2020","text":"<ul> <li>Improved contrast ratio to 4.5:1 for syntax highlighting</li> <li>Improved contrast ratio to 4.5:1 for table of contents</li> </ul>"},{"location":"about/website/changelog/#5.5.6","title":"5.5.6 August 12, 2020","text":"<ul> <li>Switched base template for <code>404.html</code> to <code>main.html</code></li> <li>Fixed #1864: GitHub organisation stats not loading</li> </ul>"},{"location":"about/website/changelog/#5.5.5","title":"5.5.5 August 11, 2020","text":"<ul> <li>Fixed missing vendor and worker distribution files</li> </ul>"},{"location":"about/website/changelog/#5.5.4","title":"5.5.4 August 11, 2020","text":"<ul> <li>Added support for sortable data tables</li> </ul>"},{"location":"about/website/changelog/#5.5.3","title":"5.5.3 August 4, 2020","text":"<ul> <li>Fixed search for languages other than English (5.5.1 regression)</li> </ul>"},{"location":"about/website/changelog/#5.5.2","title":"5.5.2 August 3, 2020","text":"<ul> <li>Improved highlight colors and spacing for <code>ins</code>, <code>del</code> and <code>mark</code></li> <li>Changed some keyboard symbols for better equivalents</li> <li>Removed focus <code>outline</code> for details and code blocks on touch devices</li> <li>Fixed margins for admonitions (5.5.1 regression)</li> <li>Fixed too small content tab labels (5.5.1 regression)</li> <li>Fixed icon repeating for custom admonition icons</li> </ul>"},{"location":"about/website/changelog/#5.5.1","title":"5.5.1 August 1, 2020","text":"<ul> <li>Improved typesetting by basing <code>font-size</code> and spacings on <code>em</code></li> <li>Improved print view by slightly scaling down <code>font-size</code></li> <li>Changed custom site title (metadata) to be suffixed with site name</li> <li>Fixed top- and bottom spacing of paragraphs inside table cells</li> </ul>"},{"location":"about/website/changelog/#5.5.0","title":"5.5.0 July 24, 2020","text":"<ul> <li>Rewrite of entire documentation</li> <li>Rewrite of syntax highlighting to be customizable with CSS variables</li> <li>Improved syntax highlighting to work with light and dark theme</li> <li>Improved <code>slate</code> color scheme to be more customizable and easier on the eyes</li> <li>Added licenses of icon sets to distribution files</li> <li>Fixed stale document titles in Google Analytics when using instant loading</li> <li>Fixed width of previous and next footer links for tablet and above</li> <li>Fixed issues with top scroll margin for footnotes</li> <li>Fixed top margin for tabbed content when using a JavaScript highlighter</li> <li>Deprecated metadata-based redirects, source links and heroes</li> </ul>"},{"location":"about/website/changelog/#5.4.0","title":"5.4.0 June 29, 2020","text":"<ul> <li>Added support to wrap searches in quotes to switch from <code>OR</code> to <code>AND</code></li> <li>Fixed highlighting of numbers in search results</li> </ul>"},{"location":"about/website/changelog/#5.3.3","title":"5.3.3 June 24, 2020","text":"<ul> <li>Added Bengali translations</li> <li>Fixed #1773: Search for numbers does not return any result (regression)</li> </ul>"},{"location":"about/website/changelog/#5.3.2","title":"5.3.2 June 21, 2020","text":"<ul> <li>Improved search typeahead experience with non-Latin characters</li> <li>Fixed #1753: Japanese search doesn't work anymore</li> </ul>"},{"location":"about/website/changelog/#5.3.1","title":"5.3.1 June 20, 2020","text":"<ul> <li>Fixed #1761: Duplication of search worker when subscribing to observable</li> </ul>"},{"location":"about/website/changelog/#5.3.0","title":"5.3.0 June 15, 2020","text":"<ul> <li>Added support for color schemes based on user preference</li> <li>Fixed #1755: Tokenizer separator setting ignored</li> </ul>"},{"location":"about/website/changelog/#5.2.3","title":"5.2.3 June 6, 2020","text":"<ul> <li>Improved search typeahead behavior for some languages (<code>de</code>, <code>fr</code>, ...)</li> <li>Improved styles for scrollbars on Firefox</li> <li>Fixed #1741: Removed <code>preconnect</code> hint for Google Analytics</li> </ul>"},{"location":"about/website/changelog/#5.2.2","title":"5.2.2 May 26, 2020","text":"<ul> <li>Fixed #1728: Legacy Edge doesn't support <code>deg</code> values in <code>hsla</code> colors</li> </ul>"},{"location":"about/website/changelog/#5.2.1","title":"5.2.1 May 22, 2020","text":"<ul> <li>Fixed color of links in table headers, e.g. footnotes</li> <li>Fixed color scheme not being applied without primary or accent color</li> <li>Fixed hover delay for links inside code blocks</li> </ul>"},{"location":"about/website/changelog/#5.2.0","title":"5.2.0 May 18, 2020","text":"<ul> <li>Added color schemes implementation + dark mode</li> <li>Fixed #1583: Missing option for separate link colors</li> </ul>"},{"location":"about/website/changelog/#5.1.7","title":"5.1.7 May 16, 2020","text":"<ul> <li>Added keyboard focus support for overflowing code blocks</li> <li>Fixed #1696: Infinite loop in some cases when using instant loading</li> </ul>"},{"location":"about/website/changelog/#5.1.6","title":"5.1.6 May 9, 2020","text":"<ul> <li>Added Burmese translations</li> <li>Added general anchor offset solution using <code>scroll-margin-top</code></li> <li>Fixed #1653: Instant loading shouldn't intercept links to <code>*.html</code> files</li> </ul>"},{"location":"about/website/changelog/#5.1.5","title":"5.1.5 May 3, 2020","text":"<ul> <li>Added <code>name</code> attribute for social links to set link <code>title</code></li> <li>Fixed #1623: Allow arbitrary links in social links</li> <li>Fixed #1664: Height of <code>iframe</code> is not adjustable</li> <li>Fixed #1667: Sidebars are scrolled to bottom on load (bug in Chrome 81+)</li> </ul>"},{"location":"about/website/changelog/#5.1.4","title":"5.1.4 April 30, 2020","text":"<ul> <li>Switched to @mdi/svg Material Design icon package</li> <li>Fixed #1655: Navigation may disappear after switching viewports</li> <li>Fixed #1659: Unnecessary scrollbar for search results on Windows</li> <li>Fixed occasional distortions for images with explicit dimensions</li> <li>Fixed errors in German translations</li> </ul>"},{"location":"about/website/changelog/#5.1.3","title":"5.1.3 April 26, 2020","text":"<ul> <li>Fixed overflowing content area after switch to flexbox</li> </ul>"},{"location":"about/website/changelog/#5.1.2","title":"5.1.2 April 26, 2020","text":"<ul> <li>Added status information to search observable</li> <li>Added status information to search modal</li> <li>Removed announcement bar from print media</li> <li>Removed media query packing logic due to race conditions</li> <li>Fixed #1520: Gracefully disable search on <code>file://</code> if Worker fails</li> <li>Fixed re-submission of query after search is initialized</li> <li>Fixed jitter of sidebars on all browsers by switching to <code>sticky</code></li> </ul>"},{"location":"about/website/changelog/#5.1.1","title":"5.1.1 April 17, 2020","text":"<ul> <li>Added new FontAwesome icons</li> <li>Fixed #1609: Instant loading doesn't honor <code>target=_blank</code></li> <li>Fixed GitHub stars count rounding errors</li> <li>Fixed GitLab stars count retrieval</li> </ul>"},{"location":"about/website/changelog/#5.1.0","title":"5.1.0 April 12, 2020","text":"<ul> <li>Added support for icons from Markdown through mkdocs-material-extensions</li> </ul>"},{"location":"about/website/changelog/#5.0.2","title":"5.0.2 April 10, 2020","text":"<ul> <li>Added CSS source maps to distribution files</li> <li>Fixed errors in Chinese (Traditional) translations</li> <li>Fixed creation of stale directory on installation from git</li> <li>Improved overflow scrolling behavior on iOS (reduced bundle size by <code>4kb</code>)</li> </ul>"},{"location":"about/website/changelog/#5.0.1","title":"5.0.1 April 7, 2020","text":"<ul> <li>Fixed syntax error in Spanish translation</li> </ul>"},{"location":"about/website/changelog/#5.0.0","title":"5.0.0 April 7, 2020","text":"<ul> <li>Reactive architecture \u2013 try <code>app.dialog$.next(\"Hi!\")</code> in the console</li> <li>Instant loading \u2013 make Material behave like a Single Page Application</li> <li>Improved CSS customization with CSS variables \u2013 set your brand's colors</li> <li>Improved CSS resilience, e.g. proper sidebar locking for customized headers</li> <li>Improved icon integration and configuration \u2013 now including over 5k icons</li> <li>Added possibility to use any icon for logo, repository and social links</li> <li>Search UI does not freeze anymore (moved to web worker)</li> <li>Search index built only once when using instant loading</li> <li>Improved extensible keyboard handling</li> <li>Support for prebuilt search indexes</li> <li>Support for displaying stars and forks for GitLab repositories</li> <li>Support for scroll snapping of sidebars and search results</li> <li>Reduced HTML and CSS footprint due to deprecation of Internet Explorer support</li> <li>Slight facelifting of some UI elements (admonitions, tables, ...)</li> </ul>"},{"location":"about/website/changelog/#4.6.3","title":"4.6.3 February 14, 2020","text":"<ul> <li>Removed optional third-party plugins from <code>requirements.txt</code></li> <li>Updated Docker image to contain all supported third-party plugins</li> </ul>"},{"location":"about/website/changelog/#4.6.2","title":"4.6.2 February 8, 2020","text":"<ul> <li>Added Romanian translations</li> <li>Fixed #1451: Inconsistent spacing for fenced code blocks</li> </ul>"},{"location":"about/website/changelog/#4.6.1","title":"4.6.1 February 8, 2020","text":"<ul> <li>Fixed #1324: Metadata author only rendering first character</li> <li>Fixed #1393: Set <code>tabindex</code> to <code>0</code> for skip to content link</li> <li>Fixed code blocks after Markdown 3.2 release</li> <li>Fixed errors in Japanese translations</li> <li>Improved Google Lighthouse score</li> </ul>"},{"location":"about/website/changelog/#4.6.0","title":"4.6.0 December 11, 2019","text":"<ul> <li>Added support for git-revision-date-localized-plugin</li> <li>Fixed invalid character in Google Fonts URL</li> </ul>"},{"location":"about/website/changelog/#4.5.1","title":"4.5.1 December 2, 2019","text":"<ul> <li>Added Thai translations</li> <li>Fixed missing assets in GitHub release <code>.zip</code> and <code>.tar.gz</code></li> </ul>"},{"location":"about/website/changelog/#4.5.0","title":"4.5.0 November 16, 2019","text":"<ul> <li>Fixed #1330: Upgraded EmojiOne to Tweomji due to licensing issues</li> <li>Fixed #1339: Temporarily pinned PyMdown and Markdown due to</li> <li>Fixed errors in Greek translations</li> <li>Improved GitHub statistics retrieval</li> </ul>"},{"location":"about/website/changelog/#4.4.3","title":"4.4.3 October 3, 2019","text":"<ul> <li>Added Estonian translations</li> <li>Fixed removal of copyright banners in minified JavaScript</li> <li>Removed unnecessary title attributes from links in table of contents</li> </ul>"},{"location":"about/website/changelog/#4.4.2","title":"4.4.2 August 27, 2019","text":"<ul> <li>Added Afrikaans translations</li> <li>Fixed broken page title when <code>h1</code> contained HTML tags</li> <li>Improved accessibility for IE users</li> <li>Removed unnecessary <code>title</code> attributes from links in navigation</li> </ul>"},{"location":"about/website/changelog/#4.4.1","title":"4.4.1 August 22, 2019","text":"<ul> <li>Added support for <code>black</code> as a primary color</li> <li>Fixed broken footer bar when <code>h1</code> contained HTML tags</li> </ul>"},{"location":"about/website/changelog/#4.4.0","title":"4.4.0 June 15, 2019","text":"<ul> <li>Added Slovenian translations</li> <li>Reverted template minification in favor of <code>mkdocs-minify-plugin</code></li> <li>Fixed #1114: Tabs don't reappear when default <code>font-size</code> is smaller than <code>16</code></li> </ul>"},{"location":"about/website/changelog/#4.3.1","title":"4.3.1 May 23, 2019","text":"<ul> <li>Fixed spelling error in Danish translations</li> </ul>"},{"location":"about/website/changelog/#4.3.0","title":"4.3.0 May 17, 2019","text":"<ul> <li>Added support for changing header through metadata title property</li> <li>Added <code>font-display: swap</code> to Google Font loading logic</li> <li>Removed whitespace from templates, saving <code>4kb</code> (<code>.7kb</code> gzipped) per request</li> <li>Fixed alignment of repository icons on tablet and desktop</li> </ul>"},{"location":"about/website/changelog/#4.2.0","title":"4.2.0 April 28, 2019","text":"<ul> <li>Added Norwegian (Nynorsk) translations</li> <li>Fixed loss of focus in non-form input elements due to search hotkeys</li> <li>Fixed #1067: Search hotkeys not working for mobile/tablet screensize</li> <li>Fixed #1068: Search not correctly aligned for tablet screensize</li> </ul>"},{"location":"about/website/changelog/#4.1.2","title":"4.1.2 April 16, 2019","text":"<ul> <li>Fixed #1072: HTML tags appearing in navigation link titles</li> </ul>"},{"location":"about/website/changelog/#4.1.1","title":"4.1.1 March 28, 2019","text":"<ul> <li>Fixed minor CSS errors detected during validation</li> </ul>"},{"location":"about/website/changelog/#4.1.0","title":"4.1.0 March 22, 2019","text":"<ul> <li>Fixed #1023: Search for Asian languages broken after Lunr.js update</li> <li>Fixed #1026: contenteditable elements loose focus on hotkeys</li> </ul>"},{"location":"about/website/changelog/#4.0.2","title":"4.0.2 March 1, 2019","text":"<ul> <li>Fixed #1012: HTML character entities appear in search result titles</li> </ul>"},{"location":"about/website/changelog/#4.0.1","title":"4.0.1 February 13, 2019","text":"<ul> <li>Fixed #762, #816: Glitch in sidebar when collapsing items</li> <li>Fixed #869: Automatically expand details before printing</li> </ul>"},{"location":"about/website/changelog/#4.0.0","title":"4.0.0 February 13, 2019","text":"<ul> <li>Added background on hover for table rows</li> <li>Removed Google Tag Manager and reverted to Google Analytics</li> <li>Removed blocks in partials - Jinja doesn't support them</li> <li>Fixed #911: Chrome breaks layout if system language is Chinese (BREAKING)</li> <li>Fixed #976: Removed FastClick</li> </ul>"},{"location":"about/website/changelog/#3.3.0","title":"3.3.0 January 29, 2019","text":"<ul> <li>Moved Google Analytics integration into <code>head</code> using Google Tag Manager</li> <li>Fixed #972: Unicode slugifier breaks table of contents blur on scroll</li> <li>Fixed #974: Additional links in table of contents break blur on scroll</li> </ul>"},{"location":"about/website/changelog/#3.2.0","title":"3.2.0 December 28, 2018","text":"<ul> <li>Added support for redirects using metadata refresh</li> <li>Fixed #921: Load Google Analytics snippet asynchronously</li> </ul>"},{"location":"about/website/changelog/#3.1.0","title":"3.1.0 November 17, 2018","text":"<ul> <li>Added support for Progressive Web App Manifest</li> <li>Fixed #915: Search bug in Safari (upgraded Lunr.js)</li> </ul>"},{"location":"about/website/changelog/#3.0.6","title":"3.0.6 October 26, 2018","text":"<ul> <li>Added Taiwanese translations</li> <li>Fixed #906: JavaScript code blocks evaluated in search results</li> </ul>"},{"location":"about/website/changelog/#3.0.5","title":"3.0.5 October 23, 2018","text":"<ul> <li>Added Croatian and Indonesian translations</li> <li>Fixed #899: Skip-to-content link invalid from 2<sup>nd</sup> level on</li> <li>Fixed #902: Missing URL filter in footer for FontAwesome link</li> </ul>"},{"location":"about/website/changelog/#3.0.4","title":"3.0.4 September 3, 2018","text":"<ul> <li>Updated Dutch translations</li> <li>Fixed #856: Removed preconnect meta tag if Google Fonts are disabled</li> </ul>"},{"location":"about/website/changelog/#3.0.3","title":"3.0.3 August 7, 2018","text":"<ul> <li>Fixed #841: Additional path levels for extra CSS and JS</li> </ul>"},{"location":"about/website/changelog/#3.0.2","title":"3.0.2 August 6, 2018","text":"<ul> <li>Fixed #839: Lunr.js stemmer imports incorrect</li> </ul>"},{"location":"about/website/changelog/#3.0.1","title":"3.0.1 August 5, 2018","text":"<ul> <li>Fixed #838: Search result links incorrect</li> </ul>"},{"location":"about/website/changelog/#3.0.0","title":"3.0.0 August 5, 2018","text":"<ul> <li>Upgraded MkDocs to 1.0 (BREAKING)</li> <li>Upgraded Python in official Docker image to 3.6</li> <li>Added Serbian and Serbo-Croatian translations</li> </ul>"},{"location":"about/website/changelog/#2.9.4","title":"2.9.4 July 29, 2018","text":"<ul> <li>Fixed build error after MkDocs upgrade</li> </ul>"},{"location":"about/website/changelog/#2.9.3","title":"2.9.3 July 29, 2018","text":"<ul> <li>Added link to home for logo in drawer</li> <li>Fixed dependency problems between MkDocs and Tornado</li> </ul>"},{"location":"about/website/changelog/#2.9.2","title":"2.9.2 June 29, 2018","text":"<ul> <li>Added Hindi and Czech translations</li> </ul>"},{"location":"about/website/changelog/#2.9.1","title":"2.9.1 June 18, 2018","text":"<ul> <li>Added support for different spellings for theme color</li> <li>Fixed #799: Added support for webfont minification in production</li> <li>Fixed #800: Added <code>.highlighttable</code> as an alias for <code>.codehilitetable</code></li> </ul>"},{"location":"about/website/changelog/#2.9.0","title":"2.9.0 June 13, 2018","text":"<ul> <li>Added support for theme color on Android</li> <li>Fixed #796: Rendering of nested tabbed code blocks</li> </ul>"},{"location":"about/website/changelog/#2.8.0","title":"2.8.0 June 10, 2018","text":"<ul> <li>Added support for grouping code blocks with tabs</li> <li>Added Material and FontAwesome icon fonts to distribution files (GDPR)</li> <li>Added note on compliance with GDPR</li> <li>Added Slovak translations</li> <li>Fixed #790: Prefixed <code>id</code> attributes with <code>__</code> to avoid name clashes</li> </ul>"},{"location":"about/website/changelog/#2.7.3","title":"2.7.3 April 26, 2018","text":"<ul> <li>Added Finnish translations</li> </ul>"},{"location":"about/website/changelog/#2.7.2","title":"2.7.2 April 9, 2018","text":"<ul> <li>Fixed rendering issue for <code>details</code> on Edge</li> </ul>"},{"location":"about/website/changelog/#2.7.1","title":"2.7.1 March 21, 2018","text":"<ul> <li>Added Galician translations</li> <li>Fixed #730: Scroll chasing error on home page if Disqus is enabled</li> <li>Fixed #736: Reset drawer and search upon back button invocation</li> </ul>"},{"location":"about/website/changelog/#2.7.0","title":"2.7.0 March 6, 2018","text":"<ul> <li>Added ability to set absolute URL for logo</li> <li>Added Hebrew translations</li> </ul>"},{"location":"about/website/changelog/#2.6.6","title":"2.6.6 February 22, 2018","text":"<ul> <li>Added preconnect for Google Fonts for faster loading</li> <li>Fixed #710: With tabs sidebar disappears if JavaScript is not available</li> </ul>"},{"location":"about/website/changelog/#2.6.5","title":"2.6.5 February 22, 2018","text":"<ul> <li>Reverted <code>--dev-addr</code> flag removal from <code>Dockerfile</code></li> </ul>"},{"location":"about/website/changelog/#2.6.4","title":"2.6.4 February 21, 2018","text":"<ul> <li>Added Catalan translations</li> <li>Fixed incorrect margins for buttons in Firefox and Safari</li> <li>Replaced package manager <code>yarn</code> with <code>npm 5.6</code></li> <li>Reverted GitHub stars rounding method</li> <li>Removed <code>--dev-addr</code> flag from <code>Dockerfile</code> for Windows compatibility</li> </ul>"},{"location":"about/website/changelog/#2.6.3","title":"2.6.3 February 18, 2018","text":"<ul> <li>Added Vietnamese translations</li> </ul>"},{"location":"about/website/changelog/#2.6.2","title":"2.6.2 February 12, 2018","text":"<ul> <li>Added Arabic translations</li> <li>Fixed incorrect rounding of amount of GitHub stars</li> <li>Fixed double-layered borders for tables</li> </ul>"},{"location":"about/website/changelog/#2.6.1","title":"2.6.1 February 11, 2018","text":"<ul> <li>Added ability to override Disqus integration using metadata</li> <li>Fixed #690: Duplicate slashes in source file URLs</li> <li>Fixed #696: Active page highlight not working with default palette</li> <li>Adjusted German translations</li> </ul>"},{"location":"about/website/changelog/#2.6.0","title":"2.6.0 February 2, 2018","text":"<ul> <li>Moved default search configuration to default translation (English)</li> <li>Added support to automatically set text direction from translation</li> <li>Added support to disable search stop word filter in translation</li> <li>Added support to disable search trimmer in translation</li> <li>Added Persian translations</li> <li>Fixed support for Polish search</li> <li>Fixed disappearing GitHub, GitLab and Bitbucket repository icons</li> </ul>"},{"location":"about/website/changelog/#2.5.5","title":"2.5.5 January 31, 2018","text":"<ul> <li>Added Hungarian translations</li> </ul>"},{"location":"about/website/changelog/#2.5.4","title":"2.5.4 January 29, 2018","text":"<ul> <li>Fixed #683: <code>gh-deploy</code> fails inside Docker</li> </ul>"},{"location":"about/website/changelog/#2.5.3","title":"2.5.3 January 25, 2018","text":"<ul> <li>Added Ukrainian translations</li> </ul>"},{"location":"about/website/changelog/#2.5.2","title":"2.5.2 January 22, 2018","text":"<ul> <li>Added default search language mappings for all localizations</li> <li>Fixed #673: Error loading non-existent search language</li> <li>Fixed #675: Uncaught reference error when search plugin disabled</li> </ul>"},{"location":"about/website/changelog/#2.5.1","title":"2.5.1 January 20, 2018","text":"<ul> <li>Fixed permalink for main headline</li> <li>Improved missing translation handling with English as a fallback</li> <li>Improved accessibility with skip-to-content link</li> </ul>"},{"location":"about/website/changelog/#2.5.0","title":"2.5.0 January 13, 2018","text":"<ul> <li>Added support for right-to-left languages</li> </ul>"},{"location":"about/website/changelog/#2.4.0","title":"2.4.0 January 11, 2018","text":"<ul> <li>Added focus state for clipboard buttons</li> <li>Fixed #400: Search bar steals tab focus</li> <li>Fixed search not closing on Enter when result is selected</li> <li>Fixed search not closing when losing focus due to Tab</li> <li>Fixed collapsed navigation links getting focus</li> <li>Fixed <code>outline</code> being cut off on Tab focus of navigation links</li> <li>Fixed bug with first search result navigation being ignored</li> <li>Removed search result navigation via Tab (use Up and Down)</li> <li>Removed <code>outline</code> resets for links</li> <li>Improved general tabbing behavior on desktop</li> </ul>"},{"location":"about/website/changelog/#2.3.0","title":"2.3.0 January 9, 2018","text":"<ul> <li>Added <code>example</code> (synonym: <code>snippet</code>) style for admonitions</li> <li>Added synonym <code>abstract</code> for <code>summary</code> style for admonitions</li> </ul>"},{"location":"about/website/changelog/#2.2.6","title":"2.2.6 December 27, 2017","text":"<ul> <li>Added Turkish translations</li> <li>Fixed unclickable area below header in case JavaScript is not available</li> </ul>"},{"location":"about/website/changelog/#2.2.5","title":"2.2.5 December 18, 2017","text":"<ul> <li>Fixed #639: Broken default favicon</li> </ul>"},{"location":"about/website/changelog/#2.2.4","title":"2.2.4 December 18, 2017","text":"<ul> <li>Fixed #638: Build breaks with Jinja &lt; 2.9</li> </ul>"},{"location":"about/website/changelog/#2.2.3","title":"2.2.3 December 13, 2017","text":"<ul> <li>Fixed #630: Admonition sets padding on any last child</li> <li>Adjusted Chinese (Traditional) translations</li> </ul>"},{"location":"about/website/changelog/#2.2.2","title":"2.2.2 December 8, 2017","text":"<ul> <li>Added Dutch translations</li> <li>Adjusted targeted link and footnote offsets</li> <li>Simplified admonition styles and fixed padding bug</li> </ul>"},{"location":"about/website/changelog/#2.2.1","title":"2.2.1 December 2, 2017","text":"<ul> <li>Fixed #616: Minor styling error with title-only admonitions</li> <li>Removed border for table of contents and improved spacing</li> </ul>"},{"location":"about/website/changelog/#2.2.0","title":"2.2.0 November 22, 2017","text":"<ul> <li>Added support for hero teaser</li> <li>Added Portuguese translations</li> <li>Fixed #586: Footnote backref target offset regression</li> <li>Fixed #605: Search stemmers not correctly loaded</li> </ul>"},{"location":"about/website/changelog/#2.1.1","title":"2.1.1 November 21, 2017","text":"<ul> <li>Replaced deprecated <code>babel-preset-es2015</code> with <code>babel-preset-env</code></li> <li>Refactored Gulp build pipeline with Webpack</li> <li>Removed right border on sidebars</li> <li>Fixed broken color transition on header</li> </ul>"},{"location":"about/website/changelog/#2.1.0","title":"2.1.0 November 19, 2017","text":"<ul> <li>Added support for <code>white</code> as a primary color</li> <li>Added support for sliding site name and title</li> <li>Fixed redundant clipboard button when using line numbers on code blocks</li> <li>Improved header appearance by making it taller</li> <li>Improved tabs appearance</li> <li>Improved CSS customizability by leveraging inheritance</li> <li>Removed scroll shadows via <code>background-attachment</code></li> </ul>"},{"location":"about/website/changelog/#2.0.4","title":"2.0.4 November 5, 2017","text":"<ul> <li>Fixed <code>details</code> not opening with footnote reference</li> </ul>"},{"location":"about/website/changelog/#2.0.3","title":"2.0.3 November 5, 2017","text":"<ul> <li>Added Japanese translations</li> <li>Fixed #540: Jumping to anchor inside <code>details</code> doesn't open it</li> <li>Fixed active link colors in footer</li> </ul>"},{"location":"about/website/changelog/#2.0.2","title":"2.0.2 November 1, 2017","text":"<ul> <li>Added Russian translations</li> <li>Fixed #542: Horizontal scrollbar between <code>1220px</code> and <code>1234px</code></li> <li>Fixed #553: Metadata values only rendering first character</li> <li>Fixed #558: Flash of unstyled content</li> <li>Fixed favicon regression caused by deprecation upstream</li> </ul>"},{"location":"about/website/changelog/#2.0.1","title":"2.0.1 October 31, 2017","text":"<ul> <li>Fixed error when initializing search</li> <li>Fixed styles for link to edit the current page</li> <li>Fixed styles on nested admonition in details</li> </ul>"},{"location":"about/website/changelog/#2.0.0","title":"2.0.0 October 31, 2017","text":"<ul> <li>Upgraded MkDocs to 0.17.1 (BREAKING)</li> <li>Added support for easier configuration of search tokenizer</li> <li>Added support to disable search</li> <li>Added Korean translations</li> </ul>"},{"location":"about/website/changelog/#1.12.2","title":"1.12.2 October 26, 2017","text":"<ul> <li>Added Italian, Norwegian, French and Chinese translations</li> </ul>"},{"location":"about/website/changelog/#1.12.1","title":"1.12.1 October 22, 2017","text":"<ul> <li>Added Polish, Swedish and Spanish translations</li> <li>Improved downward compatibility with custom partials</li> <li>Temporarily pinned MkDocs version within Docker image to 0.16.3</li> <li>Fixed #519: Missing theme configuration file</li> </ul>"},{"location":"about/website/changelog/#1.12.0","title":"1.12.0 October 20, 2017","text":"<ul> <li>Added support for setting language(s) via <code>mkdocs.yml</code></li> <li>Added support for default localization</li> <li>Added German and Danish translations</li> <li>Fixed #374: Search bar misalignment on big screens</li> </ul>"},{"location":"about/website/changelog/#1.11.0","title":"1.11.0 October 19, 2017","text":"<ul> <li>Added localization to clipboard</li> <li>Refactored localization logic</li> </ul>"},{"location":"about/website/changelog/#1.10.4","title":"1.10.4 October 18, 2017","text":"<ul> <li>Improved print styles of code blocks</li> <li>Improved search UX (don't close on enter if no selection)</li> <li>Fixed #495: Vertical scrollbar on short pages</li> </ul>"},{"location":"about/website/changelog/#1.10.3","title":"1.10.3 October 11, 2017","text":"<ul> <li>Fixed #484: Vertical scrollbar on some MathJax formulas</li> <li>Fixed #483: Footnote backref target offset regression</li> </ul>"},{"location":"about/website/changelog/#1.10.2","title":"1.10.2 October 6, 2017","text":"<ul> <li>Fixed #468: Sidebar shows scrollbar if content is shorter (in Safari)</li> </ul>"},{"location":"about/website/changelog/#1.10.1","title":"1.10.1 September 14, 2017","text":"<ul> <li>Fixed #455: Bold code blocks rendered with normal font weight</li> </ul>"},{"location":"about/website/changelog/#1.10.0","title":"1.10.0 September 1, 2017","text":"<ul> <li>Added support to make logo default icon configurable</li> <li>Fixed uninitialized overflow scrolling on main pane for iOS</li> <li>Fixed error in mobile navigation in case JavaScript is not available</li> <li>Fixed incorrect color transition for nested panes in mobile navigation</li> <li>Improved checkbox styles for Tasklist from PyMdown Extension package</li> </ul>"},{"location":"about/website/changelog/#1.9.0","title":"1.9.0 August 29, 2017","text":"<ul> <li>Added <code>info</code> (synonym: <code>todo</code>) style for admonitions</li> <li>Added <code>question</code> (synonym: <code>help</code>, <code>faq</code>) style for admonitions</li> <li>Added support for Details from PyMdown Extensions package</li> <li>Improved admonition styles to match details</li> <li>Improved styles for social links in footer</li> <li>Replaced ligatures with Unicode code points to avoid broken layout</li> <li>Upgraded PyMdown Extensions package dependency to &gt;= 3.4</li> </ul>"},{"location":"about/website/changelog/#1.8.1","title":"1.8.1 August 7, 2017","text":"<ul> <li>Fixed #421: Missing pagination for GitHub API</li> </ul>"},{"location":"about/website/changelog/#1.8.0","title":"1.8.0 August 2, 2017","text":"<ul> <li>Added support for lazy-loading of search results for better performance</li> <li>Added support for customization of search tokenizer/separator</li> <li>Fixed #424: Search doesn't handle capital letters anymore</li> <li>Fixed #419: Search doesn't work on whole words</li> </ul>"},{"location":"about/website/changelog/#1.7.5","title":"1.7.5 July 25, 2017","text":"<ul> <li>Fixed #398: Forms broken due to search shortcuts</li> <li>Improved search overall user experience</li> <li>Improved search matching and highlighting</li> <li>Improved search accessibility</li> </ul>"},{"location":"about/website/changelog/#1.7.4","title":"1.7.4 June 21, 2017","text":"<ul> <li>Fixed functional link colors in table of contents for active palette</li> <li>Fixed #368: Compatibility issues with IE11</li> </ul>"},{"location":"about/website/changelog/#1.7.3","title":"1.7.3 June 7, 2017","text":"<ul> <li>Fixed error when setting language to Japanese for site search</li> </ul>"},{"location":"about/website/changelog/#1.7.2","title":"1.7.2 June 6, 2017","text":"<ul> <li>Fixed offset of search box when <code>repo_url</code> is not set</li> <li>Fixed non-disappearing tooltip</li> </ul>"},{"location":"about/website/changelog/#1.7.1","title":"1.7.1 June 1, 2017","text":"<ul> <li>Fixed wrong <code>z-index</code> order of header, overlay and drawer</li> <li>Fixed wrong offset of targeted footnote back references</li> </ul>"},{"location":"about/website/changelog/#1.7.0","title":"1.7.0 June 1, 2017","text":"<ul> <li>Added \"copy to clipboard\" buttons to code blocks</li> <li>Added support for multilingual site search</li> <li>Fixed search term highlighting for non-latin languages</li> </ul>"},{"location":"about/website/changelog/#1.6.4","title":"1.6.4 May 24, 2017","text":"<ul> <li>Fixed #337: JavaScript error for GitHub organization URLs</li> </ul>"},{"location":"about/website/changelog/#1.6.3","title":"1.6.3 May 16, 2017","text":"<ul> <li>Fixed #329: Broken source stats for private or unknown GitHub repos</li> </ul>"},{"location":"about/website/changelog/#1.6.2","title":"1.6.2 May 15, 2017","text":"<ul> <li>Fixed #316: Fatal error for git clone on Windows</li> <li>Fixed #320: Chrome 58 creates double underline for <code>abbr</code> tags</li> <li>Fixed #323: Ligatures rendered inside code blocks</li> <li>Fixed miscalculated sidebar height due to missing margin collapse</li> <li>Changed deprecated MathJax CDN to Cloudflare</li> </ul>"},{"location":"about/website/changelog/#1.6.1","title":"1.6.1 April 23, 2017","text":"<ul> <li>Fixed following of active/focused element if search input is focused</li> <li>Fixed layer order of search component elements</li> </ul>"},{"location":"about/website/changelog/#1.6.0","title":"1.6.0 April 22, 2017","text":"<ul> <li>Added build test for Docker image on Travis</li> <li>Added search overlay for better user experience (focus)</li> <li>Added language from localizations to <code>html</code> tag</li> <li>Fixed #270: source links broken for absolute URLs</li> <li>Fixed missing top spacing for first targeted element in content</li> <li>Fixed too small footnote divider when using larger font sizes</li> </ul>"},{"location":"about/website/changelog/#1.5.5","title":"1.5.5 April 20, 2017","text":"<ul> <li>Fixed #282: Browser search (Meta+F) is hijacked</li> </ul>"},{"location":"about/website/changelog/#1.5.4","title":"1.5.4 April 8, 2017","text":"<ul> <li>Fixed broken highlighting for two or more search terms</li> <li>Fixed missing search results when only a <code>h1</code> is present</li> <li>Fixed unresponsive overlay on Android</li> </ul>"},{"location":"about/website/changelog/#1.5.3","title":"1.5.3 April 7, 2017","text":"<ul> <li>Fixed deprecated calls for template variables</li> <li>Fixed wrong palette color for focused search result</li> <li>Fixed JavaScript errors on 404 page</li> <li>Fixed missing top spacing on 404 page</li> <li>Fixed missing right spacing on overflow of source container</li> </ul>"},{"location":"about/website/changelog/#1.5.2","title":"1.5.2 April 5, 2017","text":"<ul> <li>Added requirements as explicit dependencies in <code>setup.py</code></li> <li>Fixed non-synchronized transitions in search form</li> </ul>"},{"location":"about/website/changelog/#1.5.1","title":"1.5.1 March 30, 2017","text":"<ul> <li>Fixed rendering and offset of targeted footnotes</li> <li>Fixed #238: Link on logo is not set to <code>site_url</code></li> </ul>"},{"location":"about/website/changelog/#1.5.0","title":"1.5.0 March 24, 2017","text":"<ul> <li>Added support for localization of search placeholder</li> <li>Added keyboard events for quick access of search</li> <li>Added keyboard events for search control</li> <li>Added opacity on hover for search buttons</li> <li>Added git hook to skip CI build on non-src changes</li> <li>Fixed non-resetting search placeholder when input is cleared</li> <li>Fixed error for unescaped parentheses in search term</li> <li>Fixed #229: Button to clear search missing</li> <li>Fixed #231: Escape key doesn't exit search</li> <li>Removed old-style figures from font feature settings</li> </ul>"},{"location":"about/website/changelog/#1.4.1","title":"1.4.1 March 16, 2017","text":"<ul> <li>Fixed invalid destructuring attempt on NodeList (in Safari, Edge, IE)</li> </ul>"},{"location":"about/website/changelog/#1.4.0","title":"1.4.0 March 16, 2017","text":"<ul> <li>Added support for grouping searched sections by documents</li> <li>Added support for highlighting of search terms</li> <li>Added support for localization of search results</li> <li>Fixed #216: table of contents icon doesn't show if <code>h1</code> is not present</li> <li>Reworked style and layout of search results for better usability</li> </ul>"},{"location":"about/website/changelog/#1.3.0","title":"1.3.0 March 11, 2017","text":"<ul> <li>Added support for page-specific title and description using metadata</li> <li>Added support for linking source files to documentation</li> <li>Fixed jitter and offset of sidebar when zooming browser</li> <li>Fixed incorrectly initialized tablet sidebar height</li> <li>Fixed regression for #1: GitHub stars break if <code>repo_url</code> ends with a <code>/</code></li> <li>Fixed undesired white line below copyright footer due to base font scaling</li> <li>Fixed issue with whitespace in path for scripts</li> <li>Fixed #205: support non-fixed (static) header</li> <li>Refactored footnote references for better visibility</li> <li>Reduced repaints to a minimum for non-tabs configuration</li> <li>Reduced contrast of edit button (slightly)</li> </ul>"},{"location":"about/website/changelog/#1.2.0","title":"1.2.0 March 3, 2017","text":"<ul> <li>Added <code>quote</code> (synonym: <code>cite</code>) style for admonitions</li> <li>Added help message to build pipeline</li> <li>Fixed wrong navigation link colors when applying palette</li> <li>Fixed #197: Link missing in tabs navigation on deeply nested items</li> <li>Removed unnecessary dev dependencies</li> </ul>"},{"location":"about/website/changelog/#1.1.1","title":"1.1.1 February 26, 2017","text":"<ul> <li>Fixed incorrectly displayed nested lists when using tabs</li> </ul>"},{"location":"about/website/changelog/#1.1.0","title":"1.1.0 February 26, 2017","text":"<ul> <li>Added tabs navigation feature (optional)</li> <li>Added Disqus integration (optional)</li> <li>Added a high resolution Favicon with the new logo</li> <li>Added static type checking using Facebook's Flow</li> <li>Fixed #173: Dictionary elements have no bottom spacing</li> <li>Fixed #175: Tables cannot be set to 100% width</li> <li>Fixed race conditions in build related to asset revisioning</li> <li>Fixed accidentally re-introduced Permalink on top-level headline</li> <li>Fixed alignment of logo in drawer on IE11</li> <li>Refactored styles related to tables</li> <li>Refactored and automated Docker build and PyPI release</li> <li>Refactored build scripts</li> </ul>"},{"location":"about/website/changelog/#1.0.5","title":"1.0.5 February 18, 2017","text":"<ul> <li>Fixed #153: Sidebar flows out of constrained area in Chrome 56</li> <li>Fixed #159: Footer jitter due to JavaScript if content is short</li> </ul>"},{"location":"about/website/changelog/#1.0.4","title":"1.0.4 February 16, 2017","text":"<ul> <li>Fixed #142: Documentation build errors if <code>h1</code> is defined as raw HTML</li> <li>Fixed #164: PyPI release does not build and install</li> <li>Fixed offsets of targeted headlines</li> <li>Increased sidebar font size by <code>0.12rem</code></li> </ul>"},{"location":"about/website/changelog/#1.0.3","title":"1.0.3 January 22, 2017","text":"<ul> <li>Fixed #117: Table of contents items don't blur on fast scrolling</li> <li>Refactored sidebar positioning logic</li> <li>Further reduction of repaints</li> </ul>"},{"location":"about/website/changelog/#1.0.2","title":"1.0.2 January 15, 2017","text":"<ul> <li>Fixed #108: Horizontal scrollbar in content area</li> </ul>"},{"location":"about/website/changelog/#1.0.1","title":"1.0.1 January 14, 2017","text":"<ul> <li>Fixed massive repaints happening when scrolling</li> <li>Fixed footer back reference positions in case of overflow</li> <li>Fixed header logo from showing when the menu icon is rendered</li> <li>Changed scrollbar behavior to only show when content overflows</li> </ul>"},{"location":"about/website/changelog/#1.0.0","title":"1.0.0 January 13, 2017","text":"<ul> <li>Introduced Webpack for more sophisticated JavaScript bundling</li> <li>Introduced ESLint and Stylelint for code style checks</li> <li>Introduced more accurate Material Design colors and shadows</li> <li>Introduced modular scales for harmonic font sizing</li> <li>Introduced git-hooks for better development workflow</li> <li>Rewrite of CSS using the BEM methodology and SassDoc guidelines</li> <li>Rewrite of JavaScript using ES6 and Babel as a transpiler</li> <li>Rewrite of Admonition, Permalinks and CodeHilite integration</li> <li>Rewrite of the complete typographical system</li> <li>Rewrite of Gulp asset pipeline in ES6 and separation of tasks</li> <li>Removed Bower as a dependency in favor of NPM</li> <li>Removed custom icon build in favor of the Material Design icon set</li> <li>Removed <code>_blank</code> targets on links due to vulnerability: http://bit.ly/1Mk2Rtw</li> <li>Removed unversioned assets from build directory</li> <li>Restructured templates into base templates and partials</li> <li>Added build and watch scripts in <code>package.json</code></li> <li>Added support for Metadata and Footnotes Markdown extensions</li> <li>Added support for PyMdown Extensions package</li> <li>Added support for collapsible sections in navigation</li> <li>Added support for separate table of contents</li> <li>Added support for better accessibility through REM-based layout</li> <li>Added icons for GitHub, GitLab and BitBucket integrations</li> <li>Added more detailed documentation on specimen, extensions etc.</li> <li>Added a <code>404.html</code> error page for deployment on GitHub Pages</li> <li>Fixed live reload chain in watch mode when saving a template</li> <li>Fixed variable references to work with MkDocs 0.16</li> </ul>"},{"location":"about/website/changelog/#0.2.4","title":"0.2.4 June 26, 2016","text":"<ul> <li>Fixed improperly set default favicon</li> <li>Fixed #33: Protocol relative URL for webfonts doesn't work with <code>file://</code></li> <li>Fixed #34: IE11 on Windows 7 doesn't honor <code>max-width</code> on <code>main</code> tag</li> <li>Fixed #35: Add styling for blockquotes</li> </ul>"},{"location":"about/website/changelog/#0.2.3","title":"0.2.3 May 16, 2016","text":"<ul> <li>Fixed #25: Highlight inline fenced blocks</li> <li>Fixed #26: Better highlighting for keystrokes</li> <li>Fixed #30: Suboptimal syntax highlighting for PHP</li> </ul>"},{"location":"about/website/changelog/#0.2.2","title":"0.2.2 March 20, 2016","text":"<ul> <li>Fixed #15: Document Pygments dependency for CodeHilite</li> <li>Fixed #16: Favicon could not be set through <code>mkdocs.yml</code></li> <li>Fixed #17: Put version into own container for styling</li> <li>Fixed #20: Fix rounded borders for tables</li> </ul>"},{"location":"about/website/changelog/#0.2.1","title":"0.2.1 March 12, 2016","text":"<ul> <li>Fixed #10: Invisible header after closing search bar with ESC key</li> <li>Fixed #13: Table cells don't wrap</li> <li>Fixed empty list in table of contents when no headline is defined</li> <li>Corrected wrong path for static asset monitoring in Gulpfile.js</li> <li>Set up tracking of site search for Google Analytics</li> </ul>"},{"location":"about/website/changelog/#0.2.0","title":"0.2.0 February 24, 2016","text":"<ul> <li>Fixed #6: Include multiple color palettes via <code>mkdocs.yml</code></li> <li>Fixed #7: Better colors for links inside admonition notes and warnings</li> <li>Fixed #9: Text for prev/next footer navigation should be customizable</li> <li>Refactored templates (replaced <code>if</code>/<code>else</code> with modifiers where possible)</li> </ul>"},{"location":"about/website/changelog/#0.1.3","title":"0.1.3 February 21, 2016","text":"<ul> <li>Fixed #3: Ordered lists within an unordered list have <code>::before</code> content</li> <li>Fixed #4: Click on Logo/Title without Github-Repository: <code>\"None\"</code></li> <li>Fixed #5: Page without headlines renders empty list in table of contents</li> <li>Moved Modernizr to top to ensure basic usability in IE8</li> </ul>"},{"location":"about/website/changelog/#0.1.2","title":"0.1.2 February 16, 2016","text":"<ul> <li>Fixed styles for deep navigational hierarchies</li> <li>Fixed webfont delivery problem when hosted in subdirectories</li> <li>Fixed print styles in mobile/tablet configuration</li> <li>Added option to configure fonts in <code>mkdocs.yml</code> with fallbacks</li> <li>Changed styles for admonition notes and warnings</li> <li>Set download link to latest version if available</li> <li>Set up tracking of outgoing links and actions for Google Analytics</li> </ul>"},{"location":"about/website/changelog/#0.1.1","title":"0.1.1 February 11, 2016","text":"<ul> <li>Fixed #1: GitHub stars don't work if the repo_url ends with a <code>/</code></li> <li>Updated NPM and Bower dependencies to most recent versions</li> <li>Changed footer/copyright link to Material theme to GitHub pages</li> <li>Made MkDocs building/serving in build process optional</li> <li>Set up continuous integration with Travis</li> </ul>"},{"location":"about/website/changelog/#0.1.0","title":"0.1.0 February 9, 2016","text":"<ul> <li>Initial release</li> </ul>"},{"location":"about/website/site-development/","title":"Site Development","text":""},{"location":"about/website/site-development/#ux","title":"UX","text":"<ul> <li>Ideas</li> <li>Design (Colors)</li> <li>Color Matters Example Contrast</li> <li>Universal Design</li> <li>Responsive images</li> <li>Keyword expansion</li> <li>Markdown Syntax<ul> <li>Katex</li> </ul> </li> <li>Word to Markdown<ul> <li>//ben balter, markdown to PDF</li> </ul> </li> <li>Jetbrains Mono Font</li> <li>Bootstrap icons</li> <li>Animation</li> <li>Keylogger</li> <li>Flex-Box Css-Tricks</li> </ul>"},{"location":"about/website/site-development/#svgfavicon","title":"SVG/Favicon","text":"<ul> <li>*SVG favicon generator and preview<ul> <li>Ico Builder</li> </ul> </li> <li>Pottrace</li> <li>Image magick</li> <li>How to favicon</li> <li>Favicon Checker</li> <li>Mask for safari<ul> <li>Safari Mask</li> </ul> </li> <li>Free SVGs</li> <li>Editor</li> <li>Maker Instructions</li> <li>Scour<ul> <li>SVG for Scale</li> </ul> </li> <li>Scaler<ul> <li>W3</li> </ul> </li> <li>WebP converter</li> <li>Base64/Efficiency</li> </ul>"},{"location":"about/website/site-development/#color","title":"Color","text":"<ul> <li>MaterialUi</li> <li>Happy Hues</li> <li>Color Palette Application</li> <li>Examples</li> <li>Color equations for high contrast</li> <li>Adobe Color Palette</li> <li>Slate Palette</li> <li>Palette Design</li> <li>4.5:1 Contrast Color<ul> <li>Contast</li> </ul> </li> <li>Palette Visualizer</li> </ul>"},{"location":"about/website/site-development/#security","title":"Security","text":"<ul> <li>Security Guidelines</li> <li>Site Check</li> <li>HSTS Preload</li> <li>ICANN Lookup</li> <li>MXT Toolbox</li> <li>Kinsta HSTS Missing</li> <li>Pre-Commit Log</li> <li>Content Security Policy<ul> <li>Browser Test</li> </ul> </li> <li>Validator</li> <li>HTTP Auth MDN</li> <li>CSP MOZILLA</li> <li>ValidationDisableButton</li> <li>Security Policy Header Field</li> <li>Nonce CSP</li> <li>Strict CSP</li> <li>Experte Security</li> </ul>"},{"location":"about/website/site-development/#page-speed","title":"Page Speed","text":"<ul> <li>Page Speed Analysis</li> <li>Experte Page Speed</li> <li>Image to Data URI Converter</li> <li>RedBot</li> <li>Before Speed Testing</li> <li>Ping</li> <li>GZip Compression</li> <li>HSTS Preload Checker<ul> <li>HT Acess when using subdomain</li> </ul> </li> </ul>"},{"location":"about/website/site-development/#examples-of-good-websites","title":"Examples of Good Websites","text":"<ul> <li>Colors</li> <li>Examples<ul> <li>Modern CSS</li> </ul> </li> <li>CV<ul> <li>CV2</li> </ul> </li> <li>About Page</li> <li>About</li> <li>Tags</li> <li>Format</li> <li>Coreultrasound.com</li> <li>JS<ul> <li>Velocity</li> </ul> </li> <li>Login Page<ul> <li>React Login</li> <li>Google Auth</li> </ul> </li> <li>VSCode Functions</li> <li>Bookdown</li> </ul> <ul> <li>[Mermaid * [Flowcharts]</li> </ul>"},{"location":"about/website/style-cheatsheet/","title":"Style Cheatsheet","text":""},{"location":"about/website/style-cheatsheet/#basic","title":"Basic","text":"<ul> <li>This was marked (highlight)</li> <li>This was inserted (underline) with caret</li> <li>This was also underlined, using &lt; ins &gt; </li> <li>This was deleted (strikethrough)</li> <li>Examples of super/subscripting<ul> <li>H<sub>2</sub>O using tilde</li> <li>A<sup>T</sup>A using caret</li> </ul> </li> </ul> <p>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Example of Indent using &amp; nbsp;</p> <ul> <li>Copyright (\u00a9) \u2014 \u00a9</li> <li>Registered trademark (\u00ae) \u2014 \u00ae</li> <li>Trademark (\u2122) \u2014 \u2122</li> <li>Euro (\u20ac) \u2014 \u20ac</li> <li>Left arrow (\u2190) \u2014 \u2190</li> <li>Up arrow (\u2191) \u2014 \u2191</li> <li>Right arrow (\u2192) \u2014 \u2192</li> <li>Down arrow (\u2193) \u2014 \u2193</li> <li>Degree (\u00b0) \u2014 \u00b0</li> <li>Pi (\u03c0) \u2014 \u03c0</li> </ul>"},{"location":"about/website/style-cheatsheet/#notes","title":"Notes","text":"<p>Note</p> <p>This is a quote.</p> <p>Abstract</p> <p>This is a quote.</p> <p>Info</p> <p>This is a quote.</p> <p>Tip</p> <p>This is a quote.</p> <p>Success</p> <p>This is a quote. </p> <p>Question</p> <p>This is a quote.</p> <p>Warning</p> <p>This is a quote.</p> <p>Failure</p> <p>This is a quote.</p> <p>Danger</p> <p>This is a quote. </p> <p>Bug</p> <p>This is a quote.</p> <p>Example</p> <p>This is a quote.</p> <p>Quote</p> <p>This is a quote.</p>"},{"location":"about/website/style-cheatsheet/#mermaid","title":"Mermaid","text":"<pre><code>graph LR\n  A[Start] --&gt; B{Error?};\n  B --&gt;|Yes| C[Hmm...];\n  C --&gt; D[Debug];\n  D --&gt; B;\n  B ----&gt;|No| E[Yay!];</code></pre>"},{"location":"about/website/style-cheatsheet/#grids-not-working","title":"Grids (Not working)","text":"<ul> <li> <p>:material-clock-fast Set up in 5 minutes</p> <p>Install <code>mkdocs-material</code> with <code>pip</code> and get up and running in minutes :octicons-arrow-right-24</p> </li> <li> <p>:fontawesome-brands-markdown:{ .lg .middle } It's just Markdown</p> <p>Focus on your content and generate a responsive and searchable static site</p> <p>:octicons-arrow-right-24: Reference</p> </li> <li> <p>:material-format-font:{ .lg .middle } Made to measure</p> <p>Change the colors, fonts, language, icons, logo and more with a few lines</p> <p>:octicons-arrow-right-24: Customization</p> </li> <li> <p>:material-scale-balance:{ .lg .middle } Open Source, MIT</p> <p>Material for MkDocs is licensed under MIT and available on GitHub</p> <p>:octicons-arrow-right-24: License</p> </li> </ul>"},{"location":"about/website/style-cheatsheet/#creating-definitions","title":"Creating Definitions","text":"<code>Example</code> <p>This is a definition of the example.</p>"},{"location":"about/website/style-cheatsheet/#colored-text","title":"Colored Text","text":"<p><code>Red Not working</code></p>"},{"location":"about/website/style-cheatsheet/#coded-text","title":"Coded Text","text":"<pre><code>Hi</code></pre>"},{"location":"about/website/style-cheatsheet/#codedstyled-text","title":"Coded/Styled Text","text":"Subscribe<pre><code>[Subscribe](#)\n</code></pre>"},{"location":"about/website/style-cheatsheet/#nested-notes","title":"Nested Notes","text":"Open styled details Closed nested details! <p>And more content again.</p> Success <p>And more content again.</p>"},{"location":"fellowship-guide/","title":"Cards Fellowship Guide","text":"<ul> <li>Welcome to my guide for cardiology fellowship. Please see the disclaimer on the main page.</li> <li>I've tried to include as much information as I've learned to make this as useful as possible for training.</li> <li>Feel free to suggest edits via Github. Most pages will have the ability to edit in the top right corner of the inner page text.</li> <li>These will require an approval process please be patient.</li> </ul>"},{"location":"fellowship-guide/#guides-and-resources","title":"Guides and Resources","text":"<ul> <li>ACGME Common Program Requirements (Fellowship) - 2023</li> <li>SUNY Upstate Cardiac Care Unit Survival Guide</li> <li>Emory CDU Guide</li> </ul>"},{"location":"fellowship-guide/#important-websites","title":"Important Websites","text":"<ul> <li>Microsoft Login</li> <li>NewInnovations</li> <li>OpenEvidence</li> <li>Mayo Board Review</li> <li>EKGSource</li> </ul>"},{"location":"fellowship-guide/calculators/","title":"Calculators","text":""},{"location":"fellowship-guide/calculators/#calculators","title":"Calculators","text":"<ul> <li>Enter the below parameters for resulting outputs.</li> <li>References<ul> <li>PA Catheter Normative Data</li> </ul> </li> </ul>"},{"location":"fellowship-guide/cardsfellowshipreqs/","title":"Cardiology Fellowship Competence Requirements","text":""},{"location":"fellowship-guide/cardsfellowshipreqs/#curriculum","title":"Curriculum","text":"<ul> <li>Advocate Health Example Curriculum</li> <li>According to the ACGME Program Requirements for Graduate Medical Education in Cardiovascular Disease (2019), each fellow must have the following minimum number of rotations by graduation:<ul> <li>CATH (4 months)</li> <li>Non-Invasive Rotations (6 months):<ul> <li>ECHO (3 months)</li> <li>Nuclear (2 months)</li> <li>Non-Invasive (1 month)</li> </ul> </li> <li>EP (2 months)</li> <li>Non-Laboratory clinical practice activities (9 months)</li> </ul> </li> </ul>"},{"location":"fellowship-guide/cardsfellowshipreqs/#echo-requirements","title":"Echo Requirements","text":"<ul> <li>Level I: Required for all fellows</li> <li>Level II: Additional training in 1 or more areas that enables some cardiologists to perform or interpret specific diagnostic tests and procedures or render more specialized care for patients with certain conditions</li> <li>Level II echocardiography training is required to provide independent interpretation of echocardiograms</li> <li>TTEs Performed: 150</li> <li>TTEs Interpreted: 300</li> <li>TEEs Performed and Interpreted: 50</li> <li>Stress Echos (Includes 25 for non-coronary indications): 100</li> <li>Level III: Required of individuals who intend to perform and interpret complex studies in special populations, lead a research program, direct an academic echocardiography laboratory, and/or train others in advanced aspects of echocardiography</li> </ul>"},{"location":"fellowship-guide/fellowship-excel-guide/","title":"Fellowship Excel Guide","text":"<p>Appreciate Mike Thomas for his set up with distance. Link to site</p>"},{"location":"fellowship-guide/fellowship-excel-guide/#setup-in-excel","title":"Setup in Excel","text":"<ul> <li>Find your participating specialty list on the AAMC ERAS Directory</li> <li>For this example, I will be using Cardiology</li> </ul> <ul> <li>Copy the list using ctrl+c</li> </ul> <ul> <li>Paste this into Excel using ctrl+v</li> </ul>"},{"location":"fellowship-guide/fellowship-excel-guide/#formatting","title":"Formatting","text":"<ul> <li>Delete Column C and E</li> <li>Change Column A and B width to 20</li> <li>Center align everything</li> </ul>"},{"location":"fellowship-guide/fellowship-excel-guide/#creating-headings-and-a-reference","title":"Creating Headings and a Reference","text":"<ul> <li>Insert 2 rows above column 1</li> <li>One will become our headings, one will become our reference (destination) </li> </ul>"},{"location":"fellowship-guide/fellowship-excel-guide/#adding-a-reference-city","title":"Adding a Reference City","text":"<ul> <li>Label the headings in row 2</li> <li>Label E2 as \"Latitude\"</li> <li>Label F2 as \"Longitude\"</li> <li>Label G2 as \"Population\"</li> <li>Label H2 as \"Distance\"</li> <li>Label I2 as \"Apply?\"</li> <li>Enter your preferred destination in cell B1</li> </ul>"},{"location":"fellowship-guide/fellowship-excel-guide/#using-bings-geography-plugin","title":"Using Bing's Geography plugin","text":"<ul> <li>Select your column of cities (without the Reference or headings we created above) in column 2 and navigate to \"Data\" where you will need to select \"Geography\" as seen below</li> </ul> <ul> <li>Notice the maps beside each location </li> </ul>"},{"location":"fellowship-guide/fellowship-excel-guide/#adding-latitude-longitude-and-population","title":"Adding Latitude, Longitude and Population","text":"<ul> <li>Right-click on one of your cities in column 2 and select \"latitude\"</li> <li>This will populate the E2 cell with a data value automatically</li> </ul> <ul> <li>Repeat this step for \"longitude\" and \"population\" for your cities as well as your Reference city and you should have something like below</li> </ul>"},{"location":"fellowship-guide/fellowship-excel-guide/#calculating-distance","title":"Calculating Distance","text":"<ul> <li>In cell H3, copy and paste the code below and press enter</li> </ul> <pre><code>=INT(ACOS(COS(RADIANS(90-$E$1)) * COS(RADIANS(90-E3)) + SIN(RADIANS(90-$E$1)) * SIN(RADIANS(90-E3)) * COS(RADIANS($F$1-F3))) * 3959)\n</code></pre> <ul> <li>Select cells E3 through H3 and drag these cells down</li> </ul>"},{"location":"fellowship-guide/fellowship-excel-guide/#filtering-fellowship-programs","title":"Filtering Fellowship Programs","text":"<ul> <li>To sort your programs, select all of the Headings and select \"Filter\"</li> <li>This allows you to filter by distance (See [Problem Solving (Errors)][#problem-solving-errors] below if you get #FIELD! type errors)</li> </ul>"},{"location":"fellowship-guide/fellowship-excel-guide/#excel-basic-manipulation","title":"Excel Basic Manipulation","text":"<ul> <li>Center align everything to make it pretty and color all of the text to be whatever you wish</li> <li>I chose light blue for links and black for the rest of the cells</li> </ul>"},{"location":"fellowship-guide/fellowship-excel-guide/#conditional-formatting-optional","title":"Conditional Formatting (Optional)","text":"<ul> <li>To make this spreadsheet pretty, I'll show you how to add conditional formatting. We will be making 3 rules to make our choices for application Pop</li> <li> <p>Our 1<sup>st</sup> rule will be making all \"Apply?\" column cells turn green if we enter <p>\"Yes\"</p></p> </li> <li> <p>Find \"Conditional Formatting\" on the \"Home\" panel and select \"New Rule\"</p> </li> </ul> <p></p> <ol> <li>Next, select your entire range of data including the cities as well as your \"Apply?\" column</li> <li>Under our rule, choose rule type \"Formula\" and enter the equation</li> <li>\"=$I3=\"Yes\"</li> <li>Format this to be green fill with either green or black text</li> <li>Save and apply this rule</li> </ol> <p></p> <ol> <li>Next, we'll be doing the same thing for <p>\"Maybe\"</p> and <p>\"No\"</p> but with the appropriate colors as below</li> </ol> <p></p> <ul> <li>Now, whenever you fill the \"Apply?\" column, the entire row should change colors!</li> <li>The \"Apply?\" field is also sortable by color, seen below, making this very useful when deciding where you want to apply</li> </ul> <p></p>"},{"location":"fellowship-guide/fellowship-excel-guide/#problem-solving-errors","title":"Problem Solving (Errors)","text":"<ul> <li>Occasionally you will get #FIELD! errors as seen below</li> </ul> <ul> <li>These occur because Bing doesn't have a reference to pull from causing an error when pulling the data automatically</li> <li>To resolve these, google the \"latitude\", \"longitude\", or \"population\" that is missing from the referenced location and paste it into the appropriate cell</li> </ul>"},{"location":"fellowship-guide/fellowship-excel-guide/#example-excel-file","title":"Example Excel File","text":"<ul> <li>Excel: Cards-Fellowship Example</li> <li>Download Location</li> </ul>"},{"location":"fellowship-guide/topics/","title":"Cardiology Topics","text":""},{"location":"fellowship-guide/topics/cardsdotphrases/","title":"Cardiology Dotphrases","text":""},{"location":"fellowship-guide/topics/cardsdotphrases/#aechf","title":"AECHF","text":"<ul> <li>Acute Exacerbation of known [HFrEF] w/previous LVEF [ ] on TTE [ ].</li> <li>New LVEF [ ] on TTE [ ] with evidence of clinical decompensation on presentation.</li> <li>[Euvolemic on exam today, clinically improving].</li> <li>Monitor I/Os, UOP, daily standing weights, fluid restriction &lt;2L daily.</li> <li>[Continue current medical therapy].</li> <li>[Optimizing volume status while titrating GDMT as BP allows].</li> <li>Repeat electrolytes in the morning.</li> <li>CHF powerplan in, will need close f/u with CHF clinic once outpatient.</li> </ul>"},{"location":"fellowship-guide/topics/consults/","title":"Consults","text":""},{"location":"fellowship-guide/topics/consults/#effective-consultation","title":"Effective Consultation","text":"<ul> <li>Following Dr. Goldman's suggestions, the helpful consultant will:<ul> <li>Determine the question that is being asked</li> <li>Establish the urgency of the consultation</li> <li>Gather primary data</li> <li>Communicate as briefly as appropriate</li> <li>Make specific recommendations</li> <li>Provide contingency plans</li> <li>Understand his own role in the process</li> <li>Offer educational information</li> <li>Communicate recommendations directly to the requesting physician</li> <li>Provide appropriate follow-up</li> </ul> </li> </ul>"},{"location":"fellowship-guide/topics/consults/#resources","title":"Resources","text":"<ul> <li>Reducing Unprofessional Interactions Between Consulting Physicians and Emergency Physicians</li> <li>The Washington Manual Cardiology Subspecialty Consult</li> <li>Cardiology Trials</li> <li>Deranged Physiology - Cardiology</li> <li>ACC Guidelines</li> <li>Ten Commandments of Effective Consultations by Lee Goldman, MD</li> <li>Navigating Consults as a Fellow</li> </ul>"},{"location":"fellowship-guide/topics/ekg/","title":"EKGs","text":"","tags":["EKGs"]},{"location":"fellowship-guide/topics/ekg/#resources","title":"Resources","text":"<ul> <li>EKG-Maven</li> <li>Unbound Medicine EKGs</li> <li>TheMDSite Reference Guide</li> <li>Utah Introduction to ECG Interpretation 2017-2018</li> <li>Online ECG Book</li> <li>ECG Videos</li> <li>ECG identification practice - game</li> <li>EKG for EM Physicians</li> <li>Killer ECG Patterns: Part 1</li> <li>Excaliper</li> </ul>","tags":["EKGs"]},{"location":"fellowship-guide/topics/ekg/#blogs","title":"Blogs","text":"<ul> <li>Dr. Smith's ECG Blog</li> </ul>","tags":["EKGs"]},{"location":"fellowship-guide/topics/ekg/#ekg-indications","title":"EKG Indications","text":"<ul> <li>Determine cardiac rate</li> <li>Define cardiac rhythm</li> <li>Diagnose old or new MI</li> <li>Identify intracardiac conduction disturbances</li> <li>Aid in the diagnosis of IHD, pericarditis, myocarditis, electrolyte abnormalities and pacemaker malfunction</li> </ul>","tags":["EKGs"]},{"location":"fellowship-guide/topics/imaging/","title":"Cardiac Imaging","text":"","tags":["Imaging"]},{"location":"fellowship-guide/topics/imaging/#resources","title":"Resources","text":"<p>Multimodality imaging in cardiology: a statement on behalf of the Task Force on Multimodality Imaging of the European Association of Cardiovascular Imaging</p> <p>Marc Katz MD Rundown for Cardiology Fellows</p>","tags":["Imaging"]},{"location":"fellowship-guide/topics/cardiac-critical-care/cardiogenic-shock/","title":"Cardiogenic Shock","text":"","tags":["Heart Failure","CICU","Shock"]},{"location":"fellowship-guide/topics/cardiac-critical-care/cardiogenic-shock/#definition","title":"Definition","text":"<pre><code>1. Persistent hypotension \n    - (SBP &lt;90 mmHg or MAP below baseline)\n2. Cardiac Index &lt;1.8 L/min/m^2 w/o support \n    - (&lt;2.2 L/min/m^2 with support)\n3. Adequate or elevated filling pressure \n    - (LVEDP &gt;18 mmHg, RVEDP &gt;10 mmHg)\n    - PCWP &gt;15\n    - RAP/PCWP \u22650.8\n    - CPO \u22640.6\n    - PAP &lt;1.85\n</code></pre>","tags":["Heart Failure","CICU","Shock"]},{"location":"fellowship-guide/topics/cardiac-critical-care/cardiogenic-shock/#etiology","title":"Etiology","text":"<ul> <li>Ischemic<ul> <li>Acute MI most commonly</li> </ul> </li> <li>Valve related<ul> <li>Acute Aortic or Mitral Regurgitation</li> </ul> </li> <li>Rate Related</li> <li>Cardiomyopathy</li> <li>Toxicologic</li> </ul>","tags":["Heart Failure","CICU","Shock"]},{"location":"fellowship-guide/topics/cardiac-critical-care/cardiogenic-shock/#calculating-co-ci-and-cpo","title":"Calculating CO, CI, and CPO","text":"<ul> <li>CO (Cardiac Output), L/min = VO2 / [(SaO2 - SvO2) x Hb x 13.4]<ul> <li>Where VO2 = 125 mL O2/min x BSA</li> <li>BSA = [(Height, cm x Weight, kg)/ 3,600]\u00bd</li> <li>In elderly patients (age \u226570 years), use 110 mL O2 x BSA for VO2<ul> <li>Cardiac Output Calculator</li> </ul> </li> </ul> </li> <li>CI (Cardiac Index), L/min/m2 = CO/BSA<ul> <li>SV (Stroke Volume), mL/beat = CO/HR</li> <li>Normal Values<ul> <li>CO = 4.0-8.0 L/min</li> <li>CI = 2.5-4.0 L/min/m2</li> <li>SV = 60-100 mL/beat</li> <li>MAP \u226560 mmHg</li> </ul> </li> <li>Note: SaO2 should be acquired by arterial blood gas measurement. SvO2 should be acquired by mixed venous gas from a pulmonary artery catheter. Formula assumes decimal values, not percentages</li> </ul> </li> <li>CPO (Cardiac Power), W = (CO x MAP) / 451<ul> <li>CPO &lt; 0.6 watts is indicative of hemodynamic compromise and is associated with increased risk of mortality<ul> <li>Cardiac power is the strongest hemodynamic correlate of mortality in cardiogenic shock: a report from the SHOCK trial registry</li> <li>Improved Prognostic Performance of Cardiac Power Output With Right Atrial Pressure: A Subanalysis of the ESCAPE Trial</li> </ul> </li> <li>CPO Calculator</li> </ul> </li> </ul>","tags":["Heart Failure","CICU","Shock"]},{"location":"fellowship-guide/topics/cardiac-critical-care/cardiogenic-shock/#management","title":"Management","text":"<ul> <li>Management of Cardiogenic Shock</li> <li>Contemporary Management</li> <li>Determine Shock Profile<ul> <li>Biventricular<ul> <li>RA &gt; 15, PCWP &gt; 15-18, PAPi \u2264 0.9</li> <li>VA-ECMO \u00b1 LV decompression</li> <li>TandemHeart-LVAD with TandemHeart-RVAD \u00b1 ProtekDuo (\u00b1 Oxygenator)</li> <li>Bipella</li> </ul> </li> <li>LV<ul> <li>RA &lt; 15, PCWP &gt; 15-18, PAPi &gt; 0.9, RA/PCWP &lt; 0.63</li> <li>Impella</li> <li>TandemHeart-LVAD</li> <li>Central Temporary LVAD</li> </ul> </li> <li>RV<ul> <li>RA &gt; 15, PCWP &lt; 15-18, PAPi \u2264 0.9, RA/PCWP &gt; 0.63</li> </ul> </li> </ul> </li> <li>Figure out etiology<ul> <li>Valve related</li> <li>Ischemic<ul> <li>Impella in STEMI</li> </ul> </li> <li>Rate Related</li> <li>Cardiomyopathy</li> <li>Toxicologic</li> </ul> </li> <li>Inotropic Therapy<ul> <li>Milrinone = Dobutamine</li> <li>Use in hypotension, endo-organ hypoperfusion, shock<ul> <li>Generally, presents with hypoperfusion (reduced urine output)</li> </ul> </li> <li>If due to contractile failure<ul> <li>Dobutamine + Norepinephrine to get MAP \u226565 w/ Mechanical circulatory support<ul> <li>Intra-aortic Balloon Counter Pulsation</li> </ul> </li> </ul> </li> <li>Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial</li> </ul> </li> <li>Pressors if needed for MAP &gt; 65<ul> <li>IV Vasopressor (norepinephrine)</li> <li>Levophed &gt; Dopamine<ul> <li>Useful in Pulmonary congestion for rapid dyspnea relief if preserved Blood pressure</li> </ul> </li> <li>Epinephrine is good too but more arrhythmogenic</li> </ul> </li> <li>Mechanical Cardiac Support (MCS)</li> <li>Shock Centers</li> </ul>","tags":["Heart Failure","CICU","Shock"]},{"location":"fellowship-guide/topics/cardiac-critical-care/cardiogenic-shock/#related-dotphrases","title":"Related Dotphrases","text":"","tags":["Heart Failure","CICU","Shock"]},{"location":"fellowship-guide/topics/cardiac-critical-care/cardiogenic-shock/#further-reading","title":"Further Reading","text":"<ul> <li>Manual of Cardiovascular Medicine by Brian P. Griffin MD is high yield and covers just about every topic you may encounter in the CICU. This manual is particularly useful for first-year fellows</li> <li>Managing Patients with Short-Term MCS</li> <li>Great EMCrit article</li> <li>Journal Feed</li> </ul>","tags":["Heart Failure","CICU","Shock"]},{"location":"fellowship-guide/topics/cardiac-critical-care/mechanical_support/","title":"Mechanical Support","text":"","tags":["Heart Failure","CICU","MCS","Shock"]},{"location":"fellowship-guide/topics/cardiac-critical-care/mechanical_support/#mechanical-cardiac-support-mcs","title":"Mechanical Cardiac Support (MCS)","text":"<ul> <li>Indications for MCS<ul> <li>Cardiogenic shock due to<ul> <li>Acute myocardial infarction and related mechanical complications</li> <li>Acute decompensated heart failure</li> <li>Acute myocarditis</li> <li>Post-cardiotomy shock</li> <li>Acute rejection post-cardiac transplant with hemodynamic compromise</li> </ul> </li> <li>High-risk interventions<ul> <li>Percutaneous coronary intervention</li> <li>Ventricular tachycardia ablation</li> </ul> </li> <li>Bridge to LVAD or transplant</li> <li>Right ventricular failure</li> </ul> </li> </ul>","tags":["Heart Failure","CICU","MCS","Shock"]},{"location":"fellowship-guide/topics/cardiac-critical-care/mechanical_support/#differences-in-mechanical-circulatory-support","title":"Differences in Mechanical Circulatory Support","text":"<ul> <li>Differences</li> <li>Impella<ul> <li>Decreases PCWP</li> <li>Increases coronary blood flow, reduces infarct size</li> <li>Works independently of LV function and cardiac rhythm</li> <li>Impella 2.5<ul> <li>CO: 2.5-4 L/min</li> </ul> </li> <li>Impella 5<ul> <li>CO: 5 L/min</li> <li>Requires surgical cutdown</li> </ul> </li> <li>Notes<ul> <li>Wean to P2, pull from LV on P2, change to P0 and remove</li> <li>Set to P2 to adjust</li> </ul> </li> <li>Simple Education - MCS</li> </ul> </li> <li>The Use of Cardioprotective Devices and Strategies in Patients Undergoing Percutaneous Procedures and Cardiac Surgery</li> </ul>","tags":["Heart Failure","CICU","MCS","Shock"]},{"location":"fellowship-guide/topics/cardiac-critical-care/mechanical_support/#examples","title":"Examples","text":"","tags":["Heart Failure","CICU","MCS","Shock"]},{"location":"fellowship-guide/topics/cardiac-pharm/antianginals/","title":"Anti-Anginals","text":"","tags":["Anti-Anginals","Nitrates","Angina","ACS"]},{"location":"fellowship-guide/topics/cardiac-pharm/antianginals/#nitrates","title":"Nitrates","text":"<ul> <li>General<ul> <li>MOA: Primarily vasodilators that dilate, veins, arterioles, and particularly the coronary arteries by relaxing vascular smooth muscle cells, but also venodilators<ul> <li>Their primary anti-ischemic effects are due to systemic vasodilation and decreasing cardiac preload (lowering LVEDV and LVESV) rather than coronary vasodilation</li> <li>This causes reduced LV wall stress reducing myocardial oxygen demand, and relieving anginal symptoms</li> <li>Arterial and arteriolar vasodilation can decrease SVR and blood pressure, but to a lesser degree</li> <li>They do act as coronary vasodilators, but benefit is uncertain</li> <li> <ul> <li>No direct effect on cardiac chronotropy, inotropy (contractility), LVEF</li> </ul> </li> </ul> </li> <li>USE: Chest pain relief in patients with chronic stable angina and ACS</li> <li>SE: Reflex Tachycardia<ul> <li>Concomitant use of beta-blockers to prevent</li> </ul> </li> </ul> </li> <li>Isosorbide Dinitrate<ul> <li>USE:<ul> <li>FDA Approved: Prevention or treatment (glyceryl trinitrate preferred) of angina pectoris from CAD</li> <li>Non-FDA Approved: Achalasia, DES</li> </ul> </li> </ul> </li> <li>Isosorbide Mononitrate<ul> <li>USE:<ul> <li>FDA Approved: Treatment of angina pectoris from CAD<ul> <li>Along with Non-selective BBs, can be used for prevention of recurrent variceal bleeding as secondary prophylaxis if unable to tolerate/refuse EVL<ul> <li>10mg nightly up to 20mg BID</li> </ul> </li> </ul> </li> </ul> </li> </ul> </li> <li>Sodium Nitroprusside<ul> <li>Parenteral vasodilator with quick onset and offset of action and is commonly used for rapid BP control in patients with hypertensive emergency<ul> <li>Its metabolism releases NO and Cyanide<ul> <li>Induces arteriolar and venous vasodilation</li> </ul> </li> <li>May cause reflex tachycardia and enhance ventricular contraction increasing aortic wall stress (give BB first)</li> </ul> </li> <li>SE: Irreversible Cyanide toxicity (Thiocyanate, most common in renal insufficiency), disorientation, Headache, tinnitus, Tachyphylaxis</li> <li>IV: Use only for patients with ACS or Acute pulmonary edema</li> <li>Avoid in patients with RV infarction and those on PDE-5 inhibitors</li> </ul> </li> </ul>","tags":["Anti-Anginals","Nitrates","Angina","ACS"]},{"location":"fellowship-guide/topics/cardiac-pharm/antianginals/#non-nitrates","title":"Non-Nitrates","text":"<ul> <li>Ranolazine (Ranexa)<ul> <li>MOA: Partially inhibits fatty acid oxidation and increases glucose oxidation</li> <li>Dose: 500-1000mg BID</li> <li>USE:<ul> <li>IIa: Chronic Stable Angina Refractory to other anti-anginal therapy</li> <li>Increases exercise tolerance/duration</li> </ul> </li> <li>SE: QTc prolongation in liver disease<ul> <li>No HR or BP reduction</li> </ul> </li> </ul> </li> </ul>","tags":["Anti-Anginals","Nitrates","Angina","ACS"]},{"location":"fellowship-guide/topics/cardiac-pharm/antianginals/#nitrate-induced-headaches","title":"Nitrate-Induced Headaches","text":"<ul> <li>Treatment<ul> <li>1<sup>st</sup> Line: Cold-Compress and Tylenol</li> <li>2<sup>nd</sup> Line: BBs and CCBs</li> </ul> </li> </ul>","tags":["Anti-Anginals","Nitrates","Angina","ACS"]},{"location":"fellowship-guide/topics/cardiac-pharm/antiarrhythmics/","title":"Anti-Arrhythmics","text":"","tags":["Anti-Arrhythmics","Beta-Blockers","Calcium Channel Blockers"]},{"location":"fellowship-guide/topics/cardiac-pharm/antiarrhythmics/#general","title":"General","text":"<ul> <li>A good thing to note is that all anti-arrhythmics are \"pro-arrhythmic\"</li> <li>Classified via the Vaughan Williams system</li> <li>All used to control arrhythmias by decreasing conduction:<ul> <li>Class I and III work on Arial/Ventricular myocytes</li> <li>Class II and IV work on the AV node</li> </ul> </li> <li>Alcohol<ul> <li>Promotes SNS stimulation, shortens atrial effective refractory period, increased interatrial electromechanical delays, acts via vagal pathways</li> </ul> </li> </ul>","tags":["Anti-Arrhythmics","Beta-Blockers","Calcium Channel Blockers"]},{"location":"fellowship-guide/topics/cardiac-pharm/antiarrhythmics/#class-i-na-channel-blockers","title":"Class I (Na+ Channel Blockers)","text":"<ul> <li>General<ul> <li>Inhibit phase 0 of the AP (initial depolarization)</li> <li>Prolonged QRS at faster HR (use dependence)<ul> <li>Increase in QRS duration during stress test/exercise</li> <li>Makes them useful</li> </ul> </li> <li>Use dependence (enhanced effect at faster heart rates due to tighter drug binding), seen most frequently with IC \u2265 IA and rarely IB, this is why they're so good in SVTs</li> </ul> </li> </ul>","tags":["Anti-Arrhythmics","Beta-Blockers","Calcium Channel Blockers"]},{"location":"fellowship-guide/topics/cardiac-pharm/antiarrhythmics/#class-ia","title":"Class Ia","text":"<ul> <li>General<ul> <li>Slow conduction throughout the His-Purkinje system, atria, and ventricles and prolong the refractory state</li> <li>Lengthens the action potential: Right shift<ul> <li>Preferentially binds sodium</li> <li>Act on Phase 0 of the action potential<ul> <li>Prolongation of the QRS</li> </ul> </li> <li>No potassium blocking effects<ul> <li>No QT prolongation usually</li> </ul> </li> </ul> </li> <li>SE: PVT</li> </ul> </li> <li>Procainamide<ul> <li>Acute Use: Convert/prevent AF/VT, WPW</li> <li>SE: Lupus like syndrome, increased ventricular rate in AF or AFL<ul> <li>Prolonged QT and prolonged QRS but also causes blood dyscrasias, agranulocytosis, neutropenia, thrombocytopenia, Torsades de pointes</li> <li>Caution in HF</li> <li>Hypotension, pleural effusions, rash, myalgia</li> <li>Pericarditis</li> </ul> </li> </ul> </li> <li>Quinidine<ul> <li>Acute Use: Convert/Prevent AF/VT</li> <li>Chronic Use: AF/SVT/VT Prevention</li> <li>SE: Diarrhea, nausea, vomiting, cinchonism, thrombocytopenia<ul> <li>Prolongs QRS and the QT, hearing loss, tinnitus, psychosis</li> </ul> </li> </ul> </li> <li>Disopyramide<ul> <li>Chronic Use: AF/SVT Prevention</li> <li>SE: Anticholinergic, urinary retention, constipation, dry mouth<ul> <li>Prolonged QT, QRS, Torsades de pointes</li> </ul> </li> </ul> </li> </ul>","tags":["Anti-Arrhythmics","Beta-Blockers","Calcium Channel Blockers"]},{"location":"fellowship-guide/topics/cardiac-pharm/antiarrhythmics/#class-ib","title":"Class Ib","text":"<ul> <li>Phenytoin, Mexiletine, Tocainide</li> <li>General<ul> <li>Preferentially binds sodium after initial depolarization<ul> <li>Therefore, tends to work better in ischemia</li> </ul> </li> <li>Shortens the action potential: Left shift<ul> <li>Weaker binding than Class IA agents</li> <li>Widen QRS and produce Bradycardia</li> <li>Prolong PR interval</li> </ul> </li> <li>SE: Ventricular tachycardia</li> </ul> </li> <li>Lidocaine<ul> <li>Acute Use: VT</li> <li>SE: Seizures, Dizziness, confusion, delirium, slow VT in patients with HD</li> </ul> </li> </ul>","tags":["Anti-Arrhythmics","Beta-Blockers","Calcium Channel Blockers"]},{"location":"fellowship-guide/topics/cardiac-pharm/antiarrhythmics/#class-ic","title":"Class Ic","text":"<ul> <li>General<ul> <li>Used in AFib w/ normal hearts</li> <li>Slowest rate of drug binding and slowest dissociation from Na channel receptor (works better when heart rates are high)</li> <li>Slows atrial conduction, may result in 1-1 AV conduction<ul> <li>AV node blocking agents co-prescribed?</li> </ul> </li> <li>No significant action potential effect: Left squeeze, no shift<ul> <li>Normally no QRS/QT prolongation</li> <li>More likely to prolong QRS \u2265 QT, but both are possible</li> <li>Greatest Use Dependence</li> </ul> </li> </ul> </li> <li>Flecainide<ul> <li>Acute: 300mg PO for conversion, 150mg BID maintain</li> <li>Chronic Use: AF/SVT/VT Prevention<ul> <li>Decreased contractility</li> </ul> </li> </ul> </li> <li>Propafenone (Rythmol)<ul> <li>Acute: 600mg PO for convert, 300mg TID maintain</li> <li>Chronic Use: AF/SVT/VT Prevention<ul> <li>Taste disturbances</li> </ul> </li> </ul> </li> <li>Moricizine (Ethmozine)</li> </ul>","tags":["Anti-Arrhythmics","Beta-Blockers","Calcium Channel Blockers"]},{"location":"fellowship-guide/topics/cardiac-pharm/antiarrhythmics/#class-ii-beta-adrenergic-blockers","title":"Class II (Beta-Adrenergic Blockers)","text":"<ul> <li>General<ul> <li>Work purely by blocking Beta-Adrenergic stimulation of the cardiac myocytes<ul> <li>Decreases Sinus and AV nodal conduction</li> <li>Reduces intracellular cAMP, reducing Ca2+ influx</li> </ul> </li> <li>Anti-anginal effects mediated by reducing myocardial contractility (negative inotropic) and HR (negative chronotropic), decreasing myocardial oxygen demand</li> <li>Membrane stabilizers: Carvedilol, propranolol \u2265 labetalol, metoprolol</li> <li>SE: taper slowly, decreased libido, impotence</li> </ul> </li> <li>Non-Selective (B1 = B2 blockers)<ul> <li>Can trigger bronchoconstriction in asthmatics due to B2 blockade</li> <li>Carvedilol (Coreg)<ul> <li>Also has alpha-1 blocking ability</li> <li>Target dosage in HFrEF is 25mg BID or 50mg BID if \u226585kg</li> </ul> </li> <li>Labetalol<ul> <li>Also has alpha-1 blocking ability</li> <li>Highly lipophilic</li> <li>CI: Asthma, COPD, Heart Block, may worsen heart failure</li> </ul> </li> <li>Nadolol (Corgard)<ul> <li>Chronic Use: Same as Metoprolol</li> <li>Hydrophilic</li> </ul> </li> <li>Propranolol (Inderal)</li> <li>Sotalol (Betapace)<ul> <li>Hydrophilic</li> </ul> </li> <li>Timolol</li> </ul> </li> <li>Cardio-selective (B1 \u2265 B2 blockers)<ul> <li>Atenolol<ul> <li>Hydrophilic</li> </ul> </li> <li>Bisprolol (Zebeta)</li> <li>Esmolol<ul> <li>Acute Use: AF/AFL Rate Control</li> <li>CI: Concurrent BB therapy, bradycardia, pulmonary edema, severe HF</li> </ul> </li> <li>Nebivolol (Bystolic)<ul> <li>B3 agonist also</li> </ul> </li> <li>Metoprolol (Lopressor, Toprol XL)<ul> <li>Acute Use: SVT, AF Rate Control, Exercise-induced VT, Long QT</li> <li>Chronic Use: AF Rate Control/SVT, Long QT/RVQT VT</li> <li>BB, inhibits sympathetic activity, leading to decrease in rate of impulse generation and increase in refractory period of the AV node</li> <li>No QRS prolongation</li> <li>SE: bradycardia, bronchospasm, hypotension, nasal congestion</li> <li>CI: Sinus bradycardia, 1<sup>st</sup> degree AV block (PR \u22650.24), cardiogenic shock, SSS, WPW</li> </ul> </li> </ul> </li> </ul>","tags":["Anti-Arrhythmics","Beta-Blockers","Calcium Channel Blockers"]},{"location":"fellowship-guide/topics/cardiac-pharm/antiarrhythmics/#class-iii-k-channel-blockers","title":"Class III (K+ Channel Blockers)","text":"<ul> <li>General<ul> <li>Inhibit potassium channels and prolong the refractory state of cardiac tissue (decreasing automaticity)</li> <li>All prolong QT and can cause Torsades de pointes</li> </ul> </li> <li>Amiodarone<ul> <li>MOA: Inhibits alpha receptors, beta receptors, sodium channels, and calcium channels in addition to potassium channels<ul> <li>Has partial action of all classes</li> <li>May produce QRS prolongation, QT prolongation, and/or a decrease in heart rate (bradycardia)</li> <li>Lipophilic = likes to attach to internal organs</li> </ul> </li> <li>Acute Use: AF, AFL, SVT, VT/VF</li> <li>Chronic Use: AF/VT Prevention (100-400 qd)</li> <li>SE: Sinus brady, AV block, proarrhythmic, hypo/hyperthyroid, hepatitis, optic neuropathy, blue-gray skin, elevated LFTs, corneal microdeposits (98% of pts), peripheral neuropathy, QT prolonagion, Torsades de points<ul> <li>Hyper/hypothyroidism</li> <li>Pulmonary fibrosis deadly 10% of the time, usually occurs within the 1<sup>st</sup> year of treatment and in older patients with low DLCO<ul> <li>Unlikely with \u2264200mg/day</li> </ul> </li> <li>Most Common cause of Chronic Interstitial Pneumonitis</li> </ul> </li> <li>Check: LFTs (hepatoxic), TFTs (Thyroid disorders), PFTs (Interstitial lung disease)</li> </ul> </li> <li>Bretylium</li> <li>Dofetilide (Tikosyn)<ul> <li>PubChem</li> <li>500mcg PO BID<ul> <li>Requires special training<ul> <li>Initiation</li> </ul> </li> </ul> </li> <li>Highly selective for delayed rectifier potassium current<ul> <li>Goal K: &gt;3.5 (correct before initiation)</li> <li>IV Magnesium enhances the ability of dofetilide to cardiovert AF or AFL<ul> <li>IV 4g magnesium sulfate</li> <li>Increases odds of conversion by 107%</li> </ul> </li> </ul> </li> <li>Chronic Use: AF Prevention</li> <li>SE: Headache (11%), Chest Pain (10%), Dizziness (8%), Nausea (5%), QT prolongation<ul> <li>CI: QTc &gt;440ms prior to initiation, &lt;60 BPM</li> </ul> </li> <li>CI: Cimetidine, Verapamil, Ketoconazole, Trimethoprim, TMP/SMX, Prochlorperazine, Megestrol, HCTZ, Triamterene<ul> <li>Alternatives: Omeprazole, ranitidine, antacids</li> </ul> </li> <li>Trials: DIAMOND-MI, DIAMOND-AF, and DIAMOND-CHF</li> </ul> </li> <li>Dronedarone (Multaq)<ul> <li>Chronic Use: AF Prevention</li> <li>Lacks iodine molecule of amiodarone (less effective, less harmful), 2x increased mortality in permanent AF and class III/IV HF</li> </ul> </li> <li>Ibutilide (Corvert)<ul> <li>Acute Use: Terminate (cardiovert) AF/AFL<ul> <li>Within 7 days (CI in hypokalemic or QT prolong)</li> <li>Check magnesium and potassium to minimize risk</li> <li>IV Magnesium enhances the ability of ibutilide to cardiovert AF or AFL</li> <li>IV 4g magnesium sulfate</li> <li>Increases odds of conversion by 78%</li> </ul> </li> <li>SE: Nausea, QT prolongation (8%), torsades de pointes</li> </ul> </li> <li>Sotalol (Betapace)<ul> <li>Also has BB properties</li> <li>Chronic Use: AF/VT Prevention</li> <li>SE: Hypotension, bronchospasm, long QT, Torsades de Pointes</li> </ul> </li> </ul>","tags":["Anti-Arrhythmics","Beta-Blockers","Calcium Channel Blockers"]},{"location":"fellowship-guide/topics/cardiac-pharm/antiarrhythmics/#class-iv-calcium-channel-blockers-ccbs","title":"Class IV (Calcium Channel Blockers (CCBs))","text":"<ul> <li>General<ul> <li>Delay conduction in the SA and AV nodes</li> </ul> </li> </ul>","tags":["Anti-Arrhythmics","Beta-Blockers","Calcium Channel Blockers"]},{"location":"fellowship-guide/topics/cardiac-pharm/antiarrhythmics/#non-dihydropyridine-ccbs-non-dhp","title":"Non-Dihydropyridine CCBs (Non-DHP)","text":"<ul> <li>General<ul> <li>Block non-DHP L type channels at SA/AV node<ul> <li>Prolonged PR interval at faster HR (use dependence)</li> <li>Use dependence with an increase in CCB with increasing ventricular activation.</li> <li>Prolongation of the refractory period of the av node, leading to an increased PR</li> <li>No QRS prolongation (doesn't work on phase 0)</li> </ul> </li> </ul> </li> <li>Diltiazem (Cardizem)<ul> <li>PubChem</li> <li>David Drug Guide</li> <li>Weight based</li> <li>Acute Use: SVT, AF/AFL Rate Control<ul> <li>Acute Afib: 0.25mg/kg/IV over 2 mins</li> </ul> </li> <li>Chronic Use: AF Rate Control/SVT<ul> <li>Chronic Afib: 120-360mg/day PO divided QID</li> </ul> </li> </ul> </li> <li>Verapamil (Isoptin)<ul> <li>Acute Use: SVT, AF Rate Control</li> <li>Chronic Use: AF Rate Control/RVQT VT, Idiopathic LV VT</li> <li>Avoid in: Afib or flutter in WPW, wide complex tachycardias, with BBs, asymptomatic HCM</li> <li>Can use in: Afib/Flutter w/RVR, SVT(2<sup>nd</sup> to amio), MAT, symptomatic HHCM. Severe/concentric LVH, hypertension</li> </ul> </li> </ul>","tags":["Anti-Arrhythmics","Beta-Blockers","Calcium Channel Blockers"]},{"location":"fellowship-guide/topics/cardiac-pharm/antiarrhythmics/#dihydropyridine-ccbs-dhp","title":"Dihydropyridine CCBs (DHP)","text":"<ul> <li>General<ul> <li>Increase myocardial oxygen supply via Coronary artery vasodilation</li> <li>Decreases afterload via systemic vasodilation, reducing myocardial oxygen demand</li> </ul> </li> <li>Amlodipine<ul> <li>No use dependence or prolongation of QT</li> <li>SE: Elevated Uric Acid</li> </ul> </li> <li>Felodipine<ul> <li>Do not combine with Nitrates</li> <li>May worsen angina by decreasing coronary perfusion pressure</li> </ul> </li> </ul>","tags":["Anti-Arrhythmics","Beta-Blockers","Calcium Channel Blockers"]},{"location":"fellowship-guide/topics/cardiac-pharm/antiarrhythmics/#class-v-adenosine-digoxin-magnesium-sulfate","title":"Class V (Adenosine, Digoxin, Magnesium Sulfate)","text":"<ul> <li>Adenosine (Adenocard)<ul> <li>Alpha1 agonist<ul> <li>Decreases conduction through the AV and SA node</li> <li>Lasts only seconds</li> </ul> </li> <li>Acute Use: terminate Reentrant SVT involving AV Node</li> <li>Cough flushing, chest pain, Profound pauses, Afib</li> </ul> </li> <li>Digoxin (Lanoxin)<ul> <li>MOA: Inhibits ATPase-dependent Na-K pump, increases sodium intracellularly, increasing ca+2 inside (indirect inhibition of Na/Ca exchanger)<ul> <li>Enhances vagal tone and slows AV nodal conduction (decrease HR), SA node rate, and shortens atrial refractory period</li> <li>Positive inotropy</li> <li>Amiodarone, Verapamil, quinidine, spironolactone, and propafenone increase Digoxin levels (Verapamil increases by 70-100%)</li> <li>Acute Use: AF/AFL Rate Control</li> </ul> </li> <li>Chronic Use: AF Rate Control<ul> <li>Used in patients with HF and low EF for symptomatic management<ul> <li>Does not decrease mortality but decreases hospitalizations</li> </ul> </li> </ul> </li> <li>SE: N/V, AV block, atrial tachycardia with av block, JET, EAT, fascicular tachycardia and ventricular tachycardia<ul> <li>Can cause bradyarrhythmia in younger, healthy patients or enhance automaticity and delayed after-depols leading to ventricular ectopy and tachyarrhythmias in old people with HD</li> </ul> </li> <li>Toxicity<ul> <li>Cholinergic: Vision changes (color vision), diarrhea, anorexia, nausea, vomiting, ST segments on EKG, confusion</li> <li>Hyperkalemia indicates poor prognosis</li> </ul> </li> <li>CI: Renal Failure, Decreased clearance, hypokalemia</li> <li>Antidote: Slowly normalize K+, cardiac pacer, anti-digoxin FAB, Mg2+</li> </ul> </li> </ul>","tags":["Anti-Arrhythmics","Beta-Blockers","Calcium Channel Blockers"]},{"location":"fellowship-guide/topics/cardiac-pharm/antiarrhythmics/#other-antiarrhythmic-agents","title":"Other Antiarrhythmic Agents","text":"<ul> <li>Digitalis<ul> <li>Can increase ectopy in the arteria or ventricles</li> <li>Can be used to increase vagal tone and sometimes to treat atrial fibrillation if BBs or CCBs have not been effective</li> <li>Toxicity<ul> <li>Focal Atrial tachycardia with AV block is specific<ul> <li>Increases ectopy and increased vagal tone</li> </ul> </li> </ul> </li> </ul> </li> <li>Dobutamine</li> <li>Ivabradine<ul> <li>MOA: Inhibits the hyperpolarization-activated nucleotide-gated funny channels (If) in the sinus node</li> <li>Use: Chronic Symptomatic HF w/LVEF \\&lt;35% on maximally tolerated BB who are in sinus rhythm and HR \u226570<ul> <li>Shown to reduce hospitalizations in patients with NYHA III to IV on maximally tolerated B-Blocker therapy (maximize BB first)</li> </ul> </li> </ul> </li> <li>Milrinone<ul> <li>PDE inhibitor, same as above (camp ca influx)<ul> <li>Less likely to stimulate the heart than dobutamine</li> <li>More likely for hypotension, renally dosed (nephrotoxic)</li> </ul> </li> </ul> </li> <li>Levosimendan<ul> <li>Enhance contractility via sensitization</li> <li>Promotes vasodiation</li> <li>Cardioprotective</li> <li>no myocardial o2 increase</li> <li>nly one with survival benefit</li> <li>tachy and hypotension</li> </ul> </li> <li>Dopamine</li> <li>Epinephrine</li> <li>Norepinephrine</li> <li>Isopro</li> </ul>","tags":["Anti-Arrhythmics","Beta-Blockers","Calcium Channel Blockers"]},{"location":"fellowship-guide/topics/cardiac-pharm/antihypertensives/","title":"Antihypertensives","text":"","tags":["Hypertension","Diuretics","CCBs"]},{"location":"fellowship-guide/topics/cardiac-pharm/antihypertensives/#physiology","title":"Physiology","text":"<ul> <li>RAAS disturbances can play a large role in hypertension development<ul> <li>Beta-1 blockers inhibit sympathetic activation of kidney</li> <li>Renin is produced in the JG cells of the kidney in response to hypoperfusion, B1 stimulation, renal artery stenosis, and diuretic use<ul> <li>Direct Renin inhibitors stop renin</li> </ul> </li> <li>Renin leaves the kidney to cleave angiotensinogen (made in the liver) into angiotensin I</li> <li>Angiotensin Converting Enzyme (ACE) in the pulmonary capillary endothelium converts angiotensin I into angiotensin II and inactivates Bradykinin<ul> <li>Site of ACE Inhibitor action</li> </ul> </li> <li>Angiotensin II is a potent vasoconstrictor, also promotes aldosterone production in the adrenal cortex<ul> <li>Angiotensin II blockers inhibit Angiotensin II from working on the type 1 receptor on the vascular bed and the adrenal cortex</li> <li>This prevents aldosterone production and vasoconstriction</li> </ul> </li> <li>Aldosterone acts on the principle cells of collecting ducts in the nephron to increase renal sodium and water absorption<ul> <li>Mineralocorticoid Receptor Antagonists prevent this</li> </ul> </li> <li>Therefore, any drug that blocks angiotensin II or aldosterone promotes natriuresis<ul> <li>Sodium resorption and vasoconstriction blockade decreases hypertension</li> </ul> </li> <li>The end result of RAAS activation is increased blood pressure, total body sodium and water, and blood volume</li> </ul> </li> </ul>","tags":["Hypertension","Diuretics","CCBs"]},{"location":"fellowship-guide/topics/cardiac-pharm/antihypertensives/#angiotensin-converting-enzyme-inhibitors-aceis","title":"Angiotensin Converting Enzyme Inhibitors (ACEIs)","text":"<ul> <li>MOA: Inhibit the conversion of Angiotensin I to Angiotensin II<ul> <li>ATII (vasoconstrictor, stimulates aldosterone release)</li> <li>Systemic arteriolar dilation, urine sodium loss, intravascular volume loss</li> </ul> </li> <li>Also inhibit bradykinin degradation, induce vasodilatory prostaglandin production, reduce SNS activity<ul> <li>Chronic nonproductive chough within 1 week of initiation or dosage increase (will be more delayed)</li> </ul> </li> <li>Reduce systemic BP and directly modify the permeability of the glomerular epithelium (decrease protein loss)<ul> <li>Lowering intraglomerular pressure and reducing protein excretion<ul> <li>Great for Hypertension + Protein CKD</li> </ul> </li> <li>Reduce the amount of aldosterone acting on DT, sodium loss</li> </ul> </li> <li>Slow the progression of diabetic nephropathy</li> <li>Cardioprotective and reduce ventricular remodeling after ischemia</li> <li>Use: Hypertension, decreasing urate load</li> <li>SE: Cough, Hyperkalemia, Potential GFR reduction, Angioedema, skin rash<ul> <li>May decrease ATII-mediated constriction of the efferent arteriole</li> </ul> </li> <li>Lisinopril</li> <li>Captopril<ul> <li>SE: Membranous glomerulonephritis</li> </ul> </li> <li>Enalapril<ul> <li>Useful in scleroderma renal crisis</li> <li>CI: Pregnancy, acute MI, bilateral renal artery stenosis</li> </ul> </li> </ul>","tags":["Hypertension","Diuretics","CCBs"]},{"location":"fellowship-guide/topics/cardiac-pharm/antihypertensives/#alpha-adrenergic-blockers","title":"Alpha-Adrenergic Blockers","text":"<ul> <li>General<ul> <li>Direct vasodilators used to treat hypertension, but do not affect angiotensin II or aldosterone concentrations or induce natriuresis</li> <li>Alpha receptors are found on the distal ureter, base of the detrusor, bladder neck, and urethra<ul> <li>Activation stimulates them to maintain high muscular tone for normal urinary continence</li> </ul> </li> </ul> </li> <li>Tamsulosin</li> <li>Phentolamine</li> </ul>","tags":["Hypertension","Diuretics","CCBs"]},{"location":"fellowship-guide/topics/cardiac-pharm/antihypertensives/#angiotensin-ii-receptor-blocker-arbs","title":"Angiotensin II Receptor Blocker (ARBs)","text":"<ul> <li>General<ul> <li>Bind zona glomerulosa receptors in the kidney to prevent angiotensin II from inducing expression of aldosterone on angiotensin receptors</li> <li>Do not decrease Angiotensin II levels, but do cause natriuresis and decreased aldosterone production</li> </ul> </li> <li>Valsartan (Diovan)<ul> <li>PubChem</li> </ul> </li> </ul>","tags":["Hypertension","Diuretics","CCBs"]},{"location":"fellowship-guide/topics/cardiac-pharm/antihypertensives/#beta-adrenergic-receptor-blockers-bbs-beta-blockers","title":"Beta-Adrenergic Receptor Blockers (BBs, Beta Blockers)","text":"<ul> <li>MOA:<ul> <li>Beta-1 blockers block sympathetic stimulation of the JG apparatus in the kidney</li> <li>Reduce BP by decreasing sympathetic stimulation of the heart<ul> <li>Decreases HR, lowers SV, reduces arterial pressures</li> </ul> </li> </ul> </li> <li>Use: Should be given to all patients who have had an MI or who have HF<ul> <li>Reduce ischemia-induced remodeling by lowering HR and thus myocardial oxygen demand</li> <li>Also used in AFib for rate control</li> </ul> </li> <li>Metoprolol<ul> <li>Cardio-selective BB used In CHF</li> <li>SE: asthma, impotence, masks hypoglycemia, heart block</li> </ul> </li> <li>Beta-Blocker Toxicity (BB Toxicity)<ul> <li>Symptom Onset: 2-6 hours after ingestion</li> <li>Hypotension, Bradycardia, Bronchospasm, AMS, Seizures<ul> <li>Wheezing is relatively specific</li> <li>1<sup>st</sup> degree AV block</li> </ul> </li> <li>Hypoglycemia, Prolonged PR, Bradycardia, Normal Pupils</li> <li>Management<ul> <li>Secure airway, GI decontamination, IV Fluid boluses, IV Atropine, IV Glucagon</li> <li>IV Calcium, epinephrine or norepinephrine, IV lipid emulsion all can be used in conjunction</li> </ul> </li> </ul> </li> </ul>","tags":["Hypertension","Diuretics","CCBs"]},{"location":"fellowship-guide/topics/cardiac-pharm/antihypertensives/#direct-renin-inhibitors","title":"Direct Renin Inhibitors","text":"<ul> <li>Aliskiren<ul> <li>Increases natriuresis and decreases serum angiotensin II, decreasing aldosterone production</li> </ul> </li> </ul>","tags":["Hypertension","Diuretics","CCBs"]},{"location":"fellowship-guide/topics/cardiac-pharm/antihypertensives/#calcium-channel-blockers-ccbs","title":"Calcium Channel Blockers (CCBs)","text":"<ul> <li>Vasodilation occurs as a result</li> <li>2 groups:</li> </ul>","tags":["Hypertension","Diuretics","CCBs"]},{"location":"fellowship-guide/topics/cardiac-pharm/antihypertensives/#non-dihydropyridine-ndhp-ccbs","title":"Non-Dihydropyridine (NDHP) CCBs","text":"<ul> <li>Do not have the same peripheral vasodilatory properties</li> <li>Verapamil</li> <li>Diltiazem</li> </ul>","tags":["Hypertension","Diuretics","CCBs"]},{"location":"fellowship-guide/topics/cardiac-pharm/antihypertensives/#dihydropyridine-dhp-ccbs","title":"Dihydropyridine (DHP) CCBs","text":"<ul> <li>Peripherally in arteries to decrease BP<ul> <li>No effect on heart, may cause reflex HR increase</li> <li>Peripheral Vasodilation</li> <li>Peripheral edema<ul> <li>due to preferential dilatation of precapillary vessels (arteriolar), increases hydrostatic pressure</li> </ul> </li> <li>May cause reflex tachycardia and enhance ventricular contraction increasing aortic wall stress (give BB first)</li> </ul> </li> <li>Amlodipine</li> <li>Clevidipine<ul> <li>CI: Severe Aortic Stenosis, Soy allergy, egg allergy, hyperlipidemia, lipoid nephrosis, acute pancreatitis</li> </ul> </li> <li>Nicardipine<ul> <li>CI: Severe Aortic Stenosis</li> </ul> </li> <li>Nifedipine<ul> <li>SE: headache, peripheral edema, bradycardia, constipation, flushing<ul> <li>Amiodarone Pulmonary Fibrosis</li> </ul> </li> <li>Calcium Channel Blocker Toxicity<ul> <li>Bradycardia, hypotension, Hyperglycemia</li> <li>No AMS (unlike BB Toxicity)</li> <li>Treatment<ul> <li>IV Glucagon</li> </ul> </li> </ul> </li> </ul> </li> </ul>","tags":["Hypertension","Diuretics","CCBs"]},{"location":"fellowship-guide/topics/cardiac-pharm/antihypertensives/#sulfonamide-diuretics","title":"Sulfonamide Diuretics","text":"","tags":["Hypertension","Diuretics","CCBs"]},{"location":"fellowship-guide/topics/cardiac-pharm/antihypertensives/#carbonic-anhydrase-inhibitors","title":"Carbonic Anhydrase Inhibitors","text":"<ul> <li>Acetazolamide (Diamox)<ul> <li>Works on proximal tubule of the kidney<ul> <li>Inhibits the production and reabsorption of filtered bicarbonate</li> </ul> </li> <li>Use: Diuretic, urinary alkalization, metabolic alkalosis, glaucoma, intracranial hypertension, altitude sickness</li> <li>SE: Sulfa allergy, hyperchloremic metabolic acidosis, hypokalemia<ul> <li>Ammonia Toxicity, Neuropathy</li> </ul> </li> </ul> </li> </ul>","tags":["Hypertension","Diuretics","CCBs"]},{"location":"fellowship-guide/topics/cardiac-pharm/antihypertensives/#loop-diuretics","title":"Loop Diuretics","text":"<ul> <li>MOA: Blocks Na+-K+-2Cl- symporter in the thick ascending loop of Henle<ul> <li>Induce natriuresis, but decreased blood volume stimulates renin release that increases angiotensin II and aldosterone</li> <li>Decrease urate excretion by increasing net urate reabsorption<ul> <li>Either enhanced reabsorption or reduced secretion</li> </ul> </li> <li>Use: Volume overload, CHF, edema</li> <li>SE: Gout</li> </ul> </li> <li>Furosemide (Lasix)<ul> <li>Loop diuretic used in pulmonary edema, hypertension, nephrotic syndrome and congestive heart failure</li> <li>SE: Gout (elevated uric acid), ototoxicity, allergy (sulfa), hypokalemia, alkalosis, dehydration, hypocalcemia, hypomagnesemia, interstitial nephritis</li> </ul> </li> <li>Bumetanide (Bumex)<ul> <li>SE: Allergy (sulfa)</li> </ul> </li> <li>Etacrynic Acid (Edecrin)<ul> <li>Not a sulfonamide, only loop diuretic that isn't</li> </ul> </li> <li>Indacrinone<ul> <li>Decreases reabsorption of uric acid</li> <li>Uses: Gout, hypertension</li> </ul> </li> <li>Torsemide (Demadex)</li> </ul>","tags":["Hypertension","Diuretics","CCBs"]},{"location":"fellowship-guide/topics/cardiac-pharm/antihypertensives/#thiazide-diuretics","title":"Thiazide Diuretics","text":"<ul> <li>MOA: Inhibit the reabsorption of Na+ and Cl- from the distal convoluted tubule, blocks Na-Cl symporter<ul> <li>Intravascular volume depletion via diuresis reduces peripheral vascular resistance</li> <li>Indirectly increases the basolateral Na+/Ca2+ antiporter</li> <li>Use: essential hypertension, edema, CHF, Nephrogenic DI, osteoporosis</li> <li>SE: hyperGLUC (glucose, lipids, uric acid, calcium), Allergy, Gout<ul> <li>Dose-dependent hypokalemia, hyponatremia, Metabolic Alkalosis</li> <li>Give oral potassium supplements or potassium sparing diuretic (spironolactone)</li> </ul> </li> </ul> </li> <li>Hydrochlorothiazide</li> <li>Chlorothiazide (Diuril)</li> </ul>","tags":["Hypertension","Diuretics","CCBs"]},{"location":"fellowship-guide/topics/cardiac-pharm/antihypertensives/#thiazide-like-diuretics","title":"Thiazide Like Diuretics","text":"<ul> <li>MOA: Primarily work on the DCT</li> <li>Clopamide<ul> <li>Selectively binds chloride binding site of Na-Cl symporter in the PCT on the luminal side</li> <li>Equi-osmolar excretion of water with NaCl</li> </ul> </li> <li>Chlorthalidone</li> <li>Indapamine</li> <li>Metolazone<ul> <li>Remains active even when GFR \u226430-40</li> </ul> </li> </ul>","tags":["Hypertension","Diuretics","CCBs"]},{"location":"fellowship-guide/topics/cardiac-pharm/antihypertensives/#potassium-sparing-diuretics","title":"Potassium-Sparing Diuretics","text":"<ul> <li>General<ul> <li>Work on the Collecting Tubule of the nephron</li> </ul> </li> </ul>","tags":["Hypertension","Diuretics","CCBs"]},{"location":"fellowship-guide/topics/cardiac-pharm/antihypertensives/#epithelial-sodium-channel-blockers-enac-channel","title":"Epithelial Sodium Channel Blockers (ENaC Channel)","text":"<ul> <li>Amiloride</li> <li>Triamterene</li> <li>Benzamil</li> </ul>","tags":["Hypertension","Diuretics","CCBs"]},{"location":"fellowship-guide/topics/cardiac-pharm/antihypertensives/#mineralocorticoid-aldosterone-receptor-antagonists","title":"Mineralocorticoid (Aldosterone) Receptor Antagonists","text":"<ul> <li>MOA: Renal Cortical Collecting Duct aldosterone receptor blocker<ul> <li>Competitive inhibitors of aldosterone receptors, only active in the presence of aldosterone</li> <li>Therefore aldosterone, renin, angiotensin I and II will be elevated</li> <li>SE: Hyperkalemia, gynecomastia, decreased libido, breast tenderness, menstrual irregularities</li> </ul> </li> <li>Spironolactone (Aldactone)<ul> <li>Spironolactone also blocks progesterone and androgen receptors</li> <li>More side effects, but preferred</li> <li>SE: Hyperkalemia, Gynecomastia, Amenorrhea, Other anti-androgen effects</li> </ul> </li> <li>Eplerenone (Inspra)<ul> <li>Very selective mineralocorticoid antagonist</li> <li>Low affinity for progesterone or androgen receptors</li> <li>Fewer side effects, less effective</li> </ul> </li> </ul>","tags":["Hypertension","Diuretics","CCBs"]},{"location":"fellowship-guide/topics/cardiac-pharm/antihypertensives/#osmotic-diuretics","title":"Osmotic diuretics","text":"<ul> <li>Mannitol<ul> <li>Increases tubular fluid osmolarity (increasing urine flow)</li> <li>Use: Intracranial pressure</li> <li>SE: Pulmonary edema, intravascular dehydration</li> </ul> </li> <li>Glycerol</li> <li>Urea</li> </ul>","tags":["Hypertension","Diuretics","CCBs"]},{"location":"fellowship-guide/topics/cardiac-pharm/antihypertensives/#vasopressin-receptor-inhibitors","title":"Vasopressin Receptor Inhibitors","text":"<ul> <li>Vaptans</li> <li>Demeclocycline</li> </ul>","tags":["Hypertension","Diuretics","CCBs"]},{"location":"fellowship-guide/topics/cardiac-pharm/antihypertensives/#direct-arterial-vasodilators","title":"Direct Arterial Vasodilators","text":"<ul> <li>Hydralazine<ul> <li>May increase myocardial contractility</li> <li>SE: Hypotension, reflex tachycardia, palpitations, dyspnea, hemolytic anemia, diaphoresis, lupus-like reaction, Drug associated autoimmune vasculitis</li> <li>CI: Mitral valve rheumatic heart disease</li> </ul> </li> <li>Minoxidil</li> </ul>","tags":["Hypertension","Diuretics","CCBs"]},{"location":"fellowship-guide/topics/cardiac-pharm/antihypertensives/#peripheral-selective-alpha-1-blockers","title":"Peripheral Selective Alpha 1- blockers","text":"<ul> <li>Doxazosin (Cardura)</li> <li>Prazosin</li> </ul>","tags":["Hypertension","Diuretics","CCBs"]},{"location":"fellowship-guide/topics/cardiac-pharm/lipidtherapy/","title":"Lipid Therapy","text":"<ul> <li>2018 Guideline on the Management of Blood Cholesterol</li> <li>Elevated LDL-C<ul> <li>Diet: Trans/Saturated Fats, Weight gain, Anorexia, Alcohol</li> <li>Drugs: Diuretics, Cyclosporines, Glucocorticoids, Amiodarone</li> <li>Diseases: Biliary Obstruction, Nephrotic Syndrome</li> <li>Other: Hypothyroidism, Obesity, Pregnancy</li> <li>Dietary fat has a greater impact on serum LDL-C than does dietary cholesterol intake<ul> <li>Fats should be limited to \u226430% of total caloric intake</li> <li>Saturated fats should be limited to \u226410% of calories (7% if LDL-C above goal)</li> </ul> </li> </ul> </li> <li>Elevated Triglycerides<ul> <li>2021 ACC Guideline for the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia</li> <li>Diet: Weight gain, Very low fat diets, High intake of refined carbs, Excessive Alcohol intake</li> <li>Drug: Oral estrogens, Glucocorticoids, Bile Acid Sequestrants, Protease inhibitors, Retinoic acid, Anabolic steroids, Sirolimus, Raloxifene, Tamoxifen, BB (not carvedilol), Thiazides</li> <li>Diseases: Nephrotic Syndrome, Chronic Renal Failure, Lipodystrophies</li> <li>Other: Poorly controlled diabetes, Hypothyroidism, Obesity, Pregnancy</li> </ul> </li> <li>Higher-Risk<ul> <li>The following factors that may be considered for the identification of higher-risk patients with clinical CV disease:         - Age \u226565 years, prior MI or non-hemorrhagic stroke, current daily cigarette smoking, symptomatic PVD with prior MI or stroke, history of non-MI related coronary revascularization, residual coronary artery disease with \u226540% stenosis in \u22652 large vessels, HDL \u226440 mg/dL for men and \u226450 mg/dL for women, hs-CRP \u22652 mg/L, or metabolic syndrome</li> </ul> </li> </ul>","tags":["Lipids","Statins"]},{"location":"fellowship-guide/topics/cardiac-pharm/lipidtherapy/#liver","title":"Liver","text":"<ul> <li>Statins (HMG-CoA reductase inhibitors, LDL)<ul> <li>MOA: RLS in intracellular biosynthesis of cholesterol (competitive inhibition)<ul> <li>Increases LDL receptors on liver cell membranes<ul> <li>Remove circulating LDL and digest it</li> <li>Reduces serum w/ minimal liver LDL change</li> </ul> </li> <li>Decrease CoQ10 synthesis (ubiquinone)</li> <li>Statins metabolized by CYP450 3A4<ul> <li>Lovastatin, simvastatin, atorvastatin</li> </ul> </li> </ul> </li> <li>Benefits<ul> <li>Plaque stabilization</li> <li>Inflammation Reduction, decrease CRP</li> <li>Improve endothelial function</li> <li>Decreased Thrombogenicity</li> </ul> </li> <li>Potency:<ul> <li>High Potency: lower LDL by \u226550%<ul> <li>Large LDL Decrease (20-60%, 1<sup>st</sup> line)</li> <li>Doubling dose adds 6% effect</li> </ul> </li> </ul> </li> <li>Rosuvastatin (Crestor)<ul> <li>High: 20-40mg</li> <li>Moderate: 5-10mg</li> <li>CKD \u22653 or Dialysis: 10mg</li> <li>Can be used in Cirrhosis</li> </ul> </li> <li>Atorvastatin (Lipitor)<ul> <li>High: 40-80mg</li> <li>Moderate: 10-20mg</li> <li>CKD \u22653 or Dialysis: 20mg</li> <li>Lipophilic, not renally cleared</li> </ul> </li> <li>Simvastatin (Zocor)<ul> <li>Moderate: 20-40mg</li> <li>Low: 10mg</li> <li>CKD \u22653 or Dialysis: 20mg</li> <li>Lipophilic, not renally cleared</li> </ul> </li> <li>Pravastatin (Pravachol)<ul> <li>Moderate: 40-80mg</li> <li>Low: 10-20mg</li> <li>CKD \u22653 or Dialysis: 40mg</li> <li>Least muscle SE, preferred in elevated LFTs</li> <li>Not renally cleared, can be used in Cirrhosis</li> </ul> </li> <li>Lovastatin (Mevachor)<ul> <li>Moderate: 40mg</li> <li>Low: 20mg</li> <li>CKD \u22653 or Dialysis: Not evaluated</li> <li>Lipophilic</li> </ul> </li> <li>Fluvastatin<ul> <li>Moderate: 80mg</li> <li>Low: 20-40mg</li> <li>CKD \u22653 or Dialysis: 80mg</li> <li>Least muscle SE, not renally cleared</li> </ul> </li> <li>Pitavastatin<ul> <li>Moderate: 2-4mg</li> <li>Low: 1mg</li> <li>CKD \u22653 or Dialysis: 2mg</li> </ul> </li> <li>Most effective, first line to lower cholesterol and LDL<ul> <li>Moderate HDL increase</li> <li>Moderate Triglyceride Decrease</li> </ul> </li> <li>Trials<ul> <li>IMPROVE-IT (2015)<ul> <li>Adding ezetimibe to statin further reduces CV events in the population, suggesting the maximal LDL reduction is the key mech</li> </ul> </li> </ul> </li> <li>SE: Hepatotoxicity<ul> <li>If AST/ALT \u2265 3x ULN, reduce or switch</li> <li>Myalgias (symmetrical proximal muscle weakness or tenderness)<ul> <li>1-10%, mc side effect<ul> <li>Statin-Associated Muscle Symptoms Among New Statin Users Randomly Assigned to Vitamin D or Placebo</li> </ul> </li> </ul> </li> <li>Myositis/Myopathy<ul> <li>Elevated CK</li> </ul> </li> <li>Rhabdomyolysis<ul> <li>1%, CK \u2265 10x ULN + Renal injury</li> </ul> </li> <li>Statin-associated autoimmune myopathy (HMGCR antibodies)</li> <li>High Intensity<ul> <li>Renal Dysfunction<ul> <li>More common w/Rosuvastatin/Simvastatin</li> <li>Proteinuria, Hematuria, AKI</li> <li>Switch to Atorvastatin, Fluvastatin, Pravastatin</li> </ul> </li> <li>Diabetes Mellitus<ul> <li>Increased plasma glucose concentrations</li> </ul> </li> </ul> </li> </ul> </li> <li>CI: Pregnancy, Lactation, Acute liver failure/decompensated cirrhosis<ul> <li>VATER association, TE fistulas, anal atresias</li> </ul> </li> <li>Interactions<ul> <li>Amlodipine, diltiazem, verapamil + either simvastatin or lovastatin increases risk of toxicity</li> <li>Gemfibrozil: Increased risk for muscle toxicity</li> <li>Colestipol and antacids decrease plasma concentration</li> <li>Amiodarone, cranberry, grapefruit</li> </ul> </li> <li>Monitoring<ul> <li>Lipid profile at baseline, then 6-8 weeks after</li> <li>LFTs and TSH at baseline, \u00b1 CK level</li> </ul> </li> </ul> </li> <li>Niacin<ul> <li>Drugs: Niacin</li> <li>Lipolysis Decreased in Adipose Tissues<ul> <li>Moderate LDL Decrease</li> <li>Large HDL Increase</li> <li>Moderate Triglycerides Decrease</li> </ul> </li> <li>Flushing and pruritis is caused by prostaglandin-induced peripheral vasodilation<ul> <li>Low dose aspirin may reduce symptoms</li> </ul> </li> </ul> </li> <li>Lomitapide (Juxtapid)<ul> <li>MTTP Inhibitors (VLDL)</li> </ul> </li> <li>Mitratapide (Yarvitan)<ul> <li>MTTP Inhibitors (VLDL)</li> </ul> </li> </ul>","tags":["Lipids","Statins"]},{"location":"fellowship-guide/topics/cardiac-pharm/lipidtherapy/#gi-tract","title":"GI Tract","text":"<ul> <li>Ezetimibe (Zetia)<ul> <li>Cholesterol Absorption Inhibitor at Intestinal Border, NPC1L1</li> <li>Moderate LDL Decrease (15-20%, 2<sup>nd</sup> line)</li> <li>May be used in ASCVD w/very high risk on max statin with LDL \u226570 or non-HDL \u2265100</li> <li>HDL Unchanged</li> <li>Triglycerides Unchanged</li> </ul> </li> <li>Bile Acid Sequestrants/Resins (LDL)<ul> <li>Drugs: Cholestyramine, Colesevelam (Welchol), Colestipol</li> <li>Inhibits reabsorption of bile acids, decreasing lipoprotein levels</li> <li>Alone or in combo with Stains</li> <li>Moderate LDL Decrease</li> <li>Mild HDL Increase</li> <li>Triglycerides Unchanged-Increased</li> </ul> </li> </ul>","tags":["Lipids","Statins"]},{"location":"fellowship-guide/topics/cardiac-pharm/lipidtherapy/#blood-vessels","title":"Blood Vessels","text":"<ul> <li>Fibrates (Lipoprotein lipolysis Induction, PPAR)<ul> <li>Drugs: Fenofibrate (Tricor), Gemfibrozil (Lopid)<ul> <li>Not as favorable CV effects as statins or niacin</li> </ul> </li> <li>Moderate LDL Decrease</li> <li>Moderate HDL Increase</li> <li>Large Triglycerides Decrease (35-50%)</li> </ul> </li> <li>PCSK9 Inhibitors (LDL)<ul> <li>MOA: Proprotein convertase subtilisin/kexin type 9 (PCSK9), produced by liver that leads to degradation of hepatocyte LDL receptors via internalization and destruction</li> <li>Evolocamab (Repatha)</li> <li>Alirocumab (Praluent)</li> <li>Indications<ul> <li>High Risk 40-75 + Baseline LDL \u2265190 and who do not achieve 50% reduction in LDL or LDL &lt;100 on max stat and ezetimibe</li> </ul> </li> <li>Decrease LDL-c by 60%</li> <li>Decrease TGs by 10-15%</li> <li>HDL increase by 5-10%</li> <li>Lp(a) decreased by 25-30%</li> <li>Trials<ul> <li>FOURIER (2017)<ul> <li>Among patients with clinical atherosclerotic disease and LDL \u2265 70 despite high or moderate intensity statin therapy (70% high intensity), Evolocumab resulted in an absolute 1.5% reduction in MACE at 26 months<ul> <li>Mainly from reduction in nonfatal MI, stroke, and revascularization</li> <li>No mortality benefits</li> <li>Absolute reduction in CVE was greater with more advanced CKD</li> </ul> </li> </ul> </li> <li>ODESSEY OUTCOMES (2021)<ul> <li>In recent ACS and LDL ~70 on optimized statin therapy, PCSK9 inhibitors provide clinical benefit only when lp(a) is at least mildly elevated.</li> <li>Mortality benefit in the long term</li> </ul> </li> </ul> </li> <li>SE: Injection site reaction</li> <li>Resources<ul> <li>tdlrpharmacy</li> <li>The Evolving Future of PCSK9 Inhibitors</li> </ul> </li> </ul> </li> </ul>","tags":["Lipids","Statins"]},{"location":"fellowship-guide/topics/cath/interventional-cardiology/","title":"Interventional Cardiology","text":""},{"location":"fellowship-guide/topics/cath/interventional-cardiology/#interventional-cardiology-fellow-resources","title":"Interventional Cardiology Fellow Resources","text":""},{"location":"fellowship-guide/topics/cath/interventional-cardiology/#books","title":"Books","text":"<ul> <li>Manual of Percutaneous Coronary Intervention</li> <li>Manual of Coronary Chronic Total Occlusion Intervention</li> <li>PCR-EAPCI Textbooks</li> </ul>"},{"location":"fellowship-guide/topics/cath/interventional-cardiology/#online-resources","title":"Online Resources","text":"<ul> <li>SCAI Interventional Cardiology Fellows Essentials</li> <li>SCAI Clinical Documents</li> <li>ACC Coronary Interventions Handbook</li> <li>Brilakis PCI Manual: https://www.pcimanual.org, CTO Manual<ul> <li>YouTube channel</li> </ul> </li> <li>Modern PCI Trainers WondrMedical</li> <li>Intracoronary Imaging Course WondrMedical</li> <li>Interventional Complications Course 2023</li> <li>6-in-the-A YouTube Channel</li> <li>European Interventional Cardiology Fellows Course</li> <li>PCR Trials (Interventional Cardiology Trials)</li> <li>CardioNerds Cardiac Critical Care Page</li> <li>Mount Sinai CCC Live Cases YouTube Channel</li> </ul>"},{"location":"fellowship-guide/topics/cath/interventional-cardiology/#appspodcasts","title":"Apps/Podcasts","text":"<ul> <li>PCI App</li> <li>Cardiology Apps</li> <li>Podcasts<ul> <li>(Dr. Bill Lombardi) and (Dr. Manos Brilakis)</li> </ul> </li> </ul>"},{"location":"fellowship-guide/topics/cath/interventional-cardiology/#additional-articles","title":"Additional Articles","text":"<ul> <li>Contemporary Issues in Chronic Total Occlusion Percutaneous Coronary Intervention</li> <li>The Impact of Coronary Physiology on Contemporary Clinical Decision-Making</li> <li>Management of Percutaneous Coronary Intervention Complications</li> <li>SCAI Position Statement on Optimal Percutaneous Coronary Interventional Therapy for Complex Coronary Artery Disease</li> <li>Intravascular Imaging During Percutaneous Coronary Intervention</li> <li>Improving PCI Outcomes Using Postprocedural Physiology and Intravascular Imaging</li> </ul>"},{"location":"fellowship-guide/topics/cath/invasive-cardiology/","title":"Invasive Cardiology","text":""},{"location":"fellowship-guide/topics/cath/invasive-cardiology/#cath-recommended-resources","title":"Cath Recommended Resources","text":"<ul> <li>Initially assembled by Marwan Saad, MD, and Alex Truesdell, MD with additional resources</li> </ul>"},{"location":"fellowship-guide/topics/cath/invasive-cardiology/#videos","title":"Videos","text":"<ul> <li>Radial artery access: step-by-step: by Manos Brilakis, MD</li> <li>Femoral access step-by-step: by Manos Brilakis, MD</li> <li>Cardiac catheterization techniques and angiography: by Elias Hanna, MD</li> </ul>"},{"location":"fellowship-guide/topics/cath/invasive-cardiology/#books","title":"Books","text":"<ul> <li>Kern\u2019s Cardiac Catheterization Handbook</li> <li>Grossman &amp; Baim's Cardiac Catheterization, Angiography, and Intervention</li> <li>Introductory Guide to Cardiac Catheterization</li> </ul>"},{"location":"fellowship-guide/topics/cath/invasive-cardiology/#online-resources","title":"Online Resources","text":"<ul> <li>CathSAP</li> <li>Hemodynamics and Coronary Physiology: with Morton Kern</li> <li>MonteHeart Lectures</li> <li>Essentials of Radial approach: PCR online</li> </ul>"},{"location":"fellowship-guide/topics/cath/invasive-cardiology/#guidelines","title":"Guidelines","text":"<ul> <li>ACC</li> <li>AHA</li> <li>ESC</li> <li>Chronic coronary disease</li> <li>Chest Pain</li> <li>Primary Prevention</li> <li>Coronary Artery Revascularization</li> <li>Dual Antiplatelet Therapy in Patients with Coronary Artery Disease</li> <li>ST-Elevation Myocardial Infarction</li> <li>Non-ST-Elevation Acute Coronary Syndromes</li> </ul>"},{"location":"fellowship-guide/topics/cath/invasive-cardiology/#additional-articles","title":"Additional Articles","text":"<ul> <li>SCAI Expert Consensus Update on Best Practices in the Cardiac Catheterization Laboratory</li> <li>Evidence-Based Practices in the Cardiac Catheterization Laboratory</li> <li>Modern Right Heart Catheterization: Beyond Simple Hemodynamics</li> <li>Cardiopulmonary Hemodynamics in Pulmonary Hypertension and Heart Failure</li> <li>Contemporary Arterial Access in the Cardiac Catheterization Laboratory</li> <li>Grossman's Cardiac Catheterization, Angiography and Intervention by Donald S. Baim</li> </ul> <p>!Cards Pathways</p>"},{"location":"fellowship-guide/topics/echo/aorticvalve/","title":"Aortic Valve","text":"<ul> <li>LVOT diameter CSA measurements<sup>1</sup> <sup>2</sup><ul> <li>Made at the same level as the velocity recording</li> <li>Used to calculate cross-sectional area (CSA)<ul> <li>Using inner edge of the septal endocardium and the anterior mitral leaflet in mid-systole</li> <li>Parallel and adjacent to the aortic valve or at the site of velocity measurement</li> </ul> </li> </ul> </li> <li>AV jet velocity measured by VTI<ul> <li>Velocity time integral (VTI) traced from the modal velocity</li> <li>Maximum velocity obtained from the peak of dense velocity curve</li> </ul> </li> <li>Continuity Equation valve area<ul> <li>AVA = (\\(CSA_{LVOT}\\) x \\(VTI_{LVOT}\\))/\\(VTI_{AV}\\)</li> </ul> </li> <li>Velocity Ratio and VTI Ratio, Dimensionless Index (DI)<ul> <li>Used to reduce error related to LVOT area measurements (Removes LVOT CSA from Continuity Equation) to check AVA or when there is an prosthetic AV in place</li> <li>Velocity Ratio = \\(V_{LVOT}\\)/\\(V_{AV}\\)</li> </ul> </li> </ul> <ol> <li> <p>https://resourcelibrary.edwardsconnect.com/api/v2/view?site=hv&amp;resource=370 \u21a9</p> </li> <li> <p>https://pubmed.ncbi.nlm.nih.gov/28385280/ \u21a9</p> </li> </ol>"},{"location":"fellowship-guide/topics/echo/indications/","title":"Indications","text":""},{"location":"fellowship-guide/topics/echo/indications/#echocardiography-types","title":"Echocardiography Types","text":"<ul> <li>Bicycle Stress Echo</li> <li>Dobutamine Stress Echo</li> <li>Transthoracic Echo (TTE)</li> <li>Transesophageal Echo (TEE)</li> </ul>"},{"location":"fellowship-guide/topics/echo/indications/#echocardiography-indications","title":"Echocardiography Indications","text":"<ul> <li>Class I (Useful)<ul> <li>Murmurs Table 23<ul> <li>Murmurs with cardiorespiratory symptoms</li> <li>A murmur in an asymptomatic patient if the clinical features indicate at least a moderate probability that the murmur is reflective of structural heart disease</li> </ul> </li> <li>Valvular Stenosis Table 24<ul> <li>To define the primary lesion and its etiology and judge its severity</li> <li>Define hemodynamic severity<ul> <li>Detect coexisting abnormalities</li> <li>Detect secondary lesions</li> <li>Evaluate size and function</li> <li>Establish reference point</li> </ul> </li> <li>Reevaluation after intervention or with changing signs and symptoms</li> <li>Assessment of changes in severity and ventricular compensation in patient with known valvular stenosis during pregnancy</li> <li>Reevaluation of asymptomatic patients with severe stenosis</li> </ul> </li> <li>Native Valvular Regurgitation Table 25<ul> <li>Same as Valvular Stenosis</li> <li>Reevaluation of patients with mild-moderate regurgitation with ventricular dilation without clinical symptoms (eg, virulent organism, severe hemodynamic lesion, aortic valve involvement, persistent fever or bacteremia, clinical change, or symptomatic deterioration)</li> </ul> </li> <li>Mitral Valve Prolapse Table 26<ul> <li>Assess Severity, leaflet morphology, ventricular compensation</li> </ul> </li> <li>Infective Endocarditis Table 28<ul> <li>Detection of valvular lesions</li> <li>Detection of associated abnormalities</li> <li>Reevaluation studies in complex endocarditis</li> </ul> </li> <li>Valvular Heart Disease and Prosthetic Valves Table 29<ul> <li>Timing of intervention</li> <li>Selection of therapies</li> <li>Postintervention for valve function (early) and ventricular remodeling (late)</li> </ul> </li> <li>Chest Pain Table 30<ul> <li>Diagnose underlying cardiac disease in patients with chest pain and clinical evidence of valvular, pericardial, or primary myocardial disease</li> <li>Evaluation of chest pain in patients with suspected acute myocardial ischemia, when baseline ECG is non-diagnostic and when study can be obtained during pain or soon after its abatement (see section IV)<ul> <li>The presence of regional systolic wall motion abnormalities in a patient without known CAD is a moderately accurate indicator of an increased likelihood of acute myocardial ischemia or infarction by pooled data with a positive predictive accuracy of about 50%</li> </ul> </li> <li>The absence of regional wall motion abnormalities identifies a subset of patients unlikely to have an acute infarction<sup>1</sup> with a pooled negative predictive accuracy of about 95%<sup>2</sup></li> <li>Evaluation of suspected aortic dissection</li> <li>Evaluation with severe hemodynamic instability</li> </ul> </li> <li>ACS Table 31-32<ul> <li>Diagnosis of suspected acute ischemia or infarction not evident by standard means</li> <li>Measurement of baseline LV function</li> <li>Patients with inferior myocardial infarction and bedside evidence suggesting possible RV infarction.</li> <li>Assessment of mechanical complications and mural thrombus</li> <li>Assessment of infarct size and/or extent of jeopardized myocardium</li> <li>In-hospital assessment of ventricular function when the results are used to guide therapy</li> <li>In-hospital or early postdischarge assessment of the presence/extent of inducible ischemia whenever baseline abnormalities are expected to compromise electrocardiographic interpretation</li> </ul> </li> <li>Chronic Stable Ischemic Heart Disease Table 33-34<ul> <li>Diagnosis of myocardial ischemia in symptomatic individuals (Exercise TTE)</li> <li>Assessment of global ventricular function at rest</li> <li>Assessment of myocardial viability (hibernating myocardium) for planning revascularization (Dobutamine Stress)</li> <li>Assessment of functional significance of coronary lesions (if not already known) in planning percutaneous transluminal coronary angioplasty</li> <li>Assessment of LV function when needed to guide institution and modification of drug therapy in patients with known or suspected LV dysfunction</li> <li>Assessment for restenosis after revascularization in patients with atypical recurrent symptoms (Exercise TTE)</li> </ul> </li> <li>Dyspnea/Edema/Cardiomyopathy Table 35<ul> <li>Assessment of LV size and function in patients with suspected cardiomyopathy or clinical diagnosis of heart failure</li> <li>Edema with clinical signs of elevated central venous pressure when a potential cardiac etiology is suspected or when central venous pressure cannot be estimated with confidence and clinical suspicion of heart disease is high</li> <li>Dyspnea with clinical signs of heart disease</li> <li>Patients with unexplained hypotension, especially in the intensive care unit</li> <li>Patients exposed to cardiotoxic agents, to determine the advisability of additional or increased dosages</li> <li>Reevaluation of LV function in patients with established cardiomyopathy when there has been a documented change in clinical status or to guide medical therapy</li> </ul> </li> <li>Pericardial Disease Table 36<ul> <li>Patients with suspected pericardial disease, including effusion, constriction, or effusive-constrictive process</li> <li>To follow resolution</li> </ul> </li> <li></li> <li>Pulmonary Disease Table 39<ul> <li>Suspected pulmonary hypertension</li> <li>Pulmonary emboli and suspected clots in the right atrium or ventricle or main pulmonary artery branches</li> <li>For distinguishing cardiac versus non-cardiac etiology of dyspnea in patients in whom all clinical and laboratory clues are ambiguous</li> <li>Follow-up of pulmonary artery pressures in patients with pulmonary hypertension to evaluate response to treatment</li> <li>Lung disease with clinical suspicion of cardiac involvement (suspected cor pulmonale)</li> </ul> </li> <li>Hypertension Table 40<ul> <li>When assessment of resting LV function, hypertrophy, or concentric remodeling is important in clinical decision making (see LV function)</li> <li>Detection and assessment of functional significance of concomitant coronary artery disease (see coronary disease)</li> <li>Follow-up assessment of LV size and function in patients with LV dysfunction when there has been a documented change in clinical status or to guide medical therapy</li> </ul> </li> <li>Vascular/Neurologic Events<ul> <li>Patients of any age with abrupt occlusion of a major peripheral or visceral artery</li> <li>Younger patients (typically &lt;45 years) with cerebrovascular events</li> <li>Older patients (typically &gt;45 years) with neurological events without evidence of cerebrovascular disease or other obvious cause</li> <li>Patients for whom a clinical therapeutic decision (anticoagulation, etc) will depend on the results of echocardiography</li> </ul> </li> <li>Arrhythmias and Palpitations Table 41<ul> <li>Arrhythmias with clinical suspicion of structural heart disease</li> <li>Arrhythmia in a patient with a family history of a genetically transmitted cardiac lesion associated with arrhythmia such as tuberous sclerosis, rhabdomyoma, or hypertrophic cardiomyopathy.</li> <li>Evaluation of patients as a component of the workup before electrophysiological ablative procedures.</li> </ul> </li> <li>Syncope Table 44<ul> <li>Syncope in a patient with clinically suspected heart disease</li> <li>Periexertional syncope</li> </ul> </li> <li>CVD Screening Table 45<ul> <li>Patients with a family history of genetically transmitted cardiovascular disease</li> <li>Potential donors for cardiac transplantation</li> <li>Patients with phenotypic features of Marfan syndrome or related connective tissue diseases</li> <li>Baseline and reevaluations of patients undergoing chemotherapy with cardiotoxic agents</li> </ul> </li> </ul> </li> <li>Class III (Not useful)<ul> <li>However, many murmurs in asymptomatic people are innocent and of no functional significance. Such murmurs are defined as having the following characteristics: a systolic murmur of short duration, grade 1 or 2 intensity at the left sternal border, a systolic ejection pattern, a normal S2, no other abnormal sounds or murmurs, no evidence of ventricular hypertrophy or dilation, no thrills, and the absence of an increase in intensity with the Valsalva maneuver. Such murmurs are especially common in high-output states such as pregnancy.</li> <li>Syncope Table 44<ul> <li>Classic neurogenic syncope</li> <li>Syncope in a patient for whom there is no clinical suspicion of heart disease</li> <li>Recurrent syncope in a patient in whom previous echocardiographic or other testing demonstrated a cause of syncope</li> </ul> </li> </ul> </li> </ul>"},{"location":"fellowship-guide/topics/echo/indications/#indications-for-tee-after-tte","title":"Indications for TEE after TTE","text":"<ul> <li>Left atrial thrombus</li> <li>Left atrial spontaneous contrast</li> <li>Atrial Septal Aneurysm</li> <li>Patient foramen ovale</li> <li>Aortic Atheroma</li> </ul>"},{"location":"fellowship-guide/topics/echo/indications/#indications-in-the-critically-ill","title":"Indications in the Critically Ill","text":"<ul> <li>The critically ill patient in the emergency department or intensive care unit is often managed by intubation and mechanical ventilation frequently utilizing positive end-expiratory pressure (PEEP)<ul> <li>Up to one half of such patients cannot be adequately imaged by TTE, especially those requiring &gt;10 cm PEEP</li> </ul> </li> <li>Indications for TEE Table 46<ul> <li>The hemodynamically unstable patient with suboptimal TTE images.</li> <li>The hemodynamically unstable patient on a ventilator.</li> <li>Major trauma or postoperative patients (unable to be positioned for adequate TTE).</li> <li>Suspected aortic dissection.</li> <li>Suspected aortic injury.</li> <li>Other conditions in which TEE is superior (see section on valvular disease).</li> </ul> </li> <li>Indications for TTE Table 47<ul> <li>The hemodynamically unstable patient</li> <li>Suspected aortic dissection (TEE)</li> <li>Serious blunt or penetrating chest trauma (suspected pericardial effusion or tamponade)</li> <li>Mechanically ventilated multiple-trauma or chest trauma patient</li> <li>Suspected preexisting valvular or myocardial disease in the trauma patient</li> <li>The hemodynamically unstable multiple-injury patient without obvious chest trauma but with a mechanism of injury suggesting potential cardiac or aortic injury (deceleration or crush)</li> <li>Widening of the mediastinum, postinjury suspected aortic injury (TEE)</li> <li>Potential catheter, guidewire, pacer electrode, or pericardiocentesis needle injury with or without signs of tamponade</li> </ul> </li> </ul> <ol> <li> <p>https://doi.org/10.1161%2Fcirc.65.2.7053890 \u21a9</p> </li> <li> <p>https://linkinghub.elsevier.com/retrieve/pii/000291499090143O \u21a9</p> </li> </ol>"},{"location":"fellowship-guide/topics/echo/leftatrium/","title":"Left Atrium","text":""},{"location":"fellowship-guide/topics/echo/leftatrium/#standard-definitions","title":"Standard Definitions","text":"<ul> <li>Left Atrial Area<ul> <li>The area of the left atrium at end-ventricular systole in the 4-chamber view reported in cm2</li> </ul> </li> <li>Left atrial volume<ul> <li>The volume of the left atrium at end-ventricular systole reported in mL</li> </ul> </li> <li>Left Atrial Size<ul> <li>Normal</li> <li>Reduced</li> <li>Mildly enlarged</li> <li>Moderately enlarged</li> <li>Severely enlarged</li> <li>Dilated, unable to characterize further</li> <li>Unknown</li> </ul> </li> </ul>"},{"location":"fellowship-guide/topics/echo/resources/","title":"Resources","text":"<ul> <li>Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging</li> <li>2019 ACC/AHA/ASE Key Data Elements and Definitions for Transthoracic Echocardiography: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Clinical Data Standards for Transthoracic Echocardiography) and the American Society of Echocardiography</li> <li>Echocardiography and Nuclear Cardiac Imaging in the Critical Care Unit</li> </ul>"},{"location":"fellowship-guide/topics/ep/atrial-fibrillation/","title":"Atrial Fibrillation","text":"<ul> <li>Arrhythmia Databases</li> <li>Physionet</li> <li>Physionet Database</li> </ul>","tags":["AF","Anticoagulation"]},{"location":"fellowship-guide/topics/ep/atrial-fibrillation/#general","title":"General<sup>1</sup>","text":"<ul> <li>Most Common sustained Arrhythmia</li> <li>95% of patients are &gt; 60 y/o</li> <li>Causes: Atrial enlargement, elevated atrial pressure, atrial infiltration or inflammation<ul> <li>Leads to increase in LA load and thus LA pressure thus predisposes to afib</li> <li>Precipitants of atrial dilation and/or conduction remodeling<ul> <li>Advanced age</li> <li>Systemic hypertension (MC underlying condition)</li> <li>MV dysfunction (MS/MR)</li> <li>LV failure (CHF)</li> <li>CAD and related factors (T2DM and smoking)</li> <li>Obesity and OSA</li> <li>Chronic hypoxic lung disease (COPD)</li> <li>Alcohol</li> </ul> </li> <li>Triggers of increased automaticity<ul> <li>Subclinical or Overt Hyperthyroidism</li> <li>Excessive alcohol use</li> <li>Increased sympathetic tone<ul> <li>Acute illness (sepsis, PE, MI, myocarditis)</li> <li>Cardiac Surgery (Post cardiac surgery due to pericarditis)</li> </ul> </li> <li>Sympathomimetic drugs (cocaine, theophylline, amphetamines)</li> </ul> </li> </ul> </li> </ul>","tags":["AF","Anticoagulation"]},{"location":"fellowship-guide/topics/ep/atrial-fibrillation/#definitions","title":"Definitions","text":"","tags":["AF","Anticoagulation"]},{"location":"fellowship-guide/topics/ep/atrial-fibrillation/#paroxysmal-afib-2-episodes-that-terminate-spontaneously-or-with-intervention-within-7-days-of-onset","title":"Paroxysmal AFib (\u22652 episodes that terminate spontaneously or with intervention within 7 days of onset)","text":"<ul> <li>70% at one year to 90% at 4 years of recurrence</li> <li>Triggers: Ectopic Foci (Pulmonary Ventricular sites)</li> <li>Treatment:<ul> <li>Amiodarone, Flecainide, sometimes Ablation (works better): Pulmonary vein potentials in the LA</li> </ul> </li> </ul>","tags":["AF","Anticoagulation"]},{"location":"fellowship-guide/topics/ep/atrial-fibrillation/#persistent-afib-2-episodes-each-lasts-7-days","title":"Persistent AFib (\u22652 episodes, each lasts &gt;7 days)","text":"<ul> <li>Triggers: Electrophysiologic remodeling fibrosis<ul> <li>SVC or coronary sinus most commonly</li> <li>Non-Pulmonary Ventricle sites</li> </ul> </li> <li>Treatment<ul> <li>Cardioversion if unstable</li> <li>Medical therapy</li> <li>Ablation usually doesn\u2019t work, try after medicine</li> </ul> </li> </ul>","tags":["AF","Anticoagulation"]},{"location":"fellowship-guide/topics/ep/atrial-fibrillation/#long-standing-persistent-or-permanent-afib-6-12-months","title":"Long-standing Persistent or Permanent AFib (&gt;6-12 months)","text":"<ul> <li>Triggers: Chronic Substrate Fibrosis</li> </ul>","tags":["AF","Anticoagulation"]},{"location":"fellowship-guide/topics/ep/atrial-fibrillation/#afib-w-rapid-ventricular-response-rvr","title":"AFib w/ Rapid Ventricular Response (RVR)","text":"<ul> <li>HOCM, HFpEF, Impaired cardiac function</li> <li>Symptoms<ul> <li>Exercise intolerance, fatigue, palpitations, chest pain, light headedness, hemodynamic instability</li> <li>Tachycardia-mediated cardiomyopathy</li> </ul> </li> </ul>","tags":["AF","Anticoagulation"]},{"location":"fellowship-guide/topics/ep/atrial-fibrillation/#features","title":"Features","text":"<ul> <li>Irregularly irregular rhythm w/ Narrow QRS and variable p waves<ul> <li>No distinct P waves, absent A waves, narrow QRS<ul> <li>Rate: 100-110 BPM</li> </ul> </li> <li>Disorganized atrial impulses all over the atria<ul> <li>Usually starts in LA (Pulmonary veins)</li> <li>MC location of ectopic foci (ablate them)</li> </ul> </li> <li>Multiple reentrant circuits that coexist</li> <li>P waves occur at a rate between 350-600, ventricular rates slower than atrial rates</li> <li>Rate is determined by AV nodal conduction; arises from uncoordinated or loss of atrial contraction (Chaotic rapid atrial electrical activity)</li> </ul> </li> <li>Tachycardia may continue despite beats that fail to conduct to the ventricles, indicating that the AV node is not participating in the tachycardia circuit</li> <li>Ashman Phenomenon: Aberrantly conducted beats after long-short R-R cycles</li> </ul>","tags":["AF","Anticoagulation"]},{"location":"fellowship-guide/topics/ep/atrial-fibrillation/#complications","title":"Complications","text":"<ul> <li>Loss of atrial contributions to ventricular filling</li> <li>Predisposition to thrombus formation in the left atrial appendage w/potential embolization (Thromboembolic Stroke)</li> <li>In patients with MS or HOCM, conversion to sinus rhythm increases embolic risk</li> <li>More likely for stoke 5x</li> </ul>","tags":["AF","Anticoagulation"]},{"location":"fellowship-guide/topics/ep/atrial-fibrillation/#diagnosis-and-work-up","title":"Diagnosis and Work-up","text":"<ul> <li>Diagnosis: EKG to Confirm<ul> <li>TTE and TSH/Free T4<ul> <li>To assess for atrial thrombi, hyperthyroidism, baseline for long-term</li> <li>Hypertension MCC</li> </ul> </li> <li>TEE if TTE shows valvular disease<ul> <li>Echo Features of PAF</li> </ul> </li> <li>Exercise stress test after starting medications</li> <li>Holter, telemetry to identify asymptomatic episodes</li> <li>EPS: to test for SVTs (AVNRT/MAT)</li> </ul> </li> <li>W/U: CMP, TSH, Echo</li> </ul>","tags":["AF","Anticoagulation"]},{"location":"fellowship-guide/topics/ep/atrial-fibrillation/#management","title":"Management<sup>2</sup>","text":"","tags":["AF","Anticoagulation"]},{"location":"fellowship-guide/topics/ep/atrial-fibrillation/#rhythmrate","title":"Rhythm/Rate","text":"<ul> <li>AFFIRM<sup>3</sup>: Rate-control = Rhythm-control; Rate preferred due to Adverse events</li> <li>Rate vs Rhythm Control in Recurrent Persistent Afib</li> <li>Early Rhythm Control<ul> <li>Goal: HR&lt;80 if symptoms, HR &lt;110 if none, EF &gt;40%<ul> <li>EAST-AFNET 4*<ul> <li>Improved clinical outcomes if early rhythm control in all patients diagnosed within the past 12 months w/coexisting CVD</li> <li>Aggressive rhythm control via Ablation or Amiodarone</li> </ul> </li> </ul> </li> </ul> </li> <li>RACE-II: Lenient non-inferior to strict rate-control in afib</li> <li>RAAFT-2: RFA if AAD failed as 1<sup>st</sup> line for symptomatic PAF<ul> <li>RFA recommended in patients with symptomatic PAF who have failed treatment with at least 1 Class I or Class III AAD</li> </ul> </li> </ul>","tags":["AF","Anticoagulation"]},{"location":"fellowship-guide/topics/ep/atrial-fibrillation/#acute-afib-wrvr","title":"Acute Afib w/RVR","text":"","tags":["AF","Anticoagulation"]},{"location":"fellowship-guide/topics/ep/atrial-fibrillation/#unstable-afib-wrvr","title":"Unstable Afib w/RVR","text":"<ul> <li>Immediate Cardioversion</li> </ul>","tags":["AF","Anticoagulation"]},{"location":"fellowship-guide/topics/ep/atrial-fibrillation/#stable-afib-wrvr","title":"Stable Afib w/RVR","text":"<ul> <li> <p>1B: Non-dihydropyridine CCBs or BBs</p> <ul> <li>Severe COPD: CCBs (Cardizem)</li> <li>CAD: BBs (Metoprolol Tartrate)</li> </ul> </li> <li> <p>2A: IV Magnesium</p> </li> <li>2A: Digoxin if can't use BBs or CCBs<ul> <li>Total IV loading dose:<ul> <li>Normal renal function: 8-12 mcg/kg ideal body weight (usually ~600-1,000 mcg).</li> <li>Renal insufficiency: 6-10 mcg/kg ideal body weight.</li> <li>Typically, 50% of the total loading dose is given initially, followed by 25% given twice, every six hours.<ul> <li>The first IV dose (typically ~400-600 mcg) takes effect within roughly 1-4 hours. Monitor for effect. If an adequate heart rate is achieved, then subsequent doses may be omitted. If bradycardia occurs, further administration should be held</li> </ul> </li> </ul> </li> </ul> </li> <li>2B: Amiodarone</li> <li>Radiofrequency Ablation (RFA)<ul> <li>1 year success rates approach 70-80%</li> <li>Afib recurrence after RFA in 20-40% of patients<ul> <li>OSA independently increases the risk of incident atrial fibrillation and increases the risk of recurrent AF after ablation by promoting atrial structural and electrical remodeling including atrial enlargement and low-voltage areas with conduction abnormalities<ul> <li>Treatment of OSA with CPAP improves arrhythmia-free survival post-catheter ablation</li> </ul> </li> <li>Repeat ablation is primarily considered for those with symptomatic AF recurrences (often drug-refractory) occurring at least 3 months or more post-ablation</li> <li>At 1-year follow-up more patients randomized to repeat ablation with RF (58%) were AF-free compared with those who underwent cryoablation (43%)<sup>5</sup></li> </ul> </li> <li>Complications (&lt;5%)<ul> <li>Stroke</li> <li>Pulmonary Vein Stenosis</li> <li>Esophageal injury</li> <li>Phrenic Nerve Paralysis</li> <li>Acute Pericarditis (10.2%)<ul> <li>Associated with younger age</li> </ul> </li> </ul> </li> </ul> </li> </ul>","tags":["AF","Anticoagulation"]},{"location":"fellowship-guide/topics/ep/atrial-fibrillation/#anticoagulation","title":"Anticoagulation","text":"<ul> <li>Trials<ul> <li>Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report</li> <li>AVERROES: Eliquis &gt; Aspirin alone for Stroke/VTE</li> <li>ARISTOTLE: Eliquis &gt; Warfarin for stroke, less brain bleeding</li> <li>ROCKET-AF: Xarelto is non-inferior to Warfarin</li> <li>BRIDGE: Periprocedural bridging did not reduce ATE, increased bleeding</li> </ul> </li> <li>Non-Valvular Afib<ul> <li>CHA2DS2-VASc Score (stroke risk, max is 9)<ul> <li>Anticoagulation in Non-valvular Atrial Fibrillation</li> <li>CHF, Hypertension, DM, Vascular disease (prior MI, PAD, or aortic plaque), age 65-74, female (all 1)</li> <li>Age \u226575, Stroke/TIA/Thromboembolism (all 2)<ul> <li>0 (Low Risk): None</li> <li>1 in males (Moderate) or 2 in females: None or aspirin or oral anticoagulants</li> <li>\u22652 in males (high) or \u22653 in females: Oral Anticoagulants</li> </ul> </li> </ul> </li> <li>Use warfarin at INR 2-3 or non-vitamin K antagonist oral anticoagulants to prevent thromboembolism</li> <li>Risk<ul> <li>0: 0.2% annual stroke risk</li> <li>1: 0.6%</li> <li>2: 2.2%</li> <li>3: 3.2%</li> <li>4: 4.8%</li> <li>5: 7.2%</li> <li>6: 9.7%</li> <li>7: 11.2%</li> <li>8: 10.8%</li> <li>9: 12.2%</li> </ul> </li> <li>Treatment<ul> <li>Positive net clinical benefit of chronic AC in patients with high thromboembolic risk</li> <li>DOACs Preferred<ul> <li>Similar or reduced risk of stroke, reduced risk of major bleeding and hemorrhagic stroke in patients with CKD and eGFR \u226530<sup>4</sup></li> </ul> </li> <li>DOACs &gt; Warfarin in CKD for Nonvalvular Afib</li> <li>Dabigatran vs. Warfarin</li> </ul> </li> </ul> </li> <li>Valvular Afib<ul> <li>Severe Mitral Stenosis (Valve area \u22641.5cm^2)</li> <li>Mechanical Heart Valve (any location)<ul> <li>RF: Afib, LV systolic dysfunction, prior VTE, hypercoagulable state<ul> <li>INR target 1.5 may be reasonable in newer valves</li> <li>Risk of VTE is 4% per year without AC, 2% with aspirin, &lt;1% with warfarin</li> </ul> </li> <li>Modern Bileaflet Aortic Valve w/o RF: INR 2.0-3.0</li> <li>Mitral Valve: INR 2.5-3.5</li> <li>Aortic Valve w/\u22651 RF: INR 2.5-3.5</li> <li>Aortic Valve with old-generation valve: INR 2.5-3.5</li> <li>Low-dose Aspirin: only in patients with other strong indications (Severe CAD)</li> <li>Dabigatran vs. Warfarin</li> </ul> </li> <li>Treatment<ul> <li>Warfarin preferred</li> </ul> </li> </ul> </li> </ul>","tags":["AF","Anticoagulation"]},{"location":"fellowship-guide/topics/ep/atrial-fibrillation/#resources","title":"Resources","text":"<ul> <li>2023 ACC Guideline for the Diagnosis and Management of Atrial Fibrillation</li> <li>StatPearls</li> <li>EMCrit Afib/Aflutter</li> </ul> <ol> <li> <p>https://www.ncbi.nlm.nih.gov/books/NBK526072/ \u21a9</p> </li> <li> <p>https://pubmed.ncbi.nlm.nih.gov/30144419/{:target=\"_blank\"}\u00a0\u21a9</p> </li> <li> <p>https://pubmed.ncbi.nlm.nih.gov/12466506/{:target=\"_blank\"}\u00a0\u21a9</p> </li> <li> <p>https://pubmed.ncbi.nlm.nih.gov/22894575/{:target=\"_blank\"}\u00a0\u21a9</p> </li> <li> <p>https://pubmed.ncbi.nlm.nih.gov/23210695/{:target=\"_blank\"}\u00a0\u21a9</p> </li> </ol>","tags":["AF","Anticoagulation"]},{"location":"fellowship-guide/topics/ep/cardioversion/","title":"Cardioversion","text":""},{"location":"fellowship-guide/topics/ep/cardioversion/#external-direct-current-cardioversion","title":"External Direct Current Cardioversion","text":"<ul> <li>Indications<ul> <li>Persistent Afib</li> </ul> </li> <li>Considered successful if sinus rhythm of any duration is achieved post cardioversion<ul> <li>Unsuccessful in &gt;10%<ul> <li>More likely to fail if:<ul> <li>BMI \u226530, \u226535, \u226540 are associated with 1.87, 2.50, and 4.9 Relative risk of requiring more than one attempt<sup>1</sup></li> </ul> </li> </ul> </li> </ul> </li> <li>Predictors of recurrence after catheter ablation and electrical cardioversion of atrial fibrillation: an umbrella review of meta-analyses<ul> <li>Address HTN, OSA, Depression, Metabolic Syndrome</li> <li>AADs may increase the success rate of DC cardioversion</li> </ul> </li> <li>Amiodarone pretreatment with intravenous bolus few hours before electrical cardioversion reduces short-term recurrences of atrial fibrillation</li> </ul>"},{"location":"fellowship-guide/topics/ep/cardioversion/#setup","title":"Setup","text":"<ul> <li>Goal: Optimize Transthoracic Impedance<ul> <li>Determined by position of the electrodes<ul> <li>The lower the better</li> <li>Optimal when atria completely encompassed</li> </ul> </li> <li>RAFF2: No difference between AP vs. AL pad locations in achieving cardioversion success<ul> <li>AP to have better success over AL in patients with lone AF and LA size &lt;45mm</li> </ul> </li> </ul> </li> </ul>"},{"location":"fellowship-guide/topics/ep/cardioversion/#protocol","title":"[Protocol]<sup>1</sup>","text":"<ul> <li>200J AP Biphasic Shock</li> <li> </li> <li> </li> <li>Use 2 defibrillators with crossing pad in AP and right parasternal to deliver 400J shock with external compression at end-expiration</li> <li>Position pads under fluoroscopy</li> </ul>"},{"location":"fellowship-guide/topics/ep/cardioversion/#1-external-compression-60-100n-at-end-expiration","title":"1 + External Compression (60-100N) at end-expiration","text":""},{"location":"fellowship-guide/topics/ep/cardioversion/#2-but-anterior-pad-changed-to-right-parasternal-location","title":"2 but anterior pad changed to right parasternal location","text":""},{"location":"fellowship-guide/topics/ep/cardioversion/#complications","title":"Complications","text":"<ul> <li>Asystole &gt;5s</li> <li>Severe Transient Bradycardia w/HR &lt;40 bmp (&lt;1%)</li> <li>Sustained ventricular arrhythmia</li> </ul> <ol> <li> <p>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10062296/ \u21a9\u21a9</p> </li> </ol>"},{"location":"fellowship-guide/topics/ep/cieds/","title":"Cardiovascular Implantable Electronic Devices (CIEDs)","text":""},{"location":"fellowship-guide/topics/ep/cieds/#pacemakers-ppm","title":"Pacemakers (PPM)","text":"<ul> <li>Used to maintain heart rate</li> <li>Indications<ul> <li>Complete AV block unless 2/2 MI or reversible cause</li> <li>Symptomatic Sinus Bradycardia (HR &lt;40 usually)</li> <li>Symptomatic chronotropic incompetence (Inability to achieve 85% of age-predicted maximum HR)</li> <li>Advanced 2<sup>nd</sup> Degree AV Block (Block of \u22652 consecutive P waves)</li> <li>Mobitz type II 2<sup>nd</sup> Degree AV Block (Symptomatic or Asymptomatic)</li> <li>Mobitz type I 2<sup>nd</sup> Degree AV Block (Symptomatic only)</li> <li>Afib w/bradycardia and pauses &gt;5s</li> </ul> </li> <li>Consists of a Pulse Generator (battery) and circuitry with 1,2, or 3 leads<ul> <li>Single chamber (1 lead) in RA or RV</li> <li>Dual Chamber (2 leads) in RA and RV</li> <li>Biventricular (3 leads) in RA, RV, and Cardiac Vein (to pace LV)<ul> <li>AKA cardiac resynchronization devices</li> </ul> </li> </ul> </li> <li>PG is implanted in infraclavicular region</li> <li>Malfunction or lead movement: High pacemaker lead thresholds</li> </ul>"},{"location":"fellowship-guide/topics/ep/cieds/#implantable-cardioverter-defibrillator-icd","title":"Implantable Cardioverter-Defibrillator (ICD)","text":"<ul> <li>Primary or Secondary prevention of SCD from VT/VF<ul> <li>Indicated for prevention of sudden cardiac death (SCD)</li> </ul> </li> <li>Primary Prevention<ul> <li>Prior MI and LVEF \u226430%<ul> <li>\u226540 days after MI and 3 months post PCI/CABG with an EF \u226430%</li> </ul> </li> <li>ICM/NICM w/NYHA Class II or III symptoms and LVEF \u226435% on GDMT<ul> <li>Wait for 3 months after initiation of GMDT to assess potential recovery</li> </ul> </li> </ul> </li> <li>Secondary Prevention<ul> <li>Prior VF or unstable VT without reversible cause<ul> <li>In patients with a FH of cardiac arrest or sustained, spontaneous VT</li> <li>Survivors of cardiac arrest resulting from VF or VT not explained by a reversible cause</li> <li>Syncope and sustained VT/VF on EP Study</li> <li>Brugada syndrome with syncope or ventricular arrhythmia</li> <li>Inherited Long QT syndrome not responding to \u03b2-blockers</li> </ul> </li> <li>Prior sustained VT with underlying cardiomyopathy<ul> <li>Sustained VT in the presence of structural heart disease</li> </ul> </li> </ul> </li> <li>Hypertrophic Cardiomyopathy if:<ul> <li>Primary Prevention<ul> <li>FH of SCD</li> <li>Syncope (recurrent and/or associated with exertion)</li> <li>Non-sustained VT on Holter</li> <li>Hypotensive BP response to exercise</li> <li>Extreme LVH (&gt;3cm max septal wall thickness)</li> </ul> </li> <li>Secondary<ul> <li>Survivors of cardiac arrest</li> <li>Sustained spontaneous ventricular Arrhythmias</li> </ul> </li> </ul> </li> </ul>"},{"location":"fellowship-guide/topics/ep/cieds/#cardiac-resynchronization-therapy-crt","title":"Cardiac Resynchronization Therapy (CRT)","text":"<ul> <li>Cardiac resynchronization therapy and QRS duration: systematic review, meta-analysis, and meta-regression</li> <li>Extra wire (3<sup>rd</sup> wire) in the coronary sinus for synchronizing RV/LV<ul> <li>LV pacing in LBBB</li> <li>Improves exercise tolerance, reduce the need for hospitalization, decrease overall mortality</li> </ul> </li> <li>Indications<ul> <li>LVEF \u226435% + Sinus rhythm + One:<ul> <li>QRS \u2265150ms and NYHA Class III-IV on optimal medical therapy (IA)</li> <li>QRS &gt;120ms but &lt;150ms and NYHA Class III-IV symptoms on optimal medical therapy (optional)</li> <li>NYHA Class I or II symptoms on optimal medical therapy undergoing pacemaker or ICD with anticipated frequent ventricular pacing</li> <li>Indications of Cardiac Resynchronization in Non-Left Bundle Branch Block: Clinical Review of Available Evidence</li> </ul> </li> <li>LVEF \u226430%, QRS \u2265150ms with LBBB, and NYHA Class I-II symptoms on optimal medical therapy</li> </ul> </li> <li>CRT-P: No ICD, aka BiV</li> <li>CRT-D: ICD, aka BiV-ICD or Combo device</li> </ul>"},{"location":"fellowship-guide/topics/ep/cieds/#implantable-loop-recorder-ilr","title":"Implantable Loop Recorder (ILR)","text":"<ul> <li>Continuous heart rhythm monitoring</li> <li>Use: Very rare events (&gt;30 days apart)</li> </ul>"},{"location":"fellowship-guide/topics/ep/cieds/#implantable-cardiovascular-monitor-icm","title":"Implantable Cardiovascular Monitor (ICM)","text":"<ul> <li>Intravascular hemodynamic monitoring<ul> <li>Pulmonary Artery Pressure Sensors<ul> <li>CHAMPION Trial: decrease hospitalizations in NHYA III</li> </ul> </li> </ul> </li> </ul>"},{"location":"fellowship-guide/topics/ep/conduction/","title":"Cardiac Conduction","text":""},{"location":"fellowship-guide/topics/ep/conduction/#arrhythmia-mechanisms","title":"Arrhythmia Mechanisms","text":"<ul> <li>Cellular<ul> <li>Impulse initiation<ul> <li>Automaticity (sinus brady/tachy)</li> <li>Triggered Automaticity<ul> <li>Digitalis, Torsades</li> </ul> </li> </ul> </li> <li>Excitation (Ischemic VF or AV block)</li> <li>Repolarization (Polymorphic VT or AF)</li> </ul> </li> <li> <p>Multicellular</p> <ul> <li>Cellular coupling (Ischemic VT/VF)</li> <li>Tissue Structure (AF, monomorphic VT)</li> </ul> </li> <li> <p>3 usual mechanisms of abnormal rhythms:</p> <ul> <li>Reentry<ul> <li>MC mechanism is reentry from abnormal conduction</li> <li>AVNRT (MC reentry, SVT), Atrial Flutter, most VTs</li> </ul> </li> <li>Triggered Activity</li> <li>Automaticity</li> </ul> </li> </ul>"},{"location":"fellowship-guide/topics/ep/emergencies/","title":"Emergencies","text":""},{"location":"fellowship-guide/topics/ep/emergencies/#general","title":"General","text":"<ul> <li>Part 3: Adult Basic and Advanced Life Support: 2020 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care</li> <li>Pulseless Electrical Activity (PEA)<ul> <li>Lack of pulse with persistent electrical activity</li> </ul> </li> <li>Asystole<ul> <li>Lack of all electrical activity on the cardiac monitor</li> <li>Determine cause of rhythm (hypoxemia, hyperkalemia, hemorrhage, metabolic acidosis, tension pneumothorax, cardiac tamponade, or toxins)</li> <li>Reversible causes of Asystole/PEA<ul> <li>5 Hs &amp; 5 Ts:<ul> <li>Hypovolemia, Hypoxia, Hydrogen Ions (Acidosis), Hypo/Hyperkalemia, Hypothermia</li> <li>Tension Pneumothorax, Tamponade (Cardiac), Toxins (narcotics, benzos), Thrombosis (Pulmonary or coronary), Trauma</li> </ul> </li> </ul> </li> <li>Treatment<ul> <li>CPR, Epinephrine \u00b1 Vasopressin</li> <li>Fix cause<ul> <li>No response to defibrillation</li> </ul> </li> </ul> </li> </ul> </li> <li>Sudden Cardiac Arrest and Sudden Cardiac Death<ul> <li>Sudden cessation of cardiac activity so that the victim becomes unresponsive, with no normal breathing and no signs of circulation<ul> <li>Sudden Cardiac Arrest (SCA) used to signify an event that is reversed</li> <li>Sudden Cardiac Death (SCD) used to signify if the event leads to death</li> </ul> </li> <li>Etiology<ul> <li>HCM (36%)</li> <li>Coronary artery anomalies (17%)</li> <li>Possible HCM (8.2%)</li> <li>Myocarditis (5.9%)</li> <li>Arrhythmogenic RV cardiomyopathy (4.3%)<ul> <li>Brugada Syndrome<ul> <li>Autosomal Dominant disorder due to Sodium channel gene (SCN5A) mutation found in 25-30%</li> <li>Presentation<ul> <li>Male, attacks occur at rest and during sleep<ul> <li>3<sup>rd</sup>/4<sup>th</sup> decades of life</li> <li>Polymorphic VT causing syncope</li> </ul> </li> <li>Syncope and sudden cardiac death without structural heart disease<ul> <li>20% of those without SHD</li> </ul> </li> </ul> </li> <li>EKG<ul> <li>Type 1 (Typical): \u22652mm of coved ST elevation in the right precordial leads (V1-V3) with associated T-wave inversion and RBBB appearance</li> </ul> </li> <li>Treatment<ul> <li>Asymptomatic: Controversial<ul> <li>Risk Stratification</li> </ul> </li> <li>Symptomatic: ICD</li> </ul> </li> </ul> </li> </ul> </li> <li>Long QT (3.6%)</li> <li>MCC of SDA in the immediate post-infarction period with acute MI<ul> <li>Immediate (&lt;10min):<ul> <li>Acute ischemia predisposes to Re-entrant ventricular arrhythmias (Ventricular fibrillation)</li> </ul> </li> <li>Delayed (10-60min): Abnormal automaticity leads to arrhythmias</li> </ul> </li> </ul> </li> <li>Most important factor for survival out of the hospital SCA is elapsed time to effective resuscitation<ul> <li>Includes adequate bystander CPR, prompt rhythm analysis, and defibrillation</li> <li>Defib possible: Vfib or Pulseless Vtach</li> <li>Defib not possible: Asystole, PEA<ul> <li>CPR and Epinephrine</li> </ul> </li> </ul> </li> </ul> </li> </ul>"},{"location":"fellowship-guide/topics/ep/emergencies/#wellens-syndrome-ekg","title":"Wellens Syndrome (EKG)","text":"<ul> <li>Hallmark: Deeply inverted T waves in V2/V3 (Type B, 75%) or Biphasic T waves with initial positivity and terminal negativity in V2/V3 (Type A, 25%)<ul> <li>PLUS:<ul> <li>Isoelectric or minimally elevated ST segment, less than 1mm</li> <li>Preserved precordial R-wave progression and no precordial Q waves</li> <li>Recent history of angina</li> <li>EKG without pain</li> <li>Normal or slightly elevated cardiac markers</li> </ul> </li> </ul> </li> <li>Type A often evolve into Type B</li> <li>Symptoms<ul> <li>Painless mild elevation in troponins</li> </ul> </li> <li>Complications<ul> <li>Highly specific for critical, proximal LAD stenosis<ul> <li>Large anterior wall acute MI<ul> <li>75% within weeks</li> </ul> </li> </ul> </li> </ul> </li> <li>Treatment<ul> <li>Admit to Telemetry is asymptomatic, ICU if symptomatic</li> <li>Cards consult for cath<ul> <li>Cath w/Stents (refractory to medical management)</li> </ul> </li> </ul> </li> </ul>"},{"location":"fellowship-guide/topics/ep/qtc/","title":"QTc Disorders","text":""},{"location":"fellowship-guide/topics/ep/qtc/#qtc-prolongation","title":"QTc Prolongation","text":"<ul> <li>The Risk of QTc interval Prolongation with Psychotropics</li> <li>Which psychotropics carry the greatest risk of QTc prolongation?</li> <li>Effect of a single dose of i.v. ondansetron on QTc interval in emergency department patients</li> <li>Prescription and dispensation of QT-prolonging medications in individuals receiving hemodialysis</li> </ul>"},{"location":"fellowship-guide/topics/ep/sinus_node/","title":"Sinus Nodal Arrhythmias","text":""},{"location":"fellowship-guide/topics/ep/sinus_node/#general","title":"General","text":"<ul> <li>Sinus Nodal Arrythmia with Normal Conduction<ul> <li>Sinus Tachycardia/IST</li> <li>Sinus Arrhythmia</li> <li>Sinus Bradycardia</li> </ul> </li> <li>Sinus Nodal Arrythmia with Abnormal Conduction<ul> <li>Sinus Node Re-Entrant Tachycardia</li> <li>Sick Sinus Syndrome (SSS)</li> <li>Heart Blocks<ul> <li>Sinus Blocks</li> <li>AV Blocks</li> <li>Bundle Branch Blocks</li> <li>Hemiblocks</li> </ul> </li> </ul> </li> </ul>"},{"location":"fellowship-guide/topics/ep/sinus_node/#sinus-nodal-arrythmia-with-normal-conduction","title":"Sinus Nodal Arrythmia with Normal Conduction","text":"<ul> <li>General<ul> <li>Includes Sinus Tachycardia and Inappropriate Sinus Tachycardia</li> <li>Can be Pathologic or Physiologic:<ul> <li>SA node dysfunction and AV conduction block MCCs<ul> <li>Failure of initiation or conduction</li> </ul> </li> <li>Rate of generation of impulses is reduced to &lt;60bpm</li> <li>Common in Athletes, low tone in sleep, increased vagal tone<ul> <li>May be due to hypoventilation (hypoxia)</li> </ul> </li> <li>BB and CCBS are a common cause</li> <li>Need permanent pacemaker</li> </ul> </li> <li>Diagnosis: 12-Lead EKG</li> <li>Treatment<ul> <li>Asymptomatic: Leave them alone</li> <li>Symptomatic (hypotension, shock, AMS, ischemia, HF)<ul> <li>IV Atropine</li> <li>If Inadequate response</li> <li>IV epinephrine/dopamine or transcutaneous pacing</li> </ul> </li> <li>Dual Chamber Pacemaker eventually<ul> <li>Sinus Arrhythmia</li> </ul> </li> </ul> </li> <li>Irregular Arrythmia (Normal Rate, Irregular Rhythm)</li> <li>In response to vagal tone that causes an alteration in the respiratory cycle</li> <li>Changes seen in R-R interval commonly seen in children<ul> <li>R-R Increases during inspiration, decreases during expiration</li> </ul> </li> </ul> </li> </ul>"},{"location":"fellowship-guide/topics/ep/sinus_node/#sinus-nodal-arrythmia-with-abnormal-conduction","title":"Sinus Nodal Arrythmia with Abnormal Conduction","text":"<ul> <li>Bundle Branch Block</li> <li>Sick Sinus Syndrome (SSS)<ul> <li>Intrinsic SA node disease, can progress into the SA node itself and into the perinodal area<ul> <li>Impaired SA node automaticity because of fibrosis and/or degeneration of the SA node and surrounding myocardium</li> <li>Unresponsive supraventricular (AV and junctional) automaticity foci (no escape mechanism)</li> <li>Excessive parasympathetic activity depresses the pacing of the SA node and depresses the supraventricular foci</li> </ul> </li> <li>Symptoms<ul> <li>Confusion, dizziness, fatigue, Lightheaded, palpitations, presyncope, syncope</li> <li>Bradycardia<ul> <li>MC finding on EKG</li> <li>Associated with Adam-Stokes attacks</li> <li>Can result in bradycardia-tachycardia syndrome (alternating brady and Paroxysmal SVT (often Afib))</li> </ul> </li> <li>Sinus pauses/arrests, SA exit block, or alternating bradycardia and atrial tachyarrhythmias</li> <li>Tachycardia-Bradycardia Syndrome</li> <li>EKG: Sinus Bradycardia with delayed/dropped P waves MC</li> </ul> </li> <li>Types:<ul> <li>1) Symptomatic Sinus Bradycardia</li> <li>2) Sinus pause (cessation of SA node impulse generation) and sinus arrest</li> <li>3) Sinus Node Exit Block (impulse generated normally in sinus node, but fails to conduct within the SA node or perinodal tissue)</li> <li>4) Tachycardia-Bradycardia Syndrome: Alternating tachy/bradycardia<ul> <li>TAs: Afib, Atrial Flutter, Atrial Tachycardia<ul> <li>Rapid rhythm suppresses the SA node, the SA node tries to take over after but since there is SSS, there is a long pause after rhythm termination</li> <li>A slow junctional rhythm or sinus bradycardia may take over after the pause</li> </ul> </li> </ul> </li> </ul> </li> <li>Management<ul> <li>Assess for meds:<ul> <li>Acetylcholinesterase Inhibitors (Donepezil, rivastigmine, and galantamine)<ul> <li>Associated with bradycardia, heart block, and syncope</li> <li>Substitute with memantine</li> </ul> </li> </ul> </li> <li>24 hour monitoring if arrhythmia is intermittent</li> <li>Echo indicated if syncope or near syncope</li> </ul> </li> <li>Treatment<ul> <li>Type 1 or 3: Dual Chamber Pacemaker</li> <li>Type 2: Symptoms + Sinus pauses &gt;3s: Dual Chamber Pacemaker</li> <li>Type 4: Dual Chamber Pacemaker \u00b1 Antiarrhythmic</li> </ul> </li> </ul> </li> </ul>"},{"location":"fellowship-guide/topics/ep/sinus_node/#heart-blocks","title":"Heart Blocks","text":""},{"location":"fellowship-guide/topics/ep/sinus_node/#sinus-block","title":"Sinus Block","text":"<ul> <li>Aka Sinus Nodal Block</li> <li>No P waves<ul> <li>Doesn\u2019t change subsequent timing, but may see escape beat</li> </ul> </li> <li>SSS is a type</li> </ul>"},{"location":"fellowship-guide/topics/ep/sinus_node/#av-blocks","title":"AV blocks","text":"<ul> <li>Normal: PR is 120-200ms<ul> <li>PR &gt;200ms indicate AV block</li> </ul> </li> <li>AV conduction system comprises:<ul> <li>AV node, the bundle of His and its left and right bundle branches</li> <li>3 degrees of AV blocks depending on the extent of impaired conduction</li> <li>Causes<ul> <li>Lyme, Chagas, Syphilis</li> <li>SLE Mom w/kid</li> </ul> </li> </ul> </li> <li>Congenital AV block w/ normal heart<ul> <li>Acute MI \u2013 transient 1 or 2 av block</li> </ul> </li> <li>Inferior &gt; anterior acute MI is going to cause a 2<sup>nd</sup> degree or higher</li> <li>Diagnosis: Determine the level<ul> <li>Vagal maneuvers, carotid sinus massage<ul> <li>Slow AV conduction, less effect on infra-nodal tissue</li> </ul> </li> <li>Exercise, atropine, isoproterenol</li> <li>Improve AV conduction, impair infra-nodal conduction</li> <li>1) Normal QRS (&lt;120msec)         - Likely due to delayed AV node conduction</li> <li>2) Prolonged QRS (&gt;120msec)         - Delay below AV node, may progress to 2<sup>nd</sup> degree</li> </ul> </li> <li>Medications that can cause AV Blocks (ABCD) \u2013 SA/AV nodal blockers<ul> <li>Adenosine<ul> <li>Aborts SVT, stress tests</li> </ul> </li> <li>Beta Blockers<ul> <li>Beta-1 specific (metoprolol) have greater HR affects</li> <li>Bradycardia, heart block, hypotension, AMS, normal vision</li> </ul> </li> <li>CCBs (Diltiazem and Verapamil)<ul> <li>Affects BP but not HR</li> </ul> </li> <li>Digoxin<ul> <li>Used in Atrial Fibrillation in HFrEF</li> <li>Bradycardia, heart block, hypotension, AMS, Altered Vision</li> </ul> </li> </ul> </li> </ul>"},{"location":"fellowship-guide/topics/ep/sinus_node/#1st-degree-av-block","title":"1<sup>st</sup> Degree AV Block","text":"<ul> <li>Usually, benign prolongation of AV node conduction<ul> <li>Fixed, regular rhythm with P-R interval prolonged (&gt;200ms)</li> <li>1:1 conduction of the AV node is well preserved<ul> <li>1 P wave corresponding to 1 QRS</li> </ul> </li> </ul> </li> <li>Causes are usually reversible:<ul> <li>BBs and CCBs (depress AV node conduction)</li> <li>Vagal maneuvers that increase tone (sleep)</li> <li>Transient ischemia (RCA angioplasty complication)</li> <li>Metabolic (Hyperkalemia)</li> </ul> </li> <li>Non-reversible<ul> <li>AV node sclero-degenerative diseases, MI, trauma during surgery or ablations</li> </ul> </li> <li>Treatment:<ul> <li>Usually asymptomatic: No treatment</li> </ul> </li> </ul>"},{"location":"fellowship-guide/topics/ep/sinus_node/#2nd-degree-av-block","title":"2<sup>nd</sup> Degree AV Block","text":"<ul> <li>Intermittent conduction</li> <li>Mobitz Type I (Wenckebach)<ul> <li>Block involving the AV node<ul> <li>Usually, benign AV node conduction dysfunction</li> </ul> </li> <li>Characterized by a gradual progression of the PR interval with each beat until a QRS does not follow a P wave for a single beat (P wave without a QRS)<ul> <li>The PR interval following the non-conducted wave is usually short</li> <li>RR interval is irregular</li> <li>Usually doesn\u2019t involve the bundle of His</li> </ul> </li> <li>Causes: Athletes with high vagal tone, OSA (high vagal tone)<ul> <li>RCA MI may have, usually reversible</li> <li>Fatigue/Dizziness occasionally</li> </ul> </li> <li>Treatment<ul> <li>Symptomatic: Pacemaker</li> <li>Asymptomatic: Observe</li> </ul> </li> </ul> </li> <li>Mobitz Type II (Mobitz)<ul> <li>Block of the Purkinje fiber bundles (His or Bundle Branches)</li> <li>Sudden loss of the QRS complex following a p wave without progressive P-R lengthening on prior beats (PR interval is fixed)<ul> <li>Most waves conduct 1:1 with similar PR intervals, and the non-P wave suddenly does not conduct to a QRS</li> <li>Sometimes 2 sequential P waves are followed by a QRS in the case of a 2:1 Mobitz Type II AV block, and 3 sequential P waves follow a 3:1 block</li> </ul> </li> <li>Irreversible usually:<ul> <li>Hyperkalemia, aging due to sclero-degeneration of the AV node, MI, cardiac surgery or ablation mistakes</li> </ul> </li> <li>May progress to 3<sup>rd</sup> Degree heart block, Bundle branch block</li> <li>Treatment<ul> <li>Asymptomatic or Symptomatic: Pacemaker</li> </ul> </li> </ul> </li> </ul>"},{"location":"fellowship-guide/topics/ep/sinus_node/#3rd-degree-av-block-complete-heart-block","title":"3<sup>rd</sup> Degree AV Block (Complete Heart Block)","text":"<ul> <li>Lack of conduction across the AV node (Block between SA and AV node)<ul> <li>Complete dissociation between atrial and ventricular contractions</li> </ul> </li> <li>Usually, an intrinsic AV node dysfunction<ul> <li>May occur due to extensive ischemic myocardial injury (anterior or inferior MI), sclero-degeneration of the AV node, during catheter ablation and cardiac surgery of the valves<ul> <li>Trifasicular or bifasciular can progress to complete heart block</li> </ul> </li> </ul> </li> <li>Syncope, SCD<ul> <li>Inferior MI block is usually transient<ul> <li>IV atropine if needed</li> </ul> </li> <li>Anterior MI blocks are usually permanent<ul> <li>2<sup>nd</sup>/3<sup>rd</sup> degree blocks likely need temp pacer -&gt; permanent</li> </ul> </li> <li>Infiltrative diseases of the heart such as sarcoid</li> <li>Congenital block may be asymptomatic until adolescence, still need pacemaker</li> <li>Reversible causes: hyperkalemia (hemodialysis patients or patients on ACEI), BB, CCBs, or digoxin</li> </ul> </li> <li>Atrial impulses fail to capture ventricles<ul> <li>Escape rhythm is usually present<ul> <li>Narrow (Junctional Escape) or Wide (Ventricular Escape)</li> </ul> </li> </ul> </li> <li>Ventricular asystole (syncope/death) unless an escape rhythm is initiated:<ul> <li>P waves do not relate to QRS (AV dissociation)</li> <li>Regular RR and PP intervals, Atrial Rate &gt; Ventricular Rate (&lt;50)</li> <li>P waves appear with a different rate than the ventricular escape rhythm</li> </ul> </li> <li>Symptoms<ul> <li>Lightheadedness, fatigue, SOB, or presyncope and syncope</li> <li>Adams-Stokes (or Stokes-Adams) attacks are attacks of syncope in the setting of a 3<sup>rd</sup> Degree AV Block/SVT/Afib<ul> <li>Brain blood supply insufficiency may cause LOC</li> </ul> </li> </ul> </li> <li>Treatment<ul> <li>Intermittent w/Bifasicular or Trifasicular block<ul> <li>Permanent pacemaker</li> </ul> </li> <li>Asymptomatic or Symptomatic:<ul> <li>Temporary pacemaker</li> <li>Permanent if no reversible cause found</li> </ul> </li> </ul> </li> </ul>"},{"location":"fellowship-guide/topics/ep/svt/","title":"Supraventricular Tachycardias","text":""},{"location":"fellowship-guide/topics/ep/svt/#general","title":"General","text":"<p>1) Sinus Node Origin     - Sinus Tachycardia (ST)     - Inappropriate Sinus Tachycardia (IST)     - Sinus Nodal Re-Entry Tachycardia 2) Atrial Origin     - Ectopic Atrial Tachycardia (EAT)     - Multifocal Atrial Tachycardia (MAT) 3) Junctional (AV) Arrhythmias     - Accelerated Junctional Rhythm (ARJ)     - Junctional Tachycardia         - Non-Re-Entrant Junctional Tachycardia             - Ectopic Junctional Tachycardia (JET)             - Non-Paroxysmal JT (PJRT)         - Re-Entrant Junctional Tachycardias             - AVNRT (Typical of Atypical)             - AVRT (Accessory Pathway)</p> <ul> <li>2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With SVT</li> <li>Evaluation and initial treatment of supraventricular tachycardia</li> <li>Main Point: SVTs originate at or above His-Bundle (excludes AF)<ul> <li>Originate from or are dependent on conduction through the atrium or AV node to the ventricles</li> <li>Any arrythmia initiating in the atria and involving the AV node or an accessory pathway<ul> <li>Most common type of SVT is due to AV node reentry (AVNRT)</li> </ul> </li> </ul> </li> <li>Usually there are no regular p waves (buried within the QRS), but retrograde P waves can occur<ul> <li>May be seen in the beginning or the end of a QRS complex when the atria and ventricles are not simultaneous</li> <li>Can appear as spikes on QRS complexes or as inverted P waves</li> </ul> </li> <li>Mostly narrow complex tachycardia (QRS &lt;120ms), rate ~160 bpm<ul> <li>Narrow QRS unless AV nodal dysfunction or pre-excitation</li> </ul> </li> <li>Symptoms<ul> <li>Sudden onset palpations and dizziness in a young patient, near syncope, lightheadedness, diaphoresis and chest pain</li> <li>Symptoms of palpitations: 12 lead ECG</li> </ul> </li> </ul>"},{"location":"fellowship-guide/topics/ep/svt/#sinus-nodal-atrial-tachycardias-stist","title":"Sinus Nodal Atrial Tachycardias (ST/IST)","text":""},{"location":"fellowship-guide/topics/ep/svt/#sinus-tachycardia-st","title":"Sinus Tachycardia (ST)","text":"<ul> <li>Rate &gt;100 BPM, Regular, rarely exceeds 220</li> <li>P waves before each QRS, PR interval \u2265120ms</li> <li>Upright P waves in Lead I, II, aVF, V3-V6</li> <li>Ventricular rate \u2265100 bpm         - More common than Inappropriate ST         - Gradual onset and termination</li> <li>Slowed by vagal maneuvers, sinus massage         - Usually doesn\u2019t exceed maximum for age</li> <li>(.85) x (220 - patient age) = maximum predicted         - Physiologic: Precipitated by exertion, stress, illness (panic attacks), dehydration</li> <li>Sympathetic stimulation and vagal withdrawal         - Pathologic process: Pulmonary Embolism</li> </ul>"},{"location":"fellowship-guide/topics/ep/svt/#inappropriate-sinus-tachycardia-ist","title":"Inappropriate Sinus Tachycardia (IST)","text":"<ul> <li>Rate: 100-180 BPM<ul> <li>Normal P waves, may be an ectopic atrial tachycardia w/focus near the SA node</li> </ul> </li> <li>Dysfunctional Autonomic Regulation<ul> <li>Tachycardia may continue despite beats that fail to conduct to the ventricles, indicating that the AV node is not participating in the tachycardia circuit</li> </ul> </li> <li>Symptoms<ul> <li>Fatigue, dizziness \u00b1 syncope in 30-40 y/o women</li> </ul> </li> <li>Carotid Massage: Atrial Rate may slow</li> <li>Treatment if no underlying cause:<ul> <li>1) Ivabradine 5mg PO BID (inhibits funny channel responsible for normal Sinus node automaticity, only lowers HR)</li> <li>2) BB, CCBs, Digoxin, or catheter ablation</li> </ul> </li> </ul>"},{"location":"fellowship-guide/topics/ep/svt/#sinus-nodal-re-entry-tachycardia","title":"Sinus Nodal Re-Entry Tachycardia","text":"<ul> <li>Occurs within the sinus node cluster of cells and is conducted throughout the heart in a normal fashion<ul> <li>Long RP interval, p waves are identical in axis and morphology as sinus Ps</li> </ul> </li> <li>Vagal maneuvers and adenosine will terminate</li> <li>Abrupt onset and termination</li> <li>Treatment<ul> <li>BB, CCBs, Digoxin</li> </ul> </li> </ul>"},{"location":"fellowship-guide/topics/ep/svt/#atrial-tachycardias-eatmat","title":"Atrial Tachycardias (EAT/MAT)","text":"<ul> <li>Most commonly due to enhanced or abnormal atrial automaticity or triggered activity</li> <li>AV Block: More A\u2019s than V\u2019s</li> </ul>"},{"location":"fellowship-guide/topics/ep/svt/#ectopic-focal-atrial-tachycardia-eat","title":"Ectopic (Focal) Atrial Tachycardia (EAT)","text":"<ul> <li>Rate: 150-250 BPM (slower than Atrial Flutter)</li> <li>Confined completely to atrial tissue</li> <li>Regular Atrial Tachycardia with defined p wave (Differs from normal P wave)<ul> <li>Usually paroxysmal and resolves spontaneously</li> <li>Frequent Origins: along valve annuli of LA or RA, pulmonary veins, coronary sinus musculature, SVC</li> <li>Abnormal Automaticity, triggered automaticity, a small reentry circuit confined to the atrium or atrial tissue extending into a pulmonary vein, pulmonary sinus, or vena cava</li> <li>The closer the ectopic focus is to the SA node, the closer the p-wave resemblance to Sinus Tachycardia, and the narrower the PR interval</li> <li>Atrial rate typically increases over initial 10s, then stabilizes to 150-250</li> </ul> </li> <li>Tachycardia may continue despite beats that fail to conduct to the ventricles, indicating that the AV node is not participating in the tachycardia circuit<ul> <li>1:1 AV Response<ul> <li>AVN Blockade increases AV block with continuation of Atrial Tachycardia, atrial rate unaffected (No termination)</li> </ul> </li> <li>May terminate tachycardia w/preceding warm up or cold down phase<ul> <li>Gradual initiation and gradual termination possible (long RP)</li> </ul> </li> </ul> </li> <li>Often seen in CAD, COPD, Alcohol use</li> <li>Can be Sustained, Non-sustained, Paroxysmal, Incessant<ul> <li>Sustained and Non-sustained EAT are often a precursor to AF and Aflutter</li> <li>Paroxysmal Atrial Tachycardia w/AV block: Digitalis Toxicity<ul> <li>Can increase ectopy in atria or ventricles</li> </ul> </li> <li>Incessant EAT: can cause Tachycardia Induced Cardiomyopathy</li> <li>Paroxysmal EAT: may become incessant</li> </ul> </li> <li>Carotid Massage: AV block may increase, doesn\u2019t usually revert, may uncover an ectopic atrial tachycardia</li> <li>Treatment<ul> <li>Goal: Slow ventricular rate</li> <li>Stable: BB, Diltiazem/Verapamil to decrease HR<ul> <li>Refractory/Definitive: Catheter Ablation</li> </ul> </li> <li>Unstable: Synchronized Cardioversion</li> </ul> </li> </ul>"},{"location":"fellowship-guide/topics/ep/svt/#multifocal-atrial-tachycardia-mat","title":"Multifocal Atrial Tachycardia (MAT)","text":"<ul> <li>\u22653 different P-wave morphologies prior to QRSs, Irregularly irregular rhythm<ul> <li>HR typically between 100-150</li> <li>Multiple atrial foci (multiple discrete p waves) with increased automaticity irritated by increased atrial pressures or hypoxia<ul> <li>AECOPD, Hypokalemia, Catecholamine Surge (Sepsis), PE, Pneumonia, hypomagnesemia</li> </ul> </li> <li>Clear isoelectric intervals between p waves, and the atrial rate is slower<ul> <li>Usually caused by severe pulmonary disease (COPD) or acute illness, pulmonary hypertension, coronary disease, valvular disease, hypomagnesemia, theophylline</li> </ul> </li> </ul> </li> <li>Tachycardia may continue despite beats that fail to conduct to the ventricles, indicating that the AV node is not participating in the tachycardia circuit</li> <li>Symptoms<ul> <li>Typically asymptomatic</li> </ul> </li> <li>Treatment<ul> <li>Treat Underlying Condition (generally slower)<ul> <li>CCBs/Metoprolol long-term</li> </ul> </li> <li>Acute Exacerbation: IV Metoprolol/Verapamil (CCBs)<ul> <li>Amiodarone/Ablation/Cardioversion do work in MAT</li> </ul> </li> </ul> </li> </ul>"},{"location":"fellowship-guide/topics/ep/svt/#junctional-av-arrhythmias-wo-re-entry-jetajr","title":"Junctional (AV) Arrhythmias w/o Re-entry (JET/AJR)","text":"<ul> <li>A rapid, narrow complex arrhythmia arising from the AV junction, including the Bundle of His</li> <li>VA Block: More V\u2019s than A\u2019s</li> <li>General Treatment<ul> <li>Acute: IV BB for symptoms, IV diltiazem, procainamide or verapamil</li> <li>Chronic:<ul> <li>1) Oral BB, CCBs</li> <li>2) Catheter ablation</li> </ul> </li> </ul> </li> </ul>"},{"location":"fellowship-guide/topics/ep/svt/#accelerated-junctional-rhythm-ajr","title":"Accelerated Junctional Rhythm (AJR)","text":"<ul> <li>Occurs when AV node automaticity rate is faster than SA node or Atrial Foci</li> <li>Narrow QRS (HR 60-100), retrograde P waves may be visible<ul> <li>Between 60-100 BPM w/gradual increase in rate (Automatic Focus) or after a PVC (focus of triggered automaticity)</li> <li>AV dissociation present</li> </ul> </li> <li>Often caused by digoxin toxicity (assess for upsloping ST throughout and digoxin levels), may be MI also, severe ischemic heart disease, coronary reperfusion</li> </ul>"},{"location":"fellowship-guide/topics/ep/svt/#ectopic-junctional-tachycardia-jet","title":"Ectopic Junctional Tachycardia (JET)","text":"<ul> <li>Due to automaticity within the AV node near the His-Bundle<ul> <li>Incessant tachycardia in children during perioperative congenital heart surgery, or after cardiac surgery in pts with CHF, Rare in adults</li> </ul> </li> <li>Regular atrial rate, Narrow QRS (120-220) often w/VA block<ul> <li>Regular rhythm, occasionally irregular</li> <li>AV dissociation (due to focus within AV node)<ul> <li>Can be seen with Adenosine, but rhythm not terminated</li> </ul> </li> </ul> </li> <li>Can be seen after isoproterenol use</li> <li>Treatment<ul> <li>Need rate control if symptomatic</li> <li>Risk complete AV block due to proximity to AV node if ablation</li> </ul> </li> </ul>"},{"location":"fellowship-guide/topics/ep/svt/#junctional-av-arrhythmias-with-re-entry-avnrtavrt","title":"Junctional (AV) Arrhythmias with Re-entry (AVNRT/AVRT)","text":""},{"location":"fellowship-guide/topics/ep/svt/#atrioventricular-nodal-re-entrant-tachycardia-avnrt","title":"Atrioventricular Nodal Re-entrant Tachycardia (AVNRT)","text":"<ul> <li>Most common and regular SVT in adults, more common in women<ul> <li>Re-entry is the MCC of narrow QRS complex tachycardia</li> <li>Slow/Fast pathway + PAC</li> <li>MC PSVT (60%), most common paroxysmal sustained tachycardia in young healthy adults, normally structured hearts</li> </ul> </li> <li>Paroxysmal, regular, narrow QRS tachycardia with p waves that may or may not be visible<ul> <li>HR from 150-250 bpm w/ regular ventricular response of 180-200</li> <li>P waves are rarely seen, may be seeing in the terminal aspect if QRS in V1</li> <li>RP interval is short, p wave may not be apparent</li> </ul> </li> <li>Uses AV node nodal and perinodal tissue (does not involve atria and ventricles)</li> <li>Conduction from Atrium into the AV Node that is bidirectional<ul> <li>Due to the presence of 2 conduction pathways (slow and fast) in the AV node and involving the atrium</li> <li>Normally sinus beats pass through the fast pathway and the slow pathway conduction is extinguished due to the refractory period<ul> <li>The slow pathway conducts both anterograde to the ventricle and retrograde toward the tricuspid valve (thus simultaneous conduction of atrium and ventricle)</li> <li>The fast pathway does not</li> </ul> </li> <li>AVNRTs utilize Slow conducting pathway<ul> <li>The slow pathway has transitional cells and fibers</li> <li>Usually inferior extension from AV node near His bundle along Tricuspid valve annulus to the coronary sinus floor</li> <li>If a PAC occurs during the refractory period of the fast pathway, it can initiate AVNRT that is then sustained by a reentry mechanism</li> <li>The 2 pathways then form a looped circuit with impulses traveling antegrade through the slow pathway and return through the fast pathway<ul> <li>Atria and Ventricles are not a part of circuit</li> </ul> </li> </ul> </li> </ul> </li> <li>Palpitations &gt; dizziness, dyspnea, chest pain, or SOB<ul> <li>1:1 AV response, AVN Blockade terminates Tachycardia<ul> <li>Dual electrical pathways within or near the AV node</li> </ul> </li> </ul> </li> <li>Vagal Maneuvers (Carotid sinus massage, cold-water immersion or diving reflex, Valsalva, eyeball pressure) increase parasympathetic tone in the heart and slow AV nodal conduction and increase the refractory period (terminating AVNRT)</li> <li>Treatment<ul> <li>Acute Stable: Vagal, Valsalva<ul> <li>Adenosine 15mg IVx1, 12mg IV q1-2min x1-2 as needed<ul> <li>Useful if narrow or wide and regular</li> </ul> </li> <li>CCBs, BB</li> </ul> </li> <li>Chronic: Same as above or flecainide &gt; Ablation of slow pathway</li> <li>Acute Unstable: Adenosine/Vagal &gt; Synchronized Cardioversion<ul> <li>\u00b1 BB or CCB &gt; Flecainide or propafenone if no SHD</li> <li>Amiodarone if SHD</li> </ul> </li> <li>RF catheter ablation is curative in 95%<ul> <li>First line to prevent recurrences</li> <li>Small risk of complete AV block</li> </ul> </li> </ul> </li> </ul>"},{"location":"fellowship-guide/topics/ep/svt/#atrioventricular-reciprocating-tachycardia-avrt","title":"Atrioventricular Reciprocating Tachycardia (AVRT)","text":"<ul> <li>General<ul> <li>Accessory Pathway Rhythms<ul> <li>Myocytes spanning between the upper and lower chambers across the AV groove (distinct accessory pathway)</li> <li>Atria and Ventricles are involved in this pathway, Normal AV node (unlike AVNRT)</li> </ul> </li> <li>Sudden onset, spontaneous termination</li> <li>Ventricular Preexcitation<ul> <li>Characterized by the Delta Wave<ul> <li>Indicates anterograde accessory pathway or bypass tract</li> <li>Conducts impulse from atria to ventricles w/PR &lt;120msec</li> </ul> </li> <li>Seen in Ebstein Anomaly</li> <li>Associated with increased risk of sudden death, likely 2ndary to an accessory pathway conducting to the ventricle<ul> <li>Can degenerate into VT or VF</li> <li>Lower risk if intermittent loss of preexcitation</li> </ul> </li> </ul> </li> <li>MC in children, 30% of all SVTs</li> <li>Caused by a bypass tract from the atrium to the ventricle that extends beyond the tricuspid and mitral valves, which typically block any AV conduction<ul> <li>Bypass tract may be anterograde, retrograde, or capable or both</li> <li>Pre-excitation refers to early activation of the ventricles due to impulses bypassing the AV node through this bypass tract</li> </ul> </li> <li>The accessory pathway may be concealed or manifest<ul> <li>A pathway may not be obvious on ECG and only conduct retrograde during an SVT (Concealed)</li> <li>WPW or Ventricular preexcitation are manifest due to the presence of a delta wave</li> </ul> </li> <li>HR 150-250 with regular ventricular response</li> <li>Respond to vagal maneuvers, adenosine, verapamil</li> </ul> </li> </ul>"},{"location":"fellowship-guide/topics/ep/svt/#orthodromic-avrt-retrograde-p-wave","title":"Orthodromic AVRT (Retrograde P wave)","text":"<ul> <li>90-95% of all Accessory Pathway SVTs</li> <li>Conduction through the AV node, Retrograde conduction back up through the bypass tract<ul> <li>Uses atrial and ventricular tissue, accessory pathway, AV Node, and His-Purkinje (excitation through the AV node and accessory pathway are required)</li> <li>Re-entry through accessory bundle</li> </ul> </li> <li>Paroxysmal sustained tachycardia similar to AVNRT<ul> <li>Narrow QRS complexes during tachycardia</li> <li>1:1 AV Response, AVN Blockade terminates Tachycardia</li> </ul> </li> <li>Treatment<ul> <li>Vagal maneuvers<ul> <li>Adenosine 15mg IVx1, 12mg IV q1-2min x1-2 as needed</li> </ul> </li> <li>Acute Unstable: Adenosine/Vagal &gt; Synchronized Cardioversion<ul> <li>No Pre-Excitation: CCBs or BBs</li> <li>Catheter Ablation for all AVRT</li> <li>No SHD: Propafenone, flecainide</li> <li>SHD: Amiodarone, sotalol, ibutilide</li> </ul> </li> <li>Chronic: Oral BB, CCBs if no pre-excitation</li> </ul> </li> </ul>"},{"location":"fellowship-guide/topics/ep/svt/#delta-wave-present","title":"Delta Wave Present","text":"<ul> <li>Delta wave only seen in Anterograde paths (initial slope of QRS)<ul> <li>Depolarization of the ventricular tissue from conduction of the atrium to the ventricle along the bypass tract</li> <li>No delta waves if no anterograde conduction</li> </ul> </li> </ul>"},{"location":"fellowship-guide/topics/ep/svt/#wolff-parkinson-white-disease-wpw","title":"Wolff Parkinson White Disease (WPW)","text":"<ul> <li>Accessory pathway conducts depolarization directly from atria to ventricle without traversing AV node<ul> <li>Characterized by atrial tachyarrhythmia occurring in the presence of an anterograde conducting accessory bypass tract allowing pre-excitation</li> </ul> </li> <li>Features<ul> <li>Short PR, Delta Wave, Widened QRS complexes</li> <li>Ventricular Pre-excitation during Sinus Rhythm Present<ul> <li>A-fib in 10-30%, Persistent a-fib can lead to rapid ventricular response (RVR) and eventually VFib<ul> <li>Increased risk for A fib and AVRT</li> <li>Can degenerate into VF and cause SCD</li> </ul> </li> </ul> </li> </ul> </li> <li>WPW Syndrome<ul> <li>Called WPW Syndrome when symptomatic<ul> <li>Pre-existing WPW pattern who develop symptomatic supraventricular arrhythmias involving the accessory pathway</li> <li>No longer pre-exciting the ventricles but instead form a reentrant circuit back to the atria<ul> <li>Initial widening of QRS converts to a narrow QRS with tachycardia when symptomatic<ul> <li>AVRT is MC, found in up to 80% of syndrome patients</li> <li>95% of re-entrant tachycardias</li> <li>Afib in 15-30%<ul> <li>Potentially life-threatening</li> <li>May degenerate into VF if short anterograde refractory period</li> </ul> </li> </ul> </li> </ul> </li> </ul> </li> <li>Symptoms<ul> <li>Palpitations</li> <li>Lightheadedness</li> <li>Presyncope or syncope</li> <li>Chest pain</li> </ul> </li> <li>Complications<ul> <li>SCD (1%)</li> </ul> </li> <li>WPW and Preexcitation Syndromes</li> </ul> </li> <li>W/U:<ul> <li>Asymptomatic<ul> <li>High Risk for Arrhythmias (Hx of AF or AVRT, Short Refractory Period (&lt;250ms) of the accessory pathway</li> <li>Noninvasive testing (Exercise Treadmill Test or Procainamide Challenge) and/or EPS to identify risk of SCD<ul> <li>EPS in high-risk occupations (Truck drivers, pilots, athletes)</li> <li>Intermittent loss of preexcitation w/faster HR (loss of Delta) with the above<ul> <li>Suggests longer refractory period that will not be able to conduct often enough during AF to degenerate into VF</li> <li>Low Risk</li> <li>No further Evaluation or treatment</li> </ul> </li> </ul> </li> </ul> </li> </ul> </li> <li>Treatment<ul> <li>Avoid Amiodarone/AV nodal blocking agents if possible</li> <li>BB and Verapamil are CI = cardiac arrest by decreasing the degree of concealed retrograde conduction</li> <li>Stable: No therapy</li> <li>Stable with Atrial Fibrillation: Procainamide or Ibutilide<ul> <li>Do not cause AV block because AV-node blockers promote more conduction through accessory pathway<ul> <li>Rapid ventricular response</li> </ul> </li> </ul> </li> <li>Unstable or with Atrial Fibrillation<ul> <li>Electrical Synchronized Cardioversion</li> </ul> </li> </ul> </li> </ul>"},{"location":"fellowship-guide/topics/ep/svt/#delta-wave-without-tachycardia-not-wpw","title":"Delta wave without Tachycardia (Not WPW)","text":"<ul> <li>High risk for SVTs, short PR, prolonged QRS &gt; 110</li> </ul>"},{"location":"fellowship-guide/topics/ep/svt/#pre-excitation-avrts","title":"Pre-Excitation AVRTs","text":"<ul> <li>Secondary to pre-excitation along AV accessory pathway</li> <li>Seen in Ebstein anomaly (up to 20%)</li> <li>Wide QRS tachycardia with QRS Similar to VT<ul> <li>Ventricular Pre-excitation during Sinus Rhythm:<ul> <li>Absent (Concealed Accessory pathway)</li> </ul> </li> <li>SVT w/Aberrancy (preexisting or functional BBB)</li> </ul> </li> </ul>"},{"location":"fellowship-guide/topics/ep/svt/#antidromic-avrt-wide-qrs","title":"Antidromic AVRT (Wide QRS)","text":"<ul> <li>Anterograde conduction down the bypass tract, retrograde conduction back up through the AV node/His-Purkinje System</li> <li>Wide QRS complex tachycardia with regular rhythm<ul> <li>Regular paroxysmal tachycardia<ul> <li>Occurs in 10% of patients with WPW syndrome with Tachycardia (Least common arrhythmia associated with WPW)</li> <li>Most Common Pre-Excitation Tachycardia</li> </ul> </li> </ul> </li> <li>Preexcitation in sinus rhythm</li> </ul>"},{"location":"fellowship-guide/topics/ep/svt/#atrial-fibrillation-w-preexcitation","title":"Atrial Fibrillation w/ Preexcitation","text":"<ul> <li>Irregular wide complex, or intermittently wide complex tachycardia, some &gt;250/min<ul> <li>Increased risk of SCD<ul> <li>Treatment<ul> <li>Procainamide of cardioversion</li> <li>No AV blocking agents</li> </ul> </li> </ul> </li> </ul> </li> </ul>"},{"location":"fellowship-guide/topics/ep/svt/#atrial-tachycardia-or-flutter-w-preexcitation","title":"Atrial Tachycardia or Flutter w/ Preexcitation","text":"<ul> <li>Treatment<ul> <li>Ablation is usually curative</li> </ul> </li> </ul>"},{"location":"fellowship-guide/topics/ep/svt/#pre-excitation-avrts-treatment","title":"Pre-Excitation AVRTs Treatment","text":"<ul> <li>Treatment for all:<ul> <li>No Adenosine (Vfib)</li> <li>No CCBS, BBs (hypotension)</li> <li>Offer catheter ablation</li> <li>Unstable + Wide QRS: Electrical Cardioversion</li> <li>Pre-excitation: Procainamide, ibutilide, amiodarone, propafenone</li> </ul> </li> </ul>"},{"location":"fellowship-guide/topics/ep/vt_vf/","title":"Ventricular Tachyarrhythmias","text":""},{"location":"fellowship-guide/topics/ep/vt_vf/#nonsustained-ventricular-tachycardia-nsvt","title":"Nonsustained Ventricular Tachycardia (NSVT)","text":"<ul> <li>\u22653-5 consecutive ventricular beats lasting &lt;30s<ul> <li>Patient remains hemodynamically stable</li> <li>0-4% of ambulatory patients</li> <li>Frequently asymptomatic</li> <li>W/U: EKG \u00b1 CXR/TTE</li> <li>Treatment<ul> <li>Admit if<ul> <li>High-Risk (Age &gt;45, Symptomatic, Known SHD, Concerning FH)</li> </ul> </li> </ul> </li> </ul> </li> </ul>"},{"location":"fellowship-guide/topics/ep/vt_vf/#general","title":"General","text":"<ul> <li>Patients with CHD and LV systolic dysfunction are at increased risk of ventricular arrythmias including VT and VF<ul> <li>95% of wide complex tachycardias are VT in pts with SHD</li> <li>Associated with<ul> <li>Dilated Cardiomyopathies, Brugada\u2019s syndrome, HCM, Amyloidosis/Sarcoidosis, Duchenne Muscular Dystrophy, TOF, and myocarditis</li> </ul> </li> </ul> </li> <li>Treatment in patients with Recurrent VT<ul> <li>1) Stabilize</li> <li>2) Find underlying cause (electrolyte abnormalities)<ul> <li>Order Electrolyte panel and Digoxin level</li> <li>Hypokalemia and hypomagnesemia (loop diuretics)</li> <li>Digoxin \u00b1 Hypokalemia</li> </ul> </li> </ul> </li> </ul>"},{"location":"fellowship-guide/topics/ep/vt_vf/#types","title":"Types","text":"<p>1) Fast Ventricular Tachycardias     - Monomorphic VT (MVT)     - Sustained Monomorphic VT (SMVT)     - Polymorphic VT (PVT) 2) Slow Ventricular Tachycardias 3) Ventricular Fibrillation</p>"},{"location":"fellowship-guide/topics/ep/vt_vf/#fast-ventricular-tachycardias","title":"Fast Ventricular Tachycardias","text":"<ul> <li> <p>3 consecutive premature ventricular beats (widened QRS)</p> <ul> <li>Wide QRS complex tachycardia often w/ abnormal QRS complexes and T waves in the vector opposite of the QRS</li> <li>Common, along with Vfib, post MI</li> <li>Pulse or pulseless presentation</li> </ul> </li> </ul>"},{"location":"fellowship-guide/topics/ep/vt_vf/#monomorphic-ventricular-tachycardia-mvt","title":"Monomorphic Ventricular Tachycardia (MVT)","text":"<ul> <li>Etiology<ul> <li>Rapid and repetitive firing of \u22653 premature ventricular complexes in a row with the same morphology</li> <li>Macro re-entrant circuit with conduction through and around scar tissue, reentry of an ectopic ventricular depolarization</li> <li>May be post MI (reentry)</li> </ul> </li> <li>QRS wide (&gt;0.12), uniform and stable, rate between 100-250</li> <li>AV dissociation may be apparent (regular rate between p waves)<ul> <li>Cannon A waves in the neck</li> <li>Capture beats and fusion beats possible</li> </ul> </li> <li>Symptoms<ul> <li>Palpitations, dyspnea, lightheadedness, angina, or near-syncope, syncope, seizures</li> </ul> </li> <li>Treatment<ul> <li>Stable/Pulse: IV amiodarone, metoprolol, revascularization OR Synchronized cardioversion</li> <li>Pulseless: CPR + Defibrillation \u00b1 Vasopressors</li> </ul> </li> </ul>"},{"location":"fellowship-guide/topics/ep/vt_vf/#sustained-monomorphic-ventricular-tachycardia-smvt","title":"Sustained Monomorphic Ventricular Tachycardia (SMVT)","text":"<ul> <li>Wide complex tachycardia with 2 fusion beats</li> <li>Fusion beats: capture of electrical signal though both the atrium and ventricle briefly<ul> <li>Hybrid of a normal and wide QRS complex (P waves precede fusion complex)</li> </ul> </li> <li>Treatment<ul> <li>Stable: IV Amiodarone &gt; Procainamide, sotalol, lidocaine</li> <li>Unstable: Synchronized Cardioversion</li> </ul> </li> </ul>"},{"location":"fellowship-guide/topics/ep/vt_vf/#polymorphic-ventricular-tachycardia-pvt","title":"Polymorphic Ventricular Tachycardia (PVT)","text":"<ul> <li>Triggered tachycardia, &gt;220 can cause Ventricular Fibrillation</li> <li>Wide complex, rapid and unstable</li> <li>QRSs vary in amplitude, size, and duration<ul> <li>Normal QTc = Coronary Ischemia (MI)</li> <li>Prolonged QTc = Torsade De Pointes<ul> <li>Men &gt;440ms, women &gt;460ms</li> </ul> </li> </ul> </li> <li>A) Torsade De Points (Polymorphic VT, TdP)<ul> <li>A rapid PVT with PVCs before T wave, may cause syncope</li> <li>VT with constantly changing cycle length, axis, and morphology<ul> <li>Onset: prolongation/lengthening of the QT interval which can be initiated by a PAC/PVC</li> </ul> </li> <li>Causes: Hypokalemia, hypomagnesemia, genetic Long QT<ul> <li>Medications increasing QT interval via inhibition of the rapid components of the delayed rectifier potassium current (Ikr)</li> <li>Meds: Chloroquine, hydroxychloroquine, azithromycin</li> <li>RF for drug induced: QTc &gt;500ms, QTc lengthening &gt;60ms, female, age &gt;65, bradycardia, hypokalemia, hypomagnesemia, hypocalcemia, HFrEF, \u22652 QT prolonging drugs, rapid IV admin</li> <li>30% have mutation in one of 5 QT syndrome genes</li> </ul> </li> <li>Goals<ul> <li>K &gt;4, Mg &gt;2, EKG q3-6m</li> <li>Baseline then annually if on methadone, daily if &gt;120mg</li> </ul> </li> <li>Treatment<ul> <li>Stable<ul> <li>IV Magnesium sulfate, avoid QT prolongation, lidocaine, increase HR (shortens QT)<ul> <li>Even if normal serum Mg</li> </ul> </li> <li>Temporary pacemaker, isoproterenol</li> </ul> </li> <li>Unstable: Defibrillation</li> </ul> </li> </ul> </li> </ul>"},{"location":"fellowship-guide/topics/ep/vt_vf/#general-management","title":"General Management","text":"<ul> <li>Pulse + Stable and Sustained Monomorphic<ul> <li>IV Amiodarone &gt; lidocaine<ul> <li>CI: Hypotension/unstable</li> </ul> </li> <li>Immediate Cardioversion if amiodarone fails</li> </ul> </li> <li>Pulse + Unstable and Sustained Monomorphic<ul> <li>Synchronized Cardioversion<ul> <li>Low energy shock to QRS complex that is timed</li> </ul> </li> <li>IV amiodarone to prevent VT/VF after Cardioversion</li> </ul> </li> <li>Pulseless<ul> <li>1) Defibrillation (unsynchronized Cardioversion)<ul> <li>High energy shock at a random point, multiple attempts</li> </ul> </li> <li>2) Epinephrine every 3-5 mins</li> <li>3) Amiodarone/Lidocaine</li> </ul> </li> <li>Chronic: ICD</li> </ul>"},{"location":"fellowship-guide/topics/ep/vt_vf/#slow-ventricular-tachycardias40-150-bpm","title":"Slow Ventricular Tachycardias(40-150 BPM)","text":""},{"location":"fellowship-guide/topics/ep/vt_vf/#ventricular-escape-3rd-degree-av-block","title":"Ventricular escape (3<sup>rd</sup> degree AV Block)","text":""},{"location":"fellowship-guide/topics/ep/vt_vf/#accelerated-ventricular-rhythm","title":"Accelerated Ventricular Rhythm","text":""},{"location":"fellowship-guide/topics/ep/vt_vf/#idioventricular","title":"Idioventricular","text":""},{"location":"fellowship-guide/topics/ep/vt_vf/#ventricular-fibrillation-vf","title":"Ventricular Fibrillation (VF)","text":"<ul> <li>Chaotic, irregular waveform of varying shapes and amplitude</li> <li>No coordinated contractions, identifiable p waves, QRS, or T waves</li> <li>Very rapid, irregular polymorphic rhythm<ul> <li>Disorganized electrical activity with multiple rapidly firing foci in the ventricles (Ventricles can\u2019t produce CO)</li> <li>Diffuse wide QRS segments</li> <li>Pulseless tachyarrhythmia</li> </ul> </li> <li>Most begin with Vtach</li> <li>RF: IHD, antiarrhythmics, Atrial fib w/RVR<ul> <li>Common in patients with MI</li> <li>Most common cause of SCD during acute MI</li> </ul> </li> <li>Treatment<ul> <li>Immediate Defibrillation + CPR<ul> <li>IV Epinephrine or Vasopressin without interrupting CPR if 1<sup>st</sup> defibrillation doesn\u2019t work</li> <li>IV amiodarone</li> </ul> </li> </ul> </li> </ul>"},{"location":"fellowship-guide/topics/nuc/","title":"Nuclear Cardiology","text":"<p>ASNC Guidelines</p>","tags":["Imaging"]},{"location":"fellowship-guide/topics/nuc/#other-resources","title":"Other Resources","text":"<ul> <li>Atlas of Nuclear Cardiology: Imaging Companion to Braunwald's Heart Disease : Expert Consult Ami E. Iskandrian , and Ernest V. Garcia</li> <li>Nuclear Cardiology: Understanding the Basics (John J. Mahmarian, MD) October 16, 2018</li> </ul>","tags":["Imaging"]},{"location":"fellowship-guide/topics/nuc/spect/","title":"SPECT MPI","text":"<ul> <li>Framingham Risk Stratification:<ul> <li>High Risk &gt;3%:<ul> <li>Resting LVEF &lt;35%</li> <li>High risk treadmill score \u2264-11</li> <li>Exercise LVEF &lt;35%</li> <li>Stress induced large perfusion defect</li> <li>Multiple, moderate-sized perfusion defects</li> <li>Large, fixed perfusion defect with LV dilation or increased lung uptake</li> <li>more than 2 segments of wall motion abnormalities on echo at low dobutamine does or low HR &lt;102</li> <li>Stress echo evidence of extensive ischemia</li> </ul> </li> <li>Intermediate Risk (1-3%):<ul> <li>Mild/moderate resting LV dysfunction (LVEF 35-49%)</li> <li>Duke Treadmill -11 to 5</li> <li>Stress induced moderate perfusion defect</li> <li>\u22642 segments of wall motion abnormalities on echo at high dobutamine does or low HR &lt;102</li> </ul> </li> <li>Low Risk (&lt;1%)<ul> <li>Low risk Duke treadmill score \u22655</li> <li>Normal or small defect at rest or with stress</li> <li>Normal stress echo wall motion or no change of limited resting wall motion abnormalities during stress</li> </ul> </li> </ul> </li> </ul>"},{"location":"fellowship-guide/topics/nuc/spect/#single-photon-emission-computed-tomography-spect-myocardial-perfusion-imaging-guidelines","title":"Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging Guidelines","text":"<ul> <li>Instrumentation, Acquisition, Processing, and Interpretation</li> <li>Stress, protocols, and tracers</li> <li>Quality metrics</li> </ul>"},{"location":"fellowship-guide/topics/nuc/spect/#low-risk-stress-findings-associated-with-a-cardiac-mortality-of-less-than-1-per-year","title":"LOW-RISK STRESS FINDINGS (associated with a cardiac mortality of less than 1% per year)","text":"<ul> <li> <ol> <li>Low risk treadmill score (score \u2265 5)</li> </ol> </li> <li> <ol> <li>Normal or small myocardial perfusion defect at rest or with stress</li> </ol> </li> <li> <ol> <li>Normal stress echocardiographic wall motion or no change of limited resting wall motion abnormalities during stress</li> </ol> </li> </ul>"},{"location":"fellowship-guide/topics/nuc/spect/#intermediate-risk-stress-findings-associated-with-a-1-3-per-year-cardiac-mortality","title":"INTERMEDIATE-RISK STRESS FINDINGS (associated with a 1-3% per year cardiac mortality)","text":"<ul> <li> <ol> <li>Mild/moderate resting left ventricular dysfunction (LVEF 35-49%)</li> </ol> </li> <li> <ol> <li>Intermediate risk treadmill score (-11 score to &lt; 5)</li> </ol> </li> <li> <ol> <li>Stress-induced moderate perfusion defect without LV dilation or increased lung intake (thallium-201)</li> </ol> </li> </ul>"},{"location":"fellowship-guide/topics/nuc/spect/#high-risk-stress-findings-associated-with-a-3-per-year-cardiac-mortality","title":"HIGH-RISK STRESS FINDINGS (associated with a &gt;3% per year cardiac mortality)","text":"<ul> <li> <ol> <li>Severe resting left ventricular dysfunction (LVEF &lt; 35%)</li> </ol> </li> <li> <ol> <li>High-risk treadmill score (score \u2264 -11)</li> </ol> </li> <li> <ol> <li>Severe exercise left ventricular dysfunction (exercise LVEF &lt; 35%)</li> </ol> </li> <li> <ol> <li>Stress-induced large perfusion defect (particularly if anterior)</li> </ol> </li> <li> <ol> <li>Stress-induced multiple perfusion defects of moderate size.</li> </ol> </li> <li> <ol> <li>Large, fixed perfusion defect with LV dilation or increased lung uptake (Thallium-201)</li> </ol> </li> <li> <ol> <li>Stress-induced moderate perfusion defect with LV dilation or increased lung uptake (thallium-201)</li> </ol> </li> </ul>"},{"location":"fellowship-guide/topics/nuc/spect/#balanced-ischemia","title":"Balanced Ischemia","text":"<ul> <li>High risk features on Exercise testing<ul> <li>Coronary blood low is equally or nearly equally impaired</li> <li>ST depression in multiple leads during peak stress but no evidence of ischemia on radionuclide MPI</li> </ul> </li> </ul>"},{"location":"fellowship-guide/topics/nuc/stress-testing/","title":"Stress Testing","text":""},{"location":"fellowship-guide/topics/nuc/stress-testing/#stress-testing","title":"Stress Testing","text":"<ul> <li>Update on Stress Testing[^1]</li> </ul>"},{"location":"fellowship-guide/topics/nuc/stress-testing/#exercise-treadmill-test","title":"Exercise Treadmill Test","text":"<ul> <li>[Pooled data][1]<ul> <li>Men: Sensitivity of 68% and Specificity of 77% for CAD</li> <li>Women: Sensitivity of 61% and Specificity of 70% for CAD</li> </ul> </li> <li>Not interpretable for ischemia if:<ul> <li>Old LBBB</li> <li>Unable to reach target HR</li> <li>Baseline ST elevation</li> <li>Digoxin use</li> </ul> </li> <li>Duke Treadmill Score = Exercise Time - 5x Maximal ST depressions - 4 x Angina Index<ul> <li>\u22655 is low risk</li> <li>4 to -10 is intermediate risk</li> <li>\u2264-11 is high risk</li> </ul> </li> <li>Absolute Contraindication to EXERCISE Stress Testing (Use Drugs + Imaging)<ul> <li>Inability to exercise adequately due to physical or mental impairment (85% of predicted HR unable to be reached)</li> </ul> </li> <li>Note:<ul> <li>ST depression &lt;0.5 give 0 for DTS</li> <li>Resting ST-segment depression &lt;1mm increases test sensitivity but decreases specificity with no change in overall accuracy</li> <li>Role less clear in RBBB</li> </ul> </li> <li>Exercise Capacity is the highest prognostic impact marker during exercise testing including MPI variables irrespective of CAD severity, Gender, Age</li> </ul>"},{"location":"fellowship-guide/topics/nuc/stress-testing/#stress-testing-with-imaging","title":"Stress Testing with Imaging","text":"<ul> <li>Includes:<ul> <li>Exercise Nuclear Stress</li> <li>Pharmacologic Nuclear Stress</li> <li>Dobutamine Stress Echo</li> </ul> </li> <li>Indications for Stress Testing with Imaging (MPI/Nuclear/SPECT, CMR, or Echo)<ul> <li>Indications:<ul> <li>Unable to exercise</li> <li>Baseline EKG abnormalities limiting interpretation<ul> <li>LBBB, RBBB</li> </ul> </li> <li>Indeterminate findings on Exercise Stress Test</li> </ul> </li> </ul> </li> <li>SPECT (99mTc-Sestamibi/Tetrofosmin)<ul> <li>Thallium no longer used</li> <li>SPECT MPI</li> </ul> </li> </ul>"},{"location":"fellowship-guide/topics/nuc/stress-testing/#pharmacologic-stress-testing","title":"Pharmacologic Stress Testing","text":"<ul> <li>Requires Imaging</li> <li>Indications<ul> <li>Unable/unwilling to exercise</li> <li>Contraindication to exercise<ul> <li>AAA</li> <li>Severe AS</li> <li>HOCM</li> </ul> </li> <li>LBBB/Pacemaker</li> <li>Interfering Medications</li> <li>ACS</li> </ul> </li> <li>Modes<ul> <li>Vasodilator (3.5-4x increase in myocardial blood flow)<ul> <li>Kinetics<ul> <li>Decrease SBP/DBP, increase HR</li> </ul> </li> <li>Medications<ul> <li>Dipyridamole<ul> <li>SE (50%)</li> </ul> </li> <li>Adenosine<ul> <li>10 second half-life</li> <li>4 minute and 6 minute protocols</li> <li>IV aminophylline reversal possible</li> <li>SE (80%): CP (57%), Dyspnea (15%), Flushing (25%), Headache (35%), 2<sup>nd</sup> degree AV block in 4%</li> </ul> </li> <li>Regadenoson (Lexiscan)<ul> <li>EXERRT Trial: safe to combinding low-level exercise for better heart-to-gut/liver ratios</li> <li>IV aminophylline reversal possible</li> <li>SE (86%): Dyspnea (61%), Flushing (39%), Headache (35%), Dizziness (27%), CP (12%)</li> </ul> </li> </ul> </li> <li>Absolute Contraindications<ul> <li>High-grade AV block or SSS &lt;40</li> <li>Active or severe bronchospasm (asthma, active wheezing)</li> <li>Hypotension (stimulate A2A receptors on vascular smooth muscles, magnified from rest)/Hypertension &gt;200/110</li> <li>Caffeine within 12 hours</li> <li>Theophylline within 48 hours</li> </ul> </li> <li>Relative Contraindications<ul> <li>Seizure disorder</li> <li>Severe AS</li> <li>Mobitz 1 2<sup>nd</sup>-degree AV block</li> </ul> </li> <li>Discontinue for:<ul> <li>Bronchospasm</li> <li>SBP &lt;80 mmHg</li> <li>Persistent/symptomatic 2<sup>nd</sup>/3<sup>rd</sup> degree AV block</li> <li>CP and ST depression &gt;2mm</li> </ul> </li> </ul> </li> <li>Dobutamine<ul> <li>Kinetics: Increase SBP and HR, Decrease DBP</li> <li>USE: CI to Exercise and Vasodilator Stress Testing</li> <li>SE(75%): Ischemic ST-depression (33%), CP (31%), Palpitations (29%), Significant SVT/VT (8-10%)</li> </ul> </li> </ul> </li> </ul>"},{"location":"fellowship-guide/topics/nuc/stress-testing/#positive-findings","title":"Positive Findings","text":"<ul> <li>\u2265 1mm of horizontal or downsloping ST-segment depression or elevation 8 ms after the J-point during exercise or recovery</li> <li>\u22651mm ST-elevation in a lead without a baseline Q-wave</li> <li>\u22651mm AVR elevation</li> <li>Ventricular Tachycardia</li> <li>more than 1.5-2mm of upsloping ST-segment depression 8 ms after the J-point during exercise or recovery</li> </ul>"},{"location":"fellowship-guide/topics/nuc/stress-testing/#findings-associated-with-poor-outcomes","title":"Findings associated with poor outcomes","text":"<ul> <li>Poor exercise capacity (&lt;5 METs)<ul> <li>Patients achieving \u226510 METs have a 0.1%/year rate of cardiac death and 0.7%/year rate of nonfatal MI</li> </ul> </li> <li>Exercise-induced angina during minimal expenditure</li> <li>Inability to achieve 85% age-predicted maximum HR with exercise<ul> <li>Calculated as (220 - Age)</li> </ul> </li> <li>Fall in SBP below baseline during exercise</li> <li>ST elevation</li> <li>\u2265 2mm ST-depression during minimal expenditure<ul> <li>Maximum ST-segment deviation is a strong predictor of both cardiac death and composite cardiac death and nonfatal MI</li> </ul> </li> <li>Early onset or prolonged duration of ST depression during testing<ul> <li>Rapid recovery is associated with a low rate of positive imaging or findings of CAD on angiography</li> </ul> </li> <li>ST depression in multiple leads</li> <li>Ventricular couplets or tachycardia during minimal expenditure or recovery</li> </ul>"},{"location":"im-guide/","title":"IM Guide","text":"<ul> <li>Welcome to my guide for internal medicine. Please see the disclaimer at the bottom left of the page.</li> <li>Feel free to suggest edits via Github or the contact page.</li> </ul>"},{"location":"im-guide/#general","title":"General","text":"<ul> <li>My general recommendation to excel in IM is to pick a resource and consistently study. Since most of us take STEP 3/COMLEX 3 during intern year, your initial goal should to just study to pass. I took my exam in October of my intern year and all I used for this was Anki and UWorld and did fine with not even completing UWorld and only studying 2-3 weeks<ul> <li>HOOP's STEP III Anki Deck</li> <li>WiWa Deck</li> <li>COMLEX Additional Deck (Trust me): TurnUp2Law&amp;Ethics</li> </ul> </li> <li>After your done with Level 3, give yourself a month or 3 to chill and try to catch up on how to be a good intern (which can be hard)</li> <li>Around December of my intern year I purchased MKSAP individually because I felt I wasn't learning the key points on rounds/during lecture that my peers were</li> <li>After buying MKSAP I would do blocks of 10 questions per week CONSISTENTLY and every once in awhile do an extra block or so on topics I had learned that week in the hospital<ul> <li>I tried to pick questions that related to my patients and understand why attendings/residents don't do what MKSAP recommended and tried to talk to my attendings/peers about these differences to reenforce my learning. I felt this really helped my learn what was important, what was testable, and what was more clinical practice</li> </ul> </li> <li>By the end of intern year, I was getting bored with MKSAP so I started doing the MKSAP ANKI which helped solidify the information I had already learned and retain what I could. I'd say I did about 50% of the ABIM and MKSAP decks during ALL of second year. Went very slow and tried to look up a concept a day (related to patient care), mainly using them for reference<ul> <li>Anki ABIM Decks Link<ul> <li>ABIM Deck</li> <li>MKSAP Deck</li> </ul> </li> <li>EKG Deck</li> </ul> </li> </ul>"},{"location":"im-guide/#other-resources","title":"Other Resources","text":"<ul> <li>AI<ul> <li>OpenEvidence AI</li> </ul> </li> <li>Cardiology<ul> <li>Cardioguide</li> </ul> </li> <li>FOAMed<ul> <li>EM Curious</li> </ul> </li> <li>General<ul> <li>WikiDoc</li> <li>ddxof</li> </ul> </li> <li>ICU Guides<ul> <li>University of Chicago ICU Guide</li> </ul> </li> <li>ID<ul> <li>Bugs &amp; Drugs</li> </ul> </li> <li>Internal Medicine<ul> <li>Vanderbilt's IM Resident Guide</li> <li>ACP Journal Club</li> <li>UC San Diego - Practical Guide to Clinical Medicine</li> <li>UCSF Hospitalist Handbook</li> </ul> </li> <li>Pharmacy<ul> <li>Davis Drug Guide</li> <li>Tulane's PharmWiki</li> <li>Drug Interaction Books<ul> <li>Louisville Interactions - Adults</li> <li>Louisville Interactions</li> </ul> </li> </ul> </li> <li>Teaching<ul> <li>Chalk Talks - TeachIM</li> <li>ACP - Things We Do For No Reason</li> </ul> </li> <li>Trials<ul> <li>Wiki Journal Club</li> <li>2 Minute Medicine - The Classics - Summaries</li> <li>2 Minute Medicine - The Classics - Directory</li> </ul> </li> </ul>"},{"location":"im-guide/#blogs","title":"Blogs","text":"<ul> <li>Ben White</li> <li>Autohotkey</li> <li>Nephrology Journal Club</li> </ul> <ul> <li>Language \u2013 Choose out of the 60+ supported languages</li> <li>Navigation \u2013 Clear, concise, and comprehensive navigation structure</li> <li>Blog \u2013 Access the newest pages, quick</li> <li>PowerPoint \u2013 Download PowerPoints of related topics</li> <li>Search \u2013 Utilize search running entirely in your browser</li> <li>Tags \u2013 Search tags and groups of related pages</li> </ul>"},{"location":"im-guide/cards/","title":"Cardiology","text":"<p>See the Cardiology Fellowship Guide</p>"},{"location":"im-guide/cards/chest-pain/","title":"Chest Pain","text":"","tags":["Chest Pain","ACS"]},{"location":"im-guide/cards/chest-pain/#approach-to-chest-pain","title":"Approach to Chest Pain","text":"<ul> <li>Onset, Location, Duration, Characterization<ul> <li>Modifying factors</li> </ul> </li> <li>Chest Pain in the ED (M4s)</li> <li>Chest Pain Guideline Central</li> </ul>","tags":["Chest Pain","ACS"]},{"location":"im-guide/cards/chest-pain/#classifying-angina","title":"Classifying Angina","text":"<ul> <li>Angina Pectoris: Chest pain due to &gt;70% stenosis</li> <li>Classic/Cardiac (Typical Angina): All 3 of the following<ul> <li>1) Typical location (substernal), quality (dull), and duration<ul> <li>Quality: Squeezing, tightness, pressure, constriction, fullness, heaviness, and weight</li> <li>Clenches fist over mid-sternal area</li> <li>Often radiates to the left shoulder, neck, or arm</li> <li>Builds in intensity over a few minutes (2-30mins)<ul> <li>&lt;2 mins: not MI</li> <li>2-5 minutes: Stable angina</li> <li>more than 30mins: MI</li> </ul> </li> </ul> </li> <li>2) Provoked by exercise or emotional stress</li> <li>3) Relieved by rest or nitroglycerin</li> </ul> </li> <li>Atypical Angina (Possibly Cardiac): only 2 of the 3 above</li> <li>Non-anginal: &lt;2 of the 3 above</li> </ul>","tags":["Chest Pain","ACS"]},{"location":"im-guide/cards/chest-pain/#pulmonarypleuritic-chest-pain-pleurisy-pneumonia-pericarditis-pe","title":"Pulmonary/Pleuritic Chest Pain (pleurisy, pneumonia, pericarditis, PE)","text":"<ul> <li>Sharp/stabbing pain, worse with inspiration</li> <li>Pericarditis is worse when lying flat, breathing<ul> <li>No chest wall pain</li> <li>TTE to assess for pericardial effusion</li> </ul> </li> <li>Pneumothoraxes have respiratory distress/hypoxia/tachycardia<ul> <li>Pleuritic chest pain and or dyspnea</li> <li>Peripheral or apical radiolucency, absence of lung markings beyond the lung edge</li> </ul> </li> <li>PE<ul> <li>Sudden onset dyspnea and pleuritic chest pain</li> <li>Tachypnea, tachycardia, cough, hemoptysis \u00b1 LE swelling</li> <li>CXR: atelectasis, infiltrates, pleural effusions, Westermark\u2019s Sign (peripheral hyperlucency due to oligemia)</li> </ul> </li> <li>Viral Pleurisy: inflammation of the lung pleura that presents with fever and pleuritic chest pain<ul> <li>Pleural friction rib may be present (disappears with breath holding, pericardial friction rub does not)</li> </ul> </li> <li>ESR elevated in SLE Pleuritis, Not tenderness to palpation</li> <li>CXR/Chest CT</li> </ul>","tags":["Chest Pain","ACS"]},{"location":"im-guide/cards/chest-pain/#aortic-dissection-intramural-hematoma","title":"Aortic (dissection, intramural hematoma)","text":"<ul> <li>Sudden, severe tearing pain, radiates to back, elderly, hypertension/atherosclerosis, tachycardia</li> <li>Irregular aortic contour with inward displacement of atherosclerotic calcification</li> <li>No tenderness to palpation</li> <li>Chest CT</li> </ul>","tags":["Chest Pain","ACS"]},{"location":"im-guide/cards/chest-pain/#gi-disease-spasmgerdulcer","title":"GI Disease (Spasm/GERD/Ulcer)","text":"<ul> <li>Esophageal Spasm<ul> <li>5-60 minutes</li> <li>Visceral, spontaneous, substernal, associated with cold liquids, relief with nitro</li> </ul> </li> <li>Gastric Esophageal Reflux Disease (GERD)<ul> <li>5-60 minutes</li> <li>Non-pleuritic, Non-exertional/no pain with movement, worse with recumbency, visceral/burning, relieved by antacids or food, cough, hoarseness due to aspiration, upper abdominal/substernal, associated with regurgitation, nausea, dysphagia, nocturnal pain, non-radiating</li> <li>Reflux may improve with siting up</li> <li>Endoscope \u00b1 pH testing</li> </ul> </li> </ul>","tags":["Chest Pain","ACS"]},{"location":"im-guide/cards/chest-pain/#chest-wallmusculoskeletal-msk-chest-pain","title":"Chest wall/Musculoskeletal (MSK) chest pain","text":"<ul> <li>Persistent and or prolonged pain, worse with movement or position change, often follows repetitive activity</li> <li>Costochondritis<ul> <li>Most common cause of MSK chest pain</li> <li>RF: Strenuous exercise, joint aggravation (weightlifting)</li> <li>Sharp, localized chest pain that worsens with inspiration/movement/coughing and tender to palpation of \u22651 anterior chondral joint<ul> <li>Either costochondral or sternochondral joints</li> <li>No swelling, no tachycardia/bradycardia</li> </ul> </li> <li>Usually benign and self-limiting and resolves in weeks, but may last &gt;1 year</li> <li>Normal EKG and CXR</li> <li>Treatment<ul> <li>Reassurance and symptomatic pain management</li> </ul> </li> </ul> </li> </ul>","tags":["Chest Pain","ACS"]},{"location":"im-guide/cards/chest-pain/#differential","title":"Differential","text":"<ul> <li>Rule out the scary things 1<sup>st</sup>:<ul> <li>MI</li> <li>PE</li> <li>Esophageal Rupture</li> <li>Aortic Dissection</li> <li>Pneumothorax</li> </ul> </li> </ul>","tags":["Chest Pain","ACS"]},{"location":"im-guide/cards/chest-pain/#work-up","title":"Work-up","text":"<ul> <li>EKG, CXR, Troponin(s)<ul> <li>\u00b1 D-Dimer/CTA/TTE</li> </ul> </li> <li>2021 AHA/ACC Guideline for the Evaluation and Diagnosis of Chest Pain</li> </ul>","tags":["Chest Pain","ACS"]},{"location":"im-guide/cards/chest-pain/#ekg","title":"EKG","text":"<ul> <li>Best test is EKG followed by Cardiac Enzymes every 8 hours (3 sets needed)<ul> <li>Nonischemic ECG and negative biomarkers at 0 hr and 3 hr reduces risk of MACE to less than 1%<ul> <li>Stress-testing cannot decrease risk beyond &lt;1% (not warranted)</li> </ul> </li> <li>Used to rule in or rule out STEMI</li> </ul> </li> </ul> <pre><code>graph LR\n  A[EKG] --&gt; B{STEMI?};\n  B --&gt;|Yes| C[PCI!];\n  B --&gt;|No| E[Elevated Trops?];\n  E --&gt;|Yes| F[T2MI/NSTEMI];\n  F --&gt; G[Risk Stratify]\n  G --&gt; H[High Risk*?]\n  H --&gt;|Yes| C;\n  H --&gt;|No| I[TIMI/GRACE Scores];\n  E --&gt;|No| J[Unstable Angina/Non-Cardiac CP];\n  J --&gt; K[HEART Score];\n  K --&gt;|Otherwise| G;\n  K --&gt;|ACS &lt;2% by clinical eval or HEART 0| L[Discharge];</code></pre>","tags":["Chest Pain","ACS"]},{"location":"im-guide/cards/chest-pain/#troponin","title":"Troponin","text":"<ul> <li>Causes of Troponin Elevation not related to Acute MI<ul> <li>Other causes of myocardial injury<ul> <li>Cardiac<ul> <li>Heart Failure</li> <li>Myocarditis</li> <li>Cardiomyopathy of any type</li> <li>Takotsubo Syndrome</li> <li>Cardiac Contusion</li> </ul> </li> <li>Systemic<ul> <li>Sepsis</li> <li>CKD</li> <li>Stroke, subarachnoid hemorrhage</li> <li>PE, PHTN</li> <li>Infiltrative Disease</li> <li>Chemotherapy</li> <li>Critical illness</li> <li>Strenuous exercise</li> </ul> </li> </ul> </li> <li>Myocardial injury related to acute myocardial ischemia because of oxygen supply/demand imbalance<ul> <li>Reduced myocardial perfusion<ul> <li>Coronary Spasm</li> <li>Coronary Embolism, Coronary Artery Dissection</li> <li>Sustained Bradyarrhythmia</li> <li>Hypotension or Shock</li> <li>Respiratory Failure</li> <li>Severe Anemia</li> </ul> </li> <li>Increased myocardial demand<ul> <li>Tachycardia</li> <li>Severe HTN w/ + w/o LVH</li> </ul> </li> </ul> </li> </ul> </li> </ul>","tags":["Chest Pain","ACS"]},{"location":"im-guide/cards/chest-pain/#risk-stratification","title":"Risk Stratification","text":"<ul> <li>Pretest probability of coronary artery disease<ul> <li>Low (&lt;10%):<ul> <li>Asymptomatic people of all ages</li> <li>Atypical chest pain in women age &lt;50</li> </ul> </li> <li>Intermediate (20-80%):<ul> <li>Atypical Angina in men of all ages</li> <li>Atypical Angina in women \u226550</li> <li>Typical Angina in women 30-50</li> </ul> </li> <li>High (&gt;90%):<ul> <li>Typical Angina in men \u226540</li> <li>Typical Angina in women \u226560</li> </ul> </li> </ul> </li> <li>Diagnostics<ul> <li>Low Risk<ul> <li>No additional testing needed</li> </ul> </li> <li>Intermediate Risk<ul> <li>Noninvasive evaluation with exercise or pharmacologic stress testing<ul> <li>https://pubmed.ncbi.nlm.nih.gov/24355759/</li> <li>https://pubmed.ncbi.nlm.nih.gov/24741776/</li> </ul> </li> </ul> </li> <li>High Risk<ul> <li>Coronary Angiography vs. Stress Testing</li> <li>Start pharmacologic therapy for CAD (aspirin)</li> </ul> </li> </ul> </li> <li>HEART vs. TIMI vs. GRACE<ul> <li>Predicts 6-week risk of major adverse cardiac event</li> <li>Do not use if new ST-segment elevation \u22651 mm or other new EKG changes, hypotension, life expectancy less than 1 year, or noncardiac medical/surgical/psychiatric illness determined by the provider to require admission</li> </ul> </li> </ul>","tags":["Chest Pain","ACS"]},{"location":"im-guide/cards/congenital-heart-disease/","title":"Congenital Heart Disease in Adults","text":""},{"location":"im-guide/cards/congenital-heart-disease/#patent-ductus-arteriosus-pda","title":"Patent Ductus Arteriosus (PDA)","text":"<ul> <li>Etiology<ul> <li>Usually closes after birth, adults are usually asymptomatic</li> <li>80% of neonates &lt;1200 grams</li> <li>Hemodynamically significant</li> <li>F&gt;M</li> <li>Need antibiotic prophylaxis if unrepaired and complicated by Eisenmenger syndrome or cyanotic pulmonary hypertension, or within 6 months of surgical repair, or residual deficit after surgery</li> </ul> </li> <li>Murmur<ul> <li>Continuous machine-like murmur</li> <li>Best heard over left upper sternal border<ul> <li>Small: Left infraclavicular region</li> <li>Moderate: wide pulse pressure, bounding pulses, laterally displaced apical impulse</li> <li>Large: LV overload in early childhood<ul> <li>Tachycardia, dyspnea, poor growth</li> </ul> </li> </ul> </li> <li>Left to right shunt<ul> <li>Loudest at S2</li> </ul> </li> <li>May radiate to the back</li> </ul> </li> <li>Symptoms<ul> <li>Differential Cyanosis<ul> <li>Clubbed toes, normal fingers</li> </ul> </li> <li>May develop pulmonary vascular congestion and eventual RHF</li> <li>May develop Endarteritis</li> </ul> </li> <li>Diagnosis<ul> <li>CXR: Calcification of the ductus arteriosus in adults</li> </ul> </li> <li>Complications<ul> <li>Bacterial Endocarditis/Infective endarteritis (PDA-related Endocarditis)</li> <li>Eisenmenger Syndrome<ul> <li>Right to left shunting</li> </ul> </li> <li>Pulmonary Hypertension</li> <li>Irreversible pulmonary vascular obstructive disease</li> </ul> </li> <li>Treatment<ul> <li>Prostaglandin E1 (alprostadil) to keep it open until surgical intervention</li> <li>Indomethacin &lt; Ibuprofen<ul> <li>Prostaglandin synthesis inhibitor</li> </ul> </li> <li>more than 2 weeks: Unlikely to close, Surgical closure</li> <li>more than 6-8 months: Surgery</li> <li>Adults: Surgical, endovascular approach to close</li> </ul> </li> </ul>"},{"location":"im-guide/cards/congenital-heart-disease/#anomalous-coronary-artery","title":"Anomalous Coronary Artery","text":"<ul> <li>2<sup>nd</sup> mcc of SCD with strenuous exercise in athletes behind HCM (17%)<ul> <li>Usually, benign retroaortic course and 30-40 y/o</li> </ul> </li> <li>Symptoms<ul> <li>Exertional chest pain, syncope during exercise in a young individual<ul> <li>Exertional syncope is never normal</li> </ul> </li> </ul> </li> <li>Diagnosis: Coronary CTA or MRA</li> </ul>"},{"location":"im-guide/cards/hypertension/","title":"Hypertension","text":""},{"location":"im-guide/cards/hypertension/#asymptomatic-hypertension","title":"Asymptomatic Hypertension","text":"<ul> <li>Article</li> <li>Asymptomatic Inpatient Hypertension</li> <li>Things We Do For No Reason: Antihypertensives Inpatient</li> </ul>"},{"location":"im-guide/cards/hypertension/#management","title":"Management","text":"<ul> <li>DASH: Small but significant BP reductions from diet control</li> <li>LIFE: Losartan &gt; Atenolol for same BP Reduction</li> <li>ALLHAT: Thiazide = CCB = ACEI in High-risk HTN, Thiazides may be better</li> <li>ACCOMPLISH: CCBs &gt; Diuretics when added to ACEI in High-risk HTN</li> <li>Thiazides less effective in obese, CCBs equal across weight</li> <li>HOPE: ACEI significantly reduces rate of HF in High-risk patients</li> <li>Inpatient<ul> <li>Hydralazine vs. Labetalol Inpatient</li> </ul> </li> </ul>"},{"location":"im-guide/cards/hypertension/#resistant-hypertension","title":"Resistant Hypertension","text":""},{"location":"im-guide/cards/hypertension/#hypertensive-disease-in-pregnancy","title":"Hypertensive Disease in Pregnancy","text":"<ul> <li>Diagnosis, Evaluation, and Management of the Hypertensive Disorders of Pregnancy: Executive Summary</li> </ul>"},{"location":"im-guide/cards/hypertension/#chronic-hypertension","title":"Chronic Hypertension","text":"<ul> <li>Aka Pre-existing Hypertension</li> <li> <p>140/90 diagnosed prior to pregnancy or within the first 20 weeks of gestation</p> </li> <li>Increased risk of preeclampsia and eclampsia during antepartum, intrapartum, and immediate postpartum stages<ul> <li>50% cesarean deliveries</li> </ul> </li> <li>Treatment<ul> <li>Deliver between 38-39+6 days</li> <li>Begin treatment once \u2265140/90<ul> <li>Improves pregnancy outcomes without increasing risk of small-for-gestational-age birth weight</li> <li>CHAP Study</li> <li>Labetalol<ul> <li>Starting dose 100-200mg BID, can be used TID if needed</li> <li>Max 2400mg/day (1200mg BID or 800mg TID)</li> </ul> </li> <li>Nifedipine ER<ul> <li>Starting dose 30mg Qday, can be used BID</li> <li>Max 120mg/day</li> </ul> </li> <li>Methyldopa</li> <li>Amlodipine<ul> <li>Monitor for proteinuria, headache, upper abdominal pain, visual changes, acute renal or liver failure or intrauterine growth restriction (fetal growth deceleration)</li> </ul> </li> </ul> </li> </ul> </li> </ul>"},{"location":"im-guide/cards/hypertension/#gestational-hypertension","title":"Gestational Hypertension","text":"<ul> <li>BP &gt;140/90 first found \u2265 20 weeks in a previously normotensive patient<ul> <li>2 measurements 4 or more hours apart</li> <li>Returns to baseline after pregnancy</li> <li>No end organ damage</li> <li>Usually resolved by 12 weeks postpartum</li> </ul> </li> <li>No protein in the urine</li> <li>Mild ankle edema is normal in pregnancy</li> <li>Increased risk of progression to preeclampsia, placental abruption</li> <li>Treatment<ul> <li>Delivery if &gt;37 weeks should be discussed</li> <li>&lt;160/110<ul> <li>Outpatient<ul> <li>Goal:<ul> <li>&lt;155/105 if healthy</li> <li>&lt;140/90 if comorbid conditions</li> <li>&lt;130/90 if Gestational DM</li> </ul> </li> </ul> </li> </ul> </li> <li>\u2265160/110<ul> <li>Inpatient</li> </ul> </li> <li>Medications<ul> <li>Nifedipine ER 20-30mg daily, Max 60mg BID</li> <li>Labetalol 100-200mg BID, Max 300mg QID</li> <li>Nifedipine = Labetalol &gt; Hydralazine</li> <li>Methyldopa 250-500mg BID, 500mg QID</li> <li>2<sup>nd</sup> line: Hydralazine, Thiazides<ul> <li>Acebutolol, metoprolol, pindolol, propranolol</li> <li>Amlodipine is safe</li> </ul> </li> <li>Avoid ACEI and ARBs, Atenolol, Prazosin</li> </ul> </li> </ul> </li> </ul>"},{"location":"im-guide/cards/hypertension/#postpartum-hypertension","title":"Postpartum Hypertension","text":"<ul> <li>Physiology<ul> <li>BP peaks 3-6 days postpartum in both normotensive and hypertensive women<ul> <li>Avoid NSAIDs</li> </ul> </li> </ul> </li> <li>Definition<ul> <li>Persistent: &gt;6 weeks after delivery</li> <li>Severe: \u2265160/110</li> </ul> </li> <li>Etiology<ul> <li>Gestational Hypertension</li> <li>Preeclampsia</li> <li>Chronic Hypertension</li> <li>Secondary Causes (10%)</li> </ul> </li> <li>W/U<ul> <li>Persistent or Pre-existing<ul> <li>UA, BMP, Fasting Lipids, EKG</li> </ul> </li> <li>Examine for HELLP<ul> <li>Hemolysis, Elevated LFTs, Low platelets</li> <li>Urinalysis</li> </ul> </li> <li>Evaluate for Preeclampsia/Eclampsia<ul> <li>5.7% of preeclampsia and eclampsia present de novo in the postpartum period (up to 6 weeks)</li> <li>New onset persistent HA or visual changes</li> </ul> </li> </ul> </li> <li>Treatment<ul> <li>Best Practices for Managing Postpartum Hypertension</li> <li>Symptomatic (Eclampsia/Preeclampsia) or \u2265160/110 (Severe)<ul> <li>Inpatient<ul> <li>Goal: &lt;160 and &lt;110<ul> <li>Labetalol 20mg IV q30 up to 80mg, Max 300mg then switch to oral<ul> <li>Onset 5min, peak 30min, 4hr duration</li> <li>Avoid in asthma or HF</li> </ul> </li> <li>Nifedipine IR 5-10mg capsule q30<ul> <li>Onset 5min, peak 30min, 6hr duration</li> </ul> </li> <li>Hydralazine 5mg IV, q30min up to 10mg, Max 20 IV<ul> <li>Onset 5 min, peak 30min</li> </ul> </li> <li>Alternatively<ul> <li>IV Nitro, Oral Clonidine</li> <li>IV Sodium Nitroprusside if refractory</li> </ul> </li> </ul> </li> </ul> </li> </ul> </li> <li>Asymptomatic + \u2264160/110<ul> <li>All drugs are safe for breastfeeding</li> <li>Goal: &lt;140 and &lt;90 with Comorbidities (excluding gestational DM); &lt;155/105 otherwise; Gestational DM: &lt;130/80</li> <li>Outpatient<ul> <li>F/u in 3-6 days for BP check</li> <li>Nifedipine ER 20-30mg daily, Max 60mg BID</li> <li>Labetalol 100-200mg BID, Max 300mg QID</li> <li>Methyldopa 250-500mg BID, 500mg QID</li> </ul> </li> </ul> </li> </ul> </li> </ul>"},{"location":"im-guide/cards/hypertension/#preeclampsia","title":"Preeclampsia","text":"<ul> <li>Disorder of the Placenta<ul> <li>Extravillious trophoblast fails to penetrate myometrium</li> <li>Abnormal remodeling of the spiral arteries (don\u2019t expand) causing hypoperfusion and ischemia</li> <li>Diffuse maternal endothelial dysfunction</li> <li>Vasospasm and coagulation</li> <li>Resolves with delivery</li> <li>Result of placental hypoperfusion after 18-20 weeks of gestation<ul> <li>Usually in 3<sup>rd</sup> trimester</li> </ul> </li> <li>Usually resolved by 12 weeks</li> </ul> </li> <li>RF: Prior preeclampsia (#1), primiparous women, personal or family history, Pre-existing diabetes, chronic hypertension, obesity, renal insufficiency, CKD<ul> <li>BMI &gt;30, Advanced maternal age, nulliparity</li> </ul> </li> <li>Symptoms<ul> <li>Typically after 34w</li> <li>Peripheral edema is common</li> <li>Cerebral or visual disturbances</li> <li>Abdominal pain</li> </ul> </li> <li>Labs<ul> <li>Elevation of transaminases</li> <li>Thrombocytopenia</li> <li>Renal insufficiency</li> <li>Elevated Urate</li> </ul> </li> <li>Diagnosis: New onset Hypertension (&gt;140/90) and proteinuria (\u2265300mg protein in a 24h urine collection or a urine protein/creatinine &gt; .0.3mg/g) or End-organ damage (renal failure, CNS, Liver failure, edema) at \u2265 20 weeks<ul> <li>Fibrinoid necrosis of vessels of placenta</li> <li>CXR: Pulmonary Edema</li> </ul> </li> <li>Treatment<ul> <li>Preeclampsia: IV Magnesium sulfate, Antihypertensives for \u2265160/110, Antenatal glucocorticoids<ul> <li>Labetalol IV, Hydralazine IV, Nifedipine PO</li> <li>Target 130-150/80-100</li> <li>No magnesium if Myasthenia gravis<ul> <li>Use Levetiracetam or valproate</li> </ul> </li> <li>Renal Damage: &gt;1.2 can cause mg toxicity<ul> <li>Calcium gluconate</li> </ul> </li> </ul> </li> <li>Severe: \u226534 weeks induce</li> <li>W/o Severe: \u226537 weeks</li> <li>Postpartum Thrombophylaxis should be considered</li> </ul> </li> </ul>"},{"location":"im-guide/cards/hypertension/#severe-preeclampsia","title":"Severe Preeclampsia","text":"<ul> <li>Preeclampsia + hypertension &gt;160/110 \u00b1 end-organ damage<ul> <li>Pick one:<ul> <li>Pulmonary edema, cerebral or visual symptoms, thrombocytopenia, renal insufficiency (&gt;1.1 or 2x baseline), impaired liver function(2x normal), BP \u2265160/110</li> </ul> </li> </ul> </li> <li>Most likely to progress to eclampsia</li> <li>Associated with myocardial damage or diastolic dysfunction (increased afterload)</li> <li>Complications<ul> <li>HELLP Syndrome</li> </ul> </li> <li>Treatment<ul> <li>IV labetalol, IV hydralazine, of IR nifedipine</li> <li>IV Magnesium Sulfate prophylaxis</li> <li>Severe Preeclampsia + \u226534 weeks:<ul> <li>Delivery to reduce risk of maternal death</li> </ul> </li> </ul> </li> </ul>"},{"location":"im-guide/cards/hypertension/#eclampsia","title":"Eclampsia","text":"<ul> <li>Preeclampsia plus new onset tonic-clonic seizures, generalized, brief<ul> <li>Grand mal Seizures</li> </ul> </li> <li>RF: untreated preeclampsia</li> <li>MCC of death: intracerebral hemorrhage and edma<ul> <li>PRES Syndrome</li> <li>MRI w/ posterior cerebral hemisphere enhancement</li> </ul> </li> <li>Treatment/Prevention:<ul> <li>IV Magnesium Sulfate, anti-htn meds<ul> <li>Usually 4g IV then 1g/hr</li> <li>Mg and Anti-HTNs given for 48 hours<ul> <li>25% of seizures occur within 24hrs</li> </ul> </li> <li>\u00b1 diazepam, phenytoin</li> <li>\u00b1 labetalol, hydralazine</li> <li>Decreased DTRs:<ul> <li>Mag Toxicity: Give Calcium Gluconate</li> </ul> </li> </ul> </li> <li>Acute: Airway, IV Magnesium Sulfate, Betamethasone, Induction<ul> <li>Betamethasone if &lt;34 weeks only</li> </ul> </li> <li>Delivery is only cure</li> </ul> </li> </ul>"},{"location":"im-guide/cards/hypertension/#hellp-syndrome","title":"HELLP Syndrome","text":"<ul> <li>Thrombotic microangiopathy involving the liver</li> <li>Symptoms<ul> <li>Manifestation of severe preeclampsia</li> <li>Anemia, RUQ pain, bruising/bleeding, N/V</li> <li>Hypertension, proteinuria also possible</li> </ul> </li> <li>Labs<ul> <li>Hemolysis</li> <li>Moderately elevated liver enzymes</li> <li>Low platelets (thrombocytopenia)</li> <li>Low AT3</li> </ul> </li> <li>Complications:<ul> <li>Increased risk of acute hepatic and/or renal failure, abruptio placentae</li> <li>Encephalopathy, renal insufficiency, DIC</li> </ul> </li> <li>Treatment<ul> <li>&lt;30-32w + unfavorable cervix: C/S</li> <li>&lt;34w + Stable: Steroids + delivery</li> <li> <p>34w: Prompt delivery of the neonate</p> </li> </ul> </li> </ul>"},{"location":"im-guide/cards/palpitations/","title":"Palpitations","text":"<ul> <li>Cardiac (43%)<ul> <li>Intermittent: PACs/PVCs</li> <li>Regular, Sustained: SVTs, VTs, MVPs, AR, Atrial Myxoma, Myocarditis, PE</li> <li>Irregular, Sustained: Atrial Fibrillation</li> </ul> </li> <li>Psychiatric (31%)<ul> <li>Panic attacks, anxiety, somatization<ul> <li>Longer duration (&gt;15mins)</li> </ul> </li> </ul> </li> <li>Miscellaneous (10%)<ul> <li>Thyrotoxicosis, Drugs, Ethanol, Chest wall contractions, pheochromocytoma, systemic mastocytosis</li> </ul> </li> <li>Unknown (16%)</li> </ul>"},{"location":"im-guide/cards/pericardial-disease/","title":"Pericardial Disease","text":"","tags":["Pericarditis","EKGs"]},{"location":"im-guide/cards/pericardial-disease/#pericarditis","title":"Pericarditis","text":"<ul> <li>Pericarditis, or inflammation of the pericardium, has typical ECG findings<ul> <li>These findings occur in progressive stages, all of which are seen in about 50% of cases of pericarditis:<ul> <li>Stage I (acute phase): Diffuse concave upward ST segment elevation in most leads, PR depression in most leads (may be subtle) and sometimes notching at the end of the QRS complex.</li> <li>Stage II: ST segment elevation and PR depression have resolved and T waves may be normal or flattened.</li> <li>Stage III: T waves are inverted, and the ECG is otherwise normal.</li> <li>Stage IV: T waves return to the upright position, and thus the ECG is back to normal.</li> </ul> </li> <li>Note: The ECG changes with pericarditis must be distinguished from those of early repolarization. The ST segment elevation seen in early repolarization is very similar \u2015 diffuse and concave upward. However, three things may help to distinguish pericarditis from early repolarization:<ul> <li>The ratio of the T wave amplitude to the ST elevation should be greater than 4 if early repolarization is present, meaning the T wave in early repolarization is usually 4 times the amplitude of the ST segment elevation. Another way to describe this would be that the ST segment elevation is less than 25% of the T wave amplitude in early repolarization.</li> <li>The ST segment elevation in early repolarization resolves when the person exercises.</li> <li>Early repolarization, unlike pericarditis, is a benign ECG finding that should not be associated with any symptoms.</li> </ul> </li> </ul> </li> </ul>","tags":["Pericarditis","EKGs"]},{"location":"im-guide/cards/pericardial-disease/#ekg-maven-examples","title":"EKG-Maven Examples","text":"<ul> <li>Case #3</li> <li>Case #34</li> <li>Case #60</li> <li>Case #62</li> <li>Case #71</li> <li>Case #80</li> <li>Case #256</li> <li>Case #464</li> </ul>","tags":["Pericarditis","EKGs"]},{"location":"im-guide/cards/syncope/","title":"Syncope","text":"<ul> <li>Incidence and Prognosis</li> <li>Etiology and Diagnostic Approach<ul> <li>Syncope: etiology and diagnostic approach</li> <li>Unexplained syncope--is screening for carotid sinus hypersensitivity indicated in all patients aged &gt;40 years?</li> </ul> </li> <li>Sudden transient loss of consciousness with associated loss of postural tone and spontaneous recovery<ul> <li>Results from transient cerebral hypoperfusion</li> </ul> </li> <li>W/U: H+P, EKG, Labs (CBC, CMP, SaO2, Cardiac Enzymes)  <ul> <li>Recurrent syncope, cardiac cause ruled out, atypical presentation, high risk occupation with single episode: Tilt-table tasting<ul> <li>26-80% sensitive, 90% specific</li> </ul> </li> <li>Admit if any High risk (ROSE rule, BRACES):<ul> <li>High-Risk Features(\u22651 feature increases the short-term risk of significant death or arrythmia)<ul> <li>Abnormal EKG (new change)<ul> <li>Diagnosis in 60%</li> </ul> </li> <li>History of structural heart disease or heart failure<ul> <li>Aortic Stenosis</li> </ul> </li> <li>Systolic BP &lt;90mmHg at triage</li> <li>Associated shortness of breath during syncope</li> <li>Hematocrit &lt;30%</li> <li>Advanced age with CV co-morbidities</li> <li>Family history of sudden cardiac death</li> </ul> </li> <li>BNP \u2265300</li> <li>Bradycardia \u226450</li> <li>Rectal exam with FOB</li> <li>Anemia (\u226490)</li> <li>Chest pain with syncope</li> <li>EKG with Q wave (not in lead III)</li> <li>Saturation \u226494% on RA</li> </ul> </li> </ul> </li> <li>Diagnosis and Management<ul> <li>No cause found: San Francisco Syncope Rules</li> <li>Transient loss of consciousness synopsis of NIH guidelines</li> <li>Association between symptoms and frequency of arrhythmias on 24-hour Holter monitoring</li> <li>Usefulness of 24hr Holter monitoring in unexplained syncope and high likelihood of arrythmias</li> </ul> </li> <li>Management<ul> <li>AAFP</li> <li>European Guidelines 2009</li> <li>Guideline for the Evaluation and Management of Patients With Syncope</li> <li>All Patient: Orthostatic Vitals and EKG<ul> <li>Low-Risk: Ambulatory ECG monitor</li> <li>Intermediate-Risk: Observation inpatient</li> <li>High-Risk: Admission</li> </ul> </li> </ul> </li> </ul>"},{"location":"im-guide/cards/cad/","title":"Coronary Artery Disease (CAD)","text":""},{"location":"im-guide/cards/cad/#etiology","title":"Etiology","text":"<ul> <li>Obstruction of blood flow in a coronary artery lumen, most commonly due to coronary artery atherosclerosis</li> </ul>"},{"location":"im-guide/cards/cad/#major-rf-hld-htn-smoking-dm-fh-age-45m-or-55f","title":"Major RF: HLD, HTN, Smoking, DM, FH, Age &gt;45M or 55F","text":"<ul> <li>Premature CAD: 1<sup>st</sup> degree male relative diagnosed age &lt;50 y/o or female &lt;60 y/o</li> <li>SLE is a known risk factor for accelerated atherosclerosis and premature CHD</li> </ul>"},{"location":"im-guide/cards/cad/#symptoms","title":"Symptoms","text":"<ul> <li>Subclinical or Asymptomatic CAD<ul> <li>Evidence of CAD w/o symptoms</li> </ul> </li> </ul>"},{"location":"im-guide/cards/cad/#complications","title":"Complications","text":"<ul> <li>Heart Failure<ul> <li>IHD/CAD = 60-75% of cases in developing world</li> </ul> </li> <li>Cardiac Ischemia<ul> <li>Unstable Angina: Mural thrombus</li> <li>Acute MI: Results from acute thromboses after plaque disruption</li> <li>SCD: Usually from fatal arrhythmia</li> <li>Chronic Stable Angina</li> </ul> </li> </ul>"},{"location":"im-guide/cards/cad/#management","title":"Management","text":"<ul> <li>Give all CAD patients Statins<ul> <li>Reduced risk of death by 24%, reduced risk of stroke by 31%, and reduction in need for CABG or Coronary Angioplasty by 27%</li> </ul> </li> <li>Aspirin for secondary prevention<ul> <li>Increased risk of Thromboembolic events if stopped, 70% occur within 7-10 days</li> </ul> </li> </ul>"},{"location":"im-guide/cards/cad/acs/","title":"ACS","text":"","tags":["Chest Pain","ACS"]},{"location":"im-guide/cards/cad/acs/#background","title":"Background","text":"<ul> <li>Completely or partially occluding thrombus on a disrupted atherothrombotic coronary plaque leading to myocardial ischemia</li> <li>30% mortality rate, half of which are pre-hospital<ul> <li>Decreased Cardiac Index, increased SVR, normal LVEDV<ul> <li>Acute or recent MI, CI is reduced due to myocardial dysfunction, SVR is increased to maintain organ perfusion</li> <li>LVEDV remains relatively normal in the early phase before LV remodeling \u00b1 dilatation occurs in the following weeks</li> </ul> </li> </ul> </li> </ul>","tags":["Chest Pain","ACS"]},{"location":"im-guide/cards/cad/acs/#types","title":"Types","text":"<ul> <li>ACS Includes: Unstable Angina, NSTEMI, STEMI<ul> <li>Unstable Angina: Angina w/o evidence of myocardial necrosis (normal troponin + normal EKG)</li> <li>NSTEMI: Evidence of myocardial necrosis (elevated troponin) w/o ST segment elevation</li> <li>STEMI: Elevated troponin &amp; elevation in ST segment or new LBBB with symptoms<ul> <li>\u2265 0.1 mV in at least 2 contiguous leads</li> <li>Exception, in V2-V3:<ul> <li>\u2265 0.2 mV in men older than 40 y/o</li> <li>\u2265 0.25 in men younger than 40 y/o</li> <li>\u2265 0.15 mV in women</li> </ul> </li> </ul> </li> </ul> </li> </ul>","tags":["Chest Pain","ACS"]},{"location":"im-guide/cards/cad/acs/#unstable-angina","title":"Unstable Angina","text":"<ul> <li>W/U: Troponins at 3-6 hours after symptoms onset, remeasure within 8-12<ul> <li>HEART Score in the ER</li> <li>Risk Assessment (TIMI Risk Score)<ul> <li>For TIMI, baseline needs to be normal<ul> <li>\u226565, 3x (hypertension, DM, Dyslipidemia, FH, Smoking), &gt;50% coronary stenosis, ST segment change, multiple episodes of angina in a day, increased troponin, aspirin in last week<ul> <li>Associated with increased number of all cause mortality, new or recurrent MI, or severe recurrent ischemia requiring revascularization</li> </ul> </li> <li>\u22642 = Low: Conservative w/medical therapy + stress tests within 48 hours<ul> <li>&lt;10% 2 weeks risk for serious event</li> <li>BB + Nitro + Statins + Heparin + Ticagrelor + Aspirin</li> </ul> </li> <li>3-4 = Intermediate: Early PCI within 24hrs<ul> <li>Within 25-72 hours and TIMI 3 or 4 score (intermediate): Invasive assessment + consider cath</li> </ul> </li> <li>\u22655 = High: PCI within 2 hours</li> </ul> </li> </ul> </li> </ul> </li> <li>Management<ul> <li>Admission + Continuous Telemetry + O2 if needed</li> <li>Unstable, HF, new MR, Recurrent CP, Ventricular Arrythmia: Immediate Coronary Angiography</li> <li>Acute:<ul> <li>1) 160-325mg Aspirin for all</li> <li>2) UFA w/bolus 60U/kg followed by infusion at 12U/kg/h or LMWH 1mg/kg<ul> <li>UFA is preferred for ESRD</li> </ul> </li> <li>3) P2Y12 receptor inhibitors (Clopidogrel, Prasugrel), ticagrelor if PCI</li> <li>4) BB if no contraindications<ul> <li>Reduces infarct size, lowers risk of reinfarction and early mortality</li> <li>CI: Decompensated HF, Bradycardia</li> </ul> </li> <li>IV Nitroglycerin at 10mcg/min<ul> <li>Keep BP &gt;100-110 mmHg</li> </ul> </li> <li>GP IIBIIIA if PCI (Epitifibatide, Tirofiban)</li> </ul> </li> <li>Long Term:<ul> <li>Antiplatelet, ACEI, or ARB</li> <li>ACEI (Lisinopril)</li> <li>Clopidogrel reduces MI incidence + ASA for 12 months</li> <li>BBs (metoprolol, atenolol, propranolol)</li> <li>BP control (CCBs)</li> <li>Statins, Quit Smoking</li> <li>Diet and Diabetes Control</li> <li>Exercise</li> </ul> </li> </ul> </li> </ul>","tags":["Chest Pain","ACS"]},{"location":"im-guide/cards/cad/acs/#acute-myocardial-infarction","title":"Acute Myocardial Infarction","text":"<ul> <li>Definition<ul> <li>The term acute myocardial infarction should be used when there is acute myocardial injury with clinical evidence of acute myocardial ischemia + detection of a rise and/or fall of cTn values with at least one value above the 99<sup>th</sup> percentile URL + least one of the following:<ul> <li>Symptoms of myocardial ischemia</li> <li>New ischemic ECG changes</li> <li>Development of pathological Q waves</li> <li>Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality in a pattern consistent with an ischemic etiology</li> <li>Identification of a coronary thrombus by angiography or autopsy (not for type 2 or 3 MIs)</li> </ul> </li> <li>Post-mortem demonstration of acute atherothrombosis in the artery supplying the infarcted myocardium meets criteria for type 1 MI</li> <li>Evidence of an imbalance between myocardial oxygen supply and demand unrelated to acute atherothrombosis meets criteria for type 2 MI</li> <li>Cardiac death in patients with symptoms suggestive of myocardial ischemia and presumed new ischemia ECG changes before cTn values become available or abnormal meets criteria for type 3 MI</li> </ul> </li> </ul>","tags":["Chest Pain","ACS"]},{"location":"im-guide/cards/cad/acs/#nstemi","title":"NSTEMI","text":"<ul> <li>W/U: Troponins at 3-6 hours after symptoms onset, remeasure within 8-12 HEART Score in the ER<ul> <li>HEART Score in the ER</li> <li>Risk Assessment (TIMI Risk Score)<ul> <li>GRACE score predicts in-hospital and 6 month mortality</li> </ul> </li> </ul> </li> <li>Treatment<ul> <li>Initial Stabilization<ul> <li>Aspirin: 325mg chewed immediately, 81mg QD<ul> <li>If no aspirin initially: 300mg followed by 75mg daily</li> <li>If UA or NSTEMI: UFA: Bolus of 12-55 U/kg/min up to 60-70 U/kg/min maintained at 1.5-2.5x PTT for 2-5days</li> </ul> </li> <li>0.4mg sublingual nitrogen \u00b1 10 microg/min and increased by 5-10 microgram/min every 3-5 min until relief (200 usual max) for 12-24 hours</li> <li>IV Metoprolol: 5mg IV Q5minx3, then 25-50mg Q6hrPO<ul> <li>OR IV Esmolol if COPD, Asthma</li> <li>OR CCBs if BB CI and hypertensive</li> </ul> </li> <li>O2 if &lt;90%, Aspirin, P2Y12 Inhibitor, Nitrates, BB, High-dose Statin, Anticoagulation</li> <li>&lt; 12 hours of symptom onset + PCI CI<ul> <li>Fibrinolysis<ul> <li>Higher rate of recurrent MI, Intracranial Hemorrhage, Mortality</li> </ul> </li> </ul> </li> <li>NSTE-ACS + Low-Risk: Ischemia-Guided Strategy<ul> <li>Noninvasive stress testing prior to discharge</li> </ul> </li> <li>NSTE-ACS + High Risk (Refractory angina, HF, Arrythmia or Hemodynamic instability)<ul> <li>Urgent cath</li> </ul> </li> </ul> </li> <li>Long-Term<ul> <li>ACEI if LVD, DM, Hypertension</li> <li>Therapeutic ACEI + BB + LVEF \u226440 + (DM or HF): Eplerenone is beneficial</li> </ul> </li> </ul> </li> </ul>","tags":["Chest Pain","ACS"]},{"location":"im-guide/cards/cad/acs/#stemi","title":"STEMI","text":"<ul> <li>General<ul> <li>Usually due to ruptured/eroded or unstable atherosclerotic plaques with overlying thrombus formation, leading to reduced coronary blood flow</li> <li>2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction</li> <li>Cardiogenic shock is leading cause of death, 50%<ul> <li>Restoration of Coronary blood flow (PCI &gt; Fibrinolysis)<ul> <li>Most likely to improve CV and overall long-term mortality in Acute STEMI</li> <li>SHOCK Trial</li> </ul> </li> </ul> </li> </ul> </li> <li>Symptoms<ul> <li>Pale, sweaty, may be agitated or restless</li> <li>Crushing, pressure like substernal chest pain, SOB, diaphoresis, and sometimes a history of exertional chest pain</li> <li>Often radiates down the left arm or into the jaw<ul> <li>Aortic Dissection more likely if radiation to the back</li> </ul> </li> <li>If recurrent MI:<ul> <li>Dyspnea and wheezing<ul> <li>Indicate LV impairment and pulmonary edema</li> </ul> </li> <li>Bibasilar rales \u00b1 JVD</li> </ul> </li> <li>RVMI usually have hypotension, JVD, clear lungs (inferior MI MC)<ul> <li>If RVMI w/hypotension, low-normal JVD, then give IV saline Bolus for inadequate RV preload, avoid nitrates</li> </ul> </li> </ul> </li> <li>Exam<ul> <li>Arrythmia, heart block, sinus tachycardia (Prior to BBs)</li> <li>JVP</li> <li>MR w/soft S1 and pansystolic murmur</li> <li>VSD</li> <li>Pericardial friction rub</li> <li>Aortic dissection</li> </ul> </li> <li>Diagnosis: EKG + Trops<ul> <li>EKG<ul> <li>ST-elevation at the J-point in 2 contiguous leads with the cut point: \u22651mm in all leads other than V2-V3 where the following cut-points apply:<ul> <li>\u22652mm in men \u226540y</li> <li>\u22652.5mm in men &lt;40y</li> <li>\u22651.5mm in women of any age</li> </ul> </li> <li>Depression<ul> <li>New horizontal or downsloping ST-depression \u22650.5mm in 2 continguous leads and/or T inversion \u22651mm in two contiguous leads with prominent R wave or R/S ratio &gt;1.<ul> <li>1mm in two or more contiguous limb or chest leads, 2mm elevation in leads V2/V3 in men or 1.5mm in women.</li> </ul> </li> <li>Posterior: 2mm in anterior V1-V4 with tall R waves often with ST-segment elevation in the inferior or lateral leads and ST elevation in posterior V7-V9</li> </ul> </li> </ul> </li> <li>Myoglobin rises within 1h of onset, peak at 6h, normal in 1 day</li> <li>CK-MB rises within 4-6h, peak at 1 day, normal in 2-3 days</li> <li>Troponin rises within 2-6h, peaks 2 days, normal in 4-10 days<ul> <li>Good in both acute and recent Mis</li> <li>Most sensitive and specific</li> </ul> </li> </ul> </li> <li>Acute ST-Segment Myocardial Infarction (STEMI)<ul> <li>Anterior Wall STEMI<ul> <li>Heart Failure<ul> <li>Flash pulmonary edema<ul> <li>Loop Diuretic (Furosemide), relieves pulmonary edema by decreasing the cardiac preload</li> <li>Venodilation, which further decreases the preload</li> <li>Hypotension and AKI if normo/hypovolemic (aka be careful)</li> </ul> </li> </ul> </li> </ul> </li> <li>Inferior Wall STEMI (Inferior MI)<ul> <li>General<ul> <li>ST elevation in leads II, III, and aVF</li> <li>Usually due to occlusion of the RCA &gt; LCX</li> </ul> </li> <li>Transient Bradycardia or AV block<ul> <li>Treatment<ul> <li>Usually just Atropine</li> <li>Temporary pacemaker possibly</li> </ul> </li> </ul> </li> <li>Right Ventricular MI (RVMI)<ul> <li>30-50% of Acute inferior wall Mis<ul> <li>Due to occlusion of the proximal RCA before the origin of the RV branches</li> </ul> </li> <li>Leads to impaired RV filling and often creates high sensitivity to intravascular volume depletion<ul> <li>Decreased preload and CO</li> <li>Not observed in a pure LVMI</li> </ul> </li> <li>Clear lungs + Inferior wall MI indicate RVMI</li> <li>Exam<ul> <li>Distended neck veins (JCD), clear lungs, tachycardia</li> <li>Hypotension + low/normal JVP (\u22643cm above the sternal angle) suggest Cardiogenic Shock<ul> <li>Due to inadequate RV preload</li> <li>Bolus with Isotonic Saline to increase RV preload and improve CO</li> <li>Avoid Beta blockers</li> <li>Beta blockers contraindicated in bradycardia or cardiogenic shock</li> </ul> </li> <li>Hypotension in Right Ventricular MI with low-normal JVP<ul> <li>CVP = JVP + depth to right atrium (5cm)<ul> <li>30-45 degrees, sternal angle</li> <li>Normal CVP (6-8 cm H2O)</li> <li>Elevated CVP (&gt;8 cm H2O)</li> </ul> </li> <li>Indicates inadequate RV preload</li> <li>IV saline bolus (avoid nitrates)</li> </ul> </li> </ul> </li> <li>Diagnosis: V4 on R-sided EKG is 100% specific (V4-V6R)</li> <li>Treatment<ul> <li>Initial IV Normal Saline Bolus</li> <li>Vigorous fluid resuscitation<ul> <li>\u00b1 Dopamine/dobutamine if refractory</li> </ul> </li> <li>Manage Like an Acute STEMI after</li> <li>Diuretics (volume depletion) and opiates (venous dilation) should be avoided or used in caution</li> <li>Avoid Nitrates<ul> <li>Nitrates (venous dilation) will lead to profound hypotension due to decreased RV preload</li> </ul> </li> </ul> </li> </ul> </li> </ul> </li> </ul> </li> <li>Treatment<ul> <li>Goal: Decrease Cardiac Myocardial O2 and increase O2 delivery<ul> <li>Emergent PCI has shown to have higher rates of survival in active STEMI and Cardiogenic shock than ICU stabilization initially</li> <li>2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization</li> </ul> </li> <li>ACC/AHA guideline update for the management of STEMI</li> <li>General<ul> <li>To reduce morbidity and mortality<ul> <li>Aspirin + Clopidogrel, ticagrelor + BB + ACEI/ARB + Statins \u00b1 Aldosterone antagonists</li> </ul> </li> <li>ACEI: LV dysfunction, HF, EF \u226440%, Anterior wall infarction, diabetes<ul> <li>Give ACEI/ARB within 24h to limit Ventricular Remodeling (AT2 mediated), results in dilatation of the ventricle</li> <li>SAVE: ACEI improve survival/morbidity/mortality in LV dysfunction after MI</li> </ul> </li> <li>If Pulmonary Edema w/o hypotension or hypovolemic: IV Furosemide</li> </ul> </li> <li>1) Dual Antiplatelet Therapy (DAPT)<ul> <li>P2Y12s<ul> <li>PLATO: Ticagrelor &gt; Clopidogrel in ACS including mortality</li> <li>DAPT: Continuing Thienopyridine after 12 months decreased risk of In-stent thrombosis and MI at 18 months, increased risk of bleeding</li> <li>WOEST: Bleeding w/AC + Plavix &lt; Triple Therapy w/o change in MI/Stroke/MACE</li> <li>COGENT: PPI with DAPT reduces GIB 87%, no CV event change</li> </ul> </li> <li>Acute Recommendations<ul> <li>Give chewable Aspirin (325mg) at presentation</li> <li>P2Y12 Receptor Blocker (Clopidogrel, prasugrel, ticagrelor)<ul> <li>If PCI: Loading dose of Clopidogrel 600mg or Ticagrelor 180mg</li> <li>If Fibrinolytics: Clopidogrel 300mg; 75mg if &gt;75y/o</li> </ul> </li> <li>PPI if on DAPT and high-risk for bleeding (previous bleed, PUD, active H. Pylori, Age &gt;65)<ul> <li>Decreases risk of UGIB</li> <li>Avoid Omeprazole if on Strong CYP2C19 (Plavix), use Protonix/Dexlansoprazole<ul> <li>Does not affect prasugrel or ticagrelor</li> </ul> </li> </ul> </li> </ul> </li> <li>Duration Recommendations<ul> <li>DAPT for minimum of 6-12 months after BMS/DES Placement<ul> <li>Postpone elective surgeries until done with DAPT</li> <li>Can stop P2Y12 3-7 days prior to surgery</li> <li>Continue aspirin perioperatively unless Neurosurgery</li> </ul> </li> <li>DAPT for 6 months if no stent w/ACS</li> <li>DAPT for \u226512 months for drug-eluting stent in ACS<ul> <li>Clopidogrel or Ticagrelor</li> <li>Restart ASA after cessation of P2Y12</li> <li>Premature discontinuation is the strongest predictor of stent thrombosis within 1<sup>st</sup> 12 months</li> </ul> </li> <li>DAPT &gt; 1 year if: high risk for recurrence, depressed LV function, Saphenous vein graft stenting, diabetic<ul> <li>In whom the risk &lt; benefit for up to 36m</li> <li>May use DAPT bleeding risk score</li> <li>Clopidogrel if hx of upper gi bleed</li> </ul> </li> <li>DAPT for minimum of 4 weeks in select patients after BMS<ul> <li>Use in pts with high bleeding risk</li> </ul> </li> <li>Continue DAPT for a total of 30 months if possible (Low bleeding risk)</li> <li>Continue Aspirin Indefinitely</li> <li>CAD + PAD<ul> <li>COMPASS Trial: Aspirin 100mg + Xarelto 2.5mg BID improves MACE</li> </ul> </li> <li>PCI<ul> <li>Prasugrel associated with increased bleeding, similar efficacy in those with stents</li> </ul> </li> <li>Perioperative Management<ul> <li>Elective Surgery: Defer Surgery until after minimum DAPT duration<ul> <li>Urgent Surgery: Continue P2Y12 receptor blacker or hold for shortest duration possible</li> <li>Continue aspirin unless high risk of severe surgical bleeding</li> <li>Reduces rate of early graft occlusion and overall CV morbidity and mortality in CABG, continue</li> <li>Hold P2Y12 inhibitors for 5-7 days prior to CABG</li> <li>Increased risk of significant bleeding with increased requirements for blood transfusion and possible re-op</li> </ul> </li> </ul> </li> </ul> </li> </ul> </li> <li>2) Beta-blockers (BBs) if Hypertensive/ongoing (Metoprolol)<ul> <li>Beta-Blockers not always needed (New)<ul> <li>Did not lead to a lower risk of the composite primary end point of death from any cause or new myocardial infarction than no beta-blocker</li> <li>Decrease myocardial demand, reduce incidence of ventricular arrythmias, improve long-term survival within 24 hours of presentation</li> </ul> </li> <li>Oral only, IV has no benefit</li> <li>CI: HF, High risk for Shock, Bradycardia, hypotension, heart block<ul> <li>Atropine if unstable sinus bradycardia</li> </ul> </li> </ul> </li> <li>3) O2 for arterial saturation &lt;90% (SaO2 &lt;95%, breathless, or HF)</li> <li>4) IV Opioids to relieve pain if needed</li> <li>5) Anticoagulation<ul> <li>If PCI: UFH, Enoxaparin, or Bivalirudin<ul> <li>\u00b1 Glycoprotein IIb/IIa inhibitor to UFH</li> <li>Determine Need for ongoing anticoagulation after<ul> <li>Low risk: Stop IV UFH after cath<ul> <li>Low VTE risk: SCDs</li> <li>Intermediate/High VTE risk: Give lovenox 6hr after stopping drip</li> </ul> </li> <li>Intermediate Risk: May continue IV UFH<ul> <li>If Fibrinolytics: UFH, Enoxaparin, Fondaparinux<ul> <li>For 48h up to 8 days</li> </ul> </li> </ul> </li> </ul> </li> </ul> </li> </ul> </li> <li>6) Sublingual Nitrates &gt; Morphine<ul> <li>Nitrates: 3 x 0.4mg tablets, IV afterward<ul> <li>CI: Sildenafil within 24-48 hours, Shock, RV infarction</li> </ul> </li> <li>Morphine Sulfate: 2-4mg IV at 5-15min intervals</li> <li>No nitro if hypotension, RV infarct, severe AS</li> </ul> </li> <li>7) High dose Statins ASAP after stabilization (Atorvastatin 80mg)<ul> <li>PROVE-IT: Significantly reduced CVD events following MI with High-dose Lipitor vs. Pravastatin</li> <li>Want LDL &lt; 70 1 month after</li> </ul> </li> <li>8) Prompt reperfusion with PCI or Alteplase (fibrinolytics)<ul> <li>Early Invasive Strategy</li> <li>Give IV UFH/Bivalirudin<ul> <li>Abciximab</li> </ul> </li> <li>PCI &gt; Fibrinolysis (Alteplase, not for NSTEMI or Unstable)</li> <li>Ideal first medical contact to PCI \u226490mins or \u226430mins for fibrinolytics</li> <li>Avoid Milrinone and Dobutamine in Acute STEMI<ul> <li>Increases mortality in cardiogenic shock, may cause hypotension</li> <li>Use Norepinephrine if hypotensive</li> </ul> </li> </ul> </li> <li>Reperfusion:<ul> <li>Percutaneous Transluminal Coronary Angioplasty (PTCA)</li> <li>Thrombolysis (If PTCA not available within 120min)</li> </ul> </li> <li>TIMI Grade<ul> <li>Used to quantitatively evaluate coronary blood flow</li> <li>0 = complete occlusion</li> <li>1 = faint coronary flow</li> <li>2 = delayed or sluggish but complete flow</li> <li>3 = normal flow</li> </ul> </li> <li>Initiate Reperfusion Therapy (Fibrinolysis/PCI) &lt; 12 hours of symptom onset and within 90 minutes of medical contact (120 if transporting)<ul> <li>Percutaneous Coronary Intervention (PCI)<ul> <li>PCI = Angioplasty + Stent</li> </ul> </li> </ul> </li> <li>&lt; 12 hours of symptom onset + PCI CI or &gt; 12 hours of symptom onset<ul> <li>Thrombolysis</li> <li>No PCI: Fibrinolytics within 30 mins of arrival<ul> <li>Absolute CI to fibrinolytics:<ul> <li>Ischemic stroke within 3 months, Intracranial Hemorrhage ever</li> </ul> </li> <li>Relative CI:<ul> <li>Ischemic stroke &gt;3 months, SBP &gt; 180, elevated INR on warfarin<ul> <li>Can still get FT</li> </ul> </li> </ul> </li> <li>Better if used within 12 hours, best within 60-70 minutes</li> <li>DAPT for at least 14 days up to 1 year</li> </ul> </li> </ul> </li> <li>Aldosterone antagonist if:<ul> <li>NYHA II-IV HF &amp; EF \u226435%</li> <li>On ACEI/BB, EF \u226440% and symptomatic HF or DM<ul> <li>Therapeutic ACEI + BB + LVEF \u226440 + (DM or HF): Eplerenone is beneficial<ul> <li>Improves mortality and morbidity</li> <li>Avoid if Cr &lt;30, Hyperkalemia</li> </ul> </li> </ul> </li> </ul> </li> <li>On Discharge:<ul> <li>Cardiac Rehabilitation for those with PCI</li> </ul> </li> <li>Eval for ICD if reduced EF after 40 days or 3 months after revascularization on optimal medical therapy<ul> <li>MADIT-II: ICD improves survival in pts with prior MI and severe LV dysfunction</li> </ul> </li> <li>Non-Culprit lesions<ul> <li>50% of STEMI have obstructive lesions remote form the area of infarction<ul> <li>Consider revascularization</li> </ul> </li> <li>Treat within 4-6 weeks if stable STEMI or low-complexity MCVD</li> </ul> </li> </ul> </li> </ul>","tags":["Chest Pain","ACS"]},{"location":"im-guide/cards/cad/acs/#complications","title":"Complications","text":"<ul> <li>Prognostic<ul> <li>The higher LVEF post MI, the better the prognosis</li> </ul> </li> <li>Post MI<ul> <li>Sexual activity: 2 weeks if healthy, 6 weeks if not<ul> <li>ED and decreased satisfaction are common, PDE-5s if not on nitrates</li> </ul> </li> </ul> </li> <li>Pericardial Effusion<ul> <li>Stop all AC unless Afib or LV thrombus</li> </ul> </li> <li>Post-PCI<ul> <li>Reperfusion leading to contraction band necrosis from calcium influx</li> </ul> </li> <li>3 Major Mechanical Complications<ul> <li>MR due to Papillary muscle rupture</li> <li>LV free wall rupture</li> <li>Ventricular septal rupture</li> </ul> </li> <li>0-4 Hours<ul> <li>Microscopic/Gross: None</li> <li>Complications:<ul> <li>Arrhythmia<ul> <li>Bradycardia</li> <li>AV Block</li> </ul> </li> <li>Fatal Arrhythmia<ul> <li>Ventricular Extrasystole<ul> <li>Electrical instability, risk of VF if R on T</li> <li>Most common fatal</li> </ul> </li> <li>Immediate (&lt;10mins): Acute ischemia predisposes to reentrant arrythmias<ul> <li>Ventricular Fibrillation is the MCC of SCD during acute MI</li> </ul> </li> <li>Delayed (10-60mins): Abnormal automaticity leads to arrythmias</li> </ul> </li> <li>Cardiogenic Shock<ul> <li>Severe SOB, chest pain, decreased CO, increased PCWP (indicates cardiac), causes pulmonary edema</li> </ul> </li> <li>Congestive Heart Failure<ul> <li>Inefficient pumping of the LV, decreased EF</li> </ul> </li> </ul> </li> </ul> </li> <li>4-24 hours<ul> <li>Microscopic: Coagulative necrosis, Edema, Wavy Fibers, Contraction bands</li> <li>Gross: Dark Discoloration</li> <li>Complications:<ul> <li>Fatal Arrythmia</li> <li>Reperfusion injury<ul> <li>Return of oxygen and inflammatory cells can cause reperfusion injury</li> </ul> </li> <li>Right Ventricular Failure (Acute)<ul> <li>RCA involvement</li> <li>Symptoms<ul> <li>Hypotension and clear lungs</li> <li>Kussmaul sign</li> </ul> </li> <li>Echocardiogram: Hypokinetic RV</li> </ul> </li> </ul> </li> </ul> </li> <li>1-3 days then 4-7 days (1 week)<ul> <li>Microscopic:<ul> <li>First Neutrophils (inflammation)</li> <li>Then Macrophages (cleanup)</li> </ul> </li> <li>Gross: Yellow Pallor</li> <li>Complications:<ul> <li>Acute Peri-infarct Pericarditis (PIP)<ul> <li>1-3 days after an MI \u2013 diffuse ST-segment elevation<ul> <li>Causes collagen deposition and increases risk of Ventricular free wall rupture</li> <li>More common in pts unable to be re-perfused</li> </ul> </li> <li>Symptoms<ul> <li>Pericardial friction rub with or without pleuritic chest pain with radiation to the shoulder</li> <li>Clear lungs, improves when leaning forward</li> </ul> </li> <li>Treatment<ul> <li>Self-limiting</li> <li>Increase aspirin to 650-1000mg TID</li> <li>Colchicine \u00b1 Opioids if poor control</li> <li>D/C AC if no Afib/LV Thrombus with pericardial effusion</li> <li>No NSAIDS/No Steroids</li> </ul> </li> </ul> </li> <li>Papillary Muscle Rupture (Acute to 3-5 days)<ul> <li>RCA or Dominant LCX</li> <li>Symptoms<ul> <li>Soft new holosystolic or early systolic murmur (MR at apex), 50% may have silent MR<ul> <li>No thrill</li> <li>Hyperdynamic precordium</li> </ul> </li> <li>Acute inferior MI leading to acute mitral regurgitation and pulmonary edema<ul> <li>Excessive diastolic volume overload which leads to elevated LV EDP, LV filling pressure</li> <li>Posteromedial Papillary muscle rupture</li> <li>LHF symptoms but no RHF symptoms</li> </ul> </li> <li>Acute, severe pulmonary edema</li> <li>Hypotension, dyspnea, tachypnea</li> <li>50% have silent MR</li> </ul> </li> <li>Diagnosis: TTE or TEE<ul> <li>No persistent ST-elevation</li> <li>Echo: Severe MR with flail leaflet<ul> <li>Massive mitral regurgitation secondary to acute ischemic papillary muscle rupture: the role of echocardiography</li> </ul> </li> </ul> </li> </ul> </li> <li>Interventricular Septal Rupture (Acute to 3-5 days)<ul> <li>LAD \u2013 Apical Septal Rupture</li> <li>RCA \u2013 Basal Septal Rupture</li> <li>Symptoms<ul> <li>Shock and chest pain, cardiogenic shock, palpable thrill</li> <li>Harsh new holosystolic murmur at the left sternal border (Thrill, step up O2 from RA to RV)</li> <li>Biventricular Failure<ul> <li>Causes a VSD, More RHF (JVD) &gt; LHF</li> <li>Step-up O2 between RA and RV, Left to right shunt at the level of the ventricle (pulmonary edema, JVD)</li> </ul> </li> </ul> </li> <li>Diagnosis: TTE</li> <li>Treatment<ul> <li>Prompt surgical repair</li> </ul> </li> </ul> </li> <li>Ventricular Free Wall Rupture (50% by 5 days up to 2 weeks)<ul> <li>LAD involved<ul> <li>LV leak into pericardial space due to macrophages phagocytosing infarcted tissue</li> <li>Due to hemopericardium, typically leads to cardiac tamponade</li> </ul> </li> <li>Majority are after transmural Anterior MI (&lt;1% overall)</li> <li>Symptoms<ul> <li>Sudden onset chest pain w/ profound shock, JVD<ul> <li>Acute Severe hypotension</li> <li>Distant heart sounds</li> </ul> </li> <li>Syncope w/rapid loss of pulses (PEA)</li> </ul> </li> <li>Diagnosis<ul> <li>Pericardial effusion with Cardiac tamponade on Echo</li> </ul> </li> <li>Treatment<ul> <li>Early Surgical Repair</li> </ul> </li> </ul> </li> <li>Pseudoaneurysm<ul> <li>Gradual rupture later sealed off by pericardium</li> </ul> </li> </ul> </li> </ul> </li> <li> <p>1 month</p> <ul> <li>Microscopic: Fibrosis</li> <li>Gross: None \u00b1 White Scarring</li> <li>Complications:<ul> <li>Left Ventricular Aneurysm (5 days to 3 months)<ul> <li>LAD involvement</li> <li>Scar Tissue deposition following transmural MI</li> <li>Aneurysm leads to LV enlargement</li> <li>Thin and dyskinetic myocardial wall</li> <li>Symptoms<ul> <li>Subacute CHF (HF and angina) and Persistent ST elevation/Deep q waves with systolic MR murmur, Stroke, ventricular arrythmia</li> </ul> </li> <li>Increased risk of mural thrombus due to slow blood flow</li> <li>Echo: Thin and dyskinetic myocardial wall</li> </ul> </li> <li>Dressler Syndrome (Post-MI Pericarditis)</li> <li>Hemorrhagic Pericardial Effusion</li> <li>Depression<ul> <li>20% of post-MI patients</li> <li>Sertraline and Escitalopram</li> <li>CI: Citalopram, paroxetine</li> </ul> </li> </ul> </li> </ul> </li> <li>Months to years<ul> <li>In-stent Restenosis</li> </ul> </li> </ul>","tags":["Chest Pain","ACS"]},{"location":"im-guide/cards/cad/acs/#other-resources","title":"Other Resources","text":"<ul> <li>PowerPoint: ACS Survival Guide - Seaberg CAMC/WVU 2022</li> </ul>","tags":["Chest Pain","ACS"]},{"location":"im-guide/cards/cad/stable-ischemic-disease/","title":"Stable Ischemic Disease","text":""},{"location":"im-guide/cards/cad/stable-ischemic-disease/#general","title":"General","text":"<ul> <li>Aka \"Chronic Stable Angina\"</li> </ul>"},{"location":"im-guide/cards/cad/stable-ischemic-disease/#management","title":"Management","text":"<ul> <li>Stop Smoking, Low-fat diet, 30-60 minutes of exercise 5-7 days a week</li> <li>Weight loss, BP management</li> <li>Goals of Pharmacologic Management<ul> <li>Reduce risk of MI/CV death<ul> <li>Anti-platelet<ul> <li>Aspirin or clopidogrel</li> </ul> </li> <li>4S: Statins reduce Death, MI, Revasc in Angina/MI patients<ul> <li>SATURN: Crestor better LDL reduction, no better mortality than Lipitor</li> <li>Atorvastatin (Lipitor)<ul> <li>Muscle toxicity w/concurrent Amiodarone use (0.7%)</li> </ul> </li> <li>Rosuvastatin (Crestor)<ul> <li>Crestor FDA (Renal Dosing)</li> <li>Crestor to prevent vascular events in patients with elevated CRP</li> </ul> </li> <li>Side Effects<ul> <li>Statin induced diabetes and its clinical implications</li> <li>Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis</li> <li>Statins and risk of incident diabetes: a collaborative meta-analysis of randomized statin trials</li> <li>Statin-Associated Myopathy<ul> <li>Adverse events with concomitant amiodarone and statin therapy</li> </ul> </li> <li>Asymptomatic hypothyroidism and statin-induced myopathy</li> </ul> </li> </ul> </li> <li>LVEF &lt;40% or prior MI<ul> <li>Beta-Blockers</li> </ul> </li> <li>LVEF &lt;40%, T2DM, HTN. CKD<ul> <li>ACEI/ARB</li> </ul> </li> </ul> </li> <li>Symptom alleviation and improvement of QOL<ul> <li>Beta-Blockers as initial therapy</li> <li>CCBs or LA-Nitrates if BBs can not be used or are not controlling angina</li> <li>Ranolazine if on maximal tolerable medical therapy</li> <li>COURAGE: PCI w/BMS in Stable CAD non-superior to medical therapy</li> <li>In life expectancy &lt;1, discontinuation of statin did not increase 60-day mortality</li> </ul> </li> </ul> </li> </ul>"},{"location":"im-guide/cards/cad/stable-ischemic-disease/#revascularization-cabg","title":"Revascularization (CABG)","text":"<ul> <li>[SYNTAX]: Less CV events at 1 year w/CABG vs. PCI in 3-vessel and/or LM disease3<ul> <li>17.8% vs. 12.4%; driven by need for repeat revascularization in PCI group</li> <li>Use of only paclitaxel stents, which have higher rate of angiographic restenosis than either the sirolimus- or everolimus-eluting stents</li> <li>Five-year outcomes<ul> <li>Roughly equivalent unless high Syntax score which favors surgery</li> </ul> </li> </ul> </li> <li>Syntax Score<ul> <li>The SYNTAX score is a grading system that evaluates the complexity and prognosis of patients undergoing percutaneous coronary intervention (PCI)</li> <li>Calculator</li> </ul> </li> <li>Indications for CABG<ul> <li>Class 1<ul> <li>LM w/complex CAD</li> <li>LM w/Syntax score &gt;33</li> <li>LM w/complex CAD + Syntax score &gt;33 + Suitable Candidate</li> <li>MVCAD w/suitable anatomy + Suitable Candidate + LVEF (\\(\\leq\\)) 35%</li> </ul> </li> <li>Class 2a<ul> <li>MVCAD w/suitable anatomy + Suitable Candidate + LVEF (\\(\\geq\\)) 35%<ul> <li>ISCHEMIA, FAME-2, and 10-year updates from the MASS -II trial showing a reduction in CV mortality</li> </ul> </li> </ul> </li> <li>Class 2b</li> <li>MVCAD w/suitable anatomy + LVEF &gt;50% (Note PCI also 2b)</li> <li>IMA (internal mammary artery) remains preferred choice for LAD<ul> <li>Radial preferred over SVG for 2<sup>nd</sup> most important vessel (non-LAD)<ul> <li>AATS disagrees with this without patient specifiers</li> </ul> </li> </ul> </li> </ul> </li> </ul>"},{"location":"im-guide/cards/cad/stable-ischemic-disease/#post-cabg-management","title":"Post-CABG Management","text":"<ul> <li>~10-20% readmitted within 30 days</li> <li>Consider the 3 \"I\"s<ul> <li>Infectious<ul> <li>Sternal wounds</li> </ul> </li> <li>Inflammatory<ul> <li>Pericarditis<ul> <li>Get TTE, contact primary surgeon</li> <li>May lead to Tamponade<ul> <li>Commonly presents early (&lt;7 days)</li> </ul> </li> </ul> </li> </ul> </li> <li>Ischemic<ul> <li>Myocardial Infarction</li> </ul> </li> </ul> </li> <li>Dyspnea is common post-operatively<ul> <li>Once discharged, new-onset dyspnea should be evaluated for (Most to Least likely):<ul> <li>Pleural effusion (50%), atelectasis, congestive heart failure (13%), pneumonia (2.4%) and pulmonary embolism</li> <li>Diaphragmatic Paralysis<ul> <li>Dyspnea at rest or with exertion and supine hypoxemia</li> <li>FVC dropped in the supine position</li> <li>Elevated hemidiaphragm</li> <li>Diagnosis: Confirmed via the \u201csniff test\u201d under fluroscopy</li> </ul> </li> </ul> </li> </ul> </li> <li>30% develop Atrial Fibrillation<ul> <li>Usually self-limiting if new-onset</li> <li>Return to NSR by 6-12 weeks out</li> </ul> </li> <li>30% AKI</li> <li>50-70% develop cognitive dysfunction</li> <li>Delirium in 73%</li> </ul>"},{"location":"im-guide/cards/heart-failure/acute-hf/","title":"Acute Heart Failure","text":"","tags":["Heart Failure","AECHF"]},{"location":"im-guide/cards/heart-failure/acute-hf/#categories-of-acute-heart-failure","title":"Categories of Acute Heart Failure","text":"<ul> <li>Acute Decompensated HF<ul> <li>With signs and symptoms of AHF which are mild and do not complete criteria for cardiogenic shock, pulmonary edema, or hypertensive crisis</li> </ul> </li> <li>Hypertensive AHF<ul> <li>HF w/elevated BP and relatively preserved LV function with a CXR with acute pulmonary edema</li> </ul> </li> <li>AHF with Pulmonary Edema<ul> <li>Severe respiratory distress with crackles and orthopnea</li> </ul> </li> <li>High-Output Heart Failure<ul> <li>High CO, commonly with elevated HR 2/2 arrhythmia, Thyrotoxicosis, Anemia, Paget\u2019s Disease, Iatrogenic</li> </ul> </li> <li>Right-Sided Heart Failure<ul> <li>Low CO with increased JVD, hepatomegaly, and hypotension</li> </ul> </li> <li>Cardiogenic Shock</li> </ul>","tags":["Heart Failure","AECHF"]},{"location":"im-guide/cards/heart-failure/acute-hf/#etiology","title":"Etiology","text":"<ul> <li>80-85% are Chronic HF exacerbations due to:<ul> <li>Noncompliance</li> <li>Uncontrolled hypertension</li> <li>Rapid Afib</li> </ul> </li> <li>15-20% are new onset Acute Coronary Syndrome (ACS)<ul> <li>\u00b1 MI, arrhythmias, Acute severe MR/AR</li> </ul> </li> <li>&lt;1% but Increasing Incidence<ul> <li>Stress-Induced Cardiomyopathy<ul> <li>Catecholamine Excess</li> <li>Post-menopausal women w/emotional stress, SAH, TBI</li> <li>Dyspnea and chest pain \u00b1 ST changes, T wave inversion</li> <li>Ballooning or hypokinesis of LV apex</li> <li>May be unstable but resolves in days to weeks</li> <li>Dobutamine is CI</li> </ul> </li> <li>Low-Output Heart Failure<ul> <li>Decompensated heart failure resulting from left ventricular dysfunction</li> <li>Increased afterload and preload with decreased CO</li> </ul> </li> </ul> </li> <li>Correction to: Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association</li> </ul>","tags":["Heart Failure","AECHF"]},{"location":"im-guide/cards/heart-failure/acute-hf/#labs","title":"Labs","text":"<ul> <li>ABG shows hypoxia, hypocapnia, and respiratory alkalosis<ul> <li>Less specific than proBNP and PCWP</li> <li>Respiratory alkalosis (hyperventilation) often seen in contrast with COPD which has respiratory acidosis</li> </ul> </li> <li>Risk Assessment</li> <li>Prognostic Biomarkers in the ED in HF<ul> <li>Elevated BNP has high sensitivity for AHFD, BNP &gt; 100 is indicative<ul> <li>Updating the role of natriuretic peptide levels in cardiovascular disease</li> <li>Impact of body mass and body composition on circulating levels of natriuretic peptides</li> <li>The paradox of low BNP levels in obesity</li> </ul> </li> </ul> </li> </ul>","tags":["Heart Failure","AECHF"]},{"location":"im-guide/cards/heart-failure/acute-hf/#management","title":"Management","text":"<ul> <li>4 Main Arms of Management:<ul> <li>1) Typical<ul> <li>Dry &amp; Warm</li> <li>High-Risk Features: Renal insufficiency, Biomarkers of injury, ACS, Arrhythmias, hypoxia, PE, infection</li> <li>Hypertensive: Vasodilators</li> <li>Normotensive: Diuretics</li> </ul> </li> <li>2) Pulmonary Edema<ul> <li>Wet &amp; Warm</li> <li>Severe Pulmonary congestion with hypoxia</li> <li>High-Risk Features: New onset arrhythmia, valvular disease, myocardial ischemia, CNS injury, Drug toxicity</li> <li>Hypertensive: Vasodilators</li> <li>Normotensive: Diuretics, O2, NIPPV</li> <li>Congestion: Diuretics, Vasodilators, Ultrafiltration</li> </ul> </li> <li>3) Low Output<ul> <li>Dry &amp; Cold</li> <li>Hypoperfusion w/ End organ damage</li> <li>High-Risk Features: Low pulse pressure, cool extremities, cardiorenal syndrome, hepatic congestion</li> <li>Fluid Challenge/Inotropes</li> <li>Hypertensive: Vasodilators</li> <li>Normotensive: Inotropic Therapy</li> </ul> </li> <li>4) Cardiogenic Shock<ul> <li>Wet &amp; Cold</li> <li>Hypotension, low cardiac output, and end organ failure</li> <li>High-Risk Features: Extreme distress, pulmonary congestion, Renal failure</li> <li>Inotropic Therapy/Mechanical Circulatory Support<ul> <li>Systolic &lt;90: Inotropes, Vasopressors, Diuretics, Circulatory support</li> <li>Systolic &gt;90: Vasodilators, Diuretics, Inotropes</li> </ul> </li> </ul> </li> </ul> </li> <li>Avoid BB in patients with Decompensated CHF or Bradycardia (Pulmonary edema will worsen, and slow down the HR)<ul> <li>Decrease by 50% if unresponsive to diuresis or discontinue BB<ul> <li>Daily electrolytes and CR/BUN</li> <li>\u00b1 Thiazide</li> </ul> </li> </ul> </li> <li>Diuretic Therapy<ul> <li>Initial dose 1 to 2.5 times home dose, increase by 50-100% if unresponsive at 2-6 hours<ul> <li>Diuretic Optimization Strategies Evaluation (DOSE-AHF): High-dose loops &gt; Low-dose for symptom management, fewer inpatient days; continuous = Intermittent dosing</li> <li>Furosemide IV bolus at 40mg if normal kidneys, double if not &gt;300cc UOP after 2 hours, then give BI to TID if adequate</li> </ul> </li> <li>Renal insufficiency, initial 100mg IV, doubled if necessary</li> <li>5-10% of body weight should be lost (1-2L or 2lbs initially)<ul> <li>Failure again indicates diuretic resistance</li> </ul> </li> <li>Diuretic Therapy for HF (JACC State-of-the-Art Review)</li> <li>Optimal Diuretic Strategies in HF</li> <li>Michigan Medicine Inpatient Diuretic Guideline for Patients with Acute Decompensated HF</li> </ul> </li> <li>Diuretic Resistance<ul> <li>Metolazone<ul> <li>Metolazone worsens mortality<ul> <li>Outcomes Associated With a Strategy of Adjuvant Metolazone or High\u2010Dose Loop Diuretics in Acute Decompensated Heart Failure: A Propensity Analysis</li> <li>https://www.ahajournals.org/doi/full/10.1161/JAHA.118.009149#d1e2698</li> </ul> </li> <li>Continuous infusion to get urine output \u2265100cc/hr</li> </ul> </li> <li>SGLT-2s<ul> <li>Dapagliflozin vs. metolazone in heart failure resistant to loop diuretics<ul> <li>Dapagliflozin is not superior to Metolazone, but has fewer metabolic side effects</li> </ul> </li> <li>Similarities and distinctions between acetazolamide and sodium\u2013glucose cotransporter 2 inhibitors in patients with acute heart failure: Key insights into ADVOR and EMPULSE</li> </ul> </li> <li>Acetazolamide<ul> <li>When these two trials are considered together, it is uncertain how acetazolamide led to an improvement in physical signs of fluid retention in the ADVOR trial, since the drug produced only a modest diuretic effect in ADVOR and no natriuretic effect in DIURESIS-CHF</li> <li>ADVOR: Acetazolamide in Acute Decompensated Heart Failure with Volume Overload<ul> <li>Was not significant if LVEF \u226440%, Female, GFR \u226540, &gt;60mg lasix daily, more volume overload (congestion &gt;4)</li> <li>Excluded anyone on &gt;80mg lasix, must be on 40 or more</li> <li>New diagnosed HF were excluded from the trial so results cannot be applied to them</li> <li>Congestion scoring system used in this study used variables which are reflective of extracellular dehydration but not intracellular dehydration<ul> <li>Further research can be directed to replicating efficacy demonstrated here, and preferably with multiple measurements like quantum of natriuresis, diuretic efficiency, 6 hour cumulative sodium excretion or the natriuretic response prediction equation (NRPE)</li> </ul> </li> </ul> </li> <li>Acetazolamide to increase natriuresis in congestive heart failure at high risk for diuretic resistance<ul> <li>To select a population at high risk for loop diuretic resistance, at least one out of three additional inclusion criteria had to be fulfilled: (i) serum sodium \u2264\u2009135\u2009mmol/L; (ii) serum urea/Cr ratio &gt;\u200950; or (iii) admission serum Cr increase of &gt;\u20090.3\u00a0mg/dL compared to a previous measurement within 3\u00a0months.</li> <li>The two groups did not differ with respect to the primary endpoint, that is, urinary sodium excretion in the 24\u2009h following randomization, and they also did not differ with respect to the degree of clinical decongestion or changes in NT-proBNP after 72\u2009h, but worsening renal function was more commonly seen in the acetazolamide group</li> <li>There was no difference in two groups with respect to the risk of death or heart failure hospitalization within the next 90\u2009days, although the investigators reported some divergence months after treatment had been stopped</li> </ul> </li> </ul> </li> </ul> </li> <li>STRONG-HF: Rapid up-titration of GDMT and close f/u reduced risk of 180-day all-cause death or HF readmission in AECHF admits<ul> <li>European Heart Journal</li> </ul> </li> <li>Consider IV Vasodilators (Nitroglycerin, Nitroprusside)<ul> <li>Relieves dyspnea and tachycardia due to pulmonary edema</li> <li>High BP (25%): Nitroglycerin or nitroprusside<ul> <li>Glycerin is safer, prusside (CN and Thiocyanate toxicity, Coronary steal syndrome in ACS)</li> <li>Avoid Nitroprusside in renal failure</li> <li>Nitro Tolerance after 24h possible</li> </ul> </li> <li>Normal BP (50%): Nitroglycerin or Nesiritide<ul> <li>Nesiritide, recombinant BNP (diuresis + vasodilators)<ul> <li>Binds heparin (not through same tube)</li> </ul> </li> </ul> </li> <li>Vasodilator intolerance (hypotension, decreased urine output), mcc is pulmonary edema<ul> <li>Inodilators: Positive inotropic, vasodilators<ul> <li>Dobutamine (5ng up to 20), Milrinone (50ng, then up to 1.13, renally dosed), Levosimendan (12ng)</li> </ul> </li> </ul> </li> </ul> </li> </ul>","tags":["Heart Failure","AECHF"]},{"location":"im-guide/cards/heart-failure/basics-hf/","title":"Heart Failure Basics","text":"","tags":["Heart Failure"]},{"location":"im-guide/cards/heart-failure/basics-hf/#general","title":"General","text":"<ul> <li>Definition: Any structural or functional cardiac disorder that impairs the ability of the ventricle to fill or to eject blood<ul> <li>Inability of the heart to adequately perfuse the body leading to congestion</li> <li>Any condition that leads to an alteration in LV dysfunction (structure or function) can predispose one to developing HF</li> <li>HF preferred over CHF because Congestive Heart Failure fails to include high-output states</li> </ul> </li> </ul>","tags":["Heart Failure"]},{"location":"im-guide/cards/heart-failure/basics-hf/#physiology","title":"Physiology","text":"<ul> <li>Physiology of Diuretics in Acute Heart Failure</li> </ul>","tags":["Heart Failure"]},{"location":"im-guide/cards/heart-failure/basics-hf/#etiology","title":"Etiology","text":"<ul> <li>CAD is MCC in US (&gt;50%)</li> <li>20% of Americans \u226540 y/o develop<ul> <li>AA males have highest risk and highest 5-year mortality</li> </ul> </li> </ul>","tags":["Heart Failure"]},{"location":"im-guide/cards/heart-failure/basics-hf/#types","title":"Types","text":"<ul> <li>Acute</li> <li>Chronic</li> <li>Generally, 3 Classes of HF:<ul> <li>Left Ventricular Ejection Fraction (LVEF)<ul> <li>Important in classification</li> <li>Acute is classified based on:<ul> <li>Congestion (wet vs. dry) and Perfusion (warm vs. cold)</li> </ul> </li> </ul> </li> </ul> </li> <li>A) HFrEF<ul> <li>Systolic Dysfunction, EF \u226440%</li> <li>Mcly due to ischemic heart disease (MC) and dilated cardiomyopathy</li> </ul> </li> <li>B) HFpEF<ul> <li>Diastolic Dysfunction, EF \u226550%</li> </ul> </li> <li>C) High-output Failure<ul> <li>Occurs in the setting of existing systolic or diastolic dysfunction</li> </ul> </li> </ul>","tags":["Heart Failure"]},{"location":"im-guide/cards/heart-failure/basics-hf/#classification-systems","title":"Classification Systems","text":"<ul> <li>NYHA Classifications<ul> <li>Class I<ul> <li>Cardiac Disease but without restriction</li> </ul> </li> <li>Class II<ul> <li>Slight limitation of physical activity</li> <li>Comfortable at rest</li> <li>Fatigue, palpitation, dyspnea, or anginal pain</li> <li>5-10% of NYHA class II die yearly</li> </ul> </li> <li>Class III<ul> <li>Marked limitation of physical activity</li> <li>Comfortable at rest</li> <li>Less than ordinary activity causes fatigue, palpitation, dyspnea, or anginal pain</li> </ul> </li> <li>Class IV<ul> <li>Inability to carry on any physical activity without discomfort</li> <li>HF symptoms or anginal syndrome may be present even at rest</li> <li>Physical activity makes it worse</li> <li>30-70% of NYHA class IV die yearly</li> </ul> </li> </ul> </li> <li>ACC/AHA Staging<ul> <li>Stage A<ul> <li>High risk for HF but no structural heart disease, including:<ul> <li>HTN, Atherosclerotic disease, diabetes, obesity, metabolic syndrome, cardiotoxins, FH of cardiomyopathy</li> <li>Means having HTN you have Stage A HF</li> </ul> </li> <li>Treatment<ul> <li>Treat the disorder</li> <li>Exercise can decrease all cause death or hospitalization (HF-ACTION Trial) up to 11%</li> <li>ACEIs/ARBs in select patients</li> </ul> </li> </ul> </li> <li>Stage B<ul> <li>Structural heart disease w/o symptoms, including:<ul> <li>Previous MI, valvular disease, and LVH or low LVEF</li> </ul> </li> <li>Treatment<ul> <li>ACEIs/ARBs</li> <li>BBs + Statins if MI/ACS</li> <li>ICD if indicated</li> </ul> </li> </ul> </li> <li>Stage C<ul> <li>Structural heart disease with current or prior HF symptoms</li> <li>Treatment<ul> <li>NYHA II-IV<ul> <li>Loop diuretics</li> </ul> </li> <li>NYHA III-IV + AA<ul> <li>Hydralazine/Isosorbide Dinitrate</li> </ul> </li> <li>NYHA II-IV + Cr &gt;30 and K &lt;5<ul> <li>Aldosterone antagonists</li> </ul> </li> <li>Stage A and B drugs</li> </ul> </li> </ul> </li> <li>Stage D<ul> <li>Marked symptoms at rest</li> <li>Treatment<ul> <li>As above + ICD, heart transplant</li> </ul> </li> </ul> </li> </ul> </li> </ul>","tags":["Heart Failure"]},{"location":"im-guide/cards/heart-failure/basics-hf/#symptoms","title":"Symptoms","text":"<ul> <li>Fatigue and SOB</li> <li>Progressive Dyspnea with Exercise<ul> <li>Origin: Most important mechanism is pulmonary congestion with accumulation of interstitial or intra-alveolar fluid<ul> <li>Stimulate the rapid, shallow breathing characteristic of cardiac dyspnea</li> <li>Pulmonary compliance reduction, Increased airway resistance, Anemia</li> <li>Less frequent with onset of RV failure and TR</li> </ul> </li> <li>JVD, Paroxysmal Nocturnal Dyspnea, peripheral edema, S3, orthopnea</li> <li>Cough if present is productive</li> </ul> </li> </ul>","tags":["Heart Failure"]},{"location":"im-guide/cards/heart-failure/basics-hf/#diagnosis-clinical","title":"Diagnosis: Clinical","text":"<ul> <li>Best Test: Get Echocardiogram (Transthoracic Echocardiogram)<ul> <li>To distinguish between Systolic and Diastolic HF</li> </ul> </li> <li>Cardiomegaly on CXR</li> <li>Labs: CXR, EKG, CBC w/Diff, UA, UM, Electrolytes + Calcium and magnesium<ul> <li>BUN/Cr, Glucose, Lipids, LFTs, TSH, BNP or NT-proBNP</li> <li>Troponin-I</li> </ul> </li> </ul>","tags":["Heart Failure"]},{"location":"im-guide/cards/heart-failure/basics-hf/#prognosis","title":"Prognosis","text":"<ul> <li>On GDMT of ARNI/BB/MRA/SGLT2i<ul> <li>Estimated 7.9, actual 4.9 years gained for a 50 y/o with HFrEF</li> <li>Estimated 5.0, actual 3.3 years gained for a 70 y/o with HFrEF</li> </ul> </li> </ul>","tags":["Heart Failure"]},{"location":"im-guide/cards/heart-failure/chronic-hf/","title":"Chronic Heart Failure","text":"","tags":["Heart Failure","GDMT"]},{"location":"im-guide/cards/heart-failure/chronic-hf/#basics","title":"Basics","text":"<ul> <li>2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure</li> <li>PowerPoint: CHF GDTM 2023</li> </ul>","tags":["Heart Failure","GDMT"]},{"location":"im-guide/cards/heart-failure/chronic-hf/#general","title":"General","text":"<ul> <li>Chronic Heart Failure can be classified multiple ways, most commonly by Ejection Fraction<ul> <li>Heart Failure with Preserved Ejection Fraction (HFpEF)<ul> <li>HFpEF is the most common cause of Chronic Heart Failure<ul> <li>50% of patients hospitalized with CHF<ul> <li>Exertional dyspnea, orthopnea, lower extremity edema, but normal or near normal LVEF with objective evidence of diastolic dysfunction (abnormal LV filling pressures) by echo</li> </ul> </li> </ul> </li> <li>LV diastolic dysfunction due to impaired relaxation w/EF &gt;50%</li> <li>Impaired Diastolic Filling, Decreased compliance<ul> <li>The pathophysiology of heart failure with preserved ejection fraction</li> </ul> </li> <li>Decrease in SV and Increase in EDP</li> <li>Significantly Increased LVEDP associated with Decrease in LVEDV<ul> <li>Increased afterload, increased LV thickness, decreased LV size, decreased Compliance \u2013 Decrease in Ventricular distensibility that impairs ventricular filling during diastole (EF \u226550)</li> <li>Decreased LV Compliance, Decreased Lusitropy</li> </ul> </li> <li>Normal CO w/ increased LVEDV/RVEDP, tachycardia, S4<ul> <li>Increased venous hydrostatic pressure</li> <li>Recurrent pulmonary flash edema</li> <li>2/2 hypertensive cardiac remodeling (LVH) with left atrial dilation, orthopnea, and elevated BNP<ul> <li>Mcly due to myocardial hypertrophy</li> <li>RF: Chronic hypertension (concentric LVH), Obesity &amp; sedentary lifestyle (myocardial interstitial fibrosis), CAD &amp; related RF (T2DM)</li> </ul> </li> </ul> </li> <li>Commonly due to<ul> <li>Pericardial Tamponade, Constrictive Pericarditis, Restrictive or Hypertrophic Cardiomyopathies</li> </ul> </li> <li>1) Hypertension w/Left Ventricular Hypertrophy (90%)<ul> <li>Chronic Hypertension (Concentric LV Hypertrophy)</li> <li>Primary (HCM), Secondary (Hypertension), Age, Fibrosis</li> <li>LVH shows Severe dip in V1 and rise in V6</li> </ul> </li> <li>2) Restrictive Cardiomyopathy (&lt;9%)<ul> <li>Amyloid/Sarcoid, Hemochromatosis</li> <li>Obesity/Sedentary lifestyle (myocardial interstitial fibrosis)</li> <li>Preserved systolic dysfunction, bi-atrial dilation, pulmonary hypertension in a pt with refractory HF</li> <li>Kussmaul\u2019s sign<ul> <li>Lack of typical inspiratory decline in CVP</li> <li>Associated with an S3</li> </ul> </li> </ul> </li> <li>Treatment<ul> <li>Eval for Transplant w/Advanced HF specialist</li> </ul> </li> </ul> </li> <li>Heart Failure with Reduced Ejection Fraction (HFrEF)<ul> <li>1) Ischemic Heart Disease/Cardiomyopathy (Impaired Contractility)<ul> <li>IHD/CAD = 60-75% of HF cases in developing world<ul> <li>Decreased cardiac output due to impaired contractility</li> <li>A compensatory rise in NE, Renin, and ADH</li> <li>Increases SVR</li> </ul> </li> <li>Coronary Artery Disease (CAD)</li> <li>Chronic Volume Overload (MR, AR, Shunting)</li> <li>Chronic Lung Disease (Cor pulmonale, Pulmonary vascular disorders)</li> </ul> </li> <li>2) Dilated Cardiomyopathies (Impaired Contractility)<ul> <li>30%, Defect in force generation, transmission, myocyte signaling<ul> <li>Genetic (20-50%) (Cytoskeleton mutation)</li> <li>Non-Genetic (Myocarditis, Peri-partum, Toxic (alcohol), Idiopathic)</li> <li>Infiltrative Disorders</li> </ul> </li> </ul> </li> <li>3) Valvular Heart Disease<ul> <li>15%</li> <li>Toxic/drug-induced damage (Metabolic disorder, Viral)</li> <li>Chagas disease</li> <li>Rate and Rhythm disorders (Chronic Arrythmias)</li> </ul> </li> <li>4) Hypertension<ul> <li>10%</li> </ul> </li> <li>80% die from Cardiovascular Causes (MC Cause of death)<ul> <li>Worsening HF (Cardiogenic Shock, Low Output State)</li> <li>40% Sudden Cardiac Death (VTach (most common), Bradyarrhythmia)</li> </ul> </li> <li>Hypertension contributes to 75% of patients, also DM</li> <li>Valvular heart disease also contributes (EtOH, Hypertension, Drugs)<ul> <li>Systolic Heart Failure (Contractile Failure)</li> </ul> </li> <li>Compliance (C) = EDV/EDP<ul> <li>EDV not easily measured, thus use EF = SV/EDV measured via TTE</li> </ul> </li> <li>Characterized by decreased CO/CI, increased SVR, and increased LVEDV</li> <li>Decreased CO (insufficient ventricular contractility, EF will be low)</li> <li>Decrease in SV and Increase in EDP<ul> <li>Decreased CO, increases A-a O2 and decreases renal perfusion</li> </ul> </li> <li>Increased EDP associated with Increase in EDV<ul> <li>Decreased Compliance (EF \u226440%), Increased HR</li> </ul> </li> </ul> </li> <li>Heart Failure with Improved Ejection Fraction (HFimpEF)</li> </ul> </li> </ul>","tags":["Heart Failure","GDMT"]},{"location":"im-guide/cards/heart-failure/chronic-hf/#diagnosis","title":"Diagnosis","text":"<ul> <li>A Simple, Evidence-Based Approach to Help Guide Diagnosis of Heart Failure With Preserved Ejection Fraction</li> <li>H2pEF risk score<ul> <li>Assesses likelihood of HFpEF and is used to discriminate cardiac vs. non-cardiac causes of dyspnea</li> <li>Obesity (2 points), Afib (3 points), age &gt;60 (1 point), 2 Antihypertensives (1 point), Echo E/e\u2019 ratio &gt;9 (1 point) and Echo PAS pressure &gt;35 (1 point)</li> </ul> </li> <li>Echo<ul> <li>Normal LV cavity size, increased LV wall thickness, LAE, abnormal diastolic function, elevated PAS pressure &gt;35</li> </ul> </li> <li>BNP may be normal in obese or only exertional symptoms</li> </ul>","tags":["Heart Failure","GDMT"]},{"location":"im-guide/cards/heart-failure/chronic-hf/#prognosis","title":"Prognosis","text":"<ul> <li>HFpEF<ul> <li>Cause of Death (broader than HFrEF):<ul> <li>Cardiovascular<ul> <li>Worsening HF (RHF, Restrictive cardiomyopathy)</li> <li>Sudden Death (Non-arrhythmic, Tachycardia, Bradycardia)</li> <li>Myocardial Infarction</li> <li>Vascular (Aortic Aneurysm, PE)</li> <li>Cerebrovascular (Intracranial hemorrhage, Stroke)</li> </ul> </li> <li>Non-Cardiovascular<ul> <li>Renal (ESRD, renal venous congestion)</li> <li>Resp (Failure, pulmonary hypertension, COPD)</li> <li>Infection/sepsis</li> </ul> </li> <li>Multisystem (Organ failure)</li> </ul> </li> <li>Mortality<ul> <li>Due to progressive HF and arrhythmias<ul> <li>5-year rate of 36%</li> <li>10-year rate of 63%</li> </ul> </li> </ul> </li> </ul> </li> <li>HFrEF<ul> <li>30-40% die within 1 year of diagnosis and 60-70% die within 5 years<ul> <li>On GDMT of ARNI/BB/MRA/SGLT2i<ul> <li>Estimated 7.9, actual 4.9 years gained for a 50 y/o with HFrEF</li> <li>Estimated 5.0, actual 3.3 years gained for a 70 y/o with HFrEF</li> </ul> </li> </ul> </li> </ul> </li> <li>Poor Prognostic Factors for HFrEF<ul> <li>Higher NYHA functional Class</li> <li>Exam<ul> <li>Resting Tachycardia</li> <li>Presence of an S3 gallop</li> <li>Elevated JVP</li> <li>Hypotension: BP &lt;100/60</li> </ul> </li> <li>Labs:<ul> <li>Hyponatremia</li> <li>Elevated pro-BNP levels, high NE and catecholamines, elevated troponins</li> <li>Renal insufficiency</li> <li>Low maximal oxygen consumption (peak VO2)</li> </ul> </li> <li>ECG: QRS &gt;120ms, LBBB pattern</li> <li>Echocardiography<ul> <li>Moderate to severe mitral regurgitation</li> <li>Severe LV dysfunction</li> <li>Concomitant diastolic dysfunction</li> <li>Reduced RV function</li> <li>Pulmonary Hypertension</li> </ul> </li> <li>Other:<ul> <li>Anemia</li> <li>Atrial Fibrillation</li> <li>Diabetes Mellitus</li> </ul> </li> </ul> </li> </ul>","tags":["Heart Failure","GDMT"]},{"location":"im-guide/cards/heart-failure/chronic-hf/#hfpef-management","title":"HFpEF Management","text":"<ul> <li>Diuresis<ul> <li>Caution in diastolic HF w/diuretics</li> </ul> </li> <li>Afterload reduction as needed<ul> <li>Reduce hospitalization<ul> <li>MRAs and SGLT-2s</li> </ul> </li> <li>ACEI/ARB = no mortality benefit</li> </ul> </li> <li>BP control</li> <li>Treat exacerbating conditions (CAD, OSA, Afib)</li> <li>Exercise training/cardiac rehabilitation<ul> <li>Improves functional capacity and overall quality of life</li> </ul> </li> </ul>","tags":["Heart Failure","GDMT"]},{"location":"im-guide/cards/heart-failure/chronic-hf/#treatment-to-improve-long-term-survival-in-hfref","title":"Treatment to improve long-term survival in HFrEF","text":"<ul> <li>Chronic Stable HF Optimization<ul> <li>Initial Optimized Therapy<ul> <li>ARNI/ARB/ACEI<ul> <li>NHYA I-IV with LVEF \u226440%<ul> <li>ACEI in Asymptomatic LV dysfunction<ul> <li>Slows disease progress and improves mortality</li> </ul> </li> </ul> </li> <li>Either Entresto OR ACEI/ARBs<ul> <li>PARADIGM-HF: Entresto reduced CV risk and Hospitalizations vs. ACEI</li> </ul> </li> </ul> </li> <li>Beta-Blockers (3 specific ones)<ul> <li>NHYA I-IV with LVEF \u226440%</li> <li>REVERT: BBs Reverse LV remodeling in asymptomatic LV systolic dysfunction<ul> <li>Metoprolol Succinate, Carvedilol, Bisoprolol</li> <li>Reduces hospitalization and improves mortality<ul> <li>Strongest evidence in history of MI</li> </ul> </li> </ul> </li> </ul> </li> </ul> </li> <li>Step 2 of Optimized Therapy<ul> <li>Aldosterone antagonist</li> <li>NYHA II-IV with LVEF \u226435%</li> <li>RALES: Spironolactone reduces morbidity/mortality in severe HFrEF<ul> <li>35% decrease in hospitalizations</li> <li>30% reduction in the risk of death</li> <li>Significant symptom improvement</li> <li>Gynecomastia or mastalgia in 10%</li> </ul> </li> <li>Eplerenone in patients with HF and mild symptoms<ul> <li>Eplerenone doesn\u2019t cause gynecomastia</li> </ul> </li> </ul> </li> <li>Step 3 of Optimized Therapy<ul> <li>SGLT-2 Inhibitors<ul> <li>NYHA II-IV</li> <li>SGLT2 better than Sitagliptin (Primary outcome: 13.1% vs. 17.4)<ul> <li>Reduces symptoms and improves mortality</li> </ul> </li> </ul> </li> </ul> </li> <li>Supplementary Agents<ul> <li>Diuretics<ul> <li>NYHA II-IV with Volume Overload</li> <li>Improves symptoms and reduces hospitalization</li> <li>Does not improve mortality</li> <li>Diuretic Therapy for HF (JACC State-of-the-Art Review)<ul> <li>JACC Diuretic Therapy</li> </ul> </li> <li>Optimal Diuretic Strategies in HF</li> </ul> </li> <li>Isosorbide Dinitrate + Hydralazine (Bidil)<ul> <li>Additional therapy if asymptomatic or RAS Blocker Intolerance<ul> <li>Also, in worsening systolic CHF, reduce mortality in AA</li> <li>Improves symptoms and may improve mortality</li> </ul> </li> </ul> </li> <li>Digoxin<ul> <li>Persistent symptoms despite other therapy</li> <li>Reduces hospitalizations, no mortality benefit (0.5-0.8)</li> </ul> </li> </ul> </li> <li>Avoid CCBs<ul> <li>Add Amlodipine/felodipine if high BP (no mortality improvement)</li> </ul> </li> <li>No anticoagulation unless AFib or prior VTE<ul> <li>40% complicated by Afib<ul> <li>Aggressive rhythm control</li> <li>Catheter ablation of AF (improves morbidity and mortality)</li> </ul> </li> </ul> </li> <li>Persistent Severe HF symptoms on maximal GDMT<ul> <li>Symptomatic improvement in patients treated with intermittent infusion of inotropes: a double-blind placebo controlled study</li> </ul> </li> <li>Heart Transplant Evaluation<ul> <li>1 year survival is near 90%, 12 year median survival</li> <li>Generally 65-70 w/o T2DM w/End organ damage, Cancer in the past 5 years, GFR &gt;30, No other survival decreasing illnesses, good social support and adherence</li> </ul> </li> <li>LVAD (Left Ventricular Assist Device)<ul> <li>EF &lt;25% and NYHA IV symptoms on maximal therapy with either 1-2 year predicted mortality or inotrope dependency who still want aggressive restorative care</li> </ul> </li> </ul> </li> </ul>","tags":["Heart Failure","GDMT"]},{"location":"im-guide/cards/heart-failure/chronic-hf/#other-management","title":"Other Management","text":"<ul> <li>FAIR-HF: Anemia (ferritin &lt;100, or 100-300 w/Tsat &lt;20%) + HFrEF (EF \u226445%) improved 6m walk, QOL and NYHA functional Class</li> <li>Exercise training/cardiac rehabilitation<ul> <li>Improves functional capacity and overall quality of life</li> <li>QOL</li> </ul> </li> </ul>","tags":["Heart Failure","GDMT"]},{"location":"im-guide/cards/nicm/dcm/","title":"Dilated Cardiomyopathy","text":""},{"location":"im-guide/cards/nicm/dcm/#general","title":"General","text":"<ul> <li>Dilated Ventricles with normal wall thickness, depressed myocardial contractility<ul> <li>Absence of hypertension or valvular disease</li> <li>AA ~3x more likely to develop</li> </ul> </li> <li>Left ventricular dysfunction causes progressive HF<ul> <li>Arrhythmias, conduction abnormalities, thromboembolism, SCD</li> <li>Symptomatic HF + DCM: 50% 5-year mortality</li> </ul> </li> <li>Diagnosis: Echocardiography<ul> <li>Eccentric LV hypertrophy</li> <li>Dilated ventricles with diffuse hypokinesia, low EF, CHF</li> </ul> </li> </ul>"},{"location":"im-guide/cards/nicm/dcm/#a-idiopathic-mc","title":"A) Idiopathic (MC)","text":"<ul> <li>Viral Myocarditis (Infectious):<ul> <li>Coxsackie B</li> <li>Chagas</li> <li>HIV</li> </ul> </li> </ul>"},{"location":"im-guide/cards/nicm/dcm/#b-familial","title":"B) Familial","text":""},{"location":"im-guide/cards/nicm/dcm/#c-metabolic","title":"C) Metabolic","text":"<ul> <li>Thiamine Deficiency, Obesity, DM, hyperthyroidism</li> </ul>"},{"location":"im-guide/cards/nicm/dcm/#d-alcoholic-cardiomyopathy-toxic","title":"D) Alcoholic Cardiomyopathy (Toxic)","text":"<ul> <li>CHF w/heavy alcohol consumption, macrocytic anemia, no CAD<ul> <li>History (&gt;5-10) years of excessive (&gt;7 drinks/day) of consumption</li> </ul> </li> <li>Treatment: Alcohol abstinence</li> </ul>"},{"location":"im-guide/cards/nicm/dcm/#f-hemochromatosis-dilated-restrictive-can-be-reversed-with-phlebotomy","title":"F) Hemochromatosis (Dilated &gt; Restrictive): Can be reversed with phlebotomy","text":"<ul> <li>Late hemochromatosis</li> </ul>"},{"location":"im-guide/cards/nicm/dcm/#g-other","title":"G) Other","text":"<ul> <li>Acromegaly, Cocaine</li> <li>Cancer chemo (doxorubicin, daunorubicin) - Anthracyclines</li> <li>Ephedra, Cobalt, Anabolic steroids, Chloroquine, Clozapine, Amphetamines, Methylphenidate, Catecholamines, Tachycardia, Organic Solvents (glue sniffer\u2019s heart)</li> </ul>"},{"location":"im-guide/cards/nicm/hcm/","title":"Hypertrophic Cardiomyopathy","text":""},{"location":"im-guide/cards/nicm/hcm/#general","title":"General","text":"<ul> <li>Also called Hypertrophic Obstructive Cardiomyopathy (HOCM)</li> <li>HCM is preferred as some patients with HCM have no obstruction</li> <li>Asymmetric hypertrophy of the left ventricle as compared to the rest of the heart and includes notable thickening of the Interventricular septum<ul> <li>Disordered myocytes, small vessel disease, replacement scarring, interstitial fibrosis<ul> <li>Definition: LV wall thickness \u226515mm at any location in the absence of other potential causes (HTN/VHD)</li> </ul> </li> </ul> </li> <li>100% genetic Causes (Autosomal Dominant)<ul> <li>Variable expressivity/penetrance</li> <li>Sarcomere Protein Gene Mutation (MC)<ul> <li>Defect in energy transfer from mitochondria to sarcomere and or direct dysfunction<ul> <li>Reduced SV due to impaired diastolic filling</li> </ul> </li> <li>B-myosin heavy chain MC &gt; myosin binding protein C</li> </ul> </li> <li>Hypercontraction heart<ul> <li>Massive Myocardial hypertrophy w/o dilatation<ul> <li>Myofiber disarray</li> </ul> </li> <li>Disproportionate thickening of the ventricular septum &gt; left ventricular free wall<ul> <li>Most prominent subaortic region</li> </ul> </li> <li>Abnormality: Systolic anterior motion of mitral valve, moves toward IV septum</li> </ul> </li> </ul> </li> </ul>"},{"location":"im-guide/cards/nicm/hcm/#symptoms","title":"Symptoms","text":"<ul> <li>May be asymptomatic or patient may have family with heart attack<ul> <li>Young athlete with a murmur, signs or symptoms or heart disease</li> <li>MCC of SCD &lt;35 (36%)</li> </ul> </li> <li>HF, fatigue, chest pain, palpitations, syncope, asymptomatic</li> <li>Occasional lightheadedness and vague chest discomfort when playing sports or with strenuous activity (Systolic Ejection murmur exacerbated by dehydration/impaired LV filling)</li> </ul>"},{"location":"im-guide/cards/nicm/hcm/#murmur","title":"Murmur","text":"<ul> <li>Mitral Regurgitation</li> <li>LVOT Obstruction<ul> <li>Left sternal border without carotid radiation</li> <li>Harsh systolic Crescendo/decrescendo ejection murmur<ul> <li>Worse with dehydration/impaired LV filling</li> <li>Hypertrophy causes a 4<sup>th</sup> heart sound</li> <li>Progression to HF causes a 3<sup>rd</sup> heart sound</li> </ul> </li> <li>Louder with Valsalva (decreased preload), Softer with squatting/hand grip (increased preload)</li> <li>Carotid pulse with brisk upstroke (bifid in \u2154)</li> </ul> </li> </ul>"},{"location":"im-guide/cards/nicm/hcm/#diagnosis","title":"Diagnosis","text":"<ul> <li>Confirmation: Transthoracic Echocardiography<ul> <li>2011 ACCF/AHA guidelines for diagnosis</li> </ul> </li> <li>ECG: LVH + depolarization/repolarization abnormalities<ul> <li>Abnormal in &gt;90%</li> <li>Prominent Q waves<ul> <li>Inferior and lateral indicating septal depolarization</li> </ul> </li> <li>T-wave inversions</li> </ul> </li> <li>TTE: LVH, increased LVOT gradient, SAM of mitral valve<ul> <li>Focal septal hypertrophy present</li> <li>LV diastolic function impaired</li> <li>LV cavity size decreased</li> <li>Enlarged LA</li> </ul> </li> <li>Exercise testing and family screening</li> </ul>"},{"location":"im-guide/cards/nicm/hcm/#complications","title":"Complications","text":"<ul> <li>Afib<ul> <li>20-25% develop afib</li> <li>Increased stroke risk</li> <li>Need to be treated with warfarin (CHADSVASC is not useful here)<ul> <li>Only one studied</li> </ul> </li> </ul> </li> <li>SCD<ul> <li>1% per year</li> <li>RF for SCD:<ul> <li>FH of SCD in 1<sup>st</sup> degree relative</li> <li>History of Cardiac Arrest (or sustained spontaneous VT)</li> <li>Personal history of syncope suspected to be arrhythmic in nature</li> <li>Non-sustained VT on Holter</li> <li>Failure to augment SBP on ETT (&lt;10 increase at peak exercise)</li> <li>Septal thickness \u226530mm in any segment</li> <li>EF &lt;50%</li> </ul> </li> <li>Risk stratification</li> </ul> </li> <li>Heart Failure</li> </ul>"},{"location":"im-guide/cards/nicm/hcm/#prognosis","title":"Prognosis","text":"<ul> <li>Most have normal life expectancy, no symptoms</li> </ul>"},{"location":"im-guide/cards/nicm/hcm/#management","title":"Management","text":"<ul> <li>Should not participate in high-intensity competitive sports regardless of symptoms, LVOT, or prior treatment</li> <li>Symptomatic<ul> <li>1) Non-vasodilating Beta-Blockers, ensure adequate hydration if symptomatic<ul> <li>Not Carvedilol, Labetalol</li> <li>Metoprolol should be ok</li> <li>BBs only in patients with symptoms</li> <li>Prolong diastole and decrease contractility, decreasing LVOT<ul> <li>Can be used in obstructive and non-obstructive</li> </ul> </li> <li>IV phenylephrine if acute hypotension and no fluid response</li> </ul> </li> <li>2) CCBs additionally in pts with persistent symptoms<ul> <li>Verapamil, Obstructive only</li> <li>Avoid Amlodipine/ACEI, Diuretics</li> </ul> </li> <li>3) Add Disopyramide</li> </ul> </li> <li>ICD placement<ul> <li>Wall thickness &gt;30mm</li> <li>HCM + Arrest or sustained VT (Class I recommendation)</li> <li>Syncope</li> <li>Blunted BP or hypotension during exercise</li> <li>RF above you can offer (Class IIa recommendation)</li> <li>Indicated for primary and secondary prevention of SCD in patients with \u22651 major high-risk features</li> </ul> </li> <li>Septal reduction therapy (SRT)<ul> <li>Septal myectomy or Alcohol septal ablation</li> <li>Peak LV outflow (resting or Valsalva gradient) of \u226550 mmHg and drug refractory HF/Symptoms</li> <li>Surgery if persistent/ascending aorta (septal myectomy if HF III/IV, transcatheter ethanol injection to reduce LVOT symptoms)</li> </ul> </li> </ul>"},{"location":"im-guide/cards/nicm/other/","title":"Other Cardiomyopathy","text":""},{"location":"im-guide/cards/nicm/other/#general","title":"General","text":"<ul> <li>33% improve, 33% remain the same, 33% LV function deteriorates</li> </ul>"},{"location":"im-guide/cards/nicm/other/#myocardial-infarction-with-nonobstructive-coronary-arteries-minoca","title":"Myocardial Infarction with Nonobstructive Coronary Arteries (MINOCA)","text":"<ul> <li>Defined as acute myocardial infarction (MI) with angiographically no obstructive coronary artery disease or stenosis\u2009\u2264\u200950%</li> <li>CMR: Edema in coronary regional distribution pattern<ul> <li>Late gadolinium enhancement</li> </ul> </li> </ul>"},{"location":"im-guide/cards/nicm/other/#takotsubo-cardiomyopathy-tts","title":"Takotsubo Cardiomyopathy (TTS)","text":"<ul> <li>Takotsubo cardiomyopathy: state-of-the-art review</li> <li>Update of Takotsubo cardiomyopathy: Present experience and outlook for the future</li> <li>Etiology<ul> <li>Primary<ul> <li>Idiopathic</li> <li>Psych Stress</li> </ul> </li> <li>Secondary<ul> <li>Physical Stress<ul> <li>Asthma, Surgery, Severe Trauma</li> </ul> </li> <li>Drug-Induced<ul> <li>Catecholamine Stimulation (68.2% of drug-induced TTS cases)<ul> <li>Antiarrhythmics (Flecainide, Sotalol, Amiodarone, Lidocaine, Xylocaine)</li> </ul> </li> <li>Antidepressants</li> <li>Chemotherapy (8.9%)</li> </ul> </li> </ul> </li> </ul> </li> <li>Symptoms<ul> <li>Chest pain, sudden onset</li> </ul> </li> <li>Labs<ul> <li>Troponin elevation mimicking acute MI</li> <li>Check CRP/ESR</li> <li>Check TSH/BNP</li> <li>Consider r/o pheochromocytoma</li> </ul> </li> <li>Diagnosis<ul> <li>ECG showing ST elevations</li> <li>TTE: Apical ballooning with akinesis</li> <li>LHC: Normal coronaries, needed to r/o CAD</li> <li>CMR if no culprit lesion (gold-standard for determining myocardial status)<ul> <li>LV dysfunction in a noncoronary regional distribution pattern w/ + w/o RV involvement</li> <li>Edema in NCRDP</li> <li>Abscence of significant necrosis or fibrosis</li> <li>Lack of any late gadolinium enhancement</li> </ul> </li> <li>InterTAK Diagnostic Score<ul> <li> <p>70 is high probability</p> </li> </ul> </li> <li>Recovery of wMA on CMR within 2-6 months<ul> <li>Confirms Diagnosis</li> </ul> </li> </ul> </li> <li>Treatment<ul> <li>ACEI + BBs</li> </ul> </li> </ul>"},{"location":"im-guide/cards/nicm/other/#peripartum-cardiomyopathy-ppcm","title":"Peripartum Cardiomyopathy (PPCM)","text":"<ul> <li>RF: &gt;30 y/o, Multiparity, AA, Multiple fetuses, Maternal cocaine use, Terbutaline (beta-agonist) use &gt;4 weeks</li> <li>Uncommon cause of Dilated Cardiomyopathy</li> <li>Occurs anytime from week 26 through first 6 months postpartum</li> <li>Progressive dyspnea on exertion, lower extremity edema, 3<sup>rd</sup> heart sound is suggestive of decompensated HF</li> <li>Often associated with mitral regurgitation (holosystolic murmur)</li> <li>Cardiomegaly, prominent vascular congestion, pleural effusions</li> <li>Symptoms<ul> <li>Heart failure, Dyspnea, cough, orthopnea, and peripheral edema</li> <li>Onset of HF during last month of pregnancy or within 5 months following delivery (not seen before 36 weeks)</li> <li>LV systolic dysfunction with LV ejection fraction &lt;45%</li> <li>Absence of causes of heart failure</li> <li>Absence of heart disease prior to final month of pregnancy</li> </ul> </li> <li>Diagnosis: TTE</li> <li>Prognosis<ul> <li>LVEF &gt;30% at time of diagnosis is major predictor of persistent LV dysfunction</li> </ul> </li> <li>Treatment<ul> <li>Same as HF unless Advanced HF or Unstable (delivery)<ul> <li>Not ACEI/ARBs</li> <li>Loops &gt; thiazides (fetal bleeding diathesis)</li> <li>B1 selective</li> <li>Avoid Digoxin</li> </ul> </li> </ul> </li> </ul>"},{"location":"im-guide/cards/nicm/other/#tachycardia-induced-cardiomyopathy","title":"Tachycardia-Induced Cardiomyopathy","text":"<ul> <li>Commonly due to Afib caused by structural changes in the heart<ul> <li>May also be due to atrial flutter, MAT, reentrant SVT, VT, and rarely frequent PVCs -Afib induced LV dysfunction</li> </ul> </li> <li>Cardiomyopathy due to LV dilatation and dysfunction</li> <li>Symptoms<ul> <li>Palpitations</li> <li>Progressive dyspnea, exercise intolerance, fatigue</li> </ul> </li> <li>Exam<ul> <li>HR \u2265120 for weeks/months</li> <li>Can lead to myocardial cellular changes, LV dilation, impaired LV function</li> </ul> </li> <li>Diagnosis: ECG or Ambulatory Holter</li> <li>W/U: TTE, testing to R/O MI</li> <li>Complications<ul> <li>Decompensated Heart Failure</li> </ul> </li> <li>Treatment<ul> <li>Rate or rhythm control<ul> <li>Typically results in significant or complete LV function recovery over a period of months</li> </ul> </li> </ul> </li> </ul>"},{"location":"im-guide/cards/nicm/rcm/","title":"Restrictive Cardiomyopathy","text":""},{"location":"im-guide/cards/nicm/rcm/#general","title":"General","text":"<ul> <li>Aka Restrictive Pericarditis<ul> <li>Must differentiate from Constrictive Pericarditis (which is reversible)</li> </ul> </li> <li>Infiltrative Cardiomyopathies</li> <li>Irreversible, myocardial problem<ul> <li>CHF w/LVH and normal ventricular chamber dimensions that may progress to dilated cardiomyopathy or may be thickened with granularity</li> </ul> </li> <li>Exam<ul> <li>Usually has pulmonary congestion</li> <li>S3</li> <li>Pericardial thickness &lt;2mm</li> </ul> </li> <li>Labs<ul> <li>BNP markedly elevated (BNP normal to slightly elevated in Constrictive Pericarditis)<ul> <li> <p>600 typically</p> </li> </ul> </li> </ul> </li> <li>Diagnostics<ul> <li>EKG may be normal or low voltage</li> <li>Atrial Fib early</li> <li>PA systolic pressure &gt;60</li> </ul> </li> <li>Treatment<ul> <li>Diuretics</li> <li>Thoracotomy with Pericardiectomy</li> </ul> </li> </ul>"},{"location":"im-guide/cards/nicm/rcm/#1-amyloidosis","title":"1) Amyloidosis","text":""},{"location":"im-guide/cards/nicm/rcm/#types","title":"Types","text":"<ul> <li>AL (Immunoglobulin Light-chain) Amyloidosis</li> <li>ATTR (Transthyretin Amyloid) Amyloidosis<ul> <li>More common in men</li> <li>Abnormal 99m-technetium pyrophosphate scan can be used to avoid biopsy to distinguish</li> </ul> </li> </ul>"},{"location":"im-guide/cards/nicm/rcm/#features","title":"Features","text":"<ul> <li>Cardiac<ul> <li>Restrictive cardiomyopathy<ul> <li>Concentric ventricle thickening with diffuse fibril deposits</li> <li>Cardiac amyloidosis: a practical approach to diagnosis and management</li> </ul> </li> <li>Conduction defects, low voltage</li> <li>Orthostatic hypotension</li> </ul> </li> <li>Renal<ul> <li>Nephrotic syndrome</li> <li>Peripheral edema</li> </ul> </li> <li>CNS<ul> <li>Peripheral and/or autonomic neuropathy</li> <li>Stroke</li> </ul> </li> <li>GI<ul> <li>Hepatomegaly</li> <li>Dysmotility, malabsorption</li> <li>GI bleeding</li> </ul> </li> <li>Pulm<ul> <li>Pulmonary nodules, tracheobronchial infiltration, pleural effusions</li> </ul> </li> <li>MSK<ul> <li>Enlarged tongue, shoulder pad enlargement</li> </ul> </li> <li>Skin<ul> <li>Thickening of skin, subcutaneous nodules/plaques</li> <li>Ecchymoses, periorbital purpura</li> </ul> </li> <li>Heme<ul> <li>Anemia</li> <li>Thrombocytopenia</li> </ul> </li> </ul>"},{"location":"im-guide/cards/nicm/rcm/#al-cardiomyopathy","title":"AL Cardiomyopathy","text":""},{"location":"im-guide/cards/nicm/rcm/#complications","title":"Complications","text":"<ul> <li>VT/VF<ul> <li>Much more common than in ATTR-CM</li> </ul> </li> </ul>"},{"location":"im-guide/cards/nicm/rcm/#transthyretin-amyloid-cardiomyopathy-attr-cm","title":"Transthyretin Amyloid Cardiomyopathy (ATTR-CM)","text":""},{"location":"im-guide/cards/nicm/rcm/#etiology","title":"Etiology","text":"<ul> <li>5000-7000 cases annually, male predominance, hATTR is AD<ul> <li>100 different mutations</li> <li>Mc in USA is Val122Ile (3-4% of AA, 1.5m carriers)</li> <li>Mc globally is Val30Met</li> </ul> </li> <li>Transthyretin amyloid cardiomyopathy is a rare but severe cause of restrictive cardiomyopathy, caused by the accumulation of transthyretin fibrils in the myocardium<ul> <li>Synthesized in the liver into 4 Beta-sheet-rich monomers that normally act as a carrier proteins for retinol and thyroxine</li> <li>Misfolded transthyretin aggregates and preferentially deposits in the Myocardium and Peripheral nerves</li> <li>Chromosome 18 carries the TTR protein gene<ul> <li>Mutations in gene coding can cause structural changes in TTR causing misfolding<ul> <li>Aka hATTR or hereditary ATTR</li> </ul> </li> <li>Misfolding due to normal aging is called wATTR or wild-type ATTR (more common)</li> </ul> </li> </ul> </li> </ul>"},{"location":"im-guide/cards/nicm/rcm/#symptoms","title":"Symptoms","text":"<ul> <li>CHF (fatigue/poor exercise tolerance/SOB)</li> <li>Arrhythmia</li> </ul>"},{"location":"im-guide/cards/nicm/rcm/#labs","title":"Labs","text":"<ul> <li>40-50% of ATTR have unrelated Monoclonal Gammopathy</li> </ul>"},{"location":"im-guide/cards/nicm/rcm/#diagnosis","title":"Diagnosis","text":"<ul> <li>Gold Standard: Endomyocardial biopsy with congo red staining<ul> <li>SN/SP 100% if \u22654 sites sampled</li> </ul> </li> <li>PYP and CMR</li> <li>EKG: Low voltage with poor R wave progression in precordial leads<ul> <li>25-40% of ATTR-CM patients</li> <li>Different than normal LVH people who have large waves*</li> <li>Pseudo-infarct pattern also reported</li> <li>High voltage QRS pattern in Val122Ile possible</li> <li>Abnormal mass/voltage ratio<ul> <li>Increased LV mass and low QRS voltage (&lt;5mm in limb leads, &lt;10mm in precordial leads)<ul> <li>Compare to strain pattern seen in LVH (increased QRS voltage), pericardial effusion (decreased QRS without LVH)</li> </ul> </li> </ul> </li> </ul> </li> <li>TTE: Bi-ventricular hypertrophy<ul> <li>Septal wall thickness of &gt;12mm makes it a consideration</li> <li>Increased echogenicity</li> <li>Small LV, Biatrial enlargement, thickened interatrial septum, thickened valves</li> <li>Diastolic dysfunction</li> </ul> </li> <li>Strain TTE: \u201cApical sparing\u201d with progressive worsening longitudinal strain when moving to midventricular and basal segment is characteristic<ul> <li>\u201cBulls-eye\u201d, \u201cCherry on top\u201d pattern</li> <li>Apical to basal strain ratio and apical to mid-ventricular plus basal strain<sup>1</sup></li> </ul> </li> <li>CMR:<ul> <li>With late gadolinium enhancement (CMR-LGE)<ul> <li>Diffuse late mid-myocardial gadolinium enhancement in a noncoronary distribution</li> </ul> </li> <li>The presence of diffuse transmural or subendocardial deposits can diagnose amyloidosis with a sensitivity and specificity of 85 to 90%</li> <li>Inability to \"null\" or suppress the myocardial signal on phase-sensitive inversion recovery (PSIR) imaging of LGE scan is also diagnostic</li> <li>It is seen that T1 signals are amplified in cardiac amyloidosis, similar to post-contrast extracellular volume fraction (ECV)</li> <li>CMR with parametric imaging can identify native (non-contrast) myocardial T1 signal and ECV</li> <li>Parametric imaging is believed to be a more sensitive and reliable measure of amyloid burden, and therefore can be used for treatment tracking</li> </ul> </li> <li>Nuclear Imaging is only diagnostic imaging technique<ul> <li>TC-PYP is 100% specific when Grade 2-3 present<ul> <li>No need for biopsy</li> <li>Myocardial uptake \u2265 Bone</li> </ul> </li> <li>Heart to contralateral chest uptake \u22651.5 = ATTR<ul> <li>\u22651.6 ratio have worse 5-year outcomes</li> </ul> </li> </ul> </li> <li>Genetic Testing after PYP or Biopsy<ul> <li>Differentiates hATTR from wATTR</li> </ul> </li> </ul>"},{"location":"im-guide/cards/nicm/rcm/#staging","title":"Staging","text":"<ul> <li>Mayo Clinic wATTR-CM System<ul> <li>Stage I: 66 months</li> <li>Stage II: 42 months</li> <li>Stage III: 20 months</li> </ul> </li> </ul>"},{"location":"im-guide/cards/nicm/rcm/#complications_1","title":"Complications","text":"<ul> <li>Cardiomyopathy/Diastolic Dysfunction/Heart Failure/LVH<ul> <li>TTR found in 20% of HF patients with myocardial wall thickening of more than 14mm</li> <li>More common in wATTR than hATTR</li> <li>Cardiorenal Syndrome typically ensues</li> <li>Often become BB and ACEI/ARB intolerant</li> </ul> </li> <li>Peripheral Neuropathy<ul> <li>More commonly seen in hATTR than wATTR</li> <li>Bilateral carpal tunnel syndrome<ul> <li>50% of wATTR</li> <li>Occurs 5-10 years before wATTR-CM</li> </ul> </li> <li>Lumbar stenosis<ul> <li>Spinal foraminal narrowing</li> </ul> </li> </ul> </li> <li>Spontaneous tendon ruptures are not uncommon<ul> <li>33% of wATTR-CM patients had spontaneous rupture of distal biceps tendon</li> </ul> </li> <li>Autonomic Dysfunction<ul> <li>Orthostatic hypotension</li> <li>Erectile Dysfunction</li> <li>Dyshidrosis</li> <li>GI motility issues</li> <li>More common in hATTR than wATTR<ul> <li>ACEI/ARB/BBs often poorly tolerated</li> </ul> </li> </ul> </li> <li>Arrhythmias<ul> <li>More common in wATTR than hATTR</li> <li>AFIB: 40-60% at time of diagnosis (usually persistent)<ul> <li>Often slow or controlled due to concomitant conduction disease<ul> <li>Leads to falls, syncope, falls</li> </ul> </li> </ul> </li> <li>Conduction Disease</li> <li>Ventricular Arrhythmias<ul> <li>Less common than in AL-CM</li> </ul> </li> <li>33% require pacemakers eventually</li> </ul> </li> <li>Thrombosis<ul> <li>Irregardless of Afib status</li> </ul> </li> </ul>"},{"location":"im-guide/cards/nicm/rcm/#prognosis","title":"Prognosis","text":"<ul> <li>hATTR-CM (2.5 years mean) worse than wATTR-CM (3.5 years mean)</li> <li>hATTR w/polyneuropathy w/o CM (8-10 years mean)</li> </ul>"},{"location":"im-guide/cards/nicm/rcm/#management","title":"Management","text":"<ul> <li>CHF: Loops (Bumetanide/Torsemide) for volume<ul> <li>Avoid Verapamil</li> <li>Midodrine + Compression stockings</li> </ul> </li> <li>Afib: Rhythm control to preserve atrial kick<ul> <li>Amiodarone preferred</li> <li>Lifelong AC regardless of CHADs-VASc</li> </ul> </li> <li>Patisiran (Onpattro)/Inotersen (Tegsedi)<ul> <li>Block synthesis of mutated TTR proteins by mRNA silencing</li> <li>Both approved for hATTR polyneuropathy w + w/o CM</li> </ul> </li> <li>Tafamidis (Vyndamax/Vyndaqul)<ul> <li>FDA approved for ATTR-CM</li> <li>1B per ESC</li> <li>Reduces all-cause mortality and CV hospitalization in CHF I/II but takes 2 years</li> <li>Stabilizes TTR tetramer to prevent tissue deposition</li> </ul> </li> <li>Diflusinal<ul> <li>Not FDA approved</li> <li>Stabilizes TTR tetramer to prevent tissue deposition<ul> <li>Doxycycline + Tauroursodeoxycholic Acid</li> </ul> </li> <li>Removes deposited amyloid fibrils</li> </ul> </li> <li>Liver Transplant<ul> <li>Can be used for hATTR not wATTR</li> </ul> </li> </ul>"},{"location":"im-guide/cards/nicm/rcm/#2-sarcoid-cardiomyopathy","title":"2) Sarcoid Cardiomyopathy","text":"<ul> <li>Diffuse Granulomatous involvement of the heart</li> <li>Sarcoidosis of the heart</li> </ul>"},{"location":"im-guide/cards/nicm/rcm/#3-hemochromatosis","title":"3) Hemochromatosis","text":""},{"location":"im-guide/cards/nicm/rcm/#4-lipid-storage-diseases","title":"4) Lipid Storage Diseases","text":"<ol> <li> <p>https://pubmed.ncbi.nlm.nih.gov/28298286/ \u21a9</p> </li> </ol>"},{"location":"im-guide/cards/vascular-disease/","title":"Vascular Disease","text":""},{"location":"im-guide/cards/vascular-disease/#resources","title":"Resources","text":"<ul> <li>TCAR</li> </ul>"},{"location":"im-guide/cards/vhd/","title":"Valvular Heart Disease","text":"<p>1.1. Aortic Stenosis (AS) 1.2. Mitral Regurgitation (MR)</p>"},{"location":"im-guide/cards/vhd/#valvular-heart-disease-vhd-guidelines","title":"Valvular Heart Disease (VHD) Guidelines","text":"<ul> <li>2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines<ul> <li>Summary</li> </ul> </li> <li>Valvular heart disease: the influence of changing etiology on nosology</li> </ul>"},{"location":"im-guide/cards/vhd/#grading","title":"Grading","text":"<ul> <li>Stage A: At Risk</li> <li>Stage B: Progressive</li> <li>Stage C: Asymptomatic Severe</li> <li>Stage D: Symptomatic Severe</li> </ul>"},{"location":"im-guide/cards/vhd/#evaluation","title":"Evaluation","text":"<ul> <li>Diastolic or Continuous<ul> <li>Echocardiogram</li> </ul> </li> <li>Systolic<ul> <li>Grad III or &gt;, holosystolic, late systolic<ul> <li>Echocardiogram</li> </ul> </li> <li>Grade I/II and midsystolic<ul> <li>Signs or symptoms of cardiac disease<ul> <li>Echocardiogram</li> </ul> </li> <li>Asymptomatic and no findings<ul> <li>Abnormal ECG or CXR<ul> <li>Echocardiogram</li> </ul> </li> <li>Normal ECG and CXR<ul> <li>No further workup</li> </ul> </li> </ul> </li> </ul> </li> </ul> </li> </ul>"},{"location":"im-guide/cards/vhd/as/","title":"Aortic Stenosis (AS)","text":""},{"location":"im-guide/cards/vhd/as/#etiology","title":"Etiology","text":"<ul> <li>Narrowing of the aortic valve due to either congenital bicuspid aortic valve or more commonly age-related calcification (fibrocalcific) and degeneration of the valve due to atherosclerosis<ul> <li>Have a high rate of CAD: \u2153 in those 40-60 y/o and \u2154 in those &gt;60 y/o</li> <li>Heyde Syndrome<ul> <li>Characterized by the triad of aortic stenosis, GI bleeding from angiodysplasia, and acquired von Willebrand syndrome</li> <li>Etiology<ul> <li>Increased circulatory shear forces and its effect on the physiologic confirmation and subsequent cleavage of large vWF multimers</li> </ul> </li> <li>Most often seen in men &gt;65</li> <li>Diagnosis: TTE + PFA<ul> <li>Confirm PFA w/vWF multimer analysis</li> </ul> </li> <li>Complications: GI bleeding</li> <li>Treatment<ul> <li>Aortic Valve replacement is virtually curative</li> </ul> </li> </ul> </li> </ul> </li> <li>3 MCC of Aortic Stenosis:<ul> <li>&lt;70 y/o: Bicuspid Aortic Valve (between 40-70)<ul> <li>Most common congenital Valve disorder (1-2%)<ul> <li>Bicuspid aortic valves in hearts with other congenital heart disease</li> <li>Associated with congenital aortic root dilation (i.e. thoracic aortic aneurysm)</li> <li>Bicuspid aortic valves are associated with aortic dilatation out of proportion to coexistent valvular lesions</li> </ul> </li> <li>Ejection click after S1 may be present, Senile calcific will not have this, may also be seen in PS</li> <li>Management based on predominant valve dysfunction (AR/AS)<ul> <li>Aortic Sinuses or ascending aorta \u22654.0cm: Lifelong serial imaging</li> <li>Clinical characteristics of bicuspid aortic valves in surgical patients</li> </ul> </li> </ul> </li> <li>RF: Rheumatic Heart Disease<ul> <li>Usually in the setting of MV disease</li> </ul> </li> <li>\u226570 y/o: Senile Calcific Aortic Stenosis (\u226575 usually)<ul> <li>7.5% of persons 75 y/o or older, 1.8% of persons 75 or older have moderate-to-severe AS</li> </ul> </li> </ul> </li> </ul>"},{"location":"im-guide/cards/vhd/as/#types","title":"Types","text":"<ul> <li>Supravalvular Aortic Stenosis<ul> <li>2<sup>nd</sup> Most common type of Aortic Stenosis</li> <li>Usually refers to congenital left ventricular outflow tract obstruction due to discrete or diffuse narrowing of the ascending aorta<ul> <li>Systolic murmur as seen with valvular AS, but best heart at the right first intercostal space (higher than valvular AS)</li> <li>\u00b1 unequal carotid pulses, differential blood pressure (high-pressure jet in ascending aorta), and a palpable thrill in the suprasternal notch</li> </ul> </li> <li>Develop LVH over time if significant and have coronary artery stenosis as an associated anomaly<ul> <li>Increased O2 demand, subendocardial or myocardial ischemia</li> </ul> </li> <li>Above aortic valve, LV outflow obstruction, LVH, exertional angina</li> </ul> </li> </ul>"},{"location":"im-guide/cards/vhd/as/#symptoms","title":"Symptoms","text":"<ul> <li>Asymptomatic<ul> <li>Severe: 75% die or develop symptoms within 5 years</li> </ul> </li> <li>Classic Triad: Heart Failure, Angina, and Syncope with Exercise</li> <li>Exertional dyspnea, lightheadedness or dizziness with exertion, chest pain, and syncope (late finding), progressive fatigue, and exertional lightheadedness and presyncope</li> </ul>"},{"location":"im-guide/cards/vhd/as/#exam","title":"Exam","text":"<ul> <li>Delayed carotid pulses, slowed upstroke (pulsus parvus et tardus)<ul> <li>Indicate severe stenosis but may be absent in older patients</li> <li>Sustained apical impulse</li> </ul> </li> </ul>"},{"location":"im-guide/cards/vhd/as/#murmur","title":"Murmur","text":"<ul> <li>Mid to late peaking, diamond shaped systolic ejection murmur at RUSB or suprasternal notch that radiates to the neck<ul> <li>Typically asymptomatic unless AV area &lt;1cm^2</li> </ul> </li> <li>Crescendo/decrescendo<ul> <li>The later the peak, the more severe the stenosis</li> <li>Mild: Early peaking</li> <li>Severe: Mid-Late peaking, paradoxical S2 split<ul> <li>May have Soft S2 if senile calcific</li> </ul> </li> </ul> </li> <li>Soft single S2, delayed A2 on top of P2 = S2<ul> <li>A2 soft and delayed</li> </ul> </li> <li>S4 Gallop<ul> <li>Occurs as the result of left atrial kick against a stiff left ventricle if CHF is present due to Aortic Stenosis</li> </ul> </li> <li>May have systolic thrill over the upper precordium and suprasternal notch</li> <li>Often decreased or absent aortic component of the 2<sup>nd</sup> heart sound due to decreased mobility of the aortic valve leaflets</li> </ul>"},{"location":"im-guide/cards/vhd/as/#maneuvers","title":"Maneuvers","text":"<ul> <li>Louder with squatting, Softer with Valsalva</li> <li>Right intercostal space radiating to carotids<ul> <li>May be transmitted to the apex instead of the neck (Gallavardin Effect)</li> </ul> </li> <li>Parvus et parvus/tardus pulse (slow rising/delayed pulse)<ul> <li>Usually age dependent, isolated</li> </ul> </li> </ul>"},{"location":"im-guide/cards/vhd/as/#classification","title":"Classification","text":"<ul> <li>Severity determined by mean valve Pressure Gradient (PG), peak aortic jet velocity (Vmax), or Aortic Valve Area (AVA)<ul> <li>Mild: &lt;25mmHg</li> <li>Moderate: 25-40mmHg</li> <li>Severe:<ul> <li>PG: \u226540mmHg or Vmax: \u22654.0m/s<ul> <li>HG-AS: AVR recommended</li> </ul> </li> <li>AVA: \u22641.0cm^2<ul> <li>LG-AS:<ul> <li>LF-LG: Reduced LVEF</li> <li>Paradoxical LF-LG: Preserved LVEF w/SV &lt;35</li> <li>NF-LG: index SV \u226535</li> </ul> </li> <li>HG-AS: AVR recommended</li> </ul> </li> </ul> </li> </ul> </li> <li>Low flow (LVF) gives low pressure and velocity readings, need to determine valve area:<ul> <li>Mild: 1.9-1.6cm^2</li> <li>Moderate: 1.5-1.1cm^2</li> <li>Severe: \u22641cm^2</li> </ul> </li> <li>Low gradient AS (LG-AS)<ul> <li>AVA &lt;1cm + Peak jet velocity \u22644.0ms and mean pressure gradient \u226440</li> </ul> </li> </ul>"},{"location":"im-guide/cards/vhd/as/#diagnosis-confirmation","title":"Diagnosis confirmation","text":"<ul> <li>Severe: Doppler Ultrasound (TTE)<ul> <li>Discrepancy 2/2 low SV or CAD also:<ul> <li>Left Heart Cath or Dobutamine Echo</li> </ul> </li> </ul> </li> </ul>"},{"location":"im-guide/cards/vhd/as/#prognosis","title":"Prognosis","text":"<ul> <li>Survival without Surgical Intervention (SASH)<ul> <li>Survival in AS:<ul> <li>Angina = 5 years</li> <li>Syncope = 3 years</li> <li>Heart Failure = 2 years</li> </ul> </li> <li>Worst prognosis of all valvular lesions, medical therapy is not effective, use caution when treating VF with vasodilators if due to AS</li> </ul> </li> </ul>"},{"location":"im-guide/cards/vhd/as/#treatment","title":"Treatment","text":"<ul> <li>LHC prior to valve surgery in most<ul> <li>40% require CABG as well</li> <li>Retrograde cath across a severely calcified valve increases risk of embolic stroke<ul> <li>Perform with caution and only when non-invasive techniques are not enough</li> <li>Consider CCTA instead in young patients</li> <li>Should we cross the valve: the risk of retrograde catheterization of the left ventricle in patients with aortic stenosis</li> </ul> </li> </ul> </li> <li>PARTNER-2: No difference in death or disabling stroke at 5 years after TAVR vs. SAVR for patients at intermediate surgical risk</li> <li>Mild: TTE q3-5 years</li> <li>Moderate: TTE q1-2 years</li> <li>Severe Aortic Stenosis<ul> <li>TTE every 6-12 months, life expectancy 1-2 years with symptoms</li> <li>Differentiate between pseudo-stenosis and true AS w/dobutamine stress test in low EF</li> <li>Indications for valve replacement<ul> <li>Symptoms</li> <li>LV systolic dysfunction EF &lt;50% in an asymptomatic pt</li> <li>Concomitant cardiac procedure (CABG, AA surgery)</li> </ul> </li> </ul> </li> <li>TAVR &gt; SAVR<ul> <li> <p>80 y/o, life expectancy &lt;10 years, OR above</p> </li> <li>Must not have AR</li> </ul> </li> <li>Symptomatic, Ideal<ul> <li>SAVR: Surgical Aortic Valve Replacement<ul> <li>All Stage D</li> <li>All Stage C with Severe disease on Testing, LVEF &lt;50% w/symptoms (syncope, angina, dyspnea), or undergoing other cardiac surgery (CABG)<ul> <li>Valve treatment prior to elective noncardiac surgeries</li> </ul> </li> </ul> </li> <li>TAVR: Transcatheter Aortic Valve Replacement<ul> <li>Use in pts with prohibitive risk for SAVR and predicted post-TAVR survival &gt;12m</li> </ul> </li> </ul> </li> <li>Shock/Pulmonary Edema<ul> <li>Consider Percutaneous Balloon Aortic Valvulotomy</li> </ul> </li> <li>Comorbid conditions<ul> <li>Manage concurrent conditions (AFib, CHF, CAD)</li> </ul> </li> </ul>"},{"location":"im-guide/cards/vhd/mr/","title":"Mitral Regurgitation (MR)","text":""},{"location":"im-guide/cards/vhd/mr/#general","title":"General","text":"<ul> <li>2020 Focused Update of the 2017 ACC Expert Consensus Decision Pathway on the Management of Mitral Regurgitation: A Report of the American College of Cardiology Solution Set Oversight Committee</li> </ul>"},{"location":"im-guide/cards/vhd/mr/#chronic-mitral-regurgitation","title":"Chronic Mitral Regurgitation","text":"<ul> <li>Myxomatous degeneration of the mitral valve leaflets and chordae<ul> <li>Abnormal accumulation of proteoglycans</li> </ul> </li> <li>Most common cause in developed countries is MVP<ul> <li>Rheumatic HD, Annulus dilation from LV dilation, endocarditis, CAD or MI causing papillary muscle ischemia</li> </ul> </li> <li>LV systolic dysfunction is MCC of Chronic Secondary MR</li> </ul>"},{"location":"im-guide/cards/vhd/mr/#exam","title":"Exam","text":"<ul> <li>Atrial fibrillation is common</li> <li>Severe Dyspnea, fatigue, HF due to decreased CO and increased</li> <li>Chronic severe MR can cause left atrial dilation which can lead to Afib (palpitations)</li> </ul>"},{"location":"im-guide/cards/vhd/mr/#murmur","title":"Murmur","text":"<ul> <li>Constant intensity, holosystolic murmur at the apex<ul> <li>Radiates to the axilla</li> </ul> </li> <li>S1 is soft or absent and S2 is widely split</li> <li>S3 is common if severe<ul> <li>A third heart sound may arise from volume overload, displaced apical impulse</li> </ul> </li> <li>Mid-systolic clock followed by a mid-late systolic murmur</li> <li>Progresses to a severe MR with sole holosystolic murmur w/o a click</li> </ul>"},{"location":"im-guide/cards/vhd/mr/#diagnosis-tte","title":"Diagnosis: TTE","text":"<ul> <li>LVEF is often normal or increased</li> <li>Increased left ventricular compliance in chronic MR, dilated LA</li> <li>Central regurgitation jet in secondary MR, Eccentric in RHD due to leaflet dysfunction</li> <li>Stage D or Stage C with:<ul> <li>LVEF: &lt;60%</li> <li>Symptoms</li> <li>LV enlargement with LV end systolic diameter \u226540mm</li> <li>PAH with PAP &gt;50mmHg</li> <li>New onset Atrial Fibrillation</li> </ul> </li> </ul>"},{"location":"im-guide/cards/vhd/mr/#fu","title":"F/U","text":"<ul> <li>Severe + No symptoms: Echo 6-12 months</li> </ul>"},{"location":"im-guide/cards/vhd/mr/#treatment","title":"Treatment","text":"<ul> <li>Trends in diagnosis and management</li> <li>Less than severe MR guidelines</li> <li>Significant: ACEIs/ARBs and Diuretics (Afterload reducers)<ul> <li>\u00b1 Beta blockers</li> <li>Nitroprusside</li> <li>IABP if needed</li> </ul> </li> <li>Percutaneous Valve Repair &gt; Replacement in Stage C and D<ul> <li>Reconstruction: Valve repair \u00b1 annuloplasty with an annuloplasty ring<ul> <li>Especially likely to be done with MVP, ruptured chordae, flail leaflets, endocarditis, and annular dilation</li> </ul> </li> <li>Mitral Valve reconstruction whenever possible, \u00bd the morbidity and better outcomes than replacement<ul> <li>Replacements need replaced after 15 years, also require lifelong anticoagulation</li> </ul> </li> <li>More likely to be done in MR due to Rheumatic fever</li> </ul> </li> <li>Mitral Clip (TEER)<ul> <li>Class 2a recommendation</li> <li>Transcatheter \u201cedge-to-edge\u201d percutaneous MV repair</li> <li>Clip is placed across two leaflets in their mid-part, creating a double orifice mitral valve</li> <li>For severe disease + high surgical risk</li> </ul> </li> <li>Severe<ul> <li>Regurgitant orifice area 0.4cm or greater, regurgitant volume of 60mL or greater or a vena contracta of 0.7cm or greater</li> <li>Primary (Degenerative): mid-systolic click, late mitral regurgitation, and anterior prolapse<ul> <li>LVEF &gt;60% + Asymptomatic: Echo q6-12 months</li> <li>LVEF &gt;60% + Asymptomatic + LVESD &gt;40, PASP &gt;50, or New-onset atrial fibrillation: Surgical Repair</li> <li>LVEF &gt;60% + Symptomatic: Surgical Repair &gt;&gt; Replacement when possible</li> <li>LVEF 30-60%: Surgical Repair &gt;&gt; Replacement when possible</li> </ul> </li> </ul> </li> <li>Class 1 indications for Repair: LVEF 30-60% and/or an LV End-systolic diameter of \u226540mm<ul> <li>Undergoing other cardiac procedure</li> </ul> </li> <li>Surgical MV repair unless Class III or IV and high surgical risk: TEER if anatomy is favorable and life expectancy is &gt;1 year<ul> <li>Replacement otherwise<ul> <li>LVEF &lt;30%: Medical Optimization (surgery on case-by-case basis), typically irreversible damage</li> </ul> </li> <li>GDMT as 1<sup>st</sup> line therapy (reverses remodeling) for Secondary MR (Class I)</li> </ul> </li> </ul>"},{"location":"im-guide/cards/vhd/mr/#acute-mitral-regurgitation","title":"Acute Mitral Regurgitation","text":"<ul> <li>Increased LVEDP, increased LA pressure with acute pulmonary edema and congestive heart failure</li> <li>Normal left ventricular compliance, increased LA pressure</li> <li>Causes:<ul> <li>Native:<ul> <li>Flail leaflet (endocarditis, MVP, trauma)</li> <li>Papillary muscle ischemia or rupture (MI, Trauma)</li> <li>Chordae Tendineae rupture (Endocarditis, Acute RF, trauma, spontaneous)</li> </ul> </li> <li>Prosthetic:<ul> <li>Tissue valve leaflet rupture</li> <li>Mechanical valve closure problem (thrombosis)</li> <li>Paravalvular regurgitation due to infection</li> </ul> </li> </ul> </li> </ul>"},{"location":"im-guide/cards/vhd/mr/#symptoms","title":"Symptoms","text":"<ul> <li>Acute-onset pulmonary edema</li> <li>Blowing decrescendo murmur at the apex with axillary radiation</li> <li>Severe Dyspnea</li> </ul>"},{"location":"im-guide/cards/vhd/mr/#murmur-character","title":"Murmur Character","text":"<ul> <li>Early decrescendo systolic murmur best heard at the apical impulse/apex</li> </ul>"},{"location":"im-guide/cards/vhd/mr/#diagnosis-tee","title":"Diagnosis: TEE","text":"<ul> <li>Hyperactive LV with normal to high ejection fraction and a normal sized LA</li> <li>Large left sided V waves on wedge pressure tracing</li> </ul>"},{"location":"im-guide/cards/vhd/mr/#management","title":"Management","text":"<ul> <li>Afterload reduction and diuresis</li> <li>Intra-aortic balloon pump may be helpful, unlike in severe AR</li> <li>Urgent surgery is often required<ul> <li>Other Causes:<ul> <li>Mild-Moderate MR: Mitral Annular Calcification, older adults with fibrous annulus degeneration</li> <li>Infective Endocarditis (fever, embolic findings)</li> </ul> </li> </ul> </li> </ul>"},{"location":"im-guide/derm/","title":"Dermatology","text":"<ul> <li>Actinic Keratosis<ul> <li>Mc benign lesion with malignant potential<ul> <li>Caused by chronic sun exposure<ul> <li>Review of actinic keratosis. Part I: etiology, epidemiology and clinical presentation</li> <li>Epidemiology of actinic keratoses and squamous cell carcinoma</li> </ul> </li> </ul> </li> <li>Precursor lesion to SCC<ul> <li>Up to 60% of cutaneous SCCs arise from preexisting AKs</li> </ul> </li> </ul> </li> <li>Cutaneous Tumors<ul> <li>Systematic skin cancer screening in Northern Germany</li> <li>Early diagnosis of cutaneous melanoma: revisiting the ABCD criteria</li> <li>Biopsy for malignant melanoma--are we following the guidelines?</li> </ul> </li> </ul>"},{"location":"im-guide/endo/","title":"Endocrinology","text":"<ul> <li>Diabetes Mellitus<ul> <li>Inpatient Management</li> <li>ACCORD: A1c target &lt;6.0% increased CV and all-cause mortality vs standard (7.0-7.9%)</li> <li>RABBIT-2: Basal-Bolus &gt; SSI</li> <li>FREEDOM: All-cause mortality is improved with CABG &gt; PCI w/DES in T2DM</li> <li>NICE-SUGAR: Intensive glucose control increased mortality in ICU patients</li> <li>CREDENCE: Canagliflozin 100mg/d reduces risk of ESRD and death</li> </ul> </li> <li>DKA<ul> <li>Management</li> </ul> </li> <li>Hypothyroidism<ul> <li>Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association</li> <li>Labs<ul> <li>TSH then Free Thyroxine (FT4)<ul> <li>TSH elevated: overt/subclinical</li> <li>FT4 low: overt only</li> </ul> </li> <li>T3 recommended if any:<ul> <li>Evaluation of thyrotoxicosis</li> <li>T3 Toxicosis: T3:T4 &gt; 20</li> </ul> </li> <li>Assess severity of hyperthyroidism and response to therapy</li> <li>Differentiate hyperthyroidism from destructive thyroidism<ul> <li>T3 if low</li> <li>Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists</li> <li>The significance of TSH values measured in a sensitive assay in the follow-up of hyperthyroid patients treated with radioiodine</li> </ul> </li> </ul> </li> </ul> </li> <li>Hyperthyroidism<ul> <li>General</li> </ul> </li> </ul>"},{"location":"im-guide/general/","title":"General Internal Medicine","text":"<ul> <li>Lab Errors<ul> <li>A1c<ul> <li>Pitfalls in hemoglobin A1c measurement: when results may be misleading</li> </ul> </li> </ul> </li> <li>Obesity<ul> <li>Lifestyle Modifications<ul> <li>Relative Merits of Low-Carbohydrate Versus Low-Fat Diet in Managing Obesity<ul> <li>Both Equivalent for Weight loss at 1 year</li> <li>Effects of low-carbohydrate diets versus low-fat diets on metabolic risk factors: a meta-analysis of RCTs</li> </ul> </li> <li>Low-Fat Diet</li> <li>Low-Carbohydrate Diet<ul> <li>Rapid initial weight loss</li> <li>Associated with reduced CV risk and All-cause mortality in observational studies</li> <li>Associated with increased incidence of unpleasant GI side effects</li> <li>A critical review of low-carbohydrate diets in people with Type 2 diabetes</li> </ul> </li> </ul> </li> </ul> </li> <li>PADUA<ul> <li>DVT PPX</li> </ul> </li> <li>Urinary Incontinence<ul> <li>Overview</li> <li>Treatment</li> </ul> </li> </ul>"},{"location":"im-guide/general/perioperative/","title":"Perioperative Management of Surgical Patients","text":""},{"location":"im-guide/general/perioperative/#resources","title":"Resources","text":"<ul> <li>Guide to Perioperative Evaluation</li> <li>Preoperative Clinics<ul> <li>\u201cPreoperative evaluation clinics have been shown to enhance operating room efficiency, decrease day-of-surgery cancellations, reduce hospital costs, and improve the quality of patient care.\u201d<sup>1</sup></li> </ul> </li> <li>Essential Principles of Preoperative Assessment in Internal Medicine: A Case-Based Teaching Session<ul> <li>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8339074/bin/mep_2374-8265.11178-s001.zip</li> </ul> </li> <li>Anesthesiology (07/2023) - Preoperative Evaluation in the 21<sup>st</sup> Century</li> <li>Merck Manual (09/2022) \u2013 Preoperative Evaluation</li> <li>Annals of Internal Medicine \u2013 In the clinic (11/2022) \u2013 Preoperative Evaluation for Non-cardiac Surgery</li> </ul>"},{"location":"im-guide/general/perioperative/#perioperative-risk-assessment","title":"Perioperative Risk Assessment","text":"<p>1) Stabilize acutely active cardiac disease prior to non-emergent non-cardiac surgery     * General         * Increase risk, require further evaluation before non-emergent non-cardiac surgery             * Unstable Angina or recent MI             * Decompensated HF             * Significant Arrhythmia (Symptomatic bradycardia, high grade AV block, SVT, New or recent onset VT)             * Severe Valvular Disease (Severe AS, Symptomatic MS) 2) Assess Procedural Risk     * Pts undergoing low risk surgeries have &lt;1% risk of MACE         * No further cardiac workup is needed regardless of underlying comorbidities     * 1) Cardiac Risk of Non-cardiac Surgical Procedures         * Risk of cardiac death, nonfatal cardiac arrest, nonfatal MI         * Low-Risk             * Breast (lumpectomy, mastectomy)             * Skin Surgery             * Simple Dental Work             * Endoscopic Procedure             * Cataract Extraction         * Intermediate-Risk             * Head and Neck (Thyroidectomy)             * Orthopedic (Knee Arthroplasty)             * Prostate         * High-Risk             * Aortic or other major vascular             * Intrathoracic             * Open Intraperitoneal     * 2) Cardiac Risk Stratification         * Revised Cardiac Risk Index (RCRI)             * Predictors of major cardiac complications with noncardiac surgery             * 6 Risk Predictors                 * High-risk surgery (vascular)                 * History of IHD                 * History of CHF                 * History of Stroke or TIA                 * T2DM w/Insulin                 * Pre-op Creatinine &gt;2                 * Rate of Cardiac Death, nonfatal cardiac arrest, or nonfatal MI                     * No RF: 0.4% (low risk)                     * 1 RF: 1.0% (low risk)                     * 2 RF: 2.4% (moderate risk)                     * \u22653 RF: 5.4% (high risk)             * RCRI \u22641% (low risk) can proceed directly to surgery                 * Otherwise assess functional status     * 3) Assess Functional Status         * If able to achieve \u22654 METS, generally do not require additional evaluation         * MET = volume of O2 consumed at rest (3.5mL O2 uptake/kg/min)             * &lt;4 METs:                 * Eat, dress, use toilet                 * Walk indoors in the house                 * Do light work (Vacuuming)             * \u22654 METs                 * Climb a flight of stairs                 * Run a short Distance                 * Do yardwork (Raking leaves)                 * Participate in golf, tennis, or dancing         * Otherwise needs cardiac eval w/TTE or Preop Stress Testing             * Usefulness of transthoracic echocardiography as a tool for risk stratification of patients undergoing major noncardiac surgery</p>"},{"location":"im-guide/general/perioperative/#pre-op-complication-prevention-strategies","title":"Pre-Op Complication Prevention Strategies","text":"<ul> <li>Quit smoking &gt;8 weeks prior</li> <li>Treat respiratory infections</li> <li>Aspiration Pneumonia<ul> <li>Bed elevation</li> </ul> </li> <li>Patient education<ul> <li>Chest PT, coughing, deep breathing, incentive spirometry</li> </ul> </li> <li>DECREASE-IV: Preoperative statins ASAP (Bisoprolol and Fluvastatin reduce perioperative mortality in intermediate-risk patients)</li> <li>Consider A1c in T2DM patients</li> <li>Preoperative glucocorticoids for uncontrolled COPD</li> <li>Give IV cefazolin as antimicrobial prophylaxis within 60mins of procedure</li> <li>Perioperative Management of Anemia</li> </ul>"},{"location":"im-guide/general/perioperative/#perioperative-management-of-anticoagulation","title":"Perioperative Management of Anticoagulation","text":"<ul> <li>Perioperative Management of Antithrombotic therapy</li> <li>Management of antithrombotic agents for endoscopic procedures</li> <li>Assess Elective vs. Emergent/Urgent<ul> <li>&lt;24hrs: IV VitK 2.5-5mg and PCC 30 IU/kg if needed</li> <li> <p>24hrs: IV VitK 2.5-5mg</p> </li> </ul> </li> <li>Assess Cardiac Risk of Noncardiac Surgical Procedures</li> <li>Assess Perioperative Bleeding Risk<ul> <li>https://pubmed.ncbi.nlm.nih.gov/22315257/</li> <li>https://pubmed.ncbi.nlm.nih.gov/19926021/</li> <li>High-Risk (2-day risk: 2-4%)<ul> <li>Cardiac, vascular, neurosurgical</li> <li>Intraabdominal, urologic (TURP)</li> <li>Joint replacement, laminectomy</li> <li>Renal biopsy, endoscopy with FNA</li> <li>Spinal surgery</li> <li>Major cancer surgery</li> <li>Notes<ul> <li>Temporary interruption for high bleeding risk patients</li> <li>Bridge very high thrombotic risk patients (CHA2D2-Vasc \u22656) using LMWH or UFH</li> </ul> </li> </ul> </li> <li>Low-Risk (2-day risk: \u22642%)<ul> <li>Arthrocentesis</li> <li>Coronary Angiography</li> <li>Cataracts, outpatient tooth extraction</li> <li>CVC removal, Pacemaker/ICD placement</li> <li>LN biopsy, endoscopy without needle biopsy</li> <li>Carpal Tunnel repair</li> <li>Skin biopsy, Bronchoscopy, Colonoscopy w/o biopsy</li> <li>Notes<ul> <li>Typically do not need warfarin interruption regardless of thrombotic risk</li> </ul> </li> </ul> </li> </ul> </li> <li>Assess Drug Type<ul> <li>Warfarin<ul> <li>Low-Risk surgery: No need to stop/adjust warfarin regardless of thrombotic risk<ul> <li>Continue through perioperative period</li> </ul> </li> <li>High-Risk surgery:<ul> <li>Very High VTE Risk: Bridge</li> <li>High VTE Risk: No Bridge, stop 5 days</li> <li>Low VTE Risk: Don\u2019t Stop?</li> </ul> </li> </ul> </li> <li>DOACs<ul> <li>Eliquis/Xarelto</li> <li>Dabigatran<ul> <li>Hold for 48 hours prior to surgery<ul> <li>No need for thrombin time unless unknown time of last dose (dementia/urgent sx)</li> </ul> </li> <li>If Thrombin time is normal: proceed with surgery</li> <li>Elevated Thrombin: Idarucizumab if life-threatening bleeding or urgent/emergent surgery</li> </ul> </li> </ul> </li> </ul> </li> <li>Assess Perioperative Thrombotic Risk (VTE Risk)<ul> <li>Very High Risk (&gt;10% annually)<ul> <li>Valve<ul> <li>Mechanical Mitral Valve</li> <li>Cage-ball or tilting disc mechanical aortic valve</li> </ul> </li> <li>VTE<ul> <li>Within 3 months</li> <li>Severe thrombophilia (eg. Protein C deficiency)</li> </ul> </li> <li>AF<ul> <li>AF with CHA2D2-VASc score \u22656</li> <li>AF with TIA/Stroke within 3 months</li> <li>AF with rheumatic valve disease</li> </ul> </li> </ul> </li> <li>High Risk (5-10%)<ul> <li>Valve<ul> <li>Patients with bileaflet mechanical aortic valve &amp; \u22651 other risk factor for stroke (HTN, DM)</li> </ul> </li> <li>VTE<ul> <li>VTE within 1 year but &gt;3 months</li> <li>Active malignancy within 6 months</li> <li>Non-severe thrombophilia (Heterozygous Factor V Leiden or prothrombin gene mutation)</li> </ul> </li> <li>AF<ul> <li>AF with CHA2Ds2-VASc score 4-5</li> </ul> </li> </ul> </li> <li>Moderate Risk<ul> <li>Valve<ul> <li>Patients with bileaflet mechanical aortic valve w/o other risk factor for stroke (HTN, DM)</li> </ul> </li> </ul> </li> <li>Low Risk (&lt;5% annually)<ul> <li>VTE &gt;12 months ago and no risk factors</li> </ul> </li> <li>Assess Kidney function</li> <li>High Bleed Risk Surgery<ul> <li>Very High VTE Risk<ul> <li>Perioperative Bridging w/LMWH or UFH<ul> <li>Hold warfarin for 5 days, start heparin once INR &lt;2.0</li> <li>Stop heparin the day of procedure</li> <li>Restart 24-48 hours after with warfarin</li> </ul> </li> </ul> </li> <li>Moderate-High VTE Risk<ul> <li>BRIDGE Trial \u2013 bridging didn\u2019t help unless Very High VTE Risk</li> <li>Hold DOAC for 4 half-lives (2-3 days) \u2013 6.25% of Xarelto left<ul> <li>Hold Dabigatran 48 hours</li> </ul> </li> </ul> </li> <li>Hold Warfarin for 5 days until the INR falls &lt;1.5 then perform procedure<ul> <li>Resume warfarin the evening following the procedure</li> </ul> </li> </ul> </li> <li>Low Bleed Risk Surgery<ul> <li>Very High VTE Risk<ul> <li>Warfarin<ul> <li>Continue anticoagulation<sup>2</sup></li> </ul> </li> </ul> </li> <li>Low/Moderate VTE Risk<ul> <li>Continue DOAC until day of surgery</li> <li>Stop warfarin 5 days prior; INR &lt;1.5<ul> <li>No bridging needed</li> </ul> </li> </ul> </li> </ul> </li> </ul> </li> </ul>"},{"location":"im-guide/general/perioperative/#perioperative-management-of-beta-blockers","title":"Perioperative Management of Beta-Blockers","text":"<ul> <li>Continue BBs through surgery</li> <li>Pre-operative initiation if RCRI \u22653 w/o CI<ul> <li>Start 1 week prior<ul> <li>Beta-blocker therapy in patients with a history of stable angina, previous MI, systolic HF<ul> <li>Decreases myocardial oxygen consumption, reducing HR, decreasing myocardial contractility<ul> <li>https://pubmed.ncbi.nlm.nih.gov/19884473/</li> </ul> </li> </ul> </li> </ul> </li> </ul> </li> </ul>"},{"location":"im-guide/general/perioperative/#perioperative-management-of-dapt","title":"Perioperative Management of DAPT","text":"<ul> <li>Elective Surgery: Defer Surgery until after minimum DAPT duration<ul> <li>4 weeks for select BMS, 6 months for DES</li> </ul> </li> <li>Urgent Surgery: Continue P2Y12 receptor blacker or hold for shortest duration possible</li> <li>Continue aspirin unless high risk of severe surgical bleeding<ul> <li>Reduces rate of early graft occlusion and overall CV morbidity and mortality in CABG</li> </ul> </li> <li>Hold P2Y12 inhibitors for 5-7 days prior to CABG<ul> <li>Increased risk of significant bleeding with increased requirements for blood transfusion and possible re-op</li> </ul> </li> </ul>"},{"location":"im-guide/general/perioperative/#perioperative-management-of-glucocorticoids","title":"Perioperative Management of Glucocorticoids","text":"<ul> <li>Perioperative management of patients treated with glucocorticoids</li> <li>Management of adrenal insufficiency during the stress of medical illness and surgery</li> <li>Adrenal insufficiency in high-risk surgical ICU patients</li> <li>Normal HPA Axis may not recover for up to 6-12 months after discontinuation of steroids</li> <li>No Risk (No perioperative Stress-Dose Steroids Required)<ul> <li>Daily Morning dose of prednisone &lt;5mg for any period</li> <li>Any dose of any glucocorticoid for &lt;3 weeks</li> <li>Prednisone 10mg (or its equivalent) every other day</li> </ul> </li> <li>Intermediate or Unknown Risk for AI (Preoperative Eval of HPA Axis)<ul> <li>Daily Morning dose of prednisone 5-20mg for &gt;3 weeks</li> <li>Daily Evening dose of prednisone &lt;5mg (may disrupt diurnal variation)</li> <li>Prior longer duration or higher doses of glucocorticoids in the past year</li> <li>Inhaled glucocorticoids for &gt;3 weeks, or \u22653 intra-articular or spinal glucocorticoid injections within past 3 months</li> <li>Co-syntropin Stimulation Test</li> </ul> </li> <li>High Risk (Stress-dose Glucocorticoids Perioperatively)<ul> <li>Daily Prednisone \u226520mg (or its equivalent) for &gt;3 weeks</li> <li>Any patient taking glucocorticoids who has Cushingoid features</li> <li>Stress dose when intermediate to high-risk surgery (continue and increase dose on day of surgery)<ul> <li>Hydrocortisone 100mg IV during surgery<ul> <li>50mg every 8 hours for 24 hours with rapid taper (1-2 days)</li> </ul> </li> </ul> </li> </ul> </li> <li>Only doses &gt;15mg/d are associated with increased risk for post-arthropathy infection</li> </ul>"},{"location":"im-guide/general/perioperative/#other","title":"Other","text":"<ul> <li>Rheum<ul> <li>DMARDS (methotrexate, sulfasalazine, hydroxychloroquine, leflunomide)<ul> <li>May be continued, no need to stop</li> </ul> </li> <li>Biologic Agents<ul> <li>Withheld one dosing cycle prior to hip and knee surgery</li> </ul> </li> <li>Restart after evidence of wound healing (14 days)</li> </ul> </li> <li>Antihypertensives<ul> <li>Continue CCBs</li> <li>Continue ACEI if HF, hold night before if no HF</li> <li>Hold Diuretics the morning of surgery</li> <li>Continue Statins</li> <li>Continue Clonidine</li> </ul> </li> <li>Meds to stop before Surgery<ul> <li>1-2 weeks before \u2013 Aspirin, Vitamin E<ul> <li>Platelets need 7-10 days to regenerate (Non-CABG/High-Risk)</li> </ul> </li> <li>5 days \u2013 Warfarin, drop INR to &lt;1.5 (can use vitamin K)</li> <li>3-4 days \u2013 SGLT-2s (Euglycemic diabetic ketoacidosis)</li> <li>2 days \u2013 NSAIDS<ul> <li>Reversible unlike aspirin so platelets don\u2019t need to regenerate</li> </ul> </li> <li>1-2 days \u2013 Metformin, lactic acidosis (&gt;4)</li> <li>Morning of \u2013 \u00bd dose of Insulin, give 5% dextrose intra/post-op</li> </ul> </li> <li>Labs/Testing<ul> <li>U/A in UTI and urologic procedures</li> <li>EKG in men \u226540 y/o and women \u226550 y/o, CVD, HTN, DM, Thoracic, Intraperitoneal, EM</li> <li>CKD before Surgery<ul> <li>Dialyze 24 hours prior</li> </ul> </li> </ul> </li> </ul> <ol> <li> <p>https://pubmed.ncbi.nlm.nih.gov/26927735/{:target=\"_blank\"}\u00a0\u21a9</p> </li> <li> <p>https://pubmed.ncbi.nlm.nih.gov/20131614/{:target=\"_blank\"}\u00a0\u21a9</p> </li> </ol>"},{"location":"im-guide/geri/","title":"Geriatrics","text":"<ul> <li>Delirium/Dementia<ul> <li>MIND-USA: Haldol/Ziprasidone no improvement in days alive without delirium/coma</li> <li>DELIRIA-J: Ramelteon reduced delirium</li> <li>Dementia</li> </ul> </li> <li>Depression<ul> <li>Depression and cognition in the elderly</li> <li>Diagnosis and treatment of depression and cognitive impairment in late life</li> <li>Mirtazapine: May be better than Sertraline in Geriatric Depression</li> <li>Review of the use of mirtazapine in the treatment of depression</li> </ul> </li> <li>HYVET: \u226580, treatment w/diuretic w/ or w/o ACEI trends toward reduced death/stroke</li> </ul>"},{"location":"im-guide/gi/","title":"Gastroenterology","text":"<ul> <li>Cholelithiasis</li> <li>Cirrhosis<ul> <li>Ceftriaxone reduces bacterial infection 67% in GIB, no survival benefit vs. norfloxacin</li> <li>SBP on IV ABX, IV Albumin reduces renal impairment and mortality (1.5g/kg at diagnosis and 1 g/kg on day 3)</li> </ul> </li> <li>GERD</li> <li>GI Bleeding<ul> <li>Endoscopy timing for UGIB</li> <li>Transfusion strategies for acute UGIB (\u22657 better mortality benefits than \u226510)</li> <li>Transfusion strategies</li> </ul> </li> <li>Jaundice</li> <li>PUD<ul> <li>PPI Potency</li> </ul> </li> <li>Portal Hypertension<ul> <li>Clinical Pharmacology</li> </ul> </li> <li>Transaminitis<ul> <li>Mildly Elevated Liver Transaminase Levels: Causes and Evaluation</li> </ul> </li> <li>Viral Hepatitis<ul> <li>VALENCE: Sofosbuvir-ribavirin for HCV genotypes 2 or 3</li> </ul> </li> </ul>"},{"location":"im-guide/heme-onc/","title":"Hematology/Oncology","text":""},{"location":"im-guide/heme-onc/#hematology","title":"Hematology","text":"<ul> <li>Anemia<ul> <li>Anemia of Chronic Disease<ul> <li>Advancements in anemias related to chronic conditions</li> </ul> </li> <li>Transfusion thresholds<ul> <li>TRICC: Better survival in critically ill with Hgb target of &gt;7 than &gt;10</li> <li>TRISS: Similar mortality with Hgb target of &gt;7 than &gt;9 in septic shock</li> </ul> </li> </ul> </li> <li>Breast Cancer<ul> <li>ATLAS: In ER+ BC, tamoxifen for 10 years reduced recurrence/mortality, increased endometrial cancer and PE risk</li> </ul> </li> <li>Chronic Leukemia<ul> <li>CLL<ul> <li>Ibrutinib-Rituximab &gt; FCR if &lt;70 y/o and untreated</li> </ul> </li> <li>CML<ul> <li>IRIS: Imantinib &gt; IFNa/cytarabine in delaying disease progression</li> </ul> </li> </ul> </li> <li>DIC</li> <li>General<ul> <li>Multiple CTs increase risk of leukemia and brain tumors</li> </ul> </li> <li>Iron Deficiency Anemia<ul> <li>Consensus Statement on Peri-operative management of Anemia and IDA</li> <li>IRONMAN: IV Iron not better than placebo, did not change # of pRBC transfusion during stay</li> </ul> </li> <li>Lymphomas</li> <li>Thrombocytopenia<ul> <li>EDTA-dependent pseudothrombocytopenia: further insights and recommendations for prevention of a clinically threatening artifact</li> <li>Drug-induced thrombocytopenia<ul> <li>PubMed</li> </ul> </li> </ul> </li> <li>VTE<ul> <li>SOME: Not better to screen for occult malignancy in first unprovoked VTE</li> <li>AMPLIFY: Oral Apixaban for the Treatment of Acute VTE</li> <li>PE<ul> <li>Causes of Elevated D-Dimer</li> <li>ADJUST-PE: Age-adjusted D-Dimer (Age x 10) in patients &gt;50 r/o more pts</li> <li>ERC/PROPER: Low suspicion and PERC(-) reduces VTE probability to &lt;2%<ul> <li>Also</li> </ul> </li> <li>PIOPED II: CTA is sensitive (90%) and specific (95%) for PE</li> </ul> </li> <li>DVT<ul> <li>Wells DVT Criteria<ul> <li>Rule-Out with Negative D-Dimer</li> <li>Diagnosis/Treatment</li> <li>Treatment</li> </ul> </li> <li>CLOT: Dalteparin &gt; Warfarin in preventing recurrent VTE of malignancy</li> </ul> </li> </ul> </li> </ul>"},{"location":"im-guide/heme-onc/#oncology","title":"Oncology","text":"<ul> <li>Breast Cancer</li> <li>Chemotherapy<ul> <li>General<ul> <li>Increased risk of MDS, Mixed MDS/MPN, and AML (10-20% of all cases of these cancers are chemotherapy related)<ul> <li>Therapy-Related Myeloid Leukemia</li> <li>Etiology and management of therapy-related myeloid leukemia</li> </ul> </li> </ul> </li> <li>Common Regimens<ul> <li>ABVD<ul> <li>Adriamycin, Bleomycin, Vinblastine, Dacarbazine</li> <li>Hodgkin Lymphoma</li> </ul> </li> <li>BEACOPP<ul> <li>Bleomycin, Etoposide, Adriamycin/doxorubicin, Cyclophosphamide, Oncovorin/vincristine, Procarbazine, Prednisone</li> <li>Hodgkin Lymphoma</li> </ul> </li> <li>FOLFIRI<ul> <li>Leucovorin, 5-Fluorouracil, Irinotecan</li> <li>Advanced-stage and Metastatic Colorectal Cancer</li> </ul> </li> <li>FOLFOX<ul> <li>Leucovorin, 5-Fluorouracil, Oxaliplatin</li> </ul> </li> <li>R-CHOP<ul> <li>Rituximab, Cyclophosphamide, Hydroxy-doxorubicin, Oncovorin/Vincristine, Prednisone</li> </ul> </li> </ul> </li> </ul> </li> </ul>"},{"location":"im-guide/id/","title":"Infectious Disease","text":"<ul> <li>AIDS<ul> <li>INSIGHT-START: Early initiation of anti-retroviral therapy for HIV</li> </ul> </li> <li>Antibiotics<ul> <li>Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acute Infection</li> </ul> </li> <li>Bronchitis</li> <li>Cellulitis<ul> <li>Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections: 2014 Update by the Infectious Diseases Society of America</li> </ul> </li> <li>Necrotizing Soft Tissue Infections<ul> <li>Review</li> </ul> </li> <li>Pneumonia<ul> <li>CURB-65 Score<ul> <li>CAP-START: B-Lactam was noninferior to quinolone or combo B-Lactam + Macrolide</li> <li>Diagnosis and Management</li> </ul> </li> </ul> </li> <li>Procalcitonin<ul> <li>FDA approved for initiating or discontinuing ABX in LRTIs and for discontinuing antibiotics in patients with sepsis</li> <li>Cost effectiveness ($2704 more per patient than those who didn\u2019t, not good)</li> <li>Cutoffs for specific diseases</li> </ul> </li> <li>UTI<ul> <li>Uncomplicated Cystitis</li> <li>NEJM</li> <li>American Urologic Society</li> </ul> </li> <li>Wound Care<ul> <li>Common questions about wound care</li> <li>Management of Pressure Ulcers</li> <li>Evaluation and treatment</li> </ul> </li> </ul>"},{"location":"im-guide/id/#resources","title":"Resources","text":"<ul> <li>Bugs and Drugs (Pharmacology)</li> </ul>"},{"location":"im-guide/nephro/consults/","title":"Nephrology Consults","text":""},{"location":"im-guide/nephro/consults/#resources","title":"Resources","text":"<ul> <li>Landmark Trials</li> </ul>"},{"location":"im-guide/neuro/consults/","title":"Neurology Consults","text":""},{"location":"im-guide/neuro/consults/#resources","title":"Resources","text":"<ul> <li>Involuntary Movements and Tremor Diagnosis</li> <li>NEUROMUSCULAR DISEASE CENTER - Washington University, St. Louis, MO</li> <li>Learn Neuroradiology</li> </ul>"},{"location":"im-guide/pccm/","title":"Pulmonology & Critical Care","text":"<ul> <li>Acute Respiratory Failure<ul> <li>Noninvasive Ventilation for ARF</li> </ul> </li> <li>ARDS<ul> <li>Mechanical Ventilation in ARDS</li> <li>ACURASYS: Neuromuscular blockade in 1<sup>st</sup> 48hrs reduced 28- and 90-day mortality</li> <li>PROSEVA: Proning in severe ARDS reduced 28- and 90-day mortality</li> </ul> </li> <li>Asthma<ul> <li>Novel START: Prn Budesonide+formoterol reduced risk of exacerbations vs. Albuterol</li> <li>AMAZES: Azithromycin reduced rate of asthma exacerbations, improved QOL in severe</li> </ul> </li> <li>COPD<ul> <li>Treatment<ul> <li>Antibiotics</li> <li>AECOPD<ul> <li>REDUCE: 5d is non-inferior to 14d for prevention of re-AECOPD</li> </ul> </li> <li>Pharmacotherapy<ul> <li>FLAME: LABA + LAMA &gt; LABA + ICS if mMRC \u22652 for exacerbations</li> <li>UPLIFT: Tiotropium associated with improvements in lung function, QOL, and exacerbations during 4-year period; did not reduce rate of FEV1 decline</li> </ul> </li> </ul> </li> </ul> </li> <li>ICU<ul> <li>EMCRIT: Fluids/Electrolytes</li> <li>3SITES: Subclavian less CLABSIs and DVTs than jugular/femoral, more PTX</li> <li>65: MAP target 60-65 in pts \u226565 did not have mortality difference in vasodilatory shock</li> <li>Routine vs. On-Demand CXR in MV pts in the ICU increases use 34%, no benefit</li> <li>LACTATE: Decreased in-hospital mortality and shorter ICU stay with aim of 20% reduction q2hrs for the first 8 hours in ICU; guided group received more fluids and started vasopressors earlier but did not have faster rate of reduction in lactate</li> <li>PRORATA: &lt;10% increase in mortality at 30-60 days with procalcitonin-guided ABX</li> <li>SPICE-III: Precedex had more ADE w/o improving mortality as primary sedative in MV</li> <li>SOAP-II: Dopamine = NE for 1<sup>st</sup> line; Dopamine has increased risk of arrhythmias</li> <li>Septic Shock<ul> <li>Surviving Sepsis Campaign</li> </ul> </li> </ul> </li> <li>Interstitial Lung Disease (ILD)<ul> <li>IPF</li> <li>Sarcoidosis</li> </ul> </li> <li>Lung Cancer<ul> <li>National Lung Cancer Screening Trial</li> <li>Early Palliative care in metastatic NSCLC improves QOL and improved survival</li> </ul> </li> <li>Pleural Effusion<ul> <li>Lights Criteria for Pleural Effusions</li> <li>Management<ul> <li>Management of infectious processes of the pleural space: a review</li> <li>Malignant Pleural Effusions</li> </ul> </li> </ul> </li> <li>Sleep Apnea<ul> <li>Evaluation and Management of Obesity Hypoventilation Syndrome</li> </ul> </li> </ul>"},{"location":"im-guide/pccm/#resources","title":"Resources","text":"<ul> <li>EMCrit IBCC</li> <li>CXR Atlas</li> </ul>"},{"location":"im-guide/pccm/fasthugsbid/","title":"FASTHUGSBID","text":"<ul> <li>General<ul> <li>Mnemonic for remembering ICU quaility measures</li> <li>Give your patient a fast hug (at least) once a day</li> </ul> </li> <li>F - Feeding<ul> <li>Review</li> </ul> </li> <li>A - Analgesia</li> <li>S - Sedation<ul> <li>Review Article</li> </ul> </li> <li>T - Thrombotic (VTE) Prophylaxis<ul> <li>Calculator</li> <li>Evidence<ul> <li>https://pubmed.ncbi.nlm.nih.gov/20738765/</li> <li>https://pubmed.ncbi.nlm.nih.gov/23279085/</li> </ul> </li> </ul> </li> <li>H - Head of Bed</li> <li>U - Ulcer (GI) Prophylaxis<ul> <li>VUMC SUD Guide</li> </ul> </li> <li>G - Glycemic Control<ul> <li>Review Article - Cleveland Clinic</li> </ul> </li> <li>S - Spontaneous Breathing (SBT)<ul> <li>ABCDE<ul> <li>Awakening trails for ventilated patients (SAT)</li> <li>Breathing (spontaneous) trails (SBTs)</li> <li>Coordinated effort between RT and nurse for SBT and SAT</li> <li>Delirium assessment + treatment + prevention</li> <li>Early mobilization and ambulation</li> </ul> </li> <li>Daily Tasks<ul> <li>1) Spontaneous Awakening Trail (SAT)<ul> <li>Hold all sedatives</li> </ul> </li> <li>2) Weaning Candidate<ul> <li>Adequate Oxygenation<ul> <li>PaO2 &gt; 60-70</li> <li>FiO2 &lt; 40%</li> <li>PEEP &lt; 8</li> </ul> </li> <li>Adequate Ventilation<ul> <li>PaCO2 &lt; 45</li> <li>RR &lt; 25</li> </ul> </li> <li>Arterial pH &gt; 7.25</li> <li>Good Inspiratory effort</li> </ul> </li> <li>3) RSBI Trial to screen for readiness<ul> <li>SBT for 1 minute to calculate RSBI: No support</li> <li>Rapid Shallow Breathing Index (RSBI): RR per min/ TV in L<ul> <li>Calculation to predict successful extubation</li> <li>High (\u2265105): likely to fail weaning, 95% fail<ul> <li>&lt;105: 78% successful</li> </ul> </li> </ul> </li> <li>Consider MIP (NIF) to screen alternatively</li> </ul> </li> <li>4) Spontaneous Breathing Trial (SBT) if:<ul> <li>1) pH &gt; 7.25</li> <li>2) Adequate O2 on minimal support (FiO2 &lt; 40 and PEEP &lt; 5)</li> <li>3) Intact inspiratory effort and mental alertness to protect airway</li> <li>Remains intubated and ventilatory support is turned off for 1-2hrs<ul> <li>PS, CPAP, or T-piece</li> <li>If ABG remains normal, then good candidate for extubation</li> </ul> </li> </ul> </li> <li>5) Extubation Criteria<ul> <li>Cause of intubation reversed</li> <li>RSBI &lt;105</li> </ul> </li> </ul> </li> </ul> </li> <li>B - Bowel Regimen<ul> <li>VUMC Bowel Regimen Guide</li> </ul> </li> <li>I - Indwelling Catheters</li> <li>D - De-escalation of ABX</li> </ul>"},{"location":"im-guide/pccm/general/","title":"General","text":"<ul> <li>ACLS<ul> <li>General<ul> <li>Capnography (measurement of partial pressure of CO2 in the exhales breath over time)</li> </ul> </li> </ul> </li> <li>End-tidal CO2<ul> <li>Typically gradually rises with high-quality CPR<ul> <li>Increase in CO w/ROSC will show a sudden rise in EtCO2 on capnography (Ex. 16 to 38) and is the earliest indicator of ROSC, even before a pulse is palpated</li> <li>EtCO2 of \u226410 mmHg after 20 minutes of CPR are highly unlikely to achieve ROSC</li> </ul> </li> </ul> </li> <li>Anemia<ul> <li>IRONMAN: IV Iron not better than placebo did not change RBC transfusion during ICU stay</li> </ul> </li> <li>Illness Severity Assessment<ul> <li>qSOFA</li> <li>APACHE IV</li> <li>SAPs</li> </ul> </li> <li>Disease Specific Scoring Systems<ul> <li>CURB65</li> <li>sPESI (Pulmonary Embolism Severity Index)</li> <li>PSI</li> </ul> </li> <li>ICU Delirium<ul> <li>Mobilize pt, remove catheters, provide visual and hearing aids</li> </ul> </li> <li>ICU Toxicology</li> <li>Oncologic Emergencies in the ICU</li> <li>Palliative Care in the ICU<ul> <li>https://pubmed.ncbi.nlm.nih.gov/22202706/</li> <li>https://pubmed.ncbi.nlm.nih.gov/25644909/</li> <li>https://pubmed.ncbi.nlm.nih.gov/25167087/</li> </ul> </li> </ul>"},{"location":"im-guide/pccm/general/#icu-acquired-weakness","title":"ICU-Acquired Weakness","text":"<ul> <li>Evaluation<ul> <li>Medical Research Council Muscle Scale (MRCMS) is a bedside tool used to evaluate weakness</li> </ul> </li> <li>Critical Illness Myopathy<ul> <li>RF: Steroids, Neuromuscular blocking agents, Sepsis</li> <li>Features<ul> <li>Flaccid limbs</li> <li>Facial and respiratory weakness</li> <li>Normal sensation</li> </ul> </li> <li>Normal to mild CK elevation (&lt;2000)</li> </ul> </li> <li>Critical Illness Polyneuropathy<ul> <li>RF: Sepsis</li> <li>Features<ul> <li>Flaccid limbs</li> <li>Respiratory weakness</li> <li>Distal sensory loss</li> </ul> </li> <li>Normal CK</li> </ul> </li> <li>Rhabdomyolysis<ul> <li>RF: Infection, Medications, Serotonin Syndrome, Neuroleptic Malignant Syndrome</li> <li>Features<ul> <li>Mild to moderate limb weakness</li> <li>Muscle swelling</li> <li>Myalgias</li> <li>DTRs intact</li> </ul> </li> <li>Marked CK elevation (&gt;5000)</li> </ul> </li> <li>Guillain-Barre Syndrome<ul> <li>RF: Infection</li> <li>Features<ul> <li>Progressive and symmetric</li> </ul> </li> <li>Normal CK</li> </ul> </li> <li>Prolonged Neuromuscular Blockade<ul> <li>RF: Prolonged paralytic agent use (days), often in renal or hepatic insufficiency</li> <li>Features<ul> <li>Flaccid limbs</li> <li>Respiratory weakness</li> <li>Transient improvement after anticholinesterase</li> </ul> </li> <li>Normal CK</li> </ul> </li> </ul>"},{"location":"im-guide/pccm/general/#hypothermia","title":"Hypothermia","text":"<ul> <li>Symptoms<ul> <li>Shivering, but as hypothermia progresses, shivering stops</li> <li>Moderate: Bradycardia, hypoventilation, lethargy, atrial arrhythmias, decreased shivering</li> <li>Severe: absent reflexes, ventricular arrhythmia, asystole, and apnea</li> </ul> </li> <li>Diagnosis: Temperature<ul> <li>Monitoring: Esophageal temperature probe<ul> <li>Rectal and bladder temperatures will lag the rising core temperature during the rewarming process.</li> </ul> </li> </ul> </li> <li>Treatment<ul> <li>Mild (&gt; 35.0 \u00b0C (95.0 \u00b0F))<ul> <li>Passive external warming</li> </ul> </li> <li>Moderate (28.0 - 35.0 \u00b0C (82.4 - 95.0 \u00b0F)) or (&lt;28.0 \u00b0C (82.4 \u00b0F)) w/o coma or CV collapse<ul> <li>1) Active external warming<ul> <li>Warming blankets and forced warm air, heating pads</li> </ul> </li> <li>2) Active internal warming</li> </ul> </li> <li>Severe (&lt;28.0 \u00b0C (82.4 \u00b0F)) in the setting of coma or cardiovascular collapse<ul> <li>Cardiac Arrest: Extracorporeal support, including cardiopulmonary bypass, VA ECMO</li> <li>No Cardiac Arrest: Active internal rewarming (107F fluid)<ul> <li>Infusion of heated intravenous crystalloid solution as well as lavage of the peritoneal or pleural cavities irrigation</li> </ul> </li> </ul> </li> <li>Other (Acid-Base Disturbances): HD</li> </ul> </li> </ul>"},{"location":"im-guide/pccm/general/#heat-stroke","title":"Heat Stroke","text":"<ul> <li>Strenuous activity during hot and humid weather<ul> <li>Dehydration, poor acclimatization, lack of fitness</li> </ul> </li> <li>Hyperthermia</li> <li>Core temp &gt;104F (40C) immediately after collapse plus:<ul> <li>CNS dysfunction: AMS, confusion, irritability, seizure</li> <li>Additional organ failure: DIC, Renal/Hepatic failure, ARDS</li> </ul> </li> <li>Monitoring<ul> <li>Rectal or esophageal probes</li> </ul> </li> <li>Prognosis:<ul> <li>20-60% mortality</li> </ul> </li> <li>Treatment<ul> <li>Fluid resuscitation, electrolyte correction</li> <li>No antipyretic therapy</li> <li>Exertional: Ice water immersion</li> <li>Non-Exertional: Evaporative cooling (lukewarm water with fans), high-flow cool water dousing, ice/wet towel rotation, cold shower<ul> <li>Ice Water immersion has increased mortality in elderly w/Non-Exertional Heat Stroke</li> </ul> </li> </ul> </li> </ul>"},{"location":"im-guide/pharm/autonomics/","title":"Autonomic Drugs","text":"<ul> <li>Cholinomimetic agents</li> <li>Direct Agonists<ul> <li>Bethanechol</li> <li>Used to treat urinary retention or atonic bladder</li> <li>Carbachol</li> <li>Methacholine</li> <li>Pilocarpine</li> </ul> </li> <li>Indirect Agonists (Anticholinesterases, Acetylcholinesterase Inhibitors)<ul> <li>Donepezil</li> <li>5mg qhs, max 10mg</li> <li>Metabolized by 2D6 and 3A4</li> <li>Cirrhosis reduces clearance by 20%</li> <li>Less GI SE</li> <li>Edrophonium</li> <li>Neostigmine</li> <li>Physostigmine</li> <li>Pyridostigmine</li> <li>Rivastigmine</li> <li>1.5mg BID up to 3mg BID, patch</li> <li>SE: More GI and Cardiac SE due to PNS and CNS effects</li> </ul> </li> <li>Muscarinic Antagonists (Antimuscarinics)<ul> <li>General</li> <li>May trigger angle closure glaucoma/mydriasis</li> <li>Anticholinergic effects, decrease acetylcholine activity</li> <li>Useful for treating tremor and rigidity</li> <li>Not useful for treating bradykinesia</li> <li>Atropine</li> <li>Benztropine (Cogentin)</li> <li>Trihexyphenidyl</li> <li>Glycopyrrolate</li> <li>Hycosamine</li> <li>Imipramine</li> <li>Antidepressant used to treat childhood enuresis, promotes urinary retention</li> <li>Ipratropium</li> <li>Oxybutynin</li> <li>Inhibits cholinergic input during bladder filling</li> <li>Helps improve bladder capacity and is used to treat overactive bladder (detrusor instability)</li> <li>Scopolamine</li> </ul> </li> <li>Sympathomimetic agents</li> <li>Direct Sympathomimetics<ul> <li>Albuterol</li> <li>Dobutamine</li> <li>B1 \u2265 B2/A1</li> <li>Increases myocardial contractility in decompensated HF</li> <li>Improved EF and reduced LV ESV reducing edema</li> <li>B1 stimulation (inotropic)</li> <li>Mild B2 stimulation (vasodilator)</li> <li>Increase O2 consumption bad for MI or failing MI</li> <li>Dopamine</li> <li>Epinephrine</li> <li>Alpha and Beta adrenergic</li> <li>Leads to venoconstriction, arterioconstriction, and increased contractility to increase preload, afterload, and CO</li> <li>Fenoldopam</li> <li>CI: glaucoma or increased intracerebral pressure</li> <li>Isoproterenol</li> <li>Midodrine</li> <li>Norepinephrine</li> <li>Phenylephrine</li> </ul> </li> <li>Indirect Sympathomimetics<ul> <li>Amphetamine</li> <li>Cocaine</li> <li>Ephedrine</li> </ul> </li> <li>Sympatholytic (alpha-2 agonists)<ul> <li>Clonidine (Catapres)</li> <li>Central alpha 2 agonist, reduces NE release<ul> <li>Increases gut salt and water uptake</li> </ul> </li> <li>Efficacy in treating autonomic neuropathy caused diarrhea in diabetics</li> <li>Can reduce cravings in narcotic and alcohol withdrawal, smoking cessation</li> <li>Taper by decreasing dose by 50% over 3 days</li> <li>SE: Hypertensive crisis, Hypotension, bradycardia</li> <li>Guanfacine</li> <li>Tizanidine</li> <li>Alpha-Methyldopa</li> </ul> </li> <li> <p>Alpha-blockers</p> <ul> <li>Nonselective alpha blockers</li> <li>Phenoxybenzamine</li> <li>Phentolamine<ul> <li>Useful in patients with pheochromocytoma, cocaine toxicity, amphetamine overdose, clonidine withdrawal</li> </ul> </li> <li>Alpha-1 antagonists</li> <li>Prazosin</li> <li> <p>Terazosin</p> </li> <li> <p>Doxazosin (Cardura)</p> </li> <li> <p>Tamsulosin</p> <ul> <li>Relaxes ureteral muscle and decreases intraureteral pressure</li> </ul> </li> <li>Trazodone</li> <li>Alpha-2 antagonists</li> <li>Mirtazapine (Remeron)</li> </ul> </li> </ul>"},{"location":"im-guide/pharm/blood%26anti-inflammatories/antiplatelets/","title":"Antiplatelets","text":""},{"location":"im-guide/pharm/blood%26anti-inflammatories/antiplatelets/#1-antiplatelet-drugs","title":"1) Antiplatelet Drugs","text":"<ul> <li>COX Inhibitors</li> <li>Prostaglandin Analogues (PGI2)</li> <li>Treprostinil (Remoodulin)</li> <li>Combos</li> <li>Aspirin + Clopidogrel<ul> <li>4 weeks after bare metal stent</li> <li>6 months after drug eluting stent</li> <li>Unstable angina</li> </ul> </li> <li>Aspirin + Prasugrel<ul> <li>Patients undergoing PCI</li> </ul> </li> </ul>"},{"location":"im-guide/pharm/blood%26anti-inflammatories/antiplatelets/#a-cox-inhibitors","title":"A) COX Inhibitors","text":"<ul> <li>Acetylsalicylic Acid (Aspirin)</li> <li>COX1 Inhibition (Thromboxane A2)</li> <li>COX2 Inhibition at high doses</li> <li>Overdose:<ul> <li>Gastric Lavage, Activated Charcoal</li> <li>Alkalinization of the urine (IV Sodium Bicarb)</li> <li>Goal of urine pH \u22657.5</li> <li>Dialysis if Salicylate levels \u226590-100 with acute intoxication or \u226560 ng/mL in chronic administration</li> </ul> </li> <li>Reye Syndrome<ul> <li>Use of aspirin after a URI</li> <li>Symptoms</li> <li>Acute encephalopathy w/hepatic dysfunction occurring days after recovery</li> <li>Heavy vomiting, delirium, fatty liver, seizures, coma</li> <li>Liver failure with elevated AST, ALT</li> <li>Increased PT, elevated ammonia, and hypoglycemia</li> <li>\u00b1 Renal and heart failure, Increased ICP</li> </ul> </li> </ul>"},{"location":"im-guide/pharm/blood%26anti-inflammatories/antiplatelets/#b-pde-inhibitorsthromboxane-inhibitors","title":"B) PDE Inhibitors/Thromboxane Inhibitors","text":"<ul> <li>Cyclic AMP Interference</li> <li>Dipyridamol (Persantine)</li> <li>Blocks AMP BD, inhibit Platelet activation</li> </ul>"},{"location":"im-guide/pharm/blood%26anti-inflammatories/antiplatelets/#c-pari","title":"C) PARI","text":"<ul> <li>Thrombin Receptor Interference, PAR-1 Antagonist</li> <li>Vorapaxar (Zontivity)</li> </ul>"},{"location":"im-guide/pharm/blood%26anti-inflammatories/antiplatelets/#d-p2y12","title":"D) P2Y12","text":"<ul> <li>ADP Receptor Antagonists (P2Y12 Inhibitors)</li> <li>Binds platelet ADP receptor<ul> <li>Inhibits platelet aggregation</li> <li>Used in aspirin intolerant or in coronary stents</li> </ul> </li> <li>Thienopyridine (IR)</li> <li>Require CYP450 activation</li> <li>Clopidogrel (Plavix)</li> <li>Prasugrel (Effient)<ul> <li>10x stronger, more rapid</li> <li>More bleeding risk than clopidogrel</li> <li>CI in \u226575 y/o, renal impaired, CVD</li> </ul> </li> <li>Ticlopidine (Ticlid)</li> <li>Nucleotide/side analog (R)</li> <li>Reversible, no activation needed to work</li> <li>Ticagrelor (Brilinta)<ul> <li>More rapid onset, \u2265 than clopidogrel</li> <li>SE: Dyspnea MC</li> </ul> </li> <li>Cangrelor<ul> <li>Immediate onset \u2013 1 hour</li> </ul> </li> </ul>"},{"location":"im-guide/pharm/blood%26anti-inflammatories/antiplatelets/#e-giibiiia-receptor-inhibitors","title":"E) GIIb/IIIa Receptor Inhibitors","text":"<ul> <li>GP IIb/IIIa antagonists</li> <li>Abciximab (ReoPro)<ul> <li>PCI w/o ADPRA, not renally cleared</li> <li>Monoclonal antibody</li> </ul> </li> <li>Eptifibatide (Integrilin)</li> <li>Tirofiban (Aggrastat)<ul> <li>High risk unstable angina- Eptifibutide (Integrilin)</li> </ul> </li> </ul>"},{"location":"im-guide/pharm/blood%26anti-inflammatories/antiplatelets/#f-pde3-inhibitors","title":"F) PDE3 Inhibitors","text":"<ul> <li>Cilostazole (Pletal)</li> <li>Only indicated in symptomatic claudication</li> <li>CI: HF</li> </ul>"},{"location":"im-guide/pharm/blood%26anti-inflammatories/antithrombotics/","title":"Anticoagulants","text":""},{"location":"im-guide/pharm/blood%26anti-inflammatories/antithrombotics/#a-vitamin-k-antagonists","title":"A) Vitamin K Antagonists","text":"<ul> <li>Warfarin (Coumadin)</li> <li>MOA: Vitamin K epoxide reductase inhibitor<ul> <li>Inhibits Prothrombin (II), VII, IX, X, C, S</li> </ul> </li> <li>Needs to be bridged for 5 days if HR (most surgeries)<ul> <li>Bridge when HR or valves: Use LMWH when INR \\&lt;2</li> </ul> </li> <li>Monitored via INR \u2265 PT, 97% bound to albumin</li> <li>Can be used in breastfeeding</li> <li>Reversal: INR \u2265 10 = oral vit k<ul> <li>Increased bleeding = 4F-PCC (works in minutes), IV vitamin K (12-24hrs, risk of anaphylaxis) \u2265 FFP</li> <li>Four-Factor Prothrombin Complex (4F-PCC)<ul> <li>Contains Factors II, VII, IX, and X as a lyophilized powder</li> </ul> </li> <li>Indicated in brain hemorrhage</li> <li>No bleeding, INR 4.5-10: withhold</li> <li>No bleeding, INR 3-4.5: watch and wait</li> </ul> </li> <li>CI: Pregnancy (crosses placenta)<ul> <li>Vit k, nasal hypoplasia, stippled epiphyses in first trimester</li> </ul> </li> <li>Warfarin-Induced Skin Necrosis<ul> <li>2-5 days after initiation</li> <li>Well demarcated, center lesion necrotic, thrombi in microvasculature</li> <li>Protein c or s def, initiation</li> <li>Treatment</li> <li>Vitamin K, heparin, discontinue warfatin</li> <li>\u00b1 Protein C (concentrated or in FFP)</li> </ul> </li> <li>Warfarin Metabolism<ul> <li>CYP450 Inhibitors (Increased Warfarin effect)</li> <li>Risk of Hemorrhage</li> <li>Acetaminophen, NSAIDs, Metronidazole, Amiodarone, Cimetidine, Cranberry Juice, Ginkgo biloba, VitE, omeprazole, Thyroid hormone, SSRIs</li> <li>CYP450 Inducers (Decreased Warfarin effect)</li> <li>Risk of Thrombosis</li> <li>Carbamazepine, Phenytoin, Ginseng, St. John Wort, OCPs, Phenobarbital, Rifampin, Spinach/Sprouts (Vitamin K)</li> </ul> </li> <li>INR Management<ul> <li>INR \\&lt;5 + none or minimal bleeding:</li> <li>Hold warfarin for 1-2 days or decrease dose</li> <li>INR 5-9 + none or minimal bleeding:</li> <li>Hold warfarin and resume when INR is therapeutic, give 1-2.5mg oral VitK if increased risk of bleeding</li> <li>INR \u22659 + none or minimal bleeding</li> <li>Hold warfarin and give 2.5-5mg oral VitK</li> <li>Any serious or life-threatening bleeding:</li> <li>Hold warfarin, five 10mg IV Vitk, FFP, recombinant factor VIIa, or PCC</li> </ul> </li> </ul>"},{"location":"im-guide/pharm/blood%26anti-inflammatories/antithrombotics/#b-factor-xa-inhibitors","title":"B) Factor Xa Inhibitors","text":""},{"location":"im-guide/pharm/blood%26anti-inflammatories/antithrombotics/#i-heparinsglycosaminoglycansbinds-antithrombin","title":"I) Heparins/Glycosaminoglycans/Binds Antithrombin","text":""},{"location":"im-guide/pharm/blood%26anti-inflammatories/antithrombotics/#a-unfractionated-heparin-ufh-parenteral","title":"A) Unfractionated Heparin (UFH) (Parenteral)","text":"<ul> <li>Must monitor using aPTT</li> <li>Dose dependent, saturable, weaker binding to endothelial, macrophage, hbpps</li> <li>Activates Antithrombin (III) \u2265 binds fibrin</li> <li>Accelerates Antithrombin clot inhibition<ul> <li>Inhibiting Thrombin and Factor Xa</li> </ul> </li> <li>Forms thrombin-antithrombin complex</li> <li>Can cause platelet activation?</li> <li>Causes TFPI release</li> <li>Neutralized by PF4 (platelet rich thrombi)</li> <li>Heparin Inducted Thrombocytopenia (HIT)</li> <li>Protamine sulfate (1mg to 100U) to reverse</li> <li>SE: Osteoporosis, increase bilirubin</li> </ul>"},{"location":"im-guide/pharm/blood%26anti-inflammatories/antithrombotics/#b-low-molecular-weight-heparin-lmwh-parenteral","title":"B) Low-Molecular-Weight Heparin (LMWH) (Parenteral)","text":"<ul> <li>Enoxaparin (Lovenox)</li> <li>Made from Unfractionated Heparin</li> <li>Greater capacity to potentiate factor Xa inhibition than thrombin due to being a short chain (2:1 \u2013 4:1 Xa to iia)</li> <li>VTE + Cancer</li> <li>Dose independent, renal clearance, rare resistance, no monitoring</li> <li>Little aPTT affect, measure anti-Xa to monitor (Heparin-Xa)</li> <li>Every 4 hours</li> <li>Obesity, renal insufficiency, pregnant, valves</li> </ul>"},{"location":"im-guide/pharm/blood%26anti-inflammatories/antithrombotics/#c-antithrombin-iii-inhibitors-indirect-factor-xa-inhibitors-parenteral","title":"C) Antithrombin III Inhibitors (Indirect Factor Xa inhibitors) (Parenteral)","text":"<ul> <li>Fondaparinux (Arixtra)</li> <li>(smallest heparin chains) AT3</li> <li>Can be used in surgical, ortho, VTE patients, only binds AT3, no thrombin rate inhibition, Xa only, renal cleared, can use in HIT, no antidote, no need to monitor</li> </ul>"},{"location":"im-guide/pharm/blood%26anti-inflammatories/antithrombotics/#ii-direct-factor-xa-inhibitors","title":"II) Direct Factor Xa Inhibitors","text":"<ul> <li>Factor Xa for monitoring</li> <li>Stroke prevent, long term anticoagulation in nonvalvular afib</li> <li>VTE treatment w/o cancer</li> <li>Apixaban (Eliquis)</li> <li>10mg BID for ??</li> <li>5-5mg PO BID</li> <li>Rivaroxaban (Xarelto)</li> <li>15mg BID for 21 days for VTE</li> <li>20mg PO daily with dinner</li> <li>Renal Excretion</li> <li>Edoxaban (Lixiana, Savaysa)</li> <li>60mg PO daily</li> </ul>"},{"location":"im-guide/pharm/blood%26anti-inflammatories/antithrombotics/#c-direct-thrombin-inhibitors-dtis-parenteral","title":"C) Direct Thrombin Inhibitors (DTIs) (Parenteral)","text":"<pre><code>- Inhibit Thrombin (IIa)\n- Bivalent\n  - Lepirudin/Desirudin (Revasc): Renal clearance, no metab\n  - Bivalirudin (Angiomax)\n    - Not renal, no metab\n    - Activated clotting time, aptt\n    - PCI instead of heparin\n- Univalent\n  - Argatroban (acova)\n    - Liver metabolism, not renal\n    - HIT treatment\n    - aPTT, prolongs INR\n      - measure Factor X instead to monitor warfarin\n  - Dabigatran (Pradaxa, Oral)\n    - 150mg PO BID or 75mg PO BID if Crcl = 15-30\n    - Direct Thrombin Inhibitor, Renally excreted, aPTT to monitor\n      - PPIs decrease absorption\n</code></pre> <ul> <li>D) Other<ul> <li>Antithrombin III, Protein C</li> </ul> </li> </ul>"},{"location":"im-guide/pharm/blood%26anti-inflammatories/fibrinolytics/","title":"Fibrinolytics","text":""},{"location":"im-guide/pharm/blood%26anti-inflammatories/fibrinolytics/#general","title":"General","text":"<ul> <li>Degrade thrombi</li> <li>Systemic administration: Acute MI, Acute Ischemic stroke, most Massive PE</li> <li>Catheter based: Peripheral arterial thrombi, proximal deep veins</li> <li>Drugs<ul> <li>All convert plasminogen to plasmin (zymogen to enzyme)<ul> <li>Degrades fibrin matrix</li> </ul> </li> <li>rtPA, alteplase<ul> <li>fibrin specific, plasminogen bound, activated (converts to plasmin)</li> <li>higher fibrin affinity, works better around clots</li> <li>\\&lt;75 w/\\&lt;6h of symptoms of Acute MI, Iv for 1-1.5h</li> </ul> </li> <li>Nonspecific \u2013 fibrin bound and circulating plasminogen activation \u2013 plasmin can cause lytic state<ul> <li>Streptokinase \u2013 no fibrin affinity<ul> <li>IV for Acute MI \u2013 reduce mortality<ul> <li>hypotension</li> </ul> </li> </ul> </li> <li>Urokinase \u2013 not immunogenic, catheter lysis of thrombi</li> </ul> </li> </ul> </li> </ul>"},{"location":"im-guide/pharm/blood%26anti-inflammatories/gout/","title":"Gout","text":"<ul> <li>NSAIDS</li> <li>Colchicine<ul> <li>unless used within past 14 days, hepatic dysfunction, Renal failure \\&lt;30 or P450 inhibitor<ul> <li>2mg now, 0.6mg 1 hour later</li> </ul> </li> </ul> </li> <li>Xanthine Oxidase inhibitors<ul> <li>Allopurinol<ul> <li>Test for HLA-B58:01 genotype in blacks/asians prior to starting<ul> <li>Associated with severe cutaneous adverse reactions (TEN/SJS)</li> <li>Usually associated with CKD and diuretics, high mortality</li> <li>3% in Asians, 3.8% in Blacks, \\&lt;1% in Whites</li> </ul> </li> <li>Start w/ 100mg/day</li> <li>HLA-B58:01 associated with increased risk for allopurinol hypersensitivity syndrome, especially in Asians</li> <li>Max allopurinol is 800mg/day<ul> <li>\u00bd dose if CKD \u2158</li> <li>SE: MCMC of elevated Uric Acid</li> </ul> </li> </ul> </li> <li>Febuxostat<ul> <li>80mg-120mg/day</li> <li>No renal adjustment/ increased risk of heart death</li> </ul> </li> <li>Procine-derived Uricase<ul> <li>Severe recurrent \u00b1 Tophaceous gout</li> <li>Infused every 2 weeks, lowers urate to 0</li> <li>30-50% develop abs against drug in a month</li> </ul> </li> <li>Pegloticase<ul> <li>Used in severe recurrent and/or tophaceous gout intolerant or resistant to standard therapies</li> </ul> </li> <li>Rasburicase<ul> <li>URAT1 transporter inhibitor</li> </ul> </li> </ul> </li> <li>Uricosuric agents<ul> <li>Not as effective</li> <li>CI: CKD, nephrolithiasis</li> <li>Probenecid</li> <li>Lesinurad</li> </ul> </li> </ul>"},{"location":"im-guide/pharm/blood%26anti-inflammatories/steroids/","title":"Steroids","text":""},{"location":"im-guide/pharm/blood%26anti-inflammatories/steroids/#glucocorticoids","title":"Glucocorticoids","text":"<ul> <li>Natural</li> <li>Cortisone Acetate</li> <li>Hydrocortisone<ul> <li>20mg eq, 1 anti inflame potency, 8-12hr, 1/125 mineralocorticoid</li> </ul> </li> <li>Pregnenolone</li> <li>Synthetic</li> <li>Cortisol like<ul> <li>Fludrocortisone (Florinef)</li> <li>1 mineralocorticoid potency</li> <li>Methylprednisolone</li> <li>4mg eq, 5 anti inflame, 18-36hrs, no mineralocorticoid</li> <li>Prednisolone</li> <li>5mg eq, 4 anti inflame, 18-36hrs, 1/150 mineralocorticoid</li> <li>Prednisone</li> <li>5mg eq, 4 anti inflame, 18-36hrs, 1/150 mineralocorticoid</li> </ul> </li> <li>Methasones<ul> <li>Alclometasone</li> <li>Beclometasone (Qvar)</li> <li>Betamethasone</li> <li>Clobetasol</li> <li>Clobetasone</li> <li>Dexamethasone</li> <li>0.75mg eq, 25-50 anti inflame, 36-54hrs, no mineralocorticoid</li> <li>Fluticasone</li> <li>Mometasone</li> <li>Triamcinolone</li> </ul> </li> <li>Cyclic Ketals<ul> <li>Budesonide (Pulmicort)</li> </ul> </li> <li>Anti-glucocorticoids</li> <li>Antagonists</li> <li>Aglepristone</li> <li>Ketoconazole</li> <li>Mifepristone</li> <li>Ulipristal Acetate</li> <li>Synthesis modifiers</li> <li>Ketoconazole</li> <li>Muscle Relaxants</li> <li>Succinylcholine</li> <li>CI: Burns, Neuromuscular Disease/Paraplegia, Eye Trauma, Raised ICP</li> <li>Anesthetic Induction Agents</li> <li>Propofol, Midazolam, Sodium Thiopental</li> <li>Steroids</li> <li>Cushings, Sodium retention/K+ wasting (hypertension), osteopenia, ischemic bone necrosis, myopathy</li> <li>Cancer Drugs</li> <li>Calcineurin Inhibitors<ul> <li>block T cell activation by preventing IL-2 Transcription</li> <li>Cyclosporine and Tacrolimus</li> <li>Highly Nephrotoxic</li> <li>Sirolimus (Rapamycin)</li> <li>Not nephrotoxic</li> </ul> </li> </ul>"},{"location":"im-guide/pharm/blood%26anti-inflammatories/steroids/#glucocorticoid-cessation","title":"Glucocorticoid Cessation","text":"<ul> <li>Indications</li> <li>Therapeutic benefit achieved</li> <li>Uncontrolled SE (hypertension)</li> <li>Severe complications (psychosis)</li> <li>Risks</li> <li>Adrenal insufficiency from HPA axis suppression</li> <li>When to taper</li> <li>\u22653 weeks of daily use</li> <li>Cushingoid appearance</li> </ul>"},{"location":"im-guide/pharm/chemo-id/antibiotics/","title":"Antibiotics","text":"<ul> <li>General</li> <li>Above the diaphragm (Aspiration pneumonia, lung abscesses, oral infections)<ul> <li>1) Clindamycin</li> </ul> </li> <li>Below the Diaphragm (Intra-abdominal anaerobic infections)<ul> <li>1) Metronidazole</li> </ul> </li> <li>Monitoring</li> <li>Aminoglycosides/Vancomycin<ul> <li>If IV \u22653 days or \u22652 days in a renal patient</li> </ul> </li> <li>Penicillin causing rash<ul> <li>Not a contraindication for cephalosporins</li> <li>Breathing issues, edema are CIs</li> </ul> </li> <li>Amoxicillin/Clavulanic Acid (Augmentin)</li> <li>Ampicillin/Sulbactam (Unasyn)</li> <li>Ceftriaxone</li> <li>SE: Cholestasis</li> <li>Cefazolin</li> <li>Prophylaxis for skin flora</li> <li>Cefepime</li> <li>Coverage<ul> <li>Pseudomonas, MSSA, Strep Pneumo, H. Influenzae</li> </ul> </li> <li>Misses<ul> <li>Enterococcus</li> </ul> </li> <li>SE: Neutropenia, thrombocytopenia, Seizure, Delirium, C. Difficile, Transaminitis, Hemolytic anemia, interstitial nephritis</li> <li>Ceftaroline</li> <li>5<sup>th</sup> gen cephalosporin, only one that covers MRSA</li> <li>Clindamycin</li> <li>MOA: Inhibits protein synthesis</li> <li>Effective against Bacteroides and c. perfringens</li> <li>Chloramphenicol</li> <li>50S static</li> <li>Associated w/ blood dyscrasias</li> <li>Daptomycin (Cubicin)</li> <li>Can be considered for MRSA infections when the isolate's vancomycin MIC is \u22652 nanograms/mL or when the vancomycin MIC is close to 2 nanograms/mL and the clinical response is poor<ul> <li>Test susceptibility first</li> </ul> </li> <li>Coverage<ul> <li>MRSA, VRE</li> </ul> </li> <li>SE: LFT elevations, Acute eosinophilic pneumonia, peripheral neuropathy, Falsely elevated INR, Rhabdomyolysis (CK (DC if \u22652000 or \u22651000 w/myopathy), stop statins)</li> <li>Meropenem (Merrem)</li> <li>Coverage<ul> <li>Pseudomonas</li> </ul> </li> <li>Metronidazole</li> <li>MOA: Contains a nitro group that acts as an electron sink, capturing electrons and creating free radicals which disrupts DNA synthesis via a cytotoxic intermediate (Bactericidal)</li> <li>Effective against Bacteroides, prevotella, fusobacterium, clostridium</li> <li>SE:<ul> <li>Disulfiram-like reaction (severe flushing, tachycardia, palpitations, nausea, vomiting, hypotension) with alcohol</li> <li>Metallic taste</li> <li>Headache</li> </ul> </li> <li>Piperacillin-Tazobactam (Zosyn)</li> <li>Coverage<ul> <li>Pseudomonas, Proteus</li> </ul> </li> <li>Misses<ul> <li>C. Difficile</li> </ul> </li> <li>SE: Rash, Drug fever, Prolonged PT, Leukopenia, Thrombocytopenia</li> <li>Telavancin</li> <li>Lipoglycopeptide derivative of vancomycin and can be given once daily</li> <li>More side effects than Vancomycin, worse kidney injury</li> <li>Tuberculosis Medications</li> <li>Rifampin<ul> <li>Benign, red color to body secretions</li> </ul> </li> <li>Isoniazid<ul> <li>Peripheral Neuropathy</li> <li>Use pyridoxine to prevent</li> </ul> </li> <li>Pyrazinamide<ul> <li>Benign, Hyperuricemia (Gout)</li> </ul> </li> <li>Ethambutol<ul> <li>Optic neuritis/color vision changes</li> <li>Decrease dose in renal failure</li> </ul> </li> <li>TMP/SMX</li> <li>CI: Warfarin/Methotrexate use, allergy, elderly with renal insufficiency</li> <li>Vancomycin</li> <li>Red Man Syndrome<ul> <li>MC adverse event, hypersensitivity not reaction</li> <li>Usually 5-10 minutes after starting infusion</li> <li>Diffuse erythema, pruritus, and tenderness over the skin above the waist</li> <li>\u00b1 hypotension, dyspnea if severe</li> <li>Treatment</li> <li>Stop infusion, give antihistamines, restart infusion at slower rate</li> </ul> </li> <li>Dosing Guidelines<ul> <li>Area under the curve, Mean inhibitory concentration</li> <li>Goal for AUC/MIC to be achieved in 24-48 hours</li> </ul> </li> <li>Empiric Therapy<ul> <li>AUC/MIC calculation for empiric therapy assumes MIC to be 1 nanogram/ml or less</li> </ul> </li> <li>MRSA Native Tricuspid Valve Endocarditis<ul> <li>AUC/MIC target of 400-600 mg*hour/L of Vancomycin to maximize efficacy and minimize nephrotoxicity</li> </ul> </li> <li>MRSA Prosthetic Valve Endocarditis<ul> <li>Vancomycin, Gentamicin, and Rifampin</li> </ul> </li> </ul>"},{"location":"im-guide/pharm/chemo-id/antiemetics/","title":"Antiemetics","text":""},{"location":"im-guide/pharm/chemo-id/antiemetics/#nausea-causing-medications","title":"Nausea Causing Medications","text":"<ul> <li>Aspirin, NSAIDs, Opioids</li> <li>Erythromycin, sulfonamides, Acyclovir</li> <li>Antiarrhythmics, Antihypertensives, Digoxin, Diuretics</li> <li>Contraception, Antidiabetic meds</li> <li>Anticonvulsants, Parkinson's Disease meds</li> <li>W/U: Residuals</li> </ul>"},{"location":"im-guide/pharm/chemo-id/antiemetics/#selective-5-ht3-antagonist","title":"Selective 5-HT3 Antagonist","text":"<ul> <li>MOA: Block serotonin receptors in the CNS and GI<ul> <li>Works on GI tract primarily, but CNS/PNS also</li> <li>Used in gastroenteritis</li> <li>SE: Headache, constipation, diarrhea, dry mouth, fatigue, Serotonin Syndrome, QTc Prolongation</li> <li>CI: PKU, Hepatic Impairment</li> </ul> </li> <li>Ondansetron (Zofran)<ul> <li>Dose: 4-8mg Oral, Sublingual, IV over 15 minutes</li> <li>SE: QTc Prolongation, Activating</li> </ul> </li> <li>Palonosetron (Aloxi)<ul> <li>Dose: 0.25mg IV</li> <li>No QT prolongation, 40 hour half life, better than 8mg zofran</li> <li>SE: Activating</li> </ul> </li> <li>Dolasetron</li> <li>Granisetron<ul> <li>Oral, IV, Subcutaneous, Transdermal</li> </ul> </li> </ul>"},{"location":"im-guide/pharm/chemo-id/antiemetics/#histamine-h1-receptor-antagonists","title":"Histamine (H1) Receptor Antagonists","text":"<ul> <li>Notes:<ul> <li>Works on CNS (area postrema) and in the vestibular nucleus</li> <li>SE: QTc Prolongation</li> </ul> </li> <li>Diphenhydramine (Benadryl)<ul> <li>10-50mg per dose, up to 100mg per dose, 400mg per day</li> <li>Oral, IV, IM</li> <li>SE: QTc Prolongation</li> <li>CI: Acute asthma, GI obstruction, Closed angle glaucoma</li> </ul> </li> <li>Meclizine<ul> <li>No QTc prolongation</li> </ul> </li> <li>Dimenhydrinate<ul> <li>No QTc prolongation</li> </ul> </li> <li>Cyclizine</li> <li>Mirtazapine (Remeron)</li> <li>Hydroxyzine (Vistaril)<ul> <li>Quick acting, short-term, anxiolytic, insomnia</li> <li>SE: sedation, dry mouth, constipation, urinary retention, blurry vision<ul> <li>QTc Prolongation</li> </ul> </li> </ul> </li> </ul>"},{"location":"im-guide/pharm/chemo-id/antiemetics/#phenothiazine","title":"Phenothiazine","text":"<ul> <li>Prochlorperazine (Compazine)<ul> <li>MOA: D2 antagonism \u2265 H1 = M1</li> <li>Dose: 10mg IV</li> <li>Little to no QTc prolongation</li> <li>SE: Extrapyramidal SE, M1 activity</li> </ul> </li> <li>Chlorpromazine (Thorazine)<ul> <li>MOA: D2 = H1 \u2265 M1 \u2265 5HT3</li> <li>Dose: 25mg IV/IM</li> <li>SE: Extrapyramidal SE, QTc Prolongation, M1 activity</li> </ul> </li> <li>Promethazine (Phenergan)<ul> <li>MOA: H1 \u2265 M1 \u2265 D2</li> <li>Dose: 12.5-25mg PO/IM</li> <li>SE: Extrapyramidal SE, QTc Prolongation, Most M1 activity</li> </ul> </li> </ul>"},{"location":"im-guide/pharm/chemo-id/antiemetics/#butyrophenone","title":"Butyrophenone","text":"<ul> <li>Droperidol<ul> <li>MOA: D2 Antagonism \u2265\u2265\u2265 H1</li> <li>Dose: 0.625-2.5 IV, IM</li> <li>SE: QTc Prolongation</li> </ul> </li> <li>Haloperidol<ul> <li>MOA: D2 Antagonism \u2265\u2265\u2265 H1</li> <li>Dose: 2-5 mg IV, Oral, IM</li> <li>SE: QTc Prolongation</li> </ul> </li> </ul>"},{"location":"im-guide/pharm/chemo-id/antiemetics/#benzamide","title":"Benzamide","text":"<ul> <li>Metoclopramide<ul> <li>MOA: D2 \u2265 5-H3T antagonism, Cholinergic Agonism</li> <li>10-20mg Oral, IV, IM</li> <li>SE: QTc Prolongation</li> </ul> </li> <li>Domperidone<ul> <li>MOA: D2 antagonism</li> <li>Oral</li> <li>SE: QTc Prolongation, Headache, Xerostomia</li> </ul> </li> </ul>"},{"location":"im-guide/pharm/chemo-id/antiemetics/#antimuscarinic","title":"Antimuscarinic","text":"<ul> <li>MOA: M1 antagonism</li> <li>Scopolamine<ul> <li>Transdermal</li> <li>No QTc Prolongation</li> <li>SE: Xerostomia, Blurry Vision, Fatigue</li> </ul> </li> </ul>"},{"location":"im-guide/pharm/chemo-id/antiemetics/#benzodiazepines","title":"Benzodiazepines","text":"<ul> <li>GABA-A Agonism</li> <li>SE: Anterograde amnesia</li> <li>No QTc Prolongation</li> <li>Lorazepam<ul> <li>Oral, Sublingual, IV, IM</li> </ul> </li> <li>Alprazolam<ul> <li>Oral</li> </ul> </li> </ul>"},{"location":"im-guide/pharm/chemo-id/antiemetics/#glucocorticoid","title":"Glucocorticoid","text":"<ul> <li>Dexamethasone (Decadron)</li> <li>No QTc prolongation</li> </ul>"},{"location":"im-guide/pharm/chemo-id/antiemetics/#neurokinin-receptor-antagonists","title":"Neurokinin Receptor Antagonists","text":"<ul> <li>MOA: NK1 Antagonism</li> <li>No QTc Prolongation</li> <li>Aprepitant<ul> <li>Oral</li> <li>SE: CYP3A4 Inhibitor, fatigue, Neutropenia (\u2265 in children)</li> </ul> </li> <li>Fosaprepitant<ul> <li>IV</li> <li>SE: CYP3A4 Inhibitor, fatigue, Neutropenia (\u2265 in children)</li> </ul> </li> <li>Netupitant<ul> <li>SE: CYP3A4 Inhibitor, fatigue, Neutropenia (\u2265 in children)</li> </ul> </li> <li>Rolapitant<ul> <li>SE: CYP2D5 inhibitor, Dizziness</li> </ul> </li> </ul>"},{"location":"im-guide/pharm/chemo-id/antiemetics/#dopamine-antagonists","title":"Dopamine Antagonists","text":"<ul> <li>SE: muscle spasms, restlessness</li> <li>Olanzapine (Zyprexa)</li> </ul>"},{"location":"im-guide/pharm/chemo-id/antiemetics/#appetite-stimulants-orexigenic","title":"Appetite Stimulants (Orexigenic)","text":"<ul> <li>Dronabinol</li> <li>Mirtazapine (Remeron)</li> <li>Prednisone</li> <li>Megestrol</li> <li>Lithium</li> <li>Insulin</li> </ul>"},{"location":"im-guide/pharm/chemo-id/antivirals/","title":"Antivirals","text":"<ul> <li>HAART when CD4+ \\&lt;350-500 or Viral Load \u2265 55K<ul> <li>2+1 Therapy (NRTI + Protease Inhibitor or NNRTI)</li> </ul> </li> <li>Pre-Exposure Prophylaxis (PrEP): Tenofovir Disoproxil and Emtricitabine</li> <li>Post-Exposure Prophylaxis (PEP): AZT, Lamivudine and nelfinavir for 4 weeks<ul> <li>Emtricitabine + Tenofovir Disoproxil + (Darunavir or Dolutegravir)</li> </ul> </li> <li>Pregnant<ul> <li>Efavirenz and TDF</li> </ul> </li> <li>Nucleoside RTIs (NRTIs)<ul> <li>MOA: Inhibits HIV DNA synthesis from RNA template by terminating DNA chain elongation<ul> <li>Competitive nucleoside/tide RT inhibitor</li> </ul> </li> <li>Abacavir (ABC)<ul> <li>SE: Lethal if HLA-B5701, test them, SJS</li> </ul> </li> <li>Emtricitabine (FTC)</li> <li>Lamivudine (3TC)<ul> <li>HBV activity but different dosing</li> <li>Minimal toxicity</li> </ul> </li> <li>Stavudine (d4T) and Didanosine (ddl)<ul> <li>SE: Peripheral neuropathy and Pancreatitis</li> </ul> </li> <li>Tenofovir Disoproxil Fumerate (TDF)<ul> <li>HBV activity</li> <li>SE: Nausea, Fanconi syndrome, Renal insufficiency, tubular nephrotoxicity, Osteoporosis<ul> <li>Get DEXA in Men \u226550, Post-menopausal, RF</li> </ul> </li> </ul> </li> <li>Tenofovir Alafenamide (TAF)<ul> <li>Better than TDF</li> <li>SE: Nausea, More weight gain, Less Renal insufficiency, Osteoporosis<ul> <li>Get DEXA in Men \u226550, Post-menopausal, RF</li> </ul> </li> </ul> </li> <li>Zidovudine (AZT)<ul> <li>SE: Nausea, headache, anemia and Granulocytopenia, lactic acidosis, lipodystrophy, myopathy</li> </ul> </li> </ul> </li> <li>Nonnucleoside RTIs (NNRTIs)<ul> <li>MOA: Inhibits HIV DNA synthesis from RNA template by terminating DNA chain elongation<ul> <li>Allosteric RT Inhibitor</li> </ul> </li> <li>Nevirapine<ul> <li>Hypersensitivity, rash, hepatitis</li> </ul> </li> <li>Ertavirine</li> <li>Efavirenz<ul> <li>SE: Sleep, confused, psychotic, vivid dreams, rash, dyslipidemia</li> </ul> </li> <li>Rilpivirine<ul> <li>CI: PPIs (needs food and gastric acid for absorption)</li> </ul> </li> <li>Doravirine</li> </ul> </li> <li>Protease Inhibitors<ul> <li>MOA: Inhibits HIV polyprotein cleavage<ul> <li>General: Hyperlipidemia, Hyperglycemia</li> </ul> </li> <li>Atazanavir</li> <li>Darunavir</li> <li>Lopinavir</li> <li>Indinavir<ul> <li>SE: Nephrolithiasis, hyperbilirubinemia</li> </ul> </li> </ul> </li> <li>Integrase Inhibitors<ul> <li>MOA: Inhibits HIV DNA integration into host genome</li> <li>Dolutegravir</li> <li>Elvitegravir</li> <li>Bictegravir</li> <li>Raltegravir</li> </ul> </li> <li>Fusion Inhibitors<ul> <li>MOA: Inhibits HIV fusion with target cell membrane by binding to HIV gp41</li> <li>Enfuvirtide</li> </ul> </li> <li>CCR5 Antagonist<ul> <li>MOA: Inhibits HIV entry by allosteric blocking of HIV gp120 interaction with CCR5 (tropism testing required)</li> <li>Maraviroc</li> </ul> </li> <li>Pharmacokinetic Boosters<ul> <li>Ritonavir<ul> <li>Low dose added to boost other Protease Inhibitor drug level<ul> <li>(Darunavir or Dolutegravir)</li> </ul> </li> </ul> </li> <li>Cobicistat</li> </ul> </li> </ul>"},{"location":"im-guide/pharm/chemo-id/oncologic_meds/","title":"Oncologic Medications","text":""},{"location":"im-guide/pharm/chemo-id/oncologic_meds/#general","title":"General","text":"<ul> <li>New Afib in cancer patients is associated with increased risk of HF and VTW</li> </ul>"},{"location":"im-guide/pharm/chemo-id/oncologic_meds/#common-groups","title":"Common Groups","text":"<ul> <li>ABVD<ul> <li>Adriamycin, Bleomycin, Vinblastine, Dacarbazine</li> <li>Hodgkin Lymphoma</li> </ul> </li> <li>BEACOPP<ul> <li>Bleomycin, Etoposide, Adriamycin/doxorubicin, Cyclophosphamide, Oncovorin/vincristine, Procarbazine, Prednisone</li> <li>Hodgkin Lymphoma</li> </ul> </li> <li>FOLFOX<ul> <li>Leucovorin, Fluorouracil, Oxaliplatin</li> </ul> </li> <li>R-CHOP<ul> <li>Rituximab, Cyclophosphamide, Hydroxy-doxorubicin, Oncovorin/Vincristine, Prednisone</li> </ul> </li> <li>5-Fluorouracil (5-FU)<ul> <li>MOA: Direct Inhibitor of pyrimidine synthesis (blocks thymidylate synthase), thereby blocking protein and DNA synthesis<ul> <li>Leucovorin increases 5-FU effectiveness</li> </ul> </li> <li>Anti-metabolite<ul> <li>Inflammation resolves about 2 weeks after treatment discontinuation</li> </ul> </li> <li>SE: Myelosuppression and Photosensitivity, Palmar-plant erythrodysesthesia (hand-foot syndrome), cerebellar toxicity</li> </ul> </li> <li>6-Mercaptopurine (6-MP)<ul> <li>Anti-metabolite, metabolized by xanthine oxidase (inhibited by allopurinol)<ul> <li>Side effects are worse when on allopurinol (stop or reduce)</li> <li>Thiopurine</li> </ul> </li> <li>SE: Myelosuppressive, Hepatotoxic, Interacts with allopurinol</li> <li>Azathioprine<ul> <li>Converted to 6-MU and also metabolized by xanthine oxidase, also interacts with allopurinol</li> </ul> </li> </ul> </li> <li>Alemtuzumab (Lemtrada)<ul> <li>Anti-CD52</li> <li>Use: CLL, MS</li> </ul> </li> <li>All-Trans Retinoic Acid (ATRA)<ul> <li>MOA: Inhibits transcriptional repression by PML-RARa</li> <li>Tretinoin<ul> <li>Formulation of Vitamin A, targeted therapy for Acute Promyelocytic Leukemia (M3 variant)<ul> <li>Causes immature myeloblasts to differentiate into mature myelocytes</li> </ul> </li> </ul> </li> <li>Combined with an Anthracycline (Daunorubicin, Idarubicin) for best results</li> <li>SE: Rashes, Teratogenic, DIC</li> </ul> </li> <li>Aromatase Inhibitors<ul> <li>Anastrozole, letrozole, and vorozole</li> <li>Block formation of new estrogen (good for metastatic disease)</li> <li>Give Calcium and Vitamin D supplements, Get DEXA<ul> <li>Bisphosphonates or denosumab if osteoporotic</li> </ul> </li> <li>Increased risk of osteoporosis and fracture</li> <li>SE: Arthralgia, joint stiffness and bone pain in 33%, Vaginal dryness, sexual dysfunction, CV events, hyperlipidemia, and higher risks of osteoporosis and fractures</li> </ul> </li> <li>Axitinib (Inlyta)<ul> <li>Use: RCC</li> </ul> </li> <li>Bevacizumab (Avastin)<ul> <li>Anti-VEGF</li> <li>Use: Colorectal cancer, renal cell carcinoma, non-small cell lung cancer</li> <li>SE: PRES syndrome</li> </ul> </li> <li>Bleomycin<ul> <li>Antitumor antibiotic used in testicular cancer and Hodgkin's Lymphoma</li> <li>No myelosuppression (vs. Busulfan)<ul> <li>Induces free radical formation and cause breaks in DNA</li> </ul> </li> <li>SE: Severe Pulmonary Fibrosis, Fever, and hypersensitivity</li> </ul> </li> <li>Bortezomib (Velcade)<ul> <li>MOA: Proteasome inhibitor</li> <li>SE: Peripheral Neuropathy, Herpes Reactivation<ul> <li>Prophylactic acyclovir or valacyclovir</li> </ul> </li> </ul> </li> <li>Busulfan<ul> <li>Alkylates DNA</li> <li>Pulmonary Fibrosis and myelosuppression</li> </ul> </li> <li>Capecitabine (Xeloda)<ul> <li>Adjuvant for colon cancer</li> <li>SE: Palmar-plant erythrodysesthesia (hand-foot syndrome)</li> </ul> </li> <li>Caplacizumab (Cablivi)<ul> <li>Monoclonal antibody</li> <li>Use: Severe TTP</li> </ul> </li> <li>Cetuximab (Erbitux)<ul> <li>Anti-EGFR</li> <li>Stage IV colorectal cancer, head and neck cancers</li> <li>SE: Pustular acneiform eruptions (severe), pulmonary toxicity</li> </ul> </li> <li>Chemotherapy-Induced Cardiotoxicity<ul> <li>Type I<ul> <li>Associated with Anthracyclines<ul> <li>Daunorubicin</li> <li>Doxorubicin (Adriamycin, Doxil)</li> <li>Idarubicin</li> <li>Generate free radicals to intercalate DNA<ul> <li>Causes severe tissue necrosis</li> </ul> </li> </ul> </li> <li>Myocyte Necrosis and destruction w/fibrosis<ul> <li>Progression to overt clinical heart failure</li> <li>Less likely to be reversible</li> </ul> </li> <li>SE: Dilated Cardiomyopathy with chronic use<ul> <li>Antitumor Antibiotic, myelosuppression, alopecia, severe gastric upset secondary to colonic mucositis</li> <li>Total cumulative dose is most strongly related to risk</li> </ul> </li> <li>Antidote is Dexrazoxane<ul> <li>Iron-chelating agent used for cardiac protection</li> </ul> </li> </ul> </li> <li>Type II<ul> <li>Associated with Trastuzumab</li> <li>Myocardial stunning/hibernation w/o myocyte destruction</li> <li>Asymptomatic LV systolic dysfunction</li> <li>More likely to be reversible</li> </ul> </li> </ul> </li> <li>Cyclophosphamide (Cytoxan)<ul> <li>Covalently links DNA at guanine N-7</li> <li>SE: Hemorrhagic Cystitis, SIADH (hyponatremia), bladder carcinoma, myelosuppression, sterility (acrolein, metabolite causes all the damage)<ul> <li>Cystitis can be treated with 2-Mercaptoethanesulfonate (Mensa) which binds the metabolite acrolein (bladder irritant), fluids</li> <li>Alkylating agents put patient at risk for developing secondary cancer (Acute Leukemia)</li> </ul> </li> </ul> </li> <li>Dactinomycin<ul> <li>Intercalates DNA</li> <li>Used in Wilms' Tumor, Ewing Sarcoma, Rhabdomyosarcoma</li> </ul> </li> <li>Dasatinib (Sprycel)<ul> <li>Tyrosine Kinase Inhibitor</li> <li>Used in CML</li> <li>SE: pulmonary hypertension</li> </ul> </li> <li>Daunorubicin (Cerubidine)<ul> <li>Anthracyclines</li> <li>Generate free radicals to intercalate DNA<ul> <li>Causes severe tissue necrosis</li> </ul> </li> <li>SE: Dilated Cardiomyopathy with chronic use, Mucositis, stomatitis<ul> <li>Antitumor Antibiotic, myelosuppression, alopecia, severe gastric upset secondary to colonic mucositis</li> <li>Total cumulative dose is most strongly related to risk</li> </ul> </li> <li>Antidote is Dexrazoxane<ul> <li>Iron-chelating agent used for cardiac protection</li> </ul> </li> </ul> </li> <li>Doxorubicin (Hydroxydaunomycin)<ul> <li>SE: Mucositis, stomatitis</li> </ul> </li> <li>Eculizumab<ul> <li>MOA: Monoclonal antibody against C5, blocks cleavage and blocks formation of the C5-9 complex<ul> <li>Used in Paroxysmal nocturnal hemoglobinuria</li> </ul> </li> </ul> </li> <li>Elotuzumab<ul> <li>MOA: Activating NK cells to kill MM cells, Targets SLAMF7</li> </ul> </li> <li>Erlotinib<ul> <li>SE: Pustular acneiform eruptions (weak), pulmonary toxicity</li> </ul> </li> <li>Folinic Acid (Leucovorin)</li> <li>Gefitinib<ul> <li>SE: Pustular acneiform eruptions (weak)</li> </ul> </li> <li>Hydroxyurea<ul> <li>MOA: Inhibits ribonucleotide reductase, decreasing DNA synthesis</li> <li>Use: Essential Thrombocytopenia, PCV</li> </ul> </li> <li>Ibrutinib (Imbruvica)<ul> <li>Tyrosine Kinase Inhibitor, binds BTK</li> <li>Metabolized by CYP3A4<ul> <li>Increases digoxin levels</li> </ul> </li> <li>Use: CLL, B-cell Lymphoma</li> <li>SE: Increased rates of Atrial Fibrillation (up to 16%) \u2013 Don't use CCBs</li> </ul> </li> <li>Imatinib (Gleevec)<ul> <li>MOA: Blocks ATP binding to tyrosine kinase active site</li> <li>Use: CML, GIST<ul> <li>Blocks BCR-ABL fusion</li> </ul> </li> <li>Can be held without significant change in labs, may hold for entire pregnancy without problems</li> <li>SE: Nausea</li> </ul> </li> <li>Ifosfamide<ul> <li>SE: hemorrhagic cystitis</li> </ul> </li> <li>Lenalidomide (Revlimid)</li> <li>Methotrexate<ul> <li>MOA: Folate Antagonist (Dihydrofolate Reductase Inhibitor)<ul> <li>Converts oxidized folate back into its reduced form to be used in pyrimidine synthesis<ul> <li>Can be bypassed/fixed by Leucovorin (N5-formyltetrahydrofolate)</li> </ul> </li> <li>used in Rheumatoid Arthritis also</li> <li>Stops DNA and protein synthesis hindering S-phase</li> </ul> </li> <li>SE: Myelosuppression and Abortifacient, Hepatotoxicity, stomatitis, cytopenia</li> </ul> </li> </ul>"},{"location":"im-guide/pharm/chemo-id/oncologic_meds/#microtubule-inhibitors","title":"Microtubule Inhibitors","text":"<ul> <li>Taxols/Taxanes<ul> <li>MOA: Inhibit microtubule degradation<ul> <li>Bind polymerized microtubules and stabilize the mitotic spindle so it can not break down</li> <li>Inhibiting dynein</li> <li>Cell phase: M phase</li> </ul> </li> <li>SE: Some myelosuppression</li> <li>Paclitaxel (Taxol)<ul> <li>Nab-paclitaxel (Abraxane)</li> </ul> </li> <li>Docetaxel (Taxotere)</li> </ul> </li> <li>Vinca Alkaloids<ul> <li>MOA: Inhibits microtubule production and assembly<ul> <li>Bind B-tubulin and block polymerization, therefore the mitotic spindle cannot form</li> <li>Inhibit kinesin</li> <li>Cell phase: M phase</li> </ul> </li> <li>Use: Hematologic and solid malignancies</li> <li>SE: Alopecia, Paralytic ileus/constipation</li> <li>Vincristine:<ul> <li>Use: Non-Hodgkin</li> <li>SE: Peripheral Neuropathies (Neurotoxic), Alopecia<ul> <li>Stocking and glove distribution</li> <li>Areflexia, peripheral neuritis, motor symptoms less commonly</li> <li>Autonomic dysfunction</li> <li>Paralytic ileus/constipation</li> <li>Some myelosuppression usually mild</li> </ul> </li> </ul> </li> <li>Vinblastine<ul> <li>Use: Hodgkin</li> <li>SE: Profound Bone Marrow Suppression, Alopecia</li> </ul> </li> </ul> </li> <li>Mitomycin<ul> <li>Antitumor Antibiotic</li> <li>SE: Hemolytic Uremic Syndrome</li> </ul> </li> <li>Nilotinib<ul> <li>SE: Coronary insufficiency</li> </ul> </li> <li>Nitrosoureas<ul> <li>Can cross BBB to treat brain cancer</li> <li>SE: pulmonary fibrosis</li> <li>Carmustine</li> <li>Lomustine</li> <li>Semustine</li> <li>Streptozocin</li> </ul> </li> <li>Panitumumab (Vectibix)<ul> <li>SE: Pustular acneiform eruptions (severe)</li> </ul> </li> <li>Platinum Drugs<ul> <li>General<ul> <li>Prevent nephrotoxicity with Amifostine</li> <li>Magnesium wasting (hypomagnesemia)</li> </ul> </li> <li>Carboplatin<ul> <li>Platinum Alkylating Agent<ul> <li>Hydrate well to protect the kidneys, highly emetogenic (give something for vomiting)</li> </ul> </li> <li>SE: Myelosuppression is main/dose limiting SE<ul> <li>Less other SE than Cisplatin<ul> <li>Ototoxicity and Nephrotoxicity</li> <li>Less nephrotoxic than Cisplatin</li> </ul> </li> </ul> </li> </ul> </li> <li>Cisplatin<ul> <li>Platinum Alkylating Agent<ul> <li>Prevents replication of tumor cells by causing intra-stand links within DNA</li> </ul> </li> <li>SE: Myelosuppression, Peripheral Neuropathies (stocking glove), Nephrotoxic (ATN), Ototoxic, electrolyte abnormalities, Tinnitus, N/V<ul> <li>Less nephrotoxic with aggressive hydration</li> </ul> </li> </ul> </li> <li>Oxaliplatin<ul> <li>SE: Peripheral Neuropathies (stocking glove), transient cold hypersensitivity<ul> <li>No cold items for several days after infusions</li> </ul> </li> </ul> </li> </ul> </li> <li>Ponatinib<ul> <li>SE: Coronary insufficiency</li> </ul> </li> <li>Purine Analogs<ul> <li>MOA: Cytotoxic purine analog<ul> <li>Inhibits DNA polymerase Alpha and Beta</li> <li>SE: Immunosuppression</li> </ul> </li> <li>Cladribine/Pentostatin<ul> <li>Used in symptomatic hairy cell leukemias</li> </ul> </li> </ul> </li> <li>Pyrimidine Analogs<ul> <li>MOA: Cytotoxic pyrimidine analog</li> <li>Inhibits DNA polymerase Alpha and Beta</li> <li>SE: Immunosuppression/Myelosuppression</li> <li>Gemcitabine (Gemzar)<ul> <li>Used in hematologic and solid tumors, small-cell</li> <li>SE: Severe Pulmonary Fibrosis, Hemolytic Uremic Syndrome</li> </ul> </li> <li>Cytarabine (Ara-C)<ul> <li>Aka Arabinofuranosyl Cytidine</li> <li>Used in Non-M3 AML, non-Hodgkin Lymphoma hematologic cancers only</li> <li>Cell Cycle: S phase</li> <li>SE: Megaloblastic Macrocytic anemia, cerebellar toxicity</li> </ul> </li> <li>Radiation<ul> <li>MOA: Damages DNA, preventing tumor cell division or directly killing the cells<ul> <li>Can decrease the tumor size or kill any existing tumor cells</li> </ul> </li> <li>SE: Slower wound healing, fibrosis, ulcerations, strictures, irritation, neurologic deficits, BM suppression, 2ndary cancers (sarcomas, thyroid cancer, CML)</li> <li>Goals: First line in some tumors<ul> <li>Eradicate smaller tumors</li> <li>Sensitize cancer cells to radiation therapy</li> </ul> </li> </ul> </li> </ul> </li> <li>Selective Estrogen Receptor Antagonist (SERM)<ul> <li>Tamoxifen<ul> <li>Antagonist in the breasts, Agonist in the Endometrium and bone</li> <li>SE: Deep Venous Thrombosis (DVT), hot flashes, endometrial cancer risk, teratogenic</li> </ul> </li> <li>Raloxifene<ul> <li>Antagonist in the breasts and endometrium, agonist in bone (osteoporosis treatment)</li> <li>No increased risk for cancer</li> <li>SE: Deep Venous Thrombosis (DVT), hot flashes</li> </ul> </li> </ul> </li> <li>Sunitinib (Sutent)<ul> <li>SE: PRES syndroms</li> </ul> </li> <li>Thalidomide (Thalomid)</li> <li>Topoisomerase Inhibitors<ul> <li>Cell Cycles affected: S, G2</li> <li>MOA: Eukaryotic Topoisomerase I Inhibitors<ul> <li>Topotecan<ul> <li>Used in ovarian and small cell lung cancer</li> </ul> </li> <li>Irinotecan<ul> <li>Used in Colon cancer</li> </ul> </li> <li>SE: Severe/Life-threatening Diarrhea</li> </ul> </li> <li>MOA: Eukaryotic Topoisomerase II Inhibitors<ul> <li>Etoposide</li> <li>Teniposide</li> <li>Inhibits relegation of double strand breaks caused by topoisomerase II</li> <li>Used in a regimen with bleomycin and cisplatin for testicular masses, small cell lung cancer, Hodgkin and non-Hodgkin Lymphoma</li> <li>SE: Alopecia, myelosuppression, Immunosuppression</li> </ul> </li> </ul> </li> <li>Trastuzumab<ul> <li>MOA: Anti-HER2/neu antibody<ul> <li>Binds HER2 on tumor surface and induces receptor internalization</li> </ul> </li> <li>Use: HER2 (+) Breast cancer, Gastric cancer</li> <li>SE: Type II Cardiotoxicity, pulmonary toxicity, oligohydramnios<ul> <li>Avoid pregnancy for 7 months last dose</li> </ul> </li> </ul> </li> <li>Tretinoin<ul> <li>Formulation of Vitamin A, targeted therapy for Acute Promyelocytic Leukemia (M3 variant)</li> <li>SE: Rashes, Teratogenic</li> </ul> </li> <li>Vincristine (Oncovorin)</li> </ul>"},{"location":"im-guide/pharm/chemo-id/oncologic_meds/#cancer-related-cachexia","title":"Cancer-related Cachexia","text":"<ul> <li>Hypercatabolic state characterized by appetite and weight loss with a disproportionate loss of skeletal muscle</li> <li>Treatment<ul> <li>Progesterone analogs (Megestrol acetate, Medroxyprogesterone) and corticosteroids (Dexamethasone)<ul> <li>PAs preferred in pts with longer life expectancies</li> </ul> </li> </ul> </li> </ul>"},{"location":"im-guide/pharm/endocrine/antiobesity/","title":"Antiobesity","text":"<ul> <li>Definitions</li> <li>Normal Weight: 18.5-24.9 kg/m^2</li> <li>Overweight: 25-29.9 kg/m^2<ul> <li>Measure waist + co-morbidities</li> <li>25-26.9 + co-morbidities: Lifestyle</li> <li>27-29.9 + co-morbidities: Lifestyle + Pharmacotherapy</li> </ul> </li> <li>Obese: \u226530 kg/m^2<ul> <li>Class 1: 30-34.9 kg/m^2</li> <li>Lifestyle + Pharmacotherapy</li> <li>Class 2: 35-39.9 kg/m^2</li> <li>\u22655-10% over 6m goal</li> <li>Healthy: Lifestyle + Pharmacotherapy</li> <li>With co-morbidities: Bariatric Surgery</li> <li>Class 3: \u226540 kg/m^2</li> <li>Bariatric Surgery</li> </ul> </li> <li>Bariatric Surgery</li> <li>Resolves T2DM in 73%, HTN 63%, OSA 78%, fertility, decreased 4.5y mortality</li> <li>Roux-en-Y gastric Bypass = best, 1yr: 31.2% reduction of weight, 25.5% at 5y</li> <li>Sleeve: 1yr: 25.2% reduction of weight, 18.8% at 5y</li> <li>Adjustable gastric band: 1yr: 13.7% reduction of weight, 11.7% at 5y</li> <li>Thiamine: 12-50mg daily, B12 500mcg daily or 1000mcg monthly, Folate: 400-800mcg daily, vitamin A:5000-10000 IU daily, Vitamin E: 15mg daily, VitK: 90-120mcg daily, D3: 3000IU daily, Calcium: 500-600mg TID, Iron: 18mg-60mg daily, Zinc: 8-22mg daily, Copper 1-2mg daily (8 to 1mg with zinc to prevent copper deficiency)<ul> <li>Labs 3-6m in 1<sup>st</sup> year, Q6 after</li> <li>CBC, CMP, pre-albumin, b12, thiamine, folate, vitamin A and D, PTH, iron, ferritin</li> </ul> </li> <li>Lifestyle</li> <li>Reduction in 500-750 kcal/day = 1-2 lbs per week</li> <li>150 up to 300 minutes per week</li> <li>Orlistat (Xenical, Alli)</li> <li>Indicated for use \u22653 months</li> <li>Lipase Inhibitor<ul> <li>Lowers BP ~10mmHg, reduces total cholesterol, LDL, triglycerides, risk of progression to diabetes, reduces need for diabetes meds</li> </ul> </li> <li>60mg TID to 120mg TID</li> <li>-2.6kg at 6m, -2.9kg at 12m</li> <li>SE: Liver injury, Diarrhea, flatulence, fecal urgency, dyspepsia</li> <li>Phentermine/Topiramate (Qsymia/Qnexa)</li> <li>Approved for use \u22653m and \\&lt;3m</li> <li>Appetite suppressant<ul> <li>Positive effect on CV outcomes, Lowers BP and decreases need for BP meds, increases HR slightly at max dose, reduces need for diabetes meds</li> </ul> </li> <li>8mg TID to 37.5mg daily</li> <li>5/46mg daily recommended, 15/92mg daily max<ul> <li>1kg at 12m at recommended, -10.2 kg at 12m at max</li> </ul> </li> <li>SE: constipation, xerostomia, dizziness, seizure, insomnia, depression, hypohidrosis, angle closure glaucoma, birth defects</li> <li>Naltrexone/Bupropion (Contrave)</li> <li>Approved for use \u22653m</li> <li>Appetite suppressant, opioid antagonist/aminoketone antidepressant<ul> <li>No CV benefits, reduces waist circumference, triglycerides, and HDL, reduces need for diabetes meds</li> </ul> </li> <li>16/180mg BID</li> <li>-4.1kg at 12m</li> <li>SE: Nausea, constipation, headache, vomiting, seizures, hepatotoxicity, increased BP and HR</li> <li>Liraglutide (Saxenda)</li> <li>Appetite suppressant; GLP-1 receptor agonist<ul> <li>reduces waist circumference, Lowers BP, reduces LDL and triglycerides, risk of progression to diabetes</li> </ul> </li> <li>Approved for use \u22653m</li> <li>3mg subq daily</li> <li>-4.5kg at 12 months</li> <li>SE: Nausea, hypoglycemia, diarrhea, constipation, headache, pancreatitis, GB disease, thyroid carcinoma, Thyroid tumors</li> <li>Semaglutide (Wegovy)</li> <li>Appetite suppressant; GLP-1 receptor agonist</li> <li>Approved for use \u22653m</li> <li>4mg subq weekly</li> <li>-15.3kg at 14 months</li> <li>SE: Nausea, hypoglycemia, diarrhea, constipation, headache, pancreatitis, GB disease, thyroid carcinoma, Thyroid tumors</li> <li>Diethylpropion</li> <li>FDA approved for \\&lt;3m</li> <li>25mg TID</li> <li>SR: 75mg daily</li> <li>Phendimetrazine</li> <li>FDA approved for \\&lt;3m</li> <li>5-70mg BID to TID</li> <li>SR: 105mg daily</li> <li>Benzphetamine</li> <li>FDA approved for \\&lt;3m</li> <li>20-50mg daily to TID</li> <li>Cetilistat</li> <li>Lorcaserin (Belviq)</li> <li>Metformin</li> <li>Exenatide</li> </ul>"},{"location":"im-guide/pharm/endocrine/diabetes_management/","title":"Diabetes Management","text":"<ul> <li>1) Insulin Sensitizers: Lower Glucose by their actions on the liver, muscle and adipose tissue</li> <li>A) Biguanides<ul> <li>MOA: Increases hepatic AMPK, inhibits mitochondrial hepatic gluconeogenesis and lipogenesis, increases peripheral uptake</li> <li>Reduces hepatic gluconeogenesis and glycogenolysis</li> <li>Metformin (Glucophage)</li> <li>500mg once to twice daily or 850mg once daily<ul> <li>Double dose after 5-7 days if no GI SE</li> <li>Max: 850mg BID or 1000mg BID, lower dose if GI SE</li> </ul> </li> <li>1<sup>st</sup> line therapy for T2DM, works on the liver<ul> <li>Inhibits mGPD and Complex 1</li> </ul> </li> <li>Improves fasting and postprandial hyperglycemia and hypertriglyceridemia in obese w/DM w/o Weight gain<ul> <li>Decreases A1c by 0.7-1.5%</li> </ul> </li> <li>Potential ASCVD benefit</li> <li>SE: Lactic Acidosis in renal/liver failure (alcohol misuse), diarrhea<ul> <li>20% GI upset, nausea, vomiting, no hypoglycemia</li> <li>2/2 decreasing glucose absorption in the GI tract</li> <li>B12 deficiency</li> <li>Good for obese patients</li> </ul> </li> <li>CI: Acute Renal Failure, Liver Failure, Sepsis, GFR \\&lt;30<ul> <li>Stop 48hrs before being given contrast</li> </ul> </li> </ul> </li> <li>B) Glitazones/Thiazolidinediones (TZD)<ul> <li>MOA: Bind PPPAR-gamma nuclear transcription regulator, agonists, sensitizing peripheral tissue to insulin and increasing adiponectin</li> <li>Increased GLUT1 and GLUT4, decreased FFA, decreased hepatic glucose output, increase adiponectin, and decreased adipocyte resistance, no hypoglycemia</li> <li>Works on muscle and adipose tissue</li> <li>Used in combo with metformin = no hypoglycemia</li> <li>Can reduce insulin dose up to 50%, but edema increases 10-15%</li> <li>Receptors also found in the collecting tubule of the nephron and stimulate increased sodium resorption (similar to aldosterone)<ul> <li>May use spironolactone to treat</li> </ul> </li> <li>Rosiglitazone (Avandia)</li> <li>SE: increase LDL (15%), total cholesterol, and HDL (10%), decrease FFA (8-15%), Angina or MI increase risk, edema</li> <li>Pioglitazone (Actos)</li> <li>Lowers TG (9%), and increases HDL (15%), edema</li> <li>SE: Weight gain, fluid retention and CHF, Hepatotoxic</li> <li>CI: NYHA Class III/IV, Liver dysfunction</li> <li>Black box for HF increased risk</li> <li>Generally, not used in CKD</li> </ul> </li> <li>2) Secretagogues: Stimulate insulin secretion by binding the sulfonylurea receptor</li> <li>A) Sulfonylureas<ul> <li>MOA: Closes K+ channels in pancreatic B cell membrane, causing the cell to depolarize, releasing insulin via increased Ca2+ influx</li> <li>1<sup>st</sup> Gen:</li> <li>SE: Disulfram-like effects (Hyponatremia, flushing)</li> <li>Chlorpropamide</li> <li>Tolbutamide</li> <li>Tolazamide</li> <li>2<sup>nd</sup> Gen:</li> <li>100x more potent, use in caution with CVD<ul> <li>Skip dose if pt too sick to eat (must be taken with meals, heavy sugar beverages, soda, juice, sweet tea)</li> </ul> </li> <li>Glimepiride (Amaryl)</li> <li>Glipizide (Glucotrol)<ul> <li>CI: Liver failure</li> </ul> </li> <li>Glyburide (Diabeta)<ul> <li>CI: Liver disease, CKD</li> </ul> </li> <li>SE: Hypoglycemia (especially on an empty stomach), weight gain</li> <li>Sulfonylurea poisoning</li> <li>Treatment<ul> <li>Excessive amounts of Dextrose</li> <li>Severe: Octreotide</li> </ul> </li> </ul> </li> <li>B) Meglitinide analogs<ul> <li>MOA: Similar to Sulfonylureas, different binding site on Beta cell membrane</li> <li>Take prior to meals</li> <li>No sulfur moiety, no disulfram reaction</li> <li>Repaglinide (Prandin)</li> <li>SE: Hypoglycemia (worse with renal failure), WT gain</li> <li>Nateglinide (Starlix)</li> <li>D-Phenylalanine Derivative</li> <li>Reduced postprandial risk in BP like Repaglinide</li> <li>SE: Hypoglycemia (worse with renal failure), Wt gain</li> </ul> </li> <li>3) Secretagogues: Mimic incretin effect or prolong incretin action</li> <li>A) Glucagon-like peptide 1 (GLP1) receptor agonists<ul> <li>MOA: Increase glucose dependent insulin secretion, decreases glucagon release, delays gastric emptying, increases satiety</li> <li>Mimic incretins</li> <li>More potent than DPP-4 Inhibitors</li> <li>Decrease food intake, increase insulin, decrease glucagon, decrease gastric emptying</li> <li>Associated with weight loss</li> <li>Now preferred over insulin for most patients when injectable therapy is indicated</li> <li>Dulaglutide (Trulicity)</li> <li>3<sup>rd</sup> most weight loss</li> <li>Exenatide (Byetta, Bydureon)</li> <li>CI: GFR \\&lt;30</li> <li>Liraglutide (Victoza)</li> <li>6mg subq once daily for a week, then 1.2mg daily<ul> <li>340B @ CAMC</li> </ul> </li> <li>2<sup>nd</sup> most weight loss</li> <li>LEADER Trial<ul> <li>Has FDA indication for ASCVD benefit</li> <li>Decreased CV death by 22%, ACM by 15%</li> </ul> </li> <li>Has shown CKD benefit</li> <li>Lixenatide</li> <li>Least weight loss</li> <li>Reduces CV mortality, may reduce CKD</li> <li>Semaglutide (Rybelsus, Ozempic)</li> <li>Ozempic: 0.25mg weekly for 4 weeks, then 0.5mg weekly up to 2mg weekly</li> <li>Rybelsus: 3mg oral tablet, once daily<ul> <li>Only oral GLP-1 available</li> </ul> </li> <li>Most weight loss of group</li> <li>SE: Weight loss, Nausea/Vomiting, pancreatitis, weight loss</li> <li>Lower risk of hypoglycemia, decrease CVD/MI/Stroke, decrease progression of albuminuria</li> <li>Black box warning of increased risk of thyroid C-cell tumors</li> <li>RCI: History of Pancreatitis</li> </ul> </li> <li>B) DPP4 Inhibitors<ul> <li>MOA: Inhibits DPP-4 enzyme that deactivates GLP-1</li> <li>Block the degradation of GLP-1 and GIP, thereby increasing insulin</li> <li>Can't be used with GLP-1s</li> <li>Once daily, few SE</li> <li>Linagliptin (Tradjenta)</li> <li>No dose adjustment for renal failure</li> <li>Saxagliptin (Onglyza)</li> <li>Increased risk of HF (only one in class)</li> <li>Sitagliptin (Januvia)</li> <li>Alogliptin</li> <li>Increased risk of HF (not used)</li> <li>SE: weight neutral, mild urinary or respiratory infections, nasopharyngitis</li> <li>Potential increased risk of HF, joint pain, increased risk of pancreatitis</li> </ul> </li> <li>4) Slow intestinal absorption of glucose</li> <li>A) Alpha-glucosidase inhibitors<ul> <li>MOA: Inhibits intestinal brush-border alpha-glucosidases, decreasing disaccharide absorption</li> <li>Delayed carbohydrate hydrolysis and glucose absorption in the SI, increasing absorption in the large intesine</li> <li>Decreases postprandial hyperglycemia</li> <li>Acarbose (Precose)</li> <li>Decreases postprandial hyperglycemia by 30-50%, decrease A1c by 0.5-1%, flatulence in 20-30%, abdominal pain</li> <li>3 times daily</li> <li>Decreases intestinal CHO absorption</li> <li>Miglitol (Glyset)</li> <li>CI: Decreased renal function</li> <li>SE: Diarrhea, Flatulence</li> </ul> </li> <li>5) Inhibit reabsorption of filtered glucose in the kidney</li> <li>A) Sodium glucose co-transporter 2 inhibitors (SGLT2 Inhibitors)<ul> <li>MOA: Blocks reabsorption of glucose in proximal convoluted tubule</li> <li>Causes glucosuria, weight loss is common</li> <li>Causes osmotic diuresis, decreasing BP</li> <li>Decreases progression of renal disease, Decreases CVD and MI risk if ASCVD<ul> <li>May improve CKD, still do not use if GFR \\&lt;30</li> </ul> </li> <li>Canagliflozin (Invokana)</li> <li>Has shown CKD benefit, decreased CV death by 38%, ACM by 32%, HF hospitalization by 35%</li> <li>EMPA-REG Outcome Trail</li> <li>Dapagliflozin (Farxiga)</li> <li>Has shown CKD benefit</li> <li>Empagliflozin (Jardiance)</li> <li>Has shown CKD benefit</li> <li>Has FDA indication for ASCVD benefit, improving HF outcomes</li> <li>EMPEROR Trials<ul> <li>HFpEF: Improved outcomes/Hospitalizations/QOL, Not mortality, reduced instance of hyperkalemia</li> <li>HFrEF: Improved outcomes/Hospitalizations, improved eGFR, reduced instance of hyperkalemia</li> </ul> </li> <li>Ertugliflozin (Steglatro)</li> <li>Check Cr prior to initiation</li> <li>Indication: Type 2 DM or ASCVD (or give GLP-1) with metformin</li> <li>Careful in amputation, severe PVD, neuropathy, diabetic foot ulcers</li> <li>SE: Increases glucosuria, weight loss, UTIs, Genital infections, vaginal yeast infections, hyperkalemia, dehydration, orthostatic hypotension, Fournier's gangrene, Triple risk of DKA (Euglycemic DKA), risk of lower limb infection/ulceration/amputations</li> <li>Hold for 24hrs prior to surgery or extreme sports</li> <li>Decreases risk of MI, stroke, CVD death</li> </ul> </li> <li>6) Glucagon suppression and slowing gastric emptying</li> <li>A) Amylin Analogs<ul> <li>Pramlintide (Symlin)</li> <li>Delays gastric emptying and decreases glucagon</li> <li>SE: hypoglycemia (always given with insulin), nausea/V</li> </ul> </li> <li>7) Other</li> <li>Aldose Reductase Inhibitors<ul> <li>Epalrestat</li> </ul> </li> <li>Colesevelam (Welchol)</li> <li>Bromocriptine (Cycloset)</li> <li>Sitagliptin/Metformin (Janumet)</li> </ul> <p>Insulin Preparations</p> <ul> <li>Fast Acting:</li> <li>Lispro (Humalog), Aspart (Novolog), Glulisine (Apidra)</li> <li>Peak: 0.5-1.5 hours</li> <li>Duration: 3-5 hours</li> <li>Peak coincides with food peak</li> <li>Short Acting:</li> <li>Regular Insulin (Humulin R, Novolin R)</li> <li>Peak: 2-4 hours</li> <li>Duration: 5-8 hours</li> <li>Peak may follow food peak</li> <li>Intermediate Acting:</li> <li>NPH Insulin (Humulin N, Novolin N)</li> <li>Peak: 4-12 hours</li> <li>Duration: 14+ hours</li> <li>Long Acting:</li> <li>Detemir (Levemir)<ul> <li>Peak: 4-9 hours</li> <li>Duration: 12-24 hours</li> <li>May require BID administration</li> </ul> </li> <li>Glargine (Lantus)<ul> <li>Peak: None</li> <li>Duration: 14+ hours</li> <li>Peakless effect less likely to cause hypoglycemia</li> <li>Formulations with higher concentrations of glargine (300 vs 100u/mL) have longer duration (30+ hours)</li> </ul> </li> <li>Ultra-Long Acting:</li> <li>Degludec (Tresiba)<ul> <li>Peak: None</li> <li>Duration: 42+ hours</li> <li>Formation of a soluble hexamer at the injection site</li> </ul> </li> <li>Sliding Scale</li> <li>No basal insulin given, only reactively</li> <li>Good with Basal-Bolus patient with Sliding scale on top prn</li> </ul>"},{"location":"im-guide/pharm/endocrine/osteoporosis/","title":"Osteoporosis","text":"<ul> <li>Bisphosphonates</li> <li>Oral: Must be taken first thing in the morning and on an empty stomach with \u2265 8oz of plain water. Must remain upright for 30mins (alendronate, risedronate) or 60mins (ibandronate)<ul> <li>5 year therapy, may extend to 10 if T \\&lt;-2.5 on next DEXA</li> </ul> </li> <li>CI: GFR \\&lt;30-35%, achalasia, Schatzki ring</li> <li>SE: GI, hypocalcemia, osteonecrosis of the jaw</li> <li>Alendronate (Fosamax)<ul> <li>5mg daily or 35mg weekly PO (prevention)</li> <li>10mg daily or 70mg weekly PO (treatment)</li> <li>Efficacious in preventing vertebral and non-vertebral fractures as well as hip fractures</li> <li>Approved for treatment of osteoporosis in men, glucocorticoid-induced</li> </ul> </li> <li>Risedronate (Atelvia, Actonel)<ul> <li>35mg weekly or 150mg monthly</li> <li>Efficacious in preventing vertebral and non-vertebral fractures as well as hip fractures</li> <li>Approved for treatment of osteoporosis in men, glucocorticoid-induced</li> </ul> </li> <li>Zoledronic Acid (Reclast, Zometa)<ul> <li>5mg yearly, IV only for treatment, 5mg IV every other year for prevention</li> <li>Approved for treatment of osteoporosis in men, glucocorticoid-induced</li> <li>Once a year, improved survival if given within 90 days of hip fracture</li> <li>May extend to 6 years if very high risk</li> <li>Efficacious in preventing vertebral and non-vertebral fractures as well as hip fractures</li> <li>SE: 30% have low-grade fever, myalgia, and arthralgia occurring 1-3 days after 1<sup>st</sup> administration, usually absent with subsequent infusions.</li> </ul> </li> <li>Ibandronate (Boniva)<ul> <li>150mg once a month</li> <li>Only efficacious in preventing vertebral fracture</li> <li>Approved only for treatment of postmenopausal osteoporosis</li> </ul> </li> <li>PTH Analogs</li> <li>Anabolic: stimulates osteoblasts, only ones available<ul> <li>Reserved for T \\&lt;-2.5 and a fracture (severe disease)</li> <li>Efficacious in preventing vertebral and non-vertebral fractures</li> <li>Can only be used for 2 years due to cumulative risk of osteosarcoma, use 1 on one off</li> <li>Must transition to either bisphosphonate or denosumab when discontinued (antiresorptive) within 1 month</li> <li>No holiday</li> <li>CI: CDK</li> <li>SE: Theoretical Increased risk of bone osteosarcoma</li> </ul> </li> <li>Teriparatide (Forteo)<ul> <li>MOA: Recombinant human PTH</li> <li>210mg subq monthly</li> </ul> </li> <li>Abaloparatide (Tymlos)<ul> <li>MOA: Human PTH Analog</li> <li>80mcg subcutaneous daily</li> </ul> </li> <li>Monoclonal Antibodies</li> <li>Denosumab (Prolia, Xgeva)<ul> <li>MOA: Osteoclast Inhibitor</li> <li>Monoclonal antibody inhibits RANK ligand receptors</li> <li>Antiresorptives, No need for holiday</li> <li>60mg SQ Q6 months</li> <li>Efficacious in preventing vertebral and non-vertebral fractures as well as hip fractures</li> <li>Used if unable to take bisphosphonates</li> <li>No defined treatment length</li> </ul> </li> <li>Romosozumab (Evenity)<ul> <li>Osteoblast activator</li> <li>20mcg subcutaneous daily</li> <li>Anabolic</li> <li>Associated with transient increased bone resorption (rebound) that teriparatide exacerbates (don't use)</li> <li>Efficacious in preventing vertebral and non-vertebral fractures as well as hip fractures</li> <li>1 year duration of therapy only</li> <li>Must transitioned to either bisphosphonate or denosumab when discontinued (antiresorptive) within 1 month</li> <li>No holiday</li> </ul> </li> <li>Calcium Regulator</li> <li>Calcitonin (Miacalcin)<ul> <li>200IU intranasal daily for treatment</li> <li>Calcitonin Salmon</li> <li>200-unit nasal spray</li> <li>To prevent compression fractures</li> <li>Antiresorptive, only efficacious in preventing vertebral fracture</li> </ul> </li> <li>Other</li> <li>Raloxifene (Evista)<ul> <li>CI: DVT/PE, pregnant, lactating</li> <li>Antiresorptive</li> <li>Increased risk of VTE, decreased risk of uterine/breast cancer</li> <li>Only efficacious in preventing vertebral fracture</li> </ul> </li> </ul>"},{"location":"im-guide/pharm/endocrine/thyroid_meds/","title":"Thyroid Medications","text":"<ul> <li>Levothyroxine</li> <li>6 mcg/kg per day starting in you adults<ul> <li>Retest in 6 weeks</li> </ul> </li> <li>Decreased levothyroxine absorption<ul> <li>Bile acid binding agents</li> <li>Iron, calcium, aluminum hydroxide</li> <li>PPIs, sucralfate</li> </ul> </li> <li>Increased TBG concentration<ul> <li>Oral estrogen, tamoxifen, raloxifene</li> <li>Heroin, methadone</li> </ul> </li> <li>Decreased TBG concentration (increases free thyroxine)<ul> <li>Androgens, glucocorticoids, Anabolic steroids</li> <li>Slow-release nicotinic acid (niacin)</li> </ul> </li> <li>Increased Thyroid hormone Metabolism<ul> <li>Rifampin, Phenytoin, Carbamazepine</li> </ul> </li> <li>Effects<ul> <li>Subclinical: No effects with tx</li> <li>Clinical hypothyroid: Weight loss, decrease lipids and bp</li> </ul> </li> <li>Antithyroid Drugs</li> <li>Methimazole<ul> <li>Teratogenic in first trimmest of pregnancy</li> <li>Reassess with labs at 4-6 weeks after initiation, then every 2-3 months</li> <li>Use total T3 and free T4 early on due to TSH possibly being suppressed for several months after initiation</li> <li>SE: Agranulocytosis, rarely hepatotoxicity</li> <li>Presents with fever, chills, sore throat within 90 days of starting<ul> <li>Get wBC w/differential</li> </ul> </li> </ul> </li> <li>Propylthiouracil (PTU)<ul> <li>Reassess with labs at 4-6 weeks after initiation, then every 2-3 months</li> <li>Use total T3 and free T4 early on due to TSH possibly being suppressed for several months after initiation</li> <li>SE: Agranulocytosis, hepatotoxicity more common</li> <li>Presents with fever, chills, sore throat within 90 days of starting<ul> <li>Get wBC w/differential</li> </ul> </li> </ul> </li> <li>Radioactive Iodine (RAI)<ul> <li>When the above cannot be tolerated, want to avoid surgery, and those unlikely to achieve remission ono the above alone</li> <li>Residual hypothyroidism possible in Graves' disease</li> <li>May exacerbate ophthalmopathy (exophthalmos, periorbital edema, vision changes)</li> <li>Prednisone given when moderate to severe prior to surgery</li> <li>Mild lid lag does not need prednisone</li> </ul> </li> </ul>"},{"location":"im-guide/pharm/labs-and-se/general/","title":"General","text":"<p>| UDS | | --- | --- | --- | --- | | Drug | Duration (+) \u2013 Short term | Duration (+) \u2013 Long term | False Positives | | Amphetamine | \u22642 days | \u22644 days | Atenolol, Propranolol, Bupropion, Nasal Decongestant | | Cocaine | \u22642 days | \u22647 days | High Specificity | | Cannabis | \u22643 days | 1-2 months | Hemp-containing foods | | Opioids | \u22643 days | \u22643 days | Poppy Seeds | | Phencyclidine | \u22647 days | \u22647 days | Dextromethorphan, Diphenhydramine, doxylamine, Ketamine, Tramadol, Venlafaxine|</p> <ul> <li>Measures morphine (Breakdown product of all-natural opioids)</li> <li>Morphine, heroin, codeine</li> <li>Can't detect Semisynthetic and synthetic opioids</li> <li>Oxycodone, hydrocodone, hydromorphone, fentanyl, meperidine, methadone, tramadol</li> <li>Synthetic cannabinoids</li> <li>Use Gas/Mass spectrometry</li> <li>Drug Inducers/Inhibitors/Metabolism</li> <li>Carbamazepine enhances Carbamazepine, Clonazepam, Itrazonazole metabolism</li> <li>Phenytoin enhances Cortisol, Dexamethasone, Itraconazole metabolism</li> <li>Spironolactone inhibits Digoxin metabolism</li> <li>Cimetidine inhibits Diazepam, warfarin metabolism</li> <li>Hepatic Blood flow limited</li> <li>Amitriptyline, Isoniazid, Labetalol, Meperidine, Morphine, Propranolol, Verapamil</li> <li>CYP Drugs</li> </ul> CYP Substrates Inducers Inhibitors 1A2 Acetaminophen, Duloxetine, Mirtazapine, Olanzapine, Ramelteon, Ropinirole, Tamoxifen, Tizanidine, Warfarin Green Vegetables, Grilled meat, Omeprazole, Smoking Cimetidine, Ciprofloxacin, Zileuton 2A6 2B6 Bupropion, Clopidogrel, Cyclophosphamide, Ketamine, Methadone, Promethazine, Propofol, Selegiline, Sertraline, Ticlopidine Carbamazepine, Cyclophosphamide, Fosphenytoin, Phenobarbital, Rifampin Amiodarone, amlodipine, clopidogrel, fluoxetine, ketoconazole, paroxetine, sertraline 2C8 Amiodarone, Carbamazepine, Diclofenac, Ibuprofen Barbiturates Gemfibrozil, Montelukast, Trimethoprim 2C9 Celecoxib, Diclofenac, Dronabinol, Glimepiride, Glipizide, Glyburide, Ibuprofen, Losartan, Meloxicam, Naproxen, Phenobarbital, Phenytoin, Rosuvastatin, Sulfamethoxazole, Torsemide, Valsartan Barbiturates, Carbamazepine, Phenytoin, Rifampin Amiodarone, Clopidogrel, Fluconazole, Fluvoxamine, Metronidazole, Phenytoin, Sulfamethoxazole, Valproic Acid 2C18 Tolbutamide, Phenytoin Phenobarbital 2C19 Aripiprazole, Citalopram, Clopidogreal, Diphenhydramine Barbiturates, Carbamazepine, Phenytoin Cimetidine 2D6 Amitriptyline, Carvedilol, Chlorpromazine, Clozapine, Fluoxetine, Haloperidol, Hydrocodone, Metoclopramide, Metoprolol, Nortriptyline, Oxycodone, Paroxetine, Risperidone, Selegiline, Tamoxifen, TCAs, Tramadol, Trazodone, Venlafaxine Bupropion, Diphenhydramine, Fluoxetine, Haloperidol, Paroxetine, Terbinafine 2E1 Acetaminophen Ethanol Amitriptyline, Cimetidine, Modafinil, Selegiline, Sildenafil 3A4 Acetaminophen, Barbiturates, Carbamazepine, Glucocorticoids, Phenytoin Diltiazem, Verapamil"},{"location":"im-guide/pharm/labs-and-se/labs/","title":"Labs","text":"<ul> <li>AFP (Alpha-Fetoprotein)</li> <li>\\&lt;20?</li> <li>Produced by yolk sac and fetal liver</li> <li>Elevated in HCC, Metastatic liver cancer, liver cirrhosis, hepatitis, germ cell tumors, yolk sac tumors, ataxia telangiectasia, spherocytosis, pancreatic cancer,</li> <li>False-Positive: gestational diabetes, cigarette smoking, race (higher in black women), viral hepatitis, pregnancy</li> <li>\u2265200 is 100% specific for HCC in Cirrhosis</li> <li>Albumin</li> <li>Microalbumin: Creatine ratio in the urine<ul> <li>Best test to screen for initial stages of diabetic nephropathy</li> <li>Dipstick on detects when protein \u2265300mg/24h (microalbumin)</li> </ul> </li> <li>Hyperalbuminemia<ul> <li>40% of calcium is bound to proteins (mainly albumin)</li> <li>Associated with an increase in total calcium</li> <li>Measure Ionized fraction of Calcium for accurate count</li> <li>No symptoms usually</li> </ul> </li> <li>Hypoalbuminemia<ul> <li>Decreased in malnutrition, nephrotic syndrome, acute inflammation, protein-losing enteropathies</li> <li>1) Decreased Hepatic Synthesis</li> <li>Cirrhosis</li> <li>2) Increased Urinary or GI loss</li> <li>Nephrotic Syndrome:<ul> <li>Periorbital and pedal edema that may progress to generalized edema (anasarca), ascites, and pleural effusions</li> </ul> </li> <li>Protein Losing Enteropathy<ul> <li>Diarrhea</li> </ul> </li> <li>May develop severe intravascular hypovolemia due to over-diuresis and fluid movement into the interstitial spaces</li> </ul> </li> <li>Bilirubin</li> <li>Function clearance of liver</li> <li>Increased Bilirubin (Jaundice) \u2013 Fractionate Bilirubin<ul> <li>Increased Direct Bilirubin</li> <li>Obstructive (stone, cancer) or Dubin Johnson's, Rotor</li> <li>Increased Indirect Bilirubin</li> <li>Hemolysis (bilirubin overproduction)</li> <li>Gilbert Syndrome (defective uptake)</li> <li>Crigler-Najjar or newborn (Glucuronyl transferase defect)</li> <li>Obtain Liver Enzymes: Alkaline Phosphatase</li> <li>Increased ALP (Biliary Pathology)<ul> <li>Increased GGT/ Increased AST/ALT (Ultrasound/CT)</li> <li>Bile duct obstruction, IBD w/PSC</li> <li>Metabolic Alkalosis in BDO</li> </ul> </li> <li>Mildly increased ALP<ul> <li>Increased GGT</li> <li>Increased AST/ALT: Hepatocellular Disease</li> <li>Normal GGT</li> <li>Normal Calcium: Paget's disease</li> </ul> </li> </ul> </li> <li>Increased Conjugated Bilirubin<ul> <li>Can't get rid of Bilirubin (extrahepatic dysfunction)</li> </ul> </li> <li>Increased Unconjugated Bilirubin<ul> <li>Body can't conjugate bilirubin (hepatic dysfunction or RBC breakdown)</li> <li>Hyperbilirubinemia and High LDH</li> <li>Autoimmune hemolytic anemia</li> <li>G6PD deficiency</li> <li>Mechanical RBC destruction</li> <li>Hereditary spherocytosis</li> <li>B12/Folate Deficiency</li> </ul> </li> <li>Increased Direct/Conjugated Bilirubin + Cholesterol + alkaline phosphatase<ul> <li>Cholestatic pattern</li> <li>Ultrasound (CT)</li> </ul> </li> <li>BNP</li> <li>Elevated in patients with kidney failure, old age, female</li> <li>Reduced in patients with an elevated BMI</li> <li>CA 19-9</li> <li>\\&lt;40</li> <li>Associated with Pancreatic cancer, biliary tract cancer</li> <li>Colon, esophageal, hepatic cancers, Pancreatitis, cirrhosis</li> <li>CEA (Carcinoembryonic Antigen)</li> <li>\\&lt;2.5 in non-smokers, \\&lt;5 in smokers, \u226510 is concerning for cancer</li> <li>Associated with tumor burden in colorectal cancer</li> <li>Primary ovarian cancer, Breast cancer, NSCLC, Thyroid cancer, cigarette smoking, cholecystitis, liver cirrhosis, pancreatitis, IBD, orlistat, lymphoma, melanoma, PUD, hypothyroidism, biliary obstruction</li> <li>Complement</li> <li>Hypocomplementemia<ul> <li>Genetic</li> <li>Consumption</li> <li>Underproduction<ul> <li>Eclampsia, HELLP syndrome</li> </ul> </li> <li>SLE, Vasculitis, RA, infective endocarditis</li> </ul> </li> <li>Low C2 or C4: Genetic allele deficiency</li> <li>C3: classical or alternative</li> <li>C4: SLE (classical)</li> <li>CH50: all components of classical<ul> <li>Screening for diseases states resulting in hypocomplementemia</li> </ul> </li> <li>Creatine Kinase (CK)</li> <li>Creatine phosphokinase (CPK)</li> <li>Released from muscle tissue as it is damaged</li> <li>Polymyositis, dermatomyositis, inclusion body myositis, Duchenne and Becker Muscular dystrophy</li> <li>Ceruloplasmin</li> <li>Low<ul> <li>High Urinary ceruloplasmin</li> <li>Wilsons</li> </ul> </li> <li>CRP/ESR</li> <li>Erythrocyte Sedimentation Rate and C-reactive protein</li> <li>MC APRs used<ul> <li>Helpful in determining disease activity and response to therapy</li> </ul> </li> <li>Not specific, sensitive with low to moderate pretest probability<ul> <li>ESR \u2265 100mm/hr: severe disease (malignancy, infection, vasculitis)</li> </ul> </li> <li>Elevated Ammonia (Hyperammonemia)</li> <li>MCC is hypovolemia</li> <li>Medications<ul> <li>Valproic Acid, carbamazepine, salicylates, sulfadiazine</li> </ul> </li> <li>Elevated BUN</li> <li>Tube feeds</li> <li>High Protein</li> <li>Chemotherapy</li> <li>Upper GI bleed</li> <li>Gamma-glutamyl transpeptidase (GGT)</li> <li>More specific than ALP because it is not present in bone<ul> <li>Not specific for alcohol</li> </ul> </li> <li>Increased GGT + Alkaline Phosphatase<ul> <li>Biliary Pathology</li> </ul> </li> <li>Iron</li> <li>Ferritin = storage of iron</li> <li>TIBC is always opposite of Ferritin</li> <li>Transferrin = carrier</li> <li>High Iron, Low Ferritin, Low Fe binding capacity<ul> <li>Hemochromatosis</li> </ul> </li> <li>Increased Amylase</li> <li>Pancreatic<ul> <li>Pancreatitis, pseudocysts, trauma, ERCP, CF, Carcinoma</li> </ul> </li> <li>Salivary<ul> <li>Parotitis, radiation, obstruction</li> </ul> </li> <li>GI<ul> <li>PUD, perforated bowel, Mesenteric ischemia, appendicitis, cholecystitis, celiac's</li> </ul> </li> <li>Gyne<ul> <li>Ectopic, ovarian cyst, PID</li> </ul> </li> <li>Neoplasm<ul> <li>Multiple myeloma, Pheo</li> </ul> </li> <li>Other<ul> <li>Alcohol abuse, RF (cleared renally)</li> </ul> </li> <li>Liver Damage</li> <li>AST</li> <li>ALT</li> <li>Synthetic Liver Function (Severe)<ul> <li>PT \u2013 clotting factors by hepatocytes</li> <li>Prolonged in vitamin K deficiency, warfarin, inherited or acquired factor deficiency, Antiphospholipid antibiody</li> <li>Albumin \u2013 by hepatocytes</li> </ul> </li> <li>Liver and Biliary Tree Damage</li> <li>ALP \u2013 made in liver, bile duct, kidney, placenta</li> <li>GGT \u2013 bile duct, liver, alcohol abuse</li> <li>Platelet Count</li> <li>Normal (150k-400k)</li> <li>\\&lt;50K risk of surgical bleeding</li> <li>\\&lt;10k risk of spontaneous bleeding</li> <li>Rheumatoid Factor (RF)</li> <li>RA but also in 10% of normal population</li> <li>RA will have evidence of inflammation in the hands in feet</li> <li>Serum Chromogranin A</li> <li>Well-differentiated neuroendocrine tumors</li> <li>Carcinoid tumors, hyperthyroidism, chronic atrophic gastritis, chronic PPIs, SCLC</li> <li>Less sensitive and specific than Serum Gastrin</li> </ul>"},{"location":"im-guide/pharm/labs-and-se/other/","title":"Other","text":"<ul> <li>Erythropoietin (EPO)</li> <li>Worsening Hypertension (30%), less common in Subcutaneous route<ul> <li>Prevention: Slow Hematocrit rise (goal 30-35%)</li> <li>Hypertensive encephalopathy</li> <li>Treatment</li> <li>Dialysis</li> </ul> </li> <li>Headaches (15%), Flu-like symptoms (5%)</li> <li>Red Cell Aplasia</li> <li>PDE-5 Inhibitors</li> <li>Sildenafil, Vardenafil, Tadalafil<ul> <li>All used for ED and pulmonary hypertension</li> <li>Tadalafil can also be used for BPH</li> </ul> </li> <li>SE: Cyanopsia (hypotension worse w/nitrates, alpha blockers), Blue color vision, non-arteritic anterior ischemic optic neuropathy, priapism, flushing, headache, heading loss<ul> <li>Contraindicated in patients taking alpha blockers, nitrates due to hypotension</li> </ul> </li> <li>Cholinergic Receptors</li> <li>Found on the dome of the bladder, contraction of which facilities voiding</li> <li>Phenazopyridine</li> <li>Analgesic for urinary tract mucosa frequently used to treat the dysuria of cystitis (after infection or instrumentation)</li> <li>May worsen stone formation</li> <li>L-Methylfolate (Deplin)</li> <li>Stimulates WBC and platelet production in Folate Deficiency Anemia</li> <li>Improves antidepressants effect in people with BMI \u226535</li> <li>Ofatumumab (Kesimpta)</li> <li>Dimethyl Fumarate (Tecfidera)</li> <li>SE: Nausea, vomiting, upper abdominal pain, elevated LFTs</li> <li>Other</li> <li>Permethrin<ul> <li>Inhibits Na+ Channel Deactivation</li> <li>Causing membrane depolarization</li> </ul> </li> <li>Malathion<ul> <li>Acetylcholinesterase inhibitor</li> <li>Neurotoxicity</li> </ul> </li> <li>Lindane<ul> <li>Blocks GABA channels</li> <li>Neurotoxicity</li> </ul> </li> <li>BPH Meds</li> <li>Alpha 1 Adrenergic Antagonists<ul> <li>First Line Therapy</li> <li>Tamsulosin, doxazosin, terazosin, alfuzosin, and prazosin</li> <li>Decrease systemic vascular resistance and resistance to urinary flow by relaxing the smooth muscle of the bladder neck and prostate gland, prostate capsule and urethra, reduce outlet obstruction</li> <li>SE: Orthostatic hypotension, dizziness, night sweats</li> </ul> </li> <li>5-alpha-reductase inhibitors<ul> <li>Finasteride, dutasteride</li> <li>Use with Severe symptoms, \u226540g prostates, alpha-1s not working, hypotensive patient, taking sildenafil</li> <li>Inhibit conversion of testosterone to dihydrotestosterone</li> <li>Reduce prostate gland size, takes 6-12months</li> <li>SE: Decreased libido, erectile dysfunction</li> </ul> </li> <li>Antimuscarinics<ul> <li>Tolterodine</li> <li>Used to treat overactive bladder (urinary frequency, urgency and incontinence</li> <li>SE: Urine retention, dry mouth</li> </ul> </li> <li>Memantine</li> <li>NMDA receptor (glutaminergic) antagonist</li> <li>Useful if pt with dementia cannot tolerate other drugs 2/2 nausea or vomiting</li> <li>SE: hallucinations</li> <li>Testosterone</li> <li>Topical (Fortesta, Vogelxo, Androgel, Testim)</li> <li>Subq (Androderm, Xyosted)</li> <li>Oral (Jantenzo)</li> <li>IM (Aveed)</li> <li>Alcohol Cessation</li> <li>Combo of naltrexone and acamprosate preferred</li> <li>Naltrexone<ul> <li>Mu-opioid receptor antagonist</li> <li>Can't be used on patients on opioids, liver disease (check lfts)</li> <li>Reduces 30-day readmission and ED visits when given</li> <li>SE: Nausea 10%, headache 7%, dizziness 4%, anxiety 2%</li> </ul> </li> <li>Acamprosate<ul> <li>NMDA/glutamate modulation</li> <li>Contraindicated in severe renal disease</li> <li>Usually used after withdrawal phase</li> </ul> </li> <li>Discourage alcohol relapse<ul> <li>Disulfiram (2<sup>nd</sup> line)</li> <li>Inhibits acetaldehyde dehydrogenase</li> <li>Monitor liver function (check flts)</li> <li>Can only be given to abstinent and highly motivated patients</li> <li>CI in severe cardiac disease, pregnancy, psychosis</li> </ul> </li> <li>Topiramate</li> <li>Smoking Cessation</li> <li>1) Varenicline with nicotine replacement therapy<ul> <li>Varenicline (Chantix)</li> <li>Alpha 4 beta 2 acetylcholine receptor partial agonist, diminish cravings</li> <li>Mood changes, suicidality, CV risk<ul> <li>Not any more</li> </ul> </li> <li>Nicotine Replacement Treatment</li> </ul> </li> <li>Bupropion</li> <li>Topiramate (Topamax)</li> <li>Nicotine Withdrawal</li> <li>Nicotinic acetylcholine receptors</li> <li>Irritability, fatigue, difficulty concentrating, headaches, constipation</li> </ul>"},{"location":"im-guide/pharm/labs-and-se/side_effects/","title":"Side Effects (SE)","text":"<ul> <li>Acute Dystonia</li> <li>Patient taking a 1<sup>st</sup> gen antipsychotic given a CYP2D6 inhibitor and metabolized (paroxetine/fluoxetine, Beta-Blockers)</li> <li>Treatment<ul> <li>Anticholinergics</li> <li>Benadryl</li> </ul> </li> <li>Akathisia</li> <li>Typical \u2265 Atypicals</li> <li>Pacing, restolessness</li> <li>Treatment<ul> <li>1) Decrease Dose of Antipsychotic</li> <li>If it is managing symptoms well</li> <li>2) Switch to lower EPS drug</li> <li>3) Add low dose BB, Benzodiazepine, or Benztropine, Clonidine</li> </ul> </li> <li>Aplastic Anemia</li> <li>Carbamazepine, methimazole, NSAIDs, benzene, chloramphenicol, cytostatic drugs, PTU</li> <li>Depression</li> <li>Corticosteroids, interferon, lidocaine, procainamide, beta blockers, reserpine, chloroquine, mefloquine</li> <li>Drug Associated Autoimmune Vasculitis</li> <li>Hydralazine</li> <li>Drug-Induced Diabetes</li> <li>Steroids, Calcineurin Inhibitors, Protease Inhibitors, NRTIs, Niacin, Statins, BBs, Thiazides, Vasopressors, Oral Contraceptives, Progetin Megestrol, GH, Atypical Antipsychotics, Moxifloxacin</li> <li>Elevated LFTs (DILI)</li> <li>Allopurinol, amiodarone, amoxicillin clavulanate, anabolic steroids, atorvastatin, azathioprine, carbamazepine, chlorpromazine, dantrolene, diclofenac, disulfiram, erythromycin, hydralazine, ibuprofen, infliximab, interferon beta, isoniazid, ketoconazole, methotrexate, methyldopa, nitrofurantoin, phenytoin, PTU, rifampin, simvastatin, TCAs (0.1%), TMP SMX, sulfasalazine, sulfonamides, valproate</li> <li>Azithromycin, heparin, imatinib, levofloxacin, oxacillin, phenobarbital, tamoxifen, terbinafine</li> <li>Macrolides, tetracyclines, metoclopramide, chlorpromazine, Augmentin</li> <li>Erectile disorder</li> <li>Antihypertensives (Propranolol): Decreased NE - B</li> <li>Antihypertensives (Methyldopa): Increased central NE - a</li> <li>Antidepressants (fluoxetine): Increased serotonin</li> <li>Antipsychotics (Thioridazine): Decreased Dopamine</li> <li>Inhibited ejaculation</li> <li>Antidepressants (Fluoxetine): Increased Serotonin</li> <li>Antipsychotics (Thioridazine): Decreased Dopamine</li> <li>Inhibited orgasm</li> <li>Antidepressants (Fluoxetine): Increased Serotonin</li> <li>Libido</li> <li>Reduced<ul> <li>Antidepressants (Fluoxetine): Increased serotonin</li> <li>Antihypertensives (Propranolol): Decreased NE - B</li> <li>Antihypertensives (Methyldopa): Increased central NE - a</li> </ul> </li> <li>Increased<ul> <li>Antiparkinsonian (Levodopa): Increased Dopamine</li> </ul> </li> <li>Mania/Psychosis</li> <li>Cocaine, pcp, synthetic cannabinoids, corticosteroids, levothyroxine, dopaminergic anti-parkinsonian drugs (levodopa)</li> <li>Pancytopenia</li> <li>Mycophenolate Mofetil</li> <li>Parkinsonism</li> <li>Treatment<ul> <li>1) Decreased Dose of Antipsychotic</li> <li>2) Switch to lower EPS drug</li> <li>3) Add Benztropine \u2265 Amantadine</li> </ul> </li> <li> <p>Priapism</p> <ul> <li>Persistent, painful erection that develops without sexual stimulation and has a long duration</li> <li>Antidepressants (Trazodone, SSRIs): Increased Serotonin</li> <li>Phosphodiesterase Inhibitors (Sildenafil)</li> <li>Stimulants (Methylphenidate, Cocaine)</li> <li>Medical: Leukemia, Sickle Cell disease</li> <li>Surgical: Perineal or genital trauma</li> <li>Neurogenic: Cauda Equina Syndrome</li> <li>Pseudo-parkinsonism</li> <li>Women 2x more likely</li> <li>Symptoms</li> <li>Bradykinesia</li> <li>Treatment</li> <li>Anticholinergics</li> <li>Benadryl</li> <li>Amantadine</li> <li>SJS/TEN</li> <li>Lamotrigine, carbamazepine, phenytoin, phenobarbitone</li> <li>Allopurinol if \u2265100mg/day</li> <li>Cotrimoxazole, sulfasalazine</li> <li>Penicillin's, cephalosporins, quinolones, minocycline</li> <li>Tylenol, Nevirapine, NSAIDs, Contrast</li> <li>Thrombocytopenia</li> <li>Linezolid</li> <li>Vaginal dryness</li> <li>Antihistamine (Diphenhydramine): Decreased Histamine</li> <li>Anticholinergic (Atropine): Decreased Acetylcholine</li> </ul> </li> </ul>"},{"location":"im-guide/pharm/nervous-system/anesthetics/","title":"Anesthetics","text":"<ul> <li>Analgesics</li> <li>Bolus at induction and before surgical incision</li> <li>Opioid Withdrawal<ul> <li>6-12 hours: Morphine, oxycodone</li> <li>24-48 hours: Methadone</li> </ul> </li> <li>Fentanyl<ul> <li>Metabolized by CYP3A4, High protein binding</li> <li>Safest long-acting in kidney and liver failure</li> <li>Increased bioavailability in liver failure, low dose patch</li> <li>Airway reflexes are blunted, may cause respiratory arrest</li> </ul> </li> <li>Hydrocodone<ul> <li>Metabolized by CYP2D6, low protein binding</li> <li>Increased time to analgesic onset in liver failure</li> </ul> </li> <li>Hydromorphone<ul> <li>Metabolized by liver glucuronidation, low protein binding</li> <li>Better use in kidney disease</li> <li>Reduced dose and frequency in liver failure/cirrhosis</li> </ul> </li> <li>Loperamide<ul> <li>SE: QRS prolongation, QT prolongation, Ventricular Tachycardia</li> </ul> </li> <li>Meperidine<ul> <li>Only opioid that does not cause miosis</li> <li>SE: Seizures, Serotonin syndrome</li> </ul> </li> <li>Methadone<ul> <li>SE: QT prolongation, Torsade de pointes, miosis, rash, pruritis, hypotension</li> <li>CI: naloxone concurrently</li> </ul> </li> <li>Morphine sulfate<ul> <li>Metabolized by liver glucuronidation</li> <li>Metabolites cleared by the kidney</li> <li>Avoid in liver failure and kidney failure<ul> <li>Increased bioavailability vs toxic metabolites</li> </ul> </li> <li>SE: May cause histamine release and mild hypotension</li> </ul> </li> <li>Oxycodone<ul> <li>Metabolized by CYP2D6/CYP3A4 (Unlike hydromorphone/morphine)</li> </ul> </li> <li>Remifentanil (Ultiva)<ul> <li>SE: Respiratory depression, bradycardia, hypotension, constipation, chest wall rigidity, pruritus, visual disturbances</li> </ul> </li> <li>Tramadol Hydrochloride (Ultram)<ul> <li>50mg-100mg IR QID PO/IV/IM</li> <li>50mg up to 300mg ER</li> <li>MOA: mu-opioid receptor agonist, inhibits 5-HT and NE reuptake</li> <li>Metabolized by CYP2D6/CYP3A4 (Unlike hydromorphone/morphine)</li> <li>Variable time to onset and efficacy in liver failure</li> <li>SE: Serotonin Syndrome, Seizures</li> </ul> </li> <li>Sedative-Hypnotics</li> <li>CNS depression<ul> <li>Sedation</li> <li>Hypnosis</li> <li>Anesthesia</li> <li>Coma</li> </ul> </li> <li>Benzodiazepines<ul> <li>Anxiolysis, hypnosis, amnesia, no analgesic properties</li> <li>Midazolam commonly used</li> <li>Metabolized by the liver</li> <li>Flumazenil to treat OD</li> </ul> </li> <li>Barbiturates<ul> <li>Phenobarbital</li> <li>Can be used in Crigler-Najjar II to induce UDP-glucuronyl transferase</li> </ul> </li> <li>Ketamine<ul> <li>PCP analog</li> <li>Intense analgesia, amnesia, dissociative anesthesia</li> <li>Increases HR and BP, maintains spontaneous ventilation</li> <li>Excellent bronchodilator</li> <li>Pre-medicate with benzodiazepines to limit illusions and dysphoria</li> <li>Not respiratory depressant</li> </ul> </li> <li>Thiopental (Pentothal)<ul> <li>Barbiturate, unconsciousness in 30s</li> <li>No analgesic effects</li> <li>Decreases cerebral O2 demand, excellent anticonvulsant</li> <li>Requires repeated dosing</li> <li>Hypotension, HF, Beta-blockade</li> </ul> </li> <li>Morphine<ul> <li>5mg IV</li> </ul> </li> <li>Hydromorphone (Dilaudid)<ul> <li>75mg IV</li> </ul> </li> <li>Fentanyl<ul> <li>50mcg IV (50-150mcg/hr)</li> </ul> </li> <li>Propofol (Diprivan)<ul> <li>CYP2B6 Substrate</li> <li>Antipyretic and antiemetic properties</li> <li>Mild analgesic effect</li> <li>Metabolized by the liver and plasma esterase</li> <li>SE: Severe hypotension due to myocardial depression (inhibits sympathetic drive)</li> <li>Avoid in patients with ventricular systolic dysfunction</li> <li>Prolonged sedation even after discontinuation</li> </ul> </li> <li>Dexmedetomidine (Precedex)<ul> <li>Alpha-2 Agonism</li> </ul> </li> <li>Etomidate (Amidate)<ul> <li>Inhibition of 11B-hydroxylase</li> <li>Adrenal insufficiency in elderly and critically ill</li> <li>May cause respiratory arrest</li> <li>No analgesic effects</li> <li>No change in BP</li> <li>Metabolized by the liver and plasma esterase</li> </ul> </li> <li>Halothane (Fluothane)<ul> <li>Acute Hepatic toxicity in Adult women</li> </ul> </li> <li>Nitrous Oxide (N2O)<ul> <li>Inhibition of methionine synthase, inactivates B12</li> <li>Neurotoxicity in pts with B12 deficiency</li> <li>SE: mild ICP, CBF, CMRO2, PONV, decreased hepatic/renal blood flow</li> </ul> </li> <li>Long time to induction</li> <li>Opioid Abuse</li> <li>Long time coming out anesthesia</li> <li>Absence of pseudocholinesterase</li> <li>Lambert-Eaton Myasthenia<ul> <li>Increased sensitivity to both depolarizing muscle relaxants (succinylcholine): takes more time to reaccumulate acetylcholine</li> </ul> </li> <li>Depolarizing NM blocking</li> <li>Used for endotracheal intubation usually</li> <li>Succinylcholine<ul> <li>Depolarizing agent, Increases Serum potassium</li> <li>Fastest onset, shortest Duration</li> <li>Metabolized by pseudocholinesterase</li> </ul> </li> <li>Nondepolarizing NM blocking</li> <li>Rocuronium<ul> <li>Fastest non-depolarizing agent</li> <li>Metabolized by the liver</li> </ul> </li> <li>Cisatracurium<ul> <li>Nonenzymatic breakdown</li> <li>Action not prolonged in renal or liver disease</li> </ul> </li> <li>Pancuronium<ul> <li>Non-Depolarizing</li> <li>Longest Acting</li> </ul> </li> <li>Upregulation of Acetylcholine Receptors (toup-regulation)</li> <li>Muscle trauma (burn/stroke), Guillain-Barre, polyneuropathy in critical illness<ul> <li>Succinylcholine is a depolarizing neuromuscular blocker by binding to postsynaptic Acetylcholine receptors</li> <li>influx of Na, efflux of K+</li> <li>45-60s for onset, 6-10minutes of action</li> <li>May cause cardiac arrhythmia 2ndary to hyperkalemia</li> <li>Check [K+]</li> <li>Use Non-depolarizing agents instead in pts with upregulated post-synaptic Ach receptors</li> <li>Vecuronium, rocuronium are competitive Acetylcholine receptor antagonists, do not affect postsynaptic ligand-gated ion channels<ul> <li>Anticholinesterases are used to reverse</li> </ul> </li> </ul> </li> <li>Cyclobenzaprine (Flexeril)</li> <li>Centrally acting antispasmodic</li> <li>Poorly understood, inhibition of muscle stretch reflex</li> <li>Hepatic metabolism, 4-6hr duration</li> <li>Use: acute spasm due to muscle injury/inflamamtion</li> <li>SE: Antimuscarinic effects</li> <li>Methocarbamol (Robaxin)</li> <li>Baclofen</li> <li>GABAb agonist, facilitates spinal inhibition of motor neurons</li> <li>Centrally acting spasmolytic</li> <li>Oral</li> <li>SE: Weakness, sedation, rebound spasticity on abrupt withdrawal</li> <li>Tizanidine (Zanaflex)</li> <li>Alpha2 agonist in the spinal cord</li> <li>Oral, renal and hepatic elimination</li> <li>Lasts 3-6 hours</li> <li>Use: Spasm 2/2 MS, stroke, ALS</li> <li>SE: Weakness, sedation, hypotension, hepatotoxicity (rare), rebound hypertension on abrupt withdrawal</li> <li>Dantrolene</li> <li>Blocks RyR1 Ca2+ release in the SR of skeletal muscle</li> <li>Direct acting muscle relaxant</li> </ul>"},{"location":"im-guide/pharm/nervous-system/anticonvulsants/","title":"Anticonvulsants","text":"<ul> <li>Seizures</li> <li>Partial focal, yes or no</li> <li>Simple partial focal no</li> <li>Complex partial focal yes</li> <li>Gen, abs, tonic all ye and yes</li> <li>Absence Seizures<ul> <li>Diffuse 3-Hz and wave pattern on EEG</li> <li>Short period of profound impairment with intact body tone</li> </ul> </li> <li>Generalized tonic-clonic<ul> <li>Abrupt loss of consciousness, stiffening of the muscles, rhythmic jerking of extremities, open eyes during ictus</li> <li>Most fall asleep immediately after seizure and have postictal confusion on awakening</li> </ul> </li> <li> <p>Psychogenic nonepileptic seizure (PNES)</p> <ul> <li>Conversion disorder, not true seizure</li> <li>Forceful eye closure, side to side body movements, rapid alerting and reorienting, memory recall of seizure</li> <li>NOT associated with abnormal cortical activity, lack post-ictal confusion</li> <li>Intact reflexes, pelvic thrusts</li> <li>Prolactin formal 15-30 minutes after seizure (elevated in epileptic seizure)</li> <li>Video electroencephalogram gold standard, Psychiatric Assessment</li> <li>Lack of epileptiform activity (normal EEG)</li> </ul> </li> <li> <p>Barbiturates</p> </li> <li>Phenobarbital<ul> <li>MOA: Increases GABAa action</li> <li>SE: Sedation, dependence, Megaloblastic Anemia (Impaired folic acid absorption), Decreases OCP efficacy</li> </ul> </li> <li>Pentobarbital</li> <li>Secobarbital</li> <li>Primidone<ul> <li>SE: Megaloblastic Anemia (Impaired folic acid absorption)</li> </ul> </li> <li>Carbamazepine (Tegretol)</li> <li>MOA: Blocks Na+ channels</li> <li>Anticonvulsant, anticholinergic, antineuralgic, antidiuretic</li> <li>Antiseizure, trigeminal neuralgia, bipolar</li> <li>SE: Decreases T3/T4 (increased deiodination mainly), Decreases OCP efficacy, diplopia, ataxia, blood dyscrasias, liver toxic, SIADH, SJS</li> <li>Ethosuximide (Zarontin)</li> <li>MOA: Blocks thalamic T-type Ca2+ channels</li> <li>USE: Absence seizures only</li> <li>SE: Fatigue, GI distress, Headache, itching, SJS</li> <li>Gabapentinoids</li> <li>Gabapentin (Neurontin)<ul> <li>Dose: 100mg TID up to 900mg TID</li> <li>Renally cleared</li> <li>Antacids decrease bioavailability by 20%</li> <li>MOA: Increases GABA and 5HT</li> <li>Use: Add on for seizures only</li> <li>Off-label: sleep, bipolar, migraines, fibromyalgia, anxiety, diabetic and HIV neuropathy</li> <li>SE: somnolence, ataxia, diplopia, dizziness</li> </ul> </li> <li>Pregabalin</li> <li>Lacosamide (Vimpat)</li> <li>Lamotrigine (Lamictal)</li> <li>Dose: 12.5mg BID for 2 weeks, 25mg BID for 2 weeks, 50mg BID after<ul> <li>Dose doubled w/carbamazepine, phenytoin, phenobarbital</li> <li>Dose every other day with VPA</li> <li>ODT and chewable available</li> </ul> </li> <li>MOA: Folate antagonist, voltage gated sodium channel blocker, inhibits 5HT reuptake, inhibits release of glutamate<ul> <li>Oral contraceptives decrease Lamictal by 50%</li> </ul> </li> <li>Use: Depressive symptoms of bipolar depression (not acute), partial epilepsy, Lennox-Gestalt seizures, Rhett's, Alzheimer's aggression<ul> <li>25-hour half-life</li> </ul> </li> <li>SE: Benign maculopapular rash(8%) within 4m \u2265 SJS/TEN (0.08%)<ul> <li>Worse if \\&lt;16 or with VPA</li> <li>Minimal sedation, minimal weight gain, mild dizziness, nausea</li> <li>Disrupts sleep if taken after 5pm</li> </ul> </li> <li>Levetiracetam (Keppra)</li> <li>No close monitoring needed</li> <li>SE: Fatigue, drowsiness, headache<ul> <li>Exacerbate depression, anxiety, irritability, non-specific psychiatric adverse effects</li> <li>GAD and nervousness, mc in pre-existing anxiety</li> </ul> </li> <li>Oxcarbazepine (Trileptal)</li> <li>Dose: 300mg at night up to 600mg BID, no need for food</li> <li>MOA: Monohydroxy metabolite, voltage gated sodium channel blocker<ul> <li>Decreased by ETOH and phenytoin</li> </ul> </li> <li>Use: Epilepsy, Intermittent Explosive Disorder</li> <li>SE: sedation, nausea, dizziness, vertigo, hyponatremia (3%), decreases OCP efficacy</li> <li>Phenytoin (Dilantin)</li> <li>SE: Megaloblastic Anemia (Impaired folic acid absorption), Decreases T3/T4 (increased deiodination mainly), Decreases OCP efficacy</li> <li>Fosphenytoin (Cerebyx)</li> <li>Tiagabine</li> <li>MOA: Increases GABA by inhibiting reuptake</li> <li>Use: Only focal seizures</li> <li>Topiramate (Topamax)</li> <li>Dose: 25mg at bedtime up to 25mg BID</li> <li>MOA: Increases cerebral GABA<ul> <li>Increases phenytoin and VPA</li> <li>CBZ and phenytoin decrease</li> <li>Avoid with acetazolamide</li> </ul> </li> <li>Use: Epilepsy, Migraine Prophylaxis, smoking cessation, tremor, bulimia, binge eating, anxiety, weight loss<ul> <li>24-hour half-life, Renally excreted 70%</li> </ul> </li> <li>SE: Decreases OCP efficacy, Mixed RTA by inhibiting carbonic anhydrase in proximal and distal tubules, paresthesia, weight loss, sedation, dizziness, word-finding difficulties (\u2265100mg), Cognitive suppression and sedation that does not improve with time, reduced delayed recall, slow to complete projects<ul> <li>Numbness and tingling in fingertips and peripheral extremities (may be improved by QHS dosing)</li> <li>Lowers serum bicarb, Urine pH \u22656 and hypocitraturia, increased risk for calcium phosphate stones and cardiac arrythmias in 1.5%</li> </ul> </li> <li>Valproic Acid (VPA)</li> <li>Vigabatrin</li> <li>MOA: Increases GABA, irreversible GABA transaminase inhibitor</li> <li>SE: Permanent visual loss (Black box)</li> <li>Zonisamide (Zonegran)</li> <li>Anticonvulsant Hypersensitivity Syndrome</li> <li>Occurs after recent seizure</li> <li>Can occur with phenytoin, carbamazepine, phenobarbital, lamotrigine</li> <li>Symptoms<ul> <li>Fever, rash, lymphadenopathy</li> </ul> </li> <li>Labs<ul> <li>Eosinophilia</li> <li>Elevated Transaminases</li> </ul> </li> </ul>"},{"location":"im-guide/pharm/nervous-system/cnsdrugs/","title":"CNS Drugs","text":"<ul> <li>Dopamine Agonists</li> <li>General<ul> <li>Psychosis more likely with Dopamine agonists</li> <li>Indicated for RLS/Parkinsons</li> <li>Less likely to produce on-off effect</li> </ul> </li> <li>Non-Ergot Alkaloids<ul> <li>Pramipexole (Mirapex)</li> <li>MOA: D3 receptor agonist</li> <li>Ropinirole</li> <li>MOA: D2 receptor agonist</li> <li>SE: May exacerbate impulse control disorders</li> </ul> </li> <li>Ergot Alkaloid<ul> <li>Bromocriptine</li> <li>MOA: Dopamine receptor agonist</li> </ul> </li> <li>Amantadine</li> <li>MOA: Increased endogenous dopamine release, Inhibits reuptake</li> <li>Carbidopa-Levodopa (Sinemet)</li> <li>MOA:<ul> <li>Carbidopa: Peripheral DOPA decarboxylase inhibitor</li> <li>Levodopa: Dopamine precursor</li> </ul> </li> <li>Acute SE:<ul> <li>Increased Peripheral Dopamine: GI distress, Arrythmia, Orthostatic hypotension</li> <li>Increased Central Dopamine: Neuropsych symptoms</li> </ul> </li> <li>Chronic SE:<ul> <li>Response Fluctuations (wearing-off effect)</li> <li>Not related to dose</li> <li>Dyskinesias (Choreoathetosis) of face and extremities</li> </ul> </li> <li>CI: Psychosis</li> <li>COMT Inhibitors</li> <li>Tolcapone (Tasmar)<ul> <li>CNS active (can cross BBB)</li> <li>Associated with Liver failure</li> </ul> </li> <li>Entacapone (Comtan)<ul> <li>Not active in CNS</li> </ul> </li> <li>Acetylcholinesterase Inhibitors</li> <li>Galantamine<ul> <li>4mg BID for 4 weeks and re-eval, max is 16mg BID</li> <li>Least expensive, minimal SD</li> </ul> </li> <li>Pimavanserin (Nuplazid)</li> <li>Dose: 34mg once daily only</li> <li>MOA: Non-dopaminergic atypical antipsychotic via antagonism and inverse agonism at 5HT2A receptors, minimal 5HT2C, no 5HT2B or D2<ul> <li>Metabolized CYP3A4 and CYP 3A5</li> </ul> </li> <li>Use: Psychosis due to Parkinson Disease, drug induced or regular<ul> <li>Reduces hallucinations without worsening parkinsonism</li> </ul> </li> <li>SE: Nausea (7%), Constipation (4%), Peripheral Edema (7%), Confusion (6%), possible QTc prolongation</li> </ul>"},{"location":"im-guide/pharm/nervous-system/icu/","title":"ICU","text":"<ul> <li>Sedatives/Paralytics</li> <li>Dexmedetomidine (Precedex)</li> <li>Diprovan (Propofol)</li> <li>Cisatracurium (Nimbex)</li> <li>Midazolam (Versed)</li> <li>Ketamine</li> <li>Analgesics</li> <li>Fentanyl</li> <li>Vasopressors</li> </ul> Drug Target Effect on HR/Inotropy/Ectopy Effect on SVR Effect on CO Effect on BP Effect on PVR Main Use Safe for PIV? InoDilators Dobutamine ABBBB Milrinone cAMP Isoproterenol BBBB Pure Vasopressors Vasopressin V1 &amp; V2 Phenylephrine AAAA InoPressors Norepinephrine AAAB Epinephrine Dopamine <ul> <li>InoDilators<ul> <li>Dobutamine</li> <li>Target: ABBBB</li> <li>2-20 mcg/kg/min</li> <li>High effect on SVR, BP</li> <li>Milrinone</li> <li>Target: cAMP<ul> <li>Decreases cAMP degradation</li> </ul> </li> <li>375-0.75 mcg/kg/min   SE: Hypotension, increased risk of Arrhythmias</li> <li>Isoproterenol</li> <li>Target: BBBB</li> <li>0-10 mcg/min</li> </ul> </li> <li>Pure Vasopressors<ul> <li>Vasopressin</li> <li>Target: V1 and V2</li> <li>01-0.06 U/min</li> <li>Phenylephrine</li> <li>Target: AAAA</li> <li>40-180 mcg/min</li> </ul> </li> <li>InoPressors<ul> <li>Low effect on HR/Inotropy/Ectopy</li> <li>High effect on SVR, BP</li> <li>Norepinephrine (Levophed)</li> <li>Target: AAAB</li> <li>0-40 mcg/min</li> <li>Epinephrine</li> <li>Target: ABBB</li> <li>0-20 mcg/min</li> <li>Dopamine</li> <li>Low<ul> <li>Target: Dopa-R</li> <li>1-4 mcg/kg/min</li> </ul> </li> <li>Medium<ul> <li>Target: ABBBD</li> <li>4-10 mcg/kg/min</li> </ul> </li> <li>High<ul> <li>Target: AAABD</li> <li>10-20 mcg/kg/min</li> </ul> </li> </ul> </li> </ul>"},{"location":"im-guide/pharm/nervous-system/pain_management/","title":"Pain Management","text":"<ul> <li>NSAIDs</li> <li>Salicylates<ul> <li>Aspirin (ASA)</li> <li>Slows the bd of oral hypoglycemics (decrease hypoglycemic dose)</li> <li>Monitor when used with Lithium</li> </ul> </li> <li> <p>Acetic Acid Derivatives</p> <ul> <li>Blocks COX1 and COX2</li> <li>Bromfenac (Prolensa, Bromday)</li> <li>Diclofenac (Voltaren)</li> <li>Indomethacin</li> <li>Ketorolac (Toradol)</li> <li>Oxicams</li> <li>Meloxicam (Mobic)</li> <li>Piroxicam (Feldene)</li> <li>Propionic Acid Derivatives</li> <li>Ibuprofen</li> <li>SE: Hyperkalemia, Hyponatremia, Hypokalemia + RTA (hyperchloremic metabolic acidosis, low urine anion gap)</li> <li>Naproxen</li> <li>Coxibs</li> <li>Celecoxib (Celebrex)</li> <li>COX1 completely, COX2 some</li> <li>Etodolac</li> <li>COX1 completely, COX2 some</li> <li>Parecoxib (Dynastat)</li> <li>Other</li> <li>Nabumetone (Relafen, Relifex)</li> <li>Neuropathic Pain</li> <li>Orders of loss:</li> <li>1) Pain</li> <li>2) Temperature</li> <li>3) Touch</li> <li>4) Pressure</li> <li>TCAs (Amitriptyline/Nortriptyline)</li> <li>Decrease reuptake of serotonin and norepinephrine</li> <li>Inhibition of pain signals</li> <li>Can be used in patients with Depression + Neuropathy</li> <li>CI: \u226565, pre-existing Cardiac disease</li> <li>Anticonvulsants</li> <li>Gabapentin Enacarbil (Horizant)</li> <li>Not FDA approved</li> <li>Influence synthesis/uptake of GABA<ul> <li>Does not Bind GABA-A/GABA-B</li> </ul> </li> <li>Restless leg, neuropathy, anxiety</li> <li>Gabapentin (Neurotin)</li> <li>Not FDA approved</li> <li>Antiepileptic, migraine prevention, diabetic neuropathy, RLS</li> <li>Pregabalin (Lyrica)</li> <li>Dose: 50mg BID to TID</li> <li>MOA: Decreased depolarization of neurons in CNS<ul> <li>Inhibits the release of excitatory neurotransmitters by binding voltage gated calcium modulators on nerve endings</li> <li>6x binding affinity of gabapentin</li> <li>May potentiate opioids/benzos</li> </ul> </li> <li>Use: FDA for fibromyalgia</li> <li>SE: drowsiness, weight gain, fluid retention</li> <li>Dual SNRIs (Duloxetine)</li> <li>In painful diabetic neuropathy</li> <li>Opioids (Oxycodone)</li> <li>Activation of central opioid receptors</li> <li>Capsaicin (Topical)</li> <li>Loss of membrane potential in nociceptive fibers</li> <li>Lidocaine (Topical)</li> <li>Decreased depolarization of neurons in peripheral nerves</li> <li>Milnacipran (Savella)</li> <li>SNRI</li> <li>Medical Cannabis</li> <li>Some efficacy in the treatment of chronic non-cancer pain</li> <li>Chronic inflammatory Demyelinating neuropathy</li> <li>Distal paresthesias and numbness</li> <li>Motor weakness in upper and lower extremities</li> <li>Somatic Pain</li> <li>Joint pain</li> <li>NSAIDs (Ketorolac)</li> <li>DMARDs</li> <li>Pts on prednisone \u226520mg/day, methotrexate \u226525mg/week, and azathioprine \u22653mg/kg/day should avoid live vaccines</li> <li>Nonbiologic agents (sDMARDs):</li> <li>Methotrexate (MTX, Rheumatrex, Trexall)</li> <li>MOA: Purine Antimetabolite, inhibits dihydrofolate reductase</li> <li>Most predictable benefit and well tolerated in RA</li> <li>Give with Folic Acid</li> <li>May continue through surgery w/o stopping</li> <li>SE: Hypersensitivity Pneumonitis, cytopenias even at low doses, abnormal LFTs, Infections, mucosal ulcers, GI, Abortifacient, alopecia, skin nodules, nephrotoxicity, macrocytic anemia, hepatotoxicity, stomatitis<ul> <li>May activate hepB or C, myelosuppression</li> </ul> </li> <li>CI: pregnancy, moderate to advanced renal disease, chronic liver disease, heavy alcohol use, parenchymal disease</li> <li>Cycle off for \u22651 ovulatory cycle prior to pregnancy, 3 months for males</li> <li>Methotrexate Pneumonitis<ul> <li>CXR w/interstitial infiltrates</li> <li>Not dose related</li> <li>Usually within 1<sup>st</sup> year</li> <li>Subacute w/cough, dyspnea, fever</li> <li>Bronchoscopy with BAL usually needed to R/O infection</li> <li>TX: Stop MTX, taper with glucocorticoids</li> </ul> </li> <li>Get CXR, CBC and CMP, Viral HepB/HepC titers<ul> <li>CMP/CMP every 4 weeks for 3m, then every 3m</li> <li>PFTs if COPD or dyspnea</li> </ul> </li> <li>PCN/sulfa decrease renal excretion</li> <li>Folate supplementation</li> <li>Azathioprine (AZA)</li> <li>Thiopurine</li> <li>First metabolized to 6-MP by the liver</li> <li>Then metabolized by 3 pathways<ul> <li>1) TPMT converts 6-MP to 6-MMP</li> <li>Main pathway, inactive in 11% of population</li> <li>2) HPRT states conversion of 6-MP to 6-TG</li> <li>Bone marrow suppression if high or on XO inhibitors, monitor CBC/LFTs</li> <li>Hepatotoxic levels of 6-MMP if defective</li> <li>3) XO converts 6-MP to 6-TU</li> </ul> </li> <li>More commonly used for SLE and IBD</li> <li>Test for TPMT (Thiopurine methyltransferase) prior to initiation of 6-mp or aza</li> <li>Safe in Pregnancy</li> <li>SE: Cytopenias, hepatotoxicity, GI<ul> <li>Increases risk of bone marrow toxicity</li> <li>Dose-dependent diarrhea, leukopenia, hepatotoxicity</li> </ul> </li> <li>Cyclosporine A (CYA)</li> <li>Calcineurin Inhibitor, inhibits T-cell production of IL-2</li> <li>Synergistic with MTX</li> <li>SE: Renal toxicity, hypertension</li> <li>Cyclophosphamide (CYP)</li> <li>Alkylating agent, disrupts DNA replication</li> <li>SE: malignancy, infertility, infections, cytopenia, hemorrhagic cystitis</li> <li>Hydroxychloroquine (HCQ, Plaquenil)</li> <li>MOA: TNF &amp; IL-1 suppressor</li> <li>Antimalarial</li> <li>Safe in pregnancy</li> <li>May continue through surgery w/o stopping</li> <li>SE: Retinal toxicity, neuromyopathy, hyperpigmentation<ul> <li>Annual eye exam after 5 years of continuous use</li> <li>Increased retinal tox risk:</li> <li>Retinopathy more likely with renal or liver disease</li> <li>\u226560 y/o, \u2265400mg/day, use \u22655 years, underlying retinal or macular disease</li> <li>May exacerbate psoriasis</li> <li>CBC/CMP every 3-6m</li> <li>Initiation has an increased risk of MACE/CV mortality/MI vs. Methotrexate in HF patients</li> </ul> </li> <li>CI: G6PD deficiency</li> <li>Leflunomide (LEF, Arava)</li> <li>MOA: Antimetabolite, pyrimidine synthesis inhibitor</li> <li>Initial DMARD in patients unable to take MTX</li> <li>Same baseline studies as MTX</li> <li>May continue through surgery w/o stopping if minor, stop 1-2 days before major surgeries, restart 1-2 weeks after</li> <li>SE: Pneumonitis, cytopenias, hepatotoxicity, Infections, GI</li> <li>CI: pregnancy, lactation, teratogenic<ul> <li>Give cholestyramine 8g PO TID for 11 days to eliminate drug (want leflunomide \\&lt;0.02mg/L for 2 tests 14 days apart)</li> <li>Extremely teratogenic</li> </ul> </li> <li>Mycophenolate Mofetil (MMF)</li> <li>Reversibly inhibits IMP Dehydrogenase, preventing purine synthesis of B and T cells</li> <li>SE: GI upset, pancytopenia, hypertension, hyperglycemia, less nephrotoxic and neurotoxic<ul> <li>Teratogenic</li> <li>Associated with invasive CMV infection</li> </ul> </li> <li>Sulfasalazine (SSZ, Azulfidine)</li> <li>Antibiotic/Anti-inflammatory</li> <li>RA and IBD<ul> <li>Sulfapyridine produces effects for RA</li> <li>5-ASA produces effects for IBD</li> </ul> </li> <li>SE: Cytopenias (check G6PD prior), Hepatotoxicity, oligospermia in 80% but reversible, rash, N/V/D/Ab pain, hemolytic anemia</li> <li>Give folic acid supplements</li> <li>May continue through surgery w/o stopping</li> <li>Reyes syndrome in pts given varicella vaccine</li> <li>Relatively safe during pregnancy</li> <li>CI: G6PD deficiency</li> <li>Tofacitinib (Xeljanz)</li> <li>Small-molecule JAK-\u2153 inhibitor<ul> <li>Inhibits intracellular signaling involved in T-cell activation, proinflammatory cytokine production, cytokine signaling</li> </ul> </li> <li>Refractory RA</li> <li>SE: Infections (shingles particularly), Hyperlipidemia, cytopenias, TB reactivation, Abnormal LFTs if used with MTX</li> <li>Biologic Agents (bDMARDs):</li> <li>Screening: HepB, HepC, TB</li> <li>Vaccinate with flu, pna, other vaccines</li> <li>Avoid live attenuated vaccines (nasal flu, MMR, shingles)</li> <li>Suspend biologic therapy during perioperative period</li> <li> <p>Anti-TNF Biologics:</p> <ul> <li>Monoclonal antibodies that bind and inactivate TNF</li> <li>Best used with MTX to halt and possibly reverse disease</li> <li>Use: IBD, Rheumatoid Arthritis</li> <li>Moderate to High risk patients: \\&lt;30, extensive involvement, perianal \u00b1 rectal disease, deep ulcer, prior surgery, structuring \u00b1 penetrating behavior</li> <li>SE: drug induced lupus, CNS demyelination, worsening HF, malignancy, infection</li> <li>CI: HF class III/IV, no live vaccines</li> <li>TNFi + Thiopurine (azathioprine or 6-MCP) = increased risk for hepatosplenic T-cell lymphoma<ul> <li>Adalimumab (Humira)</li> </ul> </li> <li>Humanized Monoclonal Antibody</li> <li>Soluble TNF-alpha inhibitor</li> <li>Subcutaneous<ul> <li>Certolizumab (Cimzia)</li> </ul> </li> <li>Fab' segment of humanized monoclonal antibody attached to polyethylene glycol strands</li> <li>Soluble TNF-alpha inhibitor</li> <li>Subcutaneous<ul> <li>Etanercept (Enbrel)</li> </ul> </li> <li>Fusion protein made of two p75 TNF-alpha receptors linked to IgG Fc segment, Soluble TNF receptor linked to IgG1 (not a monoclonal antibody)<ul> <li>Golimumab (Simponi)</li> </ul> </li> <li>Humanized Monoclonal Antibody</li> <li>Soluble TNF-alpha inhibitor</li> <li>Subcutaneous<ul> <li>Infliximab (Remicade)</li> </ul> </li> <li>Chimeric (mouse-human) Monoclonal Antibody</li> <li>Soluble TNF-alpha inhibitor</li> <li>SE: Arthralgias (MC)<ul> <li>Non-TNF Biologics:</li> <li>Abatacept (Orencia)</li> </ul> </li> <li>Soluble CTLA-4 receptor/IgG Fc segment chimera co-stimulation inhibitor (CD80 and CD86)</li> <li>Blocks communication</li> <li>Inhibits T-cells</li> <li>Does not block TNF-alpha</li> <li>SE: COPDE, infections, Nausea, Sinus infection, pneumonia, TB, Hyperglycemia</li> <li>Associated with COPD exacerbations in vivo</li> <li>Can't be used with biologics<ul> <li>Anakinra (Kineret)</li> </ul> </li> <li>Recombinant receptor antagonist</li> <li>IL-1 antagonist</li> <li>Less efficacious than other biologics</li> <li>Requires daily injection</li> <li>Continue for minor procedures, stop 1-2 days before major surgeries, restart 10 days later</li> <li>SE: Neutropenia, infections, injections site reaction<ul> <li>Belimumab</li> </ul> </li> <li>Humanized Monoclonal Antibody<ul> <li>Canakinumab</li> </ul> </li> <li>Humanized Monoclonal Antibody<ul> <li>Rilonacept</li> </ul> </li> <li>Dual IL-1B receptors chimerically attached to IgG Fc segment<ul> <li>Rituximab (Rituxan)</li> </ul> </li> <li>MOA: Chimeric (mouse-human) Monoclonal Antibody to CD20 surface Ig of B cells</li> <li>Stop 7 months before major surgery</li> <li>Use: CD 20+ NHL, CLL, ITP, RA</li> <li>Used with MTX, when refractory to TNFi</li> <li>SE: Serious infections (increased risk of PML), SJS/TEN, HepB reactivation, serious infusion reactions, pulmonary toxicity<ul> <li>Secukinumab</li> </ul> </li> <li>Humanized Monoclonal Antibody<ul> <li>Tocilizumab (Actemra)</li> </ul> </li> <li>Humanized Monoclonal Antibody</li> <li>IL-6 receptor antagonist</li> <li>Refractory to DMARDs \u00b1 TNFi</li> <li>SE: infections, hyperlipidemia, cytopenias, Diverticulitis/perforation, abnormal LFTs</li> <li>Increases risk of bowel perforation in pts w/history of diverticulitis</li> <li>Decreases efficiency of oral contraceptives<ul> <li>Tofacitinib</li> </ul> </li> <li>Oral targeted Synthetic Janus Kinase inhibitor</li> <li>SE: Increased risk of thrombotic events<ul> <li>Ustekinumab (Stelera)</li> </ul> </li> <li>Humanized Monoclonal Antibody</li> <li>Anti-IL-12/23 antibody</li> <li>Used in high risk resistant crohns for induction and maintenance</li> <li>Stop 1 week before procedure, restart \u226514 days later</li> <li>Acetaminophen (Tylenol)</li> <li>Metabolized within hepatic microsomes, predominantly by phase II reactions<ul> <li>90% by Glucouronidation and Sulfination to nontoxic conjugates</li> <li>5% by P450 oxidation to NAPQI</li> <li>Hepatotoxic metabolite, usually conjugates to glutathione</li> <li>5% by Direct urinary excretion</li> </ul> </li> <li>Toxicity<ul> <li>RF: Malnutrition (decreased GSH), fasting, P450 induction</li> </ul> </li> <li>Poisoning<ul> <li>Stage I (30 minutes to 4 hours)</li> <li>Asymptomatic to GI upset</li> <li>LFTs normal</li> <li>Stage II (24 hours to 72 hours)</li> <li>Initial symptoms resolve</li> <li>RUQ pain, hepatomegaly</li> <li>Increased LFTs, PT/INR, Total Bilirubin</li> <li>Stage III (72 hours to 96 hours)</li> <li>GII upset, jaundice</li> <li>CNS dysfunction (hepatic encephalopathy)</li> <li>Bleeding diathesis</li> <li>\u00b1 Acute renal failure</li> <li>LFTs \u226510k, PT/INR increase, Total Bilirubin \u22654.0, Hyperammonemia, Hypoglycemia</li> <li>MC time of death (MSOF)</li> <li>Stage IV (4 days to 2 weeks)</li> <li>Recovery</li> <li>Labs normalize</li> </ul> </li> <li>W/U: Measure Acetaminophen concentrations at 4 and 8 hours post ingestion</li> <li>Treatment<ul> <li>Rumack-Matthew Nomogram</li> <li>To predict toxicity and need for N-acetylcysteine for acute overdoses</li> <li>Activated Charcoal if within 4 hours (1g/kg)</li> <li>N-acetylcysteine if within 8 hours</li> <li>Regenerates hepatic glutathione stores (IV \u2265 oral in failure, prior to LFTs)</li> <li>Death and hepatotoxicity uncommon if NAC given within 8hrs</li> </ul> </li> <li>Triptans</li> <li>General<ul> <li>CI: Brainstem or hemiplegic Auras</li> </ul> </li> <li>Sumatriptan (Imitrex)<ul> <li>3 methods of delivery (injection, intranasal, oral)</li> <li>Combo: Sumatriptan + Naproxen</li> <li>Works better than either alone</li> </ul> </li> <li>Zolmitriptan (Zomig)</li> <li>Rizatriptan (Maxalt)<ul> <li>Works the fastest</li> <li>Propranolol increases blood levels (downward titrate)</li> </ul> </li> <li>Almotriptan (Axert)</li> <li>Eletriptan (Relpax)</li> <li>Fovatriptan (Frova)</li> <li>Naratriptan (Amerge)</li> <li>CI: complicated or basilar migraines, CHD or Prinzmetal angina, Stroke history, uncontrolled BP, pregnancy, MAOIs within 24hrs</li> </ul> </li> </ul> </li> </ul>"},{"location":"im-guide/pharm/nervous-system/sleep/","title":"Sleep Medications","text":"<ul> <li>Insomnia</li> <li>Inpatient<ul> <li>1) Ramelteon (Rozerem)</li> <li>8mg, Melatonin Agonist, Sleep onset, rapid, short duration</li> <li>2) Trazodone (Desyrel)</li> <li>3) Zyprexa/Diphenhydramine</li> </ul> </li> <li>Outpatient<ul> <li>1) Melatonin</li> <li>2) Zolpidem (Ambien), Zaleplon, Eszopiclone</li> <li>Non-Benzo GABA receptor agonists</li> <li>Best used less than 2 weeks</li> <li>3) Doxepin (Silenor)</li> <li>4) Trazodone</li> </ul> </li> <li>Sedating</li> <li>Amitriptyline (Elavil)</li> <li>Doxepin (Silenor)<ul> <li>3-6mg, TCA, H1 antagonist for sleep maintenance, H1/H2 for urticaria</li> <li>Best choice for chronic therapy, rapid onset, intermediate duration</li> </ul> </li> <li>Mirtazapine (Remeron)</li> <li>Eszopiclone (Lunesta)</li> <li>1\u22653mg, Sleep maintenance, rapid, intermediate duration<ul> <li>Increases total sleep time via increases in stage 2 NREM sleep</li> </ul> </li> <li>SE: impaired driving, memory, coordination</li> <li>Hydroxyzine (Vistaril)</li> <li>Zaleplon</li> <li>5\u226520mg, Sleep onset, rapid, short duration</li> <li>Little effect on total sleep time</li> <li>Zolpidem (Ambien)</li> <li>Sleep onset and/or Maintenance</li> <li>5-10mg rapid onset, short duration</li> <li>ER: 6.25-12.5mg rapid, intermediate duration</li> <li>Sublingual:<ul> <li>Intermezzo: 1.75-3.5mg, rapid, ultra-short duration</li> <li>Edluar: 5-10mg rapid, short duration</li> <li>Oral spray: 5-10mg rapid, short duration</li> </ul> </li> <li>Suvorexant (Belsomra)</li> <li>Orexin receptor antagonist</li> <li>Sleep onset and/or Maintenance</li> <li>10-20mg slow, long duration</li> <li>SE: Narcolepsy/Cataplexy</li> <li>Lemborexant (Dayvigo)</li> <li>Orexin receptor antagonist</li> <li>Sleep onset and/or Maintenance</li> <li>5-10mg rapid, intermediate duration</li> </ul>"},{"location":"im-guide/pharm/psychiatry/antidepressants/","title":"Antidepressants","text":"<ul> <li>Selective Serotonin Reuptake Inhibitors (SSRIs)</li> <li>Notes:<ul> <li>Increased risk of suicide in 0-24 y/o upon initiation (black box)</li> <li>More gestures and Ideations, no more completions</li> <li>Decreased risk of suicide in \u226565 y/o upon initiation (white men)</li> </ul> </li> <li>Drug Interactions:<ul> <li>Paroxetine \u2265 Sertraline \u2265 Citalopram</li> <li>Also helpful for anxiety associated depression</li> </ul> </li> <li>SE (General):<ul> <li>Sexual dysfunction is the MCC of noncompliance and MC SE (50-80%)</li> <li>Akathisia</li> <li>Early: HA/Nausea, dizziness, insomnia, anxiety</li> <li>Nonspecific: Flu-like, GI upset, Psych symptoms</li> <li>Late: sexual dysfunction and weight gain</li> </ul> </li> <li>Citalopram (Celexa)<ul> <li>Dose: 20mg up to 20-40mg daily (40mg max effective)</li> <li>Weak CYP2D6 inhibitor</li> <li>Use:</li> <li>Treats anxiety symptoms better than other SSRIs</li> <li>Least likely to have drug interaction</li> <li>Low P450</li> <li>SE: More cardiotoxic, May Prolong Qt interval (blockade of KCNH2 gene potassium channel)</li> <li>20mg: 8.5ms, 40mg: 12.6ms, 60mg: 18.5ms</li> <li>Use 20mg if \u226560 or hepatic dysfunction</li> </ul> </li> <li>Escitalopram (Lexapro)<ul> <li>Dose: 10mg up to 10-20mg daily (10mg max effective)</li> <li>Most serotonin specific of SSRIs</li> <li>Most potent SSRI</li> <li>Use: Paraphilias, GAD, Chronic pain</li> <li>Post-MI depression due to low drug reaction potential</li> <li>Low p450, fewer SE than citalopram, rapid</li> <li>SE: QTc Prolongation: 10mg: 4.5ms, 20mg: 6.6ms, 30mg: 10.7ms</li> </ul> </li> <li>Fluoxetine (Prozac)<ul> <li>Dose: 20mg up to 20-80mg daily</li> <li>Potent CYP2D6 inhibitor</li> <li>Use: OCD, Bulimia, Panic Disorder</li> <li>Can be used with olanzapine for acute bipolar depression</li> <li>Doesn't need to be tapered when stopping, long half-life</li> <li>SE: May cause agitation/anxiety and insomnia initially, sexual dysfunction, may cause weight loss</li> <li>Nausea, vomiting, diarrhea</li> <li>QTc prolongation (4.5ms)</li> </ul> </li> <li>Fluvoxamine (Luvox)<ul> <li>50mg daily, max 300mg divided daily</li> <li>CYP3A4, 2C10, 1A2 inhibitor</li> <li>Most drug interations</li> <li>Use: OCD only</li> <li>No QTc Prolongation (-5.0ms)</li> </ul> </li> <li>Paroxetine (Paxil)<ul> <li>Dose: 20mg up to 20-60mg daily (50mg max effective)</li> <li>Potent CYP2D6 inhibitor</li> <li>Use: Premature ejaculation, Body dysmorphic disorder, SAD, OCD, PTSD</li> <li>Potent CYP2D6 inhibitor</li> <li>No QTc prolongation</li> <li>SE: Most likely to have side effects, Dizziness, most sedating and anticholinergic SSRI, highest rate of sexual dysfunction, higher rate of weight gain (30%), highest rate of discontinuation syndrome, sedating, constipation</li> <li>Cardiac septal defects in kids (pulm htn)</li> </ul> </li> <li>Sertraline (Zoloft)<ul> <li>Dose: 50mg up to 50-200mg daily</li> <li>Increased absorption with food</li> <li>Weak CYP2D6</li> <li>Use: PMDD, PTSD, SAD, OCD, Post-MI</li> <li>Best for breastfeeding</li> <li>SE: delayed ejaculation, QTc Prolongation, Bruxism (better with buspirone), generic may be activating, bruising, hair loss</li> <li>3.0ms</li> <li>Most likely to cause GI upset (Nausea \u2265 Diarrhea)</li> <li>May displace warfarin increasing PTT</li> </ul> </li> <li>Selective Norepinephrine Reuptake Inhibitors (SNRIs)</li> <li>Notes:<ul> <li>Nausea (MC), Sexual dysfunction, Hypertension (not duloxetine), Pseudo-anticholinergic effects (constipation, dizziness, dry mouth, sweating, agitation, anxiety, tachycardia) due to increased synaptic NE</li> </ul> </li> <li>Duloxetine (Cymbalta)<ul> <li>Dose: 20 mg up to 60mg daily (BID dosing may decrease SE)</li> <li>Aka Yantreve</li> <li>MOA: 5HT = NE at all doses</li> <li>Moderate CYP2D6</li> <li>Use: MDD, stress incontinence, panic disorder</li> <li>FDA approved for diabetic neuropathy, fibromyalgia</li> <li>Pain with depression</li> <li>Useful in diabetics with peripheral neuropathic pain</li> <li>Rapid symptom relief, few side effects</li> <li>Only SNRI w/o BP effects</li> <li>SE: Avoid in renal failure, Hepatic failure in liver disease, may increase HbA1c, Insomnia</li> <li>Nausea, dry mouth, constipation</li> <li>Prompt discontinuation due to side effects</li> <li>Less likely to cause HTN</li> </ul> </li> <li>Desvenlafaxine (Pristiq)<ul> <li>Dose: 50mg daily</li> <li>MOA: Inhibits 5HT and NE</li> <li>Active metabolite of venlafaxine and levo-milnacipran</li> <li>Avoids hepatic CYP2D6 metabolism</li> <li>Less likely to increase BP than Effexor</li> <li>Use: MDD, GAD, Panic Disorder, Menopause, Cocaine dependence</li> <li>Rapid, few side effects, low cytochrome P-450 effects</li> <li>No Weight gain</li> </ul> </li> <li>Milnacipran<ul> <li>Racemic mixture of levo- and dextro-milnacipran</li> <li>Use: Fibromyalgia (FDA)</li> <li>No CYP450 interaction, NET \u2265SERT selectivity</li> <li>SE: HTN, Tachycardia, GI symptoms, hyperhidrosis, ED</li> </ul> </li> <li>Levo-Milnacipran (Fetzima)<ul> <li>20mg; max 40-120mg daily</li> <li>Use: MDD</li> <li>More potent enantiomer of milnacipran</li> <li>Inhibits BACE-1 (B-amyloid plaques)</li> <li>SE: HTN, Tachycardia, GI symptoms, hyperhidrosis, ED</li> </ul> </li> <li>Venlafaxine (Effexor)<ul> <li>Dose: 37.5mg up to 75-375mg daily XR</li> <li>MOA: Inhibits 5HT \u2265 NE low dose, NE \u2265 5HT at high dose</li> <li>Inhibits CYP2D6</li> <li>Use: MDD, GAD, Panic Disorder, Menopause, Cocaine dependence</li> <li>Rapid, few side effects, low cytochrome P-450 effects</li> <li>No Weight gain</li> <li>SE: May cause diastolic hypertension, activating, \"stimulant effect\", Increases diastolic BP, most cardiotoxic SNRI, headache, constipation, sweating, Anxiety and HTN in high doses, discontinuation syndrome</li> <li>Nausea and sexual side effects in 30% due to NE not 5HT</li> <li>May have withdrawal</li> </ul> </li> <li>Atypical Antidepressants</li> <li>Bupropion (Wellbutrin)<ul> <li>Dose: 150mg up to 300-450mg daily</li> <li>MOA: NE and Dopamine reuptake inhibitor, increasing activity</li> <li>Metabolized by CYP2B6 to hydroxy- which is a moderate CYP2D6 inhibitor</li> <li>CYP2B6 substrate</li> <li>Use: Smoking cessation, MDD w/seasonal pattern, Adult ADHD, Obesity</li> <li>Good for weight loss, hypersomnia, smoking cessation, no sexual side effects</li> <li>Not good for anxious patients</li> <li>SE: Agitation, insomnia, anorexia, sweating, false positive for amphetamines on UDS, headache, tremor, dry mouth, psychosis</li> <li>Avoid in pregnancy</li> <li>CI: Seizures, Bulimia and Anorexia Nervosa, epilepsy</li> <li>Check for hypokalemic, hypochloremic metabolic alkalosis (self-induced vomiting seen in Bulimia Nervosa) prior to initiating</li> <li>Seizure risk is 2% at 600mg, 0.1% with 300-450mg, almost same as other antidepressants (0.05%)</li> </ul> </li> <li>Mirtazapine (Remeron)<ul> <li>Dose: 7.5mg up to 15-45mg daily</li> <li>\\&lt;30mg = sedation</li> <li>\u226530mg = activating (more NE)</li> <li>MOA: Presynaptic Alpha-2 antagonist<ul> <li>Increased NE and 5-HT release</li> </ul> </li> <li>Selective postsynaptic 5-HT receptor antagonist<ul> <li>Increased 5-HT1 receptor neurotransmission, antagonist at 5-HT2 and 5-HT3 receptor</li> </ul> </li> <li>Antagonizes H1 receptors</li> <li>Clearance impaired in liver disease by 30%, 50% in renal disease, elderly (males 40%, females 10%)</li> <li>Use: Insomnia</li> <li>Sleep, Depression, Hunger (Weight Gain)</li> <li>Don't break it in half, sedative already</li> <li>Additive effects with alcohol and benzos (substrate)</li> <li>Increases appetite, weight gain, increases mood, sleep<ul> <li>Lacks sexual side effects</li> </ul> </li> <li>SE: Drowsiness (54%), Xerostomia (25%), Weight Gain (12%), Sedation, Thrombocytopenia, Bone marrow suppression and neutropenia, hypertriglyceridemia, increase in appetite, constipation (13%), Disorientation and tachycardia, increased cholesterol, decreased ANC</li> </ul> </li> <li>Maprotiline (Ludiomil)<ul> <li>D2 blocker (NET \u2265SERT inhibition)</li> <li>TCA like adverse effects, seizures, high NET affinity</li> <li>Use: Anxiety with depressive features</li> </ul> </li> <li>Nefazodone (Serzone)<ul> <li>50mg BID up to 300mg BID</li> <li>5-HT2A antagonists (relatively selective), Alpha1 receptor blockade, CYP3A4 inhibitor, weak Serotonin reuptake inhibitor (antagonist and agonist of serotonin receptor)</li> <li>Sedation, dose related GI effects \\&lt; SSRIs</li> <li>Rare sexual effects, hypotension</li> <li>Short half life</li> <li>Use: Insomnia</li> <li>Black Box Warning: Fulminant liver failure</li> </ul> </li> <li>Trazodone (Desyrel)<ul> <li>MOA: 5-HT2A antagonist (relatively selective), Alpha-1 receptor blockade, CYP3A4 substrate, 5HT2C receptor agonist</li> <li>Vasodilation, Short half life</li> <li>Use: Insomnia in depression</li> <li>Depression: 150mg up to 150-600mg daily</li> <li>Sleep: 25-50mg qPM</li> <li>Pronounced sedation, dose related GI effects \\&lt; SSRIs</li> <li>SE: Rare sexual effects, priapism (\\&lt;1%), hypotension, sedation</li> </ul> </li> <li>Vilazodone (Viibryd)<ul> <li>Dose: 10mg daily, goal 40mg daily, 10mg per week increase</li> <li>SSRI + 5HT1 partial agonist (MDD + GAD)</li> <li>CYP3A4</li> <li>Use:</li> <li>Less Sexual and Weight gain SE</li> <li>SE: Nausea and Diarrhea \u2265 SSRIs, discontinuation syndrome</li> </ul> </li> <li>Vortioxetine (Trintellix)<ul> <li>Serotonergic, nausea, Sexual side effects</li> <li>Processing speed increase</li> <li>SSRI + 5HT1A full agonist/5HT1B partial agonist, 5-HT3/7/1D antagonist</li> </ul> </li> <li>Monoamine Oxidase Inhibitors (MAOIs)</li> <li>Avoid: beer, wine, aged cheese, soy sauce, bananas, smoked meat</li> <li>SE: MCly Orthostatic hypotension and weight gain, paresthesia (from B6 deficiency), mania<ul> <li>highest rates of sexual dysfunction of all antidepressants, Anorgasmia</li> <li>Activation, insomnia, and restlessness</li> <li>Confusion at higher doses</li> <li>Hypertensive Crisis (0.02%)</li> <li>Delirium-like discontinuation with psychosis, excitement, and confusion</li> <li>Meperidine is specifically contraindicated</li> <li>Need 2-week washout</li> </ul> </li> <li>Nonselective<ul> <li>MOA: Irreversibly inhibit MAOA/B</li> <li>Isocarboxazid (Marplan)</li> <li>10mg BID, max 60mg daily</li> <li>Use: Geriatric Depression</li> <li>Tranylcypromine (Parnate)</li> <li>30mg daily to 60mg in divided doses</li> <li>Use: Atypical Depression</li> <li>Phenelzine (Nardil)</li> <li>15mg TID to 90mg TID</li> <li>Non-selective blockade of MAO</li> <li>More sedating than selegiline and tranylcypromine</li> <li>Pain, Eating, Panic disorders</li> </ul> </li> <li>Selective<ul> <li>Selegiline (Emsam)</li> <li>Dose: 6mg-12mg transdermal patch (24hr)</li> <li>MOA: MAO-B irreversible inhibition at low doses<ul> <li>Increased dopamine</li> <li>MAO-A inhibition if given transdermally</li> </ul> </li> <li>Use: Parkinson's drug<ul> <li>No dietary restriction if used in low dosages</li> </ul> </li> <li>SE: Orthostatic hypotension</li> <li>Rasagiline</li> </ul> </li> <li>Tricyclic Antidepressants (TCAs)</li> <li>General<ul> <li>MOA: Block NE and serotonin reuptake at synapse, some block Dopamine reuptake</li> <li>Inhibition of NE and 5-HT can trigger convulsions/seizures</li> <li>Also block muscarinic acetylcholine receptors<ul> <li>Orthostatic hypotension due to alpha blockade</li> <li>H1 receptors also blocked</li> </ul> </li> <li>Class 1A Antiarrhythmic agents at low doses, arrhythmic agents at high doses</li> <li>2<sup>nd</sup> MCC of lethal OD in US (amitriptyline \u2265 rest combined), death in 8.5/1000 OD</li> <li>SE: Convulsions, Coma, Cardiotoxicity, Respiratory Depression, Hyperpyrexia, Prolonged QRS, weight gain, sedation</li> <li>Cholinergic rebound on discontinuation (flu like)</li> <li>Delirium (amitriptyline)</li> <li>Seizures (2% clomipramine)</li> <li>Acute Hepatitis (0.1%)</li> <li>CI: Narrow-angle Glaucoma</li> </ul> </li> <li>Secondary Amines<ul> <li>General</li> <li>High affinity for blocking NE reuptake (NE \u2265 5HT)</li> <li>Fever, anticholinergic effects, weight gain</li> <li>Desipramine (Norpramin)</li> <li>Dose: 25-50mg daily up to 100-300mg daily</li> <li>Least sedating TCA (most noradrenergic)</li> <li>SE: LFT elevation (AST\u2265\u2265\u2265ALT)</li> <li>Maprotiline (Ludiomil)</li> <li>Dose: 25mg TID, max 225mg daily</li> <li>Lacks 5HT reuptake inhibition (mainly NE reuptake)</li> <li>SE: Sedating</li> <li>Nortriptyline (Pamelor)</li> <li>Dose: 25-50mg daily up to 150-200mg daily</li> <li>Use: Elderly depression, cardiac diseases, pruritus, smoking cessation, QTc Prolongation<ul> <li>Least likely to cause orthostatic hypotension (low acnticholinergic)</li> </ul> </li> </ul> </li> <li>Tertiary Amines<ul> <li>Notes:</li> <li>5HT \u2265 NE</li> <li>Have more anticholinergic side effects and sedation</li> <li>Agitation, blurry vision, fever, constipation, urinary retention, confusion</li> <li>Myotonic jerking, delirium, sedation, coma</li> <li>Amitriptyline (Elavil)</li> <li>Dose: 25-50mg daily up to 100-200mg daily</li> <li>Use: Depression w/insomnia, chronic pain</li> <li>SE: Orthostatic hypotension (causing falls), Sedating<ul> <li>Semiannual EKG due to risk of QT prolongation</li> <li>Most anticholinergic</li> </ul> </li> <li>Amoxapine (Asendin)</li> <li>Dose: 50mg BID, max 400mg daily</li> <li>MOA: D2 blocker (5HT = NE, weak DA)<ul> <li>Blockade of NE and 5-HT reuptake</li> </ul> </li> <li>Use: MDD w/Psychotic Features<ul> <li>Dopamine receptor blockade (antidepressant)</li> <li>Anti-dopaminergic effects (Parkinson's, ED)</li> <li>Unique to drug in class (may cause EPS)</li> </ul> </li> <li>SE: higher seizure risk, TD<ul> <li>Most dangerous in overdose</li> </ul> </li> <li>Clomipramine (Anafranil)</li> <li>Dose: 25mg daily, max 250mg daily</li> <li>Most serotoninergic, most sexual effects</li> <li>Use: OCD</li> <li>Doxepin (Sinequan)</li> <li>Dose: 25-75mg daily up to 100-300mg daily</li> <li>MOA: 5HT = NE, highly sedation<ul> <li>Most antihistamine</li> </ul> </li> <li>Use: GAD, PUD, pruritis</li> <li>SE: Sedating, antihistaminergic, anticholinergic</li> <li>Imipramine (Tofranil)</li> <li>Dose: 25-50mg daily up to 100-200mg daily</li> <li>MOA: 5HT = NE</li> <li>Use: Panic disorder with agoraphobia, enuresis, eating disorders, but has a high relapse rate</li> <li>SE: Orthostatic hypotension, prolonged QT, LFT elevation (AST\u2265\u2265\u2265ALT)</li> <li>Protriptyline (Vivactil)</li> <li>Less sedating than doxepin, nor/amitriptyline, imipramine</li> <li>Good for job alertness</li> </ul> </li> </ul>"},{"location":"im-guide/pharm/psychiatry/antipsychotics/","title":"Antipsychotics","text":"<ul> <li>Antipsychotics black box</li> <li>Increase the all-cause mortality of elderly patients with dementia</li> <li>Antipsychotic Most likely to cause hyperprolactinemia</li> <li>Partial dopamine agonists inhibit full dopamine antagonists</li> <li>Aripiprazole decreases Haloperidol efficacy</li> <li>1<sup>st</sup> generation antipsychotics (Typical Antipsychotics)</li> <li>General<ul> <li>Extrapyramidal Side Effects (EPS) via D2 receptor blockade in the Nigrostriatal pathway</li> </ul> </li> <li>Class: Butyrophenone<ul> <li>Haloperidol (Haldol)</li> <li>High Potency</li> <li>D2 Inverse agonist, D2 Receptor Antagonist and Alpha Antagonist</li> <li>CI: Lewy body dementia</li> <li>QTc Prolongation (7 to 15ms)</li> </ul> </li> <li> <p>Class: Phenothiazine</p> <ul> <li>Derived from methylene blue</li> <li>Use: Schizophrenia, Acute Mania<ul> <li>Improves positive symptoms, may worse negative</li> </ul> </li> <li>SE: Decrease seizure threshold</li> <li>Chlorpromazine (Thorazine)</li> <li>Low Potency</li> <li>MOA: D2 Antagonist, H1 receptor antagonist, Alpha Antagonist<ul> <li>Cholinergic Antagonist, alpha-adrenergic receptor antagonist</li> </ul> </li> <li>SE: Purple-grey metallic rash over sun exposed areas and jaundice<ul> <li>Orthostatic Hypotension, sedation</li> </ul> </li> <li>CI : Pregnancy, cardiac patients, acute glaucoma</li> <li>Fluphenazine (Prolixin)</li> <li>High Potency</li> <li>Antipsychotic can cause hypothermia</li> <li>Methylene Blue</li> <li>Prochlorperazine</li> <li>Thioridazine (Mellaril)</li> <li>Low Potency</li> <li>Cholinergic Antagonist</li> <li>Used in the past for resistant schizophrenia</li> <li>SE: Severe QTc Prolongation, Retinitis pigmentosa (decreased vision, poor night vision), blindness<ul> <li>33-41ms</li> </ul> </li> <li>Class: Thioxanthene</li> <li>Thiothixene (Navane)</li> <li>High Potency</li> <li>Class: Mesoridazine</li> <li>SE: Worst QTc Prolongation, Cardiac arrythmias (Torsades de pointes)</li> <li>39-53ms</li> <li>Class: Miscellaneous</li> <li>Pimozide (High Potency)</li> <li>Used in OCD</li> <li>Perfenazine (Trilafon)</li> <li>Medium Potency</li> <li>Molindone (Moban)</li> <li>Medium Potency</li> <li>Loxipine (Loxitane)</li> <li>Medium Potency</li> <li>Cheap, similar to atypical</li> <li>Potency (EPS):</li> <li>(Haloperidol/Trifluoperazine/Fluphenazine/Perphenazine/Thiothixene/Molindone) \u2265 (Chlorpromazine/thioridazine)</li> <li>20% get Tardive Dyskinesia</li> <li>2<sup>nd</sup> geneneration antipsychotics (Atypical Antipsychotics)</li> <li>Block D2 and antagonizes 5HT2A receptors</li> <li>Decreased extrapyramidal SE compared to 1<sup>st</sup> gen</li> <li>7-9% get Tardive Dyskinesia</li> <li>Fasting glucose and Lipids</li> <li>High Potency</li> <li>Risperidone (Risperdal)</li> <li>Dose: Daily<ul> <li>Pill, M-tabs, depot</li> </ul> </li> <li>MOA: 5HT2A receptor antagonist<ul> <li>Metabolite made by 2D6, thus avoid paroxetine, fluoxetine</li> </ul> </li> <li>Use: Mania, Psychosis, Autistic Aggression<ul> <li>Available as LAI</li> <li>Least likely to prolong QT (3.5-10ms)</li> </ul> </li> <li>SE: Most likely to cause EPS, Most likely to cause galactorrhea and increased prolactin (Hyperprolactinemia), Elevated LFTs<ul> <li>Strongest binding at dopamine receptors in pituitary</li> <li>Prolactin \u2265200 ng/mL</li> <li>Average metabolic profile</li> <li>3<sup>rd</sup> worst for Weight Gain</li> <li>Osteoporosis, decreased sex drive</li> <li>Diffuse Edema/Pedal Edema</li> <li>Starts after several days of treatment, resolves with cessation, no long-term effects</li> </ul> </li> <li>Paliperidone (Invega)</li> <li>MOA: 5HT2A receptor antagonist<ul> <li>Active metabolite of risperidone (avoids liver metabolism)</li> </ul> </li> <li>Use:<ul> <li>Available as LAI</li> <li>Low weight gain, low dyslipidemia, low diabetes risk</li> <li>No QTc prolongation (2 to 4ms)?</li> </ul> </li> <li>Low Potency:</li> <li>Clozapine (Clozaril)</li> <li>MOA: 5HT2A antagonist, H1 receptor antagonist<ul> <li>Weak D2 receptor antagonism</li> </ul> </li> <li>Use:<ul> <li>Parkinson Disease Psychosis</li> <li>6.25-75mg daily</li> <li>Treatment resistant schizophrenia after 2 other antipsychotics fail or if EPS on risperidone</li> <li>Decreases suicide risk in schizophrenia</li> <li>Least likely to cause EPS</li> <li>Least likely to cause hyperprolactinemia</li> </ul> </li> <li>Monitoring<ul> <li>Fasting glucose and lipids</li> </ul> </li> <li>SE: Most Weight Gain, Risk for diabetes and worsening lipid profile<ul> <li>QTc Prolongation: 10ms</li> <li>Neutropenia often caused by drug-induced agranulocytosis/aplastic anemia</li> <li>Get WBC and ANA (absolute neutrophil) counts</li> <li>Agranulocytosis - Neutrophil deficiency</li> <li>Pneumonia, bronchitis, sinusitis, URI</li> <li>Seizures (high risk), myocarditis</li> <li>Usually Tonic-Clonic</li> </ul> </li> <li>Olanzapine (Zyprexa)</li> <li>Pill, Zydis tabs, Relprevv injections (post-injection delirium/sedation syndrome)</li> <li>MOA: Weak D2 Antagonist, 5HT2A Inverse Agonist, Adrenergic Antagonist<ul> <li>CYP1A2, concentrations cut in half by smoking, grapefruit juice (double the dose in smokers), Carbamazepine</li> <li>31-hour half life</li> <li>Alcohol increases absorption by 25%</li> <li>Fluvoxamine, cimetidine, ciprofloxacin increased concentration</li> <li>Carbamazepine reduces olanzapine</li> </ul> </li> <li>Use:<ul> <li>Schizophrenia</li> <li>Available as LAI</li> <li>Nausea/Vomiting: 2.5-5mg IV/IM</li> <li>Little to no QTc prolongation</li> <li>Low prolactin risk</li> </ul> </li> <li>Add Fluoxetine for Bipolar depression</li> <li>SE: Sedating, Little QTc Prolongation (2 to 6.5ms)<ul> <li>Diffuse Edema</li> <li>Weight Gain (2<sup>nd</sup> worst to clozapine, 20kg average)</li> <li>Risk for diabetes and worsening lipid profile</li> </ul> </li> <li>Quetiapine (Seroquel)</li> <li>MOA: Weak D2 Antagonist, 5HT2A Antagonist, Adrenergic Antagonist, H1 agonist (Antihistamine activity)<ul> <li>Low potency compared to others</li> <li>Dilantin increases clearance 5x</li> <li>7-hour half life</li> </ul> </li> <li>Use: Anxiety, PTSD, Insomnia<ul> <li>Most sedating, good for sleep, Dry mouth</li> <li>Max 200mg for sleep prior to switching</li> <li>Low Prolactin risk</li> </ul> </li> <li>SE: Torsade de pointes, SCD, orthostatic hypotension, Cataracts<ul> <li>Little QTc Prolongation (6 to 15ms)</li> <li>3<sup>rd</sup> worst for Weight Gain</li> </ul> </li> <li>Other Potency:</li> <li>Ziprasidone (Geodon)</li> <li>Better at 80mg to 20mg, BID dosing, improved absorption w/food</li> <li>Use:<ul> <li>Low Metabolic risk profile</li> <li>Decreases cholesterol, triglycerides</li> <li>Minimal to no weight gain</li> <li>May improve concentration/depression vis 5HT-7</li> </ul> </li> <li>SE: EPS (akathisia)<ul> <li>Moderate QTc Prolongation (16 to 21ms)</li> </ul> </li> <li>Aripiprazole (Abilify)</li> <li>MOA: Partial D2 Agonist unlike the others, Partial 5HT2A agonist, strong 5HT2C agonist (less weight gain)</li> <li>Use:<ul> <li>Available as LAI</li> <li>Low Metabolic risk profile, Low Prolactin risk, low EPS</li> <li>No QTc Prolongation (-1 to -4ms)</li> </ul> </li> <li>SE: Orthostatic hypotension, Nausea/GI effects, somnolence or insomnia<ul> <li>Akathisia is more common with aripiprazole</li> <li>Treat with propranolol</li> </ul> </li> <li>Brexpiprazole (Rexulti)</li> <li>Dose: 0.5-1mg daily up to 4mg daily</li> <li>MOA: Partial D2 Agonist, Partial 5HT2A agonist</li> <li>Use: Schizophrenia, adjunctive for depression<ul> <li>Schizophrenia 2-4mg daily</li> <li>Depression: 2mg daily</li> <li>Low Prolactin risk, Low EPS</li> </ul> </li> <li>SE: weight gain, akathisia, URI, somnolence, tremor, headache, fatigue, hyperglycemia, seizures (rare)</li> <li>Cariprazine (Vraylar)</li> <li>Dose: 1.5mg up to 6mg daily</li> <li>MOA: 9x stronger at D3 than D2 partial agonist also</li> <li>10-14 days, 2 drugs, 4 weeks, 1 drug (that fixes)</li> <li>Use: Bipolar 1 mania, Schizophrenia<ul> <li>Quiets mania/hypomania</li> <li>Increases cognition</li> <li>Not sedating</li> </ul> </li> <li>SE: akathisia, EPS, weight gain, sedation, GI symptoms</li> <li>Lumateperone</li> <li>Glutamate antagonist used in schizophrenia</li> <li>Lurasidone (Latuda)</li> <li>Dose: 20mg to start, 40, 60, 80, 120mg<ul> <li>20-40 or 80mg max in liver damage</li> </ul> </li> <li>MOA: Strong D\u2156HT\u2156-HT7 antagonist, partial agonist at 5-HT1A receptor, highest atypical activity at 5-HT7<ul> <li>Metabolized via CYP3A4</li> <li>Must be taken with food (350 calories minimum increased absorption 9-19%), may be given in evening to decrease somnolence</li> <li>Peak 1-3 hours, steady state 7 days</li> </ul> </li> <li>Use: Schizophrenia, Bipolar Depression<ul> <li>80% response on 40-80mg per day</li> <li>Same as quetiapine, not superior to risperidone in schizophrenia</li> <li>Trials: PREVAIL Trial (promising as adjunct or monotherapy in Acute Schizophrenia)</li> <li>Minimal weight gain</li> <li>Low metabolic risk profile</li> <li>No QTc Prolongation</li> <li>No increase in suicidal ideation or behavior</li> </ul> </li> <li>SE: sedation, akathisia, nausea, somnolence, Parkinsonism, prolactin increase, headache, 7% increase in body weight, \u00b1 TSH increase</li> <li>Asenapine (Saphris)</li> </ul> </li> <li> <p>Pregnancy</p> </li> <li>Category B<ul> <li>Clozapine, Lurasidone, Bupropion, Maprotiline, Buspirone, Zolpidem</li> </ul> </li> <li>Bipolar on maintenance therapy<ul> <li>Do not alter even if teratogenic</li> </ul> </li> <li>Bipolar needing meds<ul> <li>Lamotrigine (Category C) \u2265 Lithium, valproate, carbamazepine (Category D)</li> <li>Carbamazepine</li> <li>Craniofacial defects, fingernail hypoplasia, developmental delay</li> <li>Increase folic acid to 4.0 mg/day through 1<sup>st</sup> trimester</li> </ul> </li> <li>Lithium<ul> <li>Ebstein's anomaly</li> </ul> </li> <li>Valproate<ul> <li>Neural tube defects, folate doesn't help (increase to 4.0)</li> <li>Formation occurs between 3<sup>rd</sup> and 4<sup>th</sup> week</li> <li>Thrombocytopenia, inhibited platelet aggregation</li> </ul> </li> <li>IV Drug abuse<ul> <li>Commonly opioids</li> <li>Associated with placenta abruption</li> <li>Treatment</li> <li>Methadone</li> <li>Buprenorphine and Naloxone</li> </ul> </li> </ul>"},{"location":"im-guide/pharm/psychiatry/anxiolytics/","title":"Anxiolytics","text":"<ul> <li>Sedative-Hypnotics</li> <li>CNS depression<ul> <li>Sedation</li> <li>Hypnosis</li> <li>Anesthesia</li> <li>Coma</li> </ul> </li> <li>Benzodiazepines</li> <li>MOA: Activate GABAa receptor binding sites<ul> <li>Lorazepam, oxazepam, and temazepam are safe in hepatic dysfunction</li> </ul> </li> <li> <p>General</p> <ul> <li>Anxiolysis, hypnosis, amnesia, no analgesic properties</li> <li>Paradoxical agitation, confusion and aggression within 1 hour of use in elderly</li> <li>Increased cognitive impairment and falls in elderly</li> <li>Withdrawal</li> <li>Life-threatening<ul> <li>Increased risk of seizures</li> <li>Anxious and irritable, insomnia, dysphoria, anxiety</li> <li>Begins typically 5-10 days after cessation if long acting, resolve in 2-4 weeks</li> </ul> </li> <li> <p>Use Longer half-life benzos to wean off shorter half-life drugs and alcohol</p> <ul> <li>\"self-taper\" by regenerating deficient brain receptors<ul> <li>Overdose with alcohol (sedative-hypnotic overdose)</li> <li>Synergistic respiratory depression when combined with opiates</li> <li>Bradycardia, hypotension, respiratory depression, CNS depression, lethargy, somnolence, hyporeflexia</li> <li>Flumazenil to treat OD</li> </ul> </li> <li>Short (half-life \\&lt;6h):<ul> <li>Triazolam (Halcion)</li> <li>Insomnia</li> <li>Oxazepam (Serax)</li> <li>Limited first pass metabolism, \"Outside The Liver\"</li> <li>Midazolam (Versed)</li> <li>Used for sedation during medical procedures</li> <li>Flumazenil to reverse</li> <li>SE: Decreased RR, hypotension, somnolence, hiccups, bronchospasm</li> <li>Clorazepate (Tranxene)</li> <li>Adjunct in management of partial seizures</li> </ul> </li> <li>Intermediate (half-life 6-24h):<ul> <li>Alprazolam (Xanax)</li> <li>Tmax: 1-2 hours, Half-Life: 12-15 hours</li> <li>Depression, panic disorder, SAD</li> <li>Medium strength (~1mg of Xanax = 2mg Ativan)</li> <li>Sedation: 0.25-0.5mg BID-TID</li> <li>Lorazepam (Ativan)</li> <li>Tmax: 1-6 hours, Half-Life: 10-20 hours</li> <li>Psychotic agitation, alcohol withdrawal, acute control of seizures</li> <li>Only IM benzodiazepine</li> <li>Weakest</li> <li>Sedation: 1-2mg daily to BID</li> <li>Hypnosis: 2-4mg</li> <li>Limited first pass metabolism, \"Outside The Liver\"</li> <li>Temazepam (Restoril)</li> <li>Insomnia</li> <li>Alprazolam has more euphoria, less sedation</li> <li>Limited first pass metabolism, \"Outside The Liver\"</li> </ul> </li> <li>Long (half-life \u226524h):<ul> <li>Diazepam (Valium)</li> <li>Tmax: 1-2 hours, Half-Life: 20-80 hours</li> <li>Muscle relaxation, analgesia, seizures, alcoholic withdrawal (seizures)</li> <li>Clonazepam (Klonopin)`</li> <li>Seizures, mania, SAD, panic disorder, OCD</li> <li>Strongest strength (~1mg of Klonopin = 2-4mg Ativan)</li> <li>Used for sleep due to longer half life</li> <li>q4hrs prn for CIWA</li> <li>Chlordiazepoxide (Librium)</li> <li>Tmax: 2-4 hours, Half-Life: 15-40 hours</li> <li>Alcohol withdrawal (particularly for agitation)</li> <li>Flurazepam (Dalmane)</li> <li>Insomnia</li> </ul> </li> <li>Barbiturates</li> <li>Phenobarbital<ul> <li>Can be used in Crigler-Najjar II to induce UDP-glucuronyl transferase</li> <li>Sedation: 15-30mg BID to TID</li> </ul> </li> <li>Promethazine (Phenegran)</li> <li>SE: Marked sedation, antiemetic</li> <li>Diphenhydrinate (Dramamine)</li> <li>Diphenhydramine (Benadryl)</li> <li>Hydroxyzine Pamoate (Atarax, Vistaril)</li> <li>SE: Marked Sedation</li> <li>Cyclizine (Marezine)</li> <li>Meclizine (Bonine)</li> <li>Doxylamine</li> <li>Nausea and vomiting in pregnancy</li> <li>Ramelteon (Rozerem)</li> <li>MOA: MT1 agonist (promotes sleep onset), MT2 agonist (shift timing of circadian system) that improves sleep onset<ul> <li>Selective melatonin agonist (MT1 and MT2 selective)</li> </ul> </li> <li>Use: Insomnia<ul> <li>Good for sleep maintenance</li> <li>DELIRIA-J (2014) \u2013 Substantial reduction in the risk of developing delirium in elderly inpatients (65-85) when given nightly for 7 days.</li> </ul> </li> <li>No tolerance or dependence</li> <li>Suvorexant (Belsomra)</li> <li>Non-Benzo GABA-A Receptor Agonists</li> <li>Non-Benzo GABA-A Receptor Agonists</li> </ul> </li> <li> <p>Alpha 1 subunit selective</p> </li> <li>Zaleplon (Sonata)</li> <li>Initial insomnia (non-benzo), 1hour action, sleep onset insomnia</li> <li>Short, insomnia</li> <li>Sleep Initiation</li> <li>Rapid onset, reduces hang-over effect</li> <li>SE: Dizziness and Somnolence</li> <li>Zolpidem (Ambien)</li> <li>Dsoe: Max 5mg females, 10mg males</li> <li>Use: Insomnia<ul> <li>ER version good for sleep maintenance</li> <li>Reduces sleep latency, nocturnal awakenings</li> <li>Increases total sleep time</li> <li>1-4.5 hours, sleep onset or maintenance</li> </ul> </li> <li>SE: Anterograde amnesia<ul> <li>Can't be used if patient has ever sleepwalked</li> </ul> </li> <li>Eszopiclone (Lunsta)</li> <li>Intermediate (6 hours), onset or maintenance</li> <li>Intermediate, insomnia</li> <li>Buspirone (Buspar)</li> <li>Dose: 5mg TID to 20mg TID max</li> <li>MOA: 5HT1a partial agonist<ul> <li>Takes 2 weeks to work</li> <li>Increased grapefruit increases buspar concentrations</li> </ul> </li> <li>Use: Anxiety, GAD<ul> <li>Non-sedating, no anticonvulsant or muscle relaxant properties</li> <li>Useful in alcoholics due to the lack of CNS potentiation</li> <li>Can be used in bruxism and Sexual side effects (inhibits 5HT2 and agonizes DA)</li> </ul> </li> <li>SE: headache, nausea, dizziness<ul> <li>Can't overdose, so safe</li> </ul> </li> </ul> </li> </ul>"},{"location":"im-guide/pharm/psychiatry/mood_stabilizers/","title":"Mood Stabilizers","text":"<ul> <li>Lithium</li> <li>Reduces suicide risk, takes 2-3 weeks to work<ul> <li>Spas have a high content of lithium</li> <li>Works better in Euphoric Bipolar Disorder</li> <li>9x higher risk for suicide when coming off of</li> </ul> </li> <li>CI: CKD, HD, Hyponatremia, diuretics</li> <li>Baseline: BUN, Cr, Calcium, Urinalysis, TSH, EKG if coronary risk</li> <li>Therapeutic level: Lithium (0.6-1.2)</li> <li>SE:<ul> <li>Hypothyroidism (add levothyroxine rather than stopping)</li> <li>Benign Leukocytosis</li> <li>Acute (GI)</li> <li>Tremor, ataxia, weakness, polyuria, vomiting, diarrhea</li> <li>AMS, Seizures, fasciculations, tremor</li> <li>Chronic (Neuro)</li> <li>Nephrogenic DI (MCC of), CKD, Thyroid dysfunction, Hyperparathyroidism: Polyuria in 50-70%</li> <li>Hypercalcemia (QT shortening)</li> <li>Treat with hemodialysis</li> </ul> </li> <li>Lithium Toxicity<ul> <li>\u22651.5 mEq/L: coarse tremor, tremulousness, confusion, arrhythmia, ataxia, nausea, diarrhea, nystagmus, hyperreflexia, dysarthria, dystonia</li> <li>Fine Tremor \u2013 treat with propranolol</li> <li>Hypothyroid \u2013 treat with levothyroxine</li> <li>Nephrogenic Diabetes Insipidus (hypernatremia)<ul> <li>Amiloride \\&lt; stopping</li> </ul> </li> <li>\u22652.5 mEq/L: Seizures, coma</li> <li>With signs of toxicity<ul> <li>Direct nephrotoxicity \u2013 renal tubular acidosis</li> </ul> </li> <li>Treat with hemodialysis</li> <li>\u22653 mEq/L: Death</li> <li>\u22654 and creatinine \u22652: AMS, Life-threatening</li> <li>Dialysis regardless</li> </ul> </li> <li>Overdose<ul> <li>Decreased renal perfusion with concurrent use of Thiazides, NSAIDS, ACEI, dehydration, tetracyclines, metronidazole</li> <li>Volume depletion (renal failure)</li> </ul> </li> <li>Valproic Acid (VPA)</li> <li> <p>Dose:</p> <ul> <li>Valproic Acid (Depakene): Tablet, liquid (TID/BID)</li> <li>Trough after 3 days</li> <li>Therapeutic level: Valproate (50-200 for seizures, \u2265100 = SE)</li> <li>Divalproex Sodium (Depakote): Tablet, sprinkle, ER, IV</li> <li>= 2 VPA + Na+</li> </ul> </li> <li> <p>MOA: increases sodium channel inactivation, increases GABA concentration by inhibiting GABA transaminase</p> <ul> <li>Adding w/alcohol, antipsychotics increase sedation</li> <li>Increases aspirin, carbamazepine, diazepam, amitriptyline, and phenobarbital</li> <li>Increases lamotrigine by double and increases SJS risk</li> <li>Decreases phenytoin and desipramine</li> <li>May augment anticoagulants</li> <li>Fluoxetine may increase VPA</li> <li>10\u201316-hour half life</li> <li>Use: Acute mania, TBI, migraines, epilepsy</li> <li>Worse than lithium at depression/SI</li> <li>Better in bipolar symptoms from cognitive disorders and migraine prophylaxis</li> <li>Better in substance abuse, rapid cycling</li> <li>SE: GI distress and liver problems, alopecia, neural tube defects</li> <li>Liver Dysfunction (monitor LFTs and platelets)</li> <li>Elevated LFTs/Hepatic failure MC during 1<sup>st</sup> 6 months</li> <li>Sedation, teratogenesis, weight gain, hair loss, PCOS</li> <li>CI: Pregnancy</li> <li>Valproic Acid Toxicity</li> <li>Somnolence, hepatotoxicity, weight and appetite changes, alopecia, insomnia, thrombocytopenia, lethargy, comatose, hypotension, tremor</li> <li>Carbamazepine (Tegretol)</li> <li>Dose: 200mg BID to target of 1200mg total per day</li> <li>Therapeutic level: Carbamazepine/CBZ (60-120)</li> <li>MOA: voltage gated sodium channel blocker</li> <li>Reduces antipsychotics, TCAs, benzos, seizure meds/mood stabilizers, warfarin, Tylenol, methadone, doxycycline, oral contraceptives</li> <li>Reduces lamotrigine</li> <li>Increased by fluoxetine, cimetidine, CCBs, gemfibrozil, grapefruit</li> <li>Decreased by ETOH and phenytoin</li> <li>Increased toxicity by VPA</li> <li>Use: Bipolar disorder, Anticonvulsant, anticholinergic, antineuralgic, antidiuretic</li> <li>Antiseizure, trigeminal neuralgia, bipolar</li> <li>2<sup>nd</sup> line mood stabilizer</li> <li>Good for rapid cycling bipolar disorder (\u22654 mood episodes/year)</li> <li>SE: Risk of aplastic anemia and agranulocytosis, SJS, neural tube, hyponatremia, cytochrome P450 induction, diplopia, vertigo, hepatotoxic</li> <li>Decreases T3/T4 (increased deiodination mainly), Decreases OCP efficacy, ataxia, blood dyscrasias</li> <li>CMP and B-HCG required</li> <li>15% benign maculopapular rash within 3 weeks, may stop and retry</li> <li>Neutropenia often caused by drug-induced agranulocytosis, aplastic anemia (2%)</li> <li>CBCs monthly for 3-6m then at that interval</li> <li>If ANC \\&lt;2000, monitor with more frequent FBCs</li> <li>If ANC \\&lt;100, discontinue</li> <li>Overdose: hepatotoxicity and sedation</li> <li>2-6 weeks after starting causative drug</li> <li>Phenytoin or carbamazepine</li> <li>SIADH (hyponatremia), cytochrome p450 induction</li> <li>Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)</li> <li>Rash, facial edema, lymphadenopathy, and fever</li> <li>Oxcarbazepine (Trileptal)</li> <li>Lamotrigine (Lamictal)</li> <li>Levetiracetam (Keppra)</li> <li>Topiramate (Topamax)</li> <li>Lacosamide (Vimpat)</li> <li>Gabapentin (Neurontin)</li> </ul> </li> </ul>"},{"location":"im-guide/pharm/psychiatry/stimulants/","title":"Stimulants","text":"<ul> <li>Methylphenidate (Ritalin, Cotempla, Concerta, Quilivant)</li> <li>Around \u2154 dosage of Adderall (10-70)</li> <li>Jornay \u2013 10 hours before</li> <li>Dexmethylphenidate (Focalin)</li> <li>Amphetamine Derivatives</li> <li>Adderall (75D/25L)</li> <li>Adzenys</li> <li>Mydayas</li> <li>Evekeo (Amphetamine Sulfate 50D/50L)</li> <li>Vyvanse</li> <li>4-6 BP, 4-5 HR increases usually</li> <li>Adderall with a lysine molecule</li> <li>Less abuse, rate limited due to RBCs</li> </ul>"},{"location":"im-guide/pharm/smooth-muscle/anaphylaxis/","title":"Anaphylaxis","text":"<ul> <li>Result of widespread response to antigen</li> <li>Massive release of histamine and other substances from mast cells and basophils</li> <li>Triggers:</li> <li>Food (nuts and shellfish), Latex, (B-lactams), Stings<ul> <li>Short term Foleys have latex</li> </ul> </li> <li>Widespread IgE-mediated response to an allergen</li> <li>Type 1 Hypersensitivity</li> <li>Typically occurs in individuals with previous or repeated exposure</li> <li>Rapid-onset hypersensitivity reaction that is characterized by respiratory compromise (Wheezing, stridor, bronchospasm), rash (urticarial rash, flushing, hives, pruritus, erythema, wheals) and decreased blood pressure (systemic vasodilation)</li> <li>\u00b1 Oropharyngeal and laryngeal edema</li> <li>Vasodilation (Hypotension and tissue edema), tachycardia</li> <li>Upper airway edema (stridor/hoarseness), bronchospasm (wheezing)<ul> <li>Rhinoconjunctivitis, poor organ perfusion, dyspnea</li> </ul> </li> <li>Nausea, Vomiting, Abdominal pain</li> <li>Life threatening: Airway obstruction due to circulatory collapse (shock)</li> <li>Severe dyspnea, labored breathing, tachypnea<ul> <li>Intubate</li> </ul> </li> <li>Treatment</li> <li>1) IM Epinephrine<ul> <li>Prevents hypotension, upper airway edema</li> <li>IV Epinephrine if no response</li> <li>Higher risk of cardiac arrhythmia thus 2<sup>nd</sup> line</li> </ul> </li> <li>2) Respiratory Support (airway management and resuscitation)</li> <li>3) IV Fluids</li> <li>\u00b1 Antihistamines, glucocorticoids</li> </ul>"},{"location":"im-guide/pharm/smooth-muscle/antihistamines/","title":"Antihistamines","text":"<ul> <li>1<sup>st</sup> Generation H1 receptor antagonists</li> <li>May antagonize muscarinic receptors leading to anticholinergic effects<ul> <li>Decrease PNS = SNS effects</li> <li>Urinary retention, retention due to impaired detrusor contraction</li> </ul> </li> <li>Azelastine (Astelin)</li> <li>2<sup>nd</sup> Generation H1 receptor antagonists</li> <li>Fexofenadine (Allegra)</li> <li>Loratadine (Claritin)</li> <li>Desloratadine (Clarinex)</li> <li>Cetirizine (Zyrtec)<ul> <li>SE: sedation, arrhythmias in overdose</li> </ul> </li> <li>H2 receptor antagonists</li> <li>Cimetidine (Tagamet)</li> <li>Famotidine (Pepcid)</li> <li>Ranitidine (Zantac)</li> </ul>"},{"location":"im-guide/pharm/smooth-muscle/antipruritics/","title":"Antipruritics","text":"<ul> <li>Antihistamines</li> <li>Diphenhydramine</li> <li>Chlorphenoxamine</li> <li>Corticosteroids</li> <li>Counterirritants</li> <li>Mint Oil, Menthol, Camphor</li> <li>Local Anesthetics</li> <li>Lidocaine</li> <li>Benzocaine</li> <li>Tetracaine</li> </ul>"},{"location":"im-guide/pharm/smooth-muscle/asthma-copd/","title":"Asthma/COPD","text":"<ul> <li>Short-Acting Beta 2 Agonists (SABAs)</li> <li>Salbutamol (Albuterol)<ul> <li>Can cause hypokalemia with muscle weakness, arrhythmias, and tremors</li> <li>EKG changes, palpitations, and HA may occur</li> <li>Albuterol</li> <li>Nebulizer: 2.5-5mg q20mins for 4 doses, then 2.5-10mg q1-4hrs</li> <li>MDI (Ventolin HFA, Proventil HFA, ProAir HFA): 4-8 puffs q30mins up to 4hrs, then every 1-4hrs PRN</li> </ul> </li> <li>Levalbterol MDI (Xopenex, Xopenex HFA)</li> <li>Pirbuterol MDI (MaxAir autohaler)</li> <li>Terbutaline</li> <li>SEs: Tremor (7%), tachycardia, anxiety<ul> <li>Hypokalemia, angina, tachyarrhythmia</li> </ul> </li> <li> <p>Long-Acting Beta 2 Agonists (LABAs)</p> <ul> <li>Not recommended without ICS in asthma due to increased mortality</li> <li>Salmeterol DPI (Serevent Diskus, Aeromax)</li> <li>Formoterol DPI (Foradil Aerolizer)</li> <li>Oxis</li> <li>Serovent</li> <li>Onbrex</li> <li>SE: Headache (17%), Tremor (8%)</li> <li>Hypertension, Rash, dizziness, hyperglycemia</li> <li>Inhaled Corticosteroid (ICSs)</li> <li>Beclomethasone MDI (QVAR)</li> <li>Budesonide DPI (Pulmicort Flexhaler)</li> <li>Flunisolide MDI (Aerospan)</li> <li>Fluticasone Propionate MDI (Flovent HFA)</li> <li>Fluticasone Furoate DPI (Arnuity Ellipta)</li> <li>Mometasone DPI (Asmanex Twisthaler)</li> <li>Triamcinolone</li> <li>Oral Corticosteroid</li> <li>Methylprednisolone</li> <li>Asthma: 32-64 mg/day PO in 1-2 doses</li> <li>40-80 mg/day IV in 1-2 doses</li> <li>Reserve IV for NPO or severe in the ICU</li> <li>Depo-Medrol 160mg IM at discharge equal to 8 days PO taper</li> <li>Prednisolone</li> <li>Prednisone</li> <li>Asthma: 40-80 mg/day PO in 1-2 doses</li> <li>Give until PEF is 70% predicted</li> <li>7\u201310-day courses do not need to be tapered</li> <li>SE: Elevated Uric Acid, Increase or decrease INR w/Warfarin</li> <li>Antimuscarinics (SAMA/LAMA)</li> <li>Short-Acting Anticholinergics (SAMAs)</li> <li>Ipratropium Bromide</li> <li>Nebulizer: Must use with albuterol</li> <li>MDI (Atrovent HFA): 4-8 puffs PRN every 2-4hrs</li> <li>Better tolerated than LAMAs</li> <li>SE: Bitter taste (20%), Xerostomia</li> <li>Urinary retention, mydriasis</li> <li>Long-Acting Anticholinergics (LAMAs)</li> <li>Tiotropium Bromide (Spiriva Handihaler)</li> <li>SE: Xerostomia (16%), Constipation<ul> <li>Rash, myalgia, dysphonia</li> </ul> </li> <li>Bretaris</li> <li>SEEbri</li> <li>Incruse Ellipta</li> <li>Combos</li> <li>SAMA/SABA</li> <li>Ipratropium + Albuterol (Combivent Respimat)</li> <li>LAMA/LABA</li> <li>Vilanterol/umeclidinium (Anoro)</li> <li>LABA/ICS</li> <li>Budesonide/Formoterol MDI (Symbicort)</li> <li>Fluticasone Furoate/Umeclidinium Bromide/Vilanterol (Trelegy Ellipta)</li> <li>Fluticasone/Salmeterol MDI (Advair HFA)</li> <li>Fluticasone/Salmeterol DPO (Advair Diskus)</li> <li>Fluticasone Furoate/Vilanterol (Breo Ellipta)</li> <li>Ipratropium Bromide/Salbutamol (Combivent)</li> <li>Mometasone/formoterol (Durela hfa)</li> <li>LAMA/LABA/ICS</li> <li>Fluticasone/Umeclidinium/Vilanterol (Trelegy Ellipta)</li> <li>Other</li> <li>Methylxanthines</li> <li>Theophylline</li> <li>SE: Caffeine-like, MAT<ul> <li>Toxicity: vomiting, hypokalemia, hyperglycemia, seizures, tachycardia, ventricular arrhythmias</li> </ul> </li> <li>Eicosanoid Inhibition</li> <li>Leukotriene Antagonists</li> <li>Montelukast (Singulair): 10 mg QD tablet</li> <li>Arachidonate 5-lipoxygenase Inhibitors</li> <li>Zileuton (Zyflo CR): 1200mg BID tablet</li> <li>Thromboxane Receptor Antagonists</li> <li>Non-xanthine PDE4 Inhibitors</li> <li>Zafirlukast (Accolate): 20mg BID tablet</li> <li>AST/ALT \u22653x normal in 3%, monitor monthly for 3 months when initiating</li> <li>Mast Cell Stabilizers</li> <li>Cromolyn Sodium Nebulizer solution</li> <li>IgE Inhibitor</li> <li>Omalizumab (Xolair): 150mg injection</li> <li>PDE-4 Inhibitors</li> <li>Roflumilast (Daliresp): 500 ug tablet QD</li> </ul> </li> </ul>"},{"location":"im-guide/pharm/special-topics/antidiarrheals/","title":"Antidiarrheals","text":"<ul> <li>CI: Bloody diarrhea, Fever</li> <li>Intestinal Adsorbents</li> <li>Bismuth</li> <li>Antipropulsives (opioids)</li> <li>General<ul> <li>Increase colonic phasic segmenting activity</li> </ul> </li> <li>Crosses BBB:<ul> <li>Diphenoxylate</li> <li>Combined with atropine to prevent abuse</li> <li>Difenoxin</li> </ul> </li> <li>Does not:<ul> <li>Eluxadoline (Viberzi)</li> <li>Loperamide (Imodium)</li> <li>No analgesia</li> </ul> </li> <li>Anti-inflammatory</li> <li>Aminosalicylates<ul> <li>Sulfasalazine</li> <li>Mesalamine</li> <li>Olsalazine</li> </ul> </li> <li>Other</li> <li>Octreotide<ul> <li>Thought to decrease the elevated pressure by decreasing splanchnic blood flow</li> </ul> </li> </ul>"},{"location":"im-guide/pharm/special-topics/contraceptives/","title":"Contraceptives","text":"<ul> <li>Oral Contraceptives</li> <li>Reduced efficacy with: Phenytoin, phenobarbital, carbamazepine, oxcarbazepine, topiramate, lamotrigine</li> <li>CI: Thromboembolism, estrogen tumors, active liver disease, pregnancy, uterine bleeding</li> <li>Typical Use Effectiveness</li> <li>1) 3-year Etonogestrel implant: 99.95%</li> <li>2) Vasectomy: 99.85%</li> <li>3) Levonorgestrel IUD: 99.8%</li> <li>4) Female Sterilization: 99.5%</li> <li>5) Copper-T IUD: 99.2%</li> <li>6) DMPA: actual 94%, theoretical 99.8%</li> <li>7) OCPs: actual 91%, theoretical 99%</li> <li>8) Male Condoms: actual 82%, theoretical 98%</li> <li>9) Female Condoms: actual 79%, theoretical 95%</li> <li>P450 induces, decrease efficacy</li> <li>Phenobarbital, phenytoin, rifampin</li> <li>Postpartum Contraception</li> <li>If \\&lt;1 month: Copper IUD or Progestin-only contraception due to risk of VTE and breastfeeding risk with Estrogen</li> <li>Age \u226535 and smoker \u226515cigs/day: No estrogen containing drugs</li> <li>Use DMPA</li> <li>Progestin Only (Subdermal Implant \u2265 Pill)</li> <li>No increase in VTE risk, can be used during breastfeeding</li> <li>Thickens cervical mucus, thins endometrium, inhibits ovulation</li> <li>Suppression of ovulation occurs unpredictably and not in all cycles</li> <li>Must be taken within 3 hours every day</li> <li>Kept up to 3 years, decreases bleeding in 50%, amenorrhea in 20%</li> <li>Unscheduled bleeding is mcc of discontinuation</li> <li>Intravaginal Rings (NuvaRing)</li> <li>Inserted for 3 weeks, removed to allow bleeding</li> <li>Increased risk of DVT</li> <li>Release estrogen and progesterone</li> <li>CI: \u226535 and smoke \u226515 cigs/day</li> <li>Combined Oral Contraceptive</li> <li>Estrogen/Progestin Contraceptives<ul> <li>Suppress ovulation via FSH/LH dampening (no surge)</li> <li>Inhibits ovulation</li> <li>Thickens cervical mucus, thins endometrium, alters uterus, fallopian tube motility</li> </ul> </li> <li>Benefits: Endometrial and ovarian cancer risk reduction, menstrual regulation, hyperandrogenism treatment</li> <li>Suppression of ovulation occurs predictably</li> <li>Yaz and Yasmin<ul> <li>Contain drospirenone (progestin w/aldosterone antagonist effect to help combat premenstrual bloating</li> </ul> </li> <li>Risks: VTEs, Hypertension, Hepatic adenoma, stroke/MI, Cervical Cancer</li> <li>CI: \u226535 and smoke \u226515 cigs/day, Severe HTN (\u2265160/100), migraine w/aura, breast cancer, liver disease, multiple CVD RF</li> <li>Depot Medroxyprogesterone Acetate (DMPA)</li> <li>Progesterone only, every 3 months</li> <li>Suppresses pulsatile release of GnRH inhibiting ovulation, thickens cervical mucus, decreases motility of fallopian tube cilia, thins endometrium</li> <li>Good for Sickle cell disease (reduces crises), Epilepsy (intrinsic anticonvulsant)</li> <li>Bad for causing weight gain, unscheduled bleeding, mood changes</li> <li>Intrauterine Device</li> <li>Release copper or progesterone</li> <li>Most effective preventative measures<ul> <li>10 year Copper-T or 5-year Levonorgestrel-containing one</li> </ul> </li> <li>Avoid copper if anemic or heavy menstrual bleeding</li> <li>CI: Abnormal uterine anatomy, cervical stenosis, leiomyoma, suspected pregnancy, PID in the past, Wilson disease</li> <li>SE: Small risk of abortion, uterine perforation, expulsion</li> <li>Subcutaneous Implant</li> <li>Etonogestrel (Nexplanon), slowly releases progesterone over 3 years</li> <li>SE: Irregular bleeding, especially in 1<sup>st</sup> 6 months<ul> <li>Breast pain</li> </ul> </li> <li>Transdermal Contraceptive Patch</li> <li>CI: \u226535 and smoke \u226515 cigs/day</li> <li>Must be changed weekly, 99% effective, nothing to remember daily</li> <li>Not approved for women \u2265200lbs, patch may fall off, Nausea, headache, weight gain, irregular bleeding, breast pain</li> <li>Tubal Ligation</li> <li>Emergency Contraception</li> <li>Copper (0-120)</li> <li>Ulipristal</li> <li>Progestin only (Levonorgestrel up to 72)</li> <li>Ethinyl Estradiol + Levonorgestrel (Yuzpe Regimen)<ul> <li>2 pills 12 hours apart within 72 hours</li> <li>Can be used up to 120 hours, reduced efficacy</li> </ul> </li> <li>Oral Contraceptives</li> </ul>"},{"location":"im-guide/pharm/special-topics/dermatology/","title":"Dermatology","text":"<ul> <li>Isotretinoin</li> <li>Teratogenic, Depression/psychosis, suicidality, hypertriglyceridemia, pancreatitis, hearing and visual loss, pseudotumor cerebri, hepatotoxicity</li> </ul>"},{"location":"im-guide/pharm/special-topics/gerd/","title":"Antacids","text":"<ul> <li>Antacids</li> <li>General:<ul> <li>Work for 1-2 hours</li> </ul> </li> <li>Magnesium (Increases Motility)</li> <li>Aluminum (Decreases Motility)</li> <li>Calcium Carbonate/Silicate</li> <li>Sodium Bicarbonate</li> <li>H2 Receptor Antagonists (H2RAs)</li> <li>MOA: Inhibit binding of histamine, released from enterochromaffin-like cells, at the H2 receptor on parietal cells and thus decreasing the hydrogen ion concentration in the stomach</li> <li>General:<ul> <li>Work for 6-10 hours, greater efficacy and can be used for prophylaxis vs antacids</li> </ul> </li> <li>Famotidine (Pepcid)<ul> <li>Least likely too interfere with P450 enzymes</li> </ul> </li> <li>Ranitidine (Zantac)</li> <li>Cimetidine (Tagamet)<ul> <li>Inhibits P450 enzymes</li> </ul> </li> <li>Proton Pump Inhibitors (PPIs)</li> <li>MOA: Decreases hydrogen ion concentration in the stomach by inhibiting the H+/K+ ATPases on parietal cells<ul> <li>Only inhibit active proton pumps, leads to weak acid inhibition</li> <li>Need 5-7 days for drug steady state</li> <li>Work faster and are more effective than H2Ras</li> <li>SE: Osteoporosis</li> <li>Nephrotoxic in CKD</li> </ul> </li> <li>Esomeprazole (Nexium)</li> <li>Lansoprazole (Prevacid)</li> <li>Omeprazole (Prilosec)</li> <li>Pantoprazole (Protonix)</li> <li>SE: Sporadic fundic gland polyps</li> <li>Prostaglandins</li> <li>Misoprostol</li> <li>Enprostil</li> <li>Other</li> <li>Bismuth Subcitrate</li> <li>Sucralfate</li> </ul>"},{"location":"im-guide/pharm/special-topics/laxatives/","title":"Laxatives","text":"<ul> <li>Treatment</li> <li>Docusate \u2265 Bisacodyl \u2265 fleet enema?</li> <li>Opioid-Induced<ul> <li>Methylnaltrexone</li> <li>Mu opioid receptor (PAM-OR) antagonist</li> </ul> </li> <li>Post-op ileus<ul> <li>Alvimopan</li> <li>Mu opioid receptor (PAM-OR) antagonist</li> <li>Quaternary amine unlike methylnaltrexone, peripherally acting</li> </ul> </li> <li>Correct potassium</li> <li>Bulk-forming Agents</li> <li>MOA: add bulk and water to stools, better for long-term maintenance</li> <li>Site: Small and Large intestines</li> <li>Onset: 12-72 hours</li> <li>Metamucil</li> <li>Citrucel</li> <li>Wheat Bran</li> <li>Flaxseeds</li> <li>Psyllium seed husk<ul> <li>Promotes peristalsis</li> </ul> </li> <li>Emollient Agents (Stool Softeners)</li> <li>MOA: Anionic surfactants that incorporate water and fats into the stool</li> <li>Notes: Prevent constipation rather than treating it</li> <li>Site: Small and Large intestines</li> <li>Onset: 12-72 hours</li> <li>Docusate (Colace, Diocto)</li> <li>Lubricant Agents</li> <li>MOA: Decrease colonic absorption of water, increase weight</li> <li>Site: Colon</li> <li>Onset: 6-8 hours</li> <li>Mineral Oil</li> <li>Osmotic Agents</li> <li>MOA: cause the intestines to hold more water, stimulates movement</li> <li>Site: Colon</li> <li>Onset: 12-72 hours oral, 25 mins \u2013 1 hour rectal</li> <li>Polyethylene Glycol (Miralax, Colyte, Golytely, Glycolax)<ul> <li>Used for bowel prep, whole bowel irrigation</li> <li>Better than lactulose</li> </ul> </li> <li>Magnesium Salts (Milk of Magnesia)</li> <li>Lactulose<ul> <li>Osmotic effect, lowers pH, decreases intestinal ammonia absorption</li> </ul> </li> <li>Sorbitol (Enema)</li> <li>Mannitol (Enema)</li> <li>Prokinetic Agents</li> <li>Prucalopride</li> <li>Saline Laxative Agents</li> <li>Site: Small and large intesitnes</li> <li>Onset: 30mins too 3 hours oral, 2-15 minutes rectal</li> <li>Sodium Bisulfate</li> <li>Sodium Phosphate</li> <li>Magnesium Hydroxide</li> <li>Magnesium Sulfate (Epsom Salt)</li> <li>Stimulant Agents</li> <li>Site: Colon</li> <li>Onset: 6-10 hours</li> <li>Senna</li> <li>Sodium Pocosulfate</li> <li>Bisacodyl (Dulcolax)</li> <li>SE: Loss of haustral folds with chronic use (melanosis coli)</li> <li>Add Osmotic laxative or docusate if not working</li> <li>Other</li> <li>Castor Oil</li> <li>Secretagogues (Chloride Channel Activators)</li> <li>Linaclotide</li> <li>Plecanatide</li> <li>Lubiprostone</li> </ul>"},{"location":"im-guide/pharm/special-topics/pregnancy/","title":"Pregnancy","text":"<ul> <li>Category B</li> <li>Clozapine, Lurasidone, Bupropion, Maprotiline, Buspirone, Zolpidem</li> <li>Bipolar on maintenance therapy</li> <li>Do not alter even if teratogenic</li> <li>Bipolar needing meds</li> <li>Lamotrigine (Category C) \u2265 Lithium, valproate, carbamazepine (Category D)</li> <li>Carbamazepine</li> <li>Craniofacial defects, fingernail hypoplasia, developmental delay</li> <li>Increase folic acid to 4.0 mg/day through 1<sup>st</sup> trimester</li> <li>Lithium</li> <li>Ebstein's anomaly</li> <li>Valproate</li> <li>Neural tube defects, folate doesn't help (increase to 4.0)<ul> <li>Formation occurs between 3<sup>rd</sup> and 4<sup>th</sup> week</li> </ul> </li> <li>Thrombocytopenia, inhibited platelet aggregation</li> <li>IV Drug abuse</li> <li>Commonly opioids</li> <li>Associated with placenta abruption</li> <li>Treatment<ul> <li>Methadone</li> <li>Buprenorphine and Naloxone</li> </ul> </li> </ul>"},{"location":"im-guide/pharm/special-topics/prostate/","title":"Prostate","text":"<ul> <li>GnRH Agonists</li> <li>MOA: Binds to GnRH receptor, causes initial release of FSH/LH followed by suppresion</li> <li>Leuprolide, Goserelin, Triptorelin, Buserelin, Histrelin</li> <li>Need anti-androgen too, at least for 1<sup>st</sup> 7 days, may make it worse</li> <li>GnRH Antagonists</li> <li>MOA: Binds to GnRH receptor and suppresses activity without initial increase in activit seen with GnRH agonists</li> <li>Degarelix, Relugolix</li> <li>Antiandrogen</li> <li>Bicalutamide</li> <li>Flutamide</li> <li>CYP17 Inhibitors</li> <li>Abiraterone + Prednisone</li> <li>Androgen Receptor Blockade</li> <li>Enzalutamide</li> <li>Apalutamide</li> <li>Tumor Vaccine</li> <li>Sipuleucel-T</li> <li>Chemotherapeutic</li> <li>MOA: Anti-microtubule agent</li> <li>Docetaxel/Cabazitaxel + Prednisone</li> </ul>"},{"location":"im-guide/pharm/special-topics/vitamins/","title":"Vitamins","text":"<ul> <li>Alcoholism</li> <li>80% have thrombocytopenia due to bone marrow suppression</li> <li>Anemia and leukopenia can also occur</li> <li>Anti-Vitamin Drugs</li> <li>Iron Deficiency</li> <li>Microcytic anemia</li> <li>Treatment<ul> <li>Iron Sucrose (Venofer)</li> <li>90 minute infusions for 3 days</li> <li>Recheck in 4-6 weeks after tx</li> <li>Iron Polysacchairde 150mg</li> <li>Every other day</li> <li>Iron Gluconate 324mg (68mg as iron) q48hrs</li> <li>\u00b1 Vitamin C</li> <li>Re-assess in 2 weeks w/ cbc/RC, Hgb in 6-8 if anemic</li> </ul> </li> <li>Vitamin B1 (Thiamine) Deficiency</li> <li>Aka Beriberi or Wernicke Encephalopathy</li> <li>Orthopedics, Neurology, and Ophthalmology Word Doc</li> <li>Prevention<ul> <li>100-200mg daily for 3-5 days, over 30 mins, IV \u2265 Oral</li> </ul> </li> <li>Vitamin B3 (Niacin) Deficiency</li> <li>Aka Pellegra</li> <li>Vitamin B6 (Pyridoxine) Deficiency</li> <li>Vitamin B9 (Folate) Deficiency</li> <li>Treatment<ul> <li>1-5mg daily for 1-4m</li> <li>Re-assess in 4 months</li> </ul> </li> <li>Vitamin B12 (Cyanocobalamin) Deficiency</li> <li>Macrocytic Anemia</li> <li>Treatment<ul> <li>Pernicious anemia 1000mcg daily IM over 1 week</li> <li>1000-2000mcg daily for life</li> <li>Other</li> <li>Once monthly IM or 1000-2000mcg daily for 1 week and then monthly</li> <li>Re-assess in 1-2 months, then 6 months, annually</li> </ul> </li> <li>Vitamin C Deficiency</li> <li>Within 3 months of deficiency, alcoholics, drug abusers<ul> <li>Impaired wound healing, perifollicular hemorrhages</li> </ul> </li> <li>Follicular hemorrhage, bleeding/receding gums, arthralgias<ul> <li>Vasomotor Instability (hot flashes) late</li> <li>Hemolytic Anemia and Edema late</li> </ul> </li> <li>Diagnosis: Serum/Leukocyte Ascorbic Acid Levels</li> <li>Treatment:<ul> <li>Oral/injectable Vitamin C</li> <li>Toxicity at high levels (ab pain, diarrhea, nausea)</li> </ul> </li> <li>Vitamin D Deficiency</li> <li>Vitamin D 25-50 = Insufficiency</li> <li>Vitamin D \\&lt;25 = Deficiency<ul> <li>Vitamin D 12-30</li> <li>Cholecalciferol 25-50mcg (1000-2000IU) daily for 6-12 weeks</li> <li>Vitamin D \\&lt;12</li> <li>Cholecalciferol 75-125mcg daily for 6-12 weeks</li> <li>Cholecalciferol 50k IU weekly oral x 6-12 weeks, then monthly</li> <li>Recheck in 3-6 months</li> </ul> </li> <li>Calcium supplementation \u22651000mg per day</li> <li> <p>Trace Mineral Deficiencies</p> <ul> <li>RF for deficiency: malabsorption, bowel resection, poor nutritional intake, and parenteral nutrition</li> <li>Chromium</li> <li>Impaired glucose control in diabetics</li> <li>Copper</li> <li>Brittle hair, Skin depigmentation, Neurologic dysfunction, sideroblastic anemia, osteoporosis</li> <li>Treatment</li> <li>Cupric Sulfate<ul> <li>IV:2 mg IV for 5 days</li> <li>Oral 8mg daily for 1 week, 6mg for 2<sup>nd</sup> week, 4mg 3<sup>rd</sup> week, 2mg after</li> </ul> </li> <li>Stop Zinc</li> <li>Selenium</li> <li>Thyroid dysfunction, cardiomyopathy, immune dysfunction</li> <li>Zinc</li> <li>Alopecia, Pustular skin rash, Hypogonadism, Impaired wound healing and taste, immune dysfunction</li> </ul> </li> </ul>"},{"location":"im-guide/pharm/tox/","title":"Overdose/Toxicities","text":"<ul> <li>General Side Effects</li> <li>Alpha-1 Antagonism (Norepinephrine)<ul> <li>Significant orthostatic hypotension/tachycardia</li> <li>MC: Risperidone/Paliperidone, Clozapine, Thioridazine, Trazodone</li> </ul> </li> <li>Dopamine receptor antagonist<ul> <li>Metoclopramide</li> <li>For nausea and vomiting, may have EPS</li> </ul> </li> <li>Histamine Antagonism (Histamine)<ul> <li>Sedation, appetite stimulation, weight gain</li> <li>MC: Quetiapine (most sedating), Olanzapine (weight), Clozapine (weight), Thioridazine</li> </ul> </li> <li>Muscarinic Antagonism (Acetylcholine)<ul> <li>Anticholinergic \u2013 Delirium, fever, tachycardia, flushing, dry mucus membranes, constipation, Confusion and hallucinations</li> <li>MC: Olanzapine, Clozapine, Thioridazine, Chlorpromazine</li> </ul> </li> <li>Side Effect Monitoring<ul> <li>EKG</li> <li>Amitriptyline/TCAs</li> <li>CBC</li> <li>Clozapine (Agranulocytosis) weekly but not carbamazepine</li> <li>Plasma levels</li> <li>Lithium, valproate</li> <li>Falls</li> <li>TCAs and Benzos</li> <li>Glucose</li> <li>Clozapine after 6 months</li> <li>Dextromethorphan (cough syrup)</li> <li>Dissociative symptoms and hallucinations</li> <li>Add Quetiapine to treat Pseudobulbar Affect</li> </ul> </li> </ul> Antipsychotic Extrapyramidal Effects \u2013 \"ADAPT\" Pharmacotherapy Acute Dystonia** (4 hours)** - Sudden, sustained contraction of neck, mouth, tongue and eye muscles - Benztropine - Diphenhydramine Akathisia** (Days to weeks)** - Subjective inner restlessness, inability to sit still, wanting to walk off - Dose dependent - Benzodiazepine (Lorazepam) - Low-Dose BB (Propranolol) - Benztropine Parkinsonism** (Weeks to months)** - Gradual-onset tremor, rigidity and bradykinesia - Benztropine\u2265 - Amantadine - Trihexyphenidyl Tardive dyskinesia** (4 months)** - Gradual onset after prolonged therapy (\u22656m): dyskinesia of mouth, face, trunk, extremities - Valbenazine - Deutetrabenazine - Switch to Clozapine or Quetiapine <ul> <li>Acetaminophen Overdose</li> <li>Gastroenteritis (non-specific) within hours, hepatoxicity within 1-2 days<ul> <li>Leading cause of hepatic failure in US</li> </ul> </li> <li>Treatment<ul> <li>Activated Charcoal and N-Acetylcysteine</li> <li>Liver Transplant</li> </ul> </li> <li>Alcohol Intoxication</li> <li>Slurred speech, incoordination, unsteady gait, attention/memory impairment, stupor, nystagmus</li> <li>Alcohol/Methanol Overdose</li> <li>Anion Gap Metabolic Acidosis</li> <li>Fomepizole<ul> <li>Inhibits alcohol dehydrogenase</li> </ul> </li> <li>Alcohol Ketoacidosis</li> <li>Slurred speech, unsteady gait, altered mentation</li> <li>High Osmolar gap</li> <li>Increased anion gap</li> <li>Metabolic acidosis due to ketosis</li> <li>Alcohol Withdrawal</li> <li>Symptoms<ul> <li>Tachycardia, diaphoresis, anxiety, hallucinations, Seizures</li> <li>Macrocytic anemia</li> <li>Mild (6-24h) \u2013 anxiety, insomnia, tremors, diaphoresis, palpitations, GI upset, intact orientation</li> <li>Seizures (12-48h) \u2013 single or multiple generalized tonic, clonic</li> <li>Alcoholic hallucinosis (12-24h) \u2013 visual, auditory, or tactile; intact orientation</li> <li>Delirium Tremens (48-96h) \u2013 unstable vitals, hallucinations, confusion</li> </ul> </li> <li>Withdrawal Prophylaxis<ul> <li>Chlordiazepoxide, Diazepam (medium-acting)</li> </ul> </li> <li>Treatment<ul> <li>IV Lorazepam \u2265 Chlordiazepoxide</li> <li>Especially in Liver disease</li> <li>IVF, Thiamine, Folate</li> <li>Thiamine prior to glucose</li> </ul> </li> <li>Anticholinergic Poisoning</li> <li>Treatment<ul> <li>Physostigmine (cholinesterase inhibitors)</li> </ul> </li> <li>Arsenic Poisoning</li> <li>Mechanism<ul> <li>Binds to sulfhydryl groups</li> <li>Disrupts cellular respiration and gluconeogenesis</li> </ul> </li> <li>Sources<ul> <li>Pesticides, insecticides</li> <li>Contaminated water, often from wells</li> <li>Pressure-treated wood</li> <li>Miners, smelters</li> </ul> </li> <li>Clinical<ul> <li>Acute: Garlic breath, vomiting, watery diarrhea, QTc prolongation</li> <li>Dehydration secondary to vomiting and diarrhea</li> <li>Seizure, delirium, coma, torsades de pointes</li> <li>Acute tubular necrosis</li> <li>Painful paresthesia, ascending weakness</li> <li>Chronic: Pigmentation, hyperkeratosis, stocking-glove neuropathy</li> <li>Cancer: Skin, bladder, kidney, and/or lung</li> <li>Mees Lines (Leukonychia striata) on the nails (hypo/hyperpigmented)</li> </ul> </li> <li>Diagnosis: Elevated urine Arsenic Levels</li> <li>Treatment<ul> <li>IM Dimercaprol (British anti-Lewisite)</li> <li>DMSA (meso-2,3-dimercaptosuccinic acid, Succimer)</li> </ul> </li> <li>Barbiturate Overdose</li> <li>Phenobarbital</li> <li>Weak Acids</li> <li>Treatment<ul> <li>Secure airway</li> <li>Enhance elimination with Sodium Bicarbonate</li> <li>Alkalinization of the urine</li> </ul> </li> <li>Benzodiazepine Overdose</li> <li>Only Benzos = CNS depression with normal vitals<ul> <li>Altered LOC, ataxia, slurred speech</li> </ul> </li> <li>Benzos + Alcohol = CNS depression with abnormal vitals<ul> <li>Alcohol will cause bradycardia, hypotension, respiratory depression, hyporeflexia</li> </ul> </li> <li>Treatment<ul> <li>RR Normal (12-20)</li> <li>Supportive Treatment</li> <li>Emesis, Lavage, Charcoal</li> <li>1 Time Acute Overdose</li> <li>Flumazenil<ul> <li>Avoid Flumazenil if chronic benzo user</li> <li>Partial agonist, may precipitate withdrawal/seizures</li> <li>Fixes CNS depression, less effective for respiratory</li> <li>SE: Re-sedation, hypotension, hypertension, seizures in long term users, arrhythmias, angina</li> </ul> </li> </ul> </li> <li>Beta Blocker Overdose</li> <li>Bradycardia, AV block, and diffuse wheezing in a CAD patient</li> <li>Drowsiness, fatigue, depression, Bradycardia, Torsade de points, worsening HF, hypertriglyceridemia, bronchoconstriction, ED, Weight gain</li> <li>Treatment<ul> <li>Hypotension: IV Glucagon</li> <li>Atropine, IV fluids</li> </ul> </li> <li>Carbon Monoxide Poisoning</li> <li>Treatment<ul> <li>100% O2</li> <li>Hyperbaric Oxygen if CO is \u226525-40%</li> <li>Lower if pregnant</li> </ul> </li> <li>Cocaine Toxicity</li> <li>Inhibits norepinephrine reuptake into the sympathetic neuron (potentiating sympathomimetic actions)<ul> <li>Alpha and beta receptor stimulation results in coronary vasoconstriction and increased HR, Systemic BP, and Myocardial O2 demand</li> <li>Enhances thrombus formation by promoting platelet activation and aggregation</li> </ul> </li> <li>Age \\&lt;30 w/o FH, severe or malignant hypertension, resistant hypertension, sudden rise in BP</li> <li>Sympathetic hyperactivity</li> <li>Symptoms<ul> <li>Personality/mood changes, sleep loss, weight loss, financial difficulties</li> <li>Chest pain, epistaxis, rhinitis, headaches</li> <li>Cocaine-related Chest Pain (CRCP)<ul> <li>Can occur due to non-cardiac causes (hemorrhagic alveolitis, pneumothorax)</li> </ul> </li> <li>Hypertension, tachycardia, dilated pupils, psychomotor agitation, tremors</li> </ul> </li> <li>Complications<ul> <li>Seizures, Acute MI, Aortic Dissection, Intracranial hemorrhage</li> </ul> </li> <li>Diagnosis: Urine Drug Screen</li> <li>Treatment of NSTEMI/Chest Pain:<ul> <li>Benzodiazepines for BP and Anxiety and O2 (lorazepam, diazepam)</li> <li>Reduce sympathetic outflow (alleviate tachycardia, hypertension)</li> <li>\u00b1 Phentolamine if above doesn't work</li> <li>Aspirin</li> <li>Nitroglycerin and CCBs for pain</li> <li>Beta blockers are contraindicated</li> <li>Would worsen coronary vasoconstriction (unopposed alpha-adrenergic stimulation)</li> <li>No fibrinolytics</li> <li>\u00b1 Immediate Cardiac Catheterization</li> </ul> </li> <li>Cyanide Accumulation and Cyanide Toxicity</li> <li>Cyanide is a potent inhibitor of cytochrome oxidase-a3 in the mitochondrial ETC<ul> <li>Inhibits cellular respiration</li> </ul> </li> <li> <p>RF: Smoke inhalation (Mc toxicity in house fires)</p> <ul> <li>Up to 90% of pts in house fires, only 35% have CO poisoning</li> <li>Sodium Nitroprusside for hypertensive emergency</li> <li>Prolonged use can lead to toxicity</li> <li>More common in patients with renal insufficiency, signs of CHF</li> <li>Onset is ~14-24 hours</li> <li>Symptoms</li> <li>Skin: Flushing before cyanosis</li> <li>CNS: HA, AMS, seizures, coma, confusion, agitation</li> <li>CV: Arrhythmias</li> <li>Resp: Tachypnea followed by respiratory depression, Pulmonary edema</li> <li>BP instability</li> <li>GI: Pain, nausea, vomiting</li> <li>\"Almond like\" odor to the breath</li> <li>Renal: Metabolic acidosis (lactic acidosis), Renal failure</li> <li>Bright red venous blood (elevated ventral venous oxyhemoglobin saturation</li> <li>Treatment</li> <li>Decontamination</li> <li>Dermal<ul> <li>Remove clothing</li> </ul> </li> <li>Ingestion<ul> <li>Activated charcoal</li> </ul> </li> <li>Antidotes<ul> <li>1) Hydroxocobalamin</li> <li>Removes cyanide from mitochondrial respiratory system</li> <li>2) Sodium Thiosulphate</li> <li>Slower onset, can't be given with #1 or through the same catheter</li> <li>3) Sodium Nitrite</li> <li>Only if ingested</li> <li>Can't be used in house fire victims due to synergistic effect with CO</li> </ul> </li> <li>Respiratory</li> <li>No mouth-to-mouth resuscitation</li> <li>Use supplemental O2/intubation</li> <li>Digitalis Toxicity</li> <li>Blocks na/k ATPase in myocardial cells</li> <li>Leading to influx of calcium, increased contractility, increased SV</li> <li>Prolongs refractory period reducing ventricular rate</li> <li>Features</li> <li>Characteristic ST depression with concave-up morphology \"hockey stick\"</li> <li>AKI w/hyperkalemia and increased creatinine</li> <li>Pain, nausea, vomiting</li> <li>Confusion</li> <li>Yellow halos around light, scotomas, blindness</li> <li>Ethylene Glycol Ingestion</li> <li>Symptoms</li> <li>Flank Pain, hematuria, oliguria, cranial nerve palsies, tetany</li> <li>Labs</li> <li>High Osmolar gap</li> <li>Increased anion gap</li> <li>Metabolic acidosis</li> <li>Calcium oxalate crystals in the urine</li> <li>Treatment</li> <li>Fomepizole or Ethanol</li> <li>Heparin</li> <li>Treatment</li> <li>Protamine</li> <li>Isopropyl Alcohol Ingestion</li> <li>CNS depression, deconjugate gaze, absent ciliary reflex</li> <li>High Osmolar gap</li> <li>No Increased Anion Gap</li> <li>No Metabolic acidosis</li> <li>Treatment</li> <li>Supportive Care</li> <li>Malignant Hypertension (Hypertensive Crisis)</li> <li>Binds to RYR1R causing CA2+ release.</li> <li>MAOI + tyramine or stimulant</li> <li>Prevents breakdown of tyramine in gut</li> <li>Enhances peripheral NE effects increasing BP</li> <li>Symptoms</li> <li>Headache following a meal (tyramine)</li> <li>Hypertension, sweating, HA, vomiting</li> <li>Sympathomimetic effect (hypertension)</li> <li>Labs</li> <li>Increased BUN</li> <li>Complications: Stroke, intracranial bleeding, death, rhabdomyolysis</li> <li>Treatment</li> <li>Stop agent</li> <li>IV phentolamine</li> <li>Dantrolene</li> <li>Nifedipine can be helpful</li> <li>Thyroxine (T4) is treated with IV thyroxine for myxedema</li> <li>Coma required more</li> <li>Methanol Ingestion</li> <li>Visual Blurring, central scotomata, afferent pupillary defect, altered mentation, epigastric pain, hyperemic optic disc</li> <li>High Osmolar gap</li> <li>Increased anion gap</li> <li>Metabolic acidosis</li> <li>Treatment</li> <li>Fomepizole (inhibits the alcohol dehydrogenase that converts methanol to formaldehyde)</li> <li>Ethanol</li> <li>Methemoglobinemia</li> <li>Formed by the oxidation of ferrous to ferric iron in hemoglobin</li> <li>Left shirt in the O2 curve because ferric iron cannot bind oxygen and this o2 binds tighter to ferrous iron in hemoglobin</li> <li>Functional anemia</li> <li>Causes: Dapsone, nitrates, topical/local anesthetics</li> <li>Treatment</li> <li>Methylene Blue</li> <li>Neuroleptic Malignant Syndrome (NMS)</li> <li>Antagonism of Dopamine (D2) receptors in the nigrostriatal pathway</li> <li>Can occur with every class of antipsychotics</li> <li>Symptoms</li> <li>Slow onset, clouding of consciousness (over 1-3 days w/delirium being the 1<sup>st</sup> symptom)</li> <li>Fever \u2265104F, confusion, delirium or catatonia</li> <li>Muscle rigidity (Lead-pipe), General muscle rigidity</li> <li>Autonomic instability (Tachypnea, hypertension, tachycardia, dysrhythmia)</li> <li>Abnormal vitals, sweating, mydriasis</li> <li>Labs</li> <li>Increased CPK, LFTs, WBCs</li> <li>Myoglobin in urine</li> <li>Treatment</li> <li>Stop antipsychotics or restart dopamine agents</li> <li>Antipsychotic meds</li> <li>May have increases Creatine Kinase and WBCs</li> <li>IV fluids, supportive care; ICU</li> <li>Benzodiazepines</li> <li>Dantrolene (skeletal muscle relaxant) or bromocriptine (dopamine agonist), amantadine (dopamine agonist) if refractory</li> <li>Opioids</li> <li>Treatment</li> <li>Buprenorphine</li> <li>Partial mu agonist, kappa antagonist</li> <li>Treats withdrawal and chronic pain</li> <li>Combined with naloxone (blocks receptor)</li> <li>Naltrexone</li> <li>Treats dependence, not withdrawal</li> <li>Methadone</li> <li>Treats withdrawl</li> <li>Organophosphate Toxicity</li> <li>Excessive salivation, miosis, lacrimation, diarrhea, emesis, urination, bronchospasm</li> <li>Bradycardia, heart block, prolonged QTc</li> <li>Treatment</li> <li>Pralidoxime</li> <li>Reverses muscle paralysis (nicotinic effects)</li> <li>Atropine</li> <li>Phencyclidine (PCP) Overdose</li> <li>NMDA and Ach Antagonism</li> <li>Particularly in the hippocampus and limbic system</li> <li>Dopamine, norepinephrine, and serotonin receptor activation</li> <li>Sigma receptor complex activation causing psychotic and anticholinergic effects</li> <li>Lasts \\&lt;8 hours</li> <li>PCP withdrawal</li> <li>Depression</li> <li>Ketamine is shorter acting</li> <li>Vertical or horizontal nystagmus, ataxia, violent behavior, hyperthermia, disorientation, delusions, muscle rigidity</li> <li>Treatment</li> <li>Psychomotor Agitation: Parenteral Benzodiazepines (lorazepam, diazepam) \u2265 Haloperidol unless seizure disorder is present</li> <li>B52 \u2013 Haloperidol, diphenhydramine, and benzodiazepine</li> <li>Phenytoin Toxicity</li> <li>Vertical Nystagmus</li> <li>Cerebellar-vestibular system affected</li> <li>Sedation, hypotension, arrhythmias, GI disturbances</li> <li>Gingival hyperplasia and hirsutism if long-term use</li> <li>2<sup>nd</sup> line anticonvulsant (after lorazepam) in treating status epilepticus</li> <li>Decreases repetitive firing of neuronal action potentials by slowing the rate of recovery of voltage gated sodium channels from inactivation</li> <li>SE: SJS</li> <li>Salicylate Poisoning</li> <li>Treatment</li> <li>Gastric Lavage, Activated charcoal, alkalinization of the urine, diuresis, dialysis</li> <li>Serotonin Discontinuation Syndrome</li> <li>RF: SSRIs with short half-life and no active metabolites</li> <li>MC with short half-life SSRIs (paroxetine \u2265 venlafaxine)</li> <li>Onset within 3 days of discontinuation, resolution within 1-2 weeks</li> <li>Fatigue, insomnia, myalgias from abrupt discontinuation in 20%</li> <li>Headaches, anxiety, agitation</li> <li>\"Weird\" sensations along arms and legs, \"electric-shock-like\" sensations in head/neck, \"rushing\" sensations in the head</li> <li>Vertigo, tremor, ataxia</li> <li>Treatment</li> <li>Restart drug and taper gradually over several weeks (6-8 weeks)</li> <li>If persistent, switch to Fluoxetine</li> <li>Serotonin Syndrome (SS)</li> <li>General</li> <li>Over stimulation of 5-HT receptors in the central grey nuclei and the medulla</li> <li>MC with stopping sertraline and fluvoxamine</li> <li>Fluoxetine has a long half-life, must be quit 5 weeks prior to MAOI, but doesn't need to be tapered<ul> <li>Tramadol (Ultram)</li> <li>Serotonergic analgesic + SSRIs</li> </ul> </li> <li>Symptoms</li> <li>Activity (hyperactivity, hyperreflexia, hypertonia, tremor, seizure)</li> <li>Myoclonus, Lower extremity rigidity, tremor</li> <li>Autonomic (hyperthermia, diaphoresis, diarrhea, mydriasis)</li> <li>Flushing, Tachycardia, hypertension</li> <li>Agitation (Need AMS)</li> <li>Anxiety, confusion, hypomania, coma</li> <li>Headaches, N/V/D, dizziness and fatigue when suddenly stopping</li> <li>Exam</li> <li>Hyperreflexia and myoclonus</li> <li>Diaphoresis, hypertension, tachycardia</li> <li>Fever/Hyperthermia, cardiovascular collapse</li> <li>Labs</li> <li>No CPK or liver enzyme changes</li> <li>Treatment</li> <li>Discontinue serotonergic meds, supportive, benzodiazepines, cyproheptadine</li> <li>Cyclobenzaprine</li> <li>Cyproheptadine (H1 receptor antagonist)</li> <li>Weakly cholinergic hypotension</li> <li>Steroids</li> <li>Glucocorticoids/Prednisone (Asthma/Lupus)</li> <li>Delusions/hallucinations. Alert and cognitively intact</li> <li>Anxiety, depression, psychosis, mania rarely</li> <li>Usually occur during the first week but may occur at any time</li> <li>Tardive Dyskinesia</li> <li>98% get worse with acute cessation of antipsychotic</li> <li>D2 receptor upregulation and super sensitivity</li> <li>Chronic blockade of dopamine receptors causes this</li> <li>Treatment</li> <li>Switch from risperidone to clozapine (atypical antipsychotic)</li> <li>VMAT2 Inhibitors</li> <li>Blocks presynaptic dopamine release<ul> <li>May cause depletion of dopamine in synaptic cleft causing depression</li> </ul> </li> <li>Deutetrabenazine (Austedo)<ul> <li>TD and Huntington's</li> </ul> </li> <li>Valbenazine (Ingrezza)</li> <li>Reserpine</li> <li>TCA (Tricarboxylic Acid) Overdose</li> <li>Features</li> <li>Antihistamine Effects</li> <li>Drowsiness, delirium, coma, seizures, respiratory depression</li> <li>Anticholinergic Effects</li> <li>Dry mouth, blurred vision, mydriasis, urinary retention</li> <li>Flushing, hyperthermia</li> <li>Hypotension, sinus tachycardia, prolonged PR/QRS/QT, Arrythmias</li> <li>QRS \u2265 100ms is MC EKG abnormality</li> <li>1500mg for \u22654 hours = death</li> <li>Treatment</li> <li>O2 and intubation, EKG monitoring</li> <li>IV fluids</li> <li>Activated charcoal if within 2 hours of ingestion (unless ileus present)</li> <li>Seizures: Benzodiazepines</li> <li>QRS \u2265100: IV Sodium Bicarbonate</li> <li>Therapy for QRS widening or ventricular arrythmia</li> <li>QRS \u2265 100msec is associated with increased risk of arrhythmias and/or seizures</li> <li>Cardioprotective and helps metabolic acidosis</li> <li>Theophylline Toxicity</li> <li>Toxic form reduced clearance or decreased metabolism in the liver</li> <li>CNS Stimulation (headache, insomnia, seizures), GI (Nausea, vomiting), and cardiac toxicity (arrhythmia)</li> <li>Measure theophylline levels</li> <li>tPA</li> <li>Treatment</li> <li>Aminocaproic Acid</li> <li>Warfarin</li> <li>Treatment</li> <li>Vitamin K, FFP</li> </ul> </li> </ul>"},{"location":"im-guide/psych/","title":"Psychiatry","text":"<p>Note: I am not a psychiatrist.</p> <ul> <li>Alcohol Use/Drug Use<ul> <li>Symptom-triggered &gt; Fixed Benzodiazepine treatment for alcohol withdrawal</li> </ul> </li> <li>Depression<ul> <li>STAR*D I: Adding bupropion or buspirone achieves remission in 30%</li> <li>STAR*D II: When citalopram fails, remission induced in 25% when switched to ER bupropion, sertraline, or ER venlafaxine</li> </ul> </li> </ul>"},{"location":"im-guide/rheum/","title":"Rheumatology","text":"<ul> <li>ANCA-Associated Vasculitis<ul> <li>RAVE: Rituximab is non-inferior to Cyclophosphamide in inducing remission</li> </ul> </li> <li>Ankylosing Spondylitis</li> <li>Gout<ul> <li>Management</li> <li>Systemic corticosteroids for acute gout</li> <li>Managing gout: how is it different in patients with chronic kidney disease?</li> </ul> </li> <li>OA<ul> <li>Management</li> </ul> </li> <li>Polymyalgia Rheumatica<ul> <li>Overview</li> </ul> </li> <li>*Pseudogout<ul> <li>RF</li> </ul> </li> <li>RA<ul> <li>TICORA: Intensive &gt; standard therapy in improving disease control at 18 months</li> </ul> </li> <li>Septic Arthritis<ul> <li>Sensitivity of ESR and CRP in ruling out Septic Arthritis</li> </ul> </li> </ul>"},{"location":"resident-guide/","title":"General Concepts","text":"<ul> <li>Basics \u2013 Basics for Medicine Residents such as how to admit, transfer, and discharge patients</li> <li>Efficiency \u2013 Tips for being both efficient and effective in Medicine</li> <li>Soft Skills \u2013 Guide to the \"Soft Skills\" of medicine such as teaching, feeback, and communication</li> <li>Interesting \u2013 Topics I've found interesting</li> <li>Blog \u2013 Blog for current and emerging ideas</li> <li>Student/Intern Reading \u2013 Links to reading for interns and residents</li> </ul>","tags":["Efficiency","Soft Skills","Basics"]},{"location":"resident-guide/interesting/","title":"Interesting","text":"","tags":["Efficiency"]},{"location":"resident-guide/interesting/#cardiology","title":"Cardiology","text":"<ul> <li>Schematic of a realistic semilunar heart valve geometry (left) and the approximated valve geometry (right)</li> </ul>","tags":["Efficiency"]},{"location":"resident-guide/student-intern-readings/","title":"Student/Resident Reading Topics","text":"<p>The best thing you can do for the IM Shelf is UWorld. There really is no replacement for it. Anki can be used to supplement but shouldn't be your primary source of information.</p> <p>Step III Anki Deck</p>","tags":["Suggested Reading","Medical Students","Residents"]},{"location":"resident-guide/student-intern-readings/#ward-resources","title":"Ward Resources","text":"<ul> <li>Internal Medicine Clerkship Guides<ul> <li>Primer to the Internal Medicine Clerkship - 2008</li> <li>NBME Medicine Subject Exam - Content Outline</li> <li>UNC Suggested Reading</li> <li>M4 ED Curriculum</li> <li>SIU Reading List - 2006</li> </ul> </li> <li>Other Clerkship Resources<ul> <li>Books by Ben White</li> </ul> </li> <li>Other<ul> <li>Incomplete ER Journal Club Articles</li> </ul> </li> </ul>","tags":["Suggested Reading","Medical Students","Residents"]},{"location":"resident-guide/student-intern-readings/#ward-topics-list","title":"Ward Topics List","text":"<p>Largely modeled after SIU's Reading list, but with topics I've commonly encountered sorted by the relative frequency I've encountered them.</p> Cardiology Highest Yield <ul> <li>Angina Pectoris &amp; ACS</li> <li>Atrial Fibrillation</li> <li>Coronary Artery Disease</li> <li>Heart Failure</li> <li>Hypertension</li> <li>Pulmonary embolus/Pulmonary embolism (PE)</li> </ul> Average Yield <ul> <li>Aortic Stenosis</li> <li>Aortic regurgitation</li> <li>Atrial flutter</li> <li>AV blocks</li> <li>Cardiomyopathy</li> <li>Cor Pulmonale</li> <li>Mitral regurgitation</li> <li>Mitral stenosis</li> <li>Multifocal atrial tachycardia</li> <li>Premature ventricular contractions (PVC)</li> <li>Prinzmetal\u2019s angina</li> <li>Ventricular Tachycardia</li> </ul> Lower Yield <ul> <li>Atrial Septal Defect (ASD)</li> <li>Cardiac Tamponade</li> <li>Congenital Heart Disease</li> <li>Junctional rhythms</li> <li>Pericarditis</li> <li>Wolf-Parkinson White</li> </ul> Endocrinology Highest Yield <ul> <li>Diabetes Mellitus<ul> <li>Hypoglycemia</li> <li>Ketoacidosis</li> <li>HHS</li> <li>Neuropathy</li> <li>Retinopathy</li> </ul> </li> <li>Hyperthyroidism</li> <li>Hypercalcemia</li> <li>Hypothyroidism</li> </ul> Average Yield <ul> <li>Cushing\u2019s disease</li> <li>Addison\u2019s disease</li> <li>Corticosteroid drug therapy</li> <li>Syndrome of inappropriate ADH secretion</li> <li>Thyroid Nodules</li> <li>Hashimoto\u2019s Thyroiditis</li> <li>Osteoporosis</li> <li>Multiple endocrine neoplasia syndromes</li> <li>Pheochromocytoma</li> <li>Galactorrhea</li> <li>Hypogonadism</li> <li>Thyroid cancer</li> </ul> Lower Yield <ul> <li>Primary hyperaldosteronism</li> <li>Acromegaly</li> <li>Diabetes insipidus</li> <li>Ectopic hormone production</li> <li>Conn\u2019s Syndrome</li> <li>Gastrinoma</li> </ul> Hematology/Oncology Highest Yield <ul> <li>Iron Deficiency Anemia</li> <li>Anemia of chronic disease</li> <li>Lymphomas</li> <li>DIC</li> <li>Thrombocytopenia</li> <li>Chronic Leukemia</li> <li>Breast Cancer</li> </ul> Average Yield <ul> <li>Macrocytic anemia</li> <li>Transfusions</li> <li>Myelofibrosis/Myelodysplasia</li> <li>Deep venous thrombosis</li> <li>Gammopathy</li> <li>Pancytopenia</li> <li>Hemoglobinopathies</li> <li>Von Willebrand's Disease</li> <li>Acute Leukemia</li> <li>Skin cancer/melanoma</li> <li>Principles of chemotherapy</li> <li>Pain management</li> <li>Prostate cancer</li> <li>Paraneoplastic Syndromes</li> <li>Monoclonal Antibody Therapy</li> </ul> Lower Yield <ul> <li>Leukopenia</li> <li>Aplastic anemia</li> <li>Hemophilia</li> <li>Chromosomes</li> <li>Flow Cytometry</li> </ul> Infectious Disease Highest Yield <ul> <li>Pneumonia/bronchitis</li> <li>UTI\u2019s</li> <li>AIDS</li> <li>Septic Shock</li> </ul> Average Yield <ul> <li>Endocarditis</li> <li>Meningitis</li> <li>Lyme disease</li> <li>URI/influenza</li> <li>Immunizations</li> <li>TB</li> <li>Histo/Other fungal diseases</li> <li>Encephalitis</li> <li>Rheumatic fever</li> <li>Lung abscess</li> <li>Sinusitis</li> <li>Herpes Zoster/Simplex</li> <li>Vaginal Discharges (STD\u2019S)</li> </ul> Lower Yield <ul> <li>Rocky Mountain Fever</li> <li>Staph Syndrome (toxic shock)</li> <li>Osteomyelitis</li> <li>Septic arthritis</li> <li>Liver abscess</li> <li>Brain abscess</li> </ul> Nephrology &amp; Urology Highest Yield <ul> <li>Acute Renal Failure</li> <li>Fluid/Electrolytes</li> </ul> Average Yield <ul> <li>Chronic Renal Failure</li> <li>Glomerulonephritis</li> <li>Acid Base balance</li> <li>Nephrotic Syndrome</li> <li>Renal Calculi</li> <li>Drug Therapy in renal disease</li> <li>Renal carcinoma</li> </ul> Lower Yield <ul> <li>Renal tubular acidoses</li> <li>Goodpasture\u2019s</li> <li>Polycystic kidneys</li> <li>Henoch-Schoenlein purpura</li> </ul> Pulmonology Highest Yield <ul> <li>COPD/Asthma/Bronchiectasis</li> <li>Lung Cancer</li> <li>Acute Respiratory Failure</li> <li>Pulmonary Emboli/DVT</li> <li>Respiratory Tract Infections</li> <li>IgE mediated disease</li> <li>Sleep Apnea/Respiratory Control</li> </ul> Average Yield <ul> <li>Pleural effusion/pneumothorax</li> <li>Sarcoidosis</li> <li>Pneumoconiosis</li> <li>Restrictive Lung disease</li> <li>Influenza</li> <li>Diffuse pulmonary fibrosis</li> <li>Pulmonary Function Tests</li> <li>Aspergillosis</li> <li>Tuberculosis</li> <li>Histoplasmosis</li> <li>Pneumothorax</li> <li>Cystic Fibrosis</li> <li>Hypersensitivity pneumonitis</li> </ul> Lower Yield <ul> <li>Mesothelioma</li> <li>CO poisoning</li> </ul> Rheumatology, Immunology and MSK Highest Yield <ul> <li>Septic Arthritis</li> <li>Rheumatoid Arthritis</li> <li>Osteoarthritis</li> <li>Systemic Lupus Erythematosus</li> <li>Gout</li> <li>Ankylosing Spondylitis</li> <li>Polymyalgia Rheumatica</li> </ul> Average Yield <ul> <li>Giant Cell Vasculitis</li> <li>Vasculitis (Wegener\u2019s, PAN, HSP, etc.)</li> <li>Reactive Arthritis (Reiter\u2019s Syndrome)</li> <li>Regional Rheumatic Problems (LBP, Tendonitis, Bursitis)</li> <li>Fibromyalgia</li> <li>Calcium Pyrophosphate Deposition Disease (CPPD)</li> <li>Sjogren\u2019s Syndrome</li> <li>Polymyositis</li> <li>Scleroderma</li> <li>Psoriatic Arthritis</li> <li>Antiphospholipid Antibody Syndrome</li> <li>Lyme Disease</li> <li>Raynaud\u2019s Phenomenon</li> <li>Entrapment Neuropathies (Carpal Tunnel Syndrome)</li> </ul> Lower Yield <ul> <li>Neuropathic Arthritis</li> <li>Relapsing Polychondritis</li> <li>Rheumatic Fever</li> <li>Amyloidosis</li> <li>Hypermobility Syndrome</li> <li>Osteonecrosis</li> <li>Hypertophic Pulmonary</li> <li>Osteoarthropathy</li> </ul> Gastroenterology Highest Yield <ul> <li>Gastroesophageal reflux disease</li> <li>Peptic ulcer disease</li> <li>Choleithiasis</li> <li>Viral hepatitis</li> <li>Colon polyps/cancer</li> <li>Jaundice</li> <li>Gastrointestinal bleeding</li> </ul> Average Yield <ul> <li>Alcoholic hepatitis</li> <li>Cirrhosis</li> <li>Complicaitons of portal hypertension</li> <li>Pancreatitis</li> <li>Inflammatory Bowel disease</li> <li>Gastroenteritis \u2013 bacterial/parasitic</li> <li>Irritable Bowel Syndrome</li> <li>Diverticular disease</li> <li>Ascites</li> <li>Esophageal stricture</li> <li>Carcinoma of the stomach</li> <li>Chronic hepatitis</li> <li>Hemorrhoids</li> <li>Rectal fissure</li> <li>Ischemic colitis</li> <li>AV malformations</li> <li>Malabsorption syndromes</li> <li>Hepatoma</li> <li>Primary biliary cirrhosis</li> <li>Pancreatic Carcinoma</li> <li>AIDS-related gastrointestinal disease</li> </ul> Lower Yield <ul> <li>Achalasia</li> <li>Esophageal webs</li> <li>Meckel\u2019s diverticulum</li> <li>Mesenteric vascular insufficiency</li> <li>Wilson\u2019s disease</li> <li>Hemochromatosis</li> <li>Zollinger-Ellison Syndrome</li> <li>Drug-induced liver disease</li> </ul> General Highest Yield <ul> <li>Hyperlipidemia</li> <li>Alcohol/drug abuse</li> <li>Preventive health care</li> </ul> Average Yield <ul> <li>Nutrition/obesity</li> <li>Geriatrics</li> <li>Depression</li> <li>Principles of clinical decision making</li> <li>Acute anxiety</li> <li>Chronic anxiety</li> </ul> Lower Yield <ul> <li>Fatigue</li> </ul> Geriatrics Highest Yield <ul> <li>Normal aging changes</li> <li>Geriatric Syndromes</li> <li>Delirium/Dementia</li> <li>Aging simulation to promote awareness</li> <li>Adaptations to promote functioning</li> </ul> Average Yield <ul> <li>Falls</li> <li>Incontinence</li> <li>Restraints</li> <li>Enhancing communication for vision and hearing losses</li> <li>Exercise</li> <li>Iatrogenesis</li> <li>Nursing Home regulations about restraints</li> <li>Changes in taste &amp; smell</li> <li>Improving nutrition</li> </ul> Lower Yield <ul> <li>Fall prevention</li> <li>Appropriate catheter usage</li> <li>Restraint alternatives</li> <li>Advance directives in relation to dementia an enteral feeding</li> </ul> Dermatology Highest Yield <ul> <li>Cutaneous Tumors<ul> <li>benign</li> <li>malignant</li> </ul> </li> <li>Cutaneous Infections<ul> <li>viral</li> <li>bacterial</li> </ul> </li> </ul> Average Yield <ul> <li>Contact dermatitis</li> <li>Psoriasis</li> <li>Acne</li> <li>Cutaneous manifestations of Systemic disease</li> <li>Collagen vascular disease</li> </ul> Lower Yield <ul> <li>Pemphigus vulgaris</li> <li>Bullous pemphigoid</li> </ul>","tags":["Suggested Reading","Medical Students","Residents"]},{"location":"resident-guide/basics/1-basics/","title":"The Basics","text":"<p>\"That sign can\u2019t stop me because I can\u2019t read\"</p>"},{"location":"resident-guide/basics/1-basics/#general-important","title":"General (Important)","text":"<ul> <li>Email Tutorial: Microsoft Office/Outlook/OneDrive/SharePoint</li> <li>See the CAMC Staff Handbook and Resident Orientation &amp; Benefits books located in the Intern Guide folder for more information on the Basics of CAMC<ul> <li>Rotation Curriculum Guides</li> </ul> </li> <li>Work/Call Schedules<ul> <li>Accessed via AMION and can be downloaded to your calendar</li> <li>Morning Report/Didactic Calendar</li> </ul> </li> <li>Duty Hours<ul> <li>Unfortunately, Very High Yield</li> <li>New Innovations<ul> <li>Where your onboarding was completed, where you will be logging you duty hours, signing into lecture, seeing your block schedule, completing evaluations and curriculum reviews</li> <li>Duty Hour Tutorial: Logging Duty Hours on New Innovations</li> <li>High Points:<ul> <li>Must be logged every 72 hours<ul> <li>You will get emails if you forget or don\u2019t log them<ul> <li>You will then get a text to log them<ul> <li>Then people get mad (So just do them)</li> </ul> </li> </ul> </li> </ul> </li> </ul> </li> </ul> </li> </ul> </li> </ul>"},{"location":"resident-guide/basics/1-basics/#general-slightly-less-important","title":"General (Slightly Less Important)","text":"<ul> <li>Advisors<ul> <li>Resident Advisor: Should have already texted/called/emailed you, text katie if they haven't</li> <li>Faculty Advisor:<ul> <li>Assigned by PD, may be changed if you vibe with another attending and they\u2019re ok with it</li> <li>Mandatory meetings at 3 months, 6 months and 1 year<ul> <li>Time for feedback/ITE scores/Learning Plan</li> </ul> </li> </ul> </li> </ul> </li> <li>Call Rooms<ul> <li>\u201cLockers are available in resident work areas for use. To receive a locker assignment and lock, a resident should contact the GME office. Assigned locks must be used. Lockers, per CAMC policy, are subject to inspection. \u201c\u2013 CAMC Staff Handbook</li> </ul> </li> <li>Calling/Phone<ul> <li>When in doubt, Dial \u201c0\u201d on any phone in the hospital<ul> <li>Links you to the operator who can direct you to the appropriate phone</li> <li>Say who you are and where you\u2019re calling from and where you\u2019re trying to reach<ul> <li>Ex. \u201cThis is doctor X with the medicine service, could you connect me with inpatient pharmacy at memorial please\u201d</li> </ul> </li> </ul> </li> </ul> </li> <li>AMS Connect<ul> <li>Most providers and almost all residents use AMS connect (how to)<ul> <li>Pages are sent both to your pager and AMS, Messages are only on AMS</li> </ul> </li> <li>Please see Onboarding to ensure your AMS is set up to receive messages.</li> </ul> </li> <li>Sick Days<ul> <li>See Leave Policy in the resident drive for more information<ul> <li>\u201cThe resident calling in sick must notify their Attending and then send email to include Chiefs, Program Coordinator and Program Director/Associate Program Directors\u201d - CAMC Staff Handbook</li> </ul> </li> <li>If Additional coverage needed:<ul> <li>A clinic resident may be considered, and patients redistributed</li> </ul> </li> </ul> </li> <li>Questions?<ul> <li>Follow the ladder:<ul> <li>Senior -&gt; Chief -&gt; Attending -&gt; APD -&gt; PD</li> </ul> </li> <li>Katie Scott is also very helpful for almost everything you could need</li> </ul> </li> </ul>"},{"location":"resident-guide/basics/2-team-expectations/","title":"Medicine Service Expectations","text":"<p>\"You're throwing fastballs at a catcher with no mitt\"</p>"},{"location":"resident-guide/basics/2-team-expectations/#use-of-abcd","title":"Use of ABCD","text":"<ul> <li>A: Pts who are acutely ill or worsening quickly, \u201cwatcher\u201d status, or never seen together as a team</li> <li>B: Pts responding to therapies but still require updates to care and ongoing hospitalization</li> <li>C: Pts pending discharge that are not able to be discharged for some defined reason (i.e., EOT for antibiotics, HD chair, placement)</li> <li>D: Pts anticipated for discharge</li> </ul>"},{"location":"resident-guide/basics/2-team-expectations/#team-responsibilities","title":"Team responsibilities","text":"<ul> <li>A/B/C/D should be set prior to rounds by intern/resident and determines presentation:<ul> <li>A/B: team dependent (full, problem focused, etc.)</li> <li>C: brief update</li> <li>D: DDEMAP</li> </ul> </li> <li>Attending rounds typically run from 9-11:30a on weekdays, team responsibility to troubleshoot difficulties with this</li> <li>See all A (including new to team) and definitive D patients in person (non-primary intern can be excused if busy).<ul> <li>Primary presenter for patient should lead patient discussion.</li> </ul> </li> <li>Interns can be split for rounds to get work done</li> <li>All team members should be prepared for rounds</li> <li>Use of AIDET, communication with patients or surrogate decision makers and appropriate use of</li> <li>Interpreter services (as well as correct documentation where appropriate)</li> <li>A note should be completed each day (H&amp;P \u2013 overnight team H&amp;P counts if completed after midnight, progress or transfer note, or discharge/transfer summary). Team should be clear about who is responsible for note (i.e. typically student, intern, or resident)</li> </ul>"},{"location":"resident-guide/basics/2-team-expectations/#attending-responsibilities","title":"Attending responsibilities","text":"<ul> <li>See all patients every day. D patients should be seen prior to 12:30 to allow for discharges.</li> <li>Coordinate teaching</li> <li>Ensure CM rounds are running appropriately (providing resident and CM team with feedback)</li> <li>Be available to help team members throughout the day</li> <li>Supply feedback on patient care, presentations, cache, and documentation</li> <li>Help in resolving conflicts between services</li> <li>Be available to staff all new admissions with primary intern/resident by 4pm on short call days and by 6pm on long call days</li> <li>Cover pager during Afternoon Report and non-Long Call/Short Call days Thursday Schools Resident responsibilities</li> <li>Resident should review plans for patients with team members (medical students and interns) from 8:30-9a so that plans are prepared for attending rounds</li> <li>Complete chart rounds prior to attending rounds on all patients every day and have a plan for every patient</li> <li>See all A and D patients prior to attending rounds, prioritize active B patients and patients with new overnight issues</li> </ul>"},{"location":"resident-guide/basics/2-team-expectations/#senior-responsibilities","title":"Senior responsibilities","text":"<ul> <li>Ensure days off are scheduled for the team and that patients are distributed appropriately each day, including who will see new admissions, who will see patients when people on the team have days off, and a reasonable distribution of the work</li> <li>Supervise and run team rounds and CM rounds with attending support</li> <li>Run list and ensure orders, consults, and discharges mostly done by 1pm</li> <li>Ensure interns are completing all assigned duties and aid with intern direct care duties (i.e., calling</li> <li>consults, arranging transitions, updating cache)</li> <li>Perform sign out on long call days</li> <li>Assist with teaching the medical student(s) and/or making time in the day for teaching</li> <li>Ensure all notes and tasks are completed by 6pm on non-long call/8pm on long call, and help to alert attending if this is not happening</li> <li>Ensure patients that need to be admitted are assigned and seen within 2 hours</li> </ul>"},{"location":"resident-guide/basics/2-team-expectations/#intern-responsibilities","title":"Intern responsibilities","text":"<ul> <li>Be the primary intern for up to 8 patients at a time and perform admissions with the team</li> <li>See all OWN patients every day, prior to rounds</li> <li>Be prepared to present on all own patients, review main plan with resident prior to rounds</li> <li>Prepare DDEMAP on discharges prior to rounds including medication reconciliation with knowledge of home medications</li> <li>Write notes on all patients or attest student notes</li> <li>Update Excel daily</li> <li>Split up between the two interns: pager connect duties during rounds, perform sign out on non-long call days</li> <li>Intern on pager duty is expected to return to the hospital if acute issues arise and to know the other intern\u2019s patients well enough to respond and appropriately cross cover until sign out to night cross-cover resident.</li> <li>Day-to-Day for Interns:<ul> <li>Checkout from Night Team<ul> <li>Senior to determine each intern\u2019s patients for the day</li> <li>Let your senior know if you have afternoon clinic</li> </ul> </li> <li>Morning Labs/Follow-up items<ul> <li>Check Morning Labs as well as any follow up items from the day prior</li> <li>Start \u201cLab\u201d &amp; \u201dBox\u201d System if desired; See Staying Organized</li> </ul> </li> <li>Replace relevant electrolytes/start new medications as needed<ul> <li>See Electrolyte Replacement Guidelines if needed</li> </ul> </li> </ul> </li> <li>Discuss with senior!</li> <li>Pre-Rounds</li> <li>Morning Report</li> <li>Rounds</li> <li>Lunch</li> <li>Didactics</li> <li>Post-Didactics</li> <li>Handoffs</li> <li>Please try your hardest to update hospital courses<ul> <li>This is especially important for discharges, end of the rotation handoff, and patients in the hospital longer than one week</li> </ul> </li> </ul>"},{"location":"resident-guide/basics/2-team-expectations/#phase-ii-medical-student-responsibilities","title":"Phase II Medical student responsibilities","text":"<p>Supporting the vibes of the entire team should be your #1 priority</p> <ul> <li>See patients you are assigned and prepare presentations for them, review main plan with resident prior to rounds</li> <li>Up to 3 notes/day with resident/intern verification/attestation</li> <li>Should be present for all of rounds</li> <li>Help with patient care duties on their patients (i.e., calling consults, helping with follow-ups, depart summary, patient education, family updates, cache updates)</li> <li>Place basic medical orders on patients if they can be co-signed by physician at appropriate intervals</li> <li>Predominantly see and present patients with A/B/D status. For C patients, if the student still follows, the intern/resident may present for efficiency.</li> </ul>"},{"location":"resident-guide/basics/2-team-expectations/#phase-iii-sub-intern-medical-student-responsibilities","title":"Phase III (Sub-intern) Medical student responsibilities","text":"<p>Again: Supporting the vibes of the entire team should be your #1 priority</p> <ul> <li>See patients you are assigned and prepare presentations for them, review main plan with resident prior to rounds</li> <li>Write H&amp;P, progress note, and discharge summaries on all patents you see</li> <li>Attending attestation/verification for progress notes/discharge summaries</li> <li>Resident attestation/verification for H&amp;P</li> <li>Should be present for all of rounds</li> <li>Perform all patient care duties on their patients (i.e., calling consults, requesting follow-ups, depart summary, patient education, family updates, cache updates)</li> <li>Place basic medical orders on patients and requesting co-signature at appropriate interval</li> </ul>"},{"location":"resident-guide/basics/4-how-to-write-admit-note/","title":"How to Write an Admission Note","text":"<p>'\u201cLike that flag is red, but not like red red\u201d'</p>"},{"location":"resident-guide/basics/4-how-to-write-admit-note/#general","title":"General","text":"<ul> <li>Should be a story that is in the format of a UWorld Stem</li> </ul>"},{"location":"resident-guide/basics/4-how-to-write-admit-note/#subjective-includes-all-the-sections-below","title":"Subjective (Includes all the sections below)","text":"<ul> <li> <p>Identifying statement (Name, Age, Sex, PMH/PSH, CC)</p> <ul> <li>Ex. Mr. Hill is a 25 y/o M w/PMH of Interstitial Lung Disease who presented to the ED on 09/04/2022 w/CC of shortness of breath. Relevantly, Mr. Hill follows w/PAC and was seen in their clinic yesterday where he was instructed to come to the ED.</li> </ul> </li> <li> <p>History of Present Illness (HPI)</p> <ul> <li>Utilize OLDCARTS<ul> <li>Asking \"When did you last feel normal\", \"Are you better, worse, or the same?\", \"What made you come in today?\", and \"What do you think this could be?\" can often be helpful in eliciting an HPI</li> <li>Ex. Today, he complained of cough, wheezing, and sob that started a week ago that he says has been quickly worsening. He says feels he feels persistent chest tightness when trying to breath that hasn\u2019t improved with his home albuterol inhaler. He states he has had some clear sputum production but not much. He denies aggravating factors, which includes exertion and laying flat.</li> </ul> </li> </ul> </li> <li> <p>Meds/Allergies/FH/SH/Other relevant history/Code Status</p> <ul> <li>You don't need to list every medication they have, but the important ones/ones relevant to the complaint need to be here<ul> <li>Call the spouse/SNF/Pharmacy if you must</li> </ul> </li> <li>Ex. He states he has been taking nitroglycerin at home daily as well as lasix 40mg QID for \"his heart.\" He denies known allergies and states he has smoked for 20 years, 1 pack per day, but denies drinking alcohol or using illicit drugs. He states his dad had ILD and that he and his father used to work in a coal mine together until last month when his dad was sent to jail. Before this, he completed his ADLs without difficulty or assistance. He denies working currently and is a full code. His wife is his MPOA.</li> </ul> </li> <li> <p>ER Course</p> <ul> <li>Vitals then PE, relevant or abnormal labs, diagnostic tests, ER assessment, ER interventions, and then \"The medicine service was called to see the patient\" or something like that.</li> <li>Ex. In the ER, he was found to be afebrile, BP 120/70, HR 85, RR 18 w/SpO2 92% on room air. He was found to be mildly dyspneic by the ER staff with intermittent use of respiratory accessory muscles. Labs were relevant for a WBC of 16.0 and Glucose of 180. CXR was without focal consolidation. EKG showed normal sinus rhythm. PNA PCR was positive for H. Influenzae. He was given 80mg IV Lasix for presumed CHF, 2L Normal Saline for Sepsis, and Remdesivir for presumed COVID in the ER. The medicine service was then called for admission.</li> </ul> </li> </ul>"},{"location":"resident-guide/basics/4-how-to-write-admit-note/#review-of-systems-ros","title":"Review of Systems (ROS)","text":"<ul> <li>Constitutional: Denies fever, chills, fatigue, weight changes, night sweats</li> <li>HEENT: Denies trauma, headache, dizziness, blurry vision, double vision, hearing loss, tinnitus, nasal congestion, sore throat, sinus pressure, ear pain change in voice, difficulty swallowing, eye pain, itchy eyes</li> <li>Resp: Denies shortness of breath, cough, sputum production, wheezing, labored breathing, dyspnea on exertion, orthopnea, PND, hemoptysis, stridor</li> <li>CV: Denies chest pain, palpitations, peripheral edema, syncope, diaphoresis, radiation, claudication</li> <li>GI: Denies nausea, vomiting, abdominal pain, diarrhea, constipation, bloody stool, change in bowel frequency, dyspepsia, melena</li> <li>GU: Denies dysuria, discharge, change in frequency, hematuria, itching, burning</li> <li>Endo: Denies polydipsia, polyuria, polyphagia, heat or cold intolerance</li> <li>MSK: Denies back pain, neck pain, joint pain, muscle pain, decreased range of motion, excessive weakness, swelling, redness</li> <li>Integumentary: Denies dryness, itching, flaking, hair loss, rashes, lesions, nail changes</li> <li>Neuro: Denies numbness, tingling, weakness, LOC, gait disturbance, seizure</li> <li>Heme: Denies history of excessive bleeding, bruising, anemia, or transfusions</li> <li>Psych: Denies anxiety, problems sleeping, depression, SI</li> </ul>"},{"location":"resident-guide/basics/4-how-to-write-admit-note/#physical-exam-pe","title":"Physical Exam (PE)","text":"<ul> <li>Constitutional: Alert, well nourished, no acute distress</li> <li>Eye: Normal conjunctiva, without scleral icterus, PERRLA, EOMI</li> <li>HENT: Atraumatic, hearing grossly intact, without nasal discharge, moist oral mucosa, grossly average neck circumference, without JVD, without sinus tenderness, clear tympanic membranes, neck nontender to palpation, without carotid bruits, without masses, without lymphadenopathy</li> <li>Resp: Clear to auscultation bilaterally, non-labored respiration on room air, without rales/rhonchi, without wheezing</li> <li>CV: Normal rate, regular rhythm, without murmurs on auscultation, gallops, or rubs</li> <li>GI: Soft, non-tender, non-distended, without obvious masses, bowel sounds present, w/o rigidity or guarding</li> <li>GU: No tenderness, no discharge, no lesions</li> <li>MSK: Extremities non-tender to palpation, without LE edema bilaterally, without obvious deficits in range of motion or strength, able to ambulate w/o assistance</li> <li>Skin: Skin is warm, dry, and pale, without rashes or lesions</li> <li>Heme/Lymph/Imm: Without obvious bleeding, without significant bruising, no lymphadenopathy</li> <li>Psychiatric: Cooperative, appropriate mood and affect, normal judgement</li> <li>Neurologic: Awake and oriented X4, No focal neuro deficits, CN II-XII intact</li> </ul>"},{"location":"resident-guide/basics/4-how-to-write-admit-note/#assessmentplan","title":"Assessment/Plan","text":"<ol> <li>Problems from your problem list auto-populate into your contextual view<ul> <li>See the examples linked below of how to generate your assessments/plans<ul> <li>PAST/PRESENT/FUTURE GAME</li> </ul> </li> <li>Preventive Measure<ul> <li>Code Status: DNR/DNI, Full Code, DNR/Ok to intubate, DNI/CPR ok</li> <li>Lines:</li> <li>VTE PPX:</li> <li>Diet:</li> <li>Disposition:</li> </ul> </li> </ul> </li> </ol>"},{"location":"resident-guide/basics/4-how-to-write-admit-note/#signature","title":"Signature","text":""},{"location":"resident-guide/basics/4-how-to-write-admit-note/#sign-note-to-attending","title":"Sign Note to Attending","text":""},{"location":"resident-guide/basics/5-transfers/","title":"Transfers","text":"<ul> <li>Transfers (Accepting team)<ul> <li>Like admitting a patient, but slightly less work as the patient has already been on another service, such as the ICU, but not always the case<ul> <li>Do not make the type \"Transfer Note\" you are unable to see this note when you go to search for it</li> </ul> </li> <li>Transfer Note (To Med Service)<ul> <li>Type: Internal Medicine Progress Note</li> <li>Note Template: Progress/SOAP Note - Brief or Transfer Note</li> <li>Title: \"CAMC IM Transfer Note\"</li> </ul> </li> <li>Update Excel List Online</li> </ul> </li> <li>Transfers (Releasing team)<ul> <li>If you are on the ICU and you are transferring a patient to the medicine service, contact the medicine service senior or MAO to transfer the patient</li> <li>Other than a standard progress note, no extra note needs to be written if you are the \"discharging\" team</li> <li>If you are on the medicine service and transferring to the ICU, a short progress note about the patient's decompensation should be written.<ul> <li>The ICU team will write an ICU Admission note rather than transfer note because it's special</li> </ul> </li> </ul> </li> </ul>"},{"location":"resident-guide/basics/6-discharge/","title":"Discharge","text":"<p>\u201cDrop a lil' knowledge on 'em\u201d</p>"},{"location":"resident-guide/basics/6-discharge/#medication-reconciliation-discharge","title":"Medication Reconciliation (Discharge)","text":"<ul> <li>Navigate to the Med Rec as seen in \u201cHow to Admit a Patient\u201d</li> <li>With your Senior, complete the Med Rec for discharge<ul> <li>This is the main opportunity to stop or change medications for the patient after discharge<ul> <li>Once this step is completed, you will see the \"check\" beside Home Medications as below.</li> </ul> </li> </ul> </li> </ul>"},{"location":"resident-guide/basics/6-discharge/#patient-instructionsfollow-upseducation","title":"Patient Instructions/Follow-Ups/Education","text":"<ul> <li>Navigate to the Inpatient Workflow Discharge Platinum and select the \u201cPatient Instructions\u201d</li> </ul> <ul> <li>The instructions can be done multiple ways and as long as you communicate to the patient what needs to be done, you can do this as you like. I utilize the Uptodate method to break it down into simple easy to digest steps. I then saved it as a dotphrase .jsdischargeinstructions<ul> <li>Just make sure to save this field as it will autopopulate into your Discharge summary</li> <li>Anywhere within the Instructions field, press Ctrl + A, then Ctrl + C</li> </ul> </li> </ul> <ul> <li> <p>Make sure to complete the Follow-ups and Patient education on the same page as you go</p> <ul> <li>Follow-ups are typically with the patient\u2019s PCP, generally I have them follow up within a few days to 10 days depending on the condition.<ul> <li>Option 1) Patient\u2019s PCP is a random person somewhere else<ul> <li>It is not required, but encouraged to notify them about their patient needing a follow up</li> </ul> </li> <li>Option 2) Patient is established with Dr. Aman, Dr. Hadley, Dr. John, Dr. Durden, or Dr. Griffith<ul> <li>You will need to Select \u201cCommunicate and Message\u201d at the top of the page to create a new message for their clinic</li> </ul> </li> <li>To do so:</li> </ul> </li> </ul> <p> </p> <p> </p> <p> </p> <ul> <li>Send this message<ul> <li>Option 3) Patient is OPCC Resident\u2019s patient<ul> <li>Same process as above but will select \u201cMEM Outpatient Care Center \u2013 TCM\u201d as the message recipient</li> </ul> </li> <li>NOTE: Do not schedule TCM visits if the patient is going to a SNF</li> </ul> </li> <li>Patient Education is to be selected based on relevance to their condition<ul> <li>Ex. Pt admitted for AECOPD could be given information on signs and symptoms of COPD exacerbation or the ALA\u2019s information on grading their COPD exacerbation severity</li> </ul> </li> </ul> </li> </ul>"},{"location":"resident-guide/basics/6-discharge/#discharge-instructions","title":"Discharge Instructions","text":"<ul> <li>Prior to generating the Discharge Instructions, make sure the Home Medications, Follow-Up, and Patient Education tabs have the green check mark beside them in the Inpatient Discharge MPage. The Order Profile should still have the red star.</li> <li> <p>Now it is time to create the patient\u2019s discharge instructions</p> <ul> <li>Type: Discharge Instructions</li> <li>Note Template: Free Text Note</li> <li>Title: \u201cCAMC IM Discharge Instructions\u201d</li> </ul> <p> </p> <p> </p> </li> <li> <p>Now, at the bottom there will be my generic instructions, delete those and press Ctrl + P</p> </li> <li>This should paste the modified instructions from your instructions tab you completed in the previous step.</li> <li>Sign and Print this page. You will give this to the patient.</li> </ul>"},{"location":"resident-guide/basics/6-discharge/#discharge-summary","title":"Discharge Summary","text":"<ul> <li>\u201cDischarge summaries are to be done within 36 hours of discharge or prior to transferring a patient to another facility\u201d</li> <li>A discharge summary can replace a progress note for the day<ul> <li>Ex. Discharge Mr. Hill at 2pm and complete discharge summary = no need for progress note that day</li> </ul> </li> <li>Type: Discharge Summary</li> <li>Note Template: Inpatient Discharge Summary</li> <li>Title: \u201cCAMC IM Discharge Summary\u201d<ol> <li>Dates of Service/Admitting Diagnosis/Primary + Secondary Discharge Diagnosis </li> <li>Procedures/Consults </li> <li>Studies<ul> <li>Use the .jsimaging_report dot phrase<ul> <li>Note: ECHOs/Vascular Studies are not added in this dotphrase and must be added manually.</li> <li>Try to delete extraneous information if possible<ul> <li>Ex.<ol> <li> </li> <li>CTA w/o Contrast</li> <li>MM/DD/YYYY 12:00:00</li> <li>IMPRESSION: Bad study</li> <li>Electronically Signed by: Reading Physician</li> <li> </li> </ol> </li> </ul> </li> </ul> </li> </ul> </li> <li>Hospital Course<ul> <li>Within the hospital course field on your Inpatient Workflow Discharge Platinum or within your inpatient workflow, you can complete the hospital course to auto populate into your discharge summary </li> </ul> </li> <li>Physical Exam/ Follow-Up Appointments/ Follow-Up Labs/Studies</li> <li>Discharge Medications/ Pending Labs and Studies/ Condition on Discharge </li> <li>Patient Instructions/Discharge Disposition/Physician Orders/Signature </li> </ol> </li> </ul>"},{"location":"resident-guide/basics/7-patient-instructions/","title":"Patient Instructions","text":"<p>\u201cDrop a lil' knowledge on 'em\u201d</p>"},{"location":"resident-guide/basics/7-patient-instructions/#patient-instructionsfollow-upseducation","title":"Patient Instructions/Follow-Ups/Education","text":"<ul> <li> <p>Navigate to the Inpatient Workflow Discharge Platinum and select the \u201cPatient Instructions\u201d</p> <p> </p> </li> <li> <p>The instructions can be done multiple ways and as long as you communicate to the patient what needs to be done, you can do this as you like. I utilize the Uptodate method to break it down into simple easy to digest steps. I then saved it as a dotphrase .jsdischargeinstructions</p> <ul> <li>Just make sure to save this field as it will autopopulate into your Discharge summary</li> </ul> </li> <li>Anywhere within the Instructions field, press Ctrl + A, then Ctrl + C </li> <li>Make sure to complete the Follow-ups and Patient education on the same page as you go</li> <li>Follow-ups are typically with the patient\u2019s PCP, generally I have them follow up within a few days to 10 days depending on the condition.<ul> <li>Option 1) Patient\u2019s PCP is a random person somewhere else<ul> <li>It is not required, but encouraged to notify them about their patient needing a follow up</li> </ul> </li> <li>Option 2) Patient is established with Dr. Aman, Dr. Hadley, Dr. John, Dr. Durden, or Dr. Griffith<ul> <li>You will need to Select \u201cCommunicate and Message\u201d at the top of the page to create a new message for their clinic</li> <li>To do so: </li> </ul> </li> </ul> </li> <li>Send this message<ul> <li>Option 3) Patient is OPCC Resident\u2019s patient<ul> <li>Same process as above but will select \u201cMEM Outpatient Care Center \u2013 TCM\u201d as the message recipient</li> </ul> </li> <li>NOTE: Do not schedule TCM visits if the patient is going to a SNF</li> </ul> </li> <li>Patient Education is to be selected based on relevance to their condition<ul> <li>Ex. Pt admitted for AECOPD could be given information on signs and symptoms of COPD exacerbation or the ALA\u2019s information on grading their COPD exacerbation severity</li> </ul> </li> </ul>"},{"location":"resident-guide/basics/8-common-inpt-problems/","title":"Common Inpatient Problems","text":""},{"location":"resident-guide/basics/8-common-inpt-problems/#tachycardia","title":"Tachycardia","text":"<ol> <li>Notify your senior.</li> <li>Get vitals first. If unstable, manage patient via ACLS guidelines. Call a Rapid Response or potentially a code if you need help.</li> <li>Go see the patient. Is this new? Are they symptomatic? Order stat EKG.</li> <li>Compare EKG to old. See cardiology section for algorithm on how to diagnose rhythm and when to use adenosine and vagal maneuvers.</li> </ol>"},{"location":"resident-guide/basics/8-common-inpt-problems/#bradycardia","title":"Bradycardia","text":"<ol> <li>Notify your senior.</li> <li>Get vitals first. Go see the patient.</li> <li>If they are symptomatic (dizzy, chest pain, syncope) or hemodynamically unstable, follow ACLS guidelines. Put patient in Trendenlenberg. Call a Rapid Response or potentially a Code if you need help.</li> <li>If stable, order atropine to the bedside and consider placing the patient on telemetry.</li> <li>Place pacer pads on the patient (can always take them off).</li> <li>If ECG shows either Type II second degree or 3<sup>rd</sup> degree AV block, consider transcutaneous pacing and possibly a transvenous pacer. Call Cardiology ASAP, and transfer to ICU.</li> <li>If patient is stable and not symptomatic, take a quick look at the chart to try and determine why this might be happening.</li> <li>DDX:</li> <li>Meds: \u03b2-blockers, Calcium-channel blockers, digoxin, amiodarone, clonidine.</li> <li>Cardiac: sick sinus syndrome, inferior MI, vasovagal (usually transient), 2<sup>nd</sup> or 3<sup>rd</sup> degree AV block, junctional rhythm.</li> <li>Autonomic N.S: neurocardiogenic syncope, carotid-sinus hypersensitivity, cough/micturition/emesis/defecation induced.</li> <li>Management (if stable):</li> <li>Take a focused H&amp;P and look at the medication administration record.</li> <li>If you think this is medication induced, consider holding a dose of the med if stable. Consider calcium or glucagon administration if you believe it to be secondary to the calcium channel or beta blocker the patient is taking.</li> <li>Put patient on telemetry to track trends. Consider sending electrolyte panel.</li> </ol>"},{"location":"resident-guide/basics/8-common-inpt-problems/#hypertension","title":"Hypertension","text":"<ul> <li>Link</li> </ul>"},{"location":"resident-guide/basics/8-common-inpt-problems/#hypotension","title":"Hypotension","text":"<ol> <li>Notify your senior.</li> <li>Start with your ABC\u2019s. Is this person symptomatic (dizzy, chest pain, unconscious...)?</li> <li>See the patient immediately. If unstable, call a Rapid Response or potentially a Code.</li> <li>Get the rest of the vitals. Is there evidence of shock (distributive, cardiogenic, hypovolemic)?</li> <li>Make sure the blood pressure is real (if the patient is stable). Measure it yourself with a manual cuff. Make sure all vitals are current.</li> <li>Is this patient\u2019s blood pressure always 80/40 and they feel fine (you will probably see this on the cardiology service)?</li> <li>Calculate the MAP: MAP &lt;60 is associated with decreased perfusion to vital organs.</li> <li>Determine what your IV access is: Make sure there are two large bore IV\u2019s and start Normal Saline wide open while you are thinking, unless the patient is in cardiogenic shock.</li> </ol>"},{"location":"resident-guide/basics/9-licensing/","title":"Licensing","text":""},{"location":"resident-guide/basics/9-licensing/#pgy-2s","title":"PGY-2s","text":"<ul> <li>Doctors of Osteopathic Medicine (DO)s<ul> <li>Yearly educational licensing is required through the WV DO Board unless you obtain your full WV license</li> <li>Full licensure is renewed every two years<ul> <li>After your PGY-1 year you are eligible to obtain your full license</li> <li>The only reason to obtain this full license is for the option to moonlight</li> </ul> </li> <li>The forms needs to apply for full licensure can be found here</li> <li>Identogo<ul> <li>Sign up to have your fingerprints done</li> </ul> </li> <li>*Optional: get passport photos done here as well (will need for later step)</li> <li>Call WVDO Board and tell them to access the PDF for this on their end in a few days</li> <li>COMLEX Board Scores<ul> <li>Are sent electronically (even though it says by mail on the NBOME website)</li> <li>Call WVDO Board once they have been sent and tell them to search for the PDF on their end</li> </ul> </li> </ul> </li> </ul>"},{"location":"resident-guide/basics/9-licensing/#pgy-3s","title":"PGY-3s","text":"<ul> <li>Your license will expire. You will need to renew this<ul> <li>Make sure to get your 32 CME hours prior to June</li> </ul> </li> </ul>"},{"location":"resident-guide/blog/","title":"Blog","text":""},{"location":"resident-guide/blog/2024/08/28/blog-support-just-landed/","title":"Blog support just landed","text":"<p>Hey there!</p>"},{"location":"resident-guide/efficiency/3-staying-organized/","title":"Staying Organized","text":"<p>'\u201cDon\u2019t play mind checkers with me, man, I\u2019m not in the mood\u201d'</p> <ul> <li>This section isn't required, just ways I try to keep myself organized<ul> <li>Always write down the Vitals in addition to any pertinent other labs such as BNP</li> <li>Print off the \"Provider Handoff\" with your patients selected as found in the menu bar at the top of Cerner</li> </ul> </li> <li>\u201cLab\u201d System<ul> <li>System for keeping track of labs/changes/trends </li> </ul> </li> </ul> <p> </p> <p> </p> <ul> <li>\u201cBox\u201d System<ul> <li>Written on the backside of the list or on the right side of the Provider Handoff<ul> <li>Marked out = Done</li> <li>Half mark = In progress or half done</li> <li>No mark = Not Done </li> </ul> </li> </ul> </li> </ul> <p> </p>"},{"location":"resident-guide/efficiency/cernerhelp/","title":"Cerner","text":"<p>2.1. Dotphrases 2.2. Cerner Shortcuts</p> <ul> <li>Cerner is an EMR<ul> <li>Useful, but dumb at the same time</li> </ul> </li> <li>Computers are very good at large computations and repetition<ul> <li>They are terrible at complex task or ones that have multiple variables<ul> <li>You must use this to your advantage<ul> <li>We as humans are pretty good at multivariable problems and having a device to do our repetitive tasks leave us more time to think about complicated problems</li> <li>Don't be like computers, be smart and use dictation, dotphrases, and favorites</li> </ul> </li> </ul> </li> </ul> </li> <li>This being said, Cerner is extra stupid. I've attached a few modules on how to make Cerner \"smarter\" and work more efficiently for YOU</li> </ul>"},{"location":"resident-guide/efficiency/cernerhelp/#proxy","title":"Proxy","text":"<ul> <li>CERNER Proxy Set Up Instructions<ul> <li>In order to provide safe and appropriate patient care, as well as to be fair to your fellow residents on Charts, it is imperative that all residents maintain proxy coverage for their CERNER Message Center during vacations and/or leave.</li> <li>Prior to vacation approval, resident coverage must be arranged as indicated on your Internal Medicine Time Off Request Form which is signed by the covering resident and submitted beforehand.  Every resident is responsible for assigning proxy access within CERNER to whomever is providing coverage: this should be done no later than the day prior to vacation week/away rotation.  <ul> <li>Additionally, if you are the covering resident who has signed the IMTO Request Form you are responsible for remembering to cover and obtain proxy access as well.  Of note, if it is decided later you are no longer able to cover (i.e. requested vacation same week at later time), the covering resident is responsible for finding coverage for both residents.  </li> </ul> </li> <li>Included here is a tutorial link, only 2 minutes long, on how to assign proxy within CERNER Message Center. Tutorial</li> <li>If you experience any difficulty assigning proxy access, please reach out to fellow residents or clinic chief prior to departing on vacation.  </li> <li>Any deficiencies during the vacation/leave time period has potential to apply to either or both residents depending on circumstance.</li> <li>Click this tab routinely (it will not change appearance to alert you for any new messages) </li> </ul> </li> <li>Frozen Screen<ul> <li>If you're experiencing a frozen screen, try the below </li> </ul> </li> </ul>"},{"location":"resident-guide/efficiency/dotphrases/","title":"Dotphrases","text":"<ul> <li>Dotphrases are autotext commands you can use to quickly insert text or data.</li> <li>Data can be imported from the chart in the form of \"Tokens\" or \"Smart Templates\"</li> <li>I will denote these with { } in this guide. Typing the text between these will not work. You must select the appropriate token</li> <li>If used correctly, they can literally save your life (and maybe your patient's)</li> <li>In the menu bar, find the \"Auto Text Copy Utility\"</li> <li>Search \"Straley, James\" on the left hand side</li> <li>Copy the following dotphrases but rename them with your own initials<ul> <li>Ex. For Dr. Ball, he could name them any one of the following ways:</li> <li>.abappointment</li> <li>/docsabappointment</li> </ul> </li> </ul>"},{"location":"resident-guide/efficiency/dotphrases/#diabetes","title":"Diabetes","text":""},{"location":"resident-guide/efficiency/dotphrases/#diabetesplan_inpatient","title":".diabetesplan_inpatient","text":"<pre><code>- Home regimen: [insert medications, insulin #U &amp; frequency].\n- A1c: \n- [Well controlled currently.]\n- Holding home meds.\n- Currently NPO.\n- Plan: [Will start SSI, Moderate Correction factor.]\n</code></pre>"},{"location":"resident-guide/efficiency/dotphrases/#diabetesplan_outpatient","title":".diabetesplan_outpatient","text":"<pre><code>- With complications: [Microalbuminuria, CKD, ulcers, retinopathy, recurrent infections]\n- Current regimen: [insert medications, insulin #U &amp; frequency]\n- Most recent A1c: [value &amp; date, controlled/uncontrolled]\n- Last ophthalmology/retinal exam: [date]\n- Last foot exam/podiatrist appt: [date]\n- Currently well controlled on current regimen.\n- Plan: [Continue current regimen]\n</code></pre>"},{"location":"resident-guide/efficiency/dotphrases/#heart-failure","title":"Heart Failure","text":""},{"location":"resident-guide/efficiency/dotphrases/#aechf","title":".aechf","text":"<pre><code>- History of [HFrEF] w/LVEF [ ] on TTE: [ ].\n- Home Regimen: [Current medical therapy].\n- Evidence of acute exacerbation with [ ]\n- [No obvious inciting incident, mild trop leak with AKI that improved with diuresis suggestive of cardiorenal process].\n- No adherence issues suspected, consider gut wall edema with poor absorption to be reason for readmission.\n- Admit to medicine service to intermediate care given risk of decompensation in the setting of known heart failure.\n- Obtain new TTE to r/o new structural cause.\n- [Holding GDMT].\n- Lasix 40mg IV qAM, prn qPM depending on UOP. Goal UOP &gt;300cc out @ 2h.\n- Monitor I/Os, Obtain daily standing weights.\n- Restrict fluid intake to &lt;2L daily.\n- Repeat BMP and Mg in the morning.\n- CHF powerplan in, will need close f/u with CHF clinic once outpatient.\n</code></pre>"},{"location":"resident-guide/efficiency/dotphrases/#heartfailure","title":".heartfailure","text":"<pre><code>- NYHA Class [ ] ACC/AHA Stage [ ] [HFrEF] w/LVEF [ ] on TTE: [ ].\n- Current Regimen: [Current medical therapy].\n- [Continue current regimen].\n</code></pre>"},{"location":"resident-guide/efficiency/dotphrases/#aki","title":"AKI","text":""},{"location":"resident-guide/efficiency/dotphrases/#aki_1","title":".aki","text":"<pre><code>- [Non-Oliguric] Stage [ ] AKI w/o underlying CKD with baseline creatinine of [ ].\n- [Likely 2/2 ATN]\n- [Creatinine improved today to]\n- [Plan to monitor I/Os. Will repeat labs in the morning for change.]\n</code></pre>"},{"location":"resident-guide/efficiency/dotphrases/#aki2ckd","title":".aki2ckd","text":"<pre><code>- [Non-Oliguric] Stage [ ] AKI on CKD Stage [III] with baseline creatinine of [ ].\n- [Pt follows w/ ]\n- [Plan for ]\n</code></pre>"},{"location":"resident-guide/efficiency/dotphrases/#ckd","title":".ckd","text":"<pre><code>- [Non-Oliguric] CKD Stage [ ] with baseline creatinine of [ ].\n- Additional co-morbidities: [T2DM/HTN]\n- Pt follows w/ [ ].\n- Plan to monitor electrolytes closely, renal diet, avoid volume overload.\n- Will get Urine Microalbumin/Cr Ratio, Urine Protein/Cr Ratio, Vitamin D, Iron w/Ferritin, PTH, and Phosphorous next visit.\n</code></pre>"},{"location":"resident-guide/efficiency/dotphrases/#anemia","title":"Anemia","text":""},{"location":"resident-guide/efficiency/dotphrases/#anemia_1","title":".anemia","text":"<pre><code>- [Acute/Chronic] [Normocytic/Macrocytic/Microcytic] Anemia w/baseline hemoglobin of [ ].\n- No overt signs of bleeding on exam.\n- Will workup with LDH, RC, Peripheral Smear.\n</code></pre>"},{"location":"resident-guide/efficiency/dotphrases/#cad","title":"CAD","text":""},{"location":"resident-guide/efficiency/dotphrases/#cad_1","title":".cad","text":"<pre><code>- Primary Cardiologist: [ ].\n- History of CAD as seen on [CT/Cath], [without] previous intervention, currently [asymptomatic.]\n- Last imaging/testing: [ ].\n- EKG: [No current evidence of ischemia.]\n- Currently on: [All should be on statin, RR of death decreased by 24%, stroke by 31%, need for CABG/Angioplasty by 27%; ASA for secondary prevention, increased risk of thromboembolic events if stopped, 70% within 7-10 days]\n- Discussed risk factor modification as tolerable (HTN, HLD, Smoking, Diabetes).\n</code></pre>"},{"location":"resident-guide/efficiency/dotphrases/#clinic","title":"Clinic","text":""},{"location":"resident-guide/efficiency/dotphrases/#clinic_plan_fu","title":".clinic_plan_f/u","text":"<pre><code>Follow-up Appointment in: [3 months for ][ ]\nInterval Items: [Outpatient Ultrasound]\nNext visit: [CBC/CMP]\n\n*********** End of Note ***********\n\n- First Last Name, MD/DO, IM PGY - 1/2/3 -\n\n**** Attending addenda to follow ****\n</code></pre>"},{"location":"resident-guide/efficiency/dotphrases/#copd","title":"COPD","text":""},{"location":"resident-guide/efficiency/dotphrases/#copd_outpatient","title":".copd_outpatient","text":"<pre><code>- COPD not on home oxygen, follows w/Dr. [ ] outpatient.\n- Continues to smoke 15 cigarettes/day.\n- On Symbicort, Spiriva.\n- LDCT will be ordered for January, previously [normal].\n- [No] interest in smoking cessation at this time.\n- Continue home inhalers.\n</code></pre>"},{"location":"resident-guide/efficiency/dotphrases/#discharge-instructions","title":"Discharge Instructions","text":""},{"location":"resident-guide/efficiency/dotphrases/#dischargeinstructions_hf","title":".dischargeinstructions_hf","text":"<pre><code>- 1) You were admitted to the hospital for: Exacerbation of Heart Failure\n- 2) What was done during your admission:\n- 3) What you need to do:\n      - Please follow up with your PCP within 1 week of discharge.\n      - Please follow-up with specialists as listed above.\n      - Please take your medications as instructed above.\n      - Return to the Emergency Room if you experience:\n                - New or worsening chest pain\n                - Shortness of breath, increased leg swelling\n                - Dizziness, seizures, or loss of consciousness\n- 4) Why it is important:\n      - [ ]\n- 5) Additional Instructions\n      - Low salt, low cholesterol/fat diet, and restrict fluid intake as directed by your doctor.\n      - Gradually increase your activity, as tolerable; schedule rest breaks as needed.\n      - Weigh yourself daily on same scale in the morning; bring your weight record to your follow-up appointment.\n      - If you gain 2 or more pounds in one day or 5 or more pounds in one week, return to the hospital.\n</code></pre>"},{"location":"resident-guide/efficiency/dotphrases/#dischargeinstructions_stent","title":".dischargeinstructions_stent","text":"<pre><code>- 1) You were admitted to the hospital for: Heart Attack/Stent Placement.\n- 2) What was done during your admission:\n- 3) What you need to do:\n      - Please follow up with your PCP within 1 week of discharge.\n      - Please follow-up with specialists as listed above.\n      - Take your aspirin and antiplatelet (Plavix, Brilinta, Effient) every day, without missing any doses.\n      - Return to the Emergency Room if you experience:\n                - New or worsening chest pain\n                - Shortness of breath, increased leg swelling\n                - Dizziness, seizures, or loss of consciousness\n- 4) Why it is important:\n      - Taking your Antiplatelet and Aspirin keep your stent open.\n      - If you have any trouble getting your medicine, please call cardiology office.\n- 5) Additional Instructions\n      - No lifting over 10lbs x 10 days. No driving x 3 days.\n      - No tubs baths, swimming pools, or hot tubs x 7 days. OK to shower.\n      - If you notice any bleeding from the cath site, hold pressure above the site and call 911.\n      - Gradually increase your activity, as tolerable; schedule rest breaks as needed.\n      - Weigh yourself daily on same scale in the morning; bring your weight record to your follow-up appointment.\n      - If you gain 2 or more pounds in one day or 5 or more pounds in one week, return to the hospital.\n</code></pre>"},{"location":"resident-guide/efficiency/dotphrases/#ed","title":"ED","text":""},{"location":"resident-guide/efficiency/dotphrases/#edchestpain","title":".edchestpain","text":"<pre><code>Acute coronary syndrome: No symptoms suggestive of acute coronary syndrome such as radiation of pain, associated diaphoresis, nausea, vomiting, or shortness of breath. Pulmonary embolism: No recent immobilization or surgery, no leg pain/swelling, no history of venous thromboembolic disease, pain is non-pleuritic and not associated with hemoptysis. Aortic dissection: No sudden onset of severe pain, no history of connective tissue disorder, no pulse deficits or blood pressure differentials. Pneumothorax: No sudden onset of dyspnea, no history of trauma, no decreased breath sounds on examination. Esophageal rupture: No history of severe vomiting, no subcutaneous emphysema on examination. Cardiac tamponade: No hypotension, no jugular venous distension, no muffled heart sounds.\n</code></pre>"},{"location":"resident-guide/efficiency/dotphrases/#edlegswelling","title":".edlegswelling","text":"<pre><code>Key diagnoses considered for leg swelling include deep vein thrombosis (DVT), cellulitis, congestive heart failure (CHF), and lymphedema. DVT is less likely given the absence of recent immobilization or surgery, no history of venous thromboembolic disease, and no associated pain or tenderness. Cellulitis is less likely given the absence of skin warmth, erythema, or tenderness. CHF is less likely given the absence of associated symptoms such as dyspnea, orthopnea, or paroxysmal nocturnal dyspnea. Lymphedema is less likely given the absence of chronicity, non-pitting nature of the swelling, and absence of associated skin changes.\n</code></pre>"},{"location":"resident-guide/efficiency/dotphrases/#edsob","title":".edsob","text":"<pre><code>Considered life-threatening diagnoses for shortness of breath: Acute coronary syndrome - no chest pain, no radiation, no associated symptoms suggestive of ACS. Pulmonary embolism - no recent immobilization or surgery, no leg pain/swelling, no history of venous thromboembolic disease, no hemoptysis. Pneumothorax - no sudden onset, no pleuritic chest pain, no history of trauma. Acute heart failure - no orthopnea, no paroxysmal nocturnal dyspnea, no leg swelling. Acute severe asthma/COPD exacerbation - no wheezing, no history of obstructive lung disease. Tension pneumothorax - no trauma, no severe or worsening dyspnea, no tracheal deviation. Anaphylaxis - no rash, no facial swelling, no recent exposure to allergens.\n</code></pre>"},{"location":"resident-guide/efficiency/dotphrases/#gerd","title":"GERD","text":""},{"location":"resident-guide/efficiency/dotphrases/#gerd_plan","title":".gerd_plan","text":"<pre><code>- No alarm features present.\n- Will evaluate for H Pylori with stool antigen test (must be off PPI prior to testing) given that dyspepsia is predominant symptom.\n- Intermittent symptoms: Antacids or H2 blocker\n- If persistent symptoms despite lifestyle modifications, will trial PPI.\n- Daily symptoms: Omeprazole, Esomeprazole, Pantoprazole 8 week trial, taken 30-60 minutes before meal (dosing: omeprazole 10mg once daily, can increase to 20mg daily in 4-8 weeks; pantoprazole 20mg once daily, can increase to 40mg daily in 4-8 weeks. Advise lowest effective dose)\n- Advised lifestyle modifications including avoidance of smoking, drinking, specific triggering foods, weight loss, avoiding NSAIDS, and avoiding lying down for 2-3 hours after eating.\n</code></pre>"},{"location":"resident-guide/efficiency/dotphrases/#hypertension","title":"Hypertension","text":""},{"location":"resident-guide/efficiency/dotphrases/#htn_outpatient","title":".htn_outpatient","text":"<pre><code>- Patient [has] BP cuff at home, checks BP [daily].\n- Compliant with current regimen of: [Amlodipine 10mg daily.]\n- Goal BP &lt; [120/80, 130/80, 140/90], currently [uncontrolled/controlled].\n- Plan: [ ]\n- Pt educated on lowering salt intake, weight loss, and increasing exercise.\n</code></pre>"},{"location":"resident-guide/efficiency/dotphrases/#inr-clinic","title":"INR Clinic","text":""},{"location":"resident-guide/efficiency/dotphrases/#inr_plan","title":".inr_plan","text":"<pre><code>- Indication: [Mechanical Aortic Valve].\n- Goal INR: [2.5-3.5].\n- INR &amp; Source (venipuncture): [ ].\n- Daily dose: [4mg and 6mg on alternating days].\n- Total weekly dose: [35mg average per week].\n- Next INR: [1 week].\n- Plan: [Will decrease to MF 6mg, remaining days 4mg for a total of 32mg weekly. Pt provided extensive education on compliance with INRs w/Jodie prior to appointment today].\n</code></pre>"},{"location":"resident-guide/efficiency/dotphrases/#physical-exam","title":"Physical Exam","text":""},{"location":"resident-guide/efficiency/dotphrases/#pe_quick","title":".pe_quick","text":"<pre><code>Constitutional: Alert, no acute distress, appears stated age\nEye: Normal conjunctiva, without scleral icterus\nHENT: Atraumatic, hearing grossly intact, without nasal discharge, moist oral mucosa, grossly average neck circumference\nResp: Clear to auscultation bilaterally, non-labored respiration on room air, without rales/rhonchi, without wheezing\nCV: Normal rate, regular rhythm, without murmurs on auscultation\nGI: Soft, non-tender, non-distended, without obvious masses, w/o rigidity or guarding\nMSK: Extremities non-tender to palpation, without LE edema bilaterally\nSkin: Skin is warm, dry, and pale\nHeme/Lymph/Imm: Without obvious bleeding, without significant bruising\nPsychiatric: Cooperative, appropriate mood and affect, normal judgement\nNeurologic: Awake and oriented X4\n</code></pre>"},{"location":"resident-guide/efficiency/dotphrases/#obesity","title":"Obesity","text":""},{"location":"resident-guide/efficiency/dotphrases/#obesity_outpatient","title":".obesity_outpatient","text":"<pre><code>- Body Mass Index Measured: [ ] kg/m2.\n- Class [III] Obesity w/BMI of [ ].\n- Counseled patient on increasing exercise to at least 150 minutes weekly, improving diet with increased vegetables/fruits, and decreasing total calorie by 500-750 kcal/day.\n- Pt not currently interested GLP-1s for weight loss, will re-address next visit.\n- Would like to be referred to bariatric center for her weight.\n- Previously trialed Ozempic but feels she did not lose any weight, made her feel unwell.\n- Referral sent.\n</code></pre>"},{"location":"resident-guide/efficiency/dotphrases/#ros","title":"ROS","text":""},{"location":"resident-guide/efficiency/dotphrases/#ros_quick","title":".ros_quick","text":"<pre><code>Constitutional: Denies fever, chills, fatigue\nHEENT: Denies trauma, headache, dizziness\nResp: Denies shortness of breath, cough, sputum production, wheezing, labored breathing, dyspnea on exertion, orthopnea\nCV: Denies chest pain, palpitations, peripheral edema, syncope\nGI: Denies nausea, vomiting, abdominal pain, diarrhea, constipation\nGU: Denies dysuria, discharge, change in frequency\nEndo: Denies polydipsia, polyuria\nMSK: Denies back pain, neck pain, joint pain, muscle pain\nIntegumentary: Denies dryness, itching, rash\nNeuro: Denies numbness, tingling, weakness, LOC\nHeme: Denies history of excessive bleeding, bruising\nPsych: Denies anxiety, problems sleeping\n</code></pre>"},{"location":"resident-guide/efficiency/dotphrases/#syncope","title":"Syncope","text":""},{"location":"resident-guide/efficiency/dotphrases/#syncope_1","title":".syncope","text":"<pre><code>- Suspected to be [Orthostatic] syncope due to [Prodrome], [Clean] EKG, [w/] RF present.\n- Low suspicion for PE (if able, PERC rule[ ])\n- Orthostatic Vital Signs: [ ]\n- CTH: [ ]\n- Admit to Telemetry to monitor for arrhythmia.\n- Continue conservative measures.\n</code></pre>"},{"location":"resident-guide/efficiency/dotphrases/#under-construction","title":"Under Construction","text":"<ol> <li>.jsappointment</li> <li>.jsclinic_header</li> <li>.jscodenote</li> <li>.jscodestatus</li> <li>.jsconsult_orders</li> <li>.jscontrolrx_hpi</li> <li>.jscontrolrx_plan</li> <li>.jsdeathpronouncement</li> <li>.jsdiabetes_insulintitration</li> <li>.jsdiabeteslabs</li> <li>.jsdischarge_dates</li> <li>.jsdischargeQIPS</li> <li>.jsimaging_radiology_report</li> <li>.jsmedicareAWV</li> <li>.jspcp</li> <li>.jsphonemsg</li> <li>.jsprevent_female</li> <li>.jsprevent_male</li> <li>.jsproblembased</li> <li>.jsssi</li> <li>.jstcm</li> <li>.jstelevisitaudio</li> <li>.jstelevisitvideo</li> <li>.jstransfusions</li> <li>.jsventsettingsonly</li> </ol>"},{"location":"resident-guide/efficiency/how-to-search-more-effectively/","title":"How to Search More Effectively Online","text":"","tags":["Search"]},{"location":"resident-guide/efficiency/how-to-search-more-effectively/#how-to-search-efficiently-online","title":"How to Search Efficiently Online","text":"<p>Here's a guide that showcase many useful search operators that you can use to search things online more efficiently.</p>","tags":["Search"]},{"location":"resident-guide/efficiency/how-to-search-more-effectively/#exclude-a-term-from-your-search","title":"Exclude a Term From Your Search","text":"<p>Add a <code>-</code> before the word to exclude.</p> <pre><code>dolphins -football\n</code></pre> <p>You'll get animals, not a football team.</p>","tags":["Search"]},{"location":"resident-guide/efficiency/how-to-search-more-effectively/#if-you-want-synonyms-in-the-result","title":"If You Want Synonyms in the Result","text":"<p>Add a <code>~</code> before the word if you want synonyms.</p> <pre><code>music ~classes\n</code></pre> <p>Here you'll get music classes, lessons, coaching, etc.</p>","tags":["Search"]},{"location":"resident-guide/efficiency/how-to-search-more-effectively/#search-within-a-specific-website","title":"Search Within a Specific Website","text":"<p>How to search inside a specific website \u2192 <code>site:</code>reddit.com</p> <pre><code>How to do that site:reddit.com\n</code></pre>","tags":["Search"]},{"location":"resident-guide/efficiency/how-to-search-more-effectively/#or-and","title":"Or and |","text":"<p>How to use OR while searching ? \u2192 <code>OR</code> or <code>|</code></p> <pre><code>Netflix | Prime &lt;=&gt; Netflix OR Prime\n</code></pre>","tags":["Search"]},{"location":"resident-guide/efficiency/how-to-search-more-effectively/#search-within-two-number-ranges","title":"Search Within Two Number Ranges","text":"<p>How to search within a range ? \u2192 <code>1993..2000</code></p> <pre><code>Movies 1993..2000\n</code></pre>","tags":["Search"]},{"location":"resident-guide/efficiency/how-to-search-more-effectively/#find-news-related-to-a-particular-location","title":"Find News Related to a Particular Location","text":"<p>How to search inside a specific location only ? \u2192 <code>location:</code>Charleston</p> <pre><code>Weather alert location:Charleston\n</code></pre>","tags":["Search"]},{"location":"resident-guide/efficiency/how-to-search-more-effectively/#filter-by-file-type","title":"Filter by File Type","text":"<p>How to search for a specific filetype ? \u2192 <code>filetype:</code>pdf</p> <pre><code>ACC Heart Failure Guidelines filetype:pdf\n</code></pre>","tags":["Search"]},{"location":"resident-guide/efficiency/how-to-search-more-effectively/#searching-for-exact-words","title":"Searching for Exact Words","text":"<p>How to search for instances of a word? \u2192 <code>\"word\"</code></p> <pre><code>\"Tom Brady\" football player\n</code></pre> <p>Gives you the results with the full name exactly as is, not just the first or last one.</p>","tags":["Search"]},{"location":"resident-guide/efficiency/how-to-search-more-effectively/#eliminate-sites-that-flood-the-results","title":"Eliminate Sites That Flood the Results","text":"<p>Want to get rid of sites that flood the results? \u2192 <code>-site:</code>pinterest.*</p> <pre><code>-site:pinterest.*\n</code></pre> <p>No results should have pinterest in the domain name. Does not exclude sites that include pinterest in the their name</p>","tags":["Search"]},{"location":"resident-guide/efficiency/important-websites/","title":"Important Websites","text":"AMION <p>                     - \u201cAM\u201d-\u201cI\u201d-\u201cON\u201d, like am I on shift?                     - Use: Resident Schedule                     - Can be used to see who is on call, who is on nights, etc.                     - Can be downloaded and synced: follow link                     - Tutorial: Finding Your Schedule on AMION                     - Password (case sensitive): wvu CAMC                     </p> AMS Connect <p>                     - Purpose: HIPPA Complaint Messaging System                     - Download the AMSConnect App from the app store                     - AMS will Email you a link to activate your account                         - Set your password, agree to the terms of service                     - Sign into the app on your phone                     - See the AMSConnect Quick Start Guide for more information                     </p> CSAPP/RxDataTrack/WV Board of Pharmacy <p>                     - Purpose: Controlled Substance Monitoring Program                     - Tutorial: Accessing WV Board of Pharmacy </p> DAVE (Database Application for Vital Events) System <p>                     - Purpose: Death Pronouncement                     - Tutorial </p> Excel Teams <p>                     - Requires login information                     - Purpose: Handoff Lists, Continuity of care </p>                  GoodRx                  <p>                     - Just download the App phone app for Providers </p> EMCRIT - Internet Book of Critical Care (IBCC) <p>                     - Use: Critical Care/EM notes </p> MDCalc <p>                     - Many useful calculators </p> New Innovations <p>                     - Use: Onboarding Material Location, Login for Morning Report and Noon Didactics, Logging Duty Hours and Procedures, Evaluations                     - Tutorial: Logging Duty Hours on New Innovation </p> Outlook <p>                     - Email, requires login information                      - Tutorial: Microsoft Office/Outlook/OneDrive/SharePoint </p> OneDrive <p>                     - Calendar, SharePoint, Microsoft Office (Microsoft Word, Microsoft PowerPoint, Microsoft Excel)                     - Tutorial: Microsoft Office/Outlook/OneDrive/SharePoint </p>                  Supplementary Resources                  <p>                     - Podcasts                         - The Curbsiders Internal Medicine                         - Louisville Lectures (IM Lecture Series)                         - Core IM                     - Blogs                         - Newyorker.com by Atul Gawande                         - Medrants.com                         - Pbfluids.com </p> UpToDate <p>                 - Purpose: Looking stuff up (I hate it but its most people's go to resource)                     </p> WV DUO <p>                     - Super Important                     - Purpose: Dual Authentication Service for Prescriptions                     - See: Onboarding -&gt; Duo Enrollment &amp; New Hire Paperwork </p> WVU Library <p>                     - MAIN LIBRARY LINK                     - Annals of Internal Medicine                     - Clinical Key                         - ^^ Go to \u201cBooks\u201d to see books we have access to                     - Harrison\u2019s                     - New England Journal of Medicine                     - Procedures Consult                     - Pubmed                     - Visual DX                     - WVU PASSWORD RESET LINK                         - Your password expires often, use this link to reset your password </p> WVU Medicine <p>                     - Purpose: WVU account                     - Click the link, \u201cClaim Account\u201d and follow the instructions. </p> WV Health Information Network (WVHIN) <p>                     - Use: See hospital records from participating facilities around WV                     - Email: info@wvhin.org                     - Title: WVHIN Access                         - Ex. \u201cTo whom this may concern, I am a resident physician at CAMC and I am requesting access to the WVHIN\u201d                     - You will be sent a link in the next 24-72 hours. Follow said link and you\u2019ll be granted access within the next few days after that. </p> Zoom <p>                     - Link if you are unable to attend in person                     - Meeting ID: 768 440 2271 </p>"},{"location":"resident-guide/efficiency/shortcuts/","title":"Shortcuts","text":""},{"location":"resident-guide/efficiency/shortcuts/#keyboard-shortcuts-for-windows","title":"Keyboard Shortcuts (for windows)","text":"<ul> <li>Copy: ctrl+c</li> <li>Paste: ctrl+p</li> <li>Cut: ctrl+x</li> <li>Undo: ctrl+z</li> <li>Redo: ctrl+y</li> </ul>"},{"location":"resident-guide/efficiency/shortcuts/#favorite-orders","title":"Favorite Orders","text":"<p>Huge time saver if you know how to structure them</p> <ul> <li>First start in Orders and right click on the yellow favorites star</li> <li>Select organize favorites </li> </ul> <p> </p> <ul> <li>Create a new folder called \u201cHome\u201d and then close this sub-window </li> </ul> <p> </p> <ul> <li>Click the yellow favorites star. Right click on the new home folder you just made and \u201cset as home folder\u201d</li> </ul> <p> </p> <ul> <li>Now, type in the orders box and find \u201cCBC w/diff AM Draw (Inpatient Only).\u201d Right click on the lab in the order confirmation screen and \u201cAdd to favorites\u201d</li> </ul> <p> </p> <ul> <li>The Screen below should pop up. Save this lab in a New Folder called \"AM Labs\"</li> </ul> <p> </p> <ul> <li>Now do this with all the labs below.</li> </ul> <p> </p> <ul> <li>Now, any time you open your orders, these labs will be the first thing that pop up saving you multiple clicks per day.</li> <li>This can be utilized to save almost anything, from powerplans to specific orders/medications.</li> </ul>"},{"location":"resident-guide/efficiency/shortcuts/#signing-documentsattending-names","title":"Signing Documents/Attending Names","text":"<ul> <li>If you can't find your physician's name (like how there are 2 David Adkins), you can select the \"Recent\" tab as shown below and their name should be there (See the blue check?). </li> </ul>"},{"location":"resident-guide/softskills/","title":"Soft Skills in Medicine","text":"","tags":["Soft Skills"]},{"location":"resident-guide/softskills/#1-communication","title":"1. Communication","text":"<ul> <li>Verbal Communication: Clear, concise, and empathetic communication with patients, families, and colleagues.</li> <li>Listening: Actively listening to patients and colleagues to understand concerns and provide appropriate care.</li> <li>Non-Verbal Communication: Using body language, facial expressions, and tone to convey empathy and understanding.</li> <li>Providing Effective Feedback</li> <li>Utilizing Received Feedback</li> </ul>","tags":["Soft Skills"]},{"location":"resident-guide/softskills/#2-empathy","title":"2. Empathy","text":"<ul> <li>Patient-Centered Care: Understanding and responding to the emotions and concerns of patients.</li> <li>Compassion: Demonstrating genuine care and concern for patients\u2019 well-being.</li> </ul>","tags":["Soft Skills"]},{"location":"resident-guide/softskills/#3-teamwork-and-collaboration","title":"3. Teamwork and Collaboration","text":"<ul> <li>Interdisciplinary Collaboration: Working effectively with other healthcare professionals to provide comprehensive care.</li> <li>Flexibility: Adapting to different roles within a team and contributing to the team\u2019s goals.</li> </ul>","tags":["Soft Skills"]},{"location":"resident-guide/softskills/#4-problem-solving","title":"4. Problem-Solving","text":"<ul> <li>Critical Thinking: Analyzing situations quickly and making informed decisions in high-pressure environments.</li> <li>Resourcefulness: Finding innovative solutions to complex medical and logistical challenges.</li> </ul>","tags":["Soft Skills"]},{"location":"resident-guide/softskills/#5-adaptability","title":"5. Adaptability","text":"<ul> <li>Flexibility: Adjusting to changes in patient needs, treatment plans, and healthcare environments.</li> <li>Resilience: Handling stress and recovering from setbacks in a demanding field.</li> </ul>","tags":["Soft Skills"]},{"location":"resident-guide/softskills/#6-time-management","title":"6. Time Management","text":"<ul> <li>Prioritization: Effectively managing time to prioritize patient care and administrative tasks.</li> <li>Keeping effective and useful notes.</li> <li>Efficiency: Balancing multiple responsibilities without compromising the quality of care.</li> </ul>","tags":["Soft Skills"]},{"location":"resident-guide/softskills/#7-leadership","title":"7. Leadership","text":"<ul> <li>Guidance: Leading a medical team or project, providing direction, and motivating others.</li> <li>Decision-Making: Taking responsibility for critical decisions and leading by example.</li> </ul>","tags":["Soft Skills"]},{"location":"resident-guide/softskills/#8-cultural-competence","title":"8. Cultural Competence","text":"<ul> <li>Awareness: Understanding and respecting diverse cultural backgrounds and practices.</li> <li>Inclusion: Providing care that is sensitive to the cultural needs and preferences of patients.</li> </ul>","tags":["Soft Skills"]},{"location":"resident-guide/softskills/#9-emotional-intelligence","title":"9. Emotional Intelligence","text":"<ul> <li>Self-Awareness: Recognizing your own emotions and how they affect your behavior and decision-making.</li> <li>Social Awareness: Understanding and managing the emotions of others, especially in stressful situations.</li> </ul>","tags":["Soft Skills"]},{"location":"resident-guide/softskills/#10-ethical-judgment","title":"10.  Ethical Judgment","text":"<ul> <li>Integrity: Adhering to ethical principles and standards in patient care and professional conduct.</li> <li>Confidentiality: Protecting patient privacy and handling sensitive information with discretion.</li> </ul>","tags":["Soft Skills"]},{"location":"resident-guide/softskills/#11-professionalism","title":"11.  Professionalism","text":"<ul> <li>Reliability: Being dependable and consistent in fulfilling your duties.</li> <li>Respect: Treating patients, families, and colleagues with respect and dignity.</li> </ul>","tags":["Soft Skills"]},{"location":"resident-guide/softskills/#12-conflict-resolution","title":"12.  Conflict Resolution","text":"<ul> <li>Mediation: Addressing and resolving conflicts within the healthcare team or with patients in a constructive manner.</li> <li>Negotiation: Finding mutually beneficial solutions to disagreements.</li> </ul>","tags":["Soft Skills"]},{"location":"resident-guide/softskills/#13-teaching-and-mentorship","title":"13.  Teaching and Mentorship","text":"<ul> <li>Knowledge Sharing: Effectively educating patients, families, and junior colleagues.</li> <li>Mentorship: Guiding and supporting the development of others in the medical field.</li> </ul>","tags":["Soft Skills"]},{"location":"resident-guide/softskills/#resources","title":"Resources","text":"<p>University of Arizona Johns Hopkins Medicine Faculty Development</p>","tags":["Soft Skills"]},{"location":"resident-guide/softskills/effectivefeedback/","title":"Effective Feedback","text":"","tags":["Soft Skills"]},{"location":"resident-guide/softskills/effectivefeedback/#w3-model-for-giving-feedback","title":"W3 Model for Giving Feedback","text":"<ul> <li>Basic (Great for medical students/Interns/problems on the fly)</li> <li>W1: What worked well?</li> <li>W2: What did not work well?</li> <li>W3: What could be done differently next time?</li> </ul>","tags":["Soft Skills"]},{"location":"resident-guide/softskills/effectivefeedback/#hopkins-model-for-feedback","title":"Hopkins Model for Feedback","text":"<p>Johns Hopkins Guide PDF</p>","tags":["Soft Skills"]},{"location":"resident-guide/softskills/feedbacktemplates/","title":"Templates for Feedback","text":"","tags":["Soft Skills"]},{"location":"resident-guide/softskills/feedbacktemplates/#general","title":"General","text":"<ul> <li>For full disclosure, some of these are feedback templates are about me, have been used by me, or have been found on the internet. Please use your best judgement when utilizing these templates. Effective and actionable feedback is crucial to learning.</li> <li>My general scale: \u201cexceptional,\u201d \u201coutstanding,\u201d \u201cexcellent,\u201d or \u201cgood,\u201d based on their clinical performance, scholarship, and extracurricular contributions<ul> <li>Exceptional (Well Above expectations): Superb clinical performance plus extraordinary scholarly/extracurricular contributions.</li> <li>Outstanding (At or Above expectations): Superb clinical performance plus significant scholarly/extracurricular contributions.</li> <li>Excellent (Meeting expectations): Proficient clinical performance plus significant scholarly/extracurricular contributions.</li> <li>Good (Room for improvement): Proficient clinical performance without significant scholarly/extracurricular contributions.</li> <li>Poor (Significant Improvement Needed)</li> </ul> </li> </ul>","tags":["Soft Skills"]},{"location":"resident-guide/softskills/feedbacktemplates/#overall-general-template","title":"Overall General Template","text":"<ul> <li>Overall, Dr. [] was exceptional. He/She performed [ well above ] what is expected of a [ middle ]-of-the-year PGY-\u00bd/3.</li> <li>Overall, Dr. [ ] was [ outstanding ]. He/She performed [at or above] what is expected of a [ beginning/middle/end ]-of-the-year PGY-[\u00bd/3].</li> </ul>","tags":["Soft Skills"]},{"location":"resident-guide/softskills/feedbacktemplates/#examples-of-areas-of-improvement","title":"Examples of Areas of Improvement","text":"<ul> <li>I have no significant points of feedback or concern for him/her.</li> <li>As he/she transitions now to the senior role, he/she can improve on delegating tasks to junior residents and sharing some of the responsibilities with his/her co-residents.</li> <li>He/She is working to communicate in ways that project unhurriedness to his/her patients even when busy, and he/she made progress in delegating tasks effectively. He/She showed good judgment, in only one case requiring more guidance and reinforcement to recognize risk of decompensation.</li> <li>I have no significant points of feedback or concern for him/her.</li> <li>Generally, I think he/she should continue to learn to utilize cerner\u2019s dictation as this will improve his/her efficiency significantly.</li> </ul>","tags":["Soft Skills"]},{"location":"resident-guide/softskills/feedbacktemplates/#exceptional-attending","title":"Exceptional - Attending","text":"<ul> <li>Dr. [ ] is simply aspirational. I've never met a person, in medicine or otherwise, who is so well suited for their job. Not only does he/she consistently go above and beyond to make himself available to help the team, his/her dedication for quality patient care is truly inspiring.</li> <li>He/She leads by example and fosters a warm, engaging, and inclusive learning environment. We're lucky to have him/her here.</li> <li>One of the best attendings I've ever worked with. Has a complex understanding of [ Endocrinology ] and really understands the big picture. Knows when to focus in on a problem or when to zoom out and look at the patient as a whole.</li> <li>Couldn't recommend him/her more. Would pay anything to keep them here at CAMC, but it\u2019s a testament to his/her character that He/She wants to continue to learn even at the attending level.</li> <li>Top tier attending. Always interested in learning and teaching, excellent delivery of complex topics while providing an environment conducive to learning. One of the calmest people i've ever met and it really furthers the team's confidence in his/her management of the critically ill.</li> <li>Top tier attending. Always interested in learning and teaching. He/She makes the whole team want to work harder to be like him/her but does so with a cheerful and approachable demeanor.</li> <li>He/She manages rounds well and is always eager to hear the team's perspective on patient management. One of the calmest attendings i've met and it really furthers the team's confidence in his/her management. I couldn't recommend someone more than I do Dr. [ ].</li> </ul>","tags":["Soft Skills"]},{"location":"resident-guide/softskills/feedbacktemplates/#exceptional-resident-senior","title":"Exceptional - Resident - Senior","text":"<ul> <li>This guy/girl exemplifies the ideal resident and is going to excel in whatever he/she chooses to do. Not only does he/she know the material well, but he/she has an unmatched work ethic.</li> <li>He/She's teachable and it always eager to learn. He/She is very well liked by everyone and communicates with staff better than any of the other residents at any level. I couldn't have asked for a better co-resident to work with.</li> <li>I couldn't recommend someone more than I do [ ]. The way he/she balances work and his/her personal life makes him/her a personal role model of mine. He/She makes the whole team want to work harder to be like him/her but does so with a cheerful and approachable demeanor.</li> <li>Excellent teammate. I really enjoyed working with [ ] because the energy he/she brings to work is fun to be around. He/She is always upbeat, energetic, and willing to help. He/She is hardworking and always willing to stay late if needed to make sure things get done. I think he/she is an excellent resident.</li> </ul>","tags":["Soft Skills"]},{"location":"resident-guide/softskills/feedbacktemplates/#exceptional-medical-student","title":"Exceptional - Medical Student","text":"<ul> <li>[] is well-read, forms meaningful connections with his/her patients, and is always eager to learn on rounds. He/She consistently went beyond the average student to gather data from multiple sources, interpret data, and present it in a way that could be easily understood and used.</li> <li>His/her presentation skills are exemplary and far exceed that of a 3<sup>rd</sup> year medical student. In addition to strong presentation skills and knowledge base, [] is a warm, engaging individual who helps others without hesitation. He/She is exceptionally inclusive, hard-working, and consistently exhibits curiosity and motivation to learn. He/She comes prepared for all types of learning situations, having researched the relevant topics so that he/she can provide quality care and participate to a degree beyond his/her required level.\u00a0I would highly recommend his/her for whichever field he/she chooses.</li> <li>[] demonstrated an exceptional fund of knowledge and he/she applied his/her understanding at the bedside in managing our patients with the level of skill we typically see in a second-year resident.</li> <li>He/She was well prepared with all the information needed to formulate treatment plans and his/her ability to prioritize and integrate bits of evidence into a cohesive and logical story was especially noteworthy. Student also has a sensitive ear for elements that don't fit into the accepted narrative and digs in to uncover the truth when needed. He/She initiated literature searches to supplement his/her understanding and to address questions raised by the team.</li> <li>He/She has a high level of emotional intelligence and this helps his/her connect effectively with a wide variety of patients, and also to function as an outstanding team member. Student was both efficient and thoughtful in his/her management of our inpatients and in the busy clinics. He/She was generous in teaching other students and nurses in a kind, respectful manner. He/She was an eager learner and a quick study with deft technical ability. His/her performance was exemplary.</li> <li>[] was an undeniable asset to our team as a sub-i. His/her enthusiastic and proactive attitude led his/her to engage in many patient care endeavors during his/her rotation, during which he/she proved herself to be a bright, capable and empathetic provider. He/She was always open and seeking feedback, and he/she was quick to incorporate it. His/her presentations on various topics were always well researched, succinct and high yield for all those listening.</li> <li>He/She knew his/her patients well and was always a helpful and pleasant member of the team. For a patient with a complex discharge plan, he/she coordinated with the case manager, family and team members to ensure a safe discharge to home. We were particularly impressed by his/her assessment of a patient's literacy level, and not only accommodating in a very sensitive way by providing more picture-based patient education materials, but also bringing this to the attention of the team. He/She was always advocating for patients and reminding us of our inherent biases and assumptions in caring for and educating patients. He/She will definitely be a strong intern at whatever program is lucky enough to have him/her.</li> <li>[] performed exceptionally well during his/her rotation. His/Her teams universally praised his/her performance, noting that he/she exhibited independence and skill at the level of an intern in the workup and management of his/her patients. He/She confidently led the team when rounding on his/her patients, and served in the role of the primary provider. His/Her patient-care skills were accurate and reliable; his/her history-taking and physical examinations were appropriately detailed and thoughtful.</li> <li>For example, he/she reported only the pertinent positives and negatives in his/her oral presentations, and regularly tailored his/her physical examinations to the chief complaint rather than simply running through a screening exam. Student was highly motivated, performed a tremendous amount of reading about his/her patients' disorders, and regularly used evidence from the medical literature in his/her patient management plans. Additionally, he/she added significant value to team discussions by bringing to rounds what he/she had learned; for example, when managing a patient with X condition, he/she read extensively on the disorder and how to best manage the patient, which he/she then taught to his/her team. He/She is poised, compassionate, and a true team player.</li> <li>I highly recommend [] without any reservations.</li> </ul>","tags":["Soft Skills"]},{"location":"resident-guide/softskills/feedbacktemplates/#great-resident-senior","title":"Great - Resident - Senior","text":"<ul> <li>Over-prepared for everything and can piece clinical information very well. He/She's well organized and presents his/her patients well. He/She's helpful and always eager to participate and learn.</li> <li>Dr. [ ] performed capably in the senior resident role, at a level higher than expected for his/her time in training. He/She ensured smooth functioning of the team by tracking key tasks and assisting the junior residents in their completion. At the same time, he/she generally gave the junior residents space to formulate their own assessments and plans prior to sharing his/her thoughts.</li> <li>He/She attended to the teaching environment, eliciting the thinking of junior learners, requesting achievable learning assignments, and sharing teaching pearls related to his/her self-directed learning. He/She went the extra mile for his/her patients, in one case locating, heating, and delivering a breakfast tray to a patient in the Emergency Department.</li> <li>I enjoyed having Dr. [ ] as a senior as he/she made the team run very smoothly. His/Her communication was effective, decisions decisive, and his/her work efficient which makes it much easier for interns to complete goal oriented tasks. Excellent team leader and takes suggestions well.</li> <li>Dr. [ ] did a great job as a senior on our one week rotation together. He/She brings good teaching points to the rounds, looks at the patient overall and is focused and on top of things. Even being early in his/her second year, he/she was doing a great job managing a full list of patients, interns and medical students. He/She also presented the educational part of morning report while on service. Always on time and ready to take care of his/her patients.</li> <li>He/She also did talks for the medical students which speaks to his/her passion for medical education. He/She also helped out his/her interns always. I would encourage him/her to keep up the great work and to keep learning. It was a pleasure working with him/her.</li> <li>Dr. [ ] did an excellent job during our time together in the MICU. Despite being a brand new second year, he/she performed at the level of a seasoned third year resident in every domain: timely evaluation and triage of patients, supervision of interns, interaction with patients and families, and making sure everything got done. He/She was by far the most effective senior resident on the service.</li> <li>Dr. [ ] always came in with a positive attitude and enjoyable to work with. He/She did well in his/her role as a senior resident in both teaching/supervising the junior residents. He/She was eager to learn and always asking questions. Dr. [ ] was very efficient, diligent and amendable in his/her work.</li> </ul>","tags":["Soft Skills"]},{"location":"resident-guide/softskills/feedbacktemplates/#great-medical-student","title":"Great - Medical Student","text":"<ul> <li>[] did a stellar job on his/her rotation. Attending physicians he/she worked with commented on his/her teamwork, broad knowledge, and impressive procedural skills. He/She thoroughly reviewed patient records ahead of time, gathered appropriately focused histories, performed a targeted physical examination, presented in a well-organized and thoughtful manner, and wrote excellent notes. He/She was able to independently synthesize the information to formulate his/her own assessment and plan, often requiring little modification by the attending. His/her knowledge level exceeds expectations. He/She worked well with all members of the team.</li> <li>Many people commented that they hoped he\u2019d consider family medicine for a specialty as he/she seemed to fit in and responded well to patients of all ages.<ul> <li>His/her understanding of the core content of family medicine, principles of preventive care, and his/her ability to put patients at ease during the exam were beyond what was expected at his/her level of training.</li> </ul> </li> <li>[] is a bright, hardworking, and capable medical student who approached this rotation with diligence and attention. Patients responded well to his/her calm demeanor, and his/her interpersonal skills reflected his/her maturity and thoughtfulness. I greatly appreciated his/her enthusiasm for the work, and he/she asked excellent questions to enhance his/her understanding of his/her patients, systems issues, and the consultation model. He/She demonstrated a strong fund of knowledge throughout the rotation, and his/her thoughtfulness about clinical care was consistently reflected in his/her notes. His/Her assessments accurately and coherently laid out the differential diagnoses for his/her patients and the reasoning behind them. He/She gave an extremely interesting and thought provoking presentation on XX disorder. He/She was a true asset to our team, and an absolute pleasure to work with during this rotation.</li> <li>[] written notes were detailed, organized and flowed logically. They contained accurate assessments and plans for moderately complex patients. Typical's oral presentations exceeded those of his/her peers in their organization, succinctness of delivery and command of his/her patients\u2019 medical information. Typical collaborated extremely well on all of his/her health care teams. He/She won praise for his/her dedication to his/her patients and his/her ability to develop a quick and meaningful rapport with them and their families. Several patients even requested him/her to be at their bedside. He/She was proactive and could be relied upon to efficiently obtain H&amp;Ps on the busy Labor and Delivery floor or in the outpatient clinic. Typical\u2019s energy and enthusiasm was appreciated by all who worked with him/her. He/She took ownership of his/her patients and kept the team updated with their progress. His/Her fund of knowledge was very good. Typical's technical skills and dexterity were good and improved steadily over the course of the rotation. Classmates found him/her to be an exceptional teammate, always willing to work hard for the needs of the team, discuss patients, and they commented that he/she was \u201ca role model for great communication skills.\u201d Nursing evaluators noted that he/she \u201ccaters to patients needs and is very helpful to the team\u201d and \u201chad a great bedside manner\u201d. Patients found him/her to be warm and supportive.</li> <li> immerses himself in solving clinical problems, and is persistent until he/she has found answers. He/She worked with a very complicated diagnostic problem of a middle-aged woman with a high sedimentation rate and serositis where the differential diagnosis and the number of consultants became extensive. He/She went out of his/her way to coordinate with consultants, residents and staff the multiple complex input and problems in his/her patient, and he/she benefited as a result.</li> <li> stood out to me amongst the other third-year students immediately through [] curiosity and dedication to hard work.</li> <li>Throughout [] time on the team, many patients remarked on what a joy it was to interact with [] on a daily basis.</li> <li> always went beyond the average to gather data from multiple sources, and interpret and present it in a way that could be easily understood and used. After examining a patient with acute biliary colic, for example, he/she researched the available imaging modalities, learned why sonography was the recommended initial study, and presented this information to the group. [ ], as a result, learned much about the interpretation of sonographic images of the gall bladder.</li> </ul>","tags":["Soft Skills"]},{"location":"resident-guide/softskills/feedbacktemplates/#average-resident-senior","title":"Average - Resident - Senior","text":"<ul> <li>Balancing task delegation and orders could be more efficient, but I believe this is something all seniors go through and that it will become better with more time as a senior.</li> </ul>","tags":["Soft Skills"]},{"location":"resident-guide/softskills/feedbacktemplates/#average-resident-intern","title":"Average - Resident - Intern","text":"<ul> <li>Dr. [] performed at the level expected of a beginning-of-year PGY-1. He/She consistently attended to fundamental patient safety behaviors such as hand hygiene. He/She elicited and addressed patient concerns in a way that demonstrated compassion (e.g. talking with a patient about their diagnosis after rounds). Dr. [] actively sought feedback and consistently attempted to incorporate feedback into his/her daily workflow. He/She showed good judgment, and his/her medical knowledge is strong. He/She is working on how to effectively discharge patients and build an effective daily workflow. He/She was occasionally late, but showed improvement by rotation's end. For points of feedback, I would recommend spending less time \"pre-rounding\" initially. It is more efficient to quickly run over the morning labs and then trying to see the patients as the nurse's shift change is at 7:00am. If you're able to see your patients before then, you get a better report about overnight events from the night nurse. Overall, I think he/she will be a good intern by year's end.</li> </ul>","tags":["Soft Skills"]},{"location":"resident-guide/softskills/feedbacktemplates/#poor-attending","title":"Poor - Attending","text":"<ul> <li>Dr. X is not fit for the teaching service and should not be assigned residents or medical students. For the vast majority of my time with him/her he/she was condescending, rude, and not interested in answering questions or providing meaningful feedback. His/Her actions are unequivocally abusive and should not be tolerated at any institution. The only teaching obtained was self-guided via UpToDate or other online resources.</li> </ul>","tags":["Soft Skills"]},{"location":"resident-guide/softskills/feedbacktemplates/#poor-student","title":"Poor - Student","text":"<ul> <li>[] had a consistent problem with being punctual in the mornings, although that did improve by the end of the rotation. His/Her motivation was fair, but most previous students have been more ambitious.</li> </ul>","tags":["Soft Skills"]},{"location":"resident-guide/softskills/residentsasteachers/","title":"Residents as Teachers","text":"","tags":["Soft Skills"]},{"location":"resident-guide/softskills/residentsasteachers/#teaching","title":"Teaching","text":"<ul> <li>As seniors, it\u2019s now your responsibility to help with teaching during and after rounds</li> <li>This is for your benefit as well as the interns/med students</li> <li>Typically like to have medical students on med service research a topic they like or one that was seen that day and present it to the team in a 2-minute talk the following day</li> <li>Not done every day\u2026 can be too much if the next day is a call day</li> <li>Keeps medical students entertained and typically you learn something</li> <li>Ex. \u201cHey Austin, can you research Cellulitis tonight and teach it to me tomorrow? Only looking for like a 2-minute brief talk\u201d</li> </ul>","tags":["Soft Skills"]},{"location":"resident-guide/softskills/residentsasteachers/#chalk-talks","title":"Chalk Talks","text":"<ul> <li>Short, 2-to-5-minute presentations</li> <li>Keep it narrow and SHORT. Digestible.</li> <li>Goal is to teach while learning the topic yourself in a simplified manner without missing the key points</li> <li>Pick a Relevant Topic (take inspiration from your patients)</li> <li>Things you only briefly touched on during rounds</li> <li>Teach them your thought process</li> <li>Debunking common myths helps (stay evidence based)</li> <li>Use figures/flow charts</li> <li>Stay FOCUSED</li> <li>Suggestions:<ul> <li>Cerebral Edema</li> <li>Anemia</li> <li>AKI</li> <li>AECOPD</li> <li>Chest Pain</li> <li>DKA</li> <li>GDMT</li> <li>Meningitis</li> <li>Uncontrolled Hypertension</li> </ul> </li> <li>TeachIM Link</li> </ul>","tags":["Soft Skills"]},{"location":"resident-guide/softskills/upperleveling101/","title":"Upper Leveling 101","text":"","tags":["Soft Skills"]},{"location":"resident-guide/softskills/upperleveling101/#expectationsresponsibilities","title":"Expectations/Responsibilities","text":"<ul> <li> <p>As seniors, the incoming interns look to you for guidance</p> <ul> <li>Be the senior you had/wanted when you first started</li> </ul> </li> <li> <p>Communicate with your team</p> <ul> <li>You\u2019re the captain of your team, but you can\u2019t steer the ship alone</li> </ul> </li> <li> <p>Talk up, not down</p> <ul> <li>We\u2019ve all been the July intern, no one needs to be put down or singled out</li> </ul> </li> <li> <p>Address concerns early</p> <ul> <li>If you\u2019re worried about something, bring it up</li> <li>This gives everyone time to fix problems before they become habits</li> <li>If you don\u2019t know how to fix a problem, ASK</li> <li>This is what the chiefs/attendings are here for</li> </ul> </li> <li> <p>You don\u2019t have to be perfect</p> <ul> <li>We all mess stuff up, but you should stick up for your interns</li> <li>Don\u2019t throw interns under the bus\u2026. This is a TEAM</li> <li>\u201cI\u2019m sorry, I\u2019m not sure what happened, but we will fix it\u201d</li> </ul> </li> <li> <p>PATIENCE</p> <ul> <li>Not an easy thing, this takes time</li> <li>Small sacrifices early will make the interns more independent later on</li> <li>Over the next year, you\u2019ll see the PGY-1\u2019s progress and you\u2019ll be amazed</li> </ul> </li> </ul>","tags":["Soft Skills"]},{"location":"resident-guide/softskills/upperleveling101/#running-the-team","title":"Running the Team","text":"<ul> <li>Ensure patients are distributed appropriately each day, including who will see new admissions, and a reasonable distribution of the work</li> <li>Supervise and run team rounds with attending support</li> <li>\u201cTask Master\u201d, keep the team moving, keep notes on important tasks</li> <li>Run list and ensure orders, consults, and discharges are complete</li> <li>Ensure interns are completing all assigned duties and aid with direct care duties (i.e., calling consults, arranging discharges, updating list)</li> <li>Perform sign out on long call days</li> <li>Assist with teaching the medical student(s) and/or making time in the day for teaching (More on this later)</li> <li>Ensure all notes and tasks are complete, prepare list for handoff</li> </ul>","tags":["Soft Skills"]},{"location":"resident-guide/softskills/utilizingfeedback/","title":"Utilizing Feedback","text":"","tags":["Soft Skills"]},{"location":"resident-guide/softskills/utilizingfeedback/#elicit-feedback","title":"Elicit Feedback","text":"<ul> <li>Communicate your needs and goals; prepare others to expect elicitation of feedback</li> <li>Ask for feedback; accept it graciously</li> <li>Perceive feedback as a potential learning tool, not a criticism or attack</li> <li>Manifest receptive body language</li> <li>Be aware of the feelings elicited in you by the feedback, and manage them appropriately</li> <li>Avoid defensive responses, even if feedback is perceived as inappropriate</li> <li>Ask for clarification or a specific example</li> <li>Ask for specific ideas about how the issue can be resolved, problem solve</li> <li>Use active listening skill: rephrase, paraphrase</li> <li>Thank the provider whenever appropriate</li> </ul>","tags":["Soft Skills"]},{"location":"resident-guide/softskills/utilizingfeedback/#tips-for-eliciting-feedback","title":"Tips for Eliciting Feedback","text":"<ul> <li>Present your perceptions, avoid excuses</li> <li>Focus on issue presented</li> <li>Try and keep own ego separate from behavior</li> <li>Keep in mind that all feedback is a reflection of the sender\u2019s mood, perceptions, and personality</li> <li>Remember that making mistakes is human and that generally the worst mistake is not to learn from one\u2019s mistakes</li> <li>Reflect on feedback after the interaction; validate it by eliciting feedback or data from other sources when appropriate</li> </ul>","tags":["Soft Skills"]},{"location":"resident-guide/blog/archive/2024/","title":"2024","text":""},{"location":"resident-guide/blog/category/blog/","title":"Blog","text":""}]}